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Background
The evaluation of innovation in surgery is a complex process
challenged by evolution of technique, operator learning curves,
inconsistent procedural quality, and strong treatment preferences
among patients and clinicians [1]. Given these challenges, the
development of early-stage novel surgical techniques has been
criticized for poor-quality study methodology and data reporting
[2, 3]. To address this, the IDEAL framework (Idea, Development,
Exploration, Assessment, Long-term follow-up) proposes a five
stage stepwise evaluation of innovative procedures to allow a
more transparent and ethical introduction of new techniques [4].
The IDEAL framework was proposed in 2009 and there has been
no systematic assessment of its use. We examine the uptake and
utilization of IDEAL by surgical innovators by reviewing the pub-
lished literature.
Methods
We searched Web of Science to identify all articles published be-
tween 1st January 2009 and 30th September 2016 that cited any of
the 11 key papers published by the IDEAL Collaboration. All abstracts
were assessed by two independent researchers to identify papers ex-
plicitly describing using IDEAL recommendations to conduct their
primary research. Included papers were reviewed and categorized by
characteristics including clinical specialty area, type of journal, coun-
try of origin, publication date, and the IDEAL stage. Each paper was
further critiqued on how well it met the specified IDEAL stage recom-
mendations [1].
Results
We identified 311 papers citing one or more of the 11 key IDEAL
papers. Of these, 30 described having followed the stage-
appropriate IDEAL recommendations to conduct their innovation
study. Interim analysis indicates considerable variation in uptake
between clinical specialties and geographical regions. We are cur-
rently undertaking more in-depth analysis on the studies of these© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeearly users of IDEAL to examine how the framework and recom-
mendations have been used. We also plan to conduct qualitative
research with the Pis of these studies to learn more about how
useful they found IDEAL as a tool for their research plan.
Discussion
Since its inception in 2009, surgical researchers worldwide are
beginning to recognize and utilize the IDEAL recommendations.
Early adopters have been concentrated within a few surgical
specialties and focused on the pre-RCT developmental stages of
IDEAL, where research guidance has previously been lacking. This
review of the literature will help the IDEAL Collaboration to learn
from the early adopters’ experiences and identify how to work
with future surgical innovators to develop IDEAL as a practical
framework in order to conduct the highest quality surgical
research.
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Background
Shoulder dysfunction and pain following breast cancer treatment is
common, impacting upon postoperative quality of life. Exercise may
improve shoulder function and reduce the risk of postoperativele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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(commencement) and exercise dosage (frequency, intensity, length of
time and type of exercise) required for optimal results. We considered
Medical Research Council (MRC) guidance for the development of a
complex intervention, which highlights the need for a planned, phased
approach based on available evidence, appropriate theoretical princi-
ples and thorough piloting. We developed a complex intervention for
the prevention of shoulder dysfunction following breast cancer treat-
ment for evaluation within the framework of a large pragmatic multi-
centre randomised controlled trial in the UK NHS setting.
Methods
Patient and public involvement (PPI) was central to the development
of the PROSPER intervention from its inception. We engaged PPI
members from the initial application phase and have had ongoing
input throughout the project. In conjunction with PPI, development
work began with a comprehensive literature review to identify sys-
tematic reviews and RCTs of shoulder-specific exercises and general
physical activity during and after breast cancer treatment. This pro-
vided the broad theoretical basis for the content of a structured exer-
cise programme which was further developed and refined in a
workshop with clinical experts, researchers, and patient representa-
tives. Individual face-to-face interviews were then conducted with
seven women previously treated for breast cancer, providing feed-
back on intervention content and patient-facing materials. The PROS-
PER intervention was pilot tested with 18 women newly diagnosed
with breast cancer, at three hospital sites, allowing further refinement
to ensure feasibility for delivery within the UK NHS.
Results
The literature review identified several systematic reviews and new
clinical trials suggesting that early structured exercise, started within
a few days of surgery, versus delayed exercise may improve shoulder
range of movement (ROM) in the short and long term. Evidence sug-
gested that shoulder flexion and abduction be restricted to 90 de-
grees for the first postoperative week to reduce risk of increased
wound drainage. There was also evidence to suggest that postopera-
tive strength training was safe and that general physical activity can
enhance physical and psychological recovery. The final PROSPER ex-
ercise intervention, underpinned by evidence, comprised of three
main components: specific exercises targeting shoulder range of
motion and upper arm muscle strength, general physical activity,
and behavioural strategies to improve adherence. The exercise
programme is structured, individualised, supported by trained phys-
iotherapists, and delivered over a 12-month period with a focus upon
self-management at home. Women randomised to the exercise
programme receive three face-to-face sessions with a physiotherap-
ist, with the option of a further three appointments that can be deliv-
ered either face-to-face or by telephone.
Conclusions
We followed the MRC theoretical framework to develop a multicompo-
nent exercise programme for the prevention of shoulder problems fol-
lowing breast cancer treatment. This complex intervention is currently
being evaluated within a large UK pragmatic RCT [ISRCTN35358984]. To
date, 105 women with newly diagnosed breast cancer have been
recruited from 12 centres across England.
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Background
Randomised controlled trials (RCTs) of physical rehabilitation inter-
ventions evaluate multi-faceted interventions that are delivered in
complex healthcare systems. In a synthesis of the outcomes of trials
of rehabilitation interventions funded by the UK National Institute for
Health Research – Health Technology Programme (NIHR-HTA), wefound that very few new interventions achieved superior outcomes
relative to controls. To date, no research has examined why so few
rehabilitation interventions that undergo testing in RCTs result in ef-
fective new treatments.
Aim
(1) To establish work that has been undertaken to develop physical
rehabilitation interventions prior to testing in an NIHR-HTA funded
RCT. (2) To examine the relationship between intervention develop-
ment and the primary outcome of experimental testing.
Methods
We included 15 superiority RCTs funded by NIHR-HTA from 1997 to
July 2016, that evaluated a physical rehabilitation programme and re-
ported their main findings in a peer-reviewed journal or NIHR-HTA
monograph. We extracted data on intervention development in re-
spect of five areas described by the credeci 2 reporting criteria for
“development” and “feasibility & piloting”: (i) description of the inter-
vention’s underlying theoretical basis; (ii) description of all of the
intervention components; (iii) illustration of any intended interactions
between different components; (iv) description of the pilot test and
its impact on the definitive intervention; (v) consideration of the con-
text’s characteristics in intervention modelling. We coded the ex-
tracted data thematically. We classified primary outcome data into
one of six categories developed by Djulbegovic et al. (2008) to differ-
entiate studies where outcomes favour the intervention, the control,
demonstrate no difference between trials arms and are conclusive or
inconclusive. To examine the relationship between intervention de-
velopment and primary outcome data, we are applying novel mixed
methods analytical techniques. We are combining the narrative data
on intervention development with the numeric data on treatment
outcomes in a joint category/themes display: for each category de-
fined by Djulbegovic et al. we will present a summary of the the-
matic data on intervention development in each trial for whom the
category applies. In this way, we will compare the intervention devel-
opment work that has been undertaken for trials that result in differ-
ent outcomes.
Results
We found that four trials were significantly in favour of the new treat-
ment, one was significantly in favour of the control, eight had a true
negative outcome and two were inconclusive. Our preliminary data ex-
traction reveals that the amount of (reported) intervention development
work undertaken prior to experimental testing differs considerably. We
are now applying our mixed methods analytical procedures to investi-
gate the relationship between outcomes and intervention development.
Conclusions
We have applied techniques for mixed methods analysis in innovative
ways to explore the relationship between intervention development
and treatment effects. This work may help us better understand the
role of intervention development in explaining why so few interven-
tions in rehabilitation that undergo experimental testing result in effect-
ive new treatments. Other factors, including the design and conduct of
fully-powered trials, may also help explain the relatively few number of
treatment successes and require further research.
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Background
It is widely agreed that, if the aim is to inform policy and practice,
randomised controlled trials (RCTs) of complex interventions should
be coupled with process evaluations. Realist evaluation provides a
strong theoretical foundation to explore complex interventions, using
a process of eliciting, testing, and refining stakeholders’ theories of
Trials 2017, 18(Suppl 1):200 Page 3 of 235how an intervention works, for whom, and in what contexts. There is
debate about the relationship between realist evaluation and RCTs.
One concern is that RCTs take place in closely controlled contexts
and so do not allow for exploration of how different contexts shape
the outcomes of an intervention. In this presentation, we will draw
on our experience of undertaking a three-phase realist process evalu-
ation alongside an RCT comparing robotic and laparoscopic surgery
to address two methodological questions: (1) To what types of trials
can realist evaluation make a meaningful contribution?; and (2) How
is that contribution best achieved?
Methods
In Phase 1, a literature review identified stakeholders’ theories concern-
ing how robotic surgery becomes embedded into practice and its im-
pacts on teamwork. These were refined through interviews with theatre
teams across nine hospitals. In Phase 2, the theories were tested
through a multi-site case study across four hospitals. Case sites were se-
lected to ensure variation in the theatre teams’ experience of robotic
surgery, an important contextual factor within the theories. Data were
collected using multiple methods: structured and ethnographic obser-
vation; video analysis; qualitative interviews; and questionnaires. In
Phase 3, interviews were conducted at case sites with staff representing
other surgical disciplines, to assess generalisability of the findings.
Results
While the RCT delivered important results on outcomes, the findings
from the realist process evaluation further enhanced our understand-
ing of the introduction of robotic surgery. The combination of
methods deployed enabled us to identify and interrogate a range of
perspectives on the differences between robotic and laparoscopic
surgery and the ways in which robotic surgery is implemented in dif-
ferent sites. Most strikingly, we were able to capture unanticipated
consequences of robotic surgery in terms of impacts on teamwork,
along with strategies used to counteract such unanticipated conse-
quences. These issues relate to the introduction of robotic surgery as
a surgeon-led process but which is dependent on support at differ-
ent levels of the organisation. The process evaluation directed our at-
tention to the importance of whole team training, experienced and
dedicated teams, and suitably sized operating theatres.
Conclusions
Realist evaluation provided a robust framework to identify and test
stakeholders’ theories on deployment of robotic surgery. The results of
this study move beyond the RCT to deliver clear guidance on how to
deploy robotic surgery and how to ensure effective teamwork when
undertaking robotic surgery. So, realist evaluation can play a valuable
role alongside pragmatic rcts of complex interventions that seek to ex-
plore effectiveness in a range of contexts, eliciting theories about how
contexts shape outcomes and then collecting empirical data to test
and refine them. Theory elicitation should happen before the RCT to
ensure it secures relevant data to support testing of identified theories.
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evaluations of healthcare interventions. However, cluster cross-over
randomised trials are novel: a recent systematic review identified
only 91 such studies [1]. While providing efficiency gains compared
to crcts, the cross-over design adds complexity to the design and
analyses. To date, the literature has been limited to the analysis of
binary outcomes [2,3].
The headpost [4] study is an international multicentre randomised
cross-over clinical trial comparing the effectiveness of the lying flat
(0°) head position with the sitting up (> = 30°) head position, applied
within the first 24 hours of admission to hospital for patients with
acute stroke, on functional outcome according to the modified
Rankin scale (MRS) by blind assessors at 90 days. A total of 114 sites
were allocated either to (a) lying flat head position or (b) sitting up
head position as the first intervention, to be applied to up to 70 con-
secutive stroke patients before crossing over to the other head pos-
ition. All eligible stroke patients presenting to the hospital from the
start date were to be prospectively and consecutively enrolled. The
primary outcome was the modified Rankin score, a 7-level ordinal
scale between 0 (completely independent) and 6 (dead), which is
commonly used in stroke trials.
This presentation outlines the statistical analysis planning and con-
duct for the headpost study, taking account of its cluster cross-over
nature. The primary efficacy analysis was conducted using a hierarch-
ical cumulative logistic regression to allow direct modelling across all
levels of clustering by including both random cluster and random
cluster-period effects. The implications for the analysis of secondary
and safety outcomes as well as strategies for sensitivity analyses and
handling of missing data, are to be discussed. The focus will be on
practicalities of analysis rather than mathematical aspects of cluster
cross-over trials.
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The clinical research enterprise cannot escape the shift from paper case
report forms (CRF) to direct data entry of case report forms. This daunting
shift has the potential to reduce the workload of clinical sites and provide
an environmentally friendly source of data collection while also improv-
ing the quality and integrity of the data by removing the chance of tran-
scription errors, minimizing missing data, allowing for real time logic and
range checks, and leading to faster database locks. For our long-term
multi-center clinical trial, the use of mobile electronic patient reported
outcomes (EPRO) for self-administered questionnaires was a clear first
step towards this shift implemented within our custom built web-based
data collection and management system called MIDAS (Multi-modal Inte-
grated Data Acquisition System). Mobile EPRO for self-administered ques-
tionnaires increases flexibility of visit flow, and allows for the collection of
sensitive information such as questions about sexual health.
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ing considerations for the aging and diverse population of the trial
for whom the use of mobile devices may be less ubiquitous. The
aging study population is majority female, and ethnically diverse.
During the implementation of EPRO for self-administered question-
naires, we kept in mind the needs of elderly participants with cogni-
tive decline, dexterity problems, and visual impairments as well as
the needs of participants who speak English as a second language or
those with disabilities in reading and writing.
Data collection via mobile data entry for six self-administered ques-
tionnaires began in August 2016 and was accompanied by a survey
to assess user acceptability. Of the 300 visits completed to date, 90%
used the mobile EPRO version with nearly 100% survey response
rate. This presentation will present the results of the survey as well
as feedback from participants and staff including utilization rates,
overall experience, font size, button size, view preference, ease of
use, and whether paper or mobile entry is preferred. We will share
results of the survey overall and by demographic subgroups using
the ~1,000 visits expected by the time of the presentation.
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Background
planet-2 (ISRCTN87736839) is an international multicentre trial of
platelet count thresholds for prophylactic platelet transfusions in pre-
term neonates. The trial commenced recruitment in June 2011 and
to date 573/660 neonates have been randomised to one of 2 arms.
Depending on their allocated threshold, the baby receives a platelet
transfusion when platelet counts drops to either below 50x10^9 or
25x10^9. The primary outcome measure for planet-2 is the propor-
tion of patients who either die or experience a major bleed up to
and including Study Day 28 (SD28). A cranial ultrasound scan (CUSS)
at SD28 is the prime marker for major intracranial bleeds at this
point.
Monitoring the Primary Outcome Data
In order to monitor the completeness of the primary outcome data,
a monthly reporting system was developed by the trial statistician to
allow close analysis of data completeness. The reports revealed
17.9% of missing primary outcome data from babies known to be
alive at SD28. A large proportion of these did not have a reported
SD28 CUSS. This was due to a variety of causes, including transfer
out of neonates prior to SD28 from the recruiting site to smaller non-
participating units.
Measures to optimise the data
The monthly reports allow the TMG to take measures to maximise
the completeness of the data obtained from the study. A transfer
pack was developed to inform new sites of required information and
an accompanying letter provided, to enable PIs to request primary
outcome data from colleagues within the new units. The SD28 win-
dow was extended from +/−3 days to −5/+10 days of SD28. This was
considered by the neonatologists on the TMG, and the independent
members of the TSC, to possess the same clinical validity. If no scan
had been obtained within the new extended timeframe, our medical
experts, or, in some cases, independent expert, were given approval
to impute the primary outcome given sufficient supporting clinical
evidence.
Result and Conclusions
This monthly report system provides the information to allow the
trial manager to contact the site teams a few days before each ran-
domised baby reaches SD28 to remind them of the need to perform
a CUSS and this has proved very effective in optimising the data
completeness.This piece of work shows the value of the statisticians and data team
on the trial management team working together to improve the sci-
entific integrity of the study. Our missing primary outcome data cur-
rently stands at approximately 1.4%. Liaising closely with research
site teams and maintaining good relationships is crucial to trial
success.
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The COPE (Consortium for Organ Preservation in Europe) include
three clinical trials to improve preservation and reconditioning strat-
egies for kidneys and livers procured for transplantation aiming to in-
crease the number and quality of grafts used.
Despite the trials being led at different centres, they are centrally
managed from one main centre where the Principal Investigator, the
project’s governance and management are based. This is one of the
reason why it was decided to set up a single ‘combined’ Data Moni-
toring Committee to oversee the three trials with a single six-
monthly meeting to review all three trials.
This seems to be the most convenient approach in similar situations/
settings as it reduces the number of meetings to organise as well as
expenses. However, it does not come without difficulties particularly
when the same person is preparing the reports for all the studies
and multiple sites and/or countries are involved.
The different benefits and challenges experienced will be illustrated
in order to provide a helpful reference to anyone that may consider
this option in similar situations.
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In recent years, a growing trend toward global research has led to
randomized controlled trials (RCTs) becoming larger and increasingly
more complex. More patients are being enrolled entailing greater
use of multisite trials, case report forms (CRFs) are more complicated,
and larger budgets are necessary to accommodate for the greater
volume of participants and sites involved in a RCT. Centralized statis-
tical monitoring (CSM) is commonly used for guaranteeing data qual-
ity by detecting data issues early, such as errors, sloppiness,
tampering, and fraud, before significant problems occur. Through
off-site central monitoring, onsite monitoring can be more efficiently
targeted. Equally important to ensuring data quality is assessing the
adequacy of the trial design and performance. Design errors, if not
discovered and addressed early, can largely bias study findings and
make a trial difficult or impossible to interpret. Poor adherence to de-
sign and a lack of oversight can result in an unsuccessful trial with
drastic ramifications, including revoking one’s clinical and research
privileges, funding, and leaving a tarnished reputation. Consequently,
the purpose of this research was to apply CSM to the monitoring of
various aspects related to the design and performance of a clinical
trial.
Study design quality metrics assessed for anomalies included adher-
ence to inclusion and exclusion criteria, recruitment, administration
of treatment, blinding, visit scheduling, patient follow-up, data
Trials 2017, 18(Suppl 1):200 Page 5 of 235submission, and the reporting of safety measures. Each metric can
be evaluated across sites as in a multisite RCT, or across clinicians to
assist in identifying potential threats to a trial’s performance. A pro-
gram was developed to apply CSM for monitoring the performance
of a clinical trial. CSM was applied monthly, in conjunction with regu-
larly scheduled risk-based monitoring. For continuous measures of trial
performance, modified boxplots described distributions, differences in
the proportion of outliers were assessed using chi-square analyses, dif-
ferences by site were examined with analysis of variance (or the non-
parametric equivalent) and further assessed using pairwise tests, and
homogeneity of variance and sites with outlying or inlying variance
were also determined. Confidence bands were used to provide add-
itional monitoring of trial performance. For categorical measures, chi-
square analyses and logistic regression were employed.
CSM applied to study design elements can be used to assess trial
performance over time throughout the duration of a study. Monitor-
ing trial performance helps to ensure the validity of a study and its
design, consistency in reporting across sites and clinicians, and that a
study's hypotheses are not being compromised. Continual monitor-
ing of study design quality metrics through CSM enables corrective
action to be taken early enough to address any potential threats to
the design of a RCT, while also simultaneously improving data quality
and the credibility of a study and its findings.
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Background
Dementia and mild cognitive impairment (MCI) pose a large and
increasing health and societal burden on the aging US population.
In 1987–1989 the NHLBI-supported prospective epidemiologic
Atherosclerosis Risk in Communities (ARIC) study enrolled 15,792
participants from 4 distinct US geographical regions in order to investi-
gate the causes of atherosclerosis and its clinical outcomes, including
cognitive function. Since visit 1 in 1987–1989, there have been 4
follow-up visits for the cohort. ARIC is uniquely suited to contribute crit-
ical information on the vascular, and potentially preventable, contribu-
tions to MCI and dementia of different origins.
Methods
The Collaborative Studies Coordinating Center (CSCC) in the Department
of Biostatistics at the University of North Carolina serves as the coordinat-
ing center for ARIC and provides the infrastructure for the data collection
using the CSCC-developed, web-based data management system, Caro-
lina Data Acquisition and Reporting Tool (CDART).
Neurocognitive test data collection in ARIC began at Visit 2 (1990–92)
and was repeated in Visits 3 (1993–95) and 4 (1996–98) using 3 neuro-
cognitive tests. An ancillary study was conducted in 2004–06 on a
subset of the ARIC cohort where the test battery was expanded. At Visit
5 (2011–13), the expanded neurocognitive test battery was collected
on 6538 participants, enabling the investigators to examine cognitive
function changes over 24 years, particularly in the areas of memory,
language and executive function. A challenge to these longitudinal
analyses has been that the neurocognitive measures change over time
due to scientific improvements in the instruments. A group of ARIC
investigators employed factor analysis to level differing cognitive test
batteries over visits to common, comparable measurements in the area
of general cognition and the 3 cognitive domains of interest (Gross
et.al., Epidemiology vol 26, no 6, 11/2015).
Objective
Visit 6 is underway with continued neurocognitive emphasis that will
allow quantification of cognitive decline, estimation of the incidence
of mild cognitive impairment (MCI) and dementia, and tracking of
progression from MCI at V5 to dementia. These measures will beimmediately available for comparison to Visit 5 factor scores through
an application called from CDART. The behind the scenes program-
ming calculates the Visit 6 factor scores for the cognitive areas of
interest allowing for immediate determination of cognitive domain
failure and generalized cognitive decline compared to Visit 5 per-
formance, despite the fact that not all participants completed the
exact same battery at each visit.
The participants who show failure in at least 1 cognitive domain and
significant global cognitive decline from Visit 5 will have additional data
collected from a proxy or informant and will undergo a complete data
review by members of the classification committee in order to deter-
mine neurocognitive status as dementia, MCI, normal, or unclassifiable.
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The aim of our online tool, is to use openly available data to help in-
form researchers, in the UK, whether a given target size, is broadly
achievable for a feasibility or pilot study investigating a specific
health condition. Information obtained from the online tool may also
further help determine a suitable recruitment period for a feasibility
or pilot study investigating a given health condition.
Ideally, data on the actual sample sizes obtain in the feasibility and
pilot studies would have been more informative than the target size
data. Unfortunately, we were unable to find an openly available
source for this data. However we feel that the target sample size
data, along with the recruitment period can provide a rough guide
to the achievability of recruitment targets for feasibility and pilot
studies. For instance, if a pilot study had a target sample size of 60
and a recruitment period of 18 months for a study investigating a
health condition you are interested in, you might want to reconsider
running a similar pilot study with a target size of 100 for 6 months.
We therefore believe that this data has value in making informed de-
cisions with regard to recruitment for a feasibility and pilot studies.
We identified UK Clinical Trial Gateway (UKCTG) as providing the best
source of UK based data to harvest. The UKCTG was set up by the
National Institute for Health Research (NIHR) to essentially help re-
cruit people to clinical trials in the UK. Because there were no facil-
ities for downloading data from the UKCTG website, a web scraping
methodological was adopted and implemented using R.
Four searches were run on the entire trial record. The following search
terms were used: "feasibility trial", "feasibility study", "pilot trial" and
"pilot study" and 3039 unique trial records were identified. The unique
trial records ids were extracted from the search results and then the
trial records were downloaded. Data such as the trial title, target sample
size, recruitment start date, recruitment end date, the longitude and
latitude of the recruiting centre were then extracted from the records,
using regular expressions, and collated into an Excel where open-
ended text fields (e.g., target sample size) were manually cleaned.
Shiny, a web application framework for R, was then used to create
an online tool to interrogate the data. For various health conditions,
specified by the researcher, the tool can be used to obtain descrip-
tive summaries and graphical displays of pilot and feasibility studies
for the following factors: period of recruitment, target sample size,
target recruitment rate per month, location of trial centres.
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Recruiting to randomised controlled trials (RCTs) can be difficult,
especially when habitual clinical practices are compared with lesser-
known or novel approaches. Surgical RCTs can be particularly chal-
lenging, due to ingrained clinician preferences and doctrine. Post-
surgical wound care is an aspect of surgery in need of high quality
evidence. It is common to apply dressings over closed wounds after
most adult operations, despite there being limited evidence to sup-
port or refute this practice. The NIHR-funded Bluebelle study aimed
to determine the feasibility of an RCT that randomises patients to dif-
ferent wound dressing strategies, including ‘no dressing’ (where the
wound is exposed to air). The funder and health care professionals
were sceptical about whether ‘no dressing’ would be acceptable to
patients and clinical professionals, and questioned whether an RCT
could successfully recruit participants. The Bluebelle study was thus
funded to investigate these uncertainties. It consisted of two phases:
a preliminary phase to explore current practice and select appropri-
ate comparators (Phase A), and an external pilot RCT (phase B). In-
formed by phase A findings, the pilot RCT sought to randomise
patients to receiving either a ‘simple dressing’, 'glue-as-a-dressing’, or
‘no dressing’. The pilot addressed a number of objectives to deter-
mine whether a full-scale RCT could be delivered. Two objectives
were to investigate whether recruitment was feasible (target of 330
patients), and explore whether the comparison groups were accept-
able to patients and health care professionals.
Methods
Adults undergoing elective and emergency abdominal surgery were
invited to take part in the pilot RCT. Recruitment took place between
March-November 2016, across four NHS hospitals in England. Re-
search nurses and surgeons provided information about the study in
advance of surgery and obtained written consent. Patients who en-
tered the RCT and health care professionals involved in their care
were invited to take part in semi-structured interviews, to explore
the acceptability of the dressing strategies under comparison. Results
Recruitment figures met or exceeded targets across all centres. The
numbers of patients approached and the proportion consenting indi-
cated that a main trial would be feasible (446 approached, 363 con-
sented, and 326 randomised, as of October 2016). Qualitative
interviews provided further evidence to suggest that randomisation
to the three dressing strategies was acceptable. Patients’ wound
healing experiences were similar across all groups, with no notable
clinical or practical concerns. Contrary to health care professionals’
prior assumptions, some patients reported practical advantages of
not having a dressing, reflecting on the ‘low maintenance’ nature of
wound care. Health care professionals did not report any particular
difficulties in caring for patients in any of the groups, and did not
perceive any changes to other aspects of their practice. The number
of recorded protocol deviations and retention rates are currently
undergoing analysis and will be available at the conference.
Conclusion
This pilot RCT demonstrated that it is feasible to recruit patients to
an RCT of different wound dressing strategies, including ‘no dress-
ing’. A full-scale trial will be designed on the basis of these findings,
providing other aspects of trial conduct (e.g. Retention) are
acceptable.
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Background
The rapid and recent global increase in prevalence of type 2 diabetes
(T2D)[1,2] is of great concern. Although adverse lifestyle behaviours(relating to diet and exercise) are recognised as important risk factors
for the development of T2D, interventions at the level of the individ-
ual to modify these are challenging. Evidence suggests that lifestyle
behaviours are passed through families, from one generation to an-
other. Therefore, when designing T2D interventions, it may be im-
portant to consider behaviours developed within the shared family
environment.
Aim
To investigate the impact of the shared family environment on risk
factors for T2D, and to determine the feasibility of conducting a fully
powered study using this methodology.
Design
Cross-sectional feasibility study of index cases diagnosed with T2D
and their first degree relatives (siblings and offspring). Index cases
were recruited from the diabetes information database (DIAMOND)
of a hospital in Northern Ireland.
Method
Sample: The DIAMOND database was screened to identify adults with
T2D, aged 45–65 years, with at least two siblings and two offspring,
willing to participate in the study. For this feasibility study 50 partici-
pants were sought (i.e.10 index cases each with 4 first degree rela-
tives, spanning two generations). Measures: A range of lifestyle
factors, biochemical and clinical markers were collected for all partici-
pants. Location of the Study: The rationale underpinning the suitabil-
ity of this location for the study was based on existing knowledge: 1.
As Northern Ireland comprises the most homogenous population
group in the UK, it was believed the majority of offspring would live
locally; 2. The close family structure encountered in Northern Ireland
would lead to strong support for research projects that involve a
family member.
Results
Recruitment: Achieving the required sample of n = 50 proved to be
impossible over an 18 month recruitment period. For example, dur-
ing a four-month screening period, coinciding with a relaxation of in-
clusion criteria 434 patients were screened, 85 were found to be
eligible for inclusion, with only 6 successfully recruited. Only 8 index
cases were secured across the study duration.
Support: Family support structures were found to be weak, with a
number of eligible candidates reporting strained family relationships
as a deterrent to participation.
Family size: Many potential index cases did not have enough siblings
and/or children required to participate.
Motivation: Index cases lacked motivation, both in relation to their
condition and willingness to participate.
Age: The tight inclusion criteria for age of index cases (45–65 years)
were found to be restrictive.
Data analysis: This proved difficult due to the small sample size and
the clustering of family data.
Conclusion
The feasibility study provided key insights, impacting on scaling up deci-
sions. We now know that identifying index cases for this study through a
hospital data base is ineffective and would be better suited to a primary
care setting. The data gathering methods and instruments worked effect-
ively. In light of the difficulties encountered in the feasibility study, it was
agreed that a fully powered study would not be developed.
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Feasibility studies are routinely performed in a variety of clinical areas
to help provide evidence prior to major monetary investment, hu-
man resource and patient recruitment to a large randomised con-
trolled trial (RCT). They can assess a variety of aspects including
recruitment potential, multi-centre operational coordination and lo-
gistical aspects of administering the intervention. As viability is their
Trials 2017, 18(Suppl 1):200 Page 7 of 235main aim, small sample sizes are used and so feasibility studies rarely
have sufficient power to assess clinically important treatment
differences.
Like other research organisations, NHS Blood and Transplant (NHSBT)
considers feasibility studies to be essential prior to significant invest-
ment in a subsequent full scale RCT. As such, NHSBT have funded a
number of feasibility studies, which have then improved the design
and conduct of RCTs and larger research projects that have ultim-
ately lead to changes in clinical practice.
The NHSBT Clinical Trials Unit has a growing portfolio of feasibility
studies in transfusion medicine with five studies having a sample size
of around the magic number of 40 patients: in set up REAL and
DRIVE, currently recruiting REDDS (ISRCTN26088319) and EFIT
(ISRCTN67540073); and completed CRYOSTAT (ISRCTN55509212). Al-
though formal sample size calculations are not needed for feasibility
studies, it is important that required patient numbers are properly
justified. Although there is some guidance on this in the literature
(for example Julious (2005), Billingham (2013), Teare (2014) and
Whitehead (2016)) the background to the sample size for our feasibil-
ity studies will be described and illustrated.
Our magic number of 40 is regarded as a compromise between the
need for a short timescale in which feasibility can be assessed, suffi-
cient data to allow recruitment rates to be determined in representa-
tive centres, and whether the study interventions can be delivered
successfully. Some general observations on the design of these stud-
ies will also be included, concluding with a summary of the research
which has resulted from our completed feasibility studies.
References
Julious SA (2005) Sample size of 12 per group rule of thumb for a pilot
study. Pharmaceutical Statistics, 4: 287–291.
Billingham SAM, Whitehead AL, Julious SA (2013) An audit of sample sizes for
pilot and feasibility trials being undertaken in the United Kingdom
registered in the United Kingdom Clinical Research Network database.
BMC Medical Research Methodology, 13: 104.
Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A and Walters
SJ (2014) Sample size requirements to estimate key design parameters
from external pilot randomised controlled trials: a simulation study.
Trials, 15: 264.
Whitehead AL, Julious SA, Cooper CL, Campbell MJ (2016) Estimating the
sample size for a pilot randomised trial to minimise the overall trial
sample size for the external pilot and main trial for a continuous
outcome variable. Statistical Methods in Medical Research,
25(3): 1057–1073.
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Background
Poor research design, conduct and analysis contribute to significant
research waste. This is further compounded by the limited reporting
and dissemination of results. Pilot and feasibility work has the poten-
tial to contribute to the success of subsequent definitive main trials.
It allows areas of methodological uncertainty in the main trial proto-
col to be addressed and resolved before the main trial begins. Whilst
it is particularly important to the design of trials of complex interven-
tions such as surgery, little is known about how to optimally design
pilot and feasibility work to inform surgical trials.
Aim
To systematically analyse the protocols and published papers of
funded pilot and feasibility studies of surgical interventions tounderstand key design features associated with the optimal design
and conduct of main surgical trials.
Methods
The NIHR Health Technology Assessment (HTA) and Research for
Patient Benefit (rfpb) programme databases (as available from the
NIHR website) were screened for pilot/feasibility studies of surgical
interventions funded between 2005 and 2015. Pilot/feasibility work
was defined as: Any research undertaken before a main study
intended to inform the design and/or conduct of a future main
study. A surgical intervention was defined as: A diagnostic, thera-
peutic or adjunctive invasive intervention performed by a trained
clinician, using hands, instruments and/or devices. Studies which
were not pilot/feasibility work or where the surgical intervention was
a co-intervention were excluded. It was rationalised that research
funded by the NIHR programmes would embrace the higher quality
methodological features necessary to identify the key design features
of interest and will have been peer-reviewed as part of the funding
process. Protocols for all included studies and the associated data
sources were collated, including, where available, published papers
from the pilot/feasibility work and the consequent main trial. A data
extraction form was developed and piloted a priori enabling elicit-
ation of the pilot/feasibility work rationale, and exploration of the as-
sociations of key design features of pilot/feasibility work with the
planning, conduct and outcome of any subsequent definitive main
trial.
Results
1341 studies funded by the HTA and rfpb NIHR programmes be-
tween 2005 and 2015 were identified and screened, with 73 (5.4%)
meeting the inclusion criteria. 30 (41%) were rcts with an internal
pilot phase and 43 (59%) were other feasibility work. This included
28 (65%) randomised pilot studies, 3 (7%) non randomised pilot stud-
ies and 12 (28%) other types of feasibility study, of which 8 (66%)
were systematic reviews. Further findings, including the rationale for
pilot/feasibility work and the associations of key design features with
main trial design and/or conduct, will be presented.
Conclusions
The findings will inform a qualitative study comprising in depth
semi-structured interviews and consensus methods to explore the
perceptions and experiences of key stakeholders involved in pilot/
feasibility studies of surgical interventions. This work is important to
develop future recommendations for the optimal design and con-
duct of pilot/feasibility work of surgical interventions.
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Background
Economic evaluation guidance states that resource use should be
valued using relevant unit costs. The most frequently used source for
valuing prescribed medication use in the UK is the British National
Formulary (BNF). However, from the perspective of the UK National
Health Service (NHS), it is not clear whether this source reflects the
true cost to the NHS.
Methods
The COMET study sought to determine the feasibility of conducting a
randomised controlled trial in young children with eczema. Children
were recruited from primary care and randomised to one of four
commonly used emollients. The study also explored the feasibility of
both collecting and costing the data required to perform an eco-
nomic evaluation in this setting. As part of this we explored whether
published prescribed medication costs from the BNF and Prescription
Cost Analysis (PCA) represented the true cost to the NHS. In order to
estimate the cost to the NHS we identified the method by which
community pharmacies are reimbursed for the medications they
Trials 2017, 18(Suppl 1):200 Page 8 of 235prescribe. Unit costs of the four intervention emollients were esti-
mated using this method and compared to unit costs from the BNF
and PCA. The total cost of study emollients prescribed over the trial
period were also estimated and compared using the different
methods.
Results
We identified a method for estimating the NHS cost of prescribed
medications dispensed by community pharmacists. This method in-
corporates the basic price of the medication, pharmacy discounts,
dispensing fees, payments for consumables and containers, and
other associated costs. The unit cost of all intervention emollients es-
timated using the alternative method were higher than costs listed
in the BNF and PCA. The largest difference in unit costs was for
Aveeno lotion, whereby the cost listed in the BNF and PCA was £5.33
and the cost estimated using the alternative method was £7.23. The
smallest difference was for Doublebase gel at £6.09 in the PCA and
£6.22 using the alternative method.
Conclusions
Using this method may lead to more accurate estimates of the true
cost to the NHS of prescribed medications, however assumptions
around pharmacy discounts were required to estimate costs. Estimat-
ing costs using this method is more time intensive when compared
to applying published unit costs from the BNF or PCA. Whilst using
this method for intervention medications can provide sensitivity ana-
lyses around intervention costs, the value added of using this
method to cost concomitant medications may be limited when con-
sidering the researcher time required.
The COMET study was independent research funded by the National
Institute for Health Research (Research for Patient Benefit
Programme, PB-PG- 0712–28056). The views expressed in the publi-
cation are those of the author(s) and not necessarily those of the
NHS, the National Institute for Health Research or the Department of
Health.
P18
Methods for extrapolation from clinical trial data to inform
economic evaluations: a taxonomy
Iryna Schlackow1, Alastair Gray2, Linda Sharples3, Chris Jackson4,
Nicky Welton5, Borislava Mihaylova2
1University of Oxford; 2Nuffield Department of Population Health,
University of Oxford); 3Leeds Institute of Clinical Trials Research,
University of Leeds; 4MRC Biostatistics Unit, Cambridge; 5School of
Social and Community Medicine, University of Bristol
Correspondence: Iryna Schlackow
Trials 2017, 18(Suppl 1):P18
Background
Lifetime economic evaluations are often performed alongside rando-
mised clinical trials, to incorporate long-term effects of interventions.
However, due to the limited duration of most randomised controlled
trials, extrapolation of components such as survival, beyond study
data is required.
Aim
To review extrapolation methods that are currently used in economic
evaluations and to provide a taxonomy of these methods while dis-
cussing motivation, advantages and limitations behind each ap-
proach in the context of a cost-effectiveness framework.
Methods and interim results
A pearl growing strategy was applied to identify manuscripts that
contained novel extrapolation methods, with the emphasis on
methods largely based on a single randomised clinical trial. Firstly, a
scoping search of the PubMed database was performed to identify
recent methodological papers. Subsequently, reference lists of in-
cluded manuscripts were checked, and finally, a panel of experts was
asked to suggest further potentially relevant published methods.
Method description was extracted using a pre-defined template. Ex-
tracted information included the context that motivated method de-
velopment (e.g. the need to incorporate cause-specific mortality);
type of data used for the extrapolation (e.g. from an RCT, general
population or a matched cohort); detailed statistical/modellingmethodology; comments on generalisability and usability (e.g. neces-
sary assumptions, incorporation of uncertainty and sensitivity analyses,
compatibility with a cost-effectiveness framework, implementation in
standard software); main strengths and comparison with other
methods. A reviewers’ opinion, based on a consensus between at least
two reviewers, was provided on whether the method accommodated
aspects commonly of interest in cost-effectiveness analyses, such as
heterogeneous population as well as the main driver behind the ex-
trapolated survival (eg major nonfatal adverse events).
Based on the identified manuscripts, and the reviewers’ comments, a
taxonomy of methods will be suggested, with methods classification
based on the main driver of survival (e.g. a single cause of death,
cause-specific mortality, non-fatal disease events or other disease
markers); underlying epidemiological disease model (e.g. Natural his-
tory of the disease and competing risks); and assumptions about the
treatment effect over time. Interdependence between these factors,
with the appropriateness, advantages and limitations of each ap-
proach and implications for performing cost-effectiveness analyses
will be discussed.
Conclusions
The choice of an appropriate method depends on a range of factors,
including presence of competing risks, specifics of the disease nat-
ural history and assumptions on the treatment effect. Care must be
taken in understanding the available options and their limitations
prior to embarking on extrapolation. The increase in availability of
relevant data is likely to contribute to emergence of novel ap-
proaches to support extrapolation efforts.
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Background
Cost-effectiveness analysis (CEA) of randomised controlled trials pro-
vide key evidence to inform health care decision making. Missing
data is a particularly challenging issue in CEA because a large propor-
tion of patients may not complete resource use or quality of life
questionnaires. Multiple imputation (MI) is commonly used to impute
the missing values by conditioning on the observed data, assuming
the data are “missing at random” (MAR). However, a major concern is
that the missing data are often related to the unobserved values, a
mechanism also known as “missing not at random” (MNAR). For ex-
ample, patients whose health is relatively poor may be less likely to
complete quality of life questionnaires, even after conditioning on
the observed data. Unless missing data are addressed appropriately
under transparent assumptions, CEA studies may provide misleading
estimates of effectiveness and cost-effectiveness, and potentially lead
to wrong decisions.
Aim
To provide an accessible framework to perform sensitivity analyses in
CEA of clinical trials with data missing not at random.
Methods
We first conducted a review of recently published CEA to assess the
extent of missing data and approaches commonly used to address
them. We also held discussions with various stakeholders (conduct-
ing or using trial-based CEA) to identify the main barriers and strat-
egies to wider use of these methods. Based on these findings, we
proposed a practical framework to conduct sensitivity analyses when
data are anticipated to be MNAR. We applied this framework to the
Ten Top Tips trial, which evaluates an intervention for weight man-
agement in primary care. This study illustrates a typical trial-based
CEA, in which key endpoints such as self-reported QOL are likely to
be MNAR.
Results
Our review provided further evidence that missing data was a com-
mon issue in trial-based CEA (median complete cases was 63%), and
Trials 2017, 18(Suppl 1):200 Page 9 of 235that sensitivity analyses under MNAR assumptions were rarely con-
ducted (4%). During our discussions with stakeholders, the main bar-
rier identified were the lack of practical guidance and software code
to perform such analyses. We found that the pattern-mixture model
was a desirable approach in CEA because it frames the sensitivity
analysis in terms of differences between observed and missing data,
which is readily understood by the different stakeholders. We illus-
trated how this approach can be easily implemented with standard
missing data methods such as MI, and provided a framework for con-
ducting sensitivity analyses under a broad range of assumptions. This
framework also addressed the elicitation of the plausible missing
data mechanisms, and the reporting of results. Application to the
Ten Top Tips trial showed that results can be very sensitive to the as-
sumptions about the missing data. For example, the intervention was
likely to be cost-effective under the MAR assumption, but appear not
cost-effective for some of the MNAR scenarios.
Conclusions
Missing data in CEA of clinical trials can result in misleading conclu-
sions. This study proposes an accessible framework to perform CEA
under a wide range of missing data assumptions, which will help fu-
ture studies provide more transparent and robust evidence to inform
decision-making.
P20
Value of sample information as a tool in clinical trial design
Anna Heath, Gianluca Baio
University College London
Correspondence: Anna Heath
Trials 2017, 18(Suppl 1):P20
The Expected Value of Sample Information (EVSI) quantifies the ex-
pected monetary value of a specific future trial. Theoretically, this
could be an important tool for trial design for two reasons. Firstly, it
would be possible to compare the monetary value of the trial directly
with its cost to determine whether the trial is worthwhile. More im-
portantly the EVSI could find the optimal trial design in terms of
monetary benefit by comparing the trial value and cost for different
trial designs.
Despite these useful features, the practical application of the EVSI in
trial design has been restricted due to computational issues. How-
ever, recently methods been developed to overcome these computa-
tional barriers allowing researchers to use the EVSI when designing
clinical trials. This will become more important as economic consider-
ations come to the forefront of decision making for Clinical Trials. We
will discuss the interpretation of the EVSI and how it can be used to
aid trial design by finding economically viable designs. We will then
discuss the recent computational advances for the EVSI that allow re-
searchers to use this tool in practice to aid their decision making.
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Background
Achieving and maintaining participant recruitment to clinical re-
search, and specifically, clinical trials in primary care, is known to be
challenging [1]. Experience gained from research supported by Keele
Clinical Trials Unit (CTU), shows that targeted Health Informatic (HI)
support early in the design phase of clinical trials may enhance the
conduct of research and improve recruitment and retention rates. A
collaborative approach involving Keele CTU and the NIHR Clinical Re-
search Network: West Midlands (CRN WM) in the use of HI has been
developed to embed clinical research within primary care settings.Background: Primary care infrastructure is complex and requires a
number of different strategies which are innovative, efficient and
transferable in order to successfully coordinate, recruit and retain
both sites and participants in primary care research.
Keele CTU is a registered UKCRC CTU, specialising in the develop-
ment and delivery of both feasibility and definitive multicentre ran-
domised clinical trials, an increasing portfolio of Clinical Trials of
Investigational Medicinal Products (CTIMPs) and epidemiology stud-
ies in both primary care settings and at the secondary care interface.
Keele CTU has a strong HI function, with over 12 years’ experience in
utilising primary care clinical systems and strong links with CRN WM.
CRN WM is one of 15 clinical research delivery arms of the NHS. They
are responsible for ensuring the effective delivery of research within
the primary care infrastructure throughout the WM area.
Methods
A joint HI Working Group (HIWG) between Keele CTU and CRN WM
has been established to oversee, develop, support, track and quality
assure the HI operational activity for research. A range of innovative
methods have been developed by the working group, which can be
embedded into existing GP clinical systems, to include; eligibility and
recruitment searches, data collection templates, pop-ups and elec-
tronic tools to aid referrals and clinical assessments. These methods
are tailored on a bespoke basis to the requirements of individual
clinical research teams to perform feasibility, identification, eligibility,
screening, recruitment, tagging and data collection functions and are
provided together with instructions for use.
Results
100% of Keele CTU supported research activity involving general
practices has utilised the HIWG. The groups’ innovations assist to imple-
ment a robust, standardised and automated method of performing re-
search activity in primary care settings. Greater precision of sample
identification, reduced paperwork and increased efficiencies can be
achieved, assisting with the retention of research participants, resulting
in accessible interrogation and interpretation of research data.
Conclusions
Whilst there is variability in CRN resourcing nationally, the HIWG
standardises the conduct of research in primary care settings, im-
proving consistency and engagement with the primary care research
infrastructure. Utilising GP clinical systems to embed research tools,
results in simple, efficient and effective methods for primary care
partners to conduct research. Scaling up of the HIWG over time will
allow the group to provide a service for other clinical research teams
conducting research in the primary care setting.
Reference
[1] Graffy J et al. Trials within trials - Researcher, funder and ethical
perspectives on the practicality and acceptability of nesting trials of
recruitment methods in existing primary care trials. 2010
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Background
The routine use of electronic patient records (EPRs) in primary care
provides opportunities and challenges for researchers conducting
clinical trials in this setting. Although the use of EPRs to search for
eligible patient populations is well established they can also be used
as a resource to improve trial conduct and quality. The Footprints in
Primary Care study is a feasibility study and pilot cluster randomised
trial exploring the acceptability of a GP practice level intervention for
frequently attending patients. Two key components of the interven-
tion are; increased continuity of care with a named GP, and delivery
of a psychosocial consultation technique called BATHE.
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Automated searches were set up within the EPR system in the four
intervention practices. These were designed to collect consultation
data, such as the number and type of consultations and name of
consulting GP, for patients eligible for the Footprints in Primary Care
study. Information on study GP use of the BATHE technique, denoted
by the GP adding a pre-specified read-code to the EPR when they
had used the technique in consultations with study patients, were
also collected. These automated searches were run in the practices
every 6 weeks during the 12 month intervention period and anon-
ymised data emailed to the research team. Consultations data were
also collected for the same patients for the 12 months prior to the
start of the study to provide a baseline comparison.
Results
The collection of data from EPRs at regular time points allowed the
research team to monitor intervention delivery whilst the study was
ongoing. This included assessment of the extent to which continuity
of care had increased and the reach and dose of the BATHE consult-
ation technique i.e. with how many patients had BATHE been used
and on how many occasions. This made it possible for issues with
intervention delivery, such as the low uptake of the BATHE technique
amongst GPs or difficulty booking appointments with the named GP,
to be followed up with study practice staff. Individualised feedback
could also be provided to practices during top-up training sessions
with the aim of improving intervention delivery. Furthermore the
positive impact of these training sessions could be demonstrated by
looking at subsequent EPR data.
Conclusions
Within the Footprints in Primary Care study the use of data from eprs
has been important for monitoring intervention delivery, reach and
dose, in providing feedback to participating practice staff, and in
helping to select a maximum-variation sample of staff and patients
for interview. This information, alongside qualitative interview and
observational data, has been instrumental to our understanding of
the feasibility and acceptability of the intervention. This approach
however is not without its challenges and further consideration is
needed regarding how the process of data collection and the colla-
tion of feedback would be delivered on a larger scale or in real-world
implementation.
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Developing procedures for biospecimen collection, processing, ship-
ping, and storage that yield high quality research samples and data
present many challenges in multi-center studies. Studies that require
real-time and batch shipments from clinical sites to numerous central
testing laboratories or biospecimen repositories increase the com-
plexities required to assure integrity of the biospecimens and related
data.
The data management development team in the Epidemiology Data
Center (EDC), Graduate School of Public Health, at the University of
Pittsburgh has designed a web-based Sample Tracking System (STS) to
streamline sample tracking and shipping from point of collection to
testing laboratories and repositories. The system is flexible, scalable,
and can be customized easily to meet the needs of individual studies.
Modules included in the STS are: entry and editing via barcode scan-
ner or keyboard, generation of shipping manifests, and receipt con-
firmation at the batch and sample level, with database audit trails for
all modules. Automated email notifications alert laboratory/repository
personnel of incoming shipments and clinical site personnel of ship-
ments received.
The STS can be implemented as a stand-alone system or integrated
with a data management system. It is efficient in regard to database
setup and implementation and is user-friendly and intuitive for siteand laboratory/repository personnel, facilitating smooth study
startup. It was designed to accommodate unlimited clinical sites, la-
boratory/repository destinations, sample types, and samples/aliquots
with minimal setup time or expertise on the part of EDC data man-
agement personnel. Data management personnel use administrative
tools to define study name, site codes, sample types, sample names/
titles, sample states (e.g. Frozen, ambient), barcode formats, labora-
tory/repository names, and protocol timepoints, and to define the re-
lationships among samples, studies, sites, and laboratories/
repositories. Optional settings are provided for default volume, vol-
ume/unit (ml, μg, slide, image), minimum and maximum volume/
unit, and earliest sample date. There are options to initialize barcodes
in the database and then utilize initialized barcodes to provide vali-
dations (e.g. Site, participant ID, sample type, timepoint) at the time
of sample entry. At the time of receipt of shipments, the system al-
lows receiving personnel to resolve issues and input comments at
the batch or sample level.
The STS is in use on several EDC projects and has facilitated
biospecimen-related processes, reduced data management effort for
system setup, maintenance, and monitoring, streamlined site and la-
boratory/repository sample-related processes, and has improved real-
time validations and the quality of sample-related data.
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The MS-Smart trial is a four-arm phase IIB randomised, double-blind
placebo controlled clinical trial comparing the efficacy of neuropro-
tective drugs in secondary progressive multiple sclerosis.
Treatment allocation is by minimisation without a site stratification
element. Participant follow up is over two years and each participant
has at least 6 post-randomisation clinic visits where trial drugs are
provided.
The cost of the trial drugs is significant so all reasonable steps should
be taken to limit oversupply at site leading to drug wastage.
Sending equal amounts of each of the four drugs to site pharmacies
leads to wastage as the treatment allocation method does not guaran-
tee a balance of allocated treatments among recruits at each site. In
addition, site pharmacies often have limited storage space and find it
difficult to accommodate deliveries of large volumes of trial drugs.
We propose that a more targeted approach to drug re-supply will ad-
dress these issues by both reducing the volumes of drugs delivered to
sites and at the same time reducing the amount of drug wastage. Utilis-
ing the central trial database allows us to identify exactly which post-
randomisation visits are upcoming at each site and to assign deliveries
to sites based upon this. So, if a site had a run of equal treatment allo-
cations then our supply algorithm will dictate that drug supplies at this
site six months later be weighted accordingly rather than issuing equal
amounts of each drug to the site. Using this mechanism will help plan-
ners more easily determine how many drugs will be needed for a trial
and allow them to reduce the amount of contingency required and
hence reduce the costs of running a drug trial.
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Background
The Robertson Centre for Biostatistics conducts and supports collab-
orative research in clinical trials through the design, conduct, analysis
Trials 2017, 18(Suppl 1):200 Page 11 of 235and interpretation of clinical trials and other well conducted studies.
The Centre’s staff consists of biostatisticians, database managers, soft-
ware developers, technicians, health informaticians, health econom-
ics, project managers and administrative staff contributing to some
120 clinical studies at present. Involvement in this volume of clinical
studies has led the Centre to identify a software solution to more ef-
fectively project manage our involvement in these studies whilst sup-
porting the requirements of the Centre’s internal Standard Operating
Procedures (sops) and Good Clinical Practice (GCP).
Methods
Over the past 6 years the Centre, in consultation with staff, has cus-
tomised and developed an MS sharepoint site to manage key project
information and activities relating to clinical studies including: Project
planning and management; Change management; Document con-
trol; Study communication; Management reporting
The MS sharepoint site has been further developed to support: Func-
tional areas; Archival; Audit Management; Centre Communication;
Risk Management
Conclusion
MS sharepoint has been a key tool in providing a consistent ap-
proach to managing projects however, it has been recognised that
the system should continue to evolve in order to meet changing
regulatory and Centre requirements.
The Centre continues to identify other areas where MS sharepoint
could be used to aid process and quality improvement.
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Background
The ICR-CTSU introduced electronic data capture (EDC) in 2012. This
necessitated development of a solution to automatically monitor
electronic case report form (ECRF) completion and track timely com-
pletion of ECRFs.
Challenges
Prior to the introduction of EDC, sites posted paper CRFs to the ICR-
CTSU. Once received, CRFs were manually tracked onto an ICR-CTSU
legacy system which also provided CRF compliance reports. With the
introduction of EDC, a solution was required to record real-time com-
pletion of ECRFs within the EDC system and to calculate ECRF com-
pliance data for review and reporting purposes.
Solution
A two part solution was developed:
1. Schedule forms were created within the EDC clinical database.
These forms display details of ECRF expected and completed dates
per trial participant for every visit and form (dependent on the par-
ticipant’s treatment allocation and pathway within the trial). The ex-
pected date of each ECRF can be calculated from any date field
captured within the EDC system and is tailored as needed depending
on requirements for each individual ECRF. The ECRF completed date
uses a standard ECRF field “date form submitted”. As forms are com-
pleted by site staff, ECRF completion progress can be viewed in real-
time on the schedule forms.
2. An in-house C#.net Windows application was developed for use by
ICR-CTSU to read the schedule form data from the EDC system and
calculate ECRF compliance data as required. Compliance data can be
provided per trial to produce outstanding ECRF reports for provision
to site and to review ECRF response rates by form and participating
site.
Conclusion
This solution provides a real-time automatic ECRF tracking system
that allows central review of ECRF compliance data as required. The
user-friendly schedule forms within the EDC clinical database alsoassist trial staff at sites with monitoring expected ECRF completion
time points for individual trial subjects.
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Background
Electronic medical records (EMRs) are now frequently used for col-
lecting patient-level data for clinical trials. With the Veterans Affairs
(VA) Healthcare System, EMR data have been widely used in clinical
trials to assess eligibility and facilitate referrals for recruitment, and
to conduct follow-up and safety monitoring. More recently, the EMR
is being used for point-of-care randomization trials and for conduct-
ing trials from central location. Despite the great potential efficiency
of using the EMR, it is of interest and importance to evaluate the in-
tegrity of data captured from the EMR through a centralized monitor-
ing algorithm without involvement of research personnel compared
to that collected by local investigators or coordinators under protocol
conditions. This investigation assesses the verification of safety data
collection.
Design
The VA NEPHRON-D study was a multi-center, double blind, ran-
domized clinical trial to assess the effect of ACEI and ARB combined
vs. ARB alone on the progression of kidney disease in individuals
with diabetes and proteinuria. The safety endpoints of the trial in-
cluded serious adverse events (SAE), acute kidney injury (AKI),
hyperkalemia and mortality. A subset of the participants (~62%)
who enrolled in a long-term follow-up substudy were consented for
data collection via the EMR. For those participants with consent,
data accumulated in their medical records during the study period
were extracted from the VA Corporate Data Warehouse (CDW). We
accessed the CDW centrally, captured the safety data and com-
pared these records with those collected by the study personnel at
VA Medical Centers participating in the VA NEPHRON-D trial. This
assessment examines both general and study-specific safety end-
points, and more importantly, provides evidence for how to use ex-
tracted EMR data for documenting SAE and study outcomes in
futures studies.
Result
Hospital admission data were obtained from CDW's acute care,
extended care, and observational care records. Study-collected
SAEs were consolidated into a single hospital stay for comparison
with EMR records. A high level of matching was found using the
CDW to verify SAE reported during the active trial for hospital ad-
missions within the VA healthcare system. Hospitalization records
that were stored as scanned notes from non-VA admissions were
not included as CDW records, which is an issue that still needs to
be addressed for obtaining a more complete data collection. Also,
identifying individual SAEs during the same hospitalization stay
requires further investigation. AKI was a major safety endpoint in
the study. Different definitions of AKI based on ICD-9 codes and
change of creatinine during hospitalization were applied in the
CDW data searches. The search results varied significantly de-
pending on the AKI definition applied. Likewise, hyperkalemia
identified by the CDW laboratory datasets had some discrepan-
cies from the active trial setting where diagnosis of hyperkalemia
was a combination of potassium level and other clinical factors.
Details of the comparisons for each safety endpoint will be
presented.
Conclusion
This investigation identifies several factors that affect the quality of
EMR-mediated safety data collection compared to active study condi-
tions and establishes the importance of an additional level of clinical
review of EMR data.
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Background
The purpose of the data-related components of an FDA regulatory
submission is to enable an FDA reviewer to understand the clinical
trial data that was collected, check the consistency of the data,
understand how analysis datasets were produced, and recreate se-
lected analyses.
Our experience is based on using the Clinical Data Interchange Stan-
dards Consortium (CDISC) standards (http://www.cdisc.org/) for pre-
paring regulatory submissions for 3 trials totalling 65,000 randomized
participants. Study Data Tabulation Model (SDTM) datasets represent
trial data in a standardised form. Analysis Data Model (ADAM) data-
sets are derived from SDTM datasets, and represent data in a form
that is easy to analyse and report on. ‘define.xml’ documents contain
metadata for SDTM and ADAM datasets. Brief guidance notes accom-
pany the datasets, explaining anything that cannot be understood
using the metadata.
Steps
The main tasks involved in producing these items are: − Assess how
collected data maps to SDTM datasets and outline this in annotated
case report forms (CRFs). - Decide which ADAM datasets are needed
for analysis, based on the Protocol and Data Analysis Plan. - Trans-
form SDTM data into relevant ADAM datasets. - Generate ‘define.xml’
metadata documents. - Validate all datasets and metadata, correcting
or documenting errors. - Produce guidance notes for the SDTM and
ADAM datasets.
We use bespoke software tools for these steps (except validation,
which is performed using industry standard software).
Software
SDTM and ADAM datasets are stored in a relational database. Data-
sets are defined and produced using a domain-specific language that
permits XML elements to be associated with parameterized units of
software which generally perform SQL code generation (which can
be executed to perform a data transformation), but which may also
do other things, such as the generation of documents. Some exam-
ples are: − Conversion of units for a defined set of lab results, while
checking that there are no unexpected combinations of lab test and
units. - Estimating dates from partial dates and upper and lower
limits. - Generating CDISC define.xml documents.
The core language has a small codebase (approx. 2000 lines of code)
and few non-standard dependencies. Most of the functionality of the
system is expressed in well-documented parameterized units
(approx. 4000 lines of code). An automated test suite (approx. 4000
lines of code) verifies the functionality of each unit.
Conclusion
Bespoke, modular and light-weight tools were useful during the de-
velopment of our process for generating regulatory submission pack-
ages because these tools are rapidly adaptable. The automated test
suite helps prevent changes from having unanticipated conse-
quences. From the perspective of programming and data modelling,
the CDISC standards have some limitations which could be readily
addressed in future versions of the standards.
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Objective
The objective is to devise solution approaches given the scenario
where, despite all best security practises being employed there existsthe possibility that malicious parties could still gain access to some
element of the system architecture, how can systems be designed to
detect malicious activity by legitimate but compromised user, appli-
cation or system accounts? Furthermore the question - when mali-
cious activity is detected, what automated and external processes
should occur must be explored.
Background
There is numerous security measures that can be employed to safe-
guard online systems, however due to the complex layered architec-
ture of today’s applications there are various potential weak points.
While following best practices should reduce the risk of malicious
parties gaining access to systems, often there are financial or bureau-
cratic obstacles to following best practices. Keeping all software and
hardware components maintained with current patches represents a
considerable amount of work and cost. Despite all this effort there is
always the potential of previously unknown zero day exploits being
discovered, new strains of malware being created and a dizzying
array of new ways to trick computer users into disclosing their cre-
dentials or granting access to third parties. An intrusion detection
system (IDS) monitors a network or systems for malicious activity or
policy violations. The use of an IDS, or combination of different IDS
systems are generally considered best practice. There are very di-
verse approaches to IDS implementation ranging from configurable
rule based systems to machine learning adaptive systems therefore it
can be advantageous to employ more than one IDS. An IDS is an im-
portant security tool however they are of limited use if a malicious
party compromises a system account and performs similar actions
e.g. Accessing the trial database. Worse still an IDS is entirely blind to
application level activity as most web applications utilise a single sys-
tem account to perform all actions.
Method
We propose integrating simple IDS methods into the application and
database layers. By identifying simple activity rules to identify un-
usual usage the application and database can react in an appropriate
manner based on the associated level of risk.
Conclusion
The authors will present an overview of IDS style methods suitable to
clinical EDC systems, how to implement them and how to structure a
framework for responding to them.
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To facilitate the comparison of patients and results by providing a
standardized guidance on how data should be analyzed for therapy,
response criteria for non-Hodgkin lymphoma (NHL) were published
in 1999 by an international working group (IWG). The revision for
both NHL and Hodgkin lymphoma (HL) was published in 2007 to in-
corporate PET and bone marrow biopsy in response assessment.
After years of experience with the 2007 criteria and recognizing the
imaging technique progress, the 2nd revision called the Lugano clas-
sification was published in 2014 to assess lymphoma therapeutic re-
sponse in clinical trials. The Lugano guidelines have enhanced
interpretation of CT assessment, imaging schedules, and PET scoring
implications, rules for handling missing anatomy and challenging
scenarios for the given therapeutic under investigation. The Lugano
classification provides a renewed opportunity to guide lymphoma
diagnosis and clinical management based on imaging findings. The
new criteria also have been increasingly adopted in many lymphoma
trials since its publication. Nevertheless, certain aspects of the new
criteria lack sufficient detail for explicit interpretation and a few fea-
tures open to potential pitfalls which need particular attention and
further discussion. For instance, the five-point scale (5-PS) for FDG-
PET assessment was incorporated to evaluate tumor metabolic re-
sponse assessment in FDG-avid lymphoma types, but the 5-PS,
Trials 2017, 18(Suppl 1):200 Page 13 of 235copied from Deauville criteria, relies on a vague description of quali-
tatively assessing “Change of the hottest lesion” And no definitive
guidance on “Significant change in FDG uptake”; moderately/mark-
edly higher than liver or whether quantitative uptake measurements
are allowed as the cut-off reference for the score 4 or 5; beside of
the imaging scan window, imaging findings on CT and FDG PET-CT
can be rarely conflicting. In addition, progressive disease with regard
to splenomegaly assesses response with regard to both the baseline
and to ‘prior increase’ which, if interpreted one way, can lead to ex-
treme enlargement without progression. On the other hand, spleno-
megaly can be caused by lymphoma-unrelated causes such as portal
hypertension or use of hematoietic growth factors which make a
question if splenomegaly alone can be used to define the progres-
sive disease. To provide the most accurate assessment of response to
therapeutic intervention, it is essential that trial oncologists and radi-
ologists not only have a tangible understanding of the Lugano Classi-
fication, but also proper insight into the practical limitations of the
criteria. We will review the essential elements and provide few exam-
ples to illustrate the limitations and ambiguity that can arise from dif-
ferent interpretations of the Lugano classification. Furthermore, some
suggestions will be made to stimulate further improvement in clinical
trial settings.
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Problem
Trialists often feel that the release of a validated database is a limit-
ing factor in the timeline of opening a clinical trial. There is an inher-
ent tension between (i) the desire to be able to change requirements
(such as Case Report Forms, eligibility and validation checks) as late
as possible and (ii) the need for those requirements to be finalised
early on so that development and testing can take place. We will de-
scribe several approaches we have taken to address this dilemma.
These focus initially on technical solutions, using our bespoke clinical
data management system, developed using MS SQL Server and.NET.
We will then expand to look at how these can be enhanced with
process changes. This has led to a culture change resulting in much
wider participation in the database development project, a livelier
dance with more partners on the dancefloor.
Our approach
The technical solution concentrates on auto-generation. In our
model, Excel is used to document the user requirements as meta-
data. This allows users to engage with a familiar tool to specify con-
ditions in a structured method. Once reviewed and finalised, the
spreadsheet is uploaded into the database and the metadata is used
to generate the database tables, triggers and procedures that pro-
vide the necessary functionality (such as audit trail, query generation,
etc.). The metadata also provides the input to a customised code
generator which produces the front-end code for data entry screens
and validations. Common code modules and standard field names
produce a consistent interface, with core functionality and generic el-
ements that can be easily reused across projects. The tempo of the
dance for the database developers moves from a waltz to a quick-
step. We have also looked at development methodology, moving
away from waterfall approaches and adopting elements of agile pro-
ject management and development into our processes. Key to this is
the phased approach, concentrating on what needs to be included
in the initial release and keeping to firm release dates, prioritising
the product backlog for each release. Self-organising teams, feasible
in larger trials units, bring more resource to a project at critical
timepoints. Workshops with the trial team help with metadatadevelopment and encourage ownership. Rapid coding approaches,
using group sessions and peer review, and group testing sessions,
implementing fixes in real-time, have also been implemented to ac-
celerate progress. The more agile dance is now perhaps a casual
group samba, involving developers, data managers, data scientists,
and business analysts.
Discussion
Ultimately though, there is a limit to how fast you can dance. The
culture change needed requires much earlier penetration into the
trial project timeline, looking at team resourcing and key decision
timepoints. Involving the database team at the earliest stages helps
with understanding how the proposed trial flow can best be imple-
mented, and with prioritisation of agreements needed for timely de-
livery of the validated database. The dance becomes a unit-wide
quadrille, with multiple partners and movements. Or, maybe more
appropriately for this conference, a ceilidh!
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Writing of a manuscript, abstract, or other document in a research
environment is a collaborative effort which oftentimes involves indi-
viduals from academia, industry, and government agencies. Topics
are proposed and must be managed according to study timelines
and may require considerable time and resources to track over the
course of a study. The data management development team in the
Epidemiology Data Center (EDC), Graduate School of Public Health,
at the University of Pittsburgh has designed a web-based Presenta-
tions and Publications System (PNP) to streamline work flow, provide
a repository for completed works, and facilitate tracking and report-
ing of the presentation and publication process.
The system is comprised of a Pre-proposal module, which allows
users to quickly enter potential topics, and a Proposal module, which
begins when a more fully developed topic is submitted.
The Pre-Proposal module facilitates sharing topic ideas and allows
topics to be ranked and prioritized. Potential collaborators use this
module to indicate an interest in participating in a writing group. Ap-
proved topics are moved into the Proposal module for development
into an abstract, manuscript or preliminary analysis proposal.
The Proposal module is used to submit a more detailed description
of the topic, set priorities for the proposal, and track and manage
the activities and content. The main page of the Proposal module
provides access to all abstracts, manuscripts, and grant proposals
submitted for the project and contains key information such as the
status of the proposal and the latest activity. Proposals are managed
via a tracking page, which has tabs for the submitted proposal form,
summary information (e.g. Stage and status of the proposal), detailed
proposal tracking activities, and a reference library. Proposal activities
are grouped into pre-defined categories (e.g. Writing group, re-
viewers, scientific meetings, and journals); these categories are also
available as individual tabs to allow reporting all manuscripts in a
particular category.
The PNP system was designed to allow the user to quickly configure
the system based on the study’s requirements through a set-up wiz-
ard. The wizard does not require that all elements be pre-defined,
but allows the users to configure the system throughout the process.
Reports created in Crystal Reports or SAS are supported by the PNP
system and allow the users to create customized reports at the pro-
ject and proposal level. Access to the PNP system is restricted ac-
cording to a user’s project role and permissions assigned.
In summary, the PNP system is a tool that can help to organize the
process of writing a manuscript, abstract, or research grant while re-
ducing the personnel time and effort needed for communication and
coordination among the collaborators.
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Background
The value of Patient and Public Involvement (PPI) in trial oversight is
increasingly recognised; at present it is a requirement for most UK re-
search funding bodies to involve PPI members in Trial Oversight
Committees (TOCs) including Trial Steering Committees (TSCs) and
Trial Management Groups (TMGs). However, there is little evidence-
based guidance to optimise their roles and inputs. The actions and
experiences of TOC members including PPI representatives were cap-
tured to inform recommendations about enhancing PPI contribution
to trial oversight. This was carried out within the context of a larger
multi-method study which aimed to explore the role and function of
TOCs, and their contribution to trial conduct.
Methods
TOC meetings of eight large phase III UK trials that were undergoing
challenges (e.g. Recruitment issues, protocol deviation or amend-
ments) were observed by a qualitative researcher and audio-
recorded. Interviews explored PPI in interviewees’ trials and where
they thought PPI contributors were best placed. PPI representatives
also reflected on their personal experience of TOC meetings, their
understanding of their roles and how they felt they had influenced
trial conduct. Data (meeting transcripts, field notes and interview
transcripts) was analysed thematically using techniques of constant
comparison.
Results
Seven TSC and six TMGs (n = 13) were observed and six of the meet-
ings had PPI present (3 TSC, 3 TMG). Sixty-six semi-structured inter-
views were carried out with fifty-two members of these TOCs which
included three PPI representatives.
Analysis revealed the importance interviewees placed on the role
of PPI to provide a patient voice within trial oversight. PPI was gen-
erally favoured within TOCs, but several tensions arose relating to
meaningful PPI implementation at TSC and TMG levels. Lack of clar-
ity about what PPI is and whether it was needed led to inclusion of
those representatives who, perhaps, were not best equipped with
the appropriate skills, experience and attributes. Representatives
who lacked detailed knowledge or familiarity with trial method-
ology and technical language found it difficult to understand and
contribute to meetings. Interviewees felt it was important when
selecting representatives to consider whether they truly had em-
pathy for the trial population or had possible ‘hidden agendas’.
Consideration of PPI representatives’ commitments and circum-
stance outside of trial oversight was important for ongoing engage-
ment and attendance. Participants saw a need for training and or
mentoring of PPI representatives to foster appropriate involvement
and contribution. However, there was no clear consensus of who
was or should be responsible for enabling or providing such train-
ing and support.
Conclusion
To truly enable PPI representatives to speak on behalf of patient or
public voice and ensure meaningful contributions of such represen-
tatives within trial oversight, more thought needs to be given to de-
signing the involvement of PPI in TOCs. This includes clarification
around roles and what would constitute optimal involvement at dif-
ferent oversight levels and stages of trials. To ensure ongoing worth-
while PPI, training and support needs of contributors needs to be
reflected upon and provided, and consideration needs to be given to
PPI selection and TOC meeting conduct to ensure attendance and
engagement is maintained.P34
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Background
The NIHR (National Institute for Health Research) is the research arm
of the NHS and is the most integrated clinical research system in the
world. It invests about one percent of the NHSD budget in research
to improve the health and wealth of the nation.
The NIHR funds the RDS (Research Design Service) to provide design
and methodological support to health and social care researchers
across England to develop grant applications to the NIHR (Programme
Grants for Applied Research, Research for Patient Benefit, Health Tech-
nology Assessment, Public Health Research, Invention for Innovations,
Health Services and Delivery Research etc.) And other national peer-
reviewed funding programmes.
The RDS is a national service delivered by ten regions covering England.
NIHR RDS (research design service) expertise
Methodological advice is provided to researchers by teams of Ad-
visers whose expertise includes statistics, qualitative research
methods, health economics, systematic reviews, health psychology
and behavioural science.
The RDS has an important role in referring individuals to appropriate
sources of advice, outside of the RDS, where appropriate. For ex-
ample, referrals to those with specialist expertise in intellectual prop-
erty or to a local Clinical Research Network for practical help in
identifying and recruiting patients to studies.
Public involvement in research
The RDS has been at the forefront of the NIHR drive to ensure that
members of the public play an important role in developing success-
ful grant applications. The RDS has been particularly active and pio-
neering in the area of Public Involvement, from design of the
research study through to dissemination of research findings.
The RDS recently worked in partnership with the Wessex Institute,
University of Southampton on a successful bid to host INVOLVE
(funded by NIHR to support active public involvement in research).
The expertise and regional networks of the RDS were recognised as
an important component of the partnership.
NIHR RDS metrics
The RDS remit includes increasing the quality and quantity of re-
search applications. Since 2009, the RDS has supported:
17,949 projects, 2,705 outline applications submitted with 1,111
shortlisted (43% success rate), 6,432 full applications submitted with
2,209 funded (36% success rate).
The RDS also provides triage for under-prepared or misplaced fund-
ing applications. Thus, reducing waste in terms of the time and re-
source used by NIHR funding programmes to review poor quality
applications.
One NIHR
The RDS is recognised as the ‘local face of the NIHR’. It has become
an intermediary between national NIHR structures (Collaboration for
Leadership in Applied Health Research and Care (CLAHRC), Clinical
Research Networks, Clinical Trials Units, Biomedical Research Centres
and NHS Trust R&D etc.) and local investigators and organisations.
The RDS has often facilitated local partnerships, to pursue ‘One NIHR’.
It has brought together various components of the NIHR at local and
regional levels, to share good practice, look for efficiencies of delivery
and to enable investigators and organisations to have a more
streamlined access to support and advice.
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opment have been well-recognized in Japan since the ICH-E9 guide-
line “Statistical Principles for Clinical Trials” Was implemented in
1998, where the guideline helped trigger the revelation that there is
a shortage of qualified statisticians who can comprehend and imple-
ment the principles outlined in the guideline and improve the quality
and integrity of the trials being conducted. Although the number of
educational programs for Master and phd level biostatisticians at uni-
versities have been greatly increased during the last two decades, at
this period, the supply of new graduates in biostatistics in Japan is
relatively steady while the demand is increased dramatically.
Different level of efforts including government, society, university, and
industry have been devoted to increasing the number of “qualified”
biostatisticians in Japan, and in October 2016, Japan Agency for Med-
ical Research and Development (AMED) have decided to fund the two
universities, Kyoto University (KU) and University of Tokyo to develop a
new program for training the next generation biostatisticians with em-
phasis in clinical trials, under the public and private partnership with
the Japan Pharmaceutical Manufacturers Association (JPMA). Each of
two universities formed the alliance to develop the program: KU with
KU Hospital and National Cerebral and Cardiovascular Center (NCVC),
and UT with UT Hospital and National Cancer Center.
In this presentation, we briefly review the current issues in MPH-level
biostatistical education and training in Japan, and outline our plan and
activities for developing the educational and training program for the
next generation biostatisticians. Our developed program is very unique
to combine the two learning approach to gain skill and knowledge of
clinical trials-related biostatistics: learnings (i) by being taught, by study-
ing it, or by researching it through structured courses/modules at KU
School of Public Health and (ii) by experiencing it in practical situations
(i.e., On-the-Job (OJT) Training) at KU Hospital or NCVC. We describe
our developed OJT training program at NCVC.
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We discuss logrank test-based methods for early efficacy or futility
evaluation in group-sequential clinical trials designed to compare
two interventions using two time-to-event outcomes. We consider
three typical situations (1) both events are non-composite and non-
fatal, (2) both events are non-composite but one event is fatal, and
(3) one event is composite but other is fatal and non-composite. We
outline strategies for rejecting the null hypothesis associated with
two inferential goals, evaluating if a test intervention is superior to a
control intervention on: (1) both outcomes (multiple co-primary end-
points: MCPE), and (2) at least one outcome (multiple primary end-
points: MPE). We provide an example to illustrate the methods and
discuss practical considerations when designing these trials.
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Background
Patients’ health outcomes and experiences are often measured using
validated questionnaires. Responses are usually scored and valuesover a certain threshold can be interpreted as clinically meaningful
or “problematic”. Standard methods to identify such thresholds re-
quire an established reference standard and the use of receiver oper-
ating characteristic (ROC) curves. We have developed a new
questionnaire to assess wounds for surgical site infection (SSI), with a
view to it being used as an outcome measure in a future trial. Valid-
ation, however, is challenging because the diagnostic accuracy of the
established reference standard is imperfect and estimates of sensitiv-
ity and specificity may therefore be biased. The aim of this study is
to explore the clinical validity and measurement properties of the
new measure in the absence of a “gold” standard.
Methods
A 16-item questionnaire assessing signs, symptoms and interventions
potentially indicative of SSI was developed using standard methods.
Patients undergoing general abdominal surgery and women under-
going caesarean section were recruited from three UK hospital trusts.
Participants were sent the new questionnaire to complete approxi-
mately 30 days after surgery and return by post (self-assessment).
Short “debriefing” questions to assess ease of completion were in-
cluded. Healthcare professionals attempted to contact participants
approximately 30–35 days after surgery and complete the new ques-
tionnaire via telephone (observer assessment). A proportion of partic-
ipants (limited by study resources) were seen face-to-face 4–8 weeks
after surgery and classified as having an SSI or not using the Center
for Disease Control (CDC) classifications for wound infection (refer-
ence standard). These assessors were blinded to participants’ self-
assessment and observer assessment. Analyses, which are ongoing,
will: 1) compare participant (self-assessment) and healthcare profes-
sional (observer assessment) responses, 2) examine the sensitivity of
the questionnaire for identifying symptoms compared to similar cri-
teria in the reference standard, 3) test a clinician-lead hypothesised
scale structure and scoring system for determining SSI outcome, 4)
examine the discriminative ability of the questionnaire to identify po-
tential SSI “problems” Using a set of receiver operating characteristic
(ROC) curves and 5) assess the reliability of the questionnaire.
Results
416 participants were recruited. Participants completed and returned
300/414 (72.5%) questionnaires (self-assessments). Healthcare profes-
sionals successfully contacted 306/414 (73.9%) participants and com-
pleted questionnaires via telephone (observer assessments). Face to
face assessments were made for 115 (27.7%) participants (reference
standard). Participants found the questionnaire quick and straightfor-
ward to complete, with few missing data. Initial analyses of partici-
pant and healthcare professional responses show that symptoms are
reported a little more severe in self-assessments compared to obser-
ver assessments; a consistent trend observed for all eight symptom-
related items. Other planned analyses are ongoing, pending add-
itional data from a pilot RCT where all participants (n = 330) were
scheduled to receive a reference standard assessment.
Conclusion
Examination of the clinical validity and measurement properties of a
new SSI outcome measure is ongoing. Different thresholds for SSI
“problem” scores may be needed when assessments are made by
participants or healthcare professionals. Qualitative work to further
understand the difference in agreement between participant and
healthcare professional reports of symptoms would be beneficial.
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Background
A systematic review published in 2014 [1] identified 198 published
core outcome sets (COS) and a recent update found that this figure
had increased to 227 by the end of that year [2]. The details of these
Trials 2017, 18(Suppl 1):200 Page 16 of 235COS, along with others that are planned and in development, are re-
corded in the COMET (Core Outcome Measures in Effectiveness Tri-
als) database. As the number of COS grows, it is important to assess
their uptake by clinical trialists because the continued development
of COS, without their implementation, could add to waste in re-
search, and would mean that those using the results of trials to make
decisions about healthcare will not realise the benefits that using
COS can provide.
In January 2012 the guidance for NIHR HTA funding recommended
‘details should include justification of the use of outcome measures
where a legitimate choice exists between alternatives. Where estab-
lished Core Outcomes exist they should be included amongst the list
of outcomes unless there is good reason to do otherwise. Please see
The COMET Initiative website at www.comet-initiative.org to identify
whether Core Outcomes have been established.’ This study will as-
sess the extent to which this recommendation has been followed by
NIHR HTA applicants from January 2012, when the recommendation
was introduced, to December 2015.
Method
The completed application form and detailed project description of
each NIHR HTA application will be examined for:
Evidence that the COMET database had been searched to establish
whether or not a COS exists
Reference to a COS study published in the COMET database
Evidence that a COS was included in the application if one exists
Evidence that a COS was not included in the application where
one exists
Reasons given for not including a COS where one exists
Rationale for outcome choice in the absence of a COS
Analysis
Following extraction of the above data, the following analysis will be
performed:
– Assessment of the number and proportion of NIHR HTA
applications referencing the COMET database or a COS
published in the COMET database
– Assessment of the number and proportion of NIHR HTA
applications using a COS, if one exists, in their research
These assessments will be used to draw conclusions about the po-
tential impact on the use of COS of a research funder’s recommenda-
tion about their use.
Results and Conclusions
Results and conclusions will be presented following examination
of all funded and non-funded applications to the NIHR HTA
researcher-led, commissioned and themed call funding streams
from January 2012 to December 2015 (n = 281). The sample con-
sists of applications for both randomised trials (n = 189) and evi-
dence syntheses (n = 92).
References
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Composite outcomes are often reported in randomised controlled tri-
als, particularly for safety endpoints. Use of a composite endpoint
can allow a study to provide information about safety when the rates
of component adverse events are low, but risks aggregating events
that are not affected by the intervention. We undertook a literature
review to explore the variability in composite outcomes used in car-
diac surgery studies, to inform the development of an objective
measure of recovery.
Methods and results
All published articles reporting at least one short-term composite
outcome assessed within three months of cardiac surgery were
identified. One hundred and fifty four papers were identified,
reporting 166 composite outcomes; 64 different adverse events
were included across the composite outcomes. Death was a com-
ponent in the majority of composites (135/166, 81%), as were
cerebrovascular events (105/166, 63%), myocardial infarction (MI)
(81/166, 49%), renal failure/acute kidney injury (AKI) (78/166, 47%)
and reoperation/revascularisation (42/166, 25%). Two “established”
composite outcomes were identified in the review, Major Adverse
Cardiac Events (MACE) and Major Adverse Cardiac and Cerebro-
vascular Events (MACCE), but the definitions for both differed
across studies. Assuming MACCE includes death, cerebrovascular
events, MI and reoperation/revascularisation, 16/166 composites
included these four components; 12 of these 16 also included
other adverse events, suggesting that the currently used compos-
ite outcomes are based on, but not restricted to, existing MACCE
definitions. Other adverse events that were commonly included
together in composite outcomes were renal failure and death/
cerebrovascular event, and prolonged ventilation and death/cere-
brovascular event.
The majority of composite outcomes were binary outcomes (any
event vs. none) that gave equal importance to all components.
Two studies investigated the relative weighting assigned to ad-
verse events in MACCE, both among patients and one among
trialists, and reported that respondents assigned different weight-
ings to each of the adverse events within the composite. Differ-
ences between the weightings assigned by patients and clinical
trialists were also reported, with patients rating MI and stroke the
same as or worse than death, but trialists rating death as the most
severe.
Discussion
This review has highlighted the variability in the way composite
outcomes for cardiac surgery studies have been defined. The
range of events included supports the need for the development
of a composite outcome including a range of adverse events to
give a more complete picture of recovery. Furthermore, these
findings support the need for composite outcomes to incorporate
weightings, particularly when adverse events differ in their impact
on patient recovery, and for the views of both patients and clini-
cians to be considered when assessing the relative importance of
different adverse events if the composite outcome is intended to
give an overall assessment of recovery. Variation was seen in the
definitions used for some events (e.g. renal failure) across studies;
there is a need for consistent definitions to be agreed to aid syn-
thesis of results from different cardiac surgery studies in meta-
analyses.
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Most contemporary methods in the field of surrogate endpoint
evaluation involve assessing the degree to which average treat-
ment effects on the surrogate and true endpoints are correlated
(i.e. The trial-level surrogacy), using data from a (generally) small
number of randomized clinical trials RCT). Because the number of
relevant clinical trials is generally small, these methods may pro-
duce estimates of trial-level surrogacy that are highly variable. To
this end, we consider the evaluation of potential surrogate end-
points within a personalized medicine framework. In particular, we
consider a two-step procedure. In step 1, the surrogate and true
endpoints are modeled as a function of treatment received, and
other patient characteristics. Using these models, we obtain esti-
mated, conditional (on patient characteristics), subject-specific
treatment effects on the true and potential surrogate endpoints for
each patient. In step 2, the estimated, subject-specific treatment ef-
fects on the true endpoint are modeled as a function of those on
the surrogate endpoint using linear regression, and the trial-level
surrogacy is estimated using the R-Squared from this model. Pre-
liminary simulation studies suggest that, in many cases (when ap-
propriate models are selected for the surrogate and true endpoint,
and when certain other assumptions hold), this estimate of trial-
level surrogacy has dramatically lower variance than some more
traditional estimates of trial-level surrogacy.
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Background
Falls are a substantial health risk in older people. The collection of ac-
curate falls data is problematic within clinical trials at several levels1.
In particular there are issues with reporting falls when these events
are associated with recall bias. Different data collection methods
have been proposed to minimise bias. In the prefit trial2 we per-
formed a study within a trial (SWAT3) to compare two common
methods’ daily falls diaries and retrospective reporting within quar-
terly questionnaires. Swats are an increasingly popular method to in-
vestigate uncertainties faced by researchers when conducting and
designing randomised controlled trials.
Methods
The prefit trial recruited community dwelling older people from pri-
mary care. We compared alternative falls reporting methods to assess
the impact on the likelihood of response, prevalence and pattern of
missing values, and agreement between data sources. We also com-
pared baseline participant characteristics by completion status. Par-
ticipants were asked to complete a four month period of prospective
fall diary completion; participants were randomly allocated to one of
the periods (baseline to 4 months, 5 months to 8 months or 9 months
to 12 months). Falls diaries were produced in a calendar format,
posted to participants in a pack of four, with a covering instruction
letter. Participants also completed follow-up questionnaires, contain-
ing a retrospective question on number of falls in the preceding
months at 4, 8, 12 and 18 months post randomisation.Results
A total of 9375 participants were requested to complete diary cards over
the three time periods. Generally, diaries were well completed with 69%
of participants completing all four diaries, and 83% completing at least
one diary card. Completion rates were consistent across each of the three
time intervals. There was a small but statistically significant increase in the
proportion of people not returning a diary over the three successive time
periods (p < 0.001). Those allocated to complete diary cards were more
likely to withdraw from follow-up questionnaires than those not allocated
to complete diaries in the same 4 month period. This was a small but con-
sistent effect over the entire study (difference in rates of ~2%). In those
participants who returned all diary cards and a corresponding question-
naire, falls were underreported in the questionnaire. People who returned
no diaries were older, had poorer levels of physical and mental health,
and had poorer cognitive function as well as a higher number of falls and
fractures reported in their corresponding follow up questionnaires.
Conclusions
This SWAT provides evidence that allocation to complete prospective
diary cards alongside four-monthly retrospective postal questionnaires
has a small but significant effect on withdrawal from the main trial.
Retrospective and prospective falls data are not consistently reported
when collected simultaneously. People who did not return diaries were
systematically in poorer health than those who completed all allocated
diary cards. Swats are an efficient additional component of RCT design
and should be considered to improve the design of future trials.
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The selection of appropriate endpoints is of paramount importance for a
clinical trial to meet its objectives. For some diseases it is difficult to
choose a single endpoint or a few multiple endpoints that measure the
disease from which a comparison of treatments can be made. This can
be especially true for some rare diseases, where a major challenge in clin-
ical trial design is the lack of a validated well-characterised efficacy end-
point. In order to assess disease severity in people with a rare condition
such as alkaptonuria (AKU) - an orphan inborn homogentisate dioxygen-
ase enzyme deficiency resulting in accumulation of homogentisic acid - a
new tool was developed. The AKU Severity Score Index (AKUSSI) incorpo-
rates multiple, clinically meaningful outcomes that can be described in a
single score. AKUSSI consists of both subjective and objective features
that have been selected on current knowledge of the disease and it is
sensitive to all morbid features of the condition. This score is a quantifi-
able, multidisciplinary assessment system, with the potential of reflecting
changes in disease severity over time. Clinical experts, patients and statis-
ticians were part of the development team. Tools like AKUSSI that de-
scribe disease manifestations can be used to compare disease across
patients at different time points for other complex and multi-systemic
diseases. Details and rationale of the AKUSSI tool that is now used as an
outcome in a Phase III efficacy study (SONIA 2) will be described, with
special attention to issues arising from the rarity of the disease.
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Background
In paediatric open-heart surgery body cooling during cardiopulmonary
bypass (CPB) is commonly used to help protect vital organs. However,
hypothermia can have detrimental effects. Thermic-1 was a parallel-
group open randomised controlled trial which recruited 59 children
undergoing heart surgery between 2002 and 2004. Patients were
randomised to receive either hypothermic (28 °C) or normothermic
(35 °C −37 °C) CPB. Thermic-2 followed on from Thermic-1, rando-
mising 141 patients between 2012 and 2014. The co-primary out-
comes included intubation time and length of post-operative stay.
Methods
Randomisation: The 10-year gap between phases saw changes in
randomisation systems. In Thermic-1 allocations were placed in
opaque sequentially numbered sealed envelopes, which were given
to the clinical fellow managing the study. Thermic-2 was managed
by the clinical trials unit with allocation determined by secure com-
puterised system. Data capture: Data capture processes also changed
between the two phases. A clinical fellow collected data on Excel
spreadsheets in Thermic 1, whereas data were collected by research
nurses in Thermic-2 and then entered into a purpose-designed data-
base. Statistical analysis: Data from the two trials were pooled in one
overall analysis adjusted for study phase. Interaction terms were
added to the models to examine differences between trial phases.
Results
Baseline characteristics: Imbalances in patient demographics were
observed in Thermic-1; participants allocated to the normothermic
group were on average 3 years older (median 7.5 years [IQR 3.5-10.6]
vs 4.3 [2.2-11.5]) and more likely to be male (68% vs. 48%). In con-
trast, in Thermic-2 no imbalance was observed; the median age was
2.3 years (0.5-5.2) in the normothermic group vs 2.9 (0.5-6.0) and
there were similar proportions of males in the two groups (43% vs.
44%). Primary outcomes: Pooling the data across both phases,
intubation time was slightly shorter in the normothermic group
(median 10.6 hours [IQR 5.9-25.3] vs 16.4 [6.1-26.6]), although this
was not statistically significant (hazard ratio [HR] 1.14, 95% CI 0.86-1.51,
p-value = 0.36). The median duration of post-operative stay was 6.0 days
in both groups (IQR 5.0-7.0); HR 1.06 (95% CI 0.80-1.40), p-value =
0.70. Examining the results by phase found no difference in treat-
ment estimates for intubation time. However a significant difference
between the two phases was found for length of stay (p-value for inter-
action = 0.079). The estimated HR was 1.57 (95% CI 0.93-2.64) in
Thermic-1, i.e. Marginally favouring the normothermic group, compared
to 0.90 (95% CI 0.65-1.26) in Thermic-2.
Discussion
The imbalance in baseline characteristics suggests that Thermic-1 re-
sults are at high risk of bias due to inadequate concealment of ran-
domisation. Allocation compliance was only collected in Thermic-2,
so the true extent of non-compliance could not be determined. Add-
itionally, the differing results for post-operative stay suggest the
study was also at risk of detection bias; the age and gender differ-
ences did not account for the difference observed. While the deci-
sion to extubate is protocol driven, the decision to discharge
patients lies with the clinical team. The results illustrate the import-
ance of methodological rigour in the design and conduct of clinical
trials and provide a valuable example of the importance of working
with methodologists.P46
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Background
Funders often encourage the use of both qualitative and quantitative
data in evaluations. Such evaluations are sometimes seen as limited
without formal approaches to the integration of qualitative and
quantitative data [1], and dismissed as multi-method rather than
truly mixed-method. Qualitative research is encouraged during feasi-
bility/pilot work [2]. We used a version of a protocol suggested by
Farmer and colleagues [3] to integrate and compare quantitative and
qualitative findings (methodological triangulation of data sets) in a
mixed-methods feasibility study of a hydrotherapy intervention for
Duchenne Muscular Dystrophy (NIHR HTA 12/144/04).
Methods
A logic model, a tool used to evaluate the implementation of a care
programme [4], was developed with collaborating interventionists.
We reviewed qualitative and quantitative datasets to identify compo-
nents of the intervention logic model (“sorting”). A convergence cod-
ing matrix summarized similarities and differences between data sets
for each of 17 logic model components, selecting examples to dem-
onstrate how each had contributed to the intervention’s success or
failure (“convergence coding”). We applied a convergence coding
scheme: “agreement”; “partial agreement”; “silence”; or, “dissonance”.
We quantified the level of agreement between data sets (“conver-
gence assessment”) And highlighted their different contributions to
the research question (“completeness comparison”). We shared the
triangulated results with team members and other selected stake-
holders at a face-to-face meeting, for feedback, allowing points of
disagreement to be discussed and changes in interpretation
incorporated.
Results
There was agreement on six components, silence on eight (areas
only amenable to qualitative assessment), and dissonance on two.
The areas of dissonance concerned session attendance and interven-
tion optimisation. In each case, a naïve reading of the quantitative
data could lead to an overly simplistic attribution of cause. For ses-
sion attendance, quantitative sub-studies pointed to illness or simple
non-appearance of the family; the qualitative data revealed that the
convenience of available timeslots played a strong role in non-
attendance for some families. Similarly, quantitative data identified
an apparent failure, on the part of several physiotherapists, to opti-
mise the intervention; the qualitative data revealed this to be part of
a misunderstanding, with therapists wrongly assuming that the study
required them to apply the manual prescriptively or extensively, ra-
ther in a focused and more achievable way proposed at training.
Those same therapists were aware and concerned that therapy was
not optimised. Qualitative research contributed data to 15/17 logic
model components; quantitative components contributed to nine.
Samples from the convergence coding matrix are presented in the
presentation. Feedback from stakeholders confirmed the account of-
fered and adequate explanation of events observed in the study.
Discussion
We selected a different methods appropriate to the commissioning
brief, but did not implement methods independently. A formal
mixed-methods approach allowed the robust use of qualitative data
used to explain quantitative findings.
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Background
The ENHANCE pilot trial aimed to test the feasibility and acceptability
of integrating case-finding for osteoarthritis, anxiety and depression
within extended primary care nurse-led long-term condition (LTC) re-
view consultations. Training was delivered to general practice nurses
(PNs) to deliver the ENHANCE reviews, supported by an adapted
EMIS LTC computer template.
Objectives
This analysis explored the extent to which data recorded by the PNs
in the ENHANCE EMIS template reflected the content of discussions
and case-finding in ENHANCE LTC review consultations. The findings
form part of a process evaluation exploring the ways in which PNs
delivered ENHANCE LTC reviews.
Methods
Patients and PNs in four general practices were asked to give consent
for their ENHANCE consultations to be audio-recorded for fidelity
checking (24 patients and seven PNs consented). 12 patients also gave
consent for the research team to access their medical record data,
which included the ENHANCE template data (entered by six PNs during
ENHANCE reviews). Consultation recordings for these 12 patients were
compared with corresponding ENHANCE EMIS template data entered
by the PNs, to identify and explore any discrepancies.
Results
Use of the ENHANCE case-finding questions in the audio-recorded
ENHANCE LTC review consultations was high. The majority of patient
responses to case-finding questions/tools in the audio-recordings
matched those recorded by PNs through the new ENHANCE EMIS
template, however, 12 discrepancies between the audio-recordings
and EMIS computer template data were identified, arising from five
of the consultations (with three PNs). Discrepancies included: re-
sponses to case-finding questions not matching; responses recorded
in the template data for questions not asked in the audio-recording;
missing template data for questions that were in the audio-
recording. Some discrepancies appeared to arise from PNs’ under-
standings of what constituted a legitimate “Yes” or “No” response to
the case-finding questions for depression and anxiety. There was also
evidence that PNs sometimes attempted to question, dismiss or nor-
malise patients’ initial responses.
Conclusions
Data demonstrate that PNs were generally recording responses to
case-finding questions using the ENHANCE EMIS template as
intended, suggesting that this process within the ENHANCE study
was feasible and accurate. PNs were asked to record patient re-
sponses on a new computer template while maintaining a patient-
centred dialogue and completing an integrated ENHANCE review
within the available timeframe, so it is unsurprising that some typing
errors or discrepancies may occur. Nonetheless, it is helpful to ac-
knowledge that these may exist, as template data is often used for fi-
delity checking of intervention delivery within trials. We have
identified difficulties in the use of case-finding questions that could
be addressed through PN training in a future main trial.
P48
Effective teamwork is crucial to maximising recruitment to
randomised controlled trials in surgical oncology
Sean Strong, Sangeetha Paramasivan, Nicola Mills, Jenny Donovan,
Jane Blazeby
University of Bristol
Correspondence: Sean Strong
Trials 2017, 18(Suppl 1):P48Background
Trials in surgical oncology frequently experience issues with recruit-
ing adequate numbers of participants. This is particularly difficult
within RCTS involving interventions which are routinely delivered by
different clinical specialties (such as surgery and oncology based
treatments). Teamwork between individual healthcare professionals
and specialty and research teams has been highlighted as a signifi-
cant factor in recruitment. This study evaluated aspects of teamwork
which were important in recruitment to three RCTs in surgical
oncology.
Methods
In depth semi structured interviews were conducted with a purpose-
ful sample of healthcare and research professionals responsible for
recruitment in three RCTs in different disease sites in surgical oncol-
ogy (oesophgago-gastric, thoracic and colorectal). Interviews were
audio recorded, transcribed verbatim and analysed thematically.
Sampling, data collection and analysis were undertaken iteratively
and concurrently.
Results
Thirty six interviews were conducted with recruiters at seven differ-
ent hospital sites. Sites in which a culture of clinical collaboration
within and across disciplines existed recruited more participants than
those in which individual clinicians tended to work in isolation. The
multidisciplinary team meeting (tumour board meeting) appeared to
facilitate cross disciplinary collaboration and was an important factor
in determining the ability of individual sites to effectively recruit. The
degree to which individual specialty teams within each centre were
in equipoise influenced study engagement.
Discussion
This study has demonstrated several aspects of teamwork that ap-
pear to be important for recruitment in trials in surgical oncology.
Understanding these aspects of teamwork will aid the development
of guidance on team relevant issues that should be considered in
trial management and the development of interventions that will fa-
cilitate teamwork and improve future recruitment to RCTs.
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Background
Neural Stem Cell Transplantation (NSCT) has been identified as a po-
tential therapeutic intervention for the treatment of Huntington’s dis-
ease (HD) (Dunnett and Rosser, 2007). This neurosurgical procedure
utilises stem cells, which are injected into the mid-brain of affected
individuals and are intended to improve symptoms (Lindvall and
Bjorkland, 2000). Previous research, utilising NSCT, has briefly ac-
knowledged ethical sensitivity including the source of cells utilised,
alongside the hopes of HD patients surrounding the intervention
(Bachoud-Levi et al., 2000). The understanding of NSCT amongst po-
tential beneficiaries has however yet to be explored in depth. With
future clinical trials being planned to explore the intervention, this
proposed qualitative project seeks to redress this gap and it is envis-
aged that the understanding gained will inform information giving,
recruitment strategies and care pathway planning in such a way as
to augment any future participant experience.
Method
The primary aim of this research is to gain insight into the perceptions
and understanding about Neural Stem Cell Transplantation (NSCT)
amongst potential recipients. The information gained is then intended
to inform and underpin the development of information giving ap-
proaches for potential NSCT recipients and ensure their issues are ad-
dressed in the development of consent procedures and care pathways.
Firstly three purposively targeted Specialist Professionals, from the field
of NSCT, have been approached via email, consented and interviewed
(semi-structured) in order to explore their past experience. The re-
corded interviews addressed their recollections of the recipient
Trials 2017, 18(Suppl 1):200 Page 20 of 235experience, their understanding, questions, queries and concerns with
regards to NSCT. A thematic analysis of these interviews has been
undertaken and used to inform and guide the development of
minimally-structured interviews with six, genetically positive, individuals
who have yet to show symptoms of HD. Emergent themes thus far in-
clude Making Sense via Contrast, Chronological Risk, Ethical Dissonance
and Familial/Community Drivers and Brakes. This second phase, using
minimally-structured qualitative interviews, is intended to elicit the per-
ceptions and understanding surrounding NSCT as an intervention
amongst potential recipients. These participants will be recruited from
an Asymptomatic Huntington’s Disease clinic.
Results
As future clinical trials of NSCT are due to be undertaken in the
United Kingdom in the near future, it is important that this (anon-
ymised) information from this thesis is shared with Professionals,
working within Clinical Trials, in order to support recruitment strat-
egies and information provision.
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Background
Trial-specific training is highly varied across trials and there is great
uncertainty on the best ways to provide training to facilitate trial
conduct.
Aims
To develop and validate the ATLAS training toolkit that can be uti-
lised by trial management teams when planning training of staff
within clinical trials. Part of the training toolkit also aims to evaluate
the process of trial-specific training provided to site staff during the
site initiation process.
Methods
The content of the training toolkit was developed by combining i)
qualitative data obtained from semi-structured interviews with trial
managers (n = 6) and healthcare professionals (n = 13) working on six
purposefully selected case studies of the ATLAS project; ii) responses
to questionnaires (n = 120) used to evaluate site staff and facilitators’
experience of site initiation training sessions, iii) a review of existing
regulations and guidance documents from various regulatory bodies
(MRC, HRA, MHRA, FDA) on training requirements in clinical research;
and iv) a review of existing literature on the processes of learning,
training and development. The training toolkit was then evaluated in
two-stages. Firstly, semi-structured follow-up interviews with the trial
managers (n = 6) facilitating trial-specific training sessions in the six
participating ATLAS studies were undertaken and the toolkit was
amended in light of the feedback received. At the second stage,
feedback was sought on the revised toolkit from trial managers at-
tending scheduled meetings (n = 2) in two established Clinical Trial
Units in Bristol.
Results
The toolkit has five components each focusing on a particular elem-
ent of the training cycle: i) Specifying initial training needs andselecting appropriate mode of delivery; ii) Designing the training
plan; iii) Delivering and documenting training; iv) Evaluating training
and v) Identifying additional training needs and re-training of staff.
Each element is supplemented by support documents (including
flowcharts and template documents) that can be utilised by trial
managers as guides when planning trial-specific staff training. Over-
all, the training toolkit was positively received and was considered a
useful reference document encouraging active thinking of staff train-
ing during the early stages of study design. Most trial managers felt
that the decision-making flowchart provided useful prompts to assist
trial managers in selecting the appropriate mode of training during
the decision-making process. The training plan template was also
viewed as a helpful document for recording decisions about the ap-
propriate level of training required for each study. The training feed-
back forms were regarded as invaluable documents in identifying
key areas where additional training is required and improving future
training sessions.
Conclusions
To the best of our knowledge this is the first training toolkit that has
been developed to assist trial managers in planning, designing, doc-
umenting and evaluating staff training within clinical research. Fur-
ther validation of the toolkit is required to assess its practical use in a
variety of clinical trial settings.
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Background
pivotalboost (CRUK/16/018) is a 4-arm phase III randomised trial in
patients with node negative, high or intermediate risk localised pros-
tate cancer currently in set-up. 1952 patients will be randomised to
receive (A) standard prostate intensity modulated radiotherapy
(IMRT); (B) A with pelvic node IMRT; (C) A with a prostate boost; or
(D) A with pelvic node IMRT and a prostate boost. The prostate boost
can be delivered by IMRT or by high dose rate brachytherapy (HDRB).
Availability of the boost arms C and D depends on: (1) A suitable
boost tumour volume identified by functional MRI. (2) Availability of
boost technologies - participating sites can open initially to A vs B
randomisation with the boost arms (i.e. 4-arm randomisation) open-
ing later. (3) Patient suitability and fitness. The study is powered to
compare each experimental arm with control. Due to the above re-
cruitment restrictions for the boost arms, power was reduced for the
boost comparisons (85% power for A vs B, 80% A vs C and A vs D),
giving a design where the trial population will be split 9:9:8:8 across
arms.
Aims
To investigate, via simulation of recruitment, how the three elements
above impact recruitment and imbalance between treatment arms
and how adaption of the allocation ratio could minimise imbalances.
Methods
We assumed recruitment would take 54 months and with staggered
opening, all 40 sites would be open by 24 months. Expected site-
specific monthly accrual rates and availability of boost technologies
were obtained via site feasibility questionnaires. An expected month
of opening and when the boost arms would be available at each site
was inferred using survey results and clinician input. Recruitment
was assumed to follow a Poisson distribution with site-specific
monthly accrual rates. For each patient accrued at a specific month
we simulated the boost volume, risk group and suitability for receiv-
ing a boost, so the patient could be allocated to the 2-arm or 4-arm
randomisation accordingly. We performed initial simulations with a
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treatment, allocation ratio to control (X:A) and probability of complet-
ing recruitment before the planned time. We explored the impact of
delays in opening the boost arms on prolonging the recruitment
period.
Results
Simulations showed that using a 1:1:1:1 allocation ratio causes an ini-
tial imbalance with more patients allocated to A and B as expected
by late opening of boost arms, which could result in an imbalance at
the end of recruitment in favour of the control arm; though infre-
quent, some simulated trials had up to 25% more patients in one
group than another. Initial use of 2:2:3:3 allocation ratio appeared to
protect against such imbalances. Recruitment by arm will be moni-
tored as the trial progresses with a planned adaption to a 1:1:1:1 allo-
cation ratio part way through recruitment.
Conclusions
Simulation of recruitment proved useful to understand the potential
imbalances that may occur during the trial and led to a cost-effective
strategy of different allocation ratios during the trial to correct for ini-
tial imbalance.
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Background
Data suggests there are 50,000 adults with learning disabilities (LD)
in England and Wales currently prescribed antipsychotic medication.
Illness in this population is high, including significant rates of challen-
ging behaviour and mental illness with particular concern over use
of anti-psychotic drugs prescribed for reasons other than treatment
of psychosis. Control of challenging behaviour is the primary reason
why such medications are prescribed, despite the absence of good
evidence of therapeutic effect for this. This innovative study was ini-
tially conducted in primary care however due to complexities sur-
rounding set up and recruitment, continued in community learning
disabilities teams as a feasibility study. The primary objective was to
assess feasibility of recruitment and retention, and explore non-
efficacy based barriers to a blinded anti-psychotic medication with-
drawal programme for adults with LD without psychosis compared
to treatment as usual. A secondary objective was to compare trial
arms regarding clinical outcomes.
Method
ANDREA-LD was a two arm individually randomised (1:1) double
blind placebo controlled drug reduction trial. The majority of recruit-
ment was through community learning disabilities teams in South
East Wales and South West England. Participants were adults with LD
prescribed risperidone for treatment of challenging behaviour with
no known current psychosis or previous recurrence of psychosis fol-
lowing prior drug reduction. Carers also consented to their involve-
ment in the trial.
The intervention was a double blinded drug reduction programme
leading to full withdrawal within six months. The control group main-
tained baseline treatment. Treatment achieved at six months was
maintained for a further three months under blind conditions. The
blind was broken at nine months following final data collection.
Feasibility outcomes were number and proportion of: (i) sites progres-
sing from initial approach to participant recruitment (ii) recruited partic-
ipants who progressed through the trial. Trial arms were also compared
regarding; Modified Overt Aggression Scale; Aberrant Behaviour Check-
list; PAS-ADD checklist; Antipsychotic Side-effect Checklist; Dyskinesia
Identification System Condensed User Scale; Client Service Receipt In-
ventory; use of other interventions for challenging behaviour; use of as
required medication; psychotropic medication use.Results
Of the 22 participants randomised, 13 (59.1%) achieved progression
through all four stages of reduction. Follow-up data at six and nine-
months post-randomisation was obtained for 17 participants (77.3%
of those randomised) with 10 intervention and seven control partici-
pants followed up. There were no significant changes in participants’
levels of aggression or challenging behaviour at the end of the
study.
Methodological challenges faced in setting up and delivering the trial
included: recruitment of principal investigators and sites equipped to
distribute medication; recruitment of participants and carers; obtain-
ing consent according to regulations surrounding trials for this vul-
nerable population; ensuring maintenance of the blind and
dispensing medication to participants; carers subjective assumptions
of trial arm allocation.
Conclusions
Results indicate that drug reduction is possible and safe. However
focused support and alternative interventions are required. The
results of the qualitative study and reflections on the challenges
faced provide important insights into the experiences of people
taking part in drug reduction studies that should influence future
trial development.
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Background
Oestrogen Receptor (ER) positive breast cancer (ERBC) is now a
chronic disease with high 5-year survival rates. However, a large pro-
portion of cases continue to be at a substantial risk of recurrence up
to 20 years from diagnosis. Trials of interventions designed to pre-
vent late recurrences in ERBC face a unique challenge. These inter-
ventions often need to be carried out in secondary care setting
when patients have already been discharged back into primary care.
Therefore recruitment from the primary care setting is important for
such trials. The IBIS-3 feasibility study is a randomised controlled trial
(RCT) of interventions in long-term survivors of ERBC with recruit-
ment rates from primary case as one of its objectives.
Method
Five Clinical Research Networks (CRNs) invited GP practices close to
trial’s participating Secondary Care Sites (SCS) to join as Participant
Identification Centres (PICs) on our behalf. GPs who agreed to partici-
pate as PICs screened their databases to identify potentially eligible
patients and wrote to these patients inviting them to participate in
the trial by contacting the trial’s central coordinating office (CCO).
The CCO further checked eligibility and referred patients to their
local SCS. After 6 months of original request, a brief survey to identify
main reasons for non-participation was sent to all GPs who declined
participation.
Results
The level of support provided to both the CCO and GPs varied across
5 CRNs potentially impacting GP participation rate. Overall, only 5%
GPs agreed to participate and only 23 of 800 (3%) subsequently
responded to the survey. The main reasons identified for non-
participation were lack of time/resources to carry out database
search (61%) and/or review medical records to confirm eligibility
(48%), request coming at a busy time (9%) e.g. Calendar or financial
year-end, and insufficient funding (26%). Encouragingly, 26% of GPs
that completed the survey indicated willingness to participate at the
time of the survey.
Conclusions
Wide variations exist in the level of support provided to GPs across
CRNs. Ensuring uniform and higher levels of support including fund-
ing to help overcome time/resources scarcity barriers is likely to
Trials 2017, 18(Suppl 1):200 Page 22 of 235improve GP participation as PICs for trials in secondary care settings.
A re-request for participation from CRNs, made at a time when prac-
tices are less busy should also be considered as a measure to im-
prove participation.
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Background
There is emerging evidence that patient and public involvement in
research (PPIR) may increase participant recruitment into randomised
controlled trials. However, it is not clear how to use PPIR to improve
trial recruitment. Whilst publicly funded trials in the UK and else-
where routinely use PPIR to improve design and conduct, such trials
on the whole do not advertise their use of PPIR to potential partici-
pants. Effective advertising of PPIR in trials to potential participants
might increase enrolment rates, through trials being perceived to be
more trustworthy, relevant and socially valid.
Aims
We aimed to develop an intervention directly advertising PPIR in a
trial to potential participants and evaluate its impact on trial recruit-
ment and response rates.
Methods
We undertook a cluster randomised controlled trial, embedded in an
ongoing “Host” Mental health trial (the “EQUIP” Trial). EQUIP was a
cluster randomised controlled trial recruiting service users with a
diagnosis of severe mental illness. In EQUIP, mental health teams in
England were randomised to an intervention group to receive train-
ing to improve service user and carer involvement in care planning,
or to a “no training” control group. The recruitment intervention ad-
vertising PPIR was informed by a systematic review, a qualitative
study of patients who declined a trial, social comparison theory and
a workshop that included mental health service users and trialists.
Using Participatory Design methods, we collaborated with PPIR part-
ners (service users and carers) to design a recruitment intervention
using a leaflet format to advertise the nature and function of the
PPIR in EQUIP to potential participants. Professional graphic design
aimed to optimise the intervention’s readability and impact. Service
users being approached into EQUIP were randomised to the PPIR
intervention or not, alongside the standard trial information. The pri-
mary outcome was the proportion of participants enrolled in EQUIP.
The secondary outcomes included the proportion expressing interest
in enrolling. Analysis was by intention to treat and used generalised
linear mixed models.
Results
We randomised 34 mental health teams and 8182 potential partici-
pants were invited. For the primary outcome, 4% of patients receiv-
ing the PPIR leaflet were enrolled vs. 5.3% in the control group. After
adjusting for mental health team cluster size, levels of deprivation
and care quality rating, the intervention was not effective for improv-
ing recruitment rates (adjusted OR = 0.75, 95% CI = 0.53 to 1.07, p =
0.113). For the secondary outcome 7.3% of potential participants re-
ceiving the PPIR leaflet responded positively to the invitation to par-
ticipate, vs. 7.9% in the control group. The intervention was not
effective for improving response rates (adjusted OR = 0.74, 95% CI =0.53 to 1.04, p = 0.082). The intervention was not effective for any
other outcomes measured.
Conclusion
This is the largest embedded trial to test the impact of a recruitment
or PPIR intervention. Advertising PPIR using a leaflet had no benefits
for improving recruitment or response rates. Our findings contrast
with the literature suggesting advertising PPIR benefits trial recruit-
ment. We will discuss implications of our findings for trial recruit-
ment, research and policy.
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Background
Recruitment to randomised controlled trials (RCT) remains one of
the key challenges in trial management. Patient aversion to ran-
domisation is often cited as a reason why patients choose not to
enroll in RCTs. For many recruiters and patients alike, ‘randomisa-
tion’ appears a challenging concept, yet one that requires commu-
nicating and understanding given its centrality to informed consent
and trial recruitment. The UK National Research Ethics Service
(NRES) has produced guidance on how to describe randomisation
simply and clearly in written patient information. We investigated
how recruiters described randomisation in recruitment appoint-
ments and compared this with a framework based on the NRES
guidance.
Methods
A maximum variation sample of 64 audio-recorded recruitment ap-
pointments was purposefully sampled from five RCTS to encompass
a range of recruiters, surgical and non-surgical trials and cancer and
non-cancer conditions. Using the NRES guidance for written patient
information as a hypothesised ideal explanation of randomisation,
an analytical framework was developed identifying five interlinked
concepts considered necessary for a clear exposition of randomisa-
tion. This analytic framework was applied to extracts from consulta-
tions during which randomisation was discussed using content
analysis, assessing whether the concepts were absent or present
and explicit or implicit, according to coding rules derived from the
data.
Results
Two key findings emerged. Firstly, recruiter explanations of and for
randomisation tended to be incomplete when evaluated against
the NRES informed framework: in nearly 45% (29) of cases, three or
fewer components were present. Only five of the 64 encounters in-
cluded mention of all five concepts and in only two of these were
all five concepts made explicit. Secondly, recruiters referred to
some concepts more frequently than others to articulate the ration-
ale for randomisation. Whilst most recruiters referred to ‘clinical
equipoise’ and ‘the need for a number of patient treatment groups’,
few referred to ‘the need for patient groups to be similar except for
the treatment allocated’. Where expressed, recruiters tended to
convey ‘the need to compare treatment effects’ and ‘that chance
determines assignment to a treatment allocation’, implicitly rather
than explicitly.
Conclusion
An evaluation of recruiter practice during recruitment consultations
across a range of trials showed that recruiters did not explicitly
communicate key concepts identified by NRES as fundamental to a
clear definition of randomisation. There is a need to understand
whether all aspects of the NRES guidance are necessary for the
communication of randomisation, and which are the key concepts
that are essential to facilitate patient understanding and assure in-
formed consent.
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Background
Stroke is a severe and often fatal or disabling condition. Despite treat-
ment effects in acute stroke being predominantly time dependent (e.g.
Thrombolysis and thrombectomy), proven treatments are hospital
based. Commencing treatment in the pre-hospital setting could dra-
matically reduce time to treatment. The rapid intervention with glyceryl
trinitrate in hypertensive stroke trial-2 (RIGHT-2) recruits patients in the
pre-hospital setting within 4 hours of stroke onset. Obtaining consent
in emergency situations can be difficult, especially when the time win-
dow for recruitment is short. Proxy consent allows patients to be re-
cruited when they lack capacity to give consent themselves, a common
scenario in people suffering a stroke. Conversely, a waiver of consent
offers the opportunity to include all eligible patients but may disregard
the initial choice of patients who have capacity to make an informed
decision regarding participation in research.
Methods
Ethics approval was obtained to allow proxy consent to enable ran-
domisation into the RIGHT-2 trial within the 4 hour recruitment win-
dow. Informed consent or proxy consent is taken at the stroke scene
or in the ambulance. Brief assessment of capacity is performed by
the paramedic explaining to the patient that they have had a sus-
pected stroke, their BP may need lowering, and that a patch will be
applied that might lower their BP. The paramedic then asks the pa-
tient what the suspected diagnosis is (‘stroke’), what might need to
be done to their BP (‘lower’), and how this will be done (‘patch’). Pa-
tients with capacity give written or witnessed oral consent to the
paramedic. If a patient lacks capacity, proxy consent is obtained from
a relative, carer or friend acting as a personal consultee, if available,
or by the paramedic witnessed by another member of the ambu-
lance staff at the scene. For participants who did not have capacity
at the time of randomisation, consent is verified in hospital with
themselves or a relative (if the participant still lacks capacity).
Results
As of 28th October 2016, 247 participants have been enrolled into
the RIGHT-2 trial. 127 (51.4%) participants gave their own consent.
Proxy consent was given by a relative/carer/friend for 97 (39.3%) par-
ticipants, and by a paramedic for 23 (9.3%) participants. The median
time to consent for all participants was 58 minutes. After the partici-
pants reached hospital, 141 (61.8%) gave their own consent, 45
(19.7%) had continued consent by a relative or close friend and 42
(18.4%) had no further consent after proxy consent was taken in the
ambulance. Patients who had proxy consent in the ambulance had a
more severe stroke, median [IQR] National Institutes of Health Stroke
Scale score 12.5 [5, 18] versus 4 [2, 7] for those who gave consent
themselves.
Conclusion
Proxy consent can ensure patients are enrolled rapidly into emer-
gency clinical trials. In the RIGHT-2 trial, patients with a severe stroke,
who may benefit from the intervention, are able to take part in the
study when they would otherwise be excluded, which boosts recruit-
ment and ensures the trial population is representative of the popu-
lation the intervention is intended for.
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Paramedics are equipped to assess and recognise patients with sus-
pected stroke in the out-of-hospital setting. Treatment is highly time-
dependent but definitive intervention for stroke is currently limited to
in-hospital therapies. Commencing treatment in the pre-hospital set-
ting could dramatically reduce time to treatment. The rapid interven-
tion with glyceryl trinitrate in hypertensive stroke trial (RIGHT-2) is
assessing the safety and efficacy of pre-hospital ambulance-based
paramedic-delivered glyceryl trinitrate (GTN) when administered ultra-
acutely after stroke. Whilst ambulance-based paramedic-delivered
stroke trials have been done in the UK in single site pilot trials, they
have not been done across multiple ambulance services and hospital
sites in the UK. It is important for paramedics to have awareness of
Good Clinical Practice (GCP) principles and to be trained in trial proce-
dures. Methods used to train paramedics need to account for the fact
that paramedics have little time at work not on shift to complete train-
ing and may be reliant on them completing training in their own time.
Methods
Paramedics working in ambulance services involved with RIGHT-2 who
express interest in recruiting patients into the trial are invited to watch
the training video. The training video lasts for 1 hour and contains de-
tails on trial procedures and elements of GCP relevant to paramedics
recruiting patients. The video is available over the internet so para-
medics are able to watch and revisit it whenever they choose so they
are able to complete the training in the small amount of time they
have available. Training has been delivered in face-to-face small group
sessions by Research Paramedics from participating ambulance trusts
and members of the RIGHT-2 team. Training has also been delivered by
a remote webinar, where the RIGHT-2 team deliver the training over
the internet, which allows for interaction between paramedics and
those delivering the training. Once paramedics have been trained they
must complete an online assessment questionnaire based around the
content of the video before they are able to recruit patients.
Result
Five ambulance services are currently recruiting into the RIGHT-2 trial.
From these, 958 paramedics expressed interest in being involved with the
RIGHT-2 trial, of which 628 (65.6%) have completed the online training as-
sessment. Feedback from paramedics suggests that face-to-face is their
preferred method of training, however, sessions need to be repeated sev-
eral times to allow paramedics who are on rotating shift patterns to at-
tend. This takes up a considerable amount of time for the research
paramedic who has to travel large distances across the ambulance ser-
vice. Remote webinars were well attended, with some paramedics attend-
ing multiple sessions to recap on key points. As with face-to-face sessions,
multiple sessions are required for a reliable uptake of paramedics.
Conclusion
Training for paramedics who recruit patients into clinical trials needs
to cover the necessary elements of GCP as well as trial procedures. It
must be easy to access and succinct in order for them to complete
training around their normal work schedule. A remote webinar pro-
vides balance between accessibility for paramedics and ability to
interact with those delivering the training.
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Background
OUTSMART is an ongoing multi-centre randomised controlled trial test-
ing whether a combined structured biomarker screening programme
and optimized immunosuppression treatment regimen can reduce risk
of graft failure in kidney transplant patients. HLA antibodies (HLA Ab+),
particularly if they contain donor specific antibodies against the graft
(DSA+) are prognostic biomarkers for graft failure. However it is unclear
how best to treat patients positive for the biomarkers.
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termine if they are positive or negative for HLA antibodies and if
HLA Ab+, whether they have donor specific antibodies (DSA+)
against the graft. Antibody screening results are initially blinded, and
then participants are randomised 1:1 to blinding or unblinding of
their HLA Ab status. The blinded group remain treated as they were
at baseline (standard care) and the unblinded HLA Ab + group are
treated with an optimized immunosuppression intervention.
The first strategy used to improve efficiency was the incorporation of
rescreening HLA Ab- participants in the trial design, with participants
converting to HLA Ab + in the unblinded group moving on to opti-
mised immunosuppression.
The known prevalence of HLA Ab+ in renal transplant recipients is ap-
proximately 25%, DSA account for 1/3rd of these, and the known inci-
dence of de novo DSA development is 3%. Sample size calculations
based on these known rates estimated requiring 2800 randomised partici-
pants for 324 DSA+ participants to allow comparison of the effect of bio-
marker led immunosuppression optimisation in these patients. Sixteen
months into recruitment both the prevalence and incidence of DSA+ was
lower than expected. This led to the application of a second strategy for
efficiency improvement; a change in the primary outcome from binary to
time to event (time to graft failure, approved by the DMC and TSC). The
sample size calculation was amended both to reflect this change and to
take into account the lower than expected DSA+ rates, retaining trial
power. The amended sample size required 165 DSA+ participants from an
estimated 2357 to be recruited. This change also meant there was already
sufficient numbers of HLA Ab+DSA- and HLA Ab- participants recruited.
As recruitment continued, the overall proportion of DSA+ participants
in the trial increased as the DSA prevalence and incidence rates normal-
ised, and also as a consequence of the increasing pool of participants
to screen as more HLA Ab- participants were randomised. The latter
sort of complexity would generally only be simplistically accounted for
in sample size calculations. Close monitoring of biomarker rates and on-
going sample size updates can address such issues and improve trial ef-
ficiency. This has led to outsmart meeting recruitment targets earlier
than expected, avoiding unnecessary randomisation of participants.
Conclusions
Pre-planned ongoing rescreening of biomarker negative participants
and flexible reconsideration of the primary outcome allowed both en-
richment for individuals with the biomarker of interest and dynamic
modification of the sample size, leading to improved trial efficiency.
Where possible, time-to-event or continuous primary outcomes should
be used in trials, especially where recruitment might be difficult and/or
biomarkers of interest are rare.
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The Pulmonary Metastasectomy in Colorectal Cancer (pulmicc) trial
completed its feasibility phase in 2015. Surgically treated colorectal
cancer patients, with newly diagnosed lung metastases, were rando-
mised to continued active monitoring or pulmonary metastasectomy
followed by active monitoring. Randomisation was a two stage
process; Stage 1 investigations assessed fitness for surgery and eligi-
bility for Stage 2 randomisation. A key trial criterion was clinician un-
certainty regarding the benefit of surgery in the light of the patient’s
test results. The trial was anticipated to be challenging for both clini-
cians and patients. Both patient information, and healthcare profes-
sional, training DVDs were produced to assist with trial discussions
and decision making. Additionally a patient survey was conducted to
examine patients’ views about the trial.
Method
Following pulmicc stage 1 tests, patients eligible for randomisation
(pulmicc stage 2) were offered an 'Accept/Decline’ Questionnaire to
complete following their decision to either proceed to randomisation
or decline pulmicc stage 2. This 16 item, Likert scale, self-report ques-
tionnaire explores aspects of trial information provision, patients’ con-
cerns about their illness, influence of friends, family and doctor, and
concerns regarding randomisation (V Jenkins, L Fallowfield, 2000). It en-
ables the collection of patients’views on key issues surrounding trial in-
formation provision and decision-making in a structured, quantitative
manner. Patients also identify their most important reason for accept-
ing or declining study participation. The questions are worded generic-
ally to enable widespread use in randomised trials.
Result
Questionnaires were returned by 54 randomised patients and 57 who
declined randomisation. The majority 106/111 (95%) indicated that
they had received sufficient written information about the study and
110/111 (99%) indicated that the doctor had told them what they
needed to know about the trial. Of patients who agreed to randomisa-
tion, 43/54 (80%) thought the trial offered the best treatment available
and 48/54 (89%) were satisfied that either treatment in the trial would
be suitable for them. Twenty five patients (44%) who declined random-
isation were satisfied that either treatment in the trial would be suitable
for them but 40/57 (70%) wanted the doctor to choose their treatment
rather than be randomised by a computer. The results did not highlight
significant problems such as patients feeling unable to say ‘no’ or con-
cerns that their illness might get worse unless they joined the study.
We have been able to use the information, together with clinicians’
views on their experiences of the feasibility phase of the trial, to iden-
tify potential barriers to recruitment and enable strategies to be put in
place to address these. Conclusion: We found the questionnaire easy to
administer and acceptable to both patients who declined or agreed to
join pulmicc stage 2. It is an efficient tool for collecting relevant views
from patients regarding potential drivers and barriers to recruitment.
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Background
The Electronic Health Record (EHR) is a rich source of clinical data
that holds promise for improving clinical trial conduct. However, little
information is available on site-level barriers to optimal use of EHR
systems in contemporary trials, particularly with respect to screening
and enrollment. More data is needed on the current use and associ-
ated challenges of using the EHR to identify trial participants.
Objective
We described existing site-level processes for using the EHR for
screening and recruitment of potential participants for an ongoing
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ment strategies and key barriers to using the EHR for trial recruit-
ment from the perspective of site coordinators.
Methods
Qualitative focus groups were conducted with 18 study coordinators
and site investigators at sites actively participating in the global multi-
center HARMONY Outcomes trial, an ongoing randomized controlled
study to evaluate the effect of albiglutide on cardiovascular events in
patients with Type 2 diabetes (Clinicaltrials.gov ID: NCT02465515). Inter-
views were conducted by a professional moderator using a semi-
structured, open-ended topic guide and were analyzed to identify com-
mon cross-site themes. Focus group participants represented research
sites in the United States (n = 14), the United Kingdom (n = 2), Canada
(n = 1), and Denmark (n = 1), with the majority based in multi-physician
or hospital-based practices.
Results
Most focus group participants reported that the EHR was the primary
modality used for screening, with the application of study-specific
EHR queries in conjunction with medical chart review to generate a
list of potentially eligible patients. In addition to EHR-based screen-
ing, most site coordinators reported using a multipronged approach
of high- and low-yield trial recruitment strategies, including asking
non-study investigators at the site to refer potentially eligible partici-
pants, posting fliers in clinics, sending mass mailings, and consulting
lists of names of past participants for future studies. Several key bar-
riers to use of the EHR system for recruitment were reported, includ-
ing limitations on accessing individual patient records without
informed consent, access to billing-only modules rather than re-
search modules, limitations on the number of search parameters,
and site-level restrictions on cold-calling patients meeting study cri-
teria. Coordinators reported that, despite these barriers, using an EHR
system has dramatically improved the perceived yield and timeframe
relative to traditional, paper-based screening methods.
Conclusions
The majority of study coordinators in an ongoing diabetes trial re-
ported that the EHR was the primary modality used to identify po-
tential trial participants. Key barriers to full use of the EHR for
recruitment included limitations on access to medical records and
lack of research modules designed to support screening. Despite
these barriers, the use of EHR systems for screening is viewed as an
improvement over non-EHR-based methods.
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A Patient Information Leaflet (PIL) is a requirement for UK health-
related research studies. Health Research Authority (HRA) guidance
lists 36 topic areas for inclusion in a PIL. However, there is limited
evidence about whether stakeholders believe these items to be of
importance when considering participation in a Randomised Con-
trolled Trial (RCT). This study identified and assessed which items of
information trial stakeholders ranked as most important and the rea-
sons for this.
Our mixed method study used aspects of Q-methodology (a card
sort technique) and simultaneous cognitive interviews (think aloud).
This mixed methods approach captures data on subjective opinions
held around a particular area of interest. The card sort technique pro-
vides participants with a set of “cards” (statements describing specific
information items) which they rank according to their opinion of rela-
tive importance. A specially formatted grid is used to capture the
relative rankings. While the participant completes the card sort, they
are encouraged to use the think-aloud technique to verbalise their
thoughts.In this study, the statements included on the cards relates to the in-
formation items recommended by HRA for inclusion in a PIL. Twenty
trial stakeholders were recruited (10 potential trial participants [PTPs]
and 10 research nurses [RNs]) completed the card sort within one-to-
one think-aloud interviews. To contextualise the card sort, PTPs were
asked to imagine they had been approached to participate in a
phase III RCT comparing treatments A and B for a chronic condition.
RNs were asked to think about potential participants making the de-
cision to take part in the same phase III RCT.
Both stakeholder groups ranked the following three statements
in their top four most important statements: “possible disadvan-
tages and risks of taking part”, “possible advantages of taking
part” and “possible side effects of trial treatment”. Both stake-
holder groups ranked “who is funding the research” among their
least important statements. There were differences between
groups in the other statements ranked as least important. RNs in-
cluded “who has approved the study”, “how have patients and
the public been involved in the design of the study” and “has
the scientific quality of the study been checked” among their
least important statements. PTPs ranked “will expenses be reim-
bursed”, “will there be any impact on any insurance policies” and
“will I receive any payments for taking part” among their least
important statements.
This study is one of the first to explore how different stakeholder
groups rank the information contained in an RCT PIL. Similarities exist
between both stakeholder groups in statements ranked as most im-
portant, but there are differences in the least important statements.
These results have implications for researchers developing PILs for
RCTs. Further research is required to identify any association between
the information provided in PILs and the decision-making process
around RCT participation.
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Background
Substantial amounts of public funds are invested in health research
worldwide. Publicly funded randomised controlled trials (RCTs) often
recruit participants at a slower than anticipated rate. Many trials fail
to reach their planned sample size within the envisaged trial time-
scale and trial funding envelope. A recent survey amongst the Direc-
tors of the Clinical Trials Units registered with the UK NIHR Clinical
Research Network identified priorities for research into the method-
ology of trials. The top three priorities were improving recruitment,
choice of outcomes, and improving retention.
Objectives
To review the consent, recruitment and retention rates for single and
multi-centre randomised control trials funded by the United King-
dom’s National Institute for Health Research (NIHR) Health Technol-
ogy Assessment (HTA) Programme.
Methods
HTA reports of individually randomised single or multi-centre rcts
published from the start of 2004 to the end of April 2016 were
reviewed.
Data extraction Information was extracted, relating to the trial char-
acteristics, sample size, recruitment and retention by two independ-
ent reviewers.
Main outcome measures Target sample size and whether it was
achieved; recruitment rates (number of participants recruited per
centre per month) and retention rates (randomised participants
retained and assessed with valid primary outcome data).
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This review identified 151 individually randomised controlled trials
from 778 NIHR HTA reports. The final recruitment target sample size
was achieved in 56% (85/151) of the RCTs and more than 80% of the
final target sample size was achieved for 79% of the RCTs (119/151).
For 34% (52/151) of trials the original sample size target was revised
(downward in 79% (41/52)). The median recruitment rate (partici-
pants per centre per month) was found to be 0.92 (IQR 0.43 to 2.79)
and the median retention rate (proportion of participants with valid
primary outcome data at follow-up) was estimated at 89% (IQR 79%
to 97%).
Conclusions
Based on this review for most publicly funded trials the recruitment
rate is likely to be between 1 and 2 participants per centre per week
(4 to 10 a month). There is considerable variation in the consent, re-
cruitment and retention rates in publicly funded RCTs. In practice, re-
cruitment rates will vary, depending on whether the target
population is acute, where opportunistic recruitment will target inci-
dent cases, or chronic, where database recruitment can effectively
target prevalent cases. It will also vary according to whether the
intervention is therapeutic or preventive and the base incidence and
prevalence rate of the condition. Investigators should bear this in
mind at the planning stage of their study and not be overly optimis-
tic about their recruitment projections.
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Background
During routine monitoring in the ethos study (a surgical trial compar-
ing Stapled Haemorrhoidopexy with Traditional Haemorrhoidectomy
for the treatment of grade II-IV haemorrhoids), it was found that the
response rates to the 12 and 24 month follow-up postal question-
naires were lower than expected. Literature reviews looking at
methods to increase response rates identified monetary incentives as
one potential way to boost response rates1-2. Two Studies With-in a
Trial (swats) were conducted within ethos to assess the effectiveness
of a small unconditional voucher and a higher value conditional vou-
cher on response rates to the postal questionnaires. Following no ef-
fect of a lower value voucher incentive (£5.00) being found in
increasing response rates in the study (SWAT1), the team designed
an additional study to evaluate if a higher value monetary incentive
would be more effective in increasing questionnaire response rates.
Methods
Participants enrolled in ethos who had not yet received their 12 and/
or 24 months follow-up questionnaires were included in SWAT2. All
participants were sent a covering letter with their postal question-
naires which informed them that they would receive a £30 high
street voucher as a token of appreciation upon receipt of a com-
pleted questionnaire. The primary analysis was a before and after
analysis of the effect of the voucher in increasing response rates at
each time-point. A sensitivity analysis was also carried out due to the
overlapping influence of SWAT 1.
Results
In total 586 and 562 participants were included in the 12 and
24 month analyses respectively in SWAT2. Results showed no statis-
tical evidence of an effect on the response rates at both 12 and
24 month time-points. Similarly, the sensitivity analyses results
showed no evidence of a difference in the 12 month response rates
after the incentive was given. At 24 months there was a slightincrease in response rates (before 71.4%, after 75.9%) but it was not
statistically significant, 95% CI [0.87,1.80].
Discussion
Both studies highlight that, despite current literature to the contrary,
the use of monetary incentives may not increase questionnaire re-
sponse rates in all study populations and could even have a negative
impact. There are a number of contextual aspects which may explain
this unexpected finding. Care is needed when introducing a new
intervention into an ongoing trial. Future evaluations of incentives
are needed to explore the impact of contextual issues which may
moderate their impact and influence in different study settings.
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Background
Non-muscle invasive bladder cancer (NMIBC) is a locally recurring dis-
ease for which patients undergo long term surveillance following ini-
tial diagnosis. CALIBER is a multicentre phase II feasibility study
comparing intravesical chemotherapy (chemoresection) with surgery
(standard of care) in patients with recurrent low risk NMIBC (2:1 che-
moresection:surgery randomisation). The primary aim is to assess
complete response to chemoresection and the trial is randomised to
test feasibility of recruitment to a larger randomised phase III trial.
It was anticipated that patient recruitment would be challenging due
to the need to identify potential participants at the time of recur-
rence prior to treatment, complex risk stratification criteria and varied
treatment pathways across participating sites. As such we developed
recruitment aids with the aim of raising awareness amongst potential
participants, ensuring site staff remain aware of the trial and promot-
ing effective liaison between site staff when suitable patients are
identified.
Methods
From the outset of the trial, ethics approved short patient informa-
tion leaflets and posters have been available to highlight the trial to
patients attending surveillance visits. A staff poster was also provided
to raise awareness amongst staff conducting surveillance. A CALIBER
specific risk calculation tool was introduced in March 2016 as an aid
to assess eligibility. We surveyed 34 participating centres about their
use of these aids and their use of the tools was compared to their
average recruitment.
Results
Responses were received from 26/34 centres. 25/26 (96%) are using
at least one of the short patient information leaflet, patient poster,
clinician poster or eligibility. Average monthly recruitment does not
appear to increase with increased use of the tools, with a median re-
cruitment of 0.21 for the 8/26 (31%) sites using two tools and 0.03
for the 6/26 (23%) sites using all four.
Since distributing the CALIBER risk calculator, the number of eligibil-
ity queries received by the coordinating clinical trials unit has sub-
stantially decreased. Initial feedback from centres suggests it is a
useful tool for local pre-screening. Centres are advised to print the
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ment this eligibility assessment.
Limitations
The impact of introduction of different tools on recruitment could
not be confirmed as most have been available since the trial com-
menced. The reduction in eligibility queries since introduction of the
recurrence calculation tool may be a result of increased centre ex-
perience. In addition, the use of tools may be confounded with fac-
tors such as centre size and frequency of patient screening for the
trial.
Conclusions
With provision of targeted recruitment aids, centre staff training and
ongoing support from the coordinating clinical trials unit, potential
barriers to recruitment in a trial with challenging patient identifica-
tion pathways and complex eligibility criteria can be managed effect-
ively. However there is no obvious increase in recruitment with
increased use of recruitment aids. In order to robustly evaluate the
impact of recruitment aid interventions they should be introduced in
a controlled manner to facilitate assessment of within and between
centre pre- and post- intervention accrual rates.
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Background
The VA Cooperative Studies Program's (CSP)1 Network of Dedicated
Enrollment Sites (NODES) is a consortium of 9 VA medical centers
(VAMCs) that have teams (Nodes) in place dedicated to conducting
CSP studies to enhance the overall performance, compliance, and
management of CSP multi-site clinical trials. Each Node site has a Dir-
ector (MD/PhD), Manager (Clinical Trial Nurse, Research Project Man-
ager), and Research Assistant(s).
CSP NODES piloted a "mentoring" (or hub-spoke) model in which a
Node site would more directly work with a study site to identify and
overcome barriers to recruitment, compliance, and data quality.
Aims
1. Determine the impact of an external research site mentoring
model on study recruitment. 2. Examine the study site-level charac-
teristics that facilitate or impede study recruitment.
Methods
The Colonoscopy Versus Fecal Immunochemical Test in Reducing
Mortality From Colorectal Cancer (CONFIRM) (CSP #577)3 study is a
large, simple, multicenter, randomized, parallel group trial directly
comparing screening colonoscopy with annual FIT screening in aver-
age risk individuals. Each of the 9 Node sites was paired with a low
performing (recruitment) CSP #577 study site. One Node site was
assigned two low recruiting sites for a total of 10 pilot sites. The re-
spective Node Manager then worked with the study site and the
West Haven CSP Coordinating Center (WHCSPCC) 4 to perform the
following:
Created a site management checklist to determine the current state
of local study operations; Used the site management checklist to
conduct interviews with site study staff; Used the feedback that was
gathered during the site interviews to create study improvement
plans that contained performance metrics to measure criteria related
to recruitment, compliance, and data quality; Held regular conference
calls independently with study sites and WHCSPCC to monitor pro-
gress. The pilot was conducted over a 6-month period from February
2016-June 2016.
Results
The ten Study sites that participated in the pilot mentorship had an
average improvement of 4.9 participants enrolled per month vs. An
average improvement of 1.3 participants enrolled per month at the
27 study sites that were not part of the pilot. Some common issues/
barriers to recruitment that the pilot sites faced are as follows: lackof recruitment at community-based outpatient clinics, lack of
utilization of the full spectrum of recruitment materials e.g. Letters,
flyers, participant screening algorithms (electronic medical records),
etc., unmotivated/disengaged study staff, lack of clinical referrals,
and uneven distribution of duties across study teams. Having a sub-
ject matter expert that was external to the CSP coordinating center
and could serve as a mentor was beneficial for the pilot sites. The
pilot provided a resource to the site that worked within a similar en-
vironment and could provide specific, site-level guidance on how to
resolve some of the recruitment issues/barriers that they faced.
Conclusion
The site mentoring model was successful in increasing participant re-
cruitment at study sites in a large, simple, multicenter, randomized,
parallel group trial in the VA healthcare system.
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Background
Clinical trials are a critical component of biomedical research and
provide valuable insights into effective means for enhancing patient
care and establishing new therapies. Recruitment into clinical trials
remains a key determinant to study completion and success. Barriers
to achieving enrollment targets include distrust of the medical com-
munity and clinical research, lack of awareness or understanding
about clinical trials and eligibility criteria, and concerns about the lo-
gistics of participation, such as required travel, the time involved with
participating, and potential costs. While various strategies have been
proposed, it is unclear how broadly they apply when different popu-
lations, diseases, and/or study goals are involved. The ability to ef-
fectively overcome challenges may require approaches that focus
more on addressing shared interests among sites in overcoming clin-
ical trial barriers.
Methods
The Department of Veterans Affairs (VA) Cooperative Studies Pro-
gram (CSP) is a clinical research infrastructure embedded within the
nation’s largest integrated health care system. The VA Network of
Dedicated Enrollment Sites (NODES) is a consortium of nine sites
intended to provide systematic site-level solutions to issues that arise
during the conduct of VA CSP clinical research [1]. Each NODES site
is represented at each VA Medical Center (VAMC) by a Director (or
team of co-directors/associate directors) and a Manager. Additionally,
each site has clinical support staff, including nurses and research as-
sistants, designated to assist multiple CSP clinical trials locally. Within
the context of a large, integrated health care system, NODES goals
are to: 1) enhance recruitment for clinical trials; 2) create study effi-
ciencies; 3) improve communication and disseminate best practices;
and 4) provide broader expertise in the design and conduct of VA
clinical research. Initial pilot activities were conducted for establish-
ing more cross-cutting approaches to improving recruitment.
Results
NODES addressed key barriers affecting clinical trial outcomes at
study-specific and organizational levels. Results of these activities are
presented in categories related to 1) implementing innovative partici-
pant recruitment strategies, 2) creating site-level efficiencies for study
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fectively evaluate site and network performance. Initial network ef-
forts produced several lessons and best practices for common
clinical trial problems. Additionally, innovations for wider adoption
across CSP studies were developed. Such strategies include mobile
recruitment, algorithmic inclusion/exclusion data programs for re-
cruitment activities, staff cross-training and mentorship, and stan-
dardized performance reporting. Some metrics were also used for
overall network performance.
Conclusion
NODES addressed barriers in various aspects of clinical trial recruit-
ment and management by working collaboratively to solve problems
with multiple stakeholders. Varied practices and operational changes
in CSP research related to recruitment, staff training and research
methodology were implemented by taking an overall, system wide
approach. Many challenges with patient recruitment experienced
within CSP are similar to those encountered by other multi-site gov-
ernment or private industry clinical trials. As a result, the solutions to
these recruitment problems presented by NODES may be transfer-
able to other healthcare settings.
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Background
Cluster randomised trials (CRTs) are increasingly implemented to as-
sess the effectiveness of interventions in settings in which individual
randomisation is impossible or challenging. Three main analysis strat-
egies have been proposed to analyse CRTs: cluster-level analysis,
mixed-models and generalised estimating equations (GEE). Whereas
the former approach maintains the nominal type I error rate, that is,
the chance to detect an effect when there is not, the last two lead to
inflated type I error rates when the number of clusters is small or the
cluster size varies. Small sample corrections have been proposed for
mixed models and GEE to circumvent this problem, but the impact
of these methods on power is still unclear.
Methods
We performed a simulation study to assess both the type I error rate
and the power of parallel two-arm CRTs with a continuous outcome
analysed with cluster-level methods, mixed models or GEE. For
cluster-level analysis, we studied the performance of a linear model
of cluster means without correction, a linear model weighted by the
cluster size or weighted by the variance components and a Wilcoxon
test. For mixed models, we assessed the performance of a Z-test, as
well as three degree of freedom corrections: Satterthwaite, Kenward-
Roger and the between-within method. Finally, for GEE, we com-
pared the performance of a Z test using model-based and robust
standard errors and a small sample correction proposed by Fay and
Graubard. We studied the impact of varying the intraclass correlation
coefficient (ICC), the number of clusters randomised and the vari-
ability in cluster size.Results
The results confirmed that when only few clusters are randomised,
inflated type I errors are observed and this inflation increases with
the ICC and with the variability in cluster size. Amongst the com-
pared methods, only the cluster-level model weighted on the vari-
ance components and mixed models with Satterthwaite or Kenward-
Roger corrections maintained the type I error rate at or below 5% in
all scenarios. Second, in terms of power, individual-level analyses out-
performed cluster-level analyses, but the power remained low for
fewer than 20 clusters randomised. Moreover, when the number of
clusters was very small (<8), the degree of freedom corrections lead
to very low type I errors (<2%), thus reducing the power to between
30 and 50%.
Conclusions
When the number of randomised clusters is small, appropriate cor-
rections must be used to maintain an appropriate type I error rate.
GEE approaches are not recommended, but a weighted cluster-level
analysis or a mixed model with a Satterthwaite or Kenward-Roger de-
gree of freedom correction can maintain an appropriate type I error.
However, these approaches lead to an important decrease in power
when fewer than 20 clusters are randomised, so adjustment of the
sample size is required at the design stage when such corrections
are used.
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Background
Tackling health inequalities has been a Scottish Government priority
since 2007. General Practitioners (GPs) at the Deep End is a collabor-
ation of general medical practices serving the 100 most deprived
populations in Scotland, based on the proportion of patients on the
practice list with postcodes in the most deprived 15% of Scottish
data zones. Eighty-six of these 100 practices are in the NHS Greater
Glasgow and Clyde Health Board area. The Deep End Links Worker
Programme was designed to prevent and reduce health inequalities
in Scotland, and support people living in the most deprived areas of
Scotland to ‘live well’ In their communities. It provides resources to
General Practices serving these populations to develop a ‘links ap-
proach’. Practices can refer patients to a Links Worker, who works
with the patient to identify and enable access to appropriate
community-based resources. The argument is that increasing and en-
abling local activities can enhance community connection, trust and
cohesion. Hence, the aim of Links Worker is to act as catalyst to hope
and self-determination, by using the strong relationship with patients
that exists in General Practices as a natural community hub. Part of
the evaluation of the programme involved a comparison of patient
and staff outcomes measured in 7 Intervention practices, with those
from 8 Comparator practices. These 15 practices were allocated to
the Intervention and Comparison arms at random, prior to the in-
volvement of the evaluation team.
Objective
The primary aim of the evaluation was to assess the effectiveness of
the Links Worker Programme in achieving the intended outcomes at
patient, practice and community levels.
Methods
A quasi-experimental evaluation design was decided by the Scottish
government as part of their funding conditions. Among 15 General
Practices that submitted a formal expression of interest in having a
Links Worker attached to their team, patients’ outcomes in 7 Gen-
erals Practices with an attached Links Worker will be compared with
those from 8 General Practices that do not have an attached Links
Worker. The intervention group are patients who were referred to
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the practice population. By design, the intervention group is very dif-
ferent from the comparator group. Therefore, simple between-group
comparisons, which would be appropriate for most randomised stud-
ies, will not be appropriate. The main statistical analyses have been
defined in terms of mixed effects regression models, to account for
clustering of outcomes at the practice level, with adjustment for dif-
ferences in baseline covariates. In addition, other methods will be ex-
plored, aiming to control for the selection bias inherent in the study
design (e.g. With respect to age, gender, deprivation and comorbidi-
ties), such as nearest neighbour matching and propensity score
analysis.
Results
The final analysis is underway. Some results of the evaluation will be
presented, with particular focus on the implications of this unusual de-
sign, and the results obtained using alternative analysis approaches.
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In comparison with conventional two-arm clinical trials, multi-arm
clinical trials provide investigators with the ability to directly compare
more than two competing treatments in a single trial setting. The
multi-arm trial design optimizes the efficiency of a trial, and even re-
duces the required total sample size if all experimental treatments
share a single control arm. It has been shown that a multi-arm trial
design can have economic and ethical benefits, such that it allows
for more efficient resource allocation and cost savings compared
with two separate trials, as well as the possibility of dropping an in-
ferior experimental treatment in the interim or even stopping the
study early if there is strong evidence for efficacy or futility.
It is common in multi-arm trials that researchers are more interested
in simultaneously monitoring all pairwise comparisons than just a
global test. Given that the probability of falsely rejecting the null hy-
pothesis is inflated when multiple pairwise hypothesis tests are per-
formed repeatedly in a single study, several multiple comparison
procedures have been generalized to the context of group sequential
testing to preserve the experiment-wise type I error rate, even when
an inferior treatment arm is dropped during interim monitoring.
Some examples are the generalization of the simple Bonferroni pro-
cedure, the Pocock’s procedure, the O’Brien-Fleming procedure, the
Fisher’s Least Significant Difference method, and the Newman-Keuls
procedure.
In this presentation, we will discuss group sequential methods for
monitoring clinical trials with multiple treatment groups. Two re-
cently completed Phase III multi-center randomized clinical trials
evaluating treatments for diabetic macular edema conducted by the
Diabetic Retinopathy Clinical Research Network (DRCR.net) will be
used as examples. We will apply several group sequential methods
to these two fixed-sample studies and demonstrate the design and
conduct of statistical interim monitoring for efficacy under two dis-
tinct scenarios: comparisons with a control group and all pairwise
comparisons.
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Phase II oncology designs commonly seek to assess the potential ef-
ficacy of a treatment. Single-arm trials can be utilised comparing
against a historic control, with decision-making cut points indicatingwhether the treatment warrants further investigation. A limitation of
single-arm designs is that the results of the trial may be unreliable
predominantly due to selection bias. Therapeutic benefits may gener-
ally be smaller than differences in outcome due to baseline charac-
teristics. Detailed description of the baseline prognostic factors is of
little help in determining for example whether a group of patients
with poor prognosis has been recruited into the trial or whether the
treatment is not truly worthy of further study. Buyse (2000) argues
that randomisation should be considered more often for early trials
of experimental treatments.
The calibrated design (Herson & Carter 1986) is a randomised single-
stage design utilising a binary endpoint. The design differs from the
typical randomised trial, as the “control” Group is not employed to
provide a comparison for the experimental treatment, but to evalu-
ate whether the sample population who receive the experimental
treatment has the capability of showing a response. The design es-
sentially constitutes two separate designs; one for the experimental
arm and one for the calibration arm. The experimental arm is set up
using a single-stage design using an exact binomial distribution
(A’Hern 2001) with corresponding “recommend” and “abandon” cut
points specified against a historic control. Outcomes in the calibra-
tion arm are used to assess whether the assumptions for the historic
control are acceptable and whether the response rate lies within the
expected range. If the response rate is not comparable, the conclu-
sions from the experimental arm are questioned.
The Myeloma UK Clinical Trials Network developed the muktwelve
trial; a randomised phase II study to assess the progression-free sur-
vival of a potential treatment regimen in relapsed and refractory
multiple myeloma. A calibration group will receive a control treat-
ment, and will be used to evaluate the validity of the historic control
used in the experimental group. Sixty patients are randomised on a
3:1 basis to experimental and control arms respectively. The sample
size was based primarily upon the experimental arm. Due to prag-
matic constraints, there is insufficient power to conduct formal hy-
pothesis testing in the calibration arm. However the inclusion of this
arm is necessary to safeguard against selection bias and give context
for the historic control rate.
We review the use of a calibration arm in phase II oncology trials and
the reasons for implementing such an approach, with an application
to the muktwelve study. We also assess the possibility of designing
the trial in a Bayesian setting, with the intention of more formally
using the calibration arm. It is postulated that the uncertainty around
the historic control rate can be better modelled by using this ap-
proach. One possibility would be to adapt the use of commensurate
priors, which can be utilized in a two-arm setting with a formal com-
parison to assess historic and concurrent heterogeneity (Hobbs, Car-
lin & Sargent 2013).
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Hypertension is the single biggest contributor to the global burden
of disease in the UK. It is widely accepted that ethnicity is one factor
that is associated with hypertension and which influences the re-
sponse to existing first-line antihypertensive treatments. In the UK
hypertension treatment is stratified by age and self-defined ethnicity
(SDE), problems associated with this include a lack of data from UK
populations supporting the current SDE stratification and no refer-
ence to South Asians – the largest ethnic minority group in the UK.
The primary objective of the AIM HY-INFORM study is to determine if
the response to existing first-line anti-hypertensive drugs differs by
ethnic group for patients on mono- or dual therapies. The work pre-
sented here will consider patients on a monotherapy treatment re-
gime. The study design is a 3-period 3-treatment cross-over trial in a
Trials 2017, 18(Suppl 1):200 Page 30 of 235multi-ethnic cohort of hypertensives using a linear mixed effects
model with subject as a random effect. With the absence of prior es-
timates of the within-subject SD, one problem with this multilevel
design is the calculation of the required sample size to ensure the
desired power to detect a single ethnic by treatment interaction.
Sample-size re-estimation designs can be used in this context to
change the sample size according to accrued information in a statis-
tically robust way. Ahead of trial recruitment, a simulation study was
carried out with the main aims of (i) Assessing the properties of the
hypothesis tests for the sample size defined in the AIM HY-INFORM
study protocol; (ii) Estimating the fixed (single ethnic by treatment
interaction) and random (within-subject SD) estimates of interest
along with their summary and performance measures; (iii) Simulating
an interim analysis after 50 subjects have completed their treatment
sequence to re-assess the sample size calculation. Results and
performance measures will show that the hypothesis-generating
procedure attains a size of 0.05 for 1000 simulations with a
protocol sample size of 660 subjects for different within and
between-subject SDs. The estimated power is in line with that
achieved in the study protocol and an underestimated assumed
within-subject SD requires a larger than planned study sample
size; providing a means of preserving the power of the study, a
distinct advantage over a fixed design.
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Background
In utero, glucose levels are normally maintained between 4–6 mmol/L.
Infants born preterm are at risk of both hyperglycaemia (20-86%) and
hypoglycaemia (17%), both of which have been associated with in-
creased mortality and morbidity. In neonatal intensive care, clinical
practice relies on intermittent blood glucose monitoring. The REACT
Trial aims to evaluate the role of real time continuous glucose monitor-
ing (CGM) in the detection and management of hyperglycaemia and
hypoglycaemia in these babies. REACT will thus provide a wealth of in-
formation, combining both continuous and clinical data, and present
challenges in statistical analyses regarding how to optimally interpret
and use these results.
Trial design
REACT is an international multicentre randomised controlled trial and
will recruit 200 subjects within 24 hours of birth, with a birth weight
<1200 g. Subjects will be randomized equally to two parallel arms.
All babies will have an Enlite sensor (Medtronic, Northridge, CA, USA)
inserted and linked to a Medtronic Minimed 640G monitor for data
collection. In the intervention arm the real time sensor data will be
used for clinical management. In the control arm the data will be col-
lected blind to the clinical team caring for the baby. In both study
arms the data will be recorded every five minutes for six days. The
primary endpoint for the trial is the difference between the arms in
the percentage of time sensor glucose is in the target range of 2.6-
10 mmol/l within the first six days of life.
Methodological challenges
Evaluating continuous data, upon which dynamic treatment deci-
sions are made, presents challenges for analysis. The primary analysis
has a clear interpretation, but it ignores the time dependence of the
data, and dichotomises the results: within/outside the target range.
Therefore it cannot detect any time-dependent treatment effects.
Furthermore, as with all dichotomisations, it is unduly influenced by
the choice of boundaries that define the target range. There is a pau-
city of alternatives that correct both of these issues, and offer a clin-
ically valuable interpretation.We propose to compare the result of the primary analysis with alterna-
tive methodologies, including time series analyses, which treat the data
continuously and incorporate the time-dependent correlation between
measurements. In addition, we are interested in determining if the
CGM data and clinical data on subject treatment can be used to further
optimize the current clinical algorithm and improve glucose control.
Trial registration and funding
This trial is registered with the ISRCTN (number 12793535) and
funded by the NIHR Efficacy and Mechanism Evaluation Programme.
The Efficacy and Mechanism Evaluation programme is funded by the
MRC and NIHR, with contributions from the CSO in Scotland, NISCHR
in Wales and the HSC R&D, Public Health Agency in Northern Ireland.
This report is managed by the NIHR Evaluation, Trials and Studies Co-
ordinating Centre (NETSCC) (Efficacy and Mechanism Evaluation, 11/
133/07 Real Time Continuous Glucose Monitoring in Neonatal Inten-
sive care). The views expressed in this publication are those of the
author(s) and not necessarily those of the MRC, NHS the National In-
stitute for Health Research or the Department of Health.
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Many strategies for treating cancers use combinations of drugs or mul-
tiple forms of treatment (e.g. Concurrent chemoradiotherapy). In most
early phase trials of two therapies (labelled as A and B, say) a fixed dose
of agent A is administered and only the dose of agent B is escalated.
The aim is to identify a recommended phase II dose combination
(RP2DC), i.e. The largest dose of agent B that, when combined with the
fixed dose of agent A, has a chance of causing a dose-limiting toxicity
(DLT) close to some predefined limit. Currently, more combination ther-
apy trials allow both treatments to be escalated; patients entering the
trial receive the best dose from a grid of possible combinations, and
one or more RP2DCs can be considered for use in phase II. However,
modelling the relationship between dose combination and toxicity can
be challenging since most parametric models require many parameters
to be flexible enough, and model assessment is impossible given the
limited data available in phase I trials.
The product of independent beta probabilities escalation (PIPE) de-
sign, a model-free approach for identifying multiple RP2DCs in dual-
agent phase I trials, is being used in ORCA-2, a phase I trial seeking
optimum dose and schedule combinations of olaparib in patients
with advanced head and neck cancer. However, the DLT observation
period for each patient is 13 weeks, with up to 40 patients planned
for a dose-escalation phase and another 10–30 patients planned for
a dose-expansion cohort. In trials using radiotherapy, some toxicities
can occur months after treatment, so long DLT observation periods
are required to ensure dlts are accurately captured and future pa-
tients are not at risk of excessive toxicity. In both settings, it is im-
practical to wait until all current patients have completed follow-up
before treating the next patient. Using data from patients that have
partially and fully completed DLT follow-up at the current time could
potentially reduce study duration and costs, particularly for trials of
combination therapies where sample sizes should be larger than
single-agent trials and recruitment is faster than expected.
We therefore propose an extension to the PIPE design that uses censored
toxicity and complete follow-up outcomes to assist with dose-escalation
decisions. We show how different recruitment rates affect both trial con-
duct and results relative to a trial that requires complete patient follow-
up. We consider scenarios where time-to-toxicity is distributed earlier, uni-
formly, or later in the DLT observation window and use an adaptive
weighting procedure that alters the amount of information each patient
provides based on previous DLT times. In the context of the ORCA-2 trial,
we obtain substantial reductions in trial duration, with comparable ex-
perimentation and recommendation properties to the planned design.
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We propose a two-stage design for a single arm clinical trial with an
early stopping rule for safety. This design employs different criteria
to assess early stopping and efficacy. The early stopping rule is based
on a criteria that can be determined more quickly than that for effi-
cacy. These separate criteria are also nested in the sense that efficacy
is a special case of, but usually not identical to, the early stopping cri-
teria. The addition of a curtailed sampling scheme allows for early
decisions to be made before all of the data has been observed. The
design readily allows for planning in terms of statistical significance,
power, and expected sample size. This method is illustrated with a
Phase II design comparing patients treated for lung cancer with a
novel drug combination to a historical control. In this example, the
early stopping rule is based on the number of patients who exhibit
progression-free survival (PFS) at 2 months post treatment follow-up.
Efficacy is judged by the number of patients who have PFS at
6 months.
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Background
Infection is a major concern in UK hospitals and it is estimated that
up to 8% of inpatients have an infection. The death rate from these
infections can reach 10-30% depending on the patient and patho-
gen. A number of non-modifiable patient factors (e.g. Comorbidities
and infection severity) are known to impact adversely on outcome.
However there are limited data available from large multicentre stud-
ies to investigate the importance of modifiable risk factors. ‘Blood
Stream Infection: Focus on outcomes’ is a multicentre, prospective
observational study with the primary aim of identifying modifiable
risk factors associated with all-cause mortality in patients with one of
six key pathogens. Modifiable data collected includes staffing levels,
antibiotic use (in particular the timing of appropriate therapy) and
use of intravenous lines.
Dataset
A total of 1,676 patients were included in the study across 5 centres.
The dataset comprises 48 modifiable and 38 non-modifiable factors.
The overall mortality rate is 20.8% (95% CI: 18.8% - 22.8%).
Analysis approach
Although the primary purpose of the study is to identify and esti-
mate the effect of modifiable factors, the analyses need to take the
non-modifiable risk factors into account. To maximise the degrees of
freedom available, the analysis was split into two stages. For the first
stage, a Cox model was fitted for the non-modifiable risk factors only
with the aim of deriving a risk scorer which quantifies each patient’s
risk of mortality. The second stage of the modelling is investigating
the modifiable risk factors and the risk score derived in the first stage
is included as a covariate (analysis underway).
Analysis challenges
The first challenge encountered was missing data; data were missing
for between 10% and 45% of patients for some of the key data
items. Secondly, in order to ensure the calculated risk score provides
the best summary of the relationship between the non-modifiable
factors and survival, it was important to ensure the most suitable
functional form of each continuous covariate was used. Finally, the
modelling required a survival analysis framework, which included en-
suring that the appropriate model assumptions were met.To overcome these challenges multiple imputation using chained
equations (“Ice” Command in Stata v14.0) was used to impute the
missing data items. Subsequently multivariable fractional polynomial
models were fitted on the imputed dataset (“Mfpmi” Command),
within a Cox model (“Stcox” Command). This command performs
backwards selection to select variables that are predictive of mortal-
ity, whilst finding the most suitable functional form of such covari-
ates, within a time to event model. Finally, the proportional hazards
assumption was checked in the final model, using standard methods.
Discussion
The use of multivariable fractional polynomials within survival ana-
lysis models using imputed data can be useful to find a best fitting
model for a dataset with missing data. The code in order to achieve
this is available in standard statistical packages, such as Stata. Frac-
tional polynomials can be difficult for non-statisticians to grasp and
may not be the best choice in settings where straightforward inter-
pretability of coefficients is required.
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Background
About 20% of patients who undergo primary total knee replacement
(TKR) surgery in the UK experience chronic pain after their operation.
The provision of healthcare services for these patients has been
found to be patchy and inconsistent in the NHS. Although chronic
pain is understood to be pain persisting for several months, the level
that pain must persist for a patient to be considered in chronic pain
is not defined. The aim of this work was to identify a cut-off point in
the pain component subscale of the Oxford Knee Score (OKS) that
could be used to identify patients in chronic pain following a primary
TKR.
Methods
We used patient-level data from the English NHS Patient Reported
Outcome Measures between 2012/13 and 2014/15. We included data
from 126,064 patients who responded to all seven pain component
questions of the six-month post-operative OKS questionnaire. The
pain component includes questions on level of pain, night pain, pain
while walking, standing up, limping, interference with work, and con-
fidence. All questions had five response levels from 0 (most pain) to
4 (no pain) so that the pain component subscale ranges from 0
(most pain) to 28 (no pain).
We adopted a data-driven approach in order to derive groups with
different levels of pain using cluster analysis. We applied a hierarch-
ical method of clustering whereby a multi-level hierarchical tree was
created by repetitively splitting data into clusters. “similar” observa-
tions (based on inter-observation distance) were placed in the same
cluster. Clusters were then split until no further dissimilarity could be
found, or until the maximum number of clusters was reached. The
cluster analysis was run for an increasing maximum number of clus-
ters from two to 10. Clusters were then examined based on their dis-
tribution over the range of the pain component subscale to identify
if the cluster with the lowest scores (highest pain) was stable as the
number of clusters increased. If a stable cluster was found, its highest
values would be identified as the cut-off point.
Results
The distribution of the hierarchical clusters over the pain component
subscale showed a changing shape for the highest pain group when
the maximum number of clusters was set to two or three, but a
largely consistent distribution was observed when the number of
clusters was set to four or higher. The highest score for the pain
component subscale for the high-pain cluster was 24 for two or three
clusters, but it converged to 14 for four clusters and above.
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Our study identified a stable high-pain group with consistent OKS
pain component scores between 0 and 14 using the hierarchical clus-
ter method. This cut-off point will provide a useful way to identify
patients for our trial on post-operative management of chronic pain
after TKR in the UK, and we expect that it will be equally useful for
other trials focused on patients with chronic pain after knee replace-
ment. Further work to better understand the uncertainty around this
cut-off point is recommended before adoption.
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Residuals in the proportional hazards (PH) model are useful in detect-
ing outliers or influential points in clinical trials by testing the propor-
tional hazards assumption and exploring functional form. Assuming
proportional hazards and non-informative censoring, the full likeli-
hood approach is used to obtain score and deviance residuals. The
first residual is based on the ideas used in obtaining the score-type
residuals in partial likelihood approach. The second type of residual
is based on the concept of the deviance residuals. We conduct simu-
lations and compare the performance of the full likelihood residuals
with other common residuals that are based on the partial likelihood
approach. In addition, the graphical approaches are used to illustrate
the applications of these residuals using some real life examples in
clinical trials.
Susan.halabi@duke.edu
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Background
Recently, Pocock and Stone (NEJM, 2016) proposed recommenda-
tions for reporting the results of randomized clinical trials depending
on whether the primary outcome was "positive" and another set of
recommendations when the outcome was "failed." We show that
these recommendations are difficult to implement in the body of pa-
pers for journals with limits on words, tables, and figures (e.g., 2700
words and 5 tables + figures for NEJM) in the main article; however,
the recommendations can be effectively implemented in online sup-
plementary tables and figures to add value to the reporting of the
RCT.
Methods
The analysis recommendations for ‘positive’ RCTs include: 1) display
of both relative and absolute risk of primary outcome; 2) use of 95%
confidence intervals; 3) analysis of parts if a composite primary out-
come; 4) analysis of secondary outcomes; and 5) subgroup analysis.
The recommendations for ‘failed’ RCTs include: 1) display of exact
p-value to assess trend; 2) use of 95% confidence intervals; 3)
power calculations; 4) subgroup analysis; 5) analysis of secondary
outcomes; 6) alternative analyses including covariate adjustment
and as-treated analysis; and 7) meta-analysis using external data.
Results
We show how these recommendations can be implicated in practice
using data from two published trials sponsored by the National Insti-
tute of Diabetes and Digestive and Kidney Disease (NIDDK), one posi-
tive and one failed: Farnesoid X nuclear receptor ligand obeticholicacid for non-cirrhotic, non-alcoholic steatohepatitis trial (Lancet,
2014) and Nortriptyline for Idiopathic Gastroparesis trial (JAMA,
2013).
Conclusions
Recommendations from Pocock and Stone can be incorporated into
the original article’s RCT’s main or supplementary analyses.
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Background
In phase I oncology clinical trials, the operating characteristics of
adaptive designs are used to evaluate the performance of adaptive
designs via a simulation study. Research has shown that no single es-
calation method has proven superior in all circumstances. Thus, an
interactive web application with a comprehensive score has been de-
veloped to find an appropriate adaptive design for conducting an
oncology phase I trial.
Methods
The web application evaluates twelve different designs: two versions
of the 3 + 3 design, accelerated titration design (ATD), biased coin
design (BCD), k-in-a-row (KIR) design, two versions of the continual
reassessment method (CRM) design, escalation with overdose control
(EWOC) design, escalation based on toxicity interval (EBTI) design,
the modified toxicity probability interval (mtpi) design, Bayesian opti-
mal interval design (BOIN) and T-statistics design. The dfcrm, bcrm
and BOIN packages in R software are used for CRM, EWOC, EBTI and
BOIN designs. Through simulation studies with a matched sample
size, a comprehensive score is used to evaluate the performance of
selected adaptive designs with desired parameters as well as differ-
ent scenarios.
Conclusions
The web tool provides an interactive graphical user interface that al-
lows users to easily conduct simulations and assess the best design for
meeting the primary objective of the proposed trial. Adaptive designs
and further information are available at http://cqs.mc.vanderbilt.edu/
shiny/adaptivedesigns/and will be updated soon.
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Background
Controlled Randomised Trials often struggle to recruit and there is
interest in innovative trial designs that can more effectively recruit
and retain patients and make the trials more efficient and patient-
centred. One innovation is the ‘cohort multiple randomised con-
trolled trial’ (CMRCT). Under a standard pragmatic RCT (pRCT) all pa-
tients are told about the different treatments in the trial arms,
including any new treatment, but only half are randomised to that
new treatment. The CMRCT design aims to make the trial consent
procedure more like standard health care, where people are only
asked to consent to treatments they are being offered and are not
told about treatments they cannot access. Under this design a sub-
stantial cohort of participants is recruited, then followed up at regu-
lar time intervals. To trial a new treatment, all eligible participants are
identified and a random sample offered the treatment. The
remaining eligible patients (those not offered the treatment)
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the trial or about treatments they will not receive. Advocates of the
CMRCT design claim significant advantages regarding recruitment,
patient centredness, and efficiency. Since the design was first pro-
posed a number of patient cohorts and related CMRCT s have been
established but very few have yet reported and good evidence for
these claims is lacking. We established the CLASSIC cohort of 4,377
patients with long-term conditions and are currently conducting a
CMRCT (PROTECTS) of a telephone-based health coaching interven-
tion. In the process of conducting PROTECTS, use of the CMRCT de-
sign has raised many methodological and statistical issues so far not
addressed in the literature. In this paper we consider these issues, re-
port how we tackled them within CLASSIC and PROTECTS, and their
implications for the design, conduct and analysis of CMRCTs.
Results
We have discovered many challenges to the use of the CMRCT de-
sign in actual practice. Primary amongst these are issues around
power and sample size calculation, and the nature of the treatment
effect being estimated, which have not previously received adequate
attention. The rate of patient non-consent to treatment is a critical
factor in determining sample sizes for both the CMRCT and the host
cohort, and also efficiency relative to a pRCT. We have also found
that some sampling practices commonly applied in pragmatic trials,
when applied to a CMRCT, can result in selection bias and the intro-
duction of unintended differences between trial arms. The fixed data
collection points that are a feature of CMRCTs can result in high vari-
ation in the intervals between measurement and treatment that is
less controllable than in more conventional designs and can cause
problems in analysis. CMRCT -specific CONSORT guidance may be
indicated.
Conclusions
The CMRCT research design is an intriguing development that may
offer several potential advantages over conventional designs. How-
ever, there are many challenges to the use of this design in actual
practice. Further research and methodological developments are
needed to determine whether, and in which contexts, the design can
live up to its initial promise.
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Background
The split-plot (S-P) design is historically associated with agriculture
studies, but more recently used in healthcare research. The S-P is a
complex design that has both cluster randomised and factorial ele-
ments, but is distinguished by two levels of randomisation: one at a
cluster-level and one at a lower or individual level. In a previous re-
view, we identified twelve S-P randomised controlled clinical trials
(RCTs). Nine reported a sample size calculation and all 9 based the
sample size on the cluster randomisation element ignoring the indi-
vidual randomisation element of the S-P design.
Objective
To estimate the optimal sample size for S-P designs and how sample
size calculations should be reported.
Methods
We used Monte-Carlo simulations to investigate the relationship be-
tween the number of clusters (5–45 per arm) with: intra-cluster cor-
relation (0.02, 0.06 and 0.1); intervention target differences at the
cluster-level and individual-level (0, 7.5, 15 for each); and statistical
power in a S-P design for both for the cluster and patient-level inter-
ventions. Current simulations assumed no interaction between inter-
ventions and a fixed cluster size of 25 but this will be extended to
varying levels of interaction and cluster sizes. Simulated data sets
were analysed using a mixed-effects model with a random-effect at
the cluster level in Stata 14.Results
We found that power for the cluster and individual-level depended on
the intervention target differences expected. If both target differences
were similar, a sample size based on the cluster-level intervention leads
to an overpowered comparison at the individual –level. The cluster-
level power is similar using simulation or applying a standard cluster
RCT formula. For a fixed cluster-level target difference, as the ICC in-
creased, there was an increase in power to detect target differences at
the individual –level due to increased overall sample size. However, if
the individual-level target difference was smaller than the cluster-level
there was a point at which the sample size and power should be based
upon the individual rather than the cluster-level target difference. For
example, we observed that when the individual-level target difference
is smaller than the cluster-level by 10% or more for an ICC of 0.01, the
sample size should be based on the individual-level difference.
Conclusion
Current sample size calculations in S-P RCTs are either non-existent
or incomplete. Researchers calculating a sample size for an S-P de-
sign should: 1. Indicate explicitly the target differences expected for
the cluster and individual-level interventions 2. Base sample size cal-
culations on the cluster-level intervention if the target differences ex-
pected at both levels are similar 3. Use simulation if a smaller target
difference at the individual-level is expected to estimate the number
of participants that need to be recruited The S-P design is an effi-
cient way to assess two interventions, when one of the interventions
needs to be randomised at the cluster-level.
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Background
In clinical research randomised controlled trials (RCTs) are seen as
the ‘gold standard’ for providing evidence to evaluate health care in-
terventions. Randomisation can ensure balance of baseline character-
istics between the intervention groups. In observational studies there
are often systematic differences between groups, typically analysed
using regression adjusting for measured confounders. However, pro-
pensity scores (PS) are an increasingly used alternative. This analysis
uses the unique opportunity provided by a large fractional factorial
RCT to investigate whether similar conclusions can be reached from
the results of the randomised interventions and their equivalent ob-
servational data from the non-randomised interventions within the
same RCT. The observational data are analysed using regression ad-
justment and propensity scores methods. The RCT investigated was
CORONIS, a 2x2x2x2x2 fractional factorial RCT comparing caesarean
section techniques on 15,935 women.
Methods
One intervention pair from CORONIS (repair of uterus: exteriorisation
vs. Intra-abdominal) is assessed for its effect on the primary outcome,
death or maternal infectious morbidity. The results of five analyses
are presented: using the randomised intervention: the unadjusted,
marginal risk ratio (RR), and using the non-randomised intervention:
logistic regression to derive the marginal RR, and an inverse probabil-
ity of treatment weighting propensity score (IPTW PS) model to de-
rive the marginal RR. The results of these analyses are compared.
Results
The unadjusted analysis of the randomised interventions provides no
evidence of a difference in effect of repair method on the primary
outcome (RR 0.94, 95% CI (0.80 to 1.11), SE = 0.08, n = 5925). Regres-
sion analysis on the non-randomised interventions adjusting for mea-
sured confounding shows similar results to that of the randomised
interventions, but is less precise (RR 1.01, 95% CI (0.72 to 1.44), SE =
0.18, n = 5894) and very similar to the IPTW PS analysis (RR 0.98, 95%
CI (0.70 to 1.39), SE = 0.18, n = 5925).
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The results from the analysis on the non-randomised interventions il-
lustrate the importance of adjusting for confounders when analysing
observational data. Results based on regression adjustment and pro-
pensity score analysis are comparable, but the latter has the added
benefit of greater transparency when assessing balance of the base-
line characteristics between the groups. It is possible for confounding
to be controlled for using standard regression adjustment or IPTW
propensity scores, though this may depend on data quality, which
this study benefited from.
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Background
Often randomised controlled trials measure an outcome repeatedly
over the study period. An area under the curve (AUC) approach sum-
marises serial measurements using a single measure. Missing data can
occur at one or more time-points; it is unclear what the optimum
method to use is when missing data are present. The aim of this work
was to explore different analysis strategies for dealing with missing
data for an AUC outcome in the ethos trial that compared two surgical
interventions, stapled haemorrhoidopexy (SH) and traditional haemor-
rhoidectomy (TH) for treating haemorrhoids. An AUC approach was
used because it was hypothesised that the interventions would have
different recovery trajectories with respect to quality of life.
Methods
The primary outcome in ethos was health related quality of life mea-
sured using the EQ-5D over a 24-month follow-up period (baseline, 1, 3
and 6 weeks post-surgery and 12 and 24 months post-randomisation).
The AUC was derived using the trapezoidal rule. There was a substantial
amount of participants with missing data (30%). The analysis strategies
were; 1) complete-case analysis (defined as data available at each time-
point); 2) minimal data analysis (including all participants with at least
one shorter-term and one longer-term follow-up measure); 3) last ob-
servation carried forward (LOCF); 4) simple imputation (intervention
group mean at that time-point); and 5) multiple imputation (MI). We
used linear regression with adjustment for design variables in Stata 14.
Simulations will be carried out to assess the statistical properties of each
methods for a range of follow-up profiles and missing data patterns.
Results
Seven hundred seventy-seven participants were randomised to SH
(389) or TH (388). Analysis of 570 participants with minimal data
favoured TH: mean difference in AUC −0.073 95% CI (−0.140, −0.006);
p = 0.034. The complete case (N = 400: −0.057 95% CI (−0.113, −0.001);
p = 0.046), simple imputation (N = 774: 0.054 95% CI (−0.089, −0.019);
p = 0.004) and MI (N = 774: −0.054 95% CI (−0.107, −0.000); p = 0.049)
analyses were similar. The LOCF analysis was not consistent with other
approaches (N = 774: 0.025 95% CI (−0.058, 0.109); p = 0.538).
Conclusion
The complete-case, minimal data, simple imputation and MI analyses
were in broad agreement, but LOCF was not. This was because SH
had a shorter recovery compared to TH, using LOCF to impute the
longer-term missing outcome biased estimates. LOCF should not be
used to impute missing data for an AUC outcome when interven-
tions have potentially different recovery trajectories.
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The standard 3 + 3 Phase I design remains the most widely used
Phase I design in practice, despite an increasing number of both
rule-based and model-based designs that range in complexity, but
generally outperform the standard (Yuan et al., 2016). Few have inte-
grated common measures of Phase I design performance such as
correct selection of the maximum tolerated dose (MTD), average
number of dose-limiting toxicities and average number of patients
treated above the MTD with a measure of overall success. We aimed
to characterize the ability to recognize a safe and efficacious drug by
the end of Phase III using six Phase I clinical trial designs, each
followed by a standard Phase II and Phase III design.
Methods
Six Phase I designs (3 + 3, CCD, BOIN, mtpi, mtpi2, and CRM), each
followed by a standard Phase II (Simon’s optimal 2-stage) and Phase
III (1:1 randomized group sequential with two interim analyses) study
were implemented. Dose limiting toxicity and response data were as-
sumed binomially distributed, and survival data exponentially distrib-
uted. Eight toxicity profiles representing gradually increasing toxicity
across dose levels, fairly constant toxicity that is considered safe, and
a jump in toxicity between two adjacent dose levels were each eval-
uated with a linear response/survival profile using 4000 simulations.
Results
As anticipated, results varied depending on the true underlying tox-
icity profile. Under the conventional assumption that toxicity grad-
ually increases with increasing dose level, all non-standard designs
had higher MTD and overall selection rates than the standard 3 + 3
design. However, the non-standard design with the highest MTD se-
lection rates, the CRM, was too aggressive and over-estimated the
true MTD most frequently, resulting in the lowest overall selection
rates among the non-standard designs. Overall selection rates for the
CCD, BOIN, mtpi, and mtpi2 were all within two percentage points of
one another and consideration of logistical complexities as well as
design familiarity in choosing among these is reasonable. For a fairly
constant toxicity profile that is safe, all non-standard designs resulted
in higher MTD and overall selection rates than the standard 3 + 3 de-
sign. The CRM appeared most aggressive in escalating and recom-
mending the highest dose level which resulted in higher overall
selection rates, followed in order by BOIN, CCD/mtpi, and mtpi2. With
a jump in toxicities between adjacent dose levels, the standard 3 + 3
design more often recognized when the MTD had been exceeded
compared to the non-standard designs; non-standard designs too
frequently over-estimated the MTD, resulting in overall success rates
that were either similar to or lower than the overall success rate
when using the standard 3 + 3 design. Thus, the conservative nature
of the standard 3 + 3 design was preferable under these scenarios. In
short, selection of a Phase I design should be based on the under-
lying toxicity profile that is anticipated, with appropriate safeguards,
and should consider the MTD selection rate in conjunction with
over-dosing and under-dosing errors that influence the overall selec-
tion rate of a favorable drug.
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Patient preference plays a role in clinical practice, and is at the heart
of patient-centered outcomes research, thus ignoring the impact on
outcomes would be unrealistic. Furthermore, a patient may have a
different psychological response to a treatment he/she deems more
favorable. Patient preference can have a substantial impact on a
study’s outcome, particularly when it is not feasible to conduct a
blinded study. While the completely randomized design, the trad-
itional clinical trial setting where individuals or clusters are randomly
allocated to one of multiple treatment groups, is the gold standard
for assessing a treatment effect (the average effect a particular
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the role patient preference may have on study outcomes; they are
not estimable in this design. The two-stage trial design first proposed
by Rucker, also known as the doubly randomized preference trial,
enables researchers to disentangle the treatment effect from those
effects resulting from choosing a treatment. While the use of the
two-stage trial design is becoming more prevalent, especially as the
emphasis for use of decision aids continues to grow and the number
of trials testing behavioral interventions increases, there is still a large
gap in the methods available to design and ultimately analyze these
trials. Often the primary outcome of interest is not measured on a
continuous scale; typically, binary outcomes (e.g. Are patients satis-
fied with their treatment) are used. In addition, we are often inter-
ested in accounting for important covariates (e.g. Age, gender, and/
or type of insurance coverage) that may have an impact on the out-
come of interest, or may influence the preference rate (e.g. Men may
have a stronger preference for a surgical intervention, while woman
may have a stronger preference for a medical intervention). Cur-
rently, no methods exist to accommodate these scenarios. We
present our extensions of the two-stage clinical trial design for sam-
ple size determination and analysis for binary outcomes with stratifi-
cation and give closed form sample size formulas.
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Background
Well-run clinical trials represent the gold standard for assessing effi-
cacy of interventions. Using observational (i.e. Non-randomized) data
to determine treatment efficacy requires statistical adjustment and
often untestable assumptions.
Objective
We determined the degree to which SEER (a large generalized co-
hort) could replicate findings from the Early Breast Cancer Trialists'
Collaborative Group Meta-Analyses of Randomized Trials (a highly se-
lective cohort). This was in part motivated by a research letter on the
subject (McGale et al. Can Observational Data Replace Randomized
Trials, Journal of Clinical Oncology 2016, 34(27):3355–3356).
Methods
We identified women diagnosed with node positive breast cancer
treated by mastectomy from 1990 to 2008 in the SEER database. We
examined the effectiveness of radiotherapy on survival outcomes
using adjusted Poisson regressions, confirmed by Cox or Fine & Grey
competing risk regressions. We compared our findings with those re-
ported in a meta-analysis of clinical trials as reported in the Journal
of Clinical Oncology.
Results
The published meta-analysis found that radiotherapy had a protect-
ive effect on breast cancer specific survival (Rate Ratio [RR] = 0.84,
95% Confidence Interval [CI] 0.76 to 0.94), and overall survival (RR =
0.89, 95% CI 0.81-0.97). In the SEER data, we found that the un-
adjusted effect of radiotherapy on breast cancer specific death was
harmful, RR = 1.29 (95% CI 1.25-1.33), but that the adjusted effect
was beneficial, RR = 0.91 (95% CI 0.88-0.94). The unadjusted effect of
radiotherapy on overall survival was RR = 1.08 (95% CI 1.05-1.11),
while the adjusted effect was 0.87 (95% CI 0.84-0.89). Adjustment for
the number of positive nodes had a primary confounder impact re-
sponsible for the qualitative discrepancy between the unadjusted
and adjusted findings.
Discussion
Although our adjusted SEER estimates were less beneficial in magni-
tude than the clinical trial estimates, they were consistent in direc-
tion and significance. Of note, clinical trial data often providesevidence of efficacy, while observational data provides evidence of
effectiveness (Piantadosi 1997). It is not surprising that the overall ef-
fectiveness of a treatment would be attenuated when used in the
general population. The discrepancy between the unadjusted and
adjusted findings highlight the importance of developing standards
for evaluating quality of observational data analyses to ensure proper
control of confounding. We are currently developing a software as-
sistant that will assist in standardization of studies using linked SEER-
Medicare data. Recently published trial findings have similar compari-
sons with observational data. Hamdy et al. (10-Year Outcomes after
Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer,
NEJM, Advance release) found no statistically significant differences
in mortality among men with localized prostate cancer randomized
to monitoring, surgery, or radiotherapy. However, fewer than 1.2% of
men in all groups died from prostate cancer at 10 years. The point
estimates were similar to a SEER-Medicare analysis (Wong et al. Sur-
vival Associated with Treatment vs Observation of Localized Prostate
Cancer in Elderly Men JAMA 2006). Unlike the randomized trial, the
observational data findings were statistically significant, perhaps be-
cause the sample size was over 50 times larger.
Conclusion
Using properly analyzed observational data can provide generalizable
effectiveness information in a non-trial population.
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Obesity continues to be a major risk factor for diabetes and is esti-
mated to cause 365,000 deaths annually in the US, thus placing it as
the third cause of death after Heart Disease and Malignant Neo-
plasms. The Look AHEAD trial sought to determine whether the
highly successful lifestyle intervention employed in the Diabetes Pre-
vention Program to reduce incident diabetes among pre-diabetic in-
dividuals is effective in reducing the incidence of major acute
cardiovascular events. The Look AHEAD trial randomly assigned
5,145 overweight or obese individuals with type 2 diabetes to either
a control intervention consisting of Diabetes Support and Education
(DSE) or an intensive lifestyle intervention (ILI) consisting of a weight
loss program and increased physical activity. The six-month intensive
intervention was tapered to a maintenance phase for the remainder
of the trial, which had a maximum follow-up of 13.5 years and 90%
statistical power to detect an 18% reduction in cardiovascular dis-
ease. After the trail was launched, the event rate in the control arm
for the primary outcome measure (a composite of death from cardio-
vascular causes, non-fatal MI and non-fatal stroke) was observed to
be only 0.7%, per year, much lower than the design event rate of
3.125% per year. In spite of an adjustment to the primary outcome
by adding hospitalization for angina as defined by American Heart
Association criteria, and extending the design follow-up from 10.5 to
13.5 years, the trial was stopped for futility after 11 years maximum
follow-up.
In an effort to understand the null results, we examined the baseline
characteristics of the enrolled trial participants and compared them
to baseline characteristics of participants in other contemporary
major clinical trials in diabetes. Look AHEAD participants were found
to be of younger age, with a higher proportion of females, a lower
proportion of history of cardiovascular disease, and shorter duration
of diabetes that those enrolled in comparable clinical trials. The pro-
file suggests a much lower risk for cardiovascular events than had
been anticipated, approaching a floor effect for benefit of an inter-
vention. The Look AHEAD experience has considerable implications
not only for estimating event rates for the purpose of sample size
calculations but for methods of managing safety concerns, screening
for eligibility as well as monitoring the characteristics of enrolled par-
ticipants in real time. These factors will be discussed in the context
of other clinical trials with null results.
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Background
Permuted Block Randomisation (PBR) was first suggested in 1952 by
Austin Bradford Hill [1] to restrict the possible degree of imbalance
that might occur in a stratified randomised trial. In the following sixty
years, several alternative methods have been proposed and well-
studied as regards the trade-off between imbalance control and pre-
dictability. Such methods include - but are not limited to - the class
of biased coin designs, the big stick design, the class of urn designs,
the maximal procedure and the block urn design, almost all of which
have shown to have lower predictability than their permuted block
counterparts. Despite the developments, recent review articles have
found that individually-randomised trials performing stratified ran-
domisation (using randomisation within mutually-exclusive strata,
rather than covariate-adaptive randomisation methods) almost exclu-
sively use PBR to generate the allocation sequence. In addition, a re-
cent article on the subject [2] stated that ‘there is no argument in the
literature to suggest that the permuted block design is better than or
even as good as the [Maximum Tolerable Imbalance] procedures’. The
question must be asked as to why statisticians continue to recommend
the use of the inferior PBR method over any other that has been shown
to be better at reducing the risk of selection bias.
Methods
Presentations were given to statisticians at the Leeds Institute for Clin-
ical Trials Research. In one, presented to an unscientifically-selected
sample of statisticians, two alternatives were introduced in a scenario
where members of independent oversight committees objected to use
of Varying-size PBR in an open-label randomised trial, requesting justifi-
cation for not using either of the suggested alternatives. (Soares and
Wu’s Big Stick Method and Zhao and Weng’s Block Urn Design) In the
second - open to all statisticians - any alternatives were presented in a
meeting, and statisticians were invited to discuss reasons for current
PBR use and invited to discuss justifications either to continue using
PBR, or to use other methods in trials involving restricted randomisa-
tion sequences within mutually-exclusive strata.
Results
Justifications given by statisticians for using PBR and varying-size PBR in-
cluded questions around the motivation of clinicians to subvert the ran-
domisation sequence, ability to correctly implement the alternative
methods, a belief that weaknesses of fixed-size permuted blocks are over-
come by use of randomly-varying block sizes and that alternative methods
do not yield sufficient reductions in predictability to justify their use.
Conclusions
Since statisticians make recommendations about appropriate methods
of allocation sequence generation, take up of better randomisation
methods depends on educating statisticians as to existence of alterna-
tive methods, that they can be readily implemented, and that the con-
vergence strategy is as big a risk of selection bias as the ‘perfect
prediction strategy’, if not moreso.
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Trials 2017, 18(Suppl 1):P94In January 2016, a new National Institutes of Health (NIH) policy went
into effect requiring that researchers consider sex as a biological vari-
able in animal and human studies (see NOT-OT-15-102 Guidance).
This requires grant applicants of NIH-funded research studies to ex-
plain how sex will be factored into research design, data analyses
and reporting, requiring strong justification for studying only one
sex. The policy is meant to increase the quality and generalizability
of biomedical research, thus enhancing the reproducibility and trans-
latability of research in the biomedical field.
We will present best practices for implementation of sex as a bio-
logical variable in the various phases of a clinical trial, and will in-
clude examples from the National Institute on Drug Abuse (NIDA)-
funded grants. The first step in implementation involves a rigorous
literature review that would explain how sex may influence the study
design based on previous preclinical or clinical research. If there is a
reasonable foundation of existing research, sex-specific hypotheses
could be generated, including primary, secondary or exploratory hy-
potheses. The next step entails developing a study design, which
should include a statistical analysis plan that provides for subgroup
analyses identifying differences in the intervention effect by sex.
Such subgroup analyses should be implemented using interaction
models to test whether the treatment effect differs across sexes, or
an analogous approach if there is no modeling. Recognizing that
most clinical trials are not powered to detect differences based on
gender, these analyses are exploratory in nature. In progress reports
and publications, the study findings should include whether sex dif-
ferences were, or were not, detected. Grantees are also required to
report annually on the enrollment of males and females so that this
can be monitored throughout the implementation of the trial.
This new policy guides researchers to take into account whether
there are biological factors related to sex which should be explored
in the study design or approached differently than originally
planned. The NIH policy will have an impact on the planning and
the conduct of clinical trials in humans and potentially new rela-
tionships between disease entities and sex will be explored and
given more weight.
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Phase I clinical trials are typically set up to establish the safety of a
proposed drug, study the pharmacokinetics and pharmacodynamics
of this drug and to identify a dose which is suitable for taking for-
ward to a further trial. Good design of Phase I studies is often chal-
lenging, due to limited evidence to inform study protocols. The
traditional approach for Phase I trials uses prespecified rules to assign
patients to dose levels and choose the recommended dose for the
next study, typically the ‘3 + 3’ design or variations. However, while
easy to implement, the operating characteristics of rule-based de-
signs tend to be unattractive. Not only can such designs lead to poor
decision making regarding the future investigation of the drug, but
they may also expose unnecessary numbers of participants to in-
appropriate doses. Adaptive designs, such as the Continual Reassess-
ment Method (CRM), which seek to model a dose–response curve
using all available information offer an alternative, and can be con-
veniently carried out within a Bayesian framework. These model-
based designs are now well-established in cancer, but much less so
in other clinical areas.
A phase I study to assess the safety, pharmacokinetic profile and
antiretroviral efficacy of C34-PEG4-Chol, a novel once-weekly pep-
tide fusion inhibitor for the treatment of HIV-infection, was set-up
with MRC funding. During the study work up, Bayesian adaptive de-
signs based on the CRM were compared with a more standard
rule-based design using simulation studies based on seven test
Trials 2017, 18(Suppl 1):200 Page 37 of 235scenarios, with the aim of choosing a design that would maximise
the scientific information gained from the study [1]. A dose-
inefficacy curve rather than the more usual dose-toxicity curve was
modelled. In determining the implementation details, five key ques-
tions were addressed: 1) how is the endpoint defined? 2) how will
the target dose be identified? 3) what are plausible scenarios? 4)
which drug doses should be available? And 5) what cohort sizes are
practical? While the results showed no optimal design for all cir-
cumstances, the trial team concluded there were clinical advan-
tages in choosing an adaptive design over the originally proposed
rule-based design.
The process of specifying and evaluating the design options was
time-consuming, and required the active involvement of all members
of the trial’s protocol development team. However, the effort was
worthwhile as the originally proposed rule-based design was re-
placed by a more efficient Bayesian adaptive design. While the out-
come to be modelled, design details and evaluation criteria are trial
specific, the principles behind their selection are general. This case
study illustrates the steps required to establish a design in a novel
context.
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Cluster randomized trials (CRTs) are increasingly being used in public
health research to test interventions that are delivered at a cluster
level (e.g., in schools, hospitals, clinics, etc.). From a statistical per-
spective, the ideal for these trials is first to consent (recruit) partici-
pating clusters, then obtain consent from individuals participating
from each cluster (if needed), and finally randomize each cluster to a
treatment arm. This ideal minimizes the possibility of bias in the esti-
mated treatment effect and preserves the internal validity of the trial.
However, this ideal requires that clusters agree to study participation
and randomization, which in practice may be difficult and instead re-
sult in clusters simply choosing not to participate in the study. Such
nonparticipation by clusters may limit the external validity of study
findings. Motivated by a school-based trial of physical activity promo-
tion programs in Ohio Appalachia, we discuss strengths and weak-
ness of an alternative approach where clusters are randomized first
and then approached for consent to study participation. This ap-
proach has the potential to improve cluster consent rates, but risks
bias due to differential participation rates by factors that may also in-
fluence the outcome. By providing a framework for when this bias
may occur and its potential magnitude, we provide guidance for fu-
ture studies about the statistical tradeoffs between (1) the traditional
consent then randomize approach and (2) the alternative randomize
then consent approach under various assumptions about cluster par-
ticipation rates and factors influencing a cluster’s decision to consent.
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Trials 2017, 18(Suppl 1):P98While randomised controlled trials remain the gold standard for the
evaluation of new therapies, the development of targeted therapies,
disease monitoring, and the concomitant increase in stratification of
patients presents new challenges in trial design. Increasingly, patient
eligibility becomes dependent on on variables which are known after
trial enrolment. Especially in conditions such as haematological ma-
lignancies, where delays in therapy can prove costly, treatment mo-
dalities may need to be amended in real time to take into account
molecular or genetic factors, where the test result is only available
some days after the start of treatment, or a patient’s minimal residual
disease status, again only available at the start of the next course of
treatment. It is therefore imperative to be able to direct therapy ap-
propriately, and allow prompt randomisation to the correct targeted
therapy. In the context of Acute Myeloid Leukaemia, there are a
number of potential targeted therapies which would typically start
after a 7–10 day course of chemotherapy. To avoid the dilution of re-
sults from patients not suitable for the therapy, randomisation needs
to take place once eligibility is known, but before targeted treat-
ment is due to start. Similarly, in an evaluation of minimal residual
disease monitoring, only those patients with a suitable target
should be randomised between monitor and no monitor. There is
therefore a need to ensure communication between clinicians, trials
office and the different accredited laboratories so that prompt and
appropriate randomisation takes place, allowing patients access to
an appropriate targeted therapy, and giving maximal power to de-
tect treatment differences. We present a generalised approach to
managing such trials, based upon an integrated computer system,
automated notification emails, and monitoring of take-up rates. The
approach is flexible enough to allow for several different targeted
therapies given in addition to chemotherapy in a factorial design,
real-time risk adapted therapy options, and the evaluation of the
benefits of sequential disease monitoring using digital PCR. The
approach builds upon the AML15 trial, which was an early rando-
mised evaluation of targeted therapy, and has been successfully
used with a network of over 100 sites in the UK, Europe, Australia
and New Zealand.P99
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Biomarker-guided treatment is a rapidly developing area of medicine,
where treatment choice is personalised according to one or more of
an individual’s biomarker measurements. A number of biomarker-
guided trial designs have been proposed in the past decade, includ-
ing both adaptive and non-adaptive trial designs which test the ef-
fectiveness of a biomarker-guided approach to treatment with the
aim of improving patient health. A better understanding of them is
needed as challenges occur in terms of trial design, analysis and
practical application, including the control of the false-positive rate,
power of the study, prevalence of the biomarker, treatment effect es-
timation and the potential increases in cost and time. We have
undertaken a comprehensive literature review based on an in-depth
search strategy with a view to providing the research community
with clarity in definition, methodology and terminology of the vari-
ous reported biomarker-guided trial designs from a total of 211 in-
cluded papers. Of these 211 included papers, 107 papers related to
biomarker-guided adaptive trial designs were reviewed in our pub-
lished paper Antoniou et al. (2016) [1]; biomarker-guided non-
adaptive trial designs were referred to in 100 papers and are
reviewed in our more recent paper to be published shortly.
Navigating the literature to gain an understanding of which trial de-
sign to implement in a given situation, and the practical implications
Trials 2017, 18(Suppl 1):200 Page 38 of 235of doing so is difficult as our reviews revealed. Hence, in order to im-
prove the understanding of the biomarker-guided trial designs and
provide valuable and much-needed guidance on their implementa-
tion we are developing a user-friendly online tool (www.bigted.org)
informed by our literature review. Bigted will provide an easily ac-
cessible resource to inform on the most optimal design when
embarking on a biomarker-guided trial including easy to navigate
graphical displays of the various trial designs. Knowledge on how to
design, implement and analyse these trials is essential for testing the
effectiveness of a biomarker-guided approach to treatment. Hence,
in this study, we focus on key statistical aspects of several of the
identified trial designs with particular focus on examining the sample
size requirement under different settings where outcome is time-to-
event. To achieve this, we applied statistical simulation methods and
here we report on our findings.
Reference
1. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided
Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Plos ONE. 2016;11(2):e0149803. doi:10.1371/journal.pone.0149803.
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Background
Implementation fidelity has been described as the extent the
intervention-as-delivered matched the intervention-as-planned. The
primary goal is to increase scientific confidence that an intervention
under evaluation has been adequately tested and that the measured
outcomes are a reliable indication of its effectiveness. This decreases
the likelihood of incorrectly accepting the null hypothesis as a result
of inadequate implementation, and of potentially effective interven-
tions being discarded. Under-evaluation or under-reporting of fidelity
can also make it difficult to replicate an intervention, and to be sure
the outcomes could be reproduced. Primary care may be particularly
vulnerable to low implementation fidelity due to a tendency towards
pragmatic trials of complex interventions being delivered by multiple
implementers across multiple settings. Although important reasons
exist for why we should invest in high quality evaluations of imple-
mentation fidelity, there is little guidance available, and little evi-
dence for which might be the optimal method in various contexts.
The aim of this study was to conduct a systematic mapping review
of methods currently in use for the assessment of implementation fi-
delity across primary care trials.
Methods
A search strategy was developed and agreed with input from all
members of the research team, two information specialists, represen-
tatives from a local group of trial managers and the extant literature.
The databases tested for citations were Medline®, Excerpta Medica
Database (Embase), and Cumulative Index to Nursing and Allied
Health Literature (CINAHL®). For each database, search terms were
adapted according to the search capabilities of that database. To be
included in the review, studies or trial protocols had to have been
published in the last 10 years and report on any primary care inter-
vention undertaken in a general practice setting in the context of a
complex effectiveness trial. This included full trials, feasibility studies
and/or pilot RCTs. Studies had to state in title or abstract that they
had included assessment or reported on implementation fidelity. The
initial searches resulted in 6253 citations across the three databases.
Electronic abstract screening by two reviewers is underway.
Next steps
Discordant decisions will be discussed and persistent discordant deci-
sion will be referred to a third reviewer for decision. Following the re-
trieval and screening of full papers and reference checking, dataextraction will be performed by one reviewer and checked by a second.
Data extraction will include information on study type, the nature of
the planned intervention, the extent of implementation fidelity assess-
ment including methods of data collection and analysis, and level of in-
tegration into outcomes evaluation. Preliminary results suggest that
implementation fidelity has been under-evaluated and under-reported
however these results will be refined through the formal mapping.
Discussion
In light of the evidence produced by our review, we will share our
recommendations for practical steps towards high quality evaluation
of implementation fidelity in the design of future primary care trials.
We will also discuss the strengths and limitations of methodological
reviews of trial conduct and how the quality of implementation fidel-
ity evaluation might be more formally appraised going forward.
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Background
The feasibility and effectiveness of novel procedures for improving
viability of organs for transplantation is a growing area of research
and assessing the various outcomes of these procedures is vital to
understanding the overall benefit relative to current practices. Under-
standing the implications of reducing discard rates, particularly in
kidney and liver transplantation, would aid in the development of
more practical analytical frameworks for assessment of these novel
procedures.
Objective
The primary objective of this systematic literature review is to iden-
tify research which assesses the clinical and economic impact of kid-
ney and liver discard rates in transplantation research in order to
understand how kidney or liver discard rates impacts on the risk of
disease progression and mortality as well as cost of care.
Methods
The following databases were searched: MEDLINE via PubMed,
EMBASE, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), the Transplant Library and the National Institute of Health
Clinical Trials database. Reference lists were also hand searched for
other relevant trials/reviews. Research focusing on Kidney or Liver
transplantation was reviewed. To be included in the review, the re-
search results needed to specify the status of and/or analytical as-
sessment of discard rates. Extracted information from studies
meeting the inclusion criteria included: author, year, title, organisa-
tion, country, study type, organ type, donor type, categorisation of
reference to discarded organs within research and outcomes re-
ported. The quality of the studies included was assessed using the
Cochrane Risk of Bias Tool; for assessing the quality of reviews, the
ROBIS bias assessment tool was applied.
Results
TBC
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The Core Outcome Measures in Effectiveness Trials (COMET) initiative
was instigated to develop the minimum set of standardised key out-
comes that should be assessed in studies, making it easier for results of
different studies to be compared, contrasted and combined. Within a
systematic review of the effects of proton beam radiation therapy (PBT)
in children with malignant Central Nervous System (CNS) tumours we
assessed the standardisation of outcome measures utilised.
Methods
Twelve electronic databases were searched from 1985 onwards.
Comparative and non-comparative studies were included. Outcomes
included overall survival (OS), surrogate survival outcomes, local/dis-
tant failure rates (LFR and DFR), response rates, toxicities, long-term
adverse events, neurocognitive outcomes and quality of survival.
Standard systematic review methods were used to minimise bias in
study identification, selection and data extraction.
Results
Seventeen studies (one single arm phase II trial and 16 case series)
included a total of 492 patients. Mean sample size of 29 (range: 6–
109), with a mean length of follow-up of 3.1 years (range: 0.1-
27.2 years). All treatment regimens assessed were multi-modality. Of
the 492 patients, 442 (90%) were newly diagnosed and 53 (10%) had
relapsed disease. Tumour types included were low-grade gliomas,
medulloblastoma or supratentorial primitive neuroectodermal
tumours(SPNET’s), ependymoma,atypical teratoid rhaboid tumours
(AT/RT), germ cell tumours, and pineoblastomas.
Fifteen studies (460 patients; 93%) reported OS, eight progression-
free survival (265 patients; 54%), three disease-free survival (144 pa-
tients; 29%) one event-free survival (8 patients; 2%), one time-to-
progression (59 patients; 12%), 12 LFR (342 patients; 70%), eight DFR
(190 patients; 39%) and five response rates (39 patients; 8%). How-
ever, all survival outcomes were measured from different time points
across the studies. Two studies (5%) measured survival from diagno-
sis, five (38%) from the start of PBT, six from completion of PBT
(28%), whilst the remaining three studies (29%) did not report base-
line timing of survival outcomes. This can potentially alter results.
One study of 31 patients (6%) reported 2-year OS from both the time
of diagnosis [68.3% (95% CI: 52.9%-88.1%)] and the end of PBT
[52.9% (95% CI: 36.0% - 77.8%)] indicating the differences in results
obtained from when baseline PBT is measured. Endocrinopathies and
ototoxicities were the most commonly reported medium-term ad-
verse events, both reported in seven studies with 229 (47%) and 126
(26%) patients respectively. There was little standardisation in the
measures used to assess either outcome. In relation to endocrinopa-
thies six different scales, including any type of endocrinopathy (un-
specified), had been utilised, and the studies employed different
criteria to define these outcomes. In terms of ototoxicities, a total of
five different scales had been used across seven studies, with only
two using standardised outcome measures. Results on neuro-
cognitive outcomes (85 patients) were highly limited.
Conclusions
There is a need to standardise outcomes and their measurement
within studies of children undergoing radiotherapy including PBT. In
particular, survival outcomes need to be measured from the com-
mencement of PBT in order to facilitate comparisons between differ-
ent studies. Long-term adverse events need to be better defined and
measured using standardised scales.
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A Bayesian NMA model is often used to estimate the effect of each
intervention compared to others synthesizing results using rank
probabilities. In several cases, a NMA is associated to a loss ofinformation due to incomplete study data retrieved through a sys-
tematic review, which are therefore excluded from the analysis. Sev-
eral methods are provided in literature to handle missing or
incomplete data in a NMA. It is often the case that only baseline and
follow-up measurement are available; to obtain data about mean
change it is necessary to consider pre-post study correlation. In a
Bayesian framework, some authors (Abrams, 2005), suggest imput-
ation strategies of pre-post correlation. In other cases, a variability
measure associated to mean change score might be unavailable. Dif-
ferent imputation methods are suggested, as those based on max-
imum standard deviation MSD imputation. The purpose of this study
is to verify the robustness of Bayesian NMA with respect to different
imputation strategies through simulations. Fifty trials are simulated in
full databases by including baseline, follow-up and Delta variation in-
formation. Baseline data are obtained by sampling from bounded 0–
100 normal distributions (X ~ N(41.8,21.5)) (Cannon, 2000), to mimick
the support of WOMAC score. Delta variation data are simulated from
normal distributions with parameters provided by a review about 6
FANS treatments. Follow up variability data are provided from gener-
ated Delta and baseline variability measures setting hypotheses on
pre-post correlation and considering, in each scenario, a sequence
from 0.3 to 0.95 by 0.05. Sample size are obtained by sampling from
an uniform 50–100 distribution. Between trial heterogeneity has
been included as a variability measure by following, for each simula-
tion setting, a sequence from 0.1 to 5 by 0.1. Each scenario provides
different combinations of heterogeneity between trials and pre-post
correlation creating 700 scenarios. For each scenario 2 imputed data-
bases are generated. In the first case, information about Delta vari-
ation are randomly removed, from full database, leaving only
baseline end follow up data, then variability of mean change is im-
puted using the correlation method. In the other case, also informa-
tion at baseline and follow up are removed, then Delta variability
isimputed with maximum standard deviation method. On simulated
dataset, NMA, with random effect and Uniform (0,5) prior on hetero-
geneity parameter, has been performed (MCMC method, 200000 iter-
ations, 4 chains). To investigate robustness of NMA, under several
scenarios and different imputation methods, the bias of rank prob-
abilities estimates has been computed in order to check models per-
formance in ranking treatments. For each scenario, the mean, bias
and the standard deviation of the first rank probability, for full and
imputed databases, have been computed. The results show that the
bias is very small for every scenario, then ranking provided by
models is robust with respect to different imputation methods. The
method is more robust to imputation in a low heterogeneity frame-
work, especially if considered trials are conducted on similar popula-
tion. Small bias is observed also for heterogeneity values similar to
expectation of NMA heterogeneity prior, indicating more robustness
if a priori knowledge is well specified.
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Background
A cluster randomized clinical trial (CRCT) is a trial that randomizes
clusters of people, but collects data on individuals. Concerns about
the quality of reporting of results from CRCTs led to the publication
of Consolidated Standards of Reporting Trials (CONSORT) statements
for CRCTs in 2008 and 2010. Additional CONSORT criteria for CRCTs
include: identification as a CRCT (title), the numbers of clusters and
individuals randomized to each group (abstract), the intracluster cor-
relation used for sample size calculation, and how clustering was
taken account in the statistical methods. A review of CRCTs pub-
lished in 2000–2008 concluded that reporting improved after CON-
SORT publication but remained suboptimal. No reviews have looked
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We sought to determine whether adherence to CONSORT guidelines
has improved and whether CRCTs could be identified in trial registries.
Methods
We focused our review on CRCTs designed to improve the care of
patients with diabetes through interventions aimed at either patients
or health care providers. We searched pubmed in September 2016
using the terms Diabetes AND ((cluster randomized) OR (cluster ran-
domised) OR (group-randomized) OR (group-randomised)). Reviews,
bibliographies, and registries were searched for additional publica-
tions. Publications were classified as: diabetes treatment, diabetes
prevention, or not diabetes and as CRCT or not. We extracted data
on the adherence to CONSORT guidelines and determined the trial
registration status for each publication (included in the publication,
registered but not included, or not registered). This information was
used to group publications by trial and we selected the primary re-
sults publication, if any, for each trial.
Results
Our search identified 557 English language publications between
2000 and 2015, 349 of which included patients with diabetes. 262
(75%) were reports of CRCT. Excluded publications used terms like
“parallel group randomized”, “cluster of risk factors”, “cluster sam-
pling”, and “Cluster analysis” or were reviews. A few excluded publi-
cations called themselves CRCT but were trials where individuals
were randomized to receive treatment in groups. An additional 54
publications were found for a total of 316 publications from 186 tri-
als: 143 primary results, 81 design, and 92 secondary. We grouped
the 143 results publications by year published: 44 in 2000–2007, 39
in 2008–2011, and 60 in 2012–2015. The percent with CRCT in the
title (18%, 51%, 63%) and the percent registered (11%, 79%, 83%) in-
creased over time. 86% had the number of clusters in the abstract,
78% discussed clusters in the statistical analysis plan, and 49% in-
cluded the sample size intracluster correlation. Only 39/86 registered
trials included the word cluster in the registration (clinicaltrials.gov
17/47, ISRCT 14/26, ACTRN 4/6, others (4/7).
Conclusions
The quality of CRCT publications has increased, but there con-
tinue to be publications that are underpowered and do not ac-
count for the effect of clustering in the analysis. Trial registries
do not currently include a code for CRCT or a structured means
of recording the number of clusters in results. The description of
CRCTs in registries needs to be improved so these trials can be
included in systematic reviews.
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Background
The number of stroke rehabilitation trials reported is rapidly increasing.
Efficient trial design contributing to advances in rehabilitation should be
informed by completed trials in the field. More than 50,000 people in
the UK each year acquire aphasia: a stroke related language impairment
affecting the ability to speak, understand speech, read and write with
significant consequences for quality of life. Existing Cochrane systematic
review evidence indicates that speech and language therapy (SLT) bene-
fits language recovery in people with aphasia, however, the specific
patient and intervention factors which predict optimal recovery and
rehabilitation are unclear. By using a wider dataset with individual pa-
tient data (IPD) analysis we are enhancing the evidence synthesis process
with the aim of addressing these evidence gaps. RELEASE (rehabilitation
and recovery of people with Aphasia after stroke) is an international
collaboration of aphasia researchers which seeks to achieve this goal.Objectives
Funded by the National Institute for Health Research (Health Services
and Delivery Research - 14/04/22) we have systematically gathered
IPD from pre-existing aphasia research datasets to examine the nat-
ural history of recovery from aphasia, the predictors of recovery and
optimal interventions (by rehabilitation regimen, delivery model and
the aims and content of treatment).
Methods
We invited contributions of primary datasets from members of the
Collaboration of Aphasia Trialists (cats). We also conducted a system-
atic search of existing published research to identify a comprehen-
sive set of potentially existing aphasia research datasets which met
our inclusion criteria. Research datasets were required to include a
minimum of 10 people, a measure of aphasia severity as a conse-
quence of stroke and information on time since stroke. We invited
researchers from these studies to contribute data and to create a
unique multilingual, international, interdisciplinary resource in this
clinical field.
Results
Following a systematic search of the literature, we screened 5276 ti-
tles (including 2346 abstracts and 1152 full texts), from which we
identified 874 eligible studies. We have received 76 study datasets
contributing IPD from 4597 people with aphasia (56 through the sys-
tematic search and 20 via cats). These data have been contributed
from 23 countries and we have identified a further 2400 IPD in the
public domain. The substantive challenge is our planned IPD meta-
analysis to examine recovery, predictors of recovery and effective-
ness of intervention approaches. Our statistical analysis plan states
that a one-stage approach will be conducted for the primary ana-
lyses, although a two-stage approach will also be explored. Network
meta-analyses and meta-regression (some of which includes sub-
group analyses) are also planned. We will discuss the methodological
challenges, particularly which arise when there are non-standardized
data, some non-randomized data, a large number of outcome mea-
surements and some degree of sparse data.
Conclusions
RELEASE is the largest systematically developed, evidence synthesis
study in the field of aphasia, and is more complex than most IPD trial
meta-analyses. Our research will not only provide important evidence
relating to the recovery of people with aphasia, but will also be an
exemplar to researchers who plan to create databases to analyse
complex individual patient data.
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Background
The implementation of adaptive design methods in phase II,
phase III or phase II/III has increased over the years [1]. There is
a need for a set of guidelines to report adaptive design method-
ology used in clinical trials in addition to the CONSORT guide-
lines [2] to ensure full transparency of trials implementing
predetermined or concurrent adaptations. The aim of this litera-
ture review is to understand the current application of adaptive
design methodology in oncology trials, and to ascertain how this
methodology is reported.
Methods
A literature search of PubMed, Embase and Ovid databases for full
text publications of phase II, phase III or phase II/III cancer trials using
adaptive design methodology during 2015 was conducted. The key
words used for the literature search are as follows: adaptive design,
flexible design, group sequential, sample size re-estimation, MAMS,
adaptive randomisation, interim analyses, adaptive seamless, bio-
marker adaptive, two-stage adaptive, dose escalation, ‘Drop the loser’,
‘Pick the winner’, multiple adaptive, adaptive enrichment.
Trials 2017, 18(Suppl 1):200 Page 41 of 235Relevant full text articles were reviewed to identify the type of adap-
tive methodology applied, if the publication explicitly stated the use
of adaptive designs and whether adaptive design methodology was
applied prospectively or concurrently.
Results
The databases produced a total of 14544 phase II, phase III, phase II/
III cancer trial related articles that were published in 2015. Of which
99/2127 (5%) for the PubMed database, 519/9573 (5%) for the
Embase database and 116/2844 (4%) for the Ovid database articles
included the search terms related to adaptive design methodology.
After the removal of duplicates, 464 articles were remaining. Of the
464 articles, 92 (20%) were full text trial related publications, 261
(56%) were abstracts, 32 (7%) were methodology or review papers
and 79 (17%) were not related to the search criteria.
The adaptive design methodology used in over half of the trials
(48/92) was applied by performing interim analyses due to safety,
efficacy or futility, 21 out of 92 trials incorporated dose escalation
methods and 14 out of 92 implemented a two-stage design. The
remaining 9 trials applied the following methods: Bayesian adap-
tive design (3/92), group sequential design (3/92) change in pri-
mary endpoint (1/92), seamless phase II to phase III (1/92),
multiple adaptive (1/92). Despite using adaptive design method-
ology, only four trials explicitly stated that it had an adaptive de-
sign. There were 89 out of 92 trials that had prospectively
planned adaptations, of which two of these also incorporated an
ad-hoc interim analysis.
Conclusion
This review has highlighted that adaptive design methodology is
rarely explicitly stated and hence supports the argument for needing
a set of guidelines to report the adaptive design methodology used
in clinical trials. Furthermore specific reporting guidelines will assist
in the consistency of reporting and ensure the ease of future identifi-
cation of trials implementing any prospective or concurrent adaptive
design methodology.
1. Hatfield, Isabella. Adaptive designs undertaken in clinical research:
a review of registered clinical trials. Trials (2016): 1273–9
2. www.consort-statement.org/consort-2010
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Background
Whilst there have been recent improvements, the practice and pro-
fession of physiotherapy (Physical Therapy) has suffered from the un-
controlled introduction and proliferation of treatments which have
an inadequate scientific basis, little or poor evaluation, and under-
exposure to rigorous scientific method. New treatment modalities
can be developed and introduced without evidence of efficacy, regu-
lation or governance. There is no requirement to collect prospective
data to support any claims or demonstrate efficacy. This approach
has resulted in numerous disparate practices which may not stand
up to rigorous evaluation or evidence based commissioning.
Description
The IDEAL framework is an established method of formalising the
systematic evaluation of innovation (and existing practice) in com-
plex clinical interventions. It has been useful for setting out an inter-
nationally based evaluation framework for surgical procedures. This
framework lends itself to other complex, non-pharmacological inter-
ventions such as Physiotherapy (Physical Therapy). We outline the
application of this framework to Physiotherapy (Physical Therapy) in
a new IDEAL-Physio framework.
Similarly to IDEAL for surgery, five stages exist; each representing a
letter of the acronym.Stage 1, the Idea phase where formal data collection should begin.
This requires quality recording of data using standardised outcome
measures. The emphasis is on explanation and description. Stage 2a,
the Development phase, is a period of iterative improvement and ad-
justment with thorough prospective data recording. It focuses on
technical details and feasibility. Stage 2b, the onset of formal Explor-
ation evaluation using systematically collected group or cohort data.
This stage is a bridge or a pilot to a full RCT. It further refines out-
come measures and takes account of learning curves. Stage 3, is a
formal comparative Assessment phase of treatment usually involving
randomised studies. It involves a full assessment of efficacy. Stage 4;
Long term follow up involves monitoring outcome, particularly in
long term conditions.
Recommendations
We recommend the use of IDEAL - Physio to help guide and evaluate
innovation with the overall strategy of providing better evidence
based care and foster innovation in Physiotherapy (Physical Therapy).
This paper outlines the principles of IDEAL - Physio and describes its
utility in changing practice on a global level.
Keywords: Physical Therapy, Innovation, Evaluation,
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Background
A funding board assessed an application for a Phase 1 three-doses
dose escalation trial of a treatment in Crohn’s Disease, but disliked
the deterministic 3 + 3 design. The principle applicant sought statis-
tical advice which led to an adaptive design with extra doses. An-
other board disliked this adaptive design and the 3 + 3 was
reinstated. The boards jointly requested a three-dose adaptive design
which was funded. This incorporated a Phase II stage, and a cross-
over design to allow placebo-controlled periods in blocked patient
pairs. The aim is to describe the use of the adaptive Bayesian Contin-
ual Reassessment method available in BCRM Software [1], for design-
ing dose escalation trials.
Methods
There was a consensus to keep the sample size near 20. A 20%
target toxicity event rate for the Maximum Tolerated Dose was set,
below the 33% relevant in oncology trials. The performance of the
3 + 3 and BCRM methods was assessed through setting a range of
likely and unlikely scenarios for the event rates at the 3 doses,
followed by simulation (3000 trial repetitions). Primary assessment
was the percentage of trials recommending each of the three
doses. The 3 + 3 with a sample size of 18 was contrasted with a
BCRM of sample size 16 specifying a one-parameter power model
and a Gamma prior.
Results
Within the software, we specified five scenarios for the event-rates
across doses. For the ‘upper dose is just safe’ scenario, BCRM outper-
formed 3 + 3 in discovering the highest dose (72% versus 62%). For
the ‘upper dose is just unsafe’ scenario, the BCRM recommended the
upper dose 54% versus 48% times, but 3 + 3 incorrectly recom-
mended the lowest dose more often (22% versus 10%). For the ‘all
event rates are ascending but lower than the target’ scenario, BCRM
recommendations across doses were superior (5%,14%,81%) relative
to 3 + 3 (34%,35%,31%). For the ‘highest dose is unexpectedly high’
scenario, both approaches recommended it in just under 10% of sim-
ulations. For the ‘highest dose is plausibly high’ scenario, both ap-
proaches recommended it approximately one-third of the time, and
BCRM recommended the correct dose more frequently than 3 + 3
(41% versus 30%).
Conclusions
Some funding boards are encouraging of researchers to adopt and
exploit the advantages of novel designs. The availability of the BCRM
software enabled a range of event-rate scenarios to be examined for
a three-dose example with moderate target rate. Across scenarios,
Trials 2017, 18(Suppl 1):200 Page 42 of 235this adaptive approach was seen generally to outperform the 3 + 3
design, with a smaller sample size. The software was flexible in allow-
ing patients to be recruited and dose-allocated in pairs, accommo-
dating a crossover element. The scenario results indicate that with
samples of a typically small size in Phase 1, there is surprisingly quite
a lot of sampling variability in the dose recommended. Simulation is
therefore an important part of adaptive and deterministic design
planning. Consideration could be given to exploring modestly raised
sample sizes, and/or a further stage of dosing around the initially rec-
ommended dose, and/or carrying forward an extra dose to Phase 2.
Reference
[1] Sweeting M, Mander A, Sabin T. Journal of Statistical Software,
2013;54(13)
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Cellular therapy for hematologic malignancies is an emerging area of
cancer therapeutics. One of the major challenges of cellular therapy re-
search is the ability to make specialized processes widely available. BMT
CTN protocol #1401 was designed to translate a single-center manufac-
turing process of a vaccine with dendritic cell/myeloma fusions to a
model where the investigational product is manufactured locally at each
participating institution. The study provides a framework for implement-
ing multi-center cancer vaccine studies requiring a unique approach for
clinical protocol and manufacturing process development, Investiga-
tional New Drug (IND) submission, site selection, training and qualifica-
tion, and data collection. The primary challenge was adapting a single-
center process to a multi-center clinical protocol. Study specific standard
operating procedures (sops) for cell collection and manufacturing were
developed utilizing the institutional sops from the single center study
and managed centrally via an SOP management process. Laboratory
staff at participating sites performed an in-depth review of the manufac-
turing sops and identified processes requiring generalization based on
available equipment and institutional-specific processes. Participating
sites were invited based on past participation and experience with den-
dritic cell vaccine clinical research. Following site selection, each institu-
tion attended training in-person and via teleconference to discuss SOP
development and familiarize key staff with the production process. Two
successful mock runs of the vaccine product were required prior to site
activation. Initiating these training procedures concurrent with protocol
development and FDA submission allowed for faster site activation upon
protocol release. The IND application included an in-depth overview of
the site training, qualification, and selection procedures to assure that all
sites were adequately trained in vaccine manufacturing. There are sev-
eral unique components of data collection and monitoring in the con-
text of cellular therapy. It is integral to the integrity of the study and
safety of the participants to monitor compliance with the manufacturing
sops to ensure that each product meets criteria for release. An electronic
system was developed to monitor vaccine production and release cen-
trally in real time. Sites are required to submit electronic reports of
any deviation from the study sops via the data system within
24 hours of knowledge of the event. These reports are reviewed by
medical monitors, and recommendations for corrective actions and
future prevention of deviations are provided to the site within five
business days. All sites will enter electronic data on the vaccine re-
lease criteria and upload the completed study specific worksheets.
These data will be reviewed and approved centrally prior to local
release of the vaccine for administration to patients. Any deviationsnoted in the worksheets will be reported and reviewed by the
medical monitors to ensure the final product is not compromised.
While there continue to be ongoing challenges, BMT CTN 1401 pro-
vides a framework for the successful implementation of a multi-
center cellular therapy clinical trial by utilizing a single-center ex-
perience in conjunction with an established clinical trials network.
Further efforts are needed to explore the application of this frame-
work to additional therapeutic areas.
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Background
Serious Adverse Events (SAEs) are routinely collected in many trials
and processed by Clinical Trials Units on a daily basis. In the past at
Nottingham Clinical Trials Unit (NCTU), saes were processed by the
Trial Manager (TM), however this could lead to problems if they were
absent, with the potential that Ss were not handled in a timely man-
ner. In 2013 a database was developed to track all incoming SAEs
Unit-wide, so that members of the team could efficiently process
SAEs on any trial within the Unit. This is done on a rolling rota basis
and TMs are responsible for ensuring cover if they are unable to
undertake their duties. This ensures all TMs have exposure to SAE
handling, irrespective of whether their own trial collects SAEs or not
and is therefore good for staff development. It also ensures full cover
across all trials, irrespective of whether the specific trial team are
available. The roll-out of this system was initially successful, however
problems later developed with standard procedures being followed
inconsistently and a lack of consistent oversight with no formal pro-
cedures in place.
Methods
Updates were made to the database design to enhance the user ex-
perience and additional reports were added. Emails were then chan-
ged from manual to automated to speed up the process of receipt
acknowledgement and sending SAEs for medical review. A thorough
training session was provided to TMs on the rota, delivered by the
Senior Trial Managers and the database developer. All trials now
have trial-specific SAE handling instructions stored centrally for easy
access; these instructions give step-by-step guidance on how to han-
dle an SAE for a particular trial.
An oversight process was then put in place which involves, at a trial
level, the specific-Trial Manager and, at a Unit-level, the team of Se-
nior Trial Managers and QA Manager. A range of easy-to-use check-
lists were produced to ensure consistent regular oversight,
undertaken on a rota basis. Oversight also includes running a series
of regular reports through the tracking database and ensuring, via
the TMs, that the database and other documentation is kept fully up-
to-date. TMs are also encouraged to use in-built reports to allow ac-
curate and timely reconciliation of SAEs.
Results
Streamlining the existing process took approximately 6 months and
was fully introduced in August 2016. Feedback from users has been
positive. The trial-specific handling instructions have been helpful to
all safety handlers and design and functionality changes to the data-
base have been received positively. Oversight is now done consist-
ently across all trials with appropriate accompanying documentation
filed, essential for audit and inspection purposes.
Conclusion
Implementing the database and rota system in 2013 was a step in
the right direction. However, streamlining the process and imple-
menting more robust oversight ensures that SAEs are handled appro-
priately and efficiently to ensure regulatory timelines are met.
Including TMs in reviewing and updating the tracker database and
relevant documentation has been essential to ensure buy-in from
users. Clear communication and training whilst updating the process
has also been crucial.
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The American Society of Clinical Oncology’s Targeted Agent and Pro-
filing Utilization Registry Study (TAPUR) is a Phase 2, non-
randomized, precision-medicine, basket trial founded in real-world
clinical practice. The TAPUR study includes investigational therapies
that are approved by the U.S. Food and Drug Administration to tar-
get genomic alterations in patients with advanced cancer known to
be a drug target or predict drug sensitivity. TAPUR is a large multi-
site study with an innovative design that allows for assignment of 1
of 15 possible study regimens by the treating physician according to
protocol defined drug-genomic alteration matching rules or guidance
from the study Molecular Tumor Board (MTB). TAPUR has broad eligi-
bility criteria, flexibility in treatment administration, and collection of
data that mirrors routine clinical care. Analysis of study endpoints re-
quires completion of cohorts defined by study drug, genomic variant,
and tumor type according to a Simon 2-stage design where cohorts
are closed or expanded based on response rate.
TAPUR’s pragmatic approach incorporates the clinician and patient
perspective into the design. For example, enrollment is expanded
through use of broader eligibility criteria, including participants with
performance status (PS) 0–2, prior malignancies or HIV, and previ-
ously treated, but stable brain metastases. To date, 19% of partici-
pants have PS = 2 and 22% reported prior malignancies. This
approach not only provides greater trial access to patients and maxi-
mizes accrual, but also increases generalizability. Drug dosing is ac-
cording to the drug label and modification is allowed through
clinician judgment. Data collection centered around routine clinical
care reduces site burden and costs, while also allowing for rapid en-
rollment since the trial can leverage existing data, critical for patients
and clinicians looking for timely treatment options.
However, there are operational challenges associated with this level of
flexibility. For example, due to the heterogeneity of tumor types and
genomic alterations, dozens of cohorts are generated that enroll slowly
(to date 82 cohorts exist for 102 participants). Therefore, total sample
size for any cohort, site or drug are difficult to estimate. In turn, an over-
all study budget is also difficult to assess since many costs, such as
drug distribution and per-case reimbursements, are related to the num-
ber of enrollments. It is important to allow for ongoing modification, in-
form collaborators about the need for fluidity of the project and
consider novel operational approaches. For example, due to challenges
in estimating allocation of drug quantities to clinical sites, the study uti-
lizes a specialty pharmacy as the drug distributor, with drug provided
on a per-participant basis at the time of order to reduce waste and
negate the need for pre-defined estimates. Lastly, while the broad eligi-
bility criteria is a clear advantage, it does require regular retraining of
clinicians to utilize their best clinical judgment when assessing eligibil-
ity. Leniency in measures such as performance status may result in an
enrolled participant unable to meet all study requirements or achieve
key study endpoints, like response evaluation.
This presentation will highlight the innovative features of the study
design, as well as design-related operational advantages and chal-
lenges for consideration.P112
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Staff within large research organisations who are responsible for
managing a number of complex studies gain a vast amount of know-
ledge and experience that is not always systematically and effectively
shared with others. Embedding a ‘Lessons Learnt’ culture within an
organisation can provide staff with the opportunity for reflection and
promote a culture of problem-solving, ensuring that best practice is
applied and mistakes are not repeated. A systematic approach to
capturing and communicating learning can help to streamline and
improve the quality of research procedures.
Background
Keele Clinical Trials Unit (CTU) aims to promote a culture where staff
learn from previous experiences and apply best practice to become more
efficient. The aim of the ‘Lessons Learnt’ database developed at Keele
CTU is to capture and learn from positive and negative events or pro-
cesses which occur during the life of a research study, and to communi-
cate these to others. The overall objective is to make improvements to,
and streamline the processes of setting up and running a research study.
Methods
A ‘Lessons Learnt’ database specification was written following the
generation of ideas by a group of experienced Trial Managers and
Data Managers. The database was built using Access, and iterative
piloting was undertaken until the group were satisfied with the data-
base functionality.
Within the database, lessons are grouped by study and are recorded
by: study registration details, stage of study (e.g. Planning and de-
sign), process area (e.g. Consent), summary of the event, impact of
the event, statement of the lesson learnt and action taken. Lessons
are searchable by others using these key items. Each lesson has a
blog, which all staff are encouraged to use to make comments, for
example, to share similar experiences or suggest solutions. Lessons
are reviewed by a core review team on a monthly basis. The review
team record their recommendations, request further actions and/or
disseminate findings to all research staff. A lesson is closed once all
actions and dissemination have been completed. Reports can be
printed from the database by the review team which, amongst other
functions, provide metrics such as stage of study where lessons are
reported, making it easier to identify recurring issues.
Results
The ‘Lessons Learnt’ database has been implemented, with staff
starting to record their positive and negative lessons. The review
team assesses the reported lessons and facilitates actions required to
implement changes needed to improve procedures. Best practice is
disseminated to all staff by e-mail, preventing reinvention of the
wheel and raising awareness of any changes to processes as a result
of learning from lessons.
Conclusions
Lessons learnt from past studies can prevent problems being re-
peated and promote adoption of positive experiences. Keele CTU is
in the process of engaging staff fully with the ‘Lessons Learnt’
process by embedding a culture of sharing and learning using a sys-
tematic approach. Future work will aim to measure the impact of the
database on the quality of research processes.
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The Emmes Corporation, which serves as the Data and Statistics Center
and the Clinical Coordinating Center for the National Institute on Drug
Abuse (NIDA)-sponsored National Drug Abuse Treatment Clinical Trials
Network (CTN), has recently updated its website with the goal to im-
prove overall study conduct, accessibility to critical information, and
overall network cohesiveness and efficiency within the multiple-protocol
NIDA CTN environment.
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critical documents for study implementation and conduct, including
training information, official communications, the protocol, the man-
ual of operations, and materials for study medications and/or other
interventions. Within each protocol-specific area of the website are
comprehensive sets of web reports, updated nightly, that describe
important study progress metrics of a protocol implementation sta-
tus timeline, recruitment, retention, data quality measures, treatment
exposure, availability of primary outcome, and regulatory compliance
measures, presented in tabular and graphical formats. Summary
reports that compare data from each protocol to the a-priori-
defined expectations of the sponsor with color codes highlight
study performance for the protocol investigative teams and spon-
sor. Similarly, regulatory reports are developed to display the sta-
tus of important regulatory documents, identifying expired or
soon-to-expire documents such as IRB approvals. These reports
allow for continuous monitoring, prompt identification and cor-
rection of problems by investigators, site staff, the sponsor, and
coordinating centers.
The website also serves as a resource for network-wide activities, in-
cluding a monthly Web Seminar as a forum for network members to
share and exchange clinical research knowledge. This webinar is
highlighted on the website and materials are stored for future refer-
ence. Committees within the network manage their own dashboard
where agendas, minutes, and other communications are posted.
There is also a website page known as the investigator toolbox
where templates, tools, sample forms, and policies and procedures
are stored and serve to guide investigators in the preparation and
execution of their clinical trials.
The design and implementation of this updated website for the NIDA
CTN has been effective in meeting the needs of both protocol-
specific as well as network-wide activities.
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Background
The Network for Excellence in Neuroscience Clinical Trials, or NEURO-
NEXT, is a National Institute of Neurological Disorders and Stroke
(NINDS, part of the U.S. National Institutes of Health, or NIH) initiative
created to conduct studies of treatments for neurological diseases
through partnerships with academia, private foundations, and indus-
try. NEURONEXT is just one of several clinical trials networks sup-
ported by NINDS (i.e., strokenet and NETT). In discussions among the
members of the networks, it has been useful to share solutions and
processes addressing problems that arise in the setting of a clinical
trials network. A dialog with researchers external to NINDS-supported
clinical trials networks may yield further benefits.
Objective
At any given time, there are likely to be multiple proposals for stud-
ies to be conducted within a clinical trials network. How these pro-
posals move from an initial concept to a full grant submission varies
by network as different solutions are crafted to the common prob-
lems of how and when to spend a network’s proposal development
resources. This work addresses the NEURONEXT approach to pro-
posal development. An overview of the pathway for a proposal is
given alongside a discussion of how the process has changed as
NEURONEXT has matured. Full protocol development requires spend-
ing a great deal of the network’s proposal development resources.
The decision of when to spend resources on multiple proposals can
be difficult with complexity increasing as the number of proposals in
the pipeline increases. This work discusses the timing of NEURONEXT
protocol development assistance and the corresponding ramifica-
tions. Also discussed are several common misperceptions that inves-
tigators have experienced during the NEURONEXT design working
group process.P115
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Background
RCTs are an essential part of providing safe healthcare. They should be
designed, conducted and analysed according to sound scientific princi-
ples to achieve their objectives; should be reported appropriately [1], and
should not cause unnecessary harms to trial subjects. As such trial proto-
cols should include a clear safety section, with definitions, procedures
and responsibilities for recording and reporting adverse outcomes. The
aim of this work is to understand the current practice regards to what
and how these outcomes are captured in non-drug intervention trials.
Methods
We identified eight non-drug trials from the Pragmatic Clinical Trials
Unit (PCTU) administrative database for inclusion. These were se-
lected because their trial documents were available to researchers
electronically. Trial protocols, standard operating procedures (SOP)
for adverse event reporting and the trial reports (where available)
were reviewed. Data were extracted on 1) study design, population
and intervention characteristics, 2) stated study objectives and out-
comes, 3) data recording, managing and reporting process regards
to adverse outcomes and 4) the use of data monitoring committees.
Results
All were multi-centre trials involving at least two sites, and conducted in
the United Kingdom. Six were individually randomised and two cluster ran-
domised, and all but two were conducted in hospitals or specialist centres.
Assessing safety outcomes was a stated objective in two studies and one
study included outcome measures on safety, though there were no specific
study objectives relating to these. All trials included a section on safety
reporting in their protocols, and the procedures for complying with report-
ing requirements were described in adverse events sops. However, what
adverse events were recorded and how these data were captured varied
across the studies. Six studies reported capturing data on all “adverse
events” (i.e. any untoward medical occurrence as per standard definition),
one captured data on related adverse events only and one study was cap-
turing serious adverse events (i.e. Adverse event which is fatal: Results in
death, is life-threatening, requires inpatient hospitalisation or prolongation
of existing hospitalisation, results in persistent or significant disability/incap-
acity or is a congenital anomaly/birth defect) only. All used adverse events
forms or logs for doing so. Two studies described implementing additional
processes for collecting adverse outcomes as supplementary to the main
procedure. These included regular data downloads from routine data col-
lection systems, questionnaires and contacts (by telephone, text or email)
from research team. Only two studies described how the standard criteria
for assessing seriousness were applied in that particular trial. All but one trial
described expected serious events in adverse events SOP, but none pro-
vided insights into how these were researched or decided upon. Six studies
had data monitoring committees in place for assessing safety parameters.
Conclusions
All trials attempted to assess adverse outcomes, but there was little evi-
dence of a clear or a consistent approach to doing so; what adverse
outcomes were captured, how these were captured varied across trials,
and how the expected adverse outcomes were researched and decided
upon was unclear. Including these aspects in trial documentation can
improve clarity.
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At our institution we are establishing a research nurse-led
programme to collect in-hospital complication data on all cardiac
surgery patients who provide consent. This initiative is part of a
wider programme of research to investigate associations between
phenotypic and genotypic characteristics with complications and
speed of recovery after cardiac surgery.
Data will be extracted from participant’s paper and electronic med-
ical notes and collated using a purpose-designed dedicated data col-
lection tool. Information can be obtained by either i) visiting the
ward daily, with the opportunity to talk to nurses involved in partici-
pants’ care, and recording events almost as they happen or ii)
extracting data after the patient has been discharged home.
Nurses who collect data for randomised trials believe that method i)
takes longer but method ii) results in events being missed. To investi-
gate these beliefs we are planning to randomise nurses (and pa-
tients) to collect the data either by method i) or method ii).
Methods
Research nurses will be assigned a random selection of patients and
told the method of data collection to use for each. All nurses will use
both methods (for different patients) and each patient will have their
data collected by different nurses using the different approaches. Pa-
tients and nurses will be assigned using a balanced incomplete block
design to ensure balance across the nurses and by collection
method. Each nurse will be blinded to the data collected by another
member of the team on the same patient. We propose to compare
data collected for completeness as well as the time taken to collect
the data.
The study is planned to run over 2 months from December 2016 and
will capture data on 96 patients. 72 patients will be reviewed twice,
once by each method and 24 patients will be assessed 4 times, twice
by each method. Six nurses in the cardiac surgery team have agreed
to take part. Each nurse will undertake 40 reviews on 16 patients.
Results and Conclusion
The study is ongoing. Full results will be presented at the meeting.
This research was funded by the National Institute for Health
Research Biomedical Research Unit in Cardiovascular Disease at the
University Hospitals Bristol NHS Foundation Trust and the University
of Bristol.
Disclaimer
This abstract presents independent research funded by the National
Institute for Health Research (NIHR). The views expressed are those
of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health.
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Trials of medical tests present a series of challenges that differ, or
have differing significance, from randomised controlled trials (RCTs)
of interventions. A lack of understanding of the test-specific chal-
lenges in the design, set up and management of trials can lead to er-
roneous results: tests can appear more or less accurate due to
inappropriate application of the eligibility criteria and differences in
care pathways; study conclusions may be compromised if disease
prevalence differs in the study from the actual target population. Bir-
mingham Clinical Trials Unit (BCTU) manages and/or provides statis-
tical support for a wide range of test evaluation trials as well as RCTs
of interventions. We have set up a working group to compare and
contrast the different challenges of the management of these trial
types to improve future trial design and management. The ten test
evaluation trials under consideration cover a wide range of medical
conditions with different tests being evaluated for screening,diagnosis and monitoring, including: BUS - Accuracy of Bladder
Ultrasound (BUS) in the diagnosis of Detrusor Overactivity (DO): a
study to evaluate if ultrasound can reduce the need for urodynamics.
Egfrc - Accuracy of glomerular filtration rate (GFR) estimation using
creatinine and cystatin C and albuminuria for monitoring disease
progression in patients with stage 3 chronic kidney disease: Prospect-
ive longitudinal study in a multi-ethnic population. ELATION - A ran-
domised trial of the efficacy and cost effectiveness of Real Time
Ultrasound Elastography in The Investigation Of Thyroid Nodules and
the diagnosis of thyroid cancer. ENDCAP development and evalu-
tions of a biomarker panel to detect enhanced neoplasia in chronic
colitis, GBS-2- Accuracy of a rapid intrapartum test to screen for ma-
ternal group B streptococcal colonisation and its potential to reduce
antibiotic usage in mothers with risk factors MEDAL - MRI to establish
diagnosis in women with pelvic pain rockets - Evaluation of diagnos-
tic tools to diagnose ovarian cancer in women referred with symp-
toms from primary care METRIC - Diagnostic accuracy for the extent
and activity of newly diagnosed and relapsed Crohn s disease
STREAMLINE-COLON, STREAMLINE-LUNG. Comprehensive staging of
newly diagnosed lung and colorectal cancer MROC - Impact of multi-
parametric MRI on staging and management decisions in women
with ovarian cancer.
From initial discussions, common themes of the challenges of test
evaluation trials are appearing, including: Challenges of site set up,
site finances, patient pathway, recruiting consecutive participants, eli-
gibility biases, obtaining reference standard diagnoses, the role of
adverse event monitoring, trial modifications, sample handling and
future-proofing sample collections. While some of these themes also
occur in RCTs, the relative importance or risks vary. These themes will
be explored in more depth and strategies used to resolve or minim-
ise the impact on the project will be reviewed.
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The informed consent process is paramount to the legal and ethical
conduct of clinical trials. Adequately explaining study details to po-
tential participants in a manner that permits comprehension and
promotes study retention is challenging; this is compounded when
recruiting populations that Institutional Review Boards (IRBs) may
view as potentially vulnerable populations, such as persons facing
concurrent mental or physical illness resulting in diminished capacity
for comprehension, or with socioeconomic issues such as unstable
housing, limited educational status, or low functional literacy. Not-
withstanding any applicable legal thresholds for a legally authorized
representative’s involvement, these factors may not negate the par-
ticipant’s autonomy and capacity to make an informed decision on
trial participation. In planning studies that involve such potentially
vulnerable populations, investigators should consider and implement
additional safeguards to ensure that informed consent materials are
readily understandable, and that the consent process balances ad-
equate coverage of required elements while avoiding overwhelm for
the participant and burden on the research team.
The National Institute on Drug Abuse National Drug Abuse Treatment
Clinical Trials Network Clinical Coordinating Center (CCC) and the Na-
tional Cancer Institute’s AIDS Malignancy Consortium (AMC) develop
clinical trials for populations that IRBs may consider vulnerable:
people living with HIV/AIDS (PLWHA) and/or persons who inject
drugs (PWID). Common challenges that CCC and AMC investigators
face during the consenting process include designing informed con-
sent materials that communicate required regulatory elements sim-
ply yet effectively, engaging the individual in the consent discussion,
and assessing comprehension. Methods to be discussed include:
Trials 2017, 18(Suppl 1):200 Page 46 of 235Consent design factors for readability; Ancillary visual and written
aids; Consent process standard operating procedures; Patient
advocate feedback and involvement; Participant comprehension
assessment.
This presentation will highlight these challenges and offer tools and
best practices for research teams to develop informed consent mate-
rials and augment consenting processes.
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Background
Randomised controlled trials deliver robust and internally valid evi-
dence, but external validity is often neglected. This can limit the rele-
vance of trial findings for routine practice and hinder the
implementation of robust evidence. External validity is a complex
concept involving reflection on trial evidence in relation to prior
knowledge, statistical understanding, biological plausibility and the
interpretation of the impact of the trial’s eligibility criteria. Design
features built into the protect trial of prostate cancer treatments facil-
itated the assessment of its external validity, and provided an oppor-
tunity to consider how trial designs should be used to improve the
external validity of trials.
Methods
A population-based cluster-trial of PSA screening using a Zelen de-
sign created an intervention arm comprising a prospective cohort
study of 80,000 men undergoing PSA testing leading to an embed-
ded trial of treatments for localised prostate cancer (protect), and a
control arm comprising usual care without formal PSA testing. All
men agreeing to participate in the intervention arm entered a pro-
spective cohort study of PSA testing and prostate cancer diagnosis.
Socio-demographic, clinical and patient-reported symptom and qual-
ity of life data were collected at recruitment and when eligible for
prostate biopsies. Men diagnosed with localised prostate cancer who
agreed to be randomised, and those who declined and chose a treat-
ment (‘preference’ group) were followed up in a comprehensive-
cohort design. This was extended to include those diagnosed
with prostate cancer but excluded from the treatment trial with
advanced cancer or excluded other group. We investigated
differences in response and/or clinical eligibility at each stage of
testing and diagnosis in the prospective cohort study. The
characteristics of the randomised men were compared with the
preference, advanced and excluded other groups in the extended
comprehensive cohort study.
Results
The Zelen design produced balanced intervention and control
groups. Prospective cohort study participants were more likely to
be healthy and from urban and less-deprived areas than non-
responders or non-attenders. At subsequent stages in the PSA test-
ing and diagnostic pathway, there were few differences between
those eligible or ineligible to proceed, or who continued or de-
clined participation according to socio-demographic and clinical
history characteristics. Men who declined randomisation ‘prefer-
ence group’ were more likely to have managerial/professional occu-
pations and less deprivation than those agreeing to randomisation.
Expected clinical differences were found between the randomised
men and the ‘excluded other’ and ‘advanced’ groups; ‘preference’
men were clinically very similar. Conclusion The data from the pro-
spective cohort study and extended comprehensive-cohort study
provide detailed information to enable consideration of theexternal validity of the protect trial. The data suggest that those
randomised are broadly representative of the source population,
with limitations in relation to the inclusion of more deprived and
ethnic group participants. The extended comprehensive-cohort pro-
vides assurance that the outcomes of the randomised group will be
clinically relevant and widely generalizable. Design features to en-
hance external validity could be adopted more widely in pragmatic
trials to investigate selection issues during eligibility assessment
and the clinical relevance of the randomised group.
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Background
Research investigating the resuscitation and management of un-
stable trauma patients is essential to improve care and save lives.
The decision to take part in a research study is voluntary and the
ethical and legal codes that govern medical practice also apply to
clinical trials. Informed consent is a vital part of the research process,
however, in emergencies this is challenging. In this review the issue
of consent in emergency research is presented with emphasis on ex-
periences from a major trauma centre.
Methods
Since 2008, all adult trauma patients (16 years) who met local criteria
for trauma team activation at The Royal London Hospital have been
screened by the Centre for Trauma Sciences Clinical Trial Unit for eli-
gibility into a portfolio of clinical trials. In all trials, agreement to enrol
a patient into a trial was obtained using a professional legally
appointed representative (PLAR) or nominated consultee (NC), in all
cases this was the trauma team leader (a physician independent of
the research study). Written consent from the patient or next of kin
was sought as soon after enrolment as appropriate by a GCP trained
researcher. All studies were reviewed and approved by a Regional
Ethics Committee (REC).
Results
More than 5000 trauma admissions have been screened for eligi-
bility into the following trials; Activation of Coagulation & Inflam-
mation in Trauma (ACIT –a prospective, observational study),
CRYOSTAT (feasibility study, non-CTIMP), itactic (Phase II non-
CTIMP), EFIT1 (feasibility study, non-CTIMP), MP4OX (Phase iia &
iib CTIMP) and synapse (Phase III CTIMP). Over 1500 patients have
been enrolled into ACIT and a further 125 patients recruited into
one of the randomised controlled trials (RCT). Following our con-
sent procedures only 70 (5%) of participants in the observational
study and 2 (2%) subjects in the combined RCTs were withdrawn
due to patient or relative refusal of consent. There was no differ-
ence in withdrawal rates between observational studies versus
rcts and no discrimination between ctimps and non-CTIMPs.
Using PLAR/NC agreement rather than seeking consent from the
patient or legally appointed representative, the average time
from admission to randomisation in the CRYOSTAT and EFIT RCTs
was 13 minutes (0–58 mins, n = 52).
Discussion
Less than 5% of total enrolled patients or their next of kin de-
clined consent to continue participation in a research trial. In re-
cent years we have experienced a switch in REC opinion with
discussions increasingly involving the use of waiver of consent in
such trials to avoid potential delays in delivering an intervention
or adversely affecting recruitment rates. Furthermore, feedback
from the ethics committees has questioned the procedure used
for obtaining informed consent as being potentially distressing
and insensitive to relatives at a difficult time. In response to this,
our protocols no longer pursue consent from bereaved relatives
and the participants are allowed to remain in the study using the
PLAR/NC agreement.
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Introduction
To discuss the role of the Efficacy and Mechanisms Evaluation
Programme in the funding of clinical research. The research funded
by the EME Programme has the potential to make a step-change in
the treatment of disease. EME research supports research primarily
aimed at establishing clinical efficacy but also embedded within this,
the Programme encourages the further understanding of treatment
and disease mechanisms.
Background
An overview of the EME Programme, in terms of its development,
purpose, objectives and vision will be presented. The Programme is
seeking to encourage studies which have novel methodological de-
signs that deliver results more efficiently, reduce the study timeline
and maximise the knowledge gained. Collaboration from academic,
clinical groups, industry and charities is encouraged.
Methods
The programme supports translational research evaluating a wide
range of novel or re-purposed interventions. The interventions may
include diagnostic or prognostic tests and decision-making tools,
drugs or biological compounds, psychological treatments, medical
devices, and public health initiatives delivered within the NHS. The
EME Programme primarily supports clinical trials, and other robustly
designed studies that test the efficacy of interventions. The interven-
tions should have the potential to improve patient care or benefit
the public.
Innovative study designs involving stratification, the use of routinely
collected digital data or novel methodologies are strongly encour-
aged. Hypothesis-driven mechanistic studies, integrated within the
efficacy study that explore the mechanisms of action of the interven-
tion or the disease, the cause of differing responses, or improve the
understanding of adverse effects are also encouraged.
Results
A wide range of studies have been funded to date and examples of
studies with novel study designs will be discussed, along with exam-
ples of mechanistic studies and what the Programme means by the
term ‘proof of concept’.
Conclusions
Studies funded through the EME Programme have the potential
to have a considerable impact on the treatment of patients in
the NHS. The Programme is keen to drive forward novel or infre-
quently used study designs that increase the value of the study,
by maximising the chances of demonstrating the benefit of an
intervention, increasing the knowledge gained or by making the
study more efficient.
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of patients with advanced breast cancer (BC). Screening for the pres-
ence of mutations in ctDNA provides a current assessment of the
genetic profile of the patient’s recurrent cancer. This is important be-
cause the mutations present in cancer cells often change over time
when the disease spreads to other sites in the body or after treat-
ment. Treatment of recurrent disease is often based on results from
primary tumour biopsy as recurrent BC may not be re-biopsied in
routine practice. Where a repeat tumour biopsy is performed due to
the heterogeneity of cancer the genetic aberrations driving the
tumour may not be present in the single biopsied sample to inform
treatment decisions. ctDNA screening is more practical and may be
more accurate than analysing tumour samples obtained through bi-
opsy, is suitable for all patients including those with inaccessible dis-
ease, more economical and more acceptable to patients. Ctdna
screening can be carried out in a greater number of patients and
could lead to a substantial reduction in the number of patients
undergoing invasive biopsies.
Plasmamatch is a multi-centre phase IIa umbrella trial platform con-
sisting of a ctDNA screening component and a therapeutic compo-
nent. The primary objective is to assess the safety and activity profile
of targeted therapies in patients with targetable mutations identified
by ctDNA screening. Patients with metastatic or recurrent locally ad-
vanced BC who have received prior systemic treatment in the ad-
vanced setting will be invited to participate. Consenting patients will
be registered for ctDNA screening and a sample of their blood will
be sent to the central laboratory for analysis. Patients with a target-
able mutation identified will be invited to enter a treatment cohort
and consenting patients will receive treatment targeted to the spe-
cific mutation identified.
Plasmamatch will be opened across a network of ~50 UK Screening
Sites, of which ~25 sites will also be designated as Treatment Sites.
Screening Only Sites will refer patients to Treatment Sites for treat-
ment cohort entry and trial treatment administration. After comple-
tion of trial treatment patients will be transferred back to the
Screening Only Site for follow-up.
Patients with specific targetable mutations identified in tumour se-
quencing performed outside of plasmamatch will be eligible to enter
one of the treatment cohorts, thereby providing a therapeutic option
for patients participating in alternative tumour sequencing initiatives.
Plasmamatch ctdna screening will also report on mutations to facili-
tate entry into trials outside of plasmamatch, should the patient not
be eligible to enter a treatment cohort in plasmamatch.
The plasmamatch umbrella trial platform is dynamic in design, such
that further genetic aberrations or molecular subtypes paired with
targeted therapies may be added in the future, providing the
addition would not compromise the completion of recruitment to
existing cohorts.
Plasmamatch adds to a growing portfolio of trials assessing the utility
of ctDNA and will seek to demonstrate the feasibility of ctDNA as a
screening tool for patients with advanced BC with the potential for
future integration into routine clinical practice.
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Separate long term follow-up studies may be considered where there
is interest in longer term outcomes that extend beyond the follow-
up period of a trial.
There is a worldwide interest in collecting long term cardiovascular
and recurrence/survival data in breast cancer patients with ‘triple
negative’ disease. BEATRICE was an international phase III trial asses-
sing adjuvant treatment in ‘triple negative’ early breast cancer, in
which patients were followed up to 5 years post randomisation.
LOTUS is a separate long term follow up study which is prospectively
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domisation) in this specific population of patients. BEATRICE recruited
over 2000 patients across 400 sites worldwide, providing a large,
already identified population of potential patients with for LOTUS.
The LOTUS trial management group agreed at the outset that recruit-
ment into LOTUS would be limited to patients already recruited to
the BEATRICE trial due to the availability of baseline data available
from BEATRICE and to utilise the established research network of
sites. In order to focus resources and efforts, only BEATRICE sites with
10 or more patients still in follow-up were invited to participate in
LOTUS (except in the UK, where all sites were approached). This
amounted to 53 sites across 19 countries and still yielded a potential
pool of up to 901 patients to reach our planned LOTUS sample size
of 250–500 patients.
LOTUS is designed to present minimal burden to aid recruitment of
both participating sites and patients for example, patient data is col-
lected annually to coincide with routine clinic visits, or can be col-
lected by phone. BEATRICE patient trial numbers are used in LOTUS
for easier data collection at sites, and to enable data linkage between
the BEATRICE and LOTUS datasets at analysis. Screening logs for sites
were pre-populated for sites to facilitate screening and recruitment
of patients. Out of the 53 BEATRICE sites that were approached to
take part in LOTUS, 32 sites agreed to take part.
We will present further details on our experience of implementing
the LOTUS trial and considerations for design of future longer term
follow-up studies.
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Background
Mail-based recruitment and follow-up is a cost-effective method of
conducting randomized trials, but requires telephone support for
queries from participants and their doctors. It is important to under-
stand the resource implications of such a telephone service.
Methods
ASCEND is a randomized trial of aspirin, and of omega-3 fatty acids,
for the primary prevention of vascular disease in people with dia-
betes. Between 2005 and 2011, 423,403 potential participants were
invited and 121,254 returned a screening form. Of these 26,462 par-
ticipants entered a 2 month placebo run-in and 15,480 were
subsequently randomized. Follow-up is by 6-monthly mailed ques-
tionnaires (since November 2014 participants can complete their
questionnaires online). A Freefone number is available for trial re-
lated queries including a 24-hour service for urgent medical issues. A
record is made of calls using a standard telephone summary within
the trial participant management system. For information govern-
ance reasons calls relating to people invited who did not consent to
join the study are not included in this analysis. Furthermore, until
March 2014, unsuccessful attempts to contact participants or their
doctors were not recorded. Therefore, this analysis underestimates
the total activity during the trial. For each call, the role of the staff
member (medical [including doctor or nurse] or administrative), the
individual calling or called (the participant, their GP or other person),
the time and date, whether the call reached the intended recipient
(for outgoing calls after March 2014) and whether the call occurred
after randomization was extracted from the study database. The pro-
portion of successful calls before and after 5 pm was compared using
a chi squared test.
Results
Up to November 2016, 52,696 calls were recorded. Of these, 8828
were recorded during the run-in period (0.33 calls per run-in partici-
pant) and 43,868 after the participant was randomized (0.42 calls per
randomized participant per year). Of 16,112 incoming calls to the trialco-ordinating centre, 51% were recorded by medical staff and 49%
by study administrators. Of the 36,584 outgoing calls, 24% were
made by medical and 76% by administrative staff. Among 20,946
outgoing calls with information about whether the intended recipi-
ent was reached, 41% were ‘successful’. The success rate was higher
for calls after 5 pm compared to those at other times (56% after
5 pm vs 40% before 5 pm; 2 138, p < 0.001) irrespective of the partic-
ipant’s age.
Conclusion
The telephone support for this mail-based trial requires substantial
input from both medical and administrative staff, but allows a large
study to be run cost-effectively. Contacting trial participants is more
effective outside working hours. These findings have resource impli-
cations for those planning similar studies.
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Objective
To describe the development and delivery of an online cognitive-
behavioural education and training package for health professionals
who treat patients with low back pain. The programme is intended
support implementation of the evidence-based Back Skills Training
programme in clinical practice.
Background
The Medical Research Council (MRC) recommends that once the ef-
fectiveness of a fully-defined intervention has been established in a
definitive Randomised Controlled Trial (RCT), the next phase is to de-
termine whether others can replicate the intervention and results in
clinical settings over the long-term. The Back Skills Training (best)
programme is an intervention based on a cognitive-behavioural ap-
proach for treating low back pain in primary care settings, and was
found to be both clinically and cost-effective in a large RCT (Lamb
et al., 2010). In order to deliver the intervention, clinicians in the trial
underwent a 2-day training workshop delivered face-to-face. Thus, in
order to replicate the intervention in clinical settings, the training
needed to be available to clinicians. Given the large number of clini-
cians and patients worldwide that could benefit from using this inter-
vention, face-to-face training was deemed unfeasible.
To ensure scalability and accessibility we translated the face-to-face
training into an online format, entitled ibest. We pilot-tested the on-
line training prototype (ibest) for feasibility, acceptability and credibil-
ity with health professionals. During the pilot testing, we identified
that despite being acceptable, feasible and credible compared to the
face-to-face training, clinicians continued to struggle to implement
the intervention in routine practice. Building on this evidence-base,
we describe how we enhanced the ibest prototype to support clini-
cians to use the evidence-based best programme in their practice.
Methods
We tailored ibest to address implementation barriers using the The-
oretical Domains Framework and the Behaviour Change Technique
(BCT) taxonomy. The selection of implementation strategies was in-
formed by evidence, clinician and expert opinion and suitability for a
sustainable online learning training package.
Results
We chose 11 BCTs to target domains of knowledge, skills, beliefs
about capabilities, beliefs about consequences, professional role, mo-
tivation and goals, and environmental context and resources. The
enhanced version of ibest has been accredited with the British
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national level implementation study in the UK.
Conclusions
Following guidance from the World Health Organisation, we have de-
scribed the selection of strategies and how these were used to en-
hance ibest for implementation. This process will inform the design
and evaluation of further implementation interventions and replica-
tion of complex interventions found to be effective from Phase III
trials.
Reference
Lamb et al., Group cognitive behavioural treatment for low-back pain in
primary care: a randomised controlled trial and cost-effectiveness
analysis. The Lancet, 2010;375:916–923.
Funding
This research was carried out at the Centre for Rehabilitation Research in
Oxford and was supported by the National Institute for Health Research
(NIHR) Collaboration for Leadership in Applied Health Research and Care
Oxford at Oxford Health NHS Foundation Trust. The views expressed are
those of the authors and not necessarily those of the NHS, the NIHR or the
Department of Health.
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Background
Increasingly researchers are developing complex interventions which
are evaluated later in randomised controlled trials. Researchers adopt
a range of approaches when developing interventions. However, in
this rapidly developing field there is little understanding of the ratio-
nales, and strengths and weaknesses, of different approaches to
intervention development for different contexts.
Aims
As part the INDEX study (identification and assessment of different
approaches to developing complex interventions), we aimed to re-
view the range of approaches to intervention development and con-
struct a typology to help researchers select the appropriate approach
for their context. We also aimed to identify an initial set of core prin-
ciples and processes of intervention development for use in a future
Delphi Study.
Methods
We undertook two interlinked systematic reviews. First, we con-
ducted a Best Fit Framework Synthesis by developing an a-priori typ-
ology of approaches to intervention development based on the
team’s knowledge base. For our first iteration, we searched Medline,
psycinfo, CINAHL, ERIC and ASSIA from July 2015 to June 2016 for
methodological literature and primary studies on intervention devel-
opment. We then reviewed our typology and for each ‘type’ identi-
fied the rationale for its use, and its strengths and weaknesses.
Further search iterations will be used to refine the typology. Sec-
ondly, we the undertook Realist Synthesis on each ‘type’ to hypothe-
sise and test key methodological principles and processes by
considering the mechanisms at work to successfully inform interven-
tion development in different contexts.
Results
We identified 144 relevant primary study papers from a total of 317
records in the first search iteration. Intervention development papers
were international: USA (56%), UK (25%), Europe (5%) and rest of the
world (14%). We identified 7 approaches to intervention develop-
ment (‘type’ in the typology) including theory-based, participatory,
person-based and pragmatic. Each type included sub-types of ap-
proaches. For example the theory-based approach included ‘Inter-
vention Mapping’ (n = 5) and ‘The Behaviour Change Wheel’ (n = 7).Following an analysis of core methodology papers and books and
primary research using each type, an initial core set of principles and
processes for developing interventions was identified; these are be-
ing refined using further search iterations.
Conclusions
We have developed a typology to facilitate intervention developers
in selecting the most appropriate approach to developing interven-
tions for their context. This will feed into further parts of the INDEX
study - Delphi, consensus workshops and qualitative interviews - to
generate guidance for researchers on how to develop interventions.
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Background
Randomised controlled trials (RCTs) of rehabilitation interventions are
generally complex, involve a broad population, multi-faceted inter-
ventions delivered in a complex healthcare system, and measure
multiple outcomes. The National Institute for Health Research Health
Technology Programme (NIHR-HTA) has funded a number of UK trials
of physical rehabilitation interventions. To date, no research has
reviewed and synthesised the outcomes of this body of work. In this
review we aimed to (a) establish the treatment outcomes of RCTs of
physiotherapy (PT), occupational therapy (OT), or speech and lan-
guage therapy (SLT) funded by the HTA, and (b) assess how often
those interventions that undergo testing in RCTs result in establish-
ing the effectiveness of new treatments.
Methods
We included all phase III superiority RCTs funded by NIHR-HTA from
1997 until July 2016, that evaluated a physical rehabilitation
programme of PT, OT or SLT and that had reported their main find-
ings either in a peer-reviewed journal or as an NIHR-HTA monograph.
We extracted data on trial design, target population, intervention de-
scriptions, primary outcome(s) and time point(s), any minimally clin-
ical important difference (MCID) identified in support of the sample
size, proposed and achieved sample size and between-group primary
outcome results with 95% confidence intervals. We categorised pri-
mary outcome data into one of six options as described by Djulbego-
vic et al. (2008): (i) statistically significant in favour of the new
treatment; (ii) statistically significant in favour of the control treat-
ment; (iii) true negative; (iv) truly inconclusive; (v) inconclusive in
favour of new treatment; or (vi) inconclusive in favour of the control
treatment. We summarised the extracted data descriptively.
Results
We included 15 studies that recruited 9035 participants, 7834 of
whom provided data primary outcomes data, of which five were
symptom-based or clinical outcomes, seven were functional mea-
sures, two were combined measures and one assessed quality of life.
Primary time points varied from immediately post-intervention to
one year. Thirteen of the studies utilised a two-arm, parallel RCT de-
sign, one used a four-arm factorial design of which only 2 arms re-
lated to physical rehabilitation and one was a cluster RCT. The target
populations, interventions and settings were diverse. Applying Djul-
begovic’s classification, four studies were significantly in favour of the
new treatment, one was significantly in favour of the control treat-
ment, eight studies had a true negative outcome, one was inconclu-
sive in favour of the new treatment was and one inconclusive in
favour of the control treatment.
Conclusions
Although most trials reported conclusive findings (13/15) very few in-
terventions tested in these trials achieved superior outcomes com-
pared with controls (4/15). Despite, therefore, a considerable
research effort in rehabilitation interventions, there are just a handful
of new interventions that outperform existing approaches available
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genuine uncertainty or clinical equipoise, the reasons why so few ex-
perimental interventions in rehabilitation that are brought to trial
achieve the results expected of them by trialists and intervention de-
velopers requires further investigation so that future trials can be tar-
geted at potentially more fruitful interventions.
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Randomised controlled trials (RCTs) are considered the highest level
of evidence. Consequently, it is important to ensure that they are de-
signed, conducted and analysed to the highest possible rigour so
that the clinical decisions that they are used to inform are valid.
There are many practical and methodological difficulties that a med-
ical researcher must overcome to conduct a successful RCT. In trials
that involve a surgical intervention, these difficulties are often magni-
fied. However, there are also additional challenges specific to surgical
trials. This work focuses on two highly prevalent challenges:
1. Surgical learning curve 2. Clustering within site and surgeon
Statistical methods have been developed with low uptake to account
for the surgical learning curve and clustering effects separately in
surgical trials. This research aims to evaluate these and determine
when and how to apply them, by considering these methodologies
individually and then jointly.
The ultimate aim of this project is to improve the design, analysis,
and generalizability of surgical trials. This will be achieved by devel-
oping understanding about when learning curves and clustering ef-
fects impact on the conclusions of an RCT by determining; the
available methodologies and the impact of incorporating these
methodologies. This will inform the impact of adjusting for these ef-
fects and their impact on interpretation. This will be done consider-
ing each effect in isolation and then in combination.
To inform this development, current practice has been established as
to how surgical learning and clustering are accounted for in trial de-
sign and analysis. A survey to establish current practice and require-
ments within UK registered Clinical Trials Units has been undertaken.
A cohort of published RCTs within medical journals and HTA mono-
graphs has been obtained establishing how statistical methodologies
are currently being applied and reported.
Results of this work will be presented with how these findings im-
pact development of methods and guidelines.
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Background & Methods
The Consortium for Organ Preservation in Europe (COPE) is conducting
several clinical studies, one of which is a multicentre, randomised,controlled, open label trial to compare the efficacy of ex-vivo normo-
thermic machine perfusion (NMP) with static cold storage (SCS) for
organ preservation prior to liver transplantation (ISRCTN 39731134). Fol-
lowing confirmation of donor and recipient eligibility, livers were rando-
mised (1:1) to either NMP or SCS, stratified by donor type (donation
after brain death (DBD) or circulatory death (DCD) and centre. At the
end of preservation, if not discarded, the liver was transplanted in the
consented recipient who was managed according to standard local
practice and protocols.
Primary outcome of the study is the difference in peak serum aspar-
tate transaminase level (AST) within 7 days post-transplant between
the two treatment arms. Secondary outcomes include Primary Non
Function, Early Allograft Dysfunction and Patient and Graft Survival.
Results
334 livers were randomised with 222 transplanted into recipients
from June 2014 to March 2016 in seven European liver transplant
centres (UK (4), Spain, Germany and Belgium). Recipients have been
followed up for 6 months and the main analysis is currently ongoing.
Discussion
Introducing a complex intervention using a non-CE marked medical
device into what is already a complex organ retrieval, preservation
and transplant process provides many methodological hurdles to
overcome. Furthermore, as the trial adopts an international multicen-
tre setting with different regulatory practices in place, several chal-
lenges were highlighted during the conduct of the trial which impact
directly on the planned analyses, results and interpretation. We will
describe the different challenges encountered and how these can be
tackled so that it will be of help in the setting of other complex inter-
vention trials in transplantation. The topics in this discussion include:
trial design and regulatory affairs, statistical and health economic
analysis.
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The Clinical Trials Research Unit (CTRU) at the Leeds Institute of Clin-
ical Trials Research (LICTR) is a large academic trials unit organised
into three divisions; Cancer, Complex Interventions and Comprehen-
sive Health Research. The unit was established in 1991 and now has
almost 200 staff running over 30 studies as well as a strong meth-
odological portfolio and other applied health research in each of the
three divisions. All of our current studies collect their data on paper
CRFs and we receive approximately 240,000 pages of data and man-
age approximately 12,100,000 data items per year. In 2006 initial at-
tempts at remote data entry proved unsuccessful largely due to poor
internet connectivity at many recruiting hospitals and systems that
were not intended to be used remotely. With recent improvements
in connectivity, systems and more widespread use of RDE, particu-
larly in the commercial setting, a decision was taken within the LICTR
to reinvest resource in conducting RDE trials. For the data manage-
ment team tasked with taking this change forward at LICTR the deci-
sion came with a series of demands and challenges to overcome.
This presentation will describe how CTRU adapted its data manage-
ment processes from data submitted on paper CRFs to data submit-
ted via RDE. Several key topics of this adaptation to RDE will be
covered comprising discussion of the central questions behind the
change, challenges faced and solutions found. Specifically, these
topics will include addressing the background questions, why we de-
layed the decision to move to RDE, what factors eventually prompted
the change and how we might interact differently with sites in terms
of training. They will also cover the challenge of replacing Microsoft
Excel based data management logs on which data management pro-
cesses, such as data verification, had often become entirely
dependent especially on larger studies. As a solution to these chal-
lenges, the design and creation of a data management dashboard
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outline our ideas for further adaptations and innovations from paper
crfs to RDE including plans for a site facing dashboard to be used by
site research staff and data managers.
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Prior experience has shown the importance of performing central
chart reviews of complex outcomes to ensure correct classification.
We conducted a randomized controlled trial of 10,000 pregnant
women across 16 clinical centers. The primary outcome was any
pregnancy associated hypertension associated with serious maternal
and infant complications, and the foremost secondary outcome was
preeclampsia. Both outcomes had many different criteria (e.g., hyper-
tension severity, proteinuria, thrombocytopenia) that would lead to a
diagnosis. Each clinical center completed an Outcome Diagnosis
Form that captured each of the elements included in the outcome
definitions. One of the more complex criteria was the abstraction of
qualifying blood pressures to determine the severity of hypertension
as each patient had multiple intrapartum measurements and some
of these measurements were deemed too labile to count towards
the definition (e.g. During labor or cesarean). This meant the start
and end of labor and cesarean were critical to the diagnosis and any
inaccuracy in the qualifying time period could result in errors. Due to
the complexity of the primary outcome and to confirm the diagnosis
of preeclampsia, the protocol subcommittee planned a central chart
review for all women whose Outcome Diagnosis Form reported preg-
nancy associated hypertension. De-identified participant medical re-
cords were reviewed by a team which consisted of two medical
doctors, a nurse coordinator, and one coordinating center represen-
tative. A total of 3,161 charts were reviewed by 21 chart review team
members who were blinded to treatment assignment. During the
chart review, data elements were discussed and concurrent re-
sponses were recorded on a new study form by the coordinating
center representative. The adjudicated outcomes were then com-
pared with the original outcomes reported by the site. Discrepancy
listings were sent to each of the clinical centers to affirm the review
committee decision. There were a total of 553 (17.5%) participants
which required changes to the diagnosis of pregnancy associated
hypertension and/or preeclampsia. Chart reviews were an important
part of the outcome adjudication and resulted in the correct classifi-
cation of the primary and major secondary outcomes.
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The American Society of Clinical Oncology’s (ASCO) Targeted Agent
and Profiling Utilization Registry Study (TAPUR), a non-randomized,
pragmatic precision medicine basket trial, provides a virtual multidis-
ciplinary Molecular Tumor Board (MTB) to support participating clin-
ical sites in identifying the appropriate study drug to target a
genomic alteration in a patient’s tumor. The TAPUR study offers pa-
tients with advanced cancer access to FDA-approved, targeted drugs
in non-indicated cancers while capturing safety and efficacy out-
comes. Drugs are matched to genomic alterations based on a set of
genomic matching rules to help guide the physician’s treatment deci-
sion. If a proposed drug-variant match is not accepted by the rulesengine or the treating physician wishes guidance in interpreting the
tumor genomic profile, TAPUR offers a virtual MTB to review cases
and identify treatment options.
The MTB is available to all participating sites and meets weekly by
webinar. MTB members at each session include at least two clinical
oncologists, one molecular pathologist, and one patient advocate.
The treating physician or other representatives from the clinical care
team also participate in the session. The MTB offers interpretation of
genomic test results and identifies potential treatment options either
within TAPUR, on other clinical trials, or with other drugs outside of
TAPUR.
MTB members for each session are identified from a large pool of ex-
perts who have been recruited to participate. Clinical site requests
for MTB review are facilitated through the study’s electronic data
capture (EDC) system. The TAPUR study team is notified of a pending
case and materials, including a clinical case summary, genomic test
report, and the pathology report for the specimen tested, are pre-
pared and distributed in advance. Following the session, the treat-
ment options with rationale are captured and reported back to the
clinical site through the EDC.
To date, 172 patients have been registered to the TAPUR study, and
102 have found a match to a TAPUR study drug and received treat-
ment. Approximately 75% of enrolled participants matched to a
study drug through the automated genomic matching rules and 25%
of participants matched through the MTB review process. In 8 of the
34 cases reviewed, although no TAPUR drug match could be identi-
fied, the MTB provided treatment options for drugs outside of TAPUR
and on other clinical trials, if available. One of TAPUR’s goals is to de-
scribe the concordance of the treatment proposed by the clinical site
with the options identified by the MTB. Thus far, proposed treatment
options are concordant in 38% of cases reviewed by the MTB.
Some challenges with convening a weekly MTB include staff time in-
volved in the coordination of sessions and variability in reviews due
to rotating volunteer participants. To minimize variability in MTB case
review outcomes, the study provides training to MTB members, and
begins each session clarifying the MTB’s role, authority, and
responsibilities.
The presentation will discuss the rationale through which ASCO
formed the TAPUR MTB, its positive impact on the study, and chal-
lenges to date. The governing and guiding processes and workflows
will also be described.
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Background
The establishment of databases to store information and results
about a clinical trial, registered under an index number, has allowed
for the identification and tracking of clinical trials. Consequently, the
download and analysis of clinical trial information, whether published
or unpublished, is possible and has allowed methodologists to take a
closer look at characteristics and trends of clinical trials. While many
trial databases exist, this report will focus on the clinicaltrials.gov
registry. Clinicaltrials.gov became operational in 2000 and is man-
dated by the United States Government.
Objective
Using a case example, we will describe some of the challenges encoun-
tered when identifying and analyzing trials registered in clinicaltrials.gov.
Methods
We downloaded the clinicaltrials.gov dataset and imported it into
two statistical programs (SAS and Stata). We limited the dataset to
interventional studies funded by the National Institutes of Health
(NIH). All methods and tabulations were performed and compared
by two independent authors.
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In attempts to characterize NIH-funded clinical trials, we encoun-
tered: (1) Difficulty importing files into the statistical programs due to
formatting issues (e.g., presence of special characters, hard returns,
commas, xml text); (2) Misclassification of trials due to misinterpret-
ation of registration fields (e.g., “funder” vs. “collaborator”; “interven-
tional” vs. “observational”); (3) Duplicate counts of same trial as a
result “obsolete” NCT identification numbers; (4) Misclassification of
trials as to funding source (e.g., trials that were funded by NIH were
not listed as being NIH-funded in registry); (5) Missing registration
fields (e.g. Number of sites, number of publications). While some of
the limitations listed are dependent on how registrants interpret and
enter information, there are steps that can be taken to improve regis-
tration. One such step would involve improving the editing process
to keep files “clean.” Providing a test environment for developers to
explore data entry options and allowing for the creation of scripts to
extract specific data from the website would also be useful. Second,
clarifying definitions of registration fields and including examples
would help avoid misinterpretation. Furthermore, refining the “other”
Categories and using drop-down menus and checkboxes to avoid
free-text would reduce incorrect entries and inconsistencies. Third,
allowing “obsolete” NCT ids to be filtered out and providing reasons
for why the ids were listed as obsolete would avoid double-counting
trials. Finally, continuing to expand and update the registry will be
important as more trials are registered in coming years, with an ul-
timate goal of having a worldwide registry for all trials.
Conclusion
Trial registries, such as clinicaltrials.gov, have allowed people to ac-
cess, download and analyze trials data that otherwise would not be
possible. However, improvements can be made to increase its useful-
ness as a tool to describe characteristics of trials and trends over
time.
P135
Using trainee-led, collaborative research to generate hypotheses
for multi-centre clinical trials
James Glasbey1, Dmitri Nepogodiev1, Richard Wilkin2, Dion G. Morton1,
Laura Magill3, Aneel A. Bhangu1, Thomas Pinkney1
1University of Birmingham; 2West Midlands Research Collaborative;
3Birmingham Clinical Trials Unit
Correspondence: James Glasbey
Trials 2017, 18(Suppl 1):P135
Background
Over the past 8 years, trainee-led surgical research collaboratives
have evolved across the UK, giving national coverage across both
general surgery and all surgical subspecialties [1]. Several of these
groups have undertaken protocol-driven, “Snap-shot” audit and re-
search projects across multiple centres. Patient identification and
follow-up periods are deliberately short, facilitating trainee involve-
ment alongside clinical schedules. This approach allows for a large
number of patients to be included in less time, prevents repetition,
and permits greater generalisability than single-centre studies. The
collaborative model of authorship dictates publication of research
output under a single, corporate authorship. In the UK, the NHS Re-
search Ethics Committee do not require formal ethical approval for
this study type, as they are fully anonymised and do not alter patient
care.
The first regional research collaborative within general surgery was
the West Midlands Research Collaborative. The methodological ex-
pertise acquired within this region has been used to design and con-
duct a number of observational cohort studies, through the Royal
College of Surgeons-funded Birmingham Surgical Trials Consortium.
In this project, we collate our progress to date.
Methods
Protocols for collaborative studies conducted with the Birmingham
Surgical Trials Consortium were collated from group websites, and
publication records. Recruitment figures, data points, and validation
statistics were extracted from secure electronic records, and pub-
lished data sets. Data was analysed using descriptive statistics.Results
Nine observational cohort studies in gastrointestinal surgery were
run through the Birmingham Surgical Trials Consortium between
2013–2016. Six (66.6%) were conducted internationally, across a total
of 92 countries, with the others being UK-only. Study questions
spanned topics in surgery and perioperative medicine; surgical site
infection, post-operative mortality, analgesia, acute kidney injury,
obesity, stoma closure, cholecystectomy and colectomy. A total of
58,500 patient-level records were included, containing 1,308,000
individual data points. The 6 studies that underwent data point valid-
ation confirmed a >95% data accuracy, and >90% case ascertainment
rate. Hypotheses generated from these studies have directly in-
formed the preparation of two major grant applications; globalsurg
Surgical Site Infection Trial (pilot work funded by a Wellcome Trust/
Medical Research Council grant), Modifying Inflammation using
Drugs Around Surgery (MIDAS, unfunded), and 3 further grant appli-
cations are in progress. All grant applications have included principle
investigators from prominent sites contributing to observational data
collection.
Discussion
We have demonstrated the ability to generate high-quality, patient-
level data across diverse settings, generating hypotheses for rando-
mised clinical trials. Validated, observational data serves as high-
quality internal pilot, and provides accurate baseline rates to power
trial interventions, across specific collaborating centres. By successful
submission of data to observational studies, site investigators dem-
onstrate their capacity for research leadership and “Self-select” for in-
volvement in future clinical trials. Corporate authorship flattens the
traditional hierarchical model research delivery and publication, and
fosters an environment of collaboration for high quality prospective
studies and their consequent clinical trials.
Reference
[1] Bhangu A, Kolias AG, Pinkney T, Hall NJ, Fitzgerald JE. Surgical research
collaboratives in the UK. Lancet. 2013 Sep 28;382(9898):1091–2.
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Background
At present the NHS is struggling to meet the demands on the ser-
vice. The idea for this study originated in a local primary care prac-
tice who felt that improvements could be made regarding how it
was managing and caring for its most frequent attenders. The idea
was developed into a RCGP award-winning intervention consisting of
several components including matching eligible patients with a
named GP, and training GPs to unpack background psychosocial is-
sues in a contained way during the consultation using the ‘BATHE’
technique.
Aim
The aim of our feasibility study was to explore the main uncertainties
to designing a full trial to evaluate effectiveness and cost-
effectiveness of this intervention in a pilot cluster RCT involving six
practices (4 intervention, 2 usual care). Two of our key objectives
were to optimise the content and delivery of staff training to support
the intervention; and to assess the extent of implementation fidelity.
Methods
As part of the feasibility work, qualitative interviews were held with
the stakeholders to build a clear description of the intervention, how
it was implemented and expected to work. To ensure a high quality
evaluation of implementation fidelity our study design included the
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qualitative) at multiple time points. Observations of implementer
training sessions and of appointment-making between patients and
reception staff, were conducted. A varied sample of face-to-face and
telephone consultations of GPs using the BATHE technique with pa-
tients were video and audio recorded and transcribed in all interven-
tion practices. Conversation analytic methods were applied to assess
fidelity to BATHE and the nature and extent of patient response in
the consultation recordings Routine monitoring data was collected
from practice records to determine how often study patients were
being matched with their named gps and patient consultation re-
cords were audited for presence of a BATHE code. All quantitative
data was analysed descriptively to determine intervention dose and
reach.
Results
Analysis of electronic medical records data throughout the 12 month
intervention period enabled us to monitor dose, reach, provide mo-
tivational feedback and document the effects of subsequent imple-
menter trainings. Observations of appointment-making in all four
intervention practices and video-recordings of all 12 implementer
trainings elicited practical barriers and facilitators that could be ad-
dressed, as well as success stories. Conversation analyses of 20 con-
sultation recordings enabled a dynamic assessment of the delivery
and receipt of BATHE in situ, that revealed common pitfalls in deliv-
ery; specified and added new dimensions to the underpinning theor-
etical assumptions of the intervention; and provided valuable real-
world examples for future training.
Discussion
The findings were used to provide tailored top-up trainings, to clarify
and help address misunderstandings and problems in implementa-
tion and to encourage implementer engagement via whole practice
and individual level feedback. Mixed methods were valuable at dif-
ferent timepoints in enabling a full exploration of what might deter-
mine the success or failure of a future trial; to optimise training and
implementation fidelity; and to understand how and why future par-
ticipants might resist or engage with the intervention.
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A common objective of an Internal Pilot is to assess the trial’s recruit-
ment rate at a pre-specified time. This is with the aim of reassuring
the Trial Steering Committee, Funders and Sponsors that the trial is
well received by patients and health practitioners, and is likely to be
completed on time and within budget. However, it is possible that a
trial’s recruitment rate cannot always be assumed to be constant
over time. Another issue is that on-going individual recruitment after
cluster randomisation will likely introduce selection bias.
For some medical conditions, such as rare, chronic conditions, the
majority of patients may already be registered at the site, and there
are very few patients presenting or leaving the care of the service. It
is possible that assessing the recruitment from the number of pa-
tients already registered at each site may tell us almost as much
about final recruitment to the trial as if we had waited until the end
of the planned recruitment period.
This raises the question: ‘When is the best time to internally assess
recruitment in a Cluster RCT?’ We consider two different stages in a
trial’s life to execute an assessment of recruitment, through an In-
ternal Pilot Study and an Internal Feasibility Study.
Internal Pilot Study: Randomise clusters, then start recruiting and fol-
lowing up individual participants, and have a go/no-go decision
based on the recruitment rate, at a point early in the planned recruit-
ment period.
Internal Feasibility Study: Start recruiting individual participants,
assess a pre-specified go/no-go decision point at the end of the
planned recruitment period based on recruitment numbers,then randomise clusters and start following up individual
participants.
Through the use of Gantt charts, and 3 contrasting research ques-
tions recently commissioned by the National Institute of Health Re-
search, we ask which internal study would be the most appropriate
for a Cluster RCT. We evaluate this in terms of minimising bias, the
confidence of the recruitment estimates, de-risking the investment
made into a potentially unfeasible trial, capitalising on preliminary
feasibility research, additional information gained (if a sample size re-
estimation could also be done), the validity of site registry lists to in-
form recruitment estimates, and other consequences of the timing in
relation to the trial’s population needs, intervention delivery and
measured outcomes.
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Background and Aims
Pilot trials are recommended to estimate certain key parameters for
a definitive randomised controlled trial (RCT). The recruitment rate
(number of participants recruited in a unit time period) is usually of
particular importance as it will inform the number of centres and re-
cruitment period required for a full trial. The BEADS external pilot
trial intended to recruit over 12 months at 3 centres (36 centre-
months of recruitment) to assess the feasibility of a definitive trial
comparing Behavioural Activation Therapy (BAT) and usual care for
treatment of post-stroke depression. Due to delays during the trial
set up, recruitment was delayed in all centres. A total of 28 centre-
months of recruitment were completed. It was suggested that re-
cruitment period should be extended to meet the original target of
12 months per centre. It was decided that the recruitment period
would not be extended and we should use the centre-months com-
pleted to estimate recruitment rate. We aimed to investigate how
many centre-months would be required to estimate the underlying
recruitment rate using simulations.
Methods
The number of participants recruited to the BEADS trial was recorded
and presented by centre and by month. Overall recruitment rate was
calculated by centre-month along with the 95% confidence interval.
Simulations were carried out to simulate extending the recruitment
period up to 80 centre-months. Data were simulated from a Poisson
distribution and further simulations were carried out using a negative
binomial distribution due to overdispersion in the pilot data. Recruit-
ment rates and their 95% confidence intervals were calculated for
each month using the simulated data to examine the precision of es-
timates from an extended pilot recruitment period. Three values of
the mean (1, 2 and 4), the recruitment rate, were used. The moving
recruitment rate was plotted against centre-month for each simula-
tion. Percentage bias and percentage coverage were calculated for
each centre-month. Bias and coverage were plotted against centre-
month to examine how these changed as recruitment period
increased.
Results
The number of participants recruited to the BEADS trial per month at
each centre ranged from 0 to 6; with a mean of 1.75 (1.12, 2.38) per
month. Results from the simulations showed that although the level
of precision increased as centre-months increased, the level of preci-
sion gained by extending pilot recruitment period from 28 to 36
centre-months was not substantial. This was the case for all values of
underlying recruitment rate and both the Poisson and negative bino-
mial simulations. Furthermore, the decrease in level of bias and in-
crease in coverage were both relatively small. Conclusions: Although
a reduction in the pilot recruitment period was not planned, an extra
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or accuracy of our estimate of underlying recruitment rate and its
95% confidence intervals. More general recommendations for pilot
recruitment can be made based on our different expected recruit-
ment rates and proposed underlying distributions.
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Background
The stepped-wedge cluster randomised trial (SW-CRT) is a complex
design for which many decisions must be made during the design
stage, such as the required number and length of steps. Feasibility
studies might help to inform these decisions and increase the likeli-
hood of the main trial’s success. However, there is currently no guid-
ance on how feasibility studies for SW-CRTs should be conducted.
This review, the first in a series of related projects, aims to establish
how often feasibility studies are being conducted for SW- CRTs and
determine which feasibility issues are currently being investigated.
Ultimately this work will lead to guidance on how feasibility studies
in SW- CRTs should be conducted.
Methods and analysis
Searches for feasibility studies for SW- CRTs were conducted in Ovid
MEDLINE, Scopus, and psycinfo. Relevant studies were identified via
titles, abstracts and full-text retrievals according to pre-defined study
inclusion criteria. Data were abstracted on the aims of these studies
and how these studies were able to inform the main trial. In order to
also identify unpublished feasibility studies for SW- CRTs, fully pub-
lished SW- CRTs were identified from the most recent systematic re-
views. The authors of these studies were contacted with the aim of
determining whether any unpublished feasibility work was con-
ducted prior to the main trial. In addition, the lead statisticians for
registered UK clinical trials units were contacted to acquire informa-
tion on feasibility work that is being undertaken by these units to in-
form SW- CRTs.
Conclusion
This review, which is pending final results, will determine how often
feasibility studies are being used to inform SW- CRTs and identify
which feasibility issues are being investigated. Any information that
is gained on how these feasibility studies have informed the main tri-
als, will allow us to gain an insight into how feasibility studies can
benefit SW- CRTs. Future qualitative work will determine which as-
pects of feasibility studies are considered most useful and what bar-
riers are commonly encountered when conducting a SW-CRT.
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Background
The stepped-wedge cluster randomised trial (SW-CRT) is a complex
design for which many decisions must be made during the design
stage. If mistakes are made when making these decisions then the
trial might prove to be unsuccessful. If the barriers to success are
known prior to the trial then a feasibility study can be conducted.
Unsuccessful trials are unlikely to be published and so the issues that
they faced, which might be common, may go unreported and there-
fore steps cannot be taken to prevent them from occurring again.
We have conducted a review of feasibility studies for SW- CRTs whichidentified the feasibility issues that are currently being investigated
for SW- CRTs. However, further issues are likely to exist given the
possible publication bias. We aim to identify conference participants
to take part in an online questionnaire which aims to identify further
feasibility issues that are encountered by SW- CRTs.
Methods
The questionnaire will consist of both closed questions and free-text
responses and will be informed by the findings of our review. Partici-
pants will be asked about the type of involvement that they have
had in SW- CRTs, as well as the issues that they have known SW-
CRTs to encounter and those that they are concerned that SW- CRTs
may face. These questions will ask the participant either about a par-
ticular issue that was identified by our review or will be open for the
participant to discuss additional issues that we have not identified.
We are interested in obtaining responses from stakeholders with a
wide range of involvements in SW- CRTs. These may be individuals
that have been involved in the design, conduct or analysis of SW-
CRTs, individuals that are conducting methodological research into
SW- CRTs, individuals that have sat on funding panels where deci-
sions have been made on grant applications for SW- CRTs or individ-
uals with any other involvement in SW- CRTs. In addition to
conference attendees, invitations to complete the online question-
naire will be sent to the authors of SW- CRTs and feasibility studies
for SW- CRTs identified by our review, authors of methodological pa-
pers on SW- CRTs, funding panel members, advisors (such as the Re-
search Design Service) and the wider community (from lists of SW-
CRT conference attendees, the Allstat mailing list, clinical trials units
etc.). The snowball technique will be implemented by encouraging
recipients to forward the questionnaire to their contacts who are also
involved in SW- CRTs.
Participants with complementary experiences of SW- CRTs may be in-
vited to take part in an interview study that will aim to build upon
the findings of the questionnaire study by gaining a greater depth of
information on the issues faced by SW- CRTs.
Conclusion
The questionnaire and interview studies will gain both a breadth and
depth of information on the issues affecting the feasibility of SW-
CRTs. These studies form the second part of a series of related pro-
jects which will ultimately lead to guidance on how feasibility studies
in SW- CRTs should be conducted.
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Introduction
Trial-based economic evaluations rely on a number of methods for
estimating resource use and costs. The use of routine data has hith-
erto been limited, with accuracy of coding, confidentiality, ownership
and access having been previously identified as significant barriers to
access. The Department of Health in England has recommended the
use of Patient Level Information and Costing Systems (PLICS) to
understand financial drivers at patient, specialty and hospital levels.
These provide an opportunity for estimating secondary care costs
within economic evaluations.
Background
As part of a randomised controlled trial comparing the use of mul-
tiple daily injections of insulin with pumped infused insulin in newly-
diagnosed paediatric Type 1 Diabetes Mellitus patients, we investi-
gated the availability and feasibility of PLICS data for estimating
diabetes-related hospital inpatient stays.
Method
We obtained consent to access patients’ electronic records from 15
participating sites. Diabetes-related, patient-level data were recorded,
on: HRG codes PA67Z and PA68Z, lengths of hospital stay, total cost
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as critical care and drug costs. Inpatient stays were costed using 3
methods based on: (i) bed days alone; (ii) Payment by results (PBR)
National Tariff reimbursement; and (iii) PLICS-reported total cost.
Confidence intervals were calculated using non-parametric bootstrap
analysis with 10,000 replications.
Results
Data relating to 82 hospital admissions were obtained for 74 patients
at 5/15 sites. The remaining hospitals (10/15) were still in the process
of setting up their PLICS systems and could only provide routine pa-
tient admissions or legacy finance database outputs in time for the
study. The diabetes-related inpatient stays (N = 67/82 episodes) were
comprised of the codes PA67Z (admission related to diabetic ketoaci-
dosis) (12/67) and PA68Z (admission related to diabetes mellitus,
without ketoacidosis or coma) (55/67). Mean costs (95% confidence
intervals) for the diabetes-related codes were: (i) bed days: £662
(£587, £741); (ii) PBR: £1252 (£1230, £1278); and (iii) PLICS: £1839
(£1339, £2425). Disaggregated PLICS costs comprised medical/
specialist nursing staff (47%), wards/overheads (30%), critical care
(8%), other clinical supply and services (6%), pharmacy/drug costs
(5%), therapies (1%) and pathology (1%) with the remainder
comprising blood supplies, imaging, operating theatre and other
diagnostic tests.
Conclusion
There is no agreed gold standard for estimating inpatient costs
for economic evaluations. Reliance on bed day costing alone risks
underestimating the total cost of an inpatient stay, especially if
the daily rate does not account for staff, critical care, wards and
overhead costs. PBR, whilst giving a more accurate cost based on
hospital reimbursement, lacks granularity and does not include
unbundled costs such as critical care, expensive drug costs and
overheads which are reimbursed at a local level. PLICS outputs
have sufficient detail to account for these shortfalls and could
provide a more robust method of inpatient cost estimation in
trial-based economic evaluations, especially where the stay in-
volves additional expensive bundles of care such as long oper-
ation times and intensive care admission.
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Background
The Incremental Cost Effectiveness Ratio (ICER) is widely used to
inform resource allocation decisions concerning health technolo-
gies. However, the ICER is a point estimate and subject to consid-
erable variability. This variability is often presented in Cost-
Effectiveness Acceptability Curves (CEAC), which have underlying
assumptions relating to both the correlation between the incre-
mental costs and the incremental effects and their distributions.
Statistical methods have been proposed to account for this in
trial-based economic evaluations. These include non-parametric
bootstrapping, and frequentist approaches such as Ordinary Least
Square regression (OLS). Bayesian methods such as Generalised
Linear Models (GLM) with Normal, Beta and Gamma distribution
in cost and effects are scarcely used in trial-based economic
evaluation, but may have utility in certain contexts, such as when
the patient-level data is non normally distributed, the analysis of
the trial is based on a small sample size, and when dealing with
imbalanced covariates.Objective
The aim of this research is to explore the applicability of alternative
regression methods, determine their precision in calculating the cost-
effectiveness analysis of clinical trials, and to assess the merits and
disadvantages of each method to reflect uncertainty.
Method
Data from two randomised controlled trials are modeled. SYCAMORE
is a double-blind, multicentre, randomised controlled trial in which
114 children with severe uveitis associated with juvenile idiopathic
arthritis are randomised in a ratio 2:1 to receive adalimumab or pla-
cebo in conjunction with methotrexate. Health utilities are obtained
from the HUI2 questionnaires completed by the participants or their
parents (or guardians). Healthcare resource use and costs are ob-
tained from the patients’ diaries and hospital data (PLICS and HES).
Folated was a three-centre, double-blind, randomised controlled trial
in which 358 patients with moderate to severe depression were ran-
domised on a ratio 1:1 to receive folic acid or placebo in addition to
their routine antidepressants. Health utilities were measured with the
euroqol EQ-5D-3 L, EQ-VAS and SF-6D questionnaires. Healthcare re-
source use was collected from patients’ self-completed question-
naires, GP records of prescribed medications and hospital data.
Frequentist and Bayesian regression methods were employed for the
health economic analysis of the trials. Results and robustness of the
models were assessed and compared.
Results
This research is currently ongoing and findings will be presented at
the conference. Discussion Frequentist regression methods are
widely used in trial-based economic evaluations of health technolo-
gies; however they have several limitations that may be overcome
using Bayesian methods. These include factors intrinsic to the clinical
trial data, such as population characteristics, study design, sampling
methodologies, skewness of cost and utility data, etc. Bayesian
methods, however, require their prior belief is generated. This re-
search will contribute to the understanding of approaches for more
efficient and robust health economic analysis of clinical trials.
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Background
Crohn’s disease (CD) is a chronic condition causing inflammation of
the digestive tract, requiring ongoing treatment. Biological drugs
have improved the quality of life for many patients. However, they
are expensive and are linked to serious adverse events. Biosimilar is
the term given by the European Medicines Agency (EMA) to a bio-
logical drug that contains a version of the active substance of an
authorised biological reference medicinal product (RMP). As the pat-
ents for RMPs expire, applications are being made for biosimilars.
The first CD biological treatment patent to expire was for Remicade
(infliximab).
The EMA takes a ‘Totality of evidence’ approach to assessing the
benefit-risk balance by requiring that a comparability exercise dem-
onstrates similarity in terms of quality characteristics, biological activ-
ity, safety and efficacy. This involves a stepwise approach to
conducting non-clinical and clinical studies. Clinical studies are con-
ducted in one population with extrapolation allowed to other indica-
tions given adequate scientific justification.
Sponsor data for infliximab biosimilars has highlighted differences to
RMPs vis-à-vis the ability to induce antibody-dependent cellular cyto-
toxicity (ADCC), which is a potential mechanism of action for anti-
TNF-alpha drugs in CD, and the number of adverse events. Whilst
regulators in Europe, Japan and Australia approved the biosimilar
Inflectra, the USA and Canada were more risk averse, first rejecting
the biosimilar before approving following sponsor submission of
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other biosimilar, Flixabi, has been approved by the EMA but with a
significant divergent position statement.
Aims and objectives
To date there has been no approach to measure quantitatively the
benefit-risk balance of biosimilars. This project aims to quantify the
benefit-risk balance for Inflectra versus Remicade in CD.
The objectives of the study are to:
– Develop a model to estimate the benefit-risk balance of Inflectra
versus Remicade.
– Use statistical methods to evaluate the impact of the surrogate
outcome ADCC on efficacy outcomes and serious adverse
events.
– Carry out, where necessary, elicitation of probability
distributions for uncertain model parameters from experts and/
or patients.
Potential impact
The ‘Totality of evidence’ approach to benefit-risk balance assess-
ment is subjective and leads to uncertainties. Sponsor-provided data
shows differences in the ability of infliximab biosimilars to induce
ADCC and there is evidence to support ADCC as a mechanism of ac-
tion in CD; certolizumab pegol, for instance, is unable to induce
ADCC and has minimal efficacy in CD. However, etanercept does in-
duce ADCC but is not effective, adding to the uncertainty.
The main concern with biosimilars is the potential for developing
anti-drug antibodies (ADAs), something which clinical trials for other
indications are unable to rule out for CD. The consequences of devel-
oping adas include reduced efficacy and adverse events, particular
serious events that are peculiar to CD including some cancers. The
main benefit is the great potential for biosimilars to offer significant
cost savings.
This work will identify the conditions that impact the benefit-risk bal-
ance for the biosimilar and will provide a methodology that could be
developed to assess the benefit-risk balance of future biosimilars.
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Background
The use of statistical analysis plans (SAPs), produced prior to un-
blinded analysis, is an accepted means of reducing bias in rando-
mised controlled trials (RCTs) by minimising selective analysis.
However, while health economics analysis plans (HEAPs) to guide
economic evaluation analysis alongside RCTs are becoming more
common, they lag far behind saps in terms of their acceptance and
standardisation, and there is a fundamental question over the value
they add to trials.
Aims
(a) To map current practice and beliefs about the appropriate imple-
mentation (or otherwise) of heaps, with a view to drawing up good
practice guidelines in future work and (b) to provide a forum in
which health economists and other interested parties engaged in
economic evaluations could open a dialogue on the need for heaps
and methods of standardisation.
Methods
A workshop was held in Bristol, UK in October 2015, to discuss issues
associated with heaps. 50 predominantly university-based partici-
pants heard presentations from speakers before breaking into
smaller groups for discussion sessions. Presented sessions included
accounts of practical experiences of using heaps in RCTs, alongside
perspectives from SAP guidelines, NICE and wider non-trial based
economics. In the discussion sessions, participants debated topics in-
cluding the appropriate content of heaps, the circumstances in whichdeviations are permissible, and the appropriate oversight and gov-
ernance of heaps.
Results and discussion
Few guidelines are available to aid health economists in compiling heaps.
Currently, substantial variation exists in the structure, format and content
of heaps, and there are questions over their purpose and appropriate
methods of oversight. Heaps may be published as part of a SAP, or as a
standalone appendix, but are commonly unpublished. Although concerns
remain over the impact of the research and bureaucratic burden involved
in producing a plan in advance (particularly given the relatively small
health economic workforce), the potential loss of useful post hoc analyses
if a plan is too rigid, and the timing of completion, there was a general
feeling that heaps would be useful. The majority (approximately 65%) of
health economists at the workshop were in favour of a combined SAP
and HEAP, rather than a standalone HEAP.
Conclusion
HEAPs are currently developed inconsistently and there is an appe-
tite for formal guidance. As it seems likely that the use of heaps will
continue to increase in the future (and potentially, be required by
funding bodies or regulators), clarity on the appropriate usage and
content would be advantageous. We therefore plan to conduct a
Delphi survey of practising health economists and other trialists to
determine suitable content for a HEAP.
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Embedding clinical trials in routine clinical care provides the oppor-
tunity to enhance efficiency and reduce costs. Diabetic retinopathy
(DR) remains a common cause of blindness and impaired vision and
treatment of advanced DR is costly. However, few trials have been
designed to investigate treatments which may retard progression
from observable DR to advanced DR because the condition usually
progresses slowly, it is challenging to identify patients at risk of pro-
gression to clinically significant DR without retinal imaging and stud-
ies require medical professionals and specialist equipment to capture
and grade retinal images. This highlights the need for streamlined tri-
als which can identify large numbers of eligible patients and follow
them cost-effectively for extended periods.
The infrastructure of NHS Scotland provides a unique setting in
which to conduct a trial with (i) low cost recruitment and (ii) record
linkage for assessments of treatment efficacy and safety. Key ele-
ments include NHS Scotland’s Diabetic Retinal Screening service
(DRS) and SCI-Diabetes. DRS provides regular retinal screening for all
250,000 patients with diabetes in Scotland. Retinal images are graded
centrally in health boards, results are posted to patients and auto-
matic referral to specialist eye clinics occurs if a patient develops clin-
ically significant DR. SCI-Diabetes is NHS Scotland’s diabetes
information system which collects and records diabetes-specific data
from primary and secondary care.
The LENS (Lowering Events in Non-proliferative retinopathy in
Scotland) trial is a streamlined randomized double blind placebo-
controlled study of fenofibrate. The aim of LENS is to investigate the
effect of fenofibrate on progression of observable DR to either
clinically significant DR or to DR which requires specialist treatment.
Fenofibrate is a generically available cholesterol-lowering medication
and pooled findings from previous cardiovascular outcome trials
have suggested that it may reduce DR progression by 30-40%. We
aim to randomise 1,060 participants in LENS and follow them for an
average of 4 years.
For recruitment, DRS will include a trial information leaflet with a
FREEPOST reply slip along with retinal screening results mailed to pa-
tients whose DR grading indicates they are eligible (about 10% of all
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domisation, either side of an eight-week active run-in, follow-up will
be conducted remotely. This will involve regular linkage by pseudo-
nymisation to multiple national registries and completion of ques-
tionnaires by computer or telephone. Registries will include DRS (for
pre-specified eye outcomes), Scottish Morbidity Records (for hospita-
lisations and outpatient visits), National Records of Scotland (for flag-
ging deaths), the Prescribing Information System and SCI-Diabetes
(for various diabetes-related outcomes). Furthermore, SCI-Diabetes
will be used after randomisation for central monitoring of biochem-
ical safety in almost real-time, based on the availability of results
from routinely collected blood samples. Study medication will be
mailed to participants by registered post.
LENS is co-ordinated by the Clinical Trial Service Unit and Epidemio-
logical Studies Unit, University of Oxford, and run in collaboration
with the Universities of Glasgow, Aberdeen, Edinburgh and Dundee,
DRS and mainland NHS Scotland health boards. It represents the first
trial to be embedded within an existing national DR screening
program.
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Background
Making a decision regarding which system to host your clinical trial
data presents a number of challenges. The scope of the system: is it
just data entry, is it web enabled, does it include randomisation and
is there a requirement for other trial management functionality, has
to be considered. The cost of the system is very important to aca-
demic clinical trials units (CTUs) not just at the stage of initial pur-
chase but the resource to maintain and setup each trial. As
technology develops multiple platform capability is becoming in-
creasingly key to the service a CTU can provide in a competitive
landscape.
Method
A review of commercial systems, open source solutions versus the
merits of developing a bespoke system was undertaken by Glasgow
Clinical Trials Unit. A list of requirements was compiled in order to
compare each system reviewed and inform the decision. It was also
considered whether a combination of systems would fulfil the entire
list even if this was not the most elegant solution. The process was
concluded by a decision to develop a bespoke system as this was
the only solution that could match all of the requirements in a single
system.
Conclusion
The authors will discuss the implications of this decision on their Unit
resource, future business and the justification for their decision. Have
they bitten of more than they can chew? Have they developed their
perfect system? What decisions have other CTUs made?
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Pharmacovigilance (PV), also referred to as drug safety, is defined as
the pharmacological science and activities related to the detection,
assessment, understanding and prevention of adverse effects or
other drug-related problems (WHO, 2002). Monitoring patient safety
is an essential component of conducting clinical trials and membersof the PV team are highly skilled medical and safety professionals
with regulatory and safety experience. However, due to the sheer
magnitude of Adverse Events (AEs) collected in many clinical trials, it
is vital to utilize innovative EDC technologies in order to improve
quality and efficiency of PV activities. Developing the safety elec-
tronic case report forms (ECRFs) in a thoughtful and systematic way
before the start of a trial can enhance data quality, facilitate coding
procedures, and enable more rapid drug safety decisions. Certain
adverse event terms can be predetermined on the ECRFs to reduce the
number of varied but similar terms, and to categorize into protocol-
specific events of interest (e.g., seizures) to allow for desired
organization of large amounts of data. This can greatly reduce the
preparation time for Data and Safety Monitoring Board (DSMB) review
and other reporting needs. Technical capabilities also allow for auto-
mated notifications to be triggered based on the use of a specific term,
severity grade, or causality designation. For example, the PV team can
be notified whenever a “related” AE is entered in the EDC system, or
when lab values exceed a certain threshold. Leveraging the EDC cap-
abilities optimizes the function of the clinical trial pharmacovigilance
practices, provides real time monitoring of safety events, and can be
made accessible for sponsors or DSMB members as needed. This pres-
entation will discuss best practices for utilizing EDC systems to facilitate
clean well-organized safety data and increasing the efficiency of phar-
macovigilance activities throughout the life of a trial.
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Background
HIV-NAT 015 study is a pediatric HIV cohort, aimed to collect long
term efficacy and safety data of treatment in HIV-infected children,
established since 2004, at HIV-NAT, the Thai Red Cross AIDS Research
Centre, Bangkok, Thailand (clinicaltrials.gov number NCT00476606).
In the first few years of this study, we collected clinical and labora-
tory data through the data entry person after each clinic visits. How-
ever, this process took time for data entry, monitoring, and had
some transcription errors.
Methods and Results
Since 2010, we developed an in-house HIV-NAT electronic health record
(EHR) to use in this study. Physician can review all medical history and
see overall growth parameters, and real time laboratory results includ-
ing CD4, plasma HIV-RNA through tables and graphs format. This EHR
can capture all adherence data by self-report and percent adherence
by pill count of antiviral therapy, HIV disclosure status, parental vital sta-
tus which is used for adherence counselling and care. The EHR can
auto-calculated body surface area after entering body weight and
height which minimized error when calculating dosage of antiviral ther-
apy in young children. Physician can directly print the auto-filled pre-
scription after seeing each patient. The EHR is directly integrated to
HIV-NAT laboratory reporting systems which reduced workload for data
entry and ensuring data safety and completeness. Nurse assistance can
process the lab request through the EHR, and make the next clinic ap-
pointment in this paperless EHR. Due to limited man-power in number
of pediatric study nurse and monitor team, this EHR is helpful in task
shifting i.e. A trained nurse assistance can replace some roles of study
nurse for administrative work, a trained data entry person can do basic
data monitoring by identify missing or out range data. Moreover, we
can perform a data search for a new research question and feasibility
survey for the new trials within a few minutes.
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This in-house EHR is efficient, reduces transcription error and illegible
data issues, saves time and cost, requires less storage space, and pro-
vides a broader set of research questions and future data analysis.
We recommend using this in-house EHR in both clinical trial center
and in general hospital.
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Background
The TEMPER study (results submitted separately) evaluates the use of
trial-specific triggered site monitoring, where centrally collected data
inform the choice of which sites should undergo monitoring visits. It
compared findings at triggered monitoring visits to findings at visits
to matched, untriggered control sites that would not otherwise have
been visited. Three multi-centre cancer trials at the MRC Clinical Trials
Unit at UCL participated in the TEMPER Study.
The TEMPER management system
To meet the specified requirements, we developed a data manage-
ment system to allow: 1) the extraction of tailored trigger data from
the participating trials databases; these had been developed in a
third-party Clinical Data Management System; 2) the ranking and se-
lection of triggered sites based on the extracted trigger data; 3) the
pairing of the chosen triggered sites with control sites based on simi-
larity criteria; 4) the collection and management of findings data
gathered in the monitoring visits to the triggered and control sites.
The system was developed in Visual Basic.NET with a SQL Server
database, which served as the main study database for TEMPER and
was used for analysis.
Trigger data
For each participating trial, a set of specific triggers was defined by the
trial team; each consisted of a narrative explaining the conditions under
which it fires. An example of a trigger narrative is: ‘More than 0.5% of
the values in the open forms are missing or queried based on total
number of fields to be entered’. The majority of trigger narratives were
implemented as automatic triggers in the system. When data was not
available in the trial database to implement an automatic trigger, for
example data was from external sources or based on subjective inter-
pretation, manual triggers were instead created in the system allowing
users to set their status to fire as necessary. The TEMPER system
allowed the trigger data to be summarised following extraction, ranked
by a trigger score based on the triggers fired, and presented to the trial
teams to inform the selection of triggered sites to visit.
Matching Algorithm
A matching algorithm was also implemented in the system which
ranked best matches to the selected triggered sites based on site
similarity while prioritising sites with lower trigger scores. Site similar-
ity was defined by participation: number of patients randomised and
number of days since first randomisation.
Results
A total of 38 triggers, 31 automatic and 7 manual, were specified for
the three participating trials. The matching algorithm paired 42 trig-
gered sites with corresponding control sites.
Conclusions
The TEMPER system implemented a novel approach on how to manage
monitoring trigger data and how to match triggered sites with control
sites; this allowed the realisation of the TEMPER study protocol.
Implications
If the TEMPER study results show the triggered monitoring strategy
to be effective, the system could be introduced to other trials in theunit. The TEMPER system design will also inform future implementa-
tions and improvements on monitoring systems at the unit, including
further research.
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Background
If patients can be followed up electronically rather than in person,
then the cost of running a clinical trial can be significantly reduced.
At study design it was estimated that 75% of patients would
complete their follow-up online, with the other 25% opting for either
postal or telephone.
Methods
As the study design allowed for three different methods of collecting
patient data, a system was required that would allow very different
types of user to access and enter data. These users would require dif-
ferent access levels to the system and to the data being entered. En-
suring patients could only access their own data was imperative,
while study staff would need access to the data of all patients that
they were in contact with. Additional complexity was introduced, as
the staff creating, maintaining and supporting the system never deal
with patients, so needed to remain blind to the patient’s personal
contact details.
Conclusion
We will discuss the different levels of access required for the differ-
ent roles, how access was provided to patients and the challenges in
creating a system to be used by patients, while remaining blind to
their identity.
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Background
For defining clinical trial endpoints and for producing reports, it is
necessary to group adverse events. For example a line reporting the
number of participants who had a stroke includes participants who
had “Haemorrhagic Stroke”, “Ischaemic Stroke”, “Cerebral Infarction”,
and several other types of stroke. Classification of events into groups
can be done using the event code, but often other properties also
need to be used. These properties include: "hospitalization required",
"cause of death", "urgent or non-urgent". Large trials can have
10,000 s of events, and hundreds of event classes. Defining event
classes and classifying events are important problems.
Methods
We describe how to use the Web Ontology Language (OWL) to ad-
dress these problems. OWL software tools exist that can represent
OWL in both human-readable and machine-readable forms; an OWL
document defining event classes can serve as both specification and
implementation. OWL permits a class to be defined as a Boolean
combination of other classes. For example STROKE can be defined as
HAEMORRHAGIC STROKE or ISCHAEMIC STROKE. Medical coding dic-
tionaries such as meddra can serve as predefined event classes. We
have converted meddra into an OWL representation so that it can be
used as the basis for defining other event classes. We deliberately
use only those features of OWL that correspond to basic set theory
because this is already understood by clinicians who define event
classes, and programmers who use them. During the process of de-
fining event classes, OWL tools can be used to check for errors. For
Trials 2017, 18(Suppl 1):200 Page 59 of 235example, it is possible to specify that two event classes should
have no events in common, or that a group of event classes
should be equivalent to some other event class. In order to use
OWL event class definitions during the production of analyses
and reports, some short ‘glue’ programs are required. Events (and
their properties) that occur during the trial are converted into an
OWL document and fed into an OWL reasoning tool. The output
from this is a list of which event classes contain which other
event classes. This is converted into a flat tabular form that can
be stored in a database and easily queried to find out which
events are in which classes.
Pros
This approach uses well-supported public domain software, so little
in-house coding is required. Since OWL has a well-defined meaning,
event class definitions can be communicated unambiguously to
others. Performance is reasonable: in a large trial (85,000 events, 200
event classes) it takes a few minutes to check class definitions for in-
consistencies, and one minute to classify all events.
Cons
It is sometimes necessary to take account of the open-world seman-
tics of OWL in order to define some event classes correctly; it is rea-
sonable to expect programmers to take the time to understand this,
but not so reasonable to expect this of clinicians.
Conclusion
We found this to be a practical way of classifying events. We expect
that OWL can be used for other classification tasks, such as the classi-
fication of drugs into related groups.
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Background
A Registry is an organized system that uses observational methods
to collect uniform data on specified outcomes in a population de-
fined by a particular disease, condition or exposure. At their core,
registries are data collection tools created for the purpose of gener-
ating clinically usable information and evidence. The data captured
in a registry typically includes information such as medical history,
demographics, disease diagnosis and outcome data.
Patient data collected in registries often overlaps with data gathered
for clinical trials. Integrating clinical trials within observational data
registries may offer opportunities to avoid duplicative data collection,
increase operational efficiencies, reduce time to database lock and
accelerate time to critical decision making, while decreasing clinical
trial costs. The objective of the Clinical Trials Transformation Initiative
(CTTI)’s Registry Trials project was create recommendations to sup-
port the practice of leveraging registries to facilitate high quality clin-
ical trials.
Methods
The CTTI Registry Trials project team conducted a literature review,
interviewed 25 experts, and then convened a multi-stakeholder ex-
pert meeting. At the expert meeting attendees discussed recommen-
dations for best practices to increase the value, acceptance, and
success of registry based clinical trials.
Results
Depending on its characteristics and capabilities (e.g. Interoperability,
connectivity, flexibility, sustainability), a registry can be used either as
an observational data source for generation of clinically actionable
evidence and hypothesis generation, or as a critical reusable compo-
nent of the clinical trial infrastructure within which prospective ran-
domized studies can be performed. Questions exist about identifying
appropriate registries, ensuring data quality/comparability, meeting
regulatory requirements, and processes for implementing a random-
ized registry trial.If the historical data created by a registry are well established to be
relevant/fit to purpose, robust and reliable, then the registry can
have a clear role in creating a sustainable infrastructure within which
regulatory trials can be conducted. Identifiable requirements and
practical considerations have not been defined in the use or modifi-
cation of existing registries and/or in design of new registries in
order to make them fit for the purpose for conducting a Randomized
Registry Clinical Trial (RRCT). Such normative standards are essential
for consistent evaluation of a registry’s suitability for generating the
clinical evidence needed for regulatory decision making in the vari-
ous phases of drug and device development. CTTI has created rec-
ommendations and tools to assist in 1) evaluation of an existing
registry’s suitability for conducting clinical trials and 2) designing a
new registry in which to conduct a clinical trial.
Conclusions
CTTI Registry Trials recommendations and tools can assist researchers
in evaluating new and existing registries to determine if embedding
randomized clinical trials is appropriate.
P153
Developing novel endpoints, generated using mobile technology,
for use in clinical trials: a clinical trials transformation initiative
(CTTI) project
Martin Landray
University of Oxford
Trials 2017, 18(Suppl 1):P153
The appropriate inclusion of mobile technology into clinical trials of-
fers significant opportunity to improve clinical endpoint ascertain-
ment. Mobile technology can provide unprecedented access to real-
world situations where multiple precise measurements on trial partic-
ipants could be made without interference to their daily life. Such
endpoints can reduce patient participation burden, increase trial
feasibility and address unmet need for endpoints in certain thera-
peutic areas and patient populations. We propose recommendations
to clarify the pathway for developing novel endpoints, generated
using mobile technology, for use in clinical trials. We describe steps
for appropriate novel endpoint selection and development, along
with an analysis of how this approach differs to traditional endpoint
development and recommendations for reducing friction in this
process. Our approach is designed to meet the needs of clinical trial-
ists, regulators and trial participants. Our multi-stakeholder team of
experts pursued a two-pronged approach to evidence gathering. Our
recommendations have been informed by both new, empirical evi-
dence generated by writing four use cases and a synthesis of exist-
ing, published approaches across therapeutic areas. Four discrete use
case teams developed proposed novel endpoints for Parkinson’s dis-
ease, heart failure and Duchenne’s muscular dystrophy using data
generated using accelerometers and a novel endpoint for diabetes
derived from data from a continuous glucose monitor. Each team in-
cluded investigators and patient reps with expertise and experience
in the disease state, engineers and mathematicians with expertise in
the specified device, regulators, nonprofit consortia and statisticians.
The systematic literature review identified 101 manuscripts where
novel endpoints were included in clinical studies.
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Background
Big databases of patient health information offer a unique opportun-
ity to be selective about which individuals are invited to participate
in clinical studies. In particular, large databases can be searched for
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ally recruit individuals at random, usually by waiting for eligible pa-
tients to present at one of the study centres. Electronic health
records allow researchers to immediately target the most relevant
and informative patients for further investigation.
Methods
Informativeness depends on an individual’s covariates (or "risk
factors"). The statistical measure of entropy is used to quantify how
much statistical information an individual is expected to provide on
the study. More informative individuals have a higher probability of
being selectively recruited onto the study.
Results
Preferential recruitment of informative individuals can potentially
lead to successful observational studies with smaller cohort sizes. Re-
sults from numerical simulations have shown that a desired level of
statistical power can be achieved with an informative cohort of 200
individuals compared to a randomly selected cohort of 300 individ-
uals. In order to illustrate how our methodology can be used in prac-
tice we simulated studies of patients with cardiovascular disease
using electronic health records from the Clinical Practice Research
Datalink.
Conclusion
The advent of large databases of patient records represents an un-
precedented opportunity for more efficient and cost effective stud-
ies. Our approach can also be applied to follow-up studies after a
clinical trial has ended in which an informative subset of the trial par-
ticipants are followed for a longer period of time. In situations when
it is prohibitively expensive to follow the full trial cohort over an ex-
tended time period our methodology may offer a more feasible
alternative.
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This abstract is not included here as it has already been published.
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Background
There are ethical, sociopolitical and scientific reasons for patient and
public involvement (PPI) in research, and many funders now require
applicants to include PPI to improve the relevance, accountability
and quality of research. However, there is evidence of challenges in
implementing PPI, and formal guidance on how to involve service
users in the conduct of trials is lacking.
Aim
To systematically investigate how PPI is approached within the Bristol
Randomised Trials Collaboration’s (BRTC’s) clinical trials unit (CTU)
portfolio of trials, and identify barriers to and facilitators of its
successful implementation, to contribute to our understanding of PPI
in trials and guidance and training in this area.
Methods
We included all currently active BRTC portfolio trials, plus those
which ended in the previous 2 years. A mixed-methods study design
was developed, involving: (1) An online survey of Trial Managers
(TMs), conducted August-September 2016, to determine how trials
included PPI and the support required from CTUs for PPI; (2)Interviews with Trial Management Group members and PPI represen-
tatives from case study trials (estimated n = 10). Case studies were se-
lected purposively to represent a range of trial designs, funding
streams and trial initiation dates. Interviews explored the perceived
value of PPI involvement and barriers to/facilitators of PPI. Quantita-
tive survey data were summarised using descriptive statistics and
interview transcripts analysed thematically. A project PPI group ad-
vised on interview topic guides, provided feedback on findings and
assisted with dissemination.
Results
21/26 TMs completed the survey. 15 trials (71%) included a PPI repre-
sentative on the trial team, 5 used another method of PPI (e.g. Via in-
put to advisory group (n = 3)/Trial Steering Committee (n = 2),
consultation of patient group (n = 1)), and one TM reported s/he did
not know of any PPI in the trial. The 15 trials that included PPI repre-
sentatives recruited 1–20 PPI representatives (mean 6.4, 1 missing),
but in practice 0–10 were regularly involved (mean 4.8, 2 missing).
None used a formal process to recruit PPI representatives.
The most common tasks undertaken by PPI representatives were re-
view of participant-facing materials and other study documents and
advising on recruitment/retention strategies. Changes made as a re-
sult of PPI related to trial documentation and design; 2 TMs reported
no changes had been made. Twelve TMs reported that PPI represen-
tatives were paid for their time, 4 said payment was not offered and
3 did not know. Payments ranged from £10-£50/hour, with 3 trials
paying in vouchers. Only 5 TMs reported that training was provided
for PPI representatives (12 reported no training, 3 did not know, 1
missing).
TMs reported that CTUs could assist with recruitment of PPI repre-
sentatives and provide guidance on integrating PPI in grant applica-
tions. Challenges reported included ‘professional PPI members’
having a different agenda to the study population, and lack of con-
tinuity in trial staff. The interviews are currently underway; findings
will be presented at the conference.
Conclusions
Survey findings show that PPI involvement in trials is currently
highly variable. PPI representatives are recruited informally, are
rarely provided with any training, and are paid inconsistently across
trials.
P158
‘Is that it?’ Using ‘explorachoc’ to engage the public with clinical
trials and health services research
Heather Morgan, Becky Bruce, Gordon Fernie, Heidi Gardner, Beatriz Goulao,
Joanna Kaniewska, Clare Robertson, Sharon Wren, Katie Gillies
University of Aberdeen
Correspondence: Heather Morgan
Trials 2017, 18(Suppl 1):P158
Background
Public engagement is the interface between research and wider soci-
ety. By helping to bring these two sometimes disparate worlds
together, engagement can increase public trust and enhance rele-
vance, accountability and transparency of, and in, research pro-
cess(es) and researchers. Engagement is also important because it
can empower people to become involved through offering their in-
sights into and feedback on our work to help ensure that the re-
search we conduct is relevant to the societies in which we live and
are striving to improve. Bringing together colleagues’ experiences of,
and interest in, public engagement with research, our team’s aim
was to employ a strategic approach to deliver public engagement ac-
tivities around clinical trials and health services research to demystify
our work and facilitate public involvement.
Methods
We designed a two-arm trial, which we called ‘explorachoc’ to: dem-
onstrate the randomisation process used in clinical trials; engage
members of the public in conversations about clinical trials and
health services research to solicit their perceptions and views; and re-
cruit to a public involvement panel. We piloted this activity at the
University of Aberdeen’s May Festival (28–29 May 2016) and ran a
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Night/Explorathon event (30 September 2016). The trial involved:
double-blinded selection of either a blue or yellow ball (with equal
chance of selecting either); depositing the ball in a large transparent
jar to demonstrate the distribution of selection; ringing a randomisa-
tion bell; being given a chocolate with a blue or yellow (white or milk
chocolate) wrapper, corresponding to the selected ball’s colour; and
ranking the chocolate on a scale of 1 (low) - 4 (high). We then en-
gaged participants in a range of conversations about the history of
clinical trials (using costumes and props to re-enact James Lind’s
scurvy trial) and our research portfolio (supported by flyers and
printed information). Finally, we asked participants whether they
would be willing to be contacted to contribute to our public involve-
ment panel.
Results
We randomised 365 people (48.5% blue) across the two events (83%
Explorathon). The median in the blue group was 4.0 Interquartile
range- IQR (3.0-4.0) and 3.5 IQR (3.0-4.0) in the yellow group (Mann
Whitney U p-value = 0.633). The resounding response was ‘Is that it?’
Regarding randomisation, which suggests that we were able to
somewhat demystify the process of randomisation. Most participants
understood the connections between clinical trials, health services re-
search and the health and social care they receive. Many recounted
anecdotes of surgical, drugs and other therapies they have experi-
enced themselves or within their families and acknowledged the im-
portance of engaging and/or being involved in the types of research
we do. 71 people volunteered their details for future contact regard-
ing public involvement.
Conclusions
We have established an approach to delivering public engagement
activities around clinical trials and health services research designed
to demystify our work and facilitate public involvement. We have a
proof of concept for an effective engagement model, enhanced by
the use of chocolate, and are building on this to develop public
engagement and involvement strategies.
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Background
The purpose of conducting a Priority Setting Partnership (PSP) is to
identify and prioritise uncertainties for a specific condition. PSPs usu-
ally follow a standardised transparent methodology, often supported
by the James Lind Alliance (JLA). They are a true collaboration be-
tween clinicians and patients/carers. It is expected that the results of
a PSP will influence the subsequent research agenda for that condi-
tion, ensuring that research meets the needs of both patients and cli-
nicians and therefore contributes to reducing research waste. The
overall aim of this study is to assess the impact on the research
agenda of all PSPs that have been conducted for skin conditions.
Objectives
We will determine what proportion of clinical trials address one or
more of the prioritised research uncertainties, and whether there are
differences between different sponsor/funding types. We will also in-
vestigate what proportion of the National Institute for Health Re-
search (NIHR) commissioned calls and themes reflect the priorities
identified by PSPs. Furthermore, we will look at the wider picture of
impact of PSPs, including how findings can be used to support non-
research activities (e.g. Services), development of diagnostic criteria
and outcome measures, and whether PSPs can act as a gateway for
individual patients/cares to progress to further involvement in
research.
Methods
We will search relevant databases and websites to identify all skin-
related PSPs that have been conducted, and then identify ongoingor published clinical trials in these disease areas. Sources will include
clinical trial registries, funder databases, PubMed, and the JLA web-
site. Where necessary, we will contact the clinical trial teams to clarify
where information is unclear, particularly around timing, to deter-
mine whether or not the trial was funded prior to the PSP results
being available. We will also survey the authors of PSPs and subse-
quent research teams to assess any wider impact of the PSPs such as
successful fellowship applications and involvement of patients as
partners in further research.
Results
Preliminary searches have identified seven PSPs in the field of skin
disease; acne, cellulitis, eczema, hair loss, hidradenitis suppurativa,
pressure ulcers and vitiligo. Work on this study is ongoing and the
full results will be available by the time of the conference.
Implications
The results of PSPs are increasingly being used by funders to priori-
tise research of importance to both patients and clinicians. However,
it is acknowledged that conducting a PSP requires considerable time
and resources, so we will evaluate the value of PSPs by assessing the
evidence of impact of those conducted in dermatology. The results
of this study should therefore be helpful for researchers considering
undertaking a PSP, and for potential funders of PSPs.
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Background
Adverse events (AEs) reporting is essential in clinical trials. The
current system for reporting (Common Toxicity Criteria and Adverse
Events, CTCAE) relies on clinicians’ interpretation of symptoms. The
value of patient self-reports of AEs and Patient Reported Outcome
Measures (proms) is recognised but robust data collection methods
are needed. Here we report the REPORT-UK study which developed
and evaluated an electronic (internet/telephone) system for self-
reporting AEs and proms during trials.
Method
249 varied diagnosis cancer patients undergoing treatment (chemo-
therapy/targeted agents/hormone therapy/radiotherapy/surgery, and
an ECOG group with performance status 2) were recruited. For
12 weeks patients were reminded (text/email) to complete weekly
AEs (NCI PRO-CTCAE) and monthly proms questionnaires (EORTC
QLQ-C30) on their preferred system. Acceptability and feasibility was
measured by recruitment rates, attrition, compliance, and patient
and staff feedback at end-of-study.
Results
Overall, the consent rate was 48%. System preference was 82% inter-
net/17% IVR (telephone). Only 13 participants withdrew and 6 died
whilst on study. 192 returned end of study questionnaires. Overall
patient compliance was good for weekly AE and monthly proms
reporting, but differed between treatment groups, and dropped over
time. Both systems were perceived as easy-to-use. Time to complete
was perceived by patients to be acceptable, although actual times
show the internet is quicker (median time 9 minutes vs. 21.5 mi-
nutes). Baseline comparisons between patient vs. Clinician-reporting
of some AEs differed substantially.
Conclusion
The study demonstrates a user-friendly electronic data collection sys-
tem, which provides information on patient compliance in a general
oncology setting but we recognise this is different to a real trial set-
ting. The system could be implemented in practice in clinical trials
alongside traditional approaches to improve data quality and safety.
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Objective
Bayesian estimation the proportion of pulmonary arterial hypertension
patients with a 30% reduction in pulmonary vascular resistance from
baseline after Background Pulmonary arterial hypertension comprises a
grouping of diseases associated with a poor prognosis. Four classes of
drug therapy targeting vasoactive pathways have been studied in ran-
domised controlled trials (RCTs) and licensed for the treatment of pre-
dominantly group 1 pulmonary arterial hypertension (PAH). These
therapies have demonstrated moderate success, with meta-analyses of
all RCT data suggesting a short-term improvement in mortality at
14 weeks [1]. Despite this, PAH in the UK still carries a 5 year survival in
idiopathic PAH of 61% and as low as 49% for PAH associated with con-
nective tissue diseases. Therefore, there remains an urgent need for the
development of new treatments, particularly as the results from com-
bination studies of these different classes of vasoactive therapies has
been to date mixed and disappointing.
Methods
The study will be a 6-month open label phase II trial of IV tocilizumab
(8 mg/kg) in 21 patients with group I PAH. Subjects will be assessed
for safety and efficacy at screening, baseline, week 4, week 8, week
12, week 16, week 20 and study end. The main outcomes are: safety
(incidence and severity of adverse events) and pulmonary vascular
resistance (dynes’s Cm-5) measured using invasive haemodynamic
assessment by right heart catheter. Prior elicitation techniques will
be used to transform experts’ knowledge about the effect of the
drug onto a distribution. Bayesian analysis will take into account the
experts’ prior to predict the mode and 95% credible interval of the
effect of tocilizumab in pulmonary vascular resistance [2].
Results
This is an ongoing project. Potential posterior distributions given dif-
ferent priors (dashed lines) and any possible result.
Conclusions
Prior elicitation is particularly useful in small trials because the
amount of information contain in the data is limited. However, the
prior can have strong effects on the posterior so removing biases in
the elicitation process is paramount.
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Background
Many clinical trials involve binary outcomes which require adjudication
to determine whether an event occurred or not (e.g. Myocardial infarc-
tion, disease progression, patient response, etc.). Incorrectly classifying
the outcome (e.g. By incorrectly adjudicating an event when the true
outcome was no event, and vice versa) can lead to biased estimates of
treatment effect and reduced power. Using adjudication approaches
which minimise the misclassification rate of outcomes is therefore im-
portant, however there is little evidence on which to base this decision.Methods
Under the assumption of non-differential assessment (i.e. That misclassi-
fication rates are the same in each treatment arm, as would typically be
the case when outcome assessors are blinded), we addressed three
questions about adjudication: (a) How many assessors should we use?
(b) When is it better to use on-site or central assessment? And (c) Should
central assessors adjudicate all outcomes, or only suspected events?
Results
We found that no one adjudication approach worked best across all
situations. The best approach will depend on specific trial characteris-
tics, mainly the misclassification rates of the site and central asses-
sors, and the correlation between assessors. In general, there will
rarely be much benefit to using more than three assessors, unless
the correlation between assessors is extremely low; for outcomes
with very high correlation between assessors, using one assessor
should be sufficient. Both site and central assessors can be appropri-
ate, and the best choice depends on which type of assessor has
lower misclassification rates. Using a combination approach in which
both the site and central assessors are involved in adjudication may
be useful when misclassification rates are unknown. Having central
assessors adjudicate only suspected events will typically increase
bias, unless the threshold for sending suspected events to the central
assessor for adjudication is extremely low.
Conclusions
No one adjudication approach works best across all situations.
Trialists should choose the most appropriate adjudication approach
based on the specific characteristics of their trial.
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Background
Many platelet transfusion trials now use bleeding as a primary outcome.
There are two important considerations when bleeding is used as an
outcome measure: how signs and symptoms of bleeding are docu-
mented and the translation of this information into a clinically significant
grade. This is fundamental to the robustness of results reported and the
ability to draw comparisons between different studies with confidence
(Estcourt et al., 2013). Currently because of the heterogeneity in the
methods used to assess, document and grade bleeding it is not always
possible to compare studies with any great confidence. If bleeding is to
be used as a main outcome measure for platelet transfusion trials, it is
important that it is defined and documented in a consistent and stan-
dardized way. This validation exercise was a prospective multi-centred,
observational study for which the main objective was to validate a
Bleeding Assessment Tool (BAT) that had been developed by the inter-
national Biomedical Excellence for Safer Transfusion (BEST) collaborative.
The BEST BAT is designed to describe the site, severity, duration and
clinical consequences of bleeding events in a standardized manner and
is intended for use in the malignant haematology patient population.
Methods
Study objectives were addressed through a repeat assessment of bleed-
ing exercise. Once the participants’ platelet count was 30x109/L they had
their bleeding status assessed using the BAT by trained assessors. The
aim was for the participant to have an assessment of bleeding repeated
by two assessors on a maximum of three consecutive days, which would
generate six individual assessments. Repeat assessments were then com-
pared for concordance i.e. Agreement in site and severity of any bleeding
observed. The two assessors were blinded to the findings of one
another's assessments and a repeat assessment had to take place as soon
as possible after the first to try to ensure that both assessors were observ-
ing the same ‘bleeding window’. A qualitative survey was used to collect
feedback from bleeding assessors as to how easy they found using the
tool. Feedback was used to refine the design of the BAT.
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Forty patients consented to participate. Thirteen trained bleeding asses-
sors collected the data. Bleeding assessments were carried out on 113
separate days, 225 bleeding assessments were compared for concord-
ance. The study found good concordance (79%) overall in observations
of bleeding. The study also highlighted key areas of focus such as train-
ing and the importance of well laid out documentation to facilitate a
standardized approach to the assessment of bleeding.
Conclusion
The ultimate aim of this study is for the BEST collaborative to use
their international influence to promote use of the validated and re-
fined BAT by researchers and clinicians working in the field of trans-
fusion medicine and clinical haematology. The standardized use of a
BAT in studies using bleeding data as a main outcome measure will
make it possible to draw reliable comparisons and to pool data from
different studies. Ultimately this has the potential to answer research
questions and to improve care for patients at a faster rate.
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Background
Diethylstilbestrol (DES) and dexamethasone (Dex) can be used alone
or in combination to treat castration-resistant prostate cancer. This
paper applies up-to-date reporting criteria and alternative statistical
analyses to the data from a randomised trial carried out to determine
optimal treatment sequencing (Dex plus deferred or immediate DES).
Methods
PSA data were reanalysed and reported according to the Prostate
Cancer Working Group 2 criteria, using waterfall plots. The ability of
PSA changes from baseline at 4, 8 and 12 weeks to predict survival
outcome was assessed. Individual patient level survival and health re-
lated quality of life (HRQOL) data were analysed using a flexible para-
metric model and a mixed effects model for repeated measures,
respectively.
Results
PSA changes from baseline at 4, 8 or 12 weeks did not predict overall
survival (P = 0.966, 0.589, 0.415, respectively). Maximum PSA decline
was associated with prolonged survival (P < 0.001), but the effect was
clinically insignificant. The flexible parametric model showed that the
hazard function was not completely proportional throughout the
trial. Fitting a parametric function that better reflected the underlying
hazard function resulted in a wider difference in median survival
(3.9 months) between the two arms than seen in the original ana-
lysis, but this was not statistically significant (P = 0.14). Immediate
DES was associated with a greater improvement in ‘global health sta-
tus’ HRQOL score (difference vs. Deferred DES = 7.85, P = 0.009).
Conclusion
The data were sensitive to the statistical approaches used. Interesting
additional information was obtained. In particular, deferring DES may
slightly reduce rather than improve patients’ HRQOL overall. All re-
sults are exploratory only.
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Knowing the Minimum Clinically Important Difference (MCID) en-
hances the interpretability of a patient-reported outcome measure
and is necessary for sample size calculations in clinical trials. The Pa-
tient Oriented Eczema Measure (POEM) is a measure of eczema
symptoms completed by patients or carers with a score of between
0 (no eczema) and 28 (very severe eczema). Previous studies have
shown that the MCID for POEM is around 3 points.
MCID calculation methods are often described as two broad categor-
ies: anchor-based methods and distribution-based methods. Anchor-
based methods ascertain how change in the measurement instru-
ment corresponds to another measure of change using an external
criterion. Distribution-based approaches are based on the distribu-
tional characteristics of the sample. Different methods measure a dif-
ferent type of change, therefore it is recommended a variety of
methods are used.
Little research to date has explored the impact of applying different
methodologies and anchors when calculating the MCID of the POEM,
and there is currently no consensus on the best anchor measure to
use to calculate the MCID for patient-reported outcomes. There has
also been no exploration into whether the use of different data time
points to calculate the MCID for the POEM may affect the results.
Objectives
36 To assess if the MCID for the POEM is convergent for different
anchor-based methods and distribution-based methods 2) To assess
whether using a patient or investigator assessment as an anchor
measure produces a different MCID for the POEM. 3) To compare the
MCID for the POEM calculated using different time points.
Methods
Secondary analysis utilising an existing trial data set (CLOTHES Trial
ISRCTN77261365). A range of methods to determine the MCID will
be compared. Anchor-based methods (including: within-patient score
change, between-patient score change, the sensitivity and specificity
method and the predictive modelling approach) will be assessed.
These anchor-based methods will be used with both a 6 point Likert
scale patient/parent global assessment (How is your/your child’s ec-
zema today?) And a 6 point Likert scale investigator global assess-
ment (How is the child’s eczema today?) As the anchor measure.
Distribution-based methods (including: effect size estimate and half
standard deviation of the baseline distribution of POEM scores) will
also be used. Where appropriate, there will be separate calculations
for the MCID in improvement and worsening of the eczema. All ana-
lyses will be repeated looking at the MCID for POEM scores at
2 months and 6 months of follow-up. Results will be available to
present at the conference.
Implications
This work will add to the knowledge around the MCID of the POEM,
which can help inform sample size calculations in future clinical trials
as well as enhance the interpretability of trial data and clinical prac-
tice records. The findings of this study will also be informative for cal-
culating the MCID of other patient-reported outcomes as it will
further understanding of how the methodology used can affect MCID
calculations. The results will determine to what degree the methods
used, the anchor measure used and the time point selected affect
the calculated MCID.
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Background
Independent adjudication of serious adverse events is common in
clinical trials, especially in open label studies where outcome assess-
ment can be prone to bias. Few studies have investigated the impact
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trial. The objective of this study was to explore the effect of inde-
pendent adjudication of serious adverse events on the safety results
of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial.
Methods
ENOS was an international multicentre trial which randomly assigned
patients with acute stroke and raised blood pressure to receive either
transdermal glyceryl trinitrate (GTN) or no GTN. Non-serious adverse
events were not recorded due to their high incidence in stroke pa-
tients and the established nature of the trial interventions. Serious
adverse events (SAEs) were reported by local investigators who were
not blinded to treatment allocation using a web-based SAE form. The
local investigators report included event classification, event diagno-
sis and evidence used to determine diagnosis, expectedness of
event, and likely causality. Independent adjudicators, blinded to
treatment allocation, reviewed the investigators reports and used evi-
dence available to confirm or alter the classification of event, with
the adjudicator’s decision being treated as the gold standard and
used in the trial analysis. As well as event classification, adjudicators
independently assessed causality, diagnosis and expectedness of
event. A list of known adverse reactions was defined in the protocol
and provided to investigators and adjudicators.
We used unweighted and weighted kappa respectively to estimate
agreement between local investigators and independent adjudicators
on diagnosis and relatedness to treatment of SAEs. The safety ana-
lysis of ENOS (chi-squared tests between treatment arms for SAE
diagnosis) was replicated using investigator reported events, and
these were compared to adjudicator reported events with a test of
homogeneity. Preliminary results are provided in this abstract, with
full results available for presentation in May.
Results
Preliminary results show that of 4011 patients enrolled in ENOS,
there were 1473 SAEs reported by local investigators, reduced to
1444 after review by adjudicators (unweighted kappa, k = 0.85). There
was fair agreement between investigators and adjudicators on
relatedness of event to treatment with 808 agreements and 644 dis-
agreements (weighted kappa, k = 0.30). However, when the related-
ness to treatment categories were dichotomised into Definitely not
or Unlikely versus Possibly, Probably or Definitely, then there were
1305 agreements and 147 disagreements (90% crude agreement,
kappa = 0.32). Repeating the trial safety analysis with investigator re-
ported events indicated that adjudication made little impact to the
majority of the results, with a similar number classified by both inves-
tigators and adjudicators.
Conclusions
Serious adverse events were largely classified correctly by local inves-
tigators with the largest disagreements arising between relatedness
of event to treatment. In a large trial, with many serious adverse
events reported, independent adjudication of these events had little
impact on trial conclusions.
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Selection of outcomes to measure in trials designed to compare dif-
ferent interventions is crucial. It has been estimated that less than
half of all outcome data collected in trials is fully reported, with miss-
ing data due to unpublished trials, poor reporting, and choosing not
to include particular results within trial reports.
Difficulties caused by heterogeneity in outcome measurement across
studies are well known. Empirical research provides strong evidence
that outcome reporting bias (ORB), defined as the results-based se-
lection for publication of a subset of the recorded outcome variables,
is a significant problem in a quarter to a third of randomised trials
and can have major impact in a fifth of systematic reviews. Ininterviews, trialists seemed unaware of the implications for the evi-
dence base of not reporting all outcomes and protocol changes.
Systematic reviewers facing these challenges should contact trialists
to try to obtain the missing data. They may subsequently apply a
statistical approach as part of a sensitivity analysis. Bias bound esti-
mation, multivariate meta-analysis, and modelling the selection
process have been proposed.
Trial registration and improved reporting should help to reduce ORB, but
for findings to influence policy and practice, outcomes chosen for meas-
urement need to be relevant to patients, public, healthcare professionals
and others making decisions about health care. So much could be
gained if an agreed core outcome set (COS) of appropriate and important
outcomes was measured and reported in all clinical trials of effectiveness
in a specific condition. The COMET (Core Outcome Measures in Effective-
ness Trials) Initiative, http://www.comet-initiative.org/, an innovative
global project, brings together people interested in COS development
and application.
This talk will review progress made with both statistical and non-
statistical solutions to this problem.
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Background
Prevalence of epilepsy in adults with an intellectual disability (ID) is
up to 20 times greater than in the general population. There is how-
ever little research assessing side effects of anti-epileptic drugs
(AEDs) in adults with ID and epilepsy. Screening tools are available to
assess AED side effects in the general adult population, and research
suggests that active monitoring is sufficient to change management
and improve quality of life (QOL). It is not known however whether
such tools can be used to identify side effects in adults with ID, or
whether included items are important and relevant to patients and
carers. Furthermore, available instruments tend to focus on the more
theoretical concept of QOL rather than on side effects of medication
per se, and their validity or suitability for use in ID populations has
not been established. A Cochrane review concluded that measure-
ment of side effects in this population was hampered by reliability of
available measures. The aim of this systematic review is therefore to
identify research on measurement and impact of AED side effects in
the adult epilepsy population. The review seeks to identify measures
developed for adults with ID where available, and also in the general
epilepsy population (i.e. Without ID), in order to identify measures
that could be adapted for an ID population. The review is the first
stage of a larger study to develop Patient Reported Outcome Mea-
sures (proms) to assess AED side effects in adults with epilepsy and
ID. The aim of the larger study is to develop appropriate versions for
patient and carers.
Methods
A systematic literature search was conducted in MEDLINE In-Process,
MEDLINE, EMBASE, SCOPUS and Web of Knowledge. The review iden-
tified studies in adults with epilepsy (and a subset of adults with ID)
taking an AED, which included a scale/outcome measure of a poten-
tial AED side effect. Studies focused on seizures as a side effect of
medical treatment (brain surgery or medication) and seizure disor-
ders not specified as epilepsy were excluded.
Results
460 papers were identified and 93 met inclusion criteria. Of 107 mea-
sures identified, six were appropriate for use with adult ID popula-
tions. Seven studies investigated adults with epilepsy and ID and
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of life. Side effects of AEDs are inconsistently and inadequately mea-
sured in ID populations and are overly reliant on carer report. The
overall burden of side effects is therefore likely to be under-reported.
Conclusions
Screening tools are available to assess AED side effects in the general
adult population, however only two outcome measures are designed
for use in ID populations. The focus of these measures is broader
than side effects alone and therefore may not pick up the full range
of side effects of importance in this group. There is a clear lack of
established and validated assessment scales for patients with ID and
epilepsy, and a need to consistently measure and report patient-
reported side effects of medication, both in clinical practice and in
trials of new medication regimes.
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Background
Surgical procedures are considered to be complex healthcare inter-
ventions. As such, multiple variations in the delivery of a procedure
with the same label are possible. Variations can be small or large,
and known or unknown, because there is often a difference between
what surgeons say they do and what is done. This project developed
and tested methods for identifying all possible variations in a particu-
lar surgical procedure to inform the design of case report forms for
use in a main study.
Methods
To identify variations in the surgical procedure, two phases of work
were undertaken: i) systematic literature review (to identify ‘known’
variations in technique) and ii) qualitative work (to identify ‘unknown’
variations and explore clinical professionals’ views on how these vari-
ations may influence outcomes of interest). The qualitative work
comprised of case studies using digital video data capture and non-
participant observation, and interviews with healthcare professionals.
To date, 6 case studies have been conducted, as well as 13 inter-
views. Observation field notes and textual descriptions of the video-
captured operations were coded and categorised into themes and
subthemes. Verbatim transcripts of the interviews and observations
were analysed through constant comparison approaches. Interview
and observation themes were compared and contrasted to inform
new lines of enquiry for exploration in further case studies and inter-
views. A long-list of themes and subthemes was synthesised from
the data collected in both phases of work. The final phase of the pro-
ject (yet to be undertaken) will refine and rationalise these themes
through consensus methods, to finalise the data items to be included
in the case report forms.
Results
The literature review identified 138 themes relating to technical vari-
ations in the surgical procedure of interest, and 50 non-technical fac-
tors including patient characteristics (e.g. Obesity), contextual
operation factors (e.g. Emergency surgery), and the grade of the op-
erating surgeon. The case studies and interviews identified 150
themes relating to technical variations and 64 non-technical factors.
The themes identified in both phases were combined, duplicates and
overlaps excluded, leaving 180 technical and 85 non-technical fac-
tors. Of these, 137 were common to both phases of work and 77
were identified during the case studies. These factors will bediscussed at a consensus meeting, during which senior clinicians will
agree on the data to collect during the main study.
Conclusion
This novel methodology incorporates multi-modal data collection to
provide insights into the ‘black box’ of complex interventions such as
surgery. It can be successfully used to identify and summarise tech-
nical variations in the delivery of complex interventions, and non-
technical factors that may influence this delivery. Both phases of this
study identified themes that would have otherwise remained ‘un-
known’ if performed in isolation. Resulting data can subsequently be
used to comprehensively and systematically design case report
forms. This study design therefore adds value by identifying and doc-
umenting all key data and variations of an intervention.
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Background
Randomised trials are difficult and costly. Like most things that
are hard, the effort expended is only worth it because we hope
to make a difference. Sadly, the benefit to potential users such
as patients, healthcare professionals and policy makers is often
smaller than it should be because trial design decisions reduce
the relevance of the trial results to their intended users and the
contexts in which they work.
To ensure trial results match the needs of potential users it is
recommended that researchers design pragmatic trials, testing
their intervention under conditions similar to those found in the
real world. PRECIS-2 is a trial design tool which encourages trial-
ists to consider how pragmatic their trial is across nine different
domains covering the population in the trial, how the interven-
tion is delivered and the outcomes measured. Whilst in principle,
a pragmatic trial should aim to emulate routine practice across
the PRECIS-2 domains, in practice compromises will have to be
made when designing trials. Little research exists to guide these
decisions.
This research explores the views of people who influence practice in
primary care towards assessing and using evidence from clinical tri-
als. The aims of the study are to assess what is important in design-
ing randomised trials, and to ascertain how the PRECIS-2 tool can be
used to make research more relevant to primary care.
Methods
We carried out semi-structured interviews with individuals or small
groups of people involved in implementing research in primary care
in the UK. We interviewed people involved with journals, guideline
development, research charities, research funders, primary care edu-
cators, clinical commissioning groups, GPs and clinical effectiveness
research. A thematic analysis of the data from the interviews was car-
ried out using the framework approach.
Results
We conducted 12 interviews across the target groups. We identified
four themes in the data, how evidence is used, aspects of trials
which are considered important when assessing evidence, views on
trial design across the nine domains of PRECIS-2, and attitudes to-
wards pragmatic trials. Most interviewees were aware of pragmatic
trials however different views existed as to what the term meant.
For some aspects of a trial, such as the flexibility given to those de-
livering the intervention, or the level of resources and expertise
made available to deliver the intervention, emulating routine prac-
tice may not be the best way to make results relevant to primary
care. Across other aspects of a trials design, for example the popu-
lation and trial setting, our work indicates a pragmatic approach is
more appropriate.
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Funders and those designing trials in should carefully consider de-
sign decisions across the PRECIS-2 domains to maximize the rele-
vance of research to primary care. Across most aspects of their
designs trials should aim to be pragmatic however there are some
important exceptions where design decisions are more complex. Dif-
fering perceptions about what it means for a trial to be pragmatic
could be helped by the use of the PRECIS-2 tool by those using evi-
dence from clinical trials to influence practice in primary care.
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Background
Mediation analysis is a way to investigate the mechanisms by which an
intervention affects an outcome. It has been proposed as a way to
‘open the black box’ of traditional epidemiology, shedding light on the
causal pathways between interventions and outcomes. Methodological
work, based on the causal inference framework, has helped formalise
the assumptions required for mediation analysis to give valid causal
conclusions. For most common approaches to mediation analysis of
randomised trials, a key assumption is that there is no confounding of
the mediator outcome association that is not controlled for in the ana-
lysis. The UK Medical Research Council recommend mediation analysis
be used as part of a process evaluation of complex interventions. Trials
which are conducted in the primary healthcare setting are often of
complex interventions, so mediation analysis could be an appropriate
method to include in any analysis plan of clinical trials in this setting.
The aim of this systematic review is to examine applications of medi-
ation analysis in clinical trials taking place in primary health care set-
tings and use the findings to provide guidance for future analysis.
Methods
We searched the Medline, Embase and Cochrane Library databases
using keywords that identify randomised trials, mediation analysis
and primary healthcare settings. Our eligibility criteria were papers
published between 2004 and 2014 which described a mediation ana-
lysis of data from a randomised trial conducted in a primary health-
care setting. Abstracts were screened for eligibility, where eligibility
was unclear from the abstract we performed full text screening. Data
extraction related to the study design features and type of mediation
analysis and assumptions was carried out independently by two au-
thors. Any disagreement was resolved with a third reviewer.
Results
A total of 138 references were identified using the electronic search
strategy and 23 studies were found to be eligible for the review.
Most studies were published post 2010 (70%), were set in the USA
(65%) and involved an intervention targeting a mental health condi-
tion. 48% of analyses involved a single mediator measured at one
time point and the others included multiple mediators or measure-
ments over time. Ten (44%) studies reported adjusting for any covari-
ates and only 2 studies discussed unmeasured confounding as a
potential limitation of their results.
Conclusions
Mediation analysis is used in research conducted in primary health-
care settings to understand the mechanisms of how an intervention
works. Most mediation analyses identified in this review failed to ad-
equately control for confounding of the mediator outcome associ-
ation. Even when potential confounding factors are included in the
analysis the consequences of unmeasured confounding are rarely
acknowledged as limitations. This could lead to invalid conclusions
being drawn from many mediation analysis of randomised trials in
primary health care settings. When planning a mediation analysis
investigators should collect data on potential mediator outcome
confounders and adjust for these variables in the analysis.P172
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Background
Expanding the role of community pharmacists is a cornerstone of UK
government policy and health promotion activities such as smoking
cessation are fundamental to this expanded role. We developed a
service optimisation and training intervention (STOP intervention),
and a cluster randomised trial was planned to evaluate the effective-
ness of this intervention. In 2015, a pilot trial was carried out to as-
sess its feasibility.
Methods
Twelve community pharmacies were assigned at random to STOP inter-
vention or usual practice using simple randomisation (allocation ratio 2:1).
Results
STOP training intervention has potential to increase the number of
smokers retained in smoking cessation services (89.5% in interven-
tion arm vs 75.0% in usual practice arm) and subsequently quit
smoking (52.6% in intervention vs 21.9% in usual practice arm). It
had limited impact on pre-specified primary outcome, throughput
(on average 43 vs 80 service users per pharmacy joined the smoking
cessation service in intervention and usual practice pharmacies,
respectively).
More importantly, the pilot was useful in highlighting the challenges
of conducting clinical trials in this important but under-researched
healthcare setting and how best to overcome them. The key issues
we identified include: complex organisational structures between
and within community pharmacies; pharmacies as businesses vs
healthcare providers; achieving balance for individual characteristics
in cluster randomisation; selecting trial outcomes; identifying factors
influencing outcomes; data collection -using case report forms vs
routine data.
Conclusions
The pilot was useful in establishing the potential impact of the
intervention on smoking cessation outcomes, and testing the
processes and procedures in place for definitive trial. We will
discuss the challenges we encountered and their methodological
implications.
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Strong treatment preferences of both clinicians and patients have
been shown to impact on recruitment, adherence to treatment allo-
cation and ultimately the success of a randomised controlled trial
(RCT). This is particularly evident when the interventions being evalu-
ated are markedly different, such as the comparison of surgery with
a non-operative approach such as physiotherapy. The aim of this
study was to explore clinicians’ views at the pre-trial stage of NIHR
HTA funded RCT of anterior cruciate ligament (ACL) deficiency man-
agement comparing surgery and rehabilitation (ACL SNNAP Surgical
Necessity in Non-Acute Patients) and to identify issues that may
influence trial feasibility.
Methods
Semi-structured qualitative interviews were undertaken with a pur-
posive sample of surgeons (n = 6) and physiotherapists (n = 6) from 6
NHS hospitals. All clinicians were experienced in the management of
ACL injuries and had expressed an interest in participating in the
ACL SNNAP trial. Interviews were analysed using an Interpretative
Phenomenological Analysis (IPA) approach.
Results
Several issues were identified which may impact on the feasibility of
this trial. Despite indicating a willingness to randomise, clinicians
expressed varying levels of uncertainty and preferences which may
impact on their ability to deliver balanced descriptions of the treat-
ment options. This was especially evident in relation to certain pa-
tient subgroups: young and highly active patients with the potential
to affect which patients clinicians approach to participate. Clinicians
indicated that patients often have strong preferences for treatment
of this injury, particularly towards surgery, and considered this as a
potential barrier to trial recruitment. Various sources were thought to
influence patients’ views towards treatment, such as how information
on the injury and its management are currently portrayed through
the internet and media.
Conclusion
Exploring clinicians’ views at the pre-trial stage enabled potential trial
specific issues to be identified. As a result of these findings, appropri-
ate training and support for recruiting teams prior to the start of re-
cruitment is being developed. Trialists may wish to consider the use
of pre-trial qualitative studies, particularly in trials where the inter-
ventions being evaluated are markedly different, to enable issues
specific to a particular trial to be identified and addressed.
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Background
Recruitment in large scale clinical trials can be hard to predict during
planning and difficult to maintain throughout the study. Many trials
fail to finish to time and target; hence, better methods for recruit-
ment predictions are needed. Two phase studies with internal pilots
and a stop-go decision before the main phase allow time for re-
estimation of recruitment.
Methods
The NIHR HTA Tranexamic acid for intracerebral Haemorrhage (TICH-
2) trial, is a large multi-centre international randomised controlled
trial, aiming to recruit 2,000 patients over two phases. The start-up
phase was planned to take 18 months, recruiting 17 patients a
month to reach a target of 300; actual recruitment was higher than
this and the start-up phase stopped six months early, when it
reached target. The main phase originally aimed to recruit 68 pa-
tients a month, reducing down to 55 patients a month after the main
phase was brought forward. Recruitment was monitored continu-
ously throughout the study in order to predict if and when the de-
sired sample size would be reached. Methods to predict futurerecruitment, using existing trial data and recruitment trends, were
developed. A system was developed for the trial website which
shows live recruitment predictions; changing with the numbers of
new participants and active sites. Averages over different periods
throughout the trial were also looked at; including cumulative aver-
ages, monthly averages and phase averages.
Results
The average recruitment over the 12 month start-up phase was 28
patients a month from 53 centres; the mean (SD) per centre was 0.17
(0.19) patients a month, with a range of 0.02 to 0.7. The monthly av-
erages from the main phase ranged from 29 to 61 patients a month,
from 108 centres; centre averages ranged from 0.03 to 3.04 patients
a month with a mean (SD) of 0.42 (0.45). The largest 15 centres re-
cruited at least one patient a month per site, whereas, some of the
smaller centres did not even recruit one patient in five months. The
average for the first 12 months of the main phase lies near the mid-
dle of the main phase averages at 42 patients a month, suggesting
this could be an ideal time to re-evaluate recruitment predictions; a
yearly average will also ensure any seasonal fluctuations are cap-
tured. After analysing the available data the trial team found that
they were unlikely to recruit to target and would need at least an-
other nine months of recruitment to reach the target sample size.
Conclusion
Predicting recruitment when planning a clinical trial is difficult,
methods for monitoring and predicting future recruitment should be
performed throughout the study. When designing trials, flexible re-
cruitment phase and end dates should be considered to allow for dif-
fering recruitment rates than originally planned. Monthly centre
averages showed larger variation in the main phase compared to the
start-up, reflecting differences between recruiting sites. Twelve
months into the main phase of a study appears a reasonable time
point to re-evaluate recruitment predictions. Similar systems are used
in our other large trials: HTA TARDIS and BHF RIGHT-2.
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Background
The SOLAS cluster randomised controlled feasibility trial aims to as-
sess the (1) acceptability of the novel 6 week group-based education
and exercise SOLAS complex intervention to patients and physiother-
apists (PTs) compared to usual individual physiotherapy, (2) feasibility
of trial procedures and sample size for a definitive trial and (3) effect
on secondary outcomes. The aim of this study was to evaluate the
feasibility of trial recruitment procedures.
Methods
It was proposed to recruit 12 to 14 clusters (PT clinics) to test feasibil-
ity across a range of settings; six clusters in each arm participating in
two waves of recruitment and enrolling six participants in each clus-
ter per wave [i.e. 144 participants, 72 per arm]. A minimum of 96 par-
ticipants [48 per arm] was required for sample size calculations. The
recruitment procedure agreed with PTs involved their screening wait-
ing lists to identify potential participants for an invitation letter, and
researcher led telephone and face-to-face screening. The recruitment
rate [total, study arm and wave] and ratio of number screened: num-
ber enrolled and reasons for exclusion at each step was calculated
after each wave.
Results
14 clusters were recruited (7 per trial arm), each site participated in
two waves of recruitment, resulting in three study waves (W1-W3).
The average cluster size in each arm was below six (Intervention:
mean (SD) = 4.92 (1.31), range 2–7; Control: mean (SD) = 5.08 (2.43),
range 1–9) with no significant difference between arms (df = 16.909,
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tion: 4.25 (1.71), 2.00-6.00; Control: 4.40 (1.95), 3.00-7.00) to W2 in
both arms (Intervention: 5.17 (1.17), 4.00-7.00; Control: 5.80 (1.79),
4.00-8.00), with a further increase in W3 in the intervention arm only
(Intervention: 5.50 (0.71), 5.00-6.00; Control: 5.00 (5.66), 1.00-9.00).
120 participants (83.3%; of n = 144 expected) were recruited (Inter-
vention n = 59; Control n = 61). The recruitment rate according to tar-
get increased in subsequent waves (W1 Target: 54, Actual: 39; W2
Target: 66, Actual: 60; W3 Target: 24, Actual: 21). Overall, 1708 poten-
tial participants were identified from the waiting list: 1136 (66.5%)
were excluded predominantly due to diagnosis (n = 879), age (n =
158), exclusion criteria (n = 133) and symptom duration (n = 53). Of
572 invitation letters, 375 (65.6%) participants responded [W1: 42.6%,
W2: 76.3%, W3: 78.3], with 224 (59.7%) excluded by telephone screen
[W1: 35%, W2: 81.3%, W3: 85.1%] mainly due to exclusion criteria
(n = 69), preference for individual PT (n = 62), inability to attend SOLAS
group (n = 30) or poor English (n = 30). A further 31 (20.5%) were ex-
cluded at face-to-face screening with 120 participants recruited, repre-
senting 21% of invitation letters [W2: 20.2%,W3: 21.6%, W4: 19.8%]. The
invitation letter was simplified after W1 following communication with
PTs, and telephone screening refined after W2.
Conclusions
The sample size was below target but sufficient for sample size calcu-
lations. Recruitment rate, cluster size and response to invitation let-
ters increased across waves as procedures were improved, but the
enrollment rate remained unchanged. Recruitment to trials of com-
plex interventions outside routine practice is challenging and war-
rants further research with patients to address their barriers and
enablers to trial participation.
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Objectives
The first objective of the TRECA (trials Engagement in Children and
Adolescents) study is to use participatory design to develop multi-
media information resources for use in healthcare trials. The study
will also evaluate the potential for multimedia information resources
to improve the quality of decision-making about participation in
healthcare trials involving children and adolescents with long-term
health conditions, and then assess the impact of these multimedia
information resources on rates of trial recruitment and retention.
Background
Randomised controlled trials are the best method for testing health
interventions whilst minimising bias. However, recruitment and sub-
sequent retention of children and adolescents in healthcare trials can
be challenging. Printed participant information sheets for potential
trial participants are often lengthy and difficult to read and under-
stand. Presenting key information about trials using multimedia may
help to overcome these limitations and better support children, ado-
lescents and their parents in deciding whether to participate in a
trial.
Methods
The TRECA study has two phases. The first TRECA phase involves a
qualitative study with children and adolescents and their parents to
inform the development of multimedia information resources,
followed by rounds of iterative user testing to refine the resources.
The multimedia information resources will contain elements of audio,
video, text and animations, including some aspects that are trial-
specific and others that pertain to any trial. The second TRECA phasewill embed the use of the multimedia information resources into six
host trials in the United Kingdom. Patients and their parents
approached to participate in the host trials will be randomly allo-
cated to one of three arms: to use the standard printed participant
information sheet; or the multimedia information resource; or both
the standard printed participant information sheets plus the multi-
media information resource. The primary outcome will be the effect
of the multimedia information resources on rate of recruitment into
the host trials. Other outcomes measured include the effect of multi-
media information resources on retention of participants in the host
trials and the impact on the quality of decision making about partici-
pation of the patient (child or adolescent) and the parents, when
compared to standard printed participant information sheets alone.
A prospective meta-analysis of the outcomes from the six host clin-
ical trials will be undertaken.
Conclusion
This study will inform whether multimedia information resources,
when developed using participatory design principles, are able to in-
crease rates of recruitment and retention of children and adolescents
in healthcare trials. There is also the potential for patients to make
better informed decisions about participation in trials (whether or
not they decide to take part) through the use of multimedia informa-
tion resources. The multimedia information resources also have the
potential to assist with providing information on other healthcare de-
cisions outside of clinical trials.
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Background
The importance of evidence based medicine is now widely recog-
nised, and randomised controlled trials (RCTs) are the gold standard
method for evaluating health technologies. Comprehensive and sys-
tematic evidence reviews are essential before embarking on RCTs,
and this information should be clearly presented to potential partici-
pants to ensure that they are fully informed about the rationale for
the trial and treatment options. However, little is known about how
health professionals present current evidence to eligible patients in
RCT consultations.
Methods
Five UK-based RCTs were purposefully selected to include a range of
trials from different clinical contexts and with different types of re-
cruiters. Consultations in which recruiters presented information
about the RCT to eligible patients were audio-recorded (n = 117).
Data relating to any presentation of uncertainty or evidence
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thematically by DE using constant comparative techniques derived
from grounded theory methodology. A subset of consultations were
independently coded by LR and SH to confirm reliability of coding.
Results
Preliminary results suggest that there was considerable variation
within and across RCTs in how recruiters discussed evidence. Some
recruiters did not introduce the concept of uncertainty about optimal
treatment or discuss any empirical evidence about treatment options
at all. These recruiters had a tendency to instead draw on anecdotes,
most commonly in the form of their experiences of patients' treat-
ment outcomes. The majority of recruiters alluded to an absence of
evidence to introduce the RCT but did not elaborate further. Where
recruiters provided information about previous studies, they tended
to summarise the findings without referring to the quality of the re-
search. Final results will be presented at the conference.
Conclusions
Clinicians and nurses play a vital role in providing detailed and accur-
ate evidence-based information to patients to facilitate informed
consent for participation in RCTs. However, this study highlights con-
siderable variability in how recruiters present evidence. It therefore
demonstrates the need for support and training to enable recruiters
to present information clearly, both in regards to summarising find-
ings and appraising the quality of this research.
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Background
The study within a trial (SWAT) concept enables trialists to assess dif-
ferent ways of designing, conducting, analysing and evaluating stud-
ies through the conduct of research embedded within a larger trial.
PRIMETIME is a prospective biomarker directed cohort study aiming
to identify a subgroup of breast cancer patients who can safely avoid
adjuvant breast radiotherapy following breast conserving surgery.
This subgroup is deemed to be at such a low risk of local relapse that
the potential benefits of radiotherapy are unlikely to outweigh the
known risks. The current uncertainty regarding the absolute benefit
of adjuvant radiotherapy (in this subgroup), the concept of avoiding
treatment, and the offer of entry into a clinical trial can be over-
whelming and challenging for patients to cope with. The uncertainty
patients face regarding healthcare decisions is known as ‘decisional
conflict’. We would like to optimise the decision making process for
patients facing this uncertainty. Decision aids are ‘interventions de-
signed to help people make specific and deliberative choices among
options by providing information about the options and outcomes
relevant to a person’s health status’. Evidence suggests decision aids
reduce decisional conflict. This SWAT is designed to investigate the
effect of a decision aid on patients’ decisional conflict over their un-
certainty regarding the absolute benefit of radiotherapy and there-
fore their decisional conflict over whether or not to enter PRIMETIME.
Proposed Method
The PRIMETIME SWAT will utilise a stepped wedge trial design. The de-
cision aid will be in video format. Decisional conflict will be assessed
using a validated decisional conflict scale in centres prior to and follow-
ing implementation of the decision aid. All centres will receive the
standard patient information sheets and be randomised to receiving
the decision aid video at increasing intervals from when their centrebegan recruiting to PRIMETIME using minimisation. The primary out-
come is to assess whether the addition of a decision aid video to stand-
ard patient information giving reduces patients’ decisional conflict. The
secondary outcome is to assess acceptance of entry into PRIMETIME.
Discussion
Investigating the impact of a decision aid on decisional conflict in a
SWAT allows us to answer important questions in an economic and
efficient manner where we are able to conduct research within the
context of a larger study. Given our hypothesis that the decision aid
will reduce decisional conflict, the choice of a stepped wedge trial
design ensures that by the end of the study all centres will have use
of the decision aid as opposed to a parallel design which may be
considered less favourably as some centres would never introduce
the decision aid. If we are able to determine that the introduction of
a decision aid reduces decisional conflict this would provide the evi-
dence required to support increasing resources into the develop-
ment and, ultimately, routine use of decision aids for patients facing
complex treatment decisions.
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Background
Recruitment into large clinical trials is difficult, with many trials not
recruiting to target. This can cause financial, ethical and practical
problems and undermine the quality of the research as large num-
bers of participants are needed to accurately assess moderate effect
sizes. Previous research has identified age, ethnicity, socioeconomic
status, and education as important influences on the success of trial
recruitment but little has been done to quantify these effects.
Methods
Using data from the MRC/BHF Heart Protection Study (HPS), the influ-
ence of demographic factors was explored at each stage of the trial re-
cruitment process (invitation, screening, pre-randomisation run-in, and
randomisation). The HPS dataset was chosen as patients had been
identified as potentially eligible from their hospital records and then
were sent a postal invitation to attend a screening visit. This method of
invitation allows large numbers of patients to be invited, and provides
a true, unselected denominator for the recruitment effort.
Results
Throughout the recruitment process, women were significantly less
likely than men to continue to the next stage: of those invited, 45% of
women vs. 51% of men attended the screening visit; of those attending
screening, 70% of women were eligible and consented to enter run-in
compared to 78% of men; and of those entering the run-in period, 82%
of women vs. 87% of men were randomised (all p < 0.001). This led to
only 18% of all women invited agreeing to enter run-in compared to
28% of men, and 11% of the overall total of women being randomised
vs. 19% of men (both p < 0.001). These gender differences were still sig-
nificant after adjusting for age, ethnicity, deprivation index as a meas-
ure of socioeconomic status, and distance from screening site. After
adjustment, women were still significantly less likely than men to at-
tend screening (OR: 0.79, 95% CI: 0.77-0.81), to enter run-in (OR: 0.57,
0.55-0.59), and to be randomised (OR: 0.69, 0.66-0.73). The REVEAL
study began recruitment 17 years after HPS. There has been a decline
in the proportion of patients agreeing to take part in CTSU trials when
identified from electronic records. Whilst the overall proportion of pa-
tients invited that were randomised was much smaller (3% in REVEAL
vs. 16% in HPS), the observed differences between men and women,
after adjustment, at screening (OR: 0.43, 0.41-0.44), at run-in (OR: 0.55,
0.51-0.59) and at randomisation (OR: 0.59, 0.53-0.66), were at least as
great as in HPS highlighting that this is an ongoing issue.
Conclusion
Further research into demographic differences in adherence to randomised
treatment and completeness of follow-up will provide a comprehensive
Trials 2017, 18(Suppl 1):200 Page 70 of 235view of the influence of gender on participation throughout these cardio-
vascular trials. In addition, qualitative research might provide insight as to
why women are less likely to participate, and how this can be addressed
to maximise the relevance of the results to both men and women.
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Background
Why so many RCTs fail to achieve their recruitment targets is an important
area of clinical practice that is poorly understood. This is especially so in
the field of palliative care as patients are often ‘hard to reach’. Palliative care
patients have a diverse range of conditions, they are cared for in a wide
variety of clinical settings and have unpredictable and complex needs.
Aims
To identify and synthesise knowledge about barriers and facilitators
to recruitment to palliative care RCTs to develop recommendations
to increase recruitment.
Methods
A systematic review with narrative synthesis. Social marketing theory
provided a theoretical framework for the review. Medline, Cinahl,
pscyinfo and Embase databases (from Jan 1990 to early October
2016) were searched. Papers included: interventional and qualitative
studies addressing recruitment, primary palliative care RCTs or re-
ports containing narrative observations about the barriers, facilitators
or strategies to increase recruitment to palliative care RCTs. Themes
within the literature were developed using thematic analysis.
Results
3832 records were screened and data extraction was carried out on 48 pa-
pers. The key barriers: gatekeeping by professionals and family care givers,
high refusal rates, the need for intensive resources and participants not
meeting eligibility criteria. Key facilitators included lead clinician support
and key messaging. Research staff on site, regular contact with clinicians
and the use of scripts/role play were seen as important recruitment strat-
egies. Most evidence is based on researchers own reports of experiences
of recruiting to palliative care RCTs rather than independent evaluation.
Conclusion
More methodological research is needed to try and reduce the waste
of resources associated with RCTs that fail to reach their desired re-
cruitment targets. Embedded clinical trials of recruitment strategies
are a possible way forward to help to quantify whether potential
strategies suggested in the literature truly have an impact.
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Background
Recruitment to randomised controlled trials (RCTs) in unplanned hos-
pital care (UHC) settings is more challenging than in the elective set-
ting because there is less time and patients are often unwell.Methods to optimise this have not been previously explored. The
aim of this study is to summarise methods to optimise recruitment
into trials in UHC settings to inform future research.
Methods
The ORRCA (Online Resource for Recruitment Research in Clinical
Trials; www.orrca.org.uk) database includes studies of all designs, sys-
tematically extracted from the literature, reporting on recruitment
into RCTs and non-randomised clinical studies.
Included in this review were any studies within ORRCA that reported
on recruitment to RCTs in an UHC setting in patients >18 years.
Abstracts, editorials, reports of mental health RCTs and studies of re-
cruitment to non-RCTs were excluded. UHC was defined as the care
received during an unpredictable admission to hospital at short no-
tice because of clinical need. This includes pre-hospital care, inten-
sive care (ICU) admissions and A&E attendances. Screening was
performed by one author (CR) with duplicate screening of 10% of
the database performed by a second author (KF).
All papers were categorised according to the recruitment study de-
sign (randomised or non-randomised) and whether an intervention
to optimise recruitment was evaluated. Additional categorisation ad-
dressed whether the paper evaluated recruitment to a real clinical
RCT (host RCT) or potential recruitment to a RCT that did not yet
exist (a ‘hypothetical RCT’).
Data extracted included i) perceived barriers to recruitment which
formed the rationale for the study, ii) barriers to recruitment identi-
fied as the result of the recruitment stud and iii) types of intervention
evaluated.
Interim results
Of 3114 articles within the ORRCA database, 39 were eligible. Dupli-
cate screening did not produce any unresolvable discrepancies. One
paper used a randomised recruitment study design to evaluate an
intervention, 11 evaluated an intervention through a non-
randomised study and 16 recruitment studies did not evaluate an
intervention. A further 11 studies report results from community sur-
veys of proposed hypothetical RCTs.
Perceived barriers to recruitment included the clinical condition of
the patient, patients impaired ability to provide valid informed con-
sent and a narrow therapeutic time window. Further barriers to re-
cruitment identified as the result of the recruitment study were
clinician’s refusal for patients to be approached, workload of the clin-
ical team, insufficient approach of eligible participants and the use of
surrogate decision makers (SDMs). Types of recruitment interventions
included obtaining consent in the pre-hospital setting (n = 3), the use
of alternative methods of consent (n = 3), on-site training/support/
education for clinical teams (n = 3), modifying the treatment window
(n = 1), the use of mobile alert technology (n = 1) and the use of a
screening log/site monitoring (n = 2). Further analysis is ongoing.
Conclusion
Rigorous comparative methodological studies to evaluate recruit-
ment interventions are lacking in this setting. Informed consent for
trial participation was the most commonly identified recruitment bar-
rier but specific methods to optimise this require further research.
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Background
Approximately 15% of the world’s population have a disability. Many
of these disabilities will have a profound effect of the person’s social,
cognitive or mental functioning, often requiring high levels of costly
health and social care support throughout the person’s life. As such,
it is imperative that they receive treatments and services that are
based upon a sound evidence base. As a case example, the evidence
base for medical, health and social care interventions for those with
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sons for this lack of robust evidence may be because the process of
conducting RCTs with disabled or impaired populations is fraught
with many methodological challenges. We need a better understand-
ing of these methodological challenges if the evidence bases are to
be developed.
Objective
To explore the methodological barriers which are hindering the de-
velopment of the evidence base for treatments and interventions for
people with cognitive or developmental disabilities, and to find pos-
sible solutions to overcoming the barriers. As a case example, the lit-
erature regarding RCTs for people with Intellectual Disabilities (ID)
was used to highlight pertinent issues.
Methods
A systematic literature review was conducted of internationally pub-
lished randomised controlled trials with people with intellectual dis-
abilities from 2000 to 2015. From a total of 7795 search results, 34
RCTs with adults with ID were reviewed to ascertain which barriers,
challenges and solutions the authors faced and reported. Quantita-
tive data were extracted in the form of frequency of reporting and
qualitative data were extracted in relation to the specific barriers
faced by the authors.
Results
A number of themes arouse including: 1) that there was a lack of de-
tail regarding how trialists made reasonable adjustments to enable
consent to be obtained, 2) that there is a lack of validated outcome
measures for people with communication or intellectual difficulties,
3) the importance of engaging with family members, carers and sup-
port staff when recruiting, and retaining and 4) that sample sizes are
regularly small and studies are often underpowered.
Conclusions
Conducting RCTs with people with disabilities, particularly intellectual
disabilities, can present unique challenges that require creative solu-
tions. To date researchers have not maximised the sharing of their
‘experience base’ regarding these challenges and solutions. As a re-
sult, the conducting of RCTs and the development of robust evi-
dence bases remains slow and the health inequalities of people with
disabilities continues to grow. Implications for the dissemination of
the ‘evidence base’ and ‘experience base’ are discussed.
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Background
Participant attrition and missing data can introduce biases, yet there
is limited evidence for successful retention strategies to maximise
collection and analysis of clinical and patient-reported outcomes
(PROMs).
Objectives
The impact of a multifaceted retention strategy developed in a long-
term cancer trial was investigated using mixed methods research.
Methods
1643 men aged 50–69 years were randomised between 1999–2009
to three localised prostate cancer treatments with a median of
10 years follow-up (protect: ISCRTN 20141297). Prostate cancer mor-
tality (primary outcome) was ascertained by an independent commit-
tee following death certificate notification. Clinical secondary
outcomes were collected annually in case report forms (CRFs) by re-
search nurses in meetings with participants (or by telephone) and
from medical records. Follow-up procedures included nurse training
including study meetings every six months, standard operating pro-
cedures, annual site monitoring visits, source data verification (SDV,
total 161) on a representative sample of participants from each siteby data managers with feedback to centres. Proms were collected
annually by postal questionnaires with a reminder letter to non-
responders. Three interventions to reduce attrition were assessed:
firstly, nurses commenced telephoning non-responders. A study pen
was later included with reminders and a shortened questionnaire
was sent to non-responders by recorded delivery. Questionnaire re-
sponse rates were compared for a six month period before and after
these interventions. There was a study website and annual partici-
pant newsletters. 18 participants were also interviewed, including
about follow-up, the transcriptions were analysed thematically.
Results
The primary outcome was ascertained for all participants and clinical
outcome data for 99% (1639) men at a median of 10 years follow-up.
Site monitoring and nurse training improved data collection. SDV
identified training issues to improve data collection and CRFs, al-
though staff time required was high.
Questionnaire response rates over six years follow-up were over 85%
for all proms and did not diminish over time. The reminder letter in-
creased the response rate from 76.4% (1045/1367) to 86.8% (1187)
and telephoning non-responders increased rates to 90.5% (1105/
1221). The shorter version of the questionnaire had some impact
(9/84 posted, 10.7%, overall 1033/1142, 90.5%). The study pen
was ineffective (1026/1142, 89.8%).
In interviews, most men found the questionnaires acceptable and
understood their purpose although they were less liked than the an-
nual nurse appointment. Some men saw questionnaires becoming
less relevant over time either because they felt they were cured or
they reported the same information annually, however, they contin-
ued to complete them. Participant newsletters were interesting and
gave a sense of belonging to a group. The study website was infre-
quently accessed, partly because it was assumed to contain no add-
itional information.
Conclusion
A multifaceted retention strategy led to very low rates of missing
clinical outcome data and participant attrition in a long-term cancer
trial. Successful retention requires multiple strategies, including on-
going staff training, regular newsletters and questionnaire reminders.
These strategies are optimally included at the design stage and
maintained throughout follow-up to reduce the potential for bias
due to participant attrition and missing data.
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Background
With less than a third of UK trials and 40% of US cancer trials failing
to achieve their recruitment targets, addressing recruitment chal-
lenges has become an important methodological priority. However,
while this focus has led to an increase in the quantity of published
research, navigating this literature to identify recruitment strategies
relevant to different types of trials has remained difficult.
Aim
The ORRCA project aims to provide an online searchable database,
categorising recruitment research according to key themes.
Data Sources
An unrestricted search of Medline (Ovid), Scopus, Cochrane Database
of Systematic Reviews (CDSR) and Cochrane Methodology Register,
Science Citation Index Expanded (SCI-EXPANDED) and Social Sciences
Trials 2017, 18(Suppl 1):200 Page 72 of 235Citation Index (SSCI) within the ISI Web of Science and ERIC in Janu-
ary 2015. Database specific search strategies were developed based
on previous work by Treweek et al. 2010.
Inclusion Criteria
Studies reporting or evaluating strategies, interventions or methods
used to recruit patients to randomised control trials, early phase tri-
als, qualitative interviews, focus groups, surveys, biobanks and cohort
studies. Case reports of recruitment challenges or successes and
studies exploring reasons for patient participation or refusal are also
included.
Methods
Articles were screened by title and abstract before a full text review
by researchers from the Hub for Trials Methodology Research Recruit-
ment Working Group (HTMR RWG) in the UK and the Health Re-
search Board for Trials Methodology Research Network (HRB-TRMN)
in Ireland. Eligible articles were categorised according to pre-defined
recruitment themes and the following types of evidence: randomised
evaluations of recruitment strategies; application of recruitment strat-
egies with or without evaluation; observations to inform future re-
cruitment strategies. Additional data were abstracted to enable
search functionality.
Results
Electronic searches identified over 40,000 articles of which 3979 re-
quired full text review. The online database (www.orrca.org.uk)
launched in August 2016 and is being updated periodically. We an-
ticipate it will contain over 2000 articles once the review process is
completed towards the end of 2016. Inbuilt search functionality al-
lows results to be filtered using categories such as recruitment
theme, level of evidence, health area, research methods, age and
gender.
With 71% of full text articles reviewed we have identified 87 rando-
mised studies or systematic reviews evaluating recruitment strat-
egies, 458 articles documenting the application of strategies and
1073 articles describing observations to inform future strategies.
Maximising patient consent was the predominant theme amongst
the 87 articles evaluating recruitment strategies with 30 (34%) asses-
sing the delivery mode of recruitment information, 15 (17%) review-
ing the format or content of patient information sheets and 14 (16%)
evaluating other aspects of the consent process.
Analysis of all recruitment themes shows that published literature fo-
cuses on describing recruitment barriers and facilitators, exploring
trial acceptability to patients and addressing cultural considerations.
Few articles explore recruiter training (n = 31) the impact of trial
reporting (n = 5) or blinding (n = 6).
We will present an overview of the methods for developing the
ORRCA database, a full analysis of recruitment themes following
completion of the literature review and suggestions for how trial
teams might use ORRCA to improve their recruitment strategies.
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Establishment & maturation of Ophthalmology Trainee Research
Networks within the UK Clinical Research Network (CRN) is currently
being encouraged. Such trainee networks already exist in surgery,
neurology & anaesthetics. Research studies supported by the trainee
networks have consistently exceeded targets for recruitment in rec-
ord time. EDNA (Early Detection of Neovascular Age Related Macular
Degeneration) is a publicly funded UK wide prospective cohort diag-
nostic study for the early detection of neovascular age-related macu-
lar degeneration (AMD). Active within 24 sites UK wide, EDNA has
struggled to recruit to target within the original timeframe. Inaddition to existing strategies to boost recruitment, the study man-
agement team decided to embark upon the establishment of a
trainee engagement exercise in EDNA similar to that seen in other
clinical specialties. During summer 2016 the EDNA Study manage-
ment team asked Principle Investigators at all EDNA sites to nomin-
ate a site trainee for the opportunity to co-own EDNA locally. This
trainee would typically be in the early stages of their career. In return
for local co-ownership of the study, opportunities for authorship, and
valuable insight into modern clinical research issues; the Co-PI’s are
expected to assist practically and clinically at local level to identify
ways in which they can positively enhance all study activities. While
taking joint responsibility for proactive recruitment to EDNA we ex-
pected all Co-PIs to promote and maintain high data completeness
and quality as well as attend all key EDNA meetings. In autumn 2016
these Co-PI trainees were inducted to EDNA. This presentation will
describe the process and experiences of establishing a Co-PI trainee
network within a UK wide diagnostic accuracy study.
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Background
Randomised controlled trials (RCTs) are regarded as the most rigor-
ous study design to evaluate healthcare interventions but recruit-
ment to them can be challenging, particularly to trials involving
surgery. Recruiter-related factors are often cited as key reasons for
this yet few interventions have been developed to support them.
The quintet Recruitment Intervention (QRI) has been embedded in
RCTs to understand and address recruitment difficulties. A cross-trial
synthesis of findings led to the identification of hidden emotional
and intellectual challenges for recruiters. These findings have been
translated into training material to improve the practice of front-line
health professionals who recruit to surgical RCTs. The aim of this
paper is to describe the training and evaluate its impact on
recruiters.
Methods
Surgeons and research nurses with a range of recruiting experience
were offered one of four workshops appropriate to their profession.
The 1-day training focused on sharing skills and evidence-based
knowledge to promote awareness and tackling of key recruitment
challenges, and to enhance self-confidence in recruiting patients to
RCTs. The workshops were broadly similar, comprising interactive
presentations, group exercises and discussion based around recruit-
ment difficulties and targeting the different needs of the different
health professionals. Recruiters-levels of self-confidence in discussing
trial recruitment with patients was assessed through 10 self-
completed questions on a 0–10 rating scale before and up to three
months after the workshop. Awareness of key recruitment challenges
and perceived impact of training on practice were assessed through
rating and Likert scales after training. Data were analysed using two-
sample t-tests, and supplemented with findings from the content
analysis of free text comments.
Results
99 participants (67 surgeons, 32 nurses) attended a workshop. There
was evidence of an increase in self-confidence scores following train-
ing (range of mean scores before training 5.1 to 6.9 and after 6.9 to
8.2, with 10 being most confident; p-values all <0.05). The greatest
increases in scores were in the areas in which they felt least
confident in prior to training, obtaining authentic informed consent
(nurses) and discussing trials with suspicious patients (surgeons). Im-
mediately after training, participants felt well aware of the challenges
of trial recruitment : Surgeons’ mean awareness score 8.8 (SD 1.2),
Trials 2017, 18(Suppl 1):200 Page 73 of 235nurses’ 8.4 (SD 1.3) (with 10 being very aware). At follow-up, half of
the surgeons reported that the training had made a lot of difference
to their trial discussions with patients (19/38, 50%), with slightly
fewer nurses reporting this (10/25, 40%). Only 2/36 surgeons and 2/
25 nurses reported the training as making no difference. Several
nurses who had received quintet RCT feedback previously felt the
training was preaching to the converted, but valued the opportunity
to reaffirm their practice. Attendees felt training had made them
aware of their training needs and improved their recruiting skills, of-
fering ideas for different approaches and explanations.
Conclusion
Quintet RCT recruitment training increased the self-confidence of sur-
geons and nurses in discussing RCTs with potential participants and
self-assessed recruitment practice. Further research will examine
whether they translate into improvements in informed consent and
RCT recruitment rates.
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Background
The Fourfold Asthma (FAST) Trial planned to recruit 2300 participants
over 22 months via 5 Research Networks (CRNs) across a mix of 8
secondary care hospitals, GP Participant Information Centres (PICs)
and GP Research Initiative Sites (RIS); a strategy used in a previous
asthma trial which involved doubling the dose of steroids [1].
Recruitment to the FAST Trial opened in May 2013. After 6 months,
recruitment was only 25% of the target due to a combination of de-
lays with contracting and recruitment in secondary care being far
lower than expected; it then became imperative to refocus our re-
cruitment strategy on primary care.
Method
Recruitment trends showed that GP practices were only active for
approx. 6 months after which the pool of potential participants was
exhausted. It was agreed by the Trial Management Group (TMG) in
February 2014 to open more RIS’ to replace inactive sites. In order to
do this close communication with the CRNs was essential. Mixed-
methods were used to train sites, including the Trial Manager train-
ing sites face-to-face or via Skype, and, for larger CRN regions, a
train-the-trainer approach was adopted in order to keep costs and
time resources down. In addition, participant information was re-
vised, the trial was promoted via various channels and the CI visited
many CRN areas to publicise the trial in primary care. In January
2015 (three months before the projected end of recruitment) an
11 month extension of recruitment was agreed with the funder
(NIHR HTA). In addition, following a sample size review at the request
of the DMC, the target sample size was revised to between 1774 and
1850 due to a higher than expected primary outcome rate.
Result
This was a major project management endeavour but on 31 January
2016 the trial completed recruitment. In total 20,695 patients were
invited to participate in the trial with a total of 1922 participants re-
cruited, on target of the revised timeline and recruitment objectives,
11 months behind the original schedule. By the time recruitment
closed 196 RIS had been opened across 15 regions; 54% of these
were opened in just 11 months. Overall 171 RIS successfully re-
cruited. In total 19% of participants were recruited from secondary
care sites, 18% from pics and 63% from RIS.
Conclusion
This trial demonstrates the importance of monitoring recruitment,
and rapidly investigating and responding to poor and unexpected
patterns in recruitment. Through close monitoring and clear report-
ing we were quickly able to take action to adapt the recruitmentstrategy to meet targets. Throughout this process we worked closely
with the NIHR HTA; this communication meant the funder was sup-
portive of the 11 month extension in recruitment.
Although the strategy was successful it was not without its draw-
backs. Many of the primary care sites had little or no previous re-
search experience, which meant they required significant support in
comparison to the secondary care sites. Lessons learnt also will be
presented.
Reference
1 Harrison. T. W., J. Obourne et al. (2004). “Doubling the dose of inhaled
corticosteroid to prevent asthma exacerbations: randomised controlled
trial” Lancet 363 (9405): 271–275
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Background
Cluster randomised trials that recruit individual participants after allo-
cation of clusters may have increased risk of between-arm differ-
ences in numbers and/or characteristics of recruited participants. This
is particularly the case when recruiters are aware of cluster allocation
and may introduce selection bias. The aim of this study was to inves-
tigate recruitment imbalance in a cluster randomised trial.
Methods
EXPONATE was a two-arm parallel cluster randomised trial of a pri-
mary care-based intervention for perinatal depression delivered by
community midwives in Nigeria. The unit of allocation was maternal
care clinic, stratified by local government area and with a recruitment
ratio of 1:1. Fifteen clinics were allocated to the intervention arm,
and 14 to usual care. All consecutive attendees were approached
about the study, and those scoring over 12 on the Edinburgh Postna-
tal Depression Scale (EPDS) were invited to participate. When recruit-
ment ceased after 16 months, a total of 686 women had been
recruited, 452 and 234 in intervention and control arms respectively.
We calculated recruitment fraction for each clinic and compared
these between arms, before and after exclusion of outlier clinics. We
compared characteristics of clinics and women by treatment arm. We
then considered whether the imbalance in recruitment could have
been anticipated and avoided.
Results
The mean (SD, range) number of women screened per cluster was
334 (331, 56–1384) and 356 (318, 25–1061) in the intervention and
control arms respectively. The mean (SD, range) number of women
recruited per cluster was 30 (30, 2–99) and 19 (15, 2–52), resulting in
recruitment fractions of 9.4% (4.6%, 3.3%-18.8%) and 5.8% (5.6%,
1.3%-24%) in the intervention and control arms respectively. The per-
centage of women who screened positive on EPDS and were not
subsequently recruited to the trial was small and similar between
arms: 4.6% (n = 22) and 7.5% (n = 19) in intervention and control
arms. A scatter plot of numbers screened versus recruited revealed
two clinics both with recruitment fractions twice the mean of other
clinics, and one clinic that screened more than five times the mean
of other clinics. All three clinics were in the intervention arm. When
these three clinics are removed from calculations, mean recruitment
fraction and total number recruited in the intervention arm is 7.3%
(3.0%, 3.3%-12.5%) and 205. When all 29 clinics are considered, we
found no marked between-arm differences in participant characteris-
tics (age/education/marital status/gestational age/clinical outcomes/
pregnancy outcomes) at baseline.
Conclusion
Although nearly twice as many women were recruited in the inter-
vention arm, there was no evidence of selection bias. It appears that
Trials 2017, 18(Suppl 1):200 Page 74 of 235the imbalance in numbers was due mainly to unusual recruitment in
three clinics, all of which were in the intervention arm. More exten-
sive feasibility work may have identified these issues. Recruitment
imbalance also potentially has implications for data analysis in trials.
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Background
Open studies have a high risk of bias in participant reported out-
comes. However, effects on recruitment, adherence and retention are
less well defined. In eczema many patients are keen to trial non-
pharmacological interventions, and hold high hopes that they are
successful. Therefore, they may not want to be randomised to a
study with a control arm. If randomised to control, they may actively
seek additional therapy and/or withdraw from the study. Waiting list
control designs randomise participants to intervention or control, but
offer the control group the intervention at a later date. Rationale for
this design include enhancing recruitment and adherence and redu-
cing differential loss to follow-up. However, there is the potential for
expectation bias as both groups are offered the intervention, and
thus exaggeration of the treatment effect, especially with participant
reported outcomes. There is also the risk of contamination between
treatment groups when the intervention is available to independ-
ently source outside of the trial. This abstract considers recruitment,
contamination, retention and treatment effects in two studies which
compared non-pharmacological interventions to usual care, in chil-
dren with eczema. One trial (SWET) examined the use of water soft-
eners for 3 months. The other (CLOTHES) examined wearing silk
clothing for 6 months. The interventions in both trials, can be inde-
pendently sourced.
Methods
The number of participants recruited, contamination between the
intervention and control groups and numbers lost to follow up in
each group were examined for each trial. The treatment effects in
each of the studies were also observed for objective and participant
reported outcomes.
Results
Both trials recruited to target (310 in 25 months (SWET), 300 in
18 months (CLOTHES). Contamination was low - No control partici-
pants had water softeners installed during the study period (SWET).
Six control participants reported wearing silk clothing during the
study period (CLOTHES). Follow-up rates were high - 96% (SWET)
and 94% (CLOTHES) - and similar between groups. In both trials,
there was no evidence of an intervention effect in objective out-
come measures (including the primary outcome). Similar differ-
ences between intervention and control groups were observed in
the mean Patient Orientated Eczema Measure score - a subjective
measure of symptoms (SWET-2.0 (95% CI −3.5 to −0.5); CLOTHES −2.8
(95% CI −3.9 to −1.8)).
Discussion
In both trials recruitment targets were met, contamination was low,
and follow-up rates were high and comparable in control and inter-
vention. It is not known if this was due to the relatively short dur-
ation of the studies, a compliant participant population or offering
the intervention to the usual care group. The consistent intervention
effect on subjective but not objective outcomes be the result of
expectation bias due to the design. However, there may be precon-
ceived expectations of benefit regardless of access to the interven-
tion. Research should be performed in this patient population to
determine whether the waiting list control design impacts on willing-
ness to participate, non-adherence and withdrawal from the study.
This should take into account the availability of the intervention, dur-
ation of the study, and participant’s prior opinions.P192
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Background
Non-compliance with the treatment assigned is a common problem in
randomised controlled trials. In order to obtain unbiased estimates of
the causal effect of the treatment received, sophisticated statistical
methods are necessary. One popular estimand is the complier average
causal effects (CACE). Approaches to estimating the CACE include
Bayesian and frequentist methods for principal stratification and
instrumental-variables (IV) estimators. These approaches are rarely used
in practice, probably because of their perceived complexity.
Methods
Here, we propose using multiple imputation (MI) methods, which have
been adopted by the clinical trials community to handle missing data
problems, to estimate CACEs and causal average treatment effects (ATE).
We propose three MI approaches. The first one imputes the potential
outcomes directly (MI-Y), assuming the non-compliance is ignorable
given the variables in the imputation model, to estimate ATEs. The
other two approaches impute the principal compliance classes, which
are assumed to be independent of randomized treatment and to have
known marginal distribution. The outcome models use to estimate
CACEs include an interaction between compliance class and random-
ized treatment, and it is the coefficient of this interaction which gives
us the CACEs. There are two possible ways of handling this interaction
term in the imputation step. The first is passive imputation (denoted
MI-C). The second is to use rejection sampling for the proposed im-
puted values. This is known as "substantive model compatible" (MI-C-
SMC) imputation. We modify the imputation model probabilities to ob-
tain conditional distribution with the desired marginals. Using a full-
factorial simulation, we investigate the finite sample properties of MI-Y,
MI-C and MI-C-SMC methods for estimating ATEs/CACEs, in terms of
coverage of the 95% confidence interval (CI) and bias. We consider set-
tings where the outcome is (i) normally distributed or (ii) binary, and
compare them to competing procedures (IV 2-stage least squares and
full Bayesian modelling) in settings where the association between
treatment received and outcome is confounded. We have two settings,
low or high confounding, i.e. There exists a variable X which is ((i)
weakly or (ii) strongly) associated with at the probability of complying
and also ((i) weakly or (ii) strongly) associated with the outcome. We
considered situations where the confounder X is (i) measured or (ii) un-
measured. We also motivate and illustrate the methods in practice
using a real clinical trial.
Results
In settings where the confounder is low, and measured, all MI methods
perform well, but when there is unmeasured confounding MI-Y results in
low coverage rate (89%). For high confounding situations, MI-C performs
well when the confounder is measured, but results in biased estimates
with unmeasured confounding. MI-C-SMC seems to perform well in all
settings considered, as do the Bayesian methods. MI-C and MI-C-SMC ap-
pear to be more efficient than 2sls methods in small sample settings.
Conclusions
Multiple imputation methods can be used to impute the unobserved
compliance classes and then used these to obtain compliance ad-
justed causal effects of treatment. MI methods may have the advan-
tage of dealing with missing data and non-compliance seamlessly,
and increased efficiency.
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Trials 2017, 18(Suppl 1):200 Page 75 of 235The typical framework for modeling data from a stepped-wedge cluster
randomised trial (SW-CRT), the Hussey and Hughes model, assumes a
common (piecewise constant) secular trend across all clusters. In some
situations this may be a tenable assumption. But, in other situations, for
example with clusters set across very different settings (for example
countries) this assumption might be implausible.
Through a simulation study we examine the influence on bias, accur-
acy and coverage of this assumption using real underlying temporal
trends from paediatric intensive care outcomes where this assump-
tion does not hold. We also examine the performance of alternative
models, including models in which time effects are ignored, common
linear time effects, cluster specific linear time effects and models in-
cluding random time effects. We consider both mixed models and
generalised estimating equations, and use a full factorial design to
examine a range of scenarios including small and large numbers of
clusters and steps; small and large inter-cluster correlations; and
small and large cluster sizes.
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Background
In a randomised controlled trial the effect of an intervention can be
estimated by calculating the difference in outcomes between the
groups. The Standard Approach uses an intention to treat analysis
(ITT) where all participants are included in the group to which they
were assigned, whether or not they received their allocated interven-
tion. An ITT analysis reduces post-randomisation selection bias, and
estimates the intervention effect under routine application, its effect-
iveness. However, an ITT analysis does not estimate efficacy, the ef-
fect of an intervention under ideal circumstances. Two approaches
are commonly used to estimate efficacy when there is non-
compliance (or non-adherence): per-protocol (PP) analysis, in which
only individuals who received the intervention they were randomised
to are included in the analysis, and an As-treated (AT) analysis in
which individuals are analysed according to the intervention they re-
ceived. Both approaches may lead to biased estimates of the treat-
ment effect since randomisation is broken.
Here we explore alternative estimates of intervention effects in a
cluster randomised trial in the presence of non-compliance.
Materials and methods
We use data from a trial of learner treatment kits (LTKs), comprising
malaria rapid diagnostic test kits (RDTs) and artemisinin-based com-
bination therapy drugs (ACTS) administered by teachers, on school
attendance by Malawian children. Observations were clustered within
schools.
The primary analysis was an ITT analysis, and additionally an AT and
a PP analysis were carried out. We will use causal modelling to ex-
plore other possible estimators of the effect of the intervention in
the presence of non-compliance. The two possible estimators we
consider are: (i) the complier average causal effect (CACE) which esti-
mates the treatment effect among compliers and involves identifying
groups of individuals with respect to their group assignment and
compliance, and comparing the outcome across groups in those
who would have complied with the intervention they were rando-
mised to, and (ii) the average treatment effect in the treated (ATT)
which estimates the average effect of treatment on those subjects
who ultimately received the treatment.
Results, conclusions and future research
The ITT and PP analyses provided no evidence of an effect of the
intervention on school attendance. However, an AT analysis sug-
gested that that children who actually used the LTKs were less likely
to be absent from school. We will present the CACE and ATT esti-
mates and explore the assumptions underpinning these effectestimators and their applicability in cluster randomised trials with
non-compliance.
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Multiple imputation (Rubin, 1978, 1996) is a widely used method
for handling incomplete data, and availability of software packages
that implement multiple imputation has allowed various practical
applications. In randomized clinical trials, the treatment assignment
is usually completely observed but other predictors may be miss-
ing, and it is important to appropriately account for incomplete
data. In this paper we consider an interaction model in a clinical
trial setting with a missing covariate and the treatment variable,
where outcome can be binary or continuous. With the interaction
model, the multivariate normal assumption is no longer satisfied,
and the usual implementation of multiple imputation under multi-
variate normal assumption can lead to biased results. We introduce
a joint model approach for imputation of missing covariates in clin-
ical trials for the linear or logistic regression setting, and evaluate
various approximation approaches in a simulation study. We recom-
mend specific approaches that incorporates interactions in the im-
putation procedure. These approaches are applied in the analysis of
clinical trial data on randomized blood products for severely injured
patients.
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Background
Like any trial, the ability to accurately estimate the required sample
size of a stepped-wedge (SW) cluster randomised trial (CRT) depends
upon the precise specification of several nuisance parameters. In
practice, providing accurate estimates for these nuisance parameters
may be difficult, and thus there is a risk that many SW- CRTs may be
conducted with undesirable operating characteristics. Trials could be
over-powered; leading to increased cost, or under-powered; increas-
ing the likelihood of a false negative result. We address this issue
here for cross-sectional SW- CRTs by proposing methods for blinded
and unblinded sample size re-estimation (SSRE).
Methods
Blinded estimators for the variance parameters of a SW-CRT ana-
lysed using the Hussey and Hughes model are developed, and
demonstrated to be unbiased in the absence of treatment and
period effects. Following this derivation, complete procedures for
blinded and unblinded SSRE after any time period in a SW-CRT
are detailed. Explicitly, we address the case where a limited num-
ber of clusters for recruitment have been set, but increased re-
cruitment within a cluster is feasible. The performance of both
procedures is then examined and contrasted through a simula-
tion study, using a recently completed SW-CRT as motivation. A
simple adjustment to more accurately control the type-I error rate
is also proposed.
Results
For our example scenario, if the two key variance parameters were
under-estimated by 50%, the SSRE procedures were able to increase
power over the conventional SW-CRT design by up to 26%. The per-
formance of the SSRE procedures is demonstrated to be robust to
the choice of re-estimation time point, whilst the proposed adjust-
ment to account for the observed type-I error rate inflation is often
able to control to approximately the nominal level.
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The considered SSRE procedures can bring substantial gains in power
when the underlying variance parameters are mis-specified. Though
there are practical issues to consider, such as the requirement for
data to be collected and stored efficiently for analysis, the proce-
dures performance means researchers should consider incorporating
SSRE in to future SW- CRTs when there is uncertainty over the values
of the variance parameters.
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Missing data in cluster randomized trials are often handled with
parametric multiple imputation (MI), assuming multivariate normality
and using random effects to incorporate clustering. Since data do
not always satisfy this assumption, a nonparametric approach to MI
is desirable. Predictive mean matching (PMM) is a nonparametric ap-
proach where missing outcomes are imputed with observed out-
comes in the data from donors that are similar to the missing cases.
It is not clear how best to extend PMM to multilevel data. Two possi-
bilities are to ignore clustering in the imputation model or to include
fixed effects for clusters. In parametric MI, ignoring clustering in the
imputation model leads to underestimation of the MI variance, while
including fixed effects for clusters tends to overestimate the variance.
A mixed effects imputation model can be used as the basis for
matching, but this is computationally intensive and increases reliance
on distributional assumptions. To simplify computation and reduce
bias in the estimated variance, we investigate a weighted PMM ap-
proach that incorporates both the fixed effects imputation model
and the imputation model that ignores clustering.
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The rank preserving structural failure time model (RPSFTM) is a
method used to adjust for treatment switching in trials with survival
outcomes. Treatment switching occurs when patients switch from
their randomised arm to the other treatment during the study. The
RPSFTM is due to Robins and Tsiatis (1991) and has been developed
by White et al. (1997, 1999).
The method is randomisation-based and uses only the randomised
treatment group, observed event times and treatment history in
order to estimate a causal treatment effect. The treatment effect, Psi,
is estimated by balancing counter-factual event times (i.e. The time
that would be observed if no treatment were received) between
treatment groups. A g-estimation procedure is used to find the value
of Psi such that a test statistic Z(Psi) = 0. Recensoring must be per-
formed as censoring becomes informative on the counter-factual
time scale.
An R package titled “Rpsftm” has been developed and is freely avail-
able for download on the CRAN website. This package implements
the method as described above. The main features are: Building dir-
ectly on the established “Survival” package to calculate the z-statistic,
and the uniroot() function to solve the estimating equation; A famil-
iar formula syntax: Surv(time, status) ~ rand(arm, rx) + covariate, to
represent the censored failure time, the rand(arm,rx) representing
the randomised treatment arm and observed proportion of time
spent on the randomised treatment, plus any adjusting covariates;
Implementation of the re-censoring method, when a theoreticalcensoring time is known; Auto-detection of perfect compliance in a
treatment arm, with corresponding adjustment to the re-censoring;
Routine output in terms of summary, and print methods; Estimates,
and confidence intervals of the causal parameter; Sensitivity analysis
to the model assumption of a common treatment effect, allowing
the user to vary the magnitude of effect of treatment between pa-
tients; Diagnostic plot to help resolve potential numerical non-
convergence issues.
We provide worked examples to illustrate the use of the package
and the methodology.
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Background
Adverse events (AEs) in oncology trials have historically been re-
ported by clinicians using National Cancer Institute’s (NCI’S) Common
Terminology Criteria for Adverse Events (CTCAE). Traditional statistical
analysis of AE data has primarily involved summary measures (e.g.,
maximum grade post-baseline) even though a variety of other ap-
proaches exist including cumulative incidence estimation in the pres-
ence of competing risks. AE data reported directly by patients using
NCI’s Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)
are similar in ordinal format to CTCAE data. PRO-CTCAE data may
introduce statistical challenges due to high baseline symptom rates
and non-ignorable missing data.
Methods
Baseline and six post-baseline scores on a five-level ordinal scale (0 =
none, 1 =mild, 2 =moderate, 3 = severe, 4 = very severe) were simu-
lated for 100 patients/arm in 1,000 two-arm trials using a multivariate
ordinal distribution for combinations of baseline prevalence rates
(5% vs 50%) and change over time (no change vs 30% increase vs
30% decrease). Between-arm comparisons included t-tests and Wil-
coxon rank-sum tests of the maximum score post-baseline (maxpb)
and a novel baseline adjustment score (bladj); chi-squared tests of
the rate of maxpb or bladj >0; general linear mixed models (GLMM)
of longitudinal scores; and Gray’s tests of the cumulative incidence of
score >0 with and without adjustment for baseline. The GLMM mod-
eled all scores allowing for random intercepts and slopes with statis-
tical significance based on the arm-by-cycle interaction effect
(unstructured covariance was used to account for within-patient cor-
relation of scores over time). Bladj was computed for each patient as
maxpb if maxpb was worse than the baseline score, or as zero if
maxpb is the same or better than baseline.
Results
When baseline prevalence was low, 30% increase vs no change
yielded high frequency (>99%) of statistically significant results using
all methods. When baseline prevalence was high for comparisons of
30% increase or decrease vs no change, maxpb (45-69%) yielded
more statistically significant results than bladj (40-63%) regardless of
statistical test, with the modeling approach (80-85%) having higher
frequency than chi-squared test (49-69%), Gray’s test (45-58%), Wil-
coxon rank-sum test (45-66%), and t-test (40-57%). In varying the
baseline prevalence (5% vs 10% vs 30% vs 50%) but maintaining the
post-baseline scores linearly increasing from 55% to 80%, rate of
maxpb >0 was 93% in all simulations compared to 93%, 91%, 83%,
and 72% for bladj.
Conclusions
Existing statistical methods for clinician-reported AE data and PRO
data are candidate methodologies for the statistical analysis of PRO-
CTCAE data. The general linear mixed model approach appears to
provide the most power for between-arm comparisons among the
tested approaches. The novel baseline adjustment method appears
to account for some but not all pre-existing symptoms.
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Background
Prior to any formal analysis of data in a clinical trial, a Statistical Ana-
lysis Plan (SAP) must be written, reviewed and approved. This docu-
ment describes how the data analysis will be performed, lists the
endpoints of interests, and defines how they will be derived. Docu-
ments and descriptions are typically written in prose, meaning that
clarity of the analysis intended by the statistician, and that under-
stood by a reviewer depend on the writing style of the person who
drafts the SAP. Assumptions made by a reviewer about the descrip-
tions of the analysis or endpoint derivation may differ from that
intended, but not specified. It is important to avoid instances of a
derivation needing to be overruled at analysis time due to disagree-
ment on what is meant by sentences both thought had clear and ob-
vious meanings, or where alternative approaches are not defined
upfront.
Results
Templates for the derivation of variables are proposed for how to
make clear how in mathematical and programming terms an end-
point is to be derived, and the analysis is to be performed. Endpoint
templates include worked examples and references. Analysis model
templates include types of variables (binary, categorical, continuous),
expected ranges for continuous variables, or meanings of values for
categorical variables, the type of model to fit, whether effects are
fixed or random. Procedures for checking assumptions are listed.
Strategies for dealing with potential analysis pitfalls are included, in-
cluding simplifying models in the case of non-convergence, non-
positive variance component for random effects and violation of
modelling assumptions.
P203
A review of design and analysis methods for pressure ulcer
research
Isabelle Smith1, Linda Sharples2, Jane Nixon2
1University of Leeds; 2University of Leeds, Leeds Institute of Clinical Trials
Research
Correspondence: Isabelle Smith
Trials 2017, 18(Suppl 1):P203
Background
Pressure ulcers (PUs) are defined as a “localized injury to the skin
and/or underlying tissue usually over a bony prominence, as a result
of pressure, or pressure in combination with shear” [1]. PUS are pain-
ful and debilitating for patients, represent a significant cost to the
NHS and are a key quality indicator for the Department of Health.
Motivation
PUs are categorised using an ordered categorical scale based on the
appearance of skin. PU classification requires clinical judgement and
misclassification can occur when undertaken by non-specialist staff,
particularly for early skin changes. For PU research, investigators assess
multiple skin sites for each patient at multiple time points, recording
whether skin is healthy or not, and the PU classification where applic-
able. During analysis these repeated measurements are often aggre-
gated into a single outcome measure, defined as development of at
least 1 category 2 PU; therefore many observations are not directly ana-
lysed. Consequently large sample sizes are required for trials of PU pre-
vention and intervention strategies. PU trials are further complicated by
missing data due to administrative or patient factors and misclassifica-
tion due to the judgement required for categorisation of skin changes.
Methods that use all observations, including repeated assessments at
multiple skin sites, such as multi-state models, have the potential to
address these problems. It is important to understand how trials are
currently designed and analysed in this context in order to develop
recommendations for optimal designs.Aim and objectives
The overall objective of this research is to transform the design and
analysis of PU trials by making better use of all data collected from
repeated measures of skin changes. The aim of this project is to re-
view currently used PU research designs, focussing on outcome mea-
surements and their analysis.
Plan of Research
We will present a review of methods used in PU trials and observa-
tional cohort studies including how data are collected and analysed
to illustrate the extent of the problem. Key manuscripts were identi-
fied through systematic reviews of published PU research. From
these a pearl-growing strategy was adopted to identify other trials
and large cohort studies. Finally experts in the field were approached
to ensure major studies were not overlooked. Data extraction was
pre-specified to include study design, frequency of assessments, as-
sessor characteristics, PU definition, primary outcome including deriv-
ation, analysis methods including relevant assumptions and
accommodation of complications such as censoring or missing data
and effect size to quantify differences in study conclusions based on
analysis methods used. Summaries of methods used in PU research
will be presented and critiqued for quality and information provided
from a statistical perspective.
Conclusion
Currently used methods for design and analysis of PU trials are ineffi-
cient and ignore many complexities that introduce variation into the
results. More efficient designs and analysis methods may reduce the
numbers of patients required and be less subject to bias. Methods
may generalise to other situations in which a disease process can be
represented by correlated longitudinal categorical data.
Reference
[1] NPUAP/EPUAP/PPPIA, Prevention and Treatment of Pressure Ulcers: Clinical
Practice Guideline. 2014, Cambridge Media: Osborne Park, Western Australia
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Background
Diary cards and questionnaires are frequently used to collect data in
clinical trials. However, data collection can be burdensome and com-
pletion may decline over time. Despite the often large volume of
data, this may be reduced to summary measures for analyses.
The CLOTHES trial randomised 300 children with moderate to severe
eczema to standard care plus silk clothing for 6 months or standard
care alone. A nested qualitative evaluation was included: 32 parents
participated in focus groups or telephone interviews. Patient-reported
symptoms were assessed weekly using online or paper questionnaires
for 6 months and during scheduled clinic visits at baseline, 2, 4 and
6 months using the Patient Orientated Eczema Measure (POEM). The
mean of participants’ weekly POEM scores was a secondary outcome
measure. We explored whether the results and conclusions would have
changed if only data collected at 2, 4 and 6 months were used in the
analyses.
Methods
For the trial analysis, the mean of participants’ Weekly scores was
analysed using a linear model weighted according to the number of
weekly questionnaires completed. This analysis was repeated using
the scores from week 8, 16 and 24 questionnaires only and the
scores collected in clinic at the same timepoints (2, 4 and 6 months).
Results of the nested qualitative study were reviewed to determine
whether completion of the weekly questionnaires had been identi-
fied as a theme.
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The difference between the two groups using all of the question-
naire data in the participant mean of the weekly scores was −2.8
(95% CI −3.9 to −1.8) in favour of the intervention group, n = 147
control, n = 145 intervention). Repeating this analysis using data
only from the questionnaires at weeks 8, 16 and 24 showed a dif-
ference of −2.6 (95% CI −3.9 to −1.3), n = 134, n = 137 respectively,
and using clinic data at 2, 4 and 6 months was −2.3 (95% CI
−3.5 to −1.1), n = 141, n = 142 respectively.
Several parents felt that questionnaire completion had been useful in
prompting more regular use of usual treatments whilst others felt
they were repeating themselves each week and this may not be
helpful (Qualitative study).
Conclusion
The results were very similar for all three analyses and conclusions
would not have changed if less data had been collected. Therefore,
weekly data collection may not be needed when summary measures
are used to compare groups. More frequent data collection may be
useful in other circumstances for example if there is a need to iden-
tify sudden flares.
The process of data collection should also be considered. Frequency
of data collection needs to be balanced against the potential for data
collection itself to act as an intervention and influence behaviour in
pragmatic trials.
Further work is needed to determine the optimum frequency of data
collection to capture both the chronic relapsing nature of eczema
and changes in condition due to an intervention. This is planned as
part of the Harmonising Outcome Measures for Eczema long term
control outcome domain.
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Background
Children who are born preterm are known to be at increased risk of
a range of developmental problems. The Preterm and After (PANDA)
study aims to provide information about the long term outcome of
children born very preterm (less than 31 gestational weeks) admitted
for acute neonatal care in the east of England. Within PANDA, the
PARCA-R questionnaire is completed by parents in order to measure
cognitive and language development at 2 years of age. These data
are added to obstetric and neonatal data collected by The Neonatal
Survey (TNS), an ongoing study of neonatal intensive care activity in
the same geographic area. It includes clinical information on the
child and their neonatal care as well as the developmental outcome
of the child; alive with no developmental delay (DD), alive with DD
and death before 2 years of age.
Aim
The aim of this project was to investigate developmental outcome at
2 years of age for children born very preterm. The PARCA-R survey
completed by the parent was used and failure to do so led to amissing outcome response. An investigation into the missingness
and its assumptions were also investigated as almost half the dataset
had a missing outcome which this abstract will concentrate on.
Subjects
The dataset is a subset of TNS and contained 2028 participants,
which included babies born very preterm admitted to neonatal care
between 2009 and 2010.
Methods
The three nominal outcomes were modelled using multinomial logis-
tic regression. Missingness was investigated by complete case ana-
lysis, Inverse Probability Weighting (IPW) and multiple imputation. To
allow for comparison between the three methods, the same covari-
ates were adjusted for in the final multinomial logistic regression out-
come models. Probabilities, odds ratios, log odds and standard errors
were used to compare the three different approaches.
Results
Missing completely at random was disregarded as the IPW missing-
ness model highlighted that the deprivation area, mother’s age and
mother’s ethnicity had an effect on whether the PARCA-R survey was
completed. For instance, mothers aged 34+ were 3.4 times more
likely to respond than mothers younger than 23 years, when control-
ling for deprivation area and mother’s ethnicity. The imputation
model also produced strong evidence of covariates predicting non-
responders. Once the investigation of missingness had been con-
ducted the same multinomial logistic regression was produced. The
optimal model predicting developmental outcome contained gesta-
tional age, sex of the baby and CRIB II score as well as a quadratic
term for gestational age. Unsurprisingly, complete case analysis
yielded very different results to the models that used IPW and mul-
tiple imputation. Odds ratios and probabilities of each outcome were
broadly similar with multiple imputation yielding smaller standard er-
rors of the odds ratios in the multinomial logistic regression.
Conclusions
IPW and multiple imputation both vary methodologically and there
are a number of limitations with both methods, however, it is proven
to produce very similar results and can be effective to use the data
available to predict the missing outcome. It is concluded multiple im-
putation is more flexible than IPW when modelling missing
outcomes.
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To investigate treatment efficacy in randomised control trials, re-
peated observations are taken on a cohort of participants and the
change in response following treatment is assessed. The commit-
ment required of participants to stay involved in the study, however,
makes this design open to both recruitment issues and attrition. A
cross-sectional design may be used in conjunction with the cohort
design to protect against these problems, recruiting additional partic-
ipants who only contribute once to the study, resulting in a ‘mixed’
design.
The EQUIP cluster randomised control trial was designed to evaluate
the efficacy of a training intervention for community mental health
teams (CMHT), employing such a mixed design. The ‘cluster cohort’
sample provided baseline data on service users prior to randomisa-
tion and follow up data at six months following baseline assessment,
via face-to-face interviews. The ‘cluster cross-sectional’ sample in-
volved all service users under the care of the cmhts not in the cohort
sample to be sent a postal questionnaire six months after randomisa-
tion. Comparison of the results of the two designs would allow exter-
nal validity of the intervention to be investigated. The combined
sample was intended to increase power to detect the intervention
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only collected in the cross-sectional design at six months post ran-
domisation, baseline data were missing in this sample, posing a
problem for the combined analysis. Two methods for overcoming
this issue were considered: using baseline as response, where a joint
model of baseline and response is fitted with all observed data, and
the missing indicator method in which an indicator variable for the
missing data is include in the model as a covariate.
These two methods will be presented with a discussion of the chal-
lenges encountered in the application of each to the cluster random-
isation trial design of the EQUIP study.
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Scoring systems based on multiple components are often used in in-
tensive care trials to characterise disease severity. Missing data in the
overall score can be substantial due to the number of contributing
components, and the problem is exacerbated if data are collected at
multiple time points. A complete case analysis is prone to selection
bias, and for component scores is highly inefficient. It is preferable to
include individuals with incomplete data in the analysis by imputing
their missing values. The imputation process should be based on
plausible assumptions about the causes of the missing data and re-
flect the longitudinal trajectory for each patient. We demonstrate
how this is facilitated by adopting a Bayesian framework, using data
from the Levosimendan for the Prevention of Acute Organ Dysfunc-
tion in Sepsis (LEOPARDs) trial.
In the LEOPARDs trial, the primary outcome was the mean daily total
Sequential Organ Failure Assessment (SOFA) score while in ICU. The
total SOFA score is the sum of five components and some of these
components are determined by multiple variables. Although 6% of
scores were missing across components, this led to 17% of the total
SOFA scores having a missing component. There was a clinical ex-
pectation that measurements may not be taken if there was no
change, or if the scores were normal. The assumption of a lack of
change is in line with the last observation carried forward (LOCF) ap-
proach. This method gives a single imputation, so does not take ac-
count of the uncertainty due to the missing data, leading to over-
precise estimates. Standard multiple imputation (MI) overcomes this
problem, but typically assumes that the probability of a missing score
does not depend on the score itself, after conditioning on observed
data. This was implausible in the LEOPARDs trial because the de-
cision on whether to take a measurement is informed by clinical
judgement about its likely value, and so the missingness is
‘informative’.
We used Bayesian Markov Chain Monte Carlo (MCMC) methods to
impute missing values at a component level, based on a selection
model factorisation which specifies a marginal distribution for the
scores (analysis model) and a conditional distribution for the missing-
ness indicators given the scores (missingness model). An autoregres-
sive process was incorporated into the analysis model to take
account of the longitudinal structure in the scores, and informative
prior distributions specified for the parameters in the missingness
model to reflect various assumptions about the missingness mechan-
ism. We applied a bootstrap approach to calculate the difference be-
tween treatment groups because of the non-normal distribution of
the daily total SOFA scores, with a separate bootstrap sample taken
at each MCMC iteration.
Results from the Bayesian analysis showed more uncertainty than
those obtained using LOCF, whilst allowing for informative missing-
ness unlike standard MI approaches. In addition, the methods
applied here accommodated both bootstrap sampling and thecomponent nature of SOFA score. We recommend that this approach
be considered more widely for informative missingness in longitu-
dinal data.
P210
Do trialists adequately pre-specify their statistical analysis
approach? A review and re-analysis
Lauren Greenberg1, Vipul Jairath2, Brennan C. Kahan1
1Queen Mary University of London; 2Department of Medicine,
Epidemiology and Biostatistics, Western University
Correspondence: Lauren Greenberg
Trials 2017, 18(Suppl 1):P210
Background
Well-designed clinical trials are the gold standard for evaluating
healthcare interventions. It is essential for the trial methodology to
be pre-specified in the protocol in order to avoid issues such as se-
lective reporting of outcome measures. However, little attention has
been paid to whether trialists are adequately pre-specifying the
method of analysis for their primary outcome in the trial protocol, or
what impact inadequate pre-specification might have on trial results.
Methods
We re-analysed primary clinical outcome data from the TRIGGER trial
to examine the impact that differing analytical approaches could
have on the trial outcome. We varied several aspects of the analysis:
(a) the patient population included in the analysis; (b) the analysis
model used; (c) the set of covariates included in the model; and (d)
methods of handling missing data. We then conducted a review of
published trial protocols to assess how well the statistical analysis ap-
proach for the primary outcome was pre-specified.
Results
Our re-analysis of TRIGGER found that the choice of statistical ana-
lysis approach had a large impact on both the estimated treatment
effect and p-value. Across the different analytical approaches, the es-
timated odds ratio ranged from 0.40 (95% CI 0.17 to 0.91; p-value
0.03) to 1.09 (95% CI 0.56 to 2.10; p-value 0.80). It was possible to ob-
tain both significant and non-significant results by varying either the
patient population included, the set of covariates used in the analysis
model or the method of handling missing data. The review of pub-
lished protocols is ongoing, however preliminary results indicate that
most trial protocols do not adequately pre-specify their analysis ap-
proach for the primary outcome.
Conclusions
The statistical analysis approach can greatly influence trial results. It
is essential that the planned analytical method is pre-specified in the
trial protocol in order to avoid selective analysis reporting.
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The primary charge of a Data Monitoring Committee (DMC) is to
monitor the safety of clinical trial subjects. Among the most import-
ant sources of safety data is adverse events (Aes) reported by
investigators.
Often, the Sponsor’s statistical analysis plan for the final study ana-
lysis simply indicates that Aes will be summarized by meddra system
organ class (SOC) and preferred term. Lengthy tables of Aes are com-
prehensive, but may overwhelm DMC members with detail and fail
to highlight relevant treatment differences, important constellations
of related Aes, or answer key questions regarding the severity, im-
pact, or timing of events.
The Statistical Data Analysis Center (SDAC) at the University of
Wisconsin-Madison specializes in producing interim reports and ana-
lyses for DMCs. Our reports are graphically based, allowing DMC
members to easily identify differences between treatment groups or
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amount of time. We employ various presentation styles, including
graphics produced in R (bar charts, stacked bars, Kaplan-Meier plots,
forest plots), and tables and listings produced in SAS; latex is used
for layout and report production.
A major challenge in AE reporting is to separate signal from noise,
drawing attention to important issues while not sacrificing complete-
ness of reporting. Our standard suite of AE analyses employs a “Drill
down” Approach, beginning with an overall summary of Aes falling
into selected categories (serious, fatal, related to treatment, leading
to treatment discontinuation, etc.), graphical summaries by SOC and
of most common preferred terms, followed by incidence tables of
preferred terms within SOC and listings of Aes of concern. Our stand-
ard displays provide visual information regarding severity as well as
incidence, and highlight treatment comparisons between groups.
Flexibility is a key feature of our reports; analyses evolve depending
on the stage of the trial as well as in response to DMC concerns, and
are often tailored to characteristics of the subjects and/or treatments
in the specific trial. We find graphical presentations useful, not only
for aggregate data, but also for examining individual subjects – for
example, to illustrate the relationship between Aes and other data
(e.g., dosing, lab data). Custom graphical displays may also address,
in aggregate or by subject, timing of Aes, recurrent events, or events
of special interest.
This poster presents examples of innovative displays designed to re-
spond to specific questions posed by the DMC, as well as our stand-
ard AE presentations for DMC reports.
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Background
Rare cancers have complications in analysis due to limited recruit-
ment, meaning the event of interest does not occur enough to ac-
curately discern which treatment arm is better. Due to unclear
knowledge of the best way of treating patients suffering from rare
diseases, a disproportionately high number of deaths occur.
We propose a method of analysing clinical trials for rare diseases
when comparing two treatments already in use, which can give a
good indication of which treatment arm is better, that does not re-
quire sample sizes of the magnitude of conventionally-powered
trials.
Merkel cell carcinoma (MCC), a skin cancer which recorded 1515
cases in the UK in a 10-year period, is one such rare disease. Cur-
rently, the main treatment method for MCC is prioritising surgery,
then administering radiotherapy to eradicate remaining cancer cells.
It was postulated whether reversing this treatment order would be
more efficacious. This question is analogous to comparing two treat-
ments in use, because patients would receive access to both radio-
therapy and surgery regardless of the outcome, and there are
arguably no losers.
Hypothesis testing using conventional levels of Type I and II error
would require in excess of 3000 patients, which is unfeasible to re-
cruit, even across countries, leading such a trial to be underpowered.
We applied our new analysis method using the statistics associated
with MCC.
Methods
The Type I error was redefined as probability of concluding a treat-
ment was better than the other when in fact it was worse, and the
minimum sample size was the sample size needed for this value of
Type I error to be to 2.5%.
To conclude ‘superiority’ using our rules, the upper limit of two-sided
95% confidence interval of the hazard ratio (HR) observed had to be
below 1.25, and the upper limit of two-sided 50% confidence interval
had to be below 1.Survival analysis was conducted with a patient having the endpoint
of interest if they died within 2 years. We simulated the survival time
of patients in a two arm trial with the treatment arm as the sole pre-
dictor and analysed the data using the Cox hazard model.
In simulations of 10,000, various sample sizes and true hrs of the
treatment arms were modelled, with the power to conclude efficacy
using the conventional null hypothesis, and the re-definition,
compared.
Results
In all examples simulated pertaining to MCC, using our rules leaded
to substantial gains in power, sometimes even a doubling.
The results of theoretical sample size equations had close concord-
ance with the powers for various sample sizes observed in
simulations.
Conclusion
By restricting the probability of making a wrong decision to be 2.5%,
the analysis method we have proposed is more robust than generic
non-inferiority tests. The interpretation of hypothesis testing from
our rule is the patient may be informed, “on the balance of probabil-
ity, this treatment is better”.
Our proposed analysis method means conducting clinical trials for
rare diseases is worthwhile after all, potentially leading to better
standard of care for patients suffering from them.
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Predictive markers are variables that identify patient subgroups with
differential response to treatment and can be useful in guiding treat-
ment decisions. Practically, predictive markers are those found to
moderate the relationship between treatment and an outcome. How-
ever, the presence of treatment effect modification is dependent
upon measurement scale of the outcome. If the absolute effect of
treatment varies across patient subgroups, treatment effect modifica-
tion is present on the additive scale. Alternatively, if the relative ef-
fect of treatment varies across patient subgroups, treatment effect
modification is present on the multiplicative scale.
Treatment effect modification on the additive scale is generally per-
ceived to be of primary interest for explaining differential treatment
response because absolute treatment effects do not depend on
baseline risks which may differ between patient subgroups. For ex-
ample, if age is, regardless of treatment, associated with the outcome
of interest, the baseline risk will vary across age subgroups. If the
relative treatment effect, say the relative risk, is found to be similar
across the age subgroups, this implies variation in the absolute treat-
ment effect across the subgroups. Specifically, this implies that pa-
tients in the subgroup(s) with a lower baseline risk have a smaller
absolute treatment compared to patients in the subgroup(s) with a
higher baseline risk. Since the absolute treatment effect conveys the
absolute magnitude of the treatment response, this variation will
likely be of interest.
However, in clinical trials with binary and time-to-event outcomes,
treatment effect modification is often assessed only on the multiplica-
tive measurement scale as this corresponds to a comparison of the
more commonly presented relative treatment effect measures (relative
risks, odds ratios, hazard ratios) across patient subgroups. This is usually
obtained from the widely used regression models for these outcome
measures, i.e. The logistic regression model and the Cox proportional
hazards regression model, by the inclusion of a product term between
treatment and the predictor of interest. The analysis of treatment effect
modification on the additive measurement scale can be less easy to
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the dependency on time.
This works aims to highlight why an analysis of treatment effect
modification on the additive scale is more informative in the evalu-
ation of markers predictive of differential treatment response and to
present how this can be performed in practice. We propose the use
of a novel measure, the Ratio of Absolute Effects (RAE) measure, as
an approach for the assessment of treatment effect modification on
the additive scale which can be calculated from the more commonly
used multiplicative regression models used for binary and time-to-
event outcomes. We suggest this measure to be particularly useful
for time-to-event outcomes as it is time invariant. Also discussed is
the use of alternative regression models on the additive scale (e.g.
The additive hazards model) from which effect modification on the
additive scale can be directly assessed.
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Background
Data from a subgroup of the Efficacy of Nitric Oxide in Stroke trial
(ENOS-early; concerning patients randomised within 6 hours of ictus,
a pre-specified subgroup) and the Rapid Intervention with Glyceryl
trinitrate in Hypertensive stroke Trial (RIGHT), suggest that glyceryl
trinitrate (GTN), when given early, improved dependency, death, dis-
ability, cognitive impairment, mood disturbance, and quality of life.
However, individual outcomes do not provide a global estimate of ef-
fect. Previous acute stroke trials have used global tests to assess the
overall effect of treatment on a group of outcomes: NINDS and IM-
AGES (the National Institute of Neurological Disorders and Stroke RT-
PA trial and the Intravenous Magnesium Efficacy in Acute Stroke trial;
Wald test for binary outcomes) and CARS (Cerebrolysin and Recovery
After Stroke trial; Wei-Lachin test for ordinal and continuous out-
comes). Transdermal GTN is a candidate treatment for ultra- and
hyper-acute stroke, potentially acting through reperfusion, haemo-
dynamic and cytoprotectant effects.
Methods
The global effects of ultra- or hyper-acute administration of GTN
were tested using three statistical approaches: the Hotelling T2
test (combines continuous variables), and Wei-Lachin and Wald
tests. Analyses using ordinal logistic regression and multiple lin-
ear regression were also performed to test the individual effects
of GTN on each outcome. Raw (and dichotomised) outcome data
at 90 days included telephone assessments of dependency (modi-
fied Rankin Scale, MRS >2), disability (Barthel index, BI < 60),
mood (short Zung depression scale, ZDS > 70), cognition (t-Mini
Mental state examination, tmmse < 14) and quality of life (health
utility status, HUS < 0.5, as derived from euroqol-5D-3 level). Data
are odds ratio (OR), mean difference (MD), Mann–Whitney esti-
mates (MW) and T2 statistic.
Results
312 patients (GTN 168, no GTN 144) were randomised within 6 hours
of ictus into ENOS-early (n = 273) and RIGHT (n = 39). GTN improved
certain individual and global outcomes for both the ENOS-early and
RIGHT trials respectively: Individual tests MRS: OR 0.55, (p = 0.0055);
0.27, (p = 0.0306) BI: MD 13.5, (p = 0.0029); 25.4, (p = 0.0724) ZDS: MD
−10.3, (p = 0.0013); −14.3, (p = 0.0631) tmmse: MD 3.5, (p = 0.0007);
4.3, (p = 0.1151) HUS: MD 0.09, (p = 0.0753); 0.21, (p = 0.0618) Global
tests Hotelling T2: T2 24.91, (p = 0.0087); 9.85, (p = 0.1763) Wei-Lachin:
MW 0.64, (p = 0.0018); 0.73, (p = 0.0301) Wald: OR 0.52, (p = 0.0011);
0.38, (p = 0.0826).Conclusions
GTN improved global aggregates of dependency, disability, mood,
cognition and quality of life data. This exploratory finding is being
tested prospectively in the ongoing 850-patient RIGHT-2 trial. Though
individual test results for RIGHT suggest that GTN only had a signifi-
cant effect on dependency (MRS), global analysis of the data (using
the Wei-Lachin test) suggested that GTN improved all outcomes.
Reporting global tests adds summary information on overall treat-
ment effects. Further, it may be advantageous to base the primary
outcome on a global analysis since global tests are statistically more
efficient; in this case, individual outcomes would be presented in
pre-specified secondary analyses. The Wei-Lachin test may be pre-
ferred since it allows analysis of ordinal and continuous variables; in
contrast, the Wald test only analyses binary outcomes, and the Hotel-
ling T2 test does not take account of direction of effect.
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Background
Due to major advances being made in clinical trials for prevention of
cardiovascular events (including stroke and transient ischaemic at-
tack, TIA), and the falling risk of recurrent events, cardiovascular pre-
vention trials are increasing in size. Since the number of trials has
also increased, it is becoming more difficult to recruit patients into
new trials. New strategies are now needed to reduce trial sample
sizes and to amplify the potential to demonstrate benefit. The inter-
national Triple Antiplatelets for Reducing Dependency after Ischae-
mic Stroke (TARDIS) trial assessed the safety and efficacy of intensive
(combined aspirin, dipyridamole and clopidogrel) versus guideline
(aspirin/dipyridamole, or clopidogrel alone) antiplatelets given for
one month in patients with acute stroke or transient ischaemic attack
(TIA).
Design
Vascular prevention studies typically count outcomes as dichotomous
events (e.g. Event vs no event) although this is inefficient statistically
and gives no indication on the severity of the recurrent event. Recur-
rent vascular events, such as stroke, could therefore be polychoto-
mised with ordering of outcome events determined by severity. A
retrospective analysis of published vascular prevention trials (includ-
ing antithrombotic, antihypertensive, lipid lowering, carotid surgery,
and hormone replacement therapy) suggested that polychotomised
outcome measures provide information on both events and their se-
verity, generate smaller numbers-needed-to-treat, and may be more
efficient statistically.
Methods
In the context of acute stroke trials, the modified Rankin scale (MRS)
is often used as the primary outcome measure, due to its sensitivity
to treatment effects. The MRS is a seven level ordered categorical
scale (0: No symptoms, 1: No significant disability, 2: Slight disability,
3: Moderate disability, 4: Moderately severe disability, 5: Severe dis-
ability, 6: Death) that assesses independence, dependency and death.
The primary objective of the TARDIS trial was to assess treatment ef-
fect on recurrence and severity of that recurrence at 90 days. There-
fore, the primary outcome consisted of a combination a) the type of
recurrent event (stroke or TIA) and b) the score from the MRS taken
at three months. This produced a six level ordered categorical poly-
chotomised scale with the following structure; Fatal stroke (MRS =6)/
Severe non-fatal stroke (MRS =4 or 5)/Moderate stroke (MRS =2 or
3)/Mild stroke (MRS =0 or 1)/TIA/No recurrent event. The assessment
of this primary outcome measure utilised the shift approach, with
the use of ordinal logistic regression analysis.
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The TARDIS trial was the first vascular prevention trial to assess pro-
spectively both recurrence and its severity, rather than recurrence
alone. This novel approach both increases statistical power through
comparing the difference in the distribution across the whole scale
of severity between the treatments, and allows the effect of treat-
ment on severity to be assessed. Such an approach can reduce trial
sample size and ultimately costs, whilst improving statistical effi-
ciency and amplifying the potential to demonstrate a treatment ef-
fect. Data will be presented once the main findings have been
presented in late 2016.
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Background
Stratification of patients into high- and low-risk categories using a
cutpoint for a continuous prognostic variable has important applica-
tions in clinical decision making. Different approaches including bio-
logical determination, median value, and clustering as well as using
correlative measures such as logrank test, minimum p-value, hazard
ratio, and log-likelihood have been used to determine the cutpoint.
Here we try to choose the most reliable correlative measure using
Monte Carlo simulation. We also apply the chosen measure to bio-
logical data (androgen receptor [AR] gene copy number) from
castration-resistant-prostate-cancer (CRPC) patients where it is as-
sumed, based on previous studies, that AR-gain (higher number of
copies of AR) patients have higher hazard rates of survival than AR-
Normal patients.
Methods
Assuming log-hazard-ratio is a logistic function of continuous prog-
nostic variable, the midpoint of the sigmoid curve (x_mp) would be
a natural choice for the cutpoint. 100,000 survival datasets were gen-
erated via Monte Carlo simulations using R language. Each simulated
dataset included 200 observations (x) with exponential distribution
(similar to the number of the patients and the distribution of AR-
copy numbers in the trial) and log-hazard-ratio (y) as a logistic func-
tion of x. Parameters of the steepness of the curve and location of
the midpoint (x_mp) were randomly assigned in each run. For every
simulated dataset, the best cutpoint was sought via the following it-
erative steps: (i) assigning 0 to all observations below copy number
x_i and 1 to all observations equal to or above copy number x_i, (ii)
fitting Cox model (for x_i), (iii) using the maximum values of the sta-
tistics of survival modelling including Hazard Ratio, Log-Likelihood -
or Cox-Snell Pseudo-R-Squared (RSQ) -, Concordance Index, Wald-
test, and Log-Rank-test as indicators (correlative measures) of the
cutpoint, (iv) calculating the difference between the cutpoints sug-
gested by each correlative measure and the true cutpoint (x_mp).
Altogether, six sets of 100,000 differences along with their medians
and interquartile ranges (IQR) were estimated. The statistical measure
associated with the smallest absolute median and IQR was chosen as
the best correlative measure. The chosen measure was used in the
trial data to determine the optimal cutpoint for AR-copy number. We
also used bootstrapping to increase reliability of the estimated cut-
point in the trial data.
Results
Median and IQR of the differences between true cutpoint (x_mp)
and the the copy numbers indicated by the highest values of Hazard
Ratio, Concordance Index, Wald test, Log-Rank, RSQ, and Log-
Likelihood were −13.39 (45.38), −3.13 (5.32), −3.10 (3.60), −2.82 (3.43),
−2.06 (3.24), and −2.06 (3.24), respectively. Consistent results were
also observed using simulated AR-copy numbers with normal distri-
bution. Thus, Log-Likelihood (or interchangeably RSQ) was chosen as
the recommended correlative measure and was used to determinethe optimal AR-copy number cutpoint for stratification of CRPC
patients.
Conclusion
Among various statistical measures of survival, Log-Likelihood is the
best correlative measure for estimating optimal cutpoint of a con-
tinuous prognostic variable with normal or exponential distribution.
Wald and Log-Rank tests are slightly less reliable and Hazard Ratio is
the least reliable correlative measure.
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Background
Approximately 60,000 patients annually undergo resection for non-
small cell lung cancer (NSCLC) in the US. Most of them will not
achieve long-term survivorship and the status of nodal involvement
is the most powerful determinant of prognosis. Accurate pathologic
nodal staging requires the combination of surgical dissection of the
appropriate hilar and mediastinal lymph nodes and thorough patho-
logic examination of lymph modes present within the lung resection
specimen. S1700 or SILENT (Strategies to Improve Lymph Node
Examination of Non-Small Cell Lung Tumors), a trial proposed by
SWOG, is designed to evaluate a lymph node specimen collection kit.
It is anticipated that this simple intervention on how the surgeon
does his/her lymph node sampling, will improve the accuracy of
pathologic nodal staging of resected lung cancer. It was determined
that a cluster randomized trial (CRT) design is necessary to address
this question. Conduct of a CRT is rarely done (to almost never) in
the Cooperative Groups within the US.
Methods
Institutions will be randomized to implement the intervention versus
usual care. Randomization will be stratified by institution characteris-
tics (3 factors: institutional volume, thoracic surgery fellowship train-
ing program, dedicated general thoracic surgeon present). In order
to randomize all institutions at the same time, a run-in phase will be
implemented to allow for sites to obtain institutional and regulatory
approvals. In addition, objectives of the run-in phase are to provide a
more accurate assessment of local accrual and preliminary estimates
of outcomes. The primary objective of this study is to compare the 3-
year disease free survival (DFS) among patients at institutions ran-
domized to implement the intervention to those randomized to
usual care. The secondary objective is to compare the frequency of
patient up-staging (from cn0/1 to pn1/2/3) following surgical resec-
tion among patients receiving intervention to those receiving usual
care. Given feasibility considerations, the planned goal is to limit par-
ticipation to 40 institutions (20 randomized to implement the inter-
vention and 20 to continue with usual care). Given historical data, it
is estimated that the intraclass correlation coefficient is 0.01. Sample
size calculations were based on Xie & Waksman. (Stat Med. 2003 Sep
30;22(18):2835–46).
Results
The study design is based on a design with 80% power to detect a
50% improvement in DFS (HR =0.67) at the 1-sided 0.025 level. We
assume uniform accrual and an average accrual rate of 15 patients/
site/year. Under independence, the total sample would be 568. Ac-
counting for within institution correlation, the total accrual is 670 pa-
tients (an inflation of 18%), accrued over 2 years with 3 years of
follow-up.
Discussion
In an era of increasing costs for cancer care, low-cost and relatively sim-
ple interventions such as the one being evaluated in SILENT are very
valuable. Careful consideration of design and implementation can lead
to a valuable resource and address an important yet simple question.
Trials 2017, 18(Suppl 1):200 Page 83 of 235P220
An assessment of the design and dissemination of phase I clinical
trials: where can we improve?
Bethan Copsey1, Ayodele Odutayo2, Jonathan Cook2, Susan Dutton2,
Douglas Altman2, Sally Hopewell2
1University of Oxford; 2Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences, University of Oxford
Correspondence: Bethan Copsey
Trials 2017, 18(Suppl 1):P220
Background
Phase I trials involve the early testing of investigational medicines in
humans in order to assess their safety, tolerability and pharmacokin-
etics. Questionable design and conduct of phase I trials has led to
long-term morbidity and mortality. There is limited information pub-
licly available regarding how these trials are conducted, monitored
and disseminated. A systematic methodological review of the ethical
submission for phase I trials was carried out to address this gap.
Methods
A representative sample (n = 426) of clinical trial protocols that re-
ceived ethical approval by the UK Health Research Authority (HRA) in
2012. We extracted details related to study design and methods from
the protocols on phase I studies. Additionally, information on serious
adverse events (SAEs) from submitted clinical study reports (CSRs)
and searched for publications (by April 2016) of the completed trials
was collated. Findings were narratively summarised.
Results
Of the 426 HRA-approved trial protocols, 54 were phase I trials (17
oncology; 37 non-oncology). Forty-five (83%) were industry funded
and 17 (31%) were first-in-human studies. All trials were registered in
a trial registry, although registry details were publicly available for
only 21; as per EU regulations. Across the included studies there
were 869 participants; the median sample size was 27 (interquartile
range 18 to 41).
Of the first-in-human studies, 13 specified an observation period be-
tween administration of the study drug to the first and subsequent
participants. Only one study provided justification for this observa-
tion period. Thirteen first-in-human studies used biological agents
but only 5 of 13 used the MABEL (minimum anticipated biological ef-
fect level) for calculating the starting dose or justified not doing so.
Of the 54 phase I trials, 32 have been completed and 24 submitted
CSRs to the HRA as of April 2016. No deaths occurred but 11 SAEs
were reported, of which 3 were deemed potentially related to the
study treatment. All treatment-related SAEs occurred in non-
oncology trials.
After a median 2.7 years since completion, only 3 of the 32 fully com-
pleted phase I trials have been published and only 10 of these 32 tri-
als have a publicly accessible trial registry entry. None of the trials
with SAEs have been published.
Discussion
These findings suggest that phase I trials are generally safe, however
there are important opportunities to improve the design, conduct
and dissemination of these studies. Methodological gaps exist which
should be addressed when planning phase I trials, particularly for
dose escalation studies. Much greater transparency through the
public registration and dissemination of findings from phase I trials
is needed to improve the safety and conduct of future studies.
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Background
Sample size must be determined when one start any prospective
study regardless of it is intervention or observational. The recentpopularity of propensity score rapidly increases its application in pro-
spective observational studies with time-to-endpoint in various areas
including cancer or cardiovascular disease and some would expect it
as an alternative of confirmatory trials. However, a limited number of
papers have discussed sample size calculation. We proposed practical
sample size re-estimation in mid-course of the study. The approach
provides not only statistical power but also the incorporating with in-
terim analysis which have to adjust type I error.
Background
There is a couple of issues in practice. One of issues is that it de-
pends on the distribution of propensity score. The score is usually es-
timated by logistic regression. However, it is not easy to assume
prior to commencing the study. Another one is that some factor
which has association with treatment selection but is not correlated
with endpoint decrease the precision of confidence interval for the
estimate of treatment effect. As result, it leads to decreasing statis-
tical power of test as previous report warned. However, identifying
these factors to be excluded would contradict the nature of propen-
sity score analysis which collects data not to miss confounding fac-
tors as much as possible. Furthermore simple stratified analysis, ex
Cox regression, is enough if it is possible to identify these factors in
advance.
Methods
We assume the situation that one would assess the new treatment
compared to the standard one. Calculate the sample size tenta-
tively if one assumes alpha level, power and an effect size delta. If
time to event is a primary endpoint, expected number of events is
determined by the method of Schoenfeld and the variation. Esti-
mate propensity score when the sample size or the number of
events reaches tentative sample size or expected number of events.
Use stratified logistic or stratified Cox model to estimate the param-
eter of the effect size. Calculate the inflation coefficient - Which is
defined as follows = (Observed Standard Error)^2/(1/(_1 × _2 × D))
where _1,_2 are the fractions of each treatment group and D is the
tentative expected number events for time to event. =(Observed
Standard Error)^2/(Assumed Variance) for binary endpoint. Calcu-
late the target sample size or the number of events as a product of
inflation coefficient - and tentative sample size or the number of
events. Do the interim analysis ad Information time as 1 if one
would like to plan. If the interim analysis is not significant or one
has not done it, do the final analysis.
Results
The operational characteristics concerning the statistical power for
various scenarios in which there is no correlation between the factor
of treatment choice and endpoint were examined by the simulation
study. The result guaranteed the statistical power as planned.
Conclusions
Our approach keeps the statistical power without any assumption of
propensity score including the distribution and the correlation be-
tween the endpoint and the factors of the treatment choice.
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Objective
To explain, demonstrate and compare methods for evaluating perso-
nalised treatment recommendations using a standard, two-arm, par-
allel randomised controlled trial.
Background
The modern paradigm of stratified medicine (also termed persona-
lised or precision medicine) seeks to move beyond a one-size-fits all
approach, that treats patient populations as a whole, towards one
that identifies patient strata with different disease pathways or re-
sponses to treatment. A major aspect of stratified medicine is to pro-
vide personalised treatment recommendations (PTR’S): an algorithm
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ment response using biomarkers, a patient’s measureable characteris-
tics collected at clinical visit. A PTR may be constructed using a
single biomarker, or using multiple biomarkers. After estimating a
PTR, the next step is to assess whether the expected outcome under
a PTR improves on the expected outcome under an alternative policy
– one where either everybody receives the treatment or everybody
receives the control condition. The evaluation of a PTR differs from
the evaluation of prognostic or diagnostic models because, for any
individual, the object of inference (whether a subject benefited from
treatment) remains unobserved. This is because the individual treat-
ment effect cannot be separated from prognostic effects. Therefore
standard methods of model evaluation, for example ROC-curve ana-
lysis, are inappropriate in this context.
Methods
This presentation will cover two methods for evaluating a PTR using
a standard, two-armed randomised controlled trial. The first, termed
the inverse probability weighting (IPW) approach, uses a weighted
average of the outcome in those lucky to have been randomised to
the treatment they were recommended under the PTR. The second
is an augmented version of the IPW (AIPW), developed using semi-
parametric theory, that borrows information from a regression model
for the outcome under treatment or control, to establish a more effi-
cient estimator. Monte-Carlo simulations are used to compare the
statistical properties of the IPW and AIPW methods using a range of
data generating scenarios. These methods will be demonstrated with
application to data from a randomised controlled trial for Chronic Fa-
tigue Syndrome Patients, using the user-written Stata command
ptr.ado. Inference for these parameters will also be discussed.
Results
Simulations demonstrate that the AIPW method is consistently
shown to be more efficient, even when the parametric model for the
outcome used in the AIPW procedure is misspecified.
Conclusions
The evaluation of a PTR is qualitatively different from the evaluation
of a model used for diagnosis or prognosis. There are two methods
available for establishing whether the outcome under a PTR is an im-
provement (or not) on an alternative policy where everybody is given
the treatment/control conditions. These methods are easily imple-
mented in standard statistical software; for example using our user-
written Stata command ptr.ado. Of the two methods, the AIPW is
demonstrably more efficient than the IPW.
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The Lung- MAP trial (Lung Cancer Master Protocol), launched in
2014, is an umbrella protocol to evaluate targeted therapies in bio-
marker selected patients for previously-treated stage IV or recurrent
non-small cell lung cancer. It is the first precision medicine trial
launched with the support of the National Cancer Institute in the
United States. Moreover, Lung-MAP is designed as a pathway for
FDA approval of investigational therapies that successfully meet
study objectives.
Lung-MAP activated with 4 biomarker-driven sub-studies and one
sub-study for patients with no matching biomarkers; all sub-studies
were randomized with docetaxel as the control in 4 of 5 sub-studies.
While the standard of care (docetaxel) had been unchanged for de-
cades in this patient population, within the first year of the study,
the Checkmate 017 trial (Brahmer NEJM 2015), demonstrating that
nivolumab is superior to docetaxel in this patient, changed the treat-
ment paradigm for this population.
In December 2015, a major revision of the trial was implemented
with modifications to the patient population and design of thebiomarker-driven sub-studies in response to the approval of im-
munotherapies in our study population. As of November 3, 2016, 4
sub-studies have been closed to accrual, 1 new non-match sub-study
has been activated, 1 new biomarker-driven sub-study is expected to
open to accrual by the end of 2016, 1 new non-match sub-study for
immune-therapy (IO) exposed patients is expected to activate in the
first quarter of 2017, and an additional biomarker-driven sub-study is
expected to be activated mid-2017. The anticipated study schema is
included below.
The Lung-MAP trial is a continually evolving study. The study team
continues to evaluate new biomarker/investigational therapy pairs,
including immunotherapy drugs and biomarkers, and combinations
of therapies. Conduct of such a study requires a substantial amount
of effort and on-going attention beyond the conduct of a stand-
alone clinical trial. This presentation will provide an overview of the
current status of Lung-MAP, both active and closed studies, discuss
some lessons learned in the conduct of these so-called platform
trials, and a view into the future of Lung-MAP.
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Background
Performance bias arises from unintended deviations from the
intended intervention, comparator or co-interventions that occur
differentially by allocated group. Conventionally, it can be re-
duced through blinding of healthcare providers and patients;
however, this represents a major challenge in surgical settings
and other strategies are therefore required. Standardisation of
surgical intervention and co-interventions, and monitoring adher-
ence to these standards, represents one solution for reducing
performance bias. The aim of this study, therefore, was to sys-
tematically explore the issue of performance bias in randomised
controlled trials in surgery, to inform the design and delivery of
future studies.
Methods
In order to explore the issue of performance bias in depth, a narrow
clinical field (appendicitis) was selected. Rcts evaluating at least one
surgical intervention (defined as procedures that cut a patient's tis-
sues, involving the use of a sterile environment, anaesthesia, antisep-
tic conditions, surgical instruments, and suturing or stapling) for
patients with appendicitis were identified. Because there is no formal
tool for assessing performance bias, information from existing litera-
ture relating to various aspects of performance bias was used to
guide data extraction: i) blinding (Cochrane Risk of Bias tool), ii)
standardisation (CONSORT-NPT and SPIRIT statements). An inductive
approach was used, whereby an initial extraction form was used and
where new themes relating to performance bias were identified, the
form was modified to incorporate these and all trials reviewed using
the new form.
Results
45 rcts met the inclusion criteria. Six compared surgical and non-
surgical treatments, and 39 compared different surgical ap-
proaches (open versus laparoscopic surgery, n = 35; laparoscopic
versus single-port surgery, n = 4). In the six RCTs comparing surgi-
cal and non-surgical treatments, blinding of participants was not
undertaken and there was no information relating to healthcare
professionals or trial personnel. In the 39 comparing different sur-
gical procedures, information about blinding was rarely reported.
Eight, seven, and five studies reported that blinding of partici-
pants, healthcare professionals and trial personnel was attempted,
respectively. Just one RCT reported that the success of blinding
was evaluated. Data extraction and analysis is ongoing and fur-
ther results (relating to standardisation) will be available for pres-
entation at the conference.
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Preliminary results from this study indicate that surgical RCTs are
likely to be at high risk of performance bias. Although blinding of
surgeons performing operations was not possible in this clinical area,
blinding of patients, other healthcare professionals and trial
personnel was plausible yet rarely undertaken. This may be because
existing guidance is difficult to apply in a surgical setting. A potential
solution would be to improve the process of quality assurance in rcts,
by i) clearly defining interventions and co-interventions, ii) standar-
dising their delivery, and iii) careful monitoring and reporting of ad-
herence to these standards. Further work is required to explore how
this might be achieved in surgical RCTs.
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Background
Randomized controlled trials (RCTs) are considered the gold standard
to assess the efficacy and safety of new treatment interventions and
compare conventional therapies. RCTs are used to support decision-
making, and guidelines recommendations. However, despite their
clinical importance, RCTs have some limitations as they are at high
risk for bias, can over and/or underestimate treatment interventions,
which limit their generalizability. It's estimated that poor quality trials
have led to 30% - 40% overestimation of the treatment. Therefore,
the quality of reported RCTs is still questionable and multiple studies
have concluded that RCTs are yet hindered by several limitations
making risk-benefit assessment, which is an essential element for
RCTs quality, a challenge in certain medical conditions for healthcare
professionals. With the largely emerging data and new treatments
that required pharmaceutical companies to do more RCTs, the need
for assessing the quality of RCT becomes increasingly important. The
Consolidated Standards of Reporting Trails (CONSORT) statement is a
tool designed to assess the quality of RCTs reported and significantly
improve the quality of RCTs. To our knowledge there is no current
data in the literature regarding the quality of RCTs conducted in
Saudi Arabia (KSA). Given the increasing number of RCTs being con-
ducted in the region, it is essential to gain an understanding on the
quality of reporting of these RCTs, which might impact future regula-
tions for conducting such studies in the country.
Objective
To assess the reporting quality of RCTs conducted in KSA from 2005
and above using the CONSORT tool.
Method
Electronic search of the following databases: Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), EMBASE, MEDLINE via Ovid will beconducted. An attempt to identify unpublished data by searching
clinical trial registries, through clinicaltrails.gov, and the Saudi Food
and Drug Administration (SFDA) registry will be conducted. The
search strategy will contain a combination of mesh terms and key-
words relevant to the study design. Identified RCTs will be exported
to Endnote X7 to check and remove any duplication. All titles and
abstracts of identified RCTs will be screened by two investigators for
potential relevance. Reference lists of potential studies, systematic re-
views and meta-analysis will be also reviewed manually to identify
relevant original RCTs. Search will be limited to RCTs either phase II,
III and IV, published in 2005 and above in both English and Arabic
language. Studies conducted in KSA as part of international multicen-
ter RCTs, non-therapeutical RCTs will be excluded. The protocol of
this study was submitted for publication to the International pro-
spective register of systematic reviews PROSPERO.
Results
Pending
Discussion
This study will assess the quality of reporting of RCTs conducted in
KSA given the increasing number of RCTs being conducted in the re-
gion and the limited data in the literature regarding the quality of
RCTs reporting conducted. Findings achieved from this STUDY might
help in identifying CURRENT strengths and gaps that may impact the
Good Clinical Practice in the clinical setting in KSA.
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Background
The goal of this study was to compare confounding effect of patient
population characteristics on the comparative effectiveness of indi-
vidual antiembolic interventions in non-valvular atrial fibrillation (AF):
novel oral anticoagulants (NOACs) (apixaban, dabigatran, edoxaban,
rivaroxaban), vitamin K antagonists (VKA), aspirin, and the Watchman
device.
Methods
We performed network meta-analysis of randomized clinical trials
(RCTs) that enrolled 200 patients with non-valvular AF, mean or me-
dian follow-up Six months, with published reports in the English lan-
guage. NOAC phase II studies were excluded. Placebo/control arm
received either placebo or no treatment. All-cause mortality served
as the primary outcome. Results of unadjusted and adjusted meta-
regression analyses were compared. The following confounders were
included, one-by-one: time in therapeutic range (TTR), CHADS2 score,
mean/median duration of follow-up, mean age, the percentage of
males, the percentage of VKA-naïve, the percentage of secondary
prevention patients.
Results
A total of 21 RCTs (96,017 non-valvular AF patients; median age 72y;
65% males; median follow-up 1.7y). In unadjusted analysis, in com-
parison to placebo/control, use of aspirin (OR 0.82 (95%CI 0.68-0.99)),
VKA (OR 0.69 (95%CI 0.57-0.85)), apixaban (OR 0.62 (95%CI 0.50-
0.78)), dabigatran (OR 0.62 (95%CI 0.50-0.78), edoxaban (OR 0.62
(95%CI 0.50-0.77), rivaroxaban (OR 0.58 (95%CI 0.44-0.77)), and the
Watchman device (OR 0.47 (95%CI 0.25-0.88)) significantly reduced
all-cause mortality. Apixaban (OR 0.89 (95%CI 0.80-0.99)), dabigatran
(OR 0.90 (95%CI 0.82-0.99)), and edoxaban (OR 0.89 (95%CI 0.82-
0.96)) reduced risk of all-cause death as compared to VKA. Life-
saving effect of Watchman device and NOACs was supported not
only by 95% confidence intervals (CIS) but also, importantly, by 95%
probability intervals (PRIs). However, 95% PRI for aspirin crossed the
‘no effect’ line, indicating that life-saving effect of aspirin might not
be confirmed in future RCTs if ever conducted. After adjustment for
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CHADS2), no antiembolic intervention was statistically significantly
better than placebo/control, and there was no significant difference
between VKA and NOACs, or other antiembolic interventions. Conclu-
sion: Adjusted meta-regression analysis allows to study confounding
effects of RCT population characteristics on results of network meta-
analysis.
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Background
Systematic reviews of randomised controlled trials provide the best
evidence on the benefits and harms of healthcare interventions.
However, trials within meta-analyses are often affected by varying
amounts of internal bias caused by methodological flaws. Currently,
there is no consensus over how to make allowance for biases in
meta-analysis. Two methods for adjustment for within-trial biases in
meta-analysis have recently been proposed. The first uses empirical
(generic) evidence on the magnitude of biases observed in a large
collection of meta-analyses; the second uses expert opinion informed
by detailed assessment of the potential biases affecting each trial.
The objectives of this research are to investigate the extent to which
these two approaches agree, and to explore how they could be inte-
grated in order to gain the advantages of both.
Methods
To investigate agreement between generic evidence and detailed
trial assessment, we asked three assessors with access to summary
trial descriptions to rank pairs of trials from 30 sampled meta-
analyses according to severity of bias. We compared the assessor
rankings to rankings based on a bias model fitted to the sampled
meta-analyses. Analyses were performed for biases associated with
sequence generation, allocation concealment and blinding. Subse-
quently, we explored methods for bias adjustment based on bias dis-
tributions derived from generic evidence, detailed trial assessment or
combinations of the two. Generic distributions were derived from a
hierarchical model fitted to 64 meta-analyses from the Cochrane
Database of Systematic Reviews. Opinion-based distributions were
averaged across 12 assessors who read summary information on
each trial in a new meta-analysis, and independently gave their opin-
ions on bias. We developed three different approaches to combine
generic evidence with detailed trial assessment. The first method sta-
tistically combines the generic and opinion-based bias distributions.
In two alternative methods, assessors are provided with generic bias
distributions and summary trial information, and asked to give their
opinion on where in the distribution the particular trial might lie (nu-
merically or by selecting broad areas of the distribution). In two case
study meta-analyses, we adjusted for bias according to the set of dis-
tributions derived using each of the three approaches.
Results
Good agreement was observed between data-based and opinion-
based approaches to ranking pairs of trials according to risk of bias.
Among the assessor opinions judging that one trial was more biased,
the proportion that agreed with the ranking based on evidence-
based fitted biases was highest for allocation concealment (79%) and
blinding (79%) and lowest for sequence generation (59%). In an ex-
ample meta-analysis, bias-adjustment based on generic evidence
had the effect of shifting the intervention odds ratio towards the null
by 28%, and between-trial variance reduced substantially by 56%. Ex-
pert opinions have been obtained recently and the final bias adjust-
ment results based on these are pending.
Discussion
Adjustment for biases is useful in meta-analyses synthesizing all
available evidence. We recommend an integrated approach to biasadjustment, informed by both available generic evidence and elicited
opinion. Choice of integrated approach may be based on the prefer-
ences of the systematic review authors.
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Background
Online registration of trial protocols has been implemented to sup-
port transparency and good clinical practice for the conduct of a trial.
One aspect is to ensure that the primary outcome is pre-specified
prior to any data being collected and interim analysis performed.
This is to discourage the outcomes being selectively chosen for
reporting based on significant p-values. We aimed to examine the
status of randomised clinical trials (RCT) whose primary outcome
changed between protocol registration and published paper, and to
quantify the impact of this change on the resulting treatment effect
estimates.
Method
We searched registered RCT from Medline and EMBASE between
2011 and 2015 and randomly selected 5% of searched articles for
each year. Articles were excluded if they are not RCT or trials with
multiple primary outcomes. For each included trial, we collected in-
formation on the primary outcome reported in the article and in the
registered protocol. Trials were classified as having a changed pri-
mary outcome if there was an inconsistency between the registered
and published outcome. Additional information on effect size, type
of outcome, type of study design, post-randomisation exclusions
were extracted. For consistency, we inverted the effect estimates
where necessary so that each trial indicated an odds ratio less than 1
(where the active group has more favourable result than the control
group). The relative odds ratio (that is, the summary odds ratio for
trials with a primary outcome change divided by those without) was
calculated and a value less than 1 indicated larger treatment effects
in trials with changed primary outcome compared to trials whose pri-
mary outcome was the same between the protocol and final
publication.
Results
Among 29,749 searched articles (Medline: 28,810, EMBASE: 939),
1,488 articles were selected in this study. Of the 487 eligible tri-
als, 63 (12.9%) published articles were reported with no or an un-
clear description of primary outcome. 21(4.3%) studies were
registered with no or an unclear description of primary outcome.
75 (15.4%) trials were registered after the completion of the
study. Among the remaining trials with primary outcome clearly
registered and reported, 29.0% (95/328) showed some discrepan-
cies in primary outcome between trial registration and published
article. Further excluding 33 trials due to uncalculated data, there
were 295 trials that could be included in the bias assessment
and we found a clearly larger intervention effect (pooled ratio of
odds ratios 0.79 (95% confidence interval 0.68 to 0.91), p =
0.0012) among trials with changed primary outcome compared to
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consistent after adjustments for type of outcome, type of study
design, post-randomisation exclusions, and variance of log odds
ratio (0.79 (0.69 to 0.92), p = 0.0019).
Conclusion
Trials that deviated from the originally registered outcome showed
larger intervention effects than trials whose primary outcome was
unaltered from the original protocol registration. This highlights the
important role of trial registration prior to the initiation of trial and
the need for clear specification of the primary outcome.
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Advanced Automatic Crash Notification (AACN) systems aim to re-
duce both over- and under-triage from motor vehicle crashes (MVC)
by using vehicle telemetry data to predict risk of serious injury and
thus aiding first responders in the triage decision making process.
Reducing under-triage (UT) translates into transporting severely in-
jured occupants to a level-I or II trauma center (TC) and reducing
over-triage (OT) means transporting occupants with lesser injuries to
a non-trauma center (non-TC). Treating more severely injured occu-
pants initially at tcs reduces death and disability, and treating occu-
pants with minor injuries at non-tcs leads to better hospital resource
utilization and decreased healthcare costs.
In order to estimate the need for transport to a TC or non-TC,
current AACN systems model the risk of severely injured occupants
using injury severity scores (ISS) as the outcome. ISS are a well-
known measure based on the Abbreviated Injury Scale (AIS) coding
lexicon where occupants with ISS > = 16 indicate severe injuries re-
quiring treatment at a TC, while ISS < 16 may be treated at a non-
TC. Our group has developed an AACN algorithm, the Occupant
Transportation Decision Algorithm (OTDA), using an injury-based
approach rather than AIS severity alone. We have identified three
facets of injury that contribute to need for treatment at a TC: sever-
ity, time sensitivity and predictability. Severity is a measure of an
injury’s mortality, time sensitivity quantifies its urgency and predict-
ability is its likelihood of being missed upon evaluation by first re-
sponders at the scene. These three components are then jointly
optimized to create a list of 240 injuries, each with a yes/no indica-
tor of being on the Target Injury List (TIL). We believe that the TIL
gives a better picture of the extent of injury severity and need of
treatment at a TC or non-TC.
The OTDA was implemented using data from National Automotive
Sampling System-Crashworthiness Data System 2000–2011, which in-
cluded 38,970 cases. The OTDA uses multivariable logistic regression
to predict the risk of an occupant sustaining an injury on the TIL for
specified crash conditions. In addition to using an injury-based ap-
proach for modeling the risk of severely injury occupants, another
novel feature of the OTDA compared to other AACN systems is that
the OTDA uses a genetic algorithm to optimize each of the compo-
nents and determines the risk threshold for the decision to transport
to a TC or non-TC. The goal of the optimization was to minimize UT
and OT, ideally producing UT rates < 5% and OT rates < 50% as rec-
ommended by the American College of Surgeons (ACS).
Results of the OTDA produced UT rates ranging from 3-16% depend-
ing on the crash mode and OT rates meeting the ACS 50% recom-
mendation. The OTDA also showed improved UT rates compared to
other AACN algorithms in literature. We believe the OTDA will aid
emergency personnel to make the correct triage decision for an oc-
cupant after a MVC. With nation-wide implementation, we estimate a
potential benefit of improved triage decision-making for 165,000 oc-
cupants annually.P232
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The AIDS Malignancy Consortium (AMC) is a National Cancer Institute
supported multicenter clinical trials group founded in 1995 to sup-
port innovative trials for AIDS-related cancers. In 2010 the AMC ex-
panded operations internationally and opened 4 sites located in sub-
Saharan African countries with a high prevalence of HIV. The goal of
this expansion was to build a cancer clinical trials network in sub-
Saharan Africa (SSA) that was capable of conducting contextually
appropriate therapeutic and prevention trials in a variety of HIV-
associated cancers and contributing to the AMC’S scientific agenda.
The AMC Operations and Data Management Center (AMC ODMC)
provides data management and site management support for both
domestic and international AMC trials. Over the past 7 years, the
AMC ODMC has supported 3 trials in SSA and identified a number
challenges to trial implementation and activation.
The key challenges the AMC ODMC faced in implementing these
trials included identifying research priorities, developing multicenter
trials that are appropriate across a diverse group of trials sites, con-
ducting clinical research trials within the public healthcare system, in-
adequate infrastructure, availability of qualified staff, and identifying
and addressing site logistical barriers such as drug and supply needs.
Furthermore, the importance of supporting capacity-building activ-
ities such as training of health care staff at the research sites is part
of the AMC’S mandate in SSA and requires additional site manage-
ment support. Currently, there are 2 open trials and 4 trials in ex-
pected to open within the next 18 months across 7 sites in Sub-
Saharan Africa, including sites in Zimbabwe, Uganda, Kenya, Malawi,
Tanzania and South Africa. Site management lessons learned from
these trials may be applicable to other international trials and par-
ticularly relevant to those designed for implementation in developing
countries where both human and material resources may be limited.
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Background
We have recently completed recruitment to a large multicentre trial
with recruitment sites in both primary and secondary care. Opening
a recruitment site is a substantial amount of work: it requires ap-
provals to be in place; a site agreement to be signed by all parties;
site initiation/training; copies of CVs, GCP certificates and a com-
pleted delegation log to be returned to the study office; for the site
to have received a site file and study documentation; and in this
study, an estimate from the site of number eligible patients to be
invited.
As in previous studies, spreadsheets were maintained to log informa-
tion about contacts, documents returned, CVs and GCP certificates,
such that a green-light form could be populated for sign off prior to
opening the site. However, given the number of recruitment sites in-
volved, this logging of information was very time-consuming. We
reviewed our processes, and, where possible, have implemented al-
ternative processes that are likely to generate efficiencies in recruit-
ment site set-up. These are described below.
Sites opened
In total, 175 recruitment sites were identified (36 secondary care sites
and 139 primary care sites). 141 sites were opened to recruitment
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ondary care sites opened to recruitment, 31 recruited and 5 did not.
Of the 105 primary care sites opened to recruitment, 86 recruited
participants and 19 did not.
There were a number of reasons why sites did not open to recruit-
ment. The most common reason was that the site did not return
documentation to the study office (CVs, GCPs certificates, delegation
log, site agreement). A few sites actively withdrew from the study be-
fore being green-lighted due to staff changeover or perceived lack of
eligible patients.
Once opened, some sites failed to recruit any patients to the study.
Reasons for this included staff changeover and lack of eligible pa-
tients, competing priorities and eligible patients who did not agree
to take part.
Lessons learned
We identified potential for efficiencies in terms of logging informa-
tion about sites and staff. Minimal information was already logged
onto the study website (to register a site to enable randomisation
and collection of study data and to maintain appropriate website ac-
cess for site staff). For future studies, the website template has been
amended to include: (i) an additional web form to log information
about the site, including approvals in place, progress of site agree-
ment, etc.; and (ii) a web form to log information about site staff, in-
cluding CVs received, date of GCP training, along with the facility to
upload CVs/GCP certificates onto the website. In addition, the web-
site template facilitates the upload and storage of local documents.
Having such systems in place is likely to generate trial efficiencies: be
time-saving for trial office staff, recording information in a single
place and allow the green-light forms to be generated automatically;
have capacity to run regular reports (for example progress reports on
site set-up); and generate notifications for, for example renewal of
GCP training.
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Background
Within our trials unit two trials have recently been suspended, and
then restarted. While there is a fairly mature literature on early ter-
mination of studies, there is a paucity of literature about the tempor-
ary suspension of studies.
We aimed to document reasons for trial suspensions using data avail-
able on publically available registers of clinical trials (clinicaltrials.gov
and ISRCTN).
Methods
Clinicaltrials.gov define a ‘suspended’ study as a ‘study that has
stopped recruiting or enrolling participants early, but may start
again’. We searched clinicaltrials.gov for interventional studies which
had their recruitment status recorded as ‘suspended': the search was
run on 29 June 2016. ISRCTN do not have an equivalent term for sus-
pended trials. The closest term is ‘stopped’ which includes studies
that have never started along with those that have stopped prema-
turely. We searched ISRCTN for interventional studies which had their
status recorded as ‘stopped’: the search was run between 18 July
and 12 August 2016.
For each suspended trial, a code was assigned to each trial to classify
the reason for the suspension. The coding framework was developed
inductively and continually refined during the process of coding.
Results
837 trials registered on clinicaltrials.gov had their recruitment status
designated as suspended. 403 trials registered on ISRCTN were re-
corded as ‘stopped’. It was not possible to identify the reason for sus-
pension/stopping for 40% of those recorded as suspended on
clinicaltrials.gov and 8% of those recorded as stopped on ISRCTN:
either no reason was given, or the reason was not clear or ambiguous.The review of reasons for suspension identified five main themes:
drug/intervention issues (drug/intervention safety issues, drug/inter-
vention supply issues); trial evaluation (futility, review of trial/changes
to protocol); funding (funding issues); recruitment (primarily slow ac-
crual, but some cases of rapid accrual); and running of the trial (oper-
ational issues, staffing, wider organisational issues). The proportions
of trials suspended/stopped for each of these reasons differed be-
tween the two trial registers. 19% of those suspended on clinical-
trials.gov had been suspended because of drug/intervention safety
issues compared to 6% of ISRCTN. The proportions suspended/
stopped for the other reasons are: trial evaluation 29% in clinical-
trials.gov vs 18% in ISRCTN; funding 17% vs 31%; recruitment (20%
vs 36%), running of the trial (15% vs 9%).
Discussion
The observation that there are differences in the relative importance
of reasons why trials are suspended/stopped may reflect the types of
trials registered on the two registries.
A number of those registered as ‘suspended’ on clinicaltrials.gov
appeared to have been terminated early (with no intention of
restarting) or completed rather than suspended. More guidance for
those maintaining records on trial registries may aid the consistency
of recording.
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Background
Randomised controlled trials (RCTs) of therapy interventions are be-
coming increasingly common, and provide a series of challenges.
Here we discuss our experience from the PD COMM Pilot (A Pilot
Randomised Controlled Trial Of Lee Silverman Voice Treatment Ver-
sus Standard NHS Speech And Language Therapy Versus Control In
Parkinson’s Disease) trial. Problems with speech or voice are common
with people with Parkinson’s (PWP). Miller (2006) noted how changes
in communication led to increased physical and mental demands
during conversation, an increased reliance on family members and/
or carers, an increased likelihood of reduced participation and social
withdrawal. Two types of speech and language (SLT) therapy are
available to PWP: NHS SLT an individually tailored intervention of ~6-
8 sessions per local practice and Lee Silverman Voice Treatment
(LSVT) a structured set of 16 sessions over 4 weeks focussed on vol-
ume. There is little evidence that either is effective. PD COMM Pilot
examined the feasibility of a full scale trial, and to optimise the de-
sign. Intervention-based issues and solutions are discussed below.
Recruitment
as the intervention was dependent on speech and language
therapists (salts) being available to start therapy within 4–6 weeks,
bottlenecks occurred e.g. School holidays, staff turnover. Good com-
munication between the research nurses and salts was vital and sites
were allowed to pause recruitment if salts were unable to start ther-
apy within the trial timelines. While this slowed recruitment, 95% of
59 participants had received therapy by the 3 month primary end-
point. Staffing: There were a number of potential issues 1. Did the
level of experience of staff treating participants in the NHS and LSVT
arms differ? 2. Does the beliefs of the salts? Regarding patient suit-
ability for interventions or treatment preference impact the results?
3. Limited research experience of many salts. 17 therapists only saw
1 participant, 11 saw only participants in 1 arm and 8 saw partici-
pants in both. The trial provided a supportive network for salts to ex-
change information. These potential issues will be examined in more
detail in the substantive trial where an in-depth process evaluation
will also be performed.
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Does the content of the interventions change over time? The trial
kept treatment records and has explored the dose and content.
The numbers of participants randomised to each treatment arm
at individual sites were too small to test for changes over time,
however this will be examined in the substantive trial. Logistic is-
sues: Frequently the Trust providing the intervention was differ-
ent to the recruiting site. This produced a number of issues e.g.
Recognition including SFT funding is associated with recruitment
not the treatment site. Further, the catchment areas of the Trusts
may only partially overlap. In some cases, the only resolution was
for sites to only recruit from a subset of potential participants
dependent on treatment sites’ catchment area. Communication,
support and recognition of different perspectives and priorities
has built a research group that will form the basis of the sub-
stantive trial: 10 of the 11 pilot sites were happy to participate in
the substantive trial.
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Background
In November 2016, the Integrated Addendum to ICH-GCP E6 (R2) will
advise trial sponsors to develop a risk-based approach to clinical trial
monitoring. This new process is commonly known as risk based mon-
itoring (RBM). To date, a variety of tools have been developed to
guide RBM. However, a gold standard approach does not exist. This
review aims to identify and examine RBM tools.
Methods
Review of published and grey literature using a detailed search-
strategy and cross-checking of reference lists. This review included
academic and commercial instruments that met the Organisation for
Economic Co-operation and Development (OECD) classification of
RBM tools.
Results
Ninety-one potential RBM tools were identified and 24 were eligible
for inclusion. These tools were published between 2000 and 2015.
Eight tools were paper based or electronic questionnaires and 16 op-
erated as Service as a System (SAAS). Risk associated with the investi-
gational medicinal product (IMP), phase of the clinical trial and study
population were examined by all tools and suitable mitigation guid-
ance through on-site and centralised monitoring was provided.
Conclusion
RBM tools for clinical trials are a relatively new, their features and use
varies widely and they continue to evolve. This makes it difficult to
identify the “best” RBM technique or tool. For example, equivalence
testing is required to determine if RBM strategies directed by paper
based and SAAS based RBM tools are comparable. Such research
could be embedded within multi-centre clinical trials and conducted
as a SWAT (Study within a Trial).
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Objective
A primary responsibility of Data Coordinating Centers (DCC) for
multi-center research networks is tracking individual center IRB ap-
provals. In networks with high numbers of studies and clinical cen-
ters (CCs) the amount of documentation can be overwhelming and
burdensome to manage. A team of DCC programmers and coordina-
tors developed simple electronic tools and processes to fulfill this
responsibility.
Background
Since tracking approvals is intended to protect participant data
and ensure data was obtained and released to the DCC in an
ethical manner consistent with regulatory oversight, we identified
ways to innovate and simplify processes. Historically, tracking has
been done on paper involving complex filing systems; however,
technological advancements expanded options for executing this
responsibility.
Methods
Programmers developed an in-house Microsoft Access database used
to track receipt of IRB approvals for numerous studies from multiple
ccs. The custom database has capacity to monitor approval expir-
ation dates for an unlimited number of studies and ccs, and it can
generate automated reports displaying information on all docu-
mented approvals. The system has functionality to produce reports
organized by individual protocol and/or CC, as well as the ability to
highlight IRB approvals that must be renewed within the next three
months. Coordinators formalized communication procedures for col-
lecting updated approvals and informing ccs of the status of infor-
mation currently on file. We established a central email account to
which ccs submit updated documentation. Upon receipt of docu-
mentation a DCC coordinator acknowledges delivery, files documen-
tation, and enters updated information into the database. Monthly, a
DCC coordinator generates automated individual center IRB reports
and posts them to the research network private website. Ccs receive
an email notification from the DCC and can then access their center
reports through the website. Based on these reports ccs determine
what documentation must be sent to the DCC to keep their records
up to date.
Results
The development and implementation of a database increased ef-
ficiencies both for ccs and DCC s. The processes reduced the vol-
ume of email regarding IRB approvals sent to ccs. Individual
emails to ccs notifying them an approval is about to expire are
no longer necessary. Instead, a single monthly email is sent to all
ccs indicating updated IRB reports have been posted and should
be reviewed. Automated highlighting of approvals that will expire
soon has also reduced the burden on the DCC coordinators and
minimized the likelihood of oversight. The creation of a central
database and formalized procedures have streamlined internal
regulatory processes for DCC staff. If questions arise about an ap-
proval for a specific CC, DCC staff can access the database to
look up information needed.
Conclusions
Although an initial investment is needed to design a database, de-
velopment and formalization of these processes have resulted in
significant time and cost savings throughout the organization’s ten-
ure as a DCC. The flexible nature of an Access database makes it an
efficient and suitable solution for tracking a growing number of
studies in research networks that may have a fluid composition of
centers over time.
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Background
Keele Clinical Trials Unit (CTU), based within the Faculty of
Medicine and Health Sciences at Keele University, is a UK Clinical
Research Collaboration registered CTU specialising in the develop-
ment and delivery of large multicentre clinical trials testing
treatments and health services, as well as conducting large epi-
demiological studies in primary and secondary care settings. Keele
CTU supports the design, delivery and analysis of research studies.
Keele CTU works closely with the Patient and Public Involvement
and Engagement (PPIE) Team located within the Institute for
Primary Care and Health Sciences at Keele University. The PPIE
Team have a Research User Group (RUG) which consists of people
with experience of, or carers of close relatives with, long-term con-
ditions. The CTU Project Management team are pivotal in ensuring
the success of research studies and work closely with the RUG to
achieve this.
This abstract provides examples of the role and impact of PPIE in the
conduct of research and presents perspectives from the Project
Management team on PPIE contribution to the delivery of research
studies.
Methods
The RUG plays an essential role in each stage of research design and
delivery, helping to ensure that the research is ethical and acceptable
to research participants. We asked the Project Management team for
examples of the ways in which involvement of the RUG had benefit-
ted the studies they managed, and for their perceptions of the
impact the RUG had on research. Responses were collated and orga-
nised thematically to provide a description of PPIE contribution and
its impact.
Results
The RUG are involved in a variety of activities including assisting
with grant application, intervention development, document de-
sign, ethical approval, development of recruitment and retention
strategies, patient simulation, quality assurance, study monitoring
and dissemination of findings. To highlight the contribution and
impact of the RUG two specific examples are presented in this
abstract. The RUG played an active role in developing a ‘usual
care’ leaflet for a trial of an intervention for hand osteoarthritis.
Their contribution made the leaflet clear, practical and acceptable
to patients. The RUG provided valuable ideas about how to ap-
proach patients in a GP waiting room to enrol them into a study
which involved video-recording a GP consultation. They made
realistic and patient-centred suggestions for how this could be
achieved ethically.
The overall impact of the RUG involvement is captured in the follow-
ing quotes from the Project Management team: “Valuable team
members”, “Enhance research relevance”, “Unique contributions and
viewpoints”, “Patient perspectives”, “Essential role”.
Conclusions
Well managed, high quality research can provide evidence for
best practice in diagnosis, treatment, management and prognosis
to improve outcomes for patients. RUG involvement in research
design and delivery forms an integral role in the pathway which
provides the best evidence for both funders and clinicians, and
contributes to the best care for patients. The Project Manage-
ment team greatly value the views, opinions and suggestions
made by the RUG. The personal experiences of those living with,
or supporting those with, the research condition of interest,
strengthens study design and greatly enhances the research rele-
vance for the public.P239
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Background
Data collection consumes a substantial portion of the resources
used in any randomised trial. In addition to the participant
identifier, the most important data collected is the primary out-
come; it drives the sample size calculation and should be the
main focus of the research effort. Most trials also collect sec-
ondary outcomes to supplement the primary. These additional
data are often collected to monitor safety, maintain quality and
ensure regulatory and data management requirements are ful-
filled. Many trials also collect outcome data not listed in the
trial protocol.
Adding ancillary and exploratory data collection can result in a
substantial portion of a trial’s limited resources, in time, money
and participant burden, being devoted to collecting data that are
not directly linked to answering the research question. The cost
of this is not trivial: a large US study of drug trials estimated that
non-core data collection costs $3.7 billion annually. As part of the
Trial Forge initiative (a systematic approach to making trials more
efficient) here we describe our categorisation of the distribution
of data collection effort in a range of trials.
Methods
We have developed a list of 16 data categories (e.g. Partici-
pant identification, eligibility, demographics, health economics
and safety data), along with guidance on what each category
might contain. A standard operating procedure describes how
to go through a trial’s data collection forms to categorise each
collected data item. Data categorisation is done independently
in pairs, one person having in-depth knowledge of the trial,
the other independent of the trial. Any disagreement is re-
solved through discussion, with the rest of the project team
being brought in if necessary. Current work has focused on
piloting our materials and method with three trials run from
three different UK Trials Units. We will extend this work to fur-
ther trials run from more Trials Units prior to the SCT/ICTMC
conference.
Results
Our preliminary results suggest that trial teams spend more
time collecting data than they do collecting outcomes: some-
times less than 50% of the data collected is linked to primary
and secondary outcomes. The largest single category is almost
always secondary outcomes, which range between 28% and
52% in the three trials categorised to date. Primary outcome
data ranges from 1.2% to 14.2%. Safety and regulatory data
accounted for between 1.1% and 13%. In one of the three tri-
als 2,530 data items were collected, 78.8% of which were
mandatory.
Conclusions
Our early results suggest that a substantial proportion of trial
data is not outcome data. Primary outcomes accounted for less
than 15% of all data collected; secondary outcomes were at
least 3 times as many but in two trials represented over 20
times as much. Should the remaining trials in our study follow
this pattern then, given the expense of collecting, storing and
cleaning data, it suggests trialists should have an increased
awareness of the burden and costs associated with adding
data items to data collection forms. Regulators and others
should bear in mind the burden their requirements may place
on trial teams.
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Background
The ending of a clinical trial may be challenging, particularly if staff
are required to withdraw the investigated treatment(s); however, this
aspect of trial work is surprisingly under-researched. To address this
gap, we explored the experiences of staff involved in closing out a
trial which entailed withdrawal of treatment (insulin pumps) from
some patients.
Methods
Interviews were conducted with n = 22 staff, recruited from seven
trial sites. Data were analysed thematically.
Results
Staff described a number of ethical and emotional challenges at
close-out, many of which had been unforeseen when the trial
began. A key challenge for staff was that, while patients gave their
agreement to participate on the understanding that pump treat-
ment could be withdrawn, they often found themselves benefiting
from this regimen in ways they could not have foreseen. Hence, as
the trial progressed, patients became increasingly anxious about
withdrawal of treatment. This situation forced staff to consider
whether the consent patients had given at the outset remained
valid; it also presented them with a dilemma at close-out because
many of those who had wanted to remain on a pump did not meet
the clinical criteria required for post-trial funding. When deciding
whether to withdraw treatment, staff not only had to take funding
pressures and patient distress into account, they also found them-
selves caught between an ethic of Hippocratic individualism and
one of utilitarianism. These conflicting pressures and ethical consid-
erations resulted in staff decision-making varying across the sites,
an issue which some described as a further source of ethical un-
ease. Staff concluded that, had there been more advanced planning
and discussion, and greater accountability to an ethics committee,
some of the challenges they had confronted at closeout could have
been lessened or even prevented.
Conclusions
The same kinds of ethical issues which may vex staff at the begin-
ning of a trial (e.g. Patients having unrealistic expectations of trial
participation; staff experiencing conflicts between research and
clinical roles) may re-present themselves at the end. To safeguard
the wellbeing of staff and patients, greater planning, coordination
and ethical oversight should go into the close-out of trials involving
withdrawal of treatment(s).
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Background
Conducting research can be a time consuming, difficult and challen-
ging process. Guidance and pragmatic advice focusing on randomised
controlled trial conduct are available but do not necessarily constitute
comprehensive guidance. Standardised trial management tools, have
previously outlined key elements constituting a successful trial as a
method of ensuring good practice in research trials: initiation, planning,
execution, monitoring, and analysis. Despite existing tools and guid-
ance, lessons are also frequently learnt during the development and
conduct of trials however rarely are these experiences shared for thebenefit of others. For the wider research team, the key focus will always
be on the execution and delivery of a study. We therefore evaluated
the acceptability of clinical trials management, focusing on study
execution and monitoring, as implemented in the NIHR HTA funded
Obsessive Compulsive Treatment Efficacy Trial (OCTET).
Context
OCTET was a randomised controlled trial investigating the effectiveness
of low intensity interventions for the treatment of obsessive-compulsive
disorder (OCD). Two trial managers coordinated the study. This included
managing and coordinating personnel working across a variety of roles
within the study - research assistants, clinical practitioners, site leads, and
independent committee members.
Methods
Workshops, questionnaires and semi-structured interviews were used
to explore acceptability of trials management methods with a spe-
cific focus on the execution and monitoring of the study. Members
of the OCTET Trial research team were asked to comment, both posi-
tively and negatively, on their experience of the management, proce-
dures, training, and their overall involvement in the trial. 9 members
participated in the workshop, 10 completed a questionnaire and 20
were interviewed as part of qualitative work for the main OCTET
study. Data was collected and analysed using thematic analysis, with
the key phases of this approach adhered to.
Results
Six key themes associated with study execution and monitoring were
identified within the data: support; communication; processes; re-
sources; training and ethos. Clear and open communication and enthu-
siasm and accessibility of the trial managers and Chief Investigator
were noted across all themes as an important facet of the successful
running of the trial. Clear resources and training materials were also
found to be crucial in helping staff to work within the trial setting how-
ever constructive suggestions were also made for improvement.
Conclusion
Organisation, openness, and positivity are crucial for executing a trial
successfully, whilst clear and focused processes and resources are es-
sential in monitoring and controlling the progress of a trial. Trial
managers should therefore consider developing these elements
when setting up a study. There is however, always room for improve-
ment and the continued sharing of effective techniques will help to
further evolve efficient trial management.
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Background
Integral to the development of new trial proposals and a key consid-
eration for funders is the assessment of feasibility of recruiting the
planned sample size. Estimated accrual figures provided by sites are
usually based on local clinical experience of the relevant patient
population, data from internal audits of number of patients seen and
previous experience of recruitment to trials. These estimates are used
during trial development to inform trial design and plan recruitment
timelines and as such have a substantial impact on the funding sup-
port requested. We aimed to assess how close actual recruitment to-
tals were to the estimates provided at the funding application stage
to determine if evidence-based correction factors could be defined.
Methods
Six oncology trials covering a range of disease sites and treatment
modalities were selected from the ICR-CTSU portfolio. Individual sites’
estimated annual recruitment was compared with the average an-
nual accrual observed. The proportion of sites which failed to open
following initial expression of interest at funding application stage
and number of sites which opened which were not included in the
original funding application were also reviewed.
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One hundred & twenty two sites were on the funding applications of
the six trials reviewed, representing 82 centres in total, some listed
for >1 trial. Sites estimated they would recruit a total of 446 patients
per annum. Of those which opened, only 7/77 (9%) exceeded their
recruitment estimates. 8/77 sites (10%) recruited 0-40% less than
predicted, 28/77 sites (36%) 40-80% less and 31 sites (40%) 80-100%
less. Three sites did not provide recruitment estimates. Median
percentage reduction between predicted and actual recruitment per
site was 74% (inter quartile range 91 to 44). 45/122 of sites did not
proceed to open the respective trial (37%). Of the sites which partici-
pated in each trial, 48% were not originally included on the funding
applications. These sites contributed an average of 17% of target ac-
crual of the six trials. Over all trials, average observed annual accrual
was 66% of that estimated by sites.
Conclusion
Potential participating sites substantially overestimate accrual at the
funding application stage. This has consequences for trial develop-
ment as it impacts assessments of trial feasibility and planned re-
cruitment period. Sites which express interest and then fail to open
can also skew the recruitment estimates; however this appears to be
mitigated to a certain extent by those sites which do not provide ex-
pressions of interest at funding application stage but proceed to
open the trial at a later date. Estimating projected trial accrual is
challenging for sites and trials units. Options for improving recruit-
ment estimations, including use of national electronic health records
and documenting provenance of recruitment estimates (e.g. Local
audits), should be considered. Our data suggests feasibility of accrual
should be routinely reassessed per site once funding approval is
confirmed.
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Background
Conduct of clinical studies traditionally involves study teams ap-
proaching clinicians to screen and find potential study participants.
This can be both time-consuming and labour intensive for clinicians
and researchers. Leveraging Electronic Healthcare Records (I) as a re-
source to locate and screen eligible study participants is often under-
utilised but significantly reduces pre-screening activities. An example
of the advantage of this method is illustrated in the following study
investigating the association between air pollution and COPD exacer-
bations using portable air monitors and symptom diaries. Using I
data within the Clinical Practice Research Datalink (CPRD), we
screened for eligible patients in primary care practices, based on the
protocol inclusion/exclusion criteria. CPRD data are comprised of con-
tinually provided anonymised UK electronic primary care records to
enable clinical studies into improving public health.
Methods
The CPRD I database was interrogated to create a pre-screened list of
patients located in practices close to the research sites in central
London. The search engine used a study-specific validated codelist and
algorithm. Using diagnostic codes alone, this algorithm had a Positive
Predictive Value (PPV) of 86.5% which is improved slightly by including
use of antibiotics and oral corticosteroids in previous 12 months and
spirometry; spirometry was not used as a screening criterion within the
I but was subsequently performed at the research site. Patients were
excluded if they were either current smokers or aged < 35 years old.
Participating GPs were provided with a pre-screened list from which to
identify and select suitable patients to receive information about the
study. Potential participants could contact the research team directly to
be enrolled.Results
Eighty-one practices were approached of which 24 (29%) con-
sented to participate, resulting in a pre-screened list of 904 pa-
tients. There were 314 screen-failures (35%) of which 55% were
“unable/unsuitable” to participate in the study for reasons such as
housebound, dementia and other co-morbidities; a further 29% of
screen-failures were excluded for reasons associated with COPD
diagnoses and exacerbations, lastly, 16% were either transferred
out or deceased. 590 patients were invited of which 209 responded:
141/209 (67%) declined to participate and 61/209 (29%) agreed to
participate. The main reasons for declining were: study too
demanding (43%); not interested (14%); currently facing health
issues (15%).
Conclusion
The use of CPRD data enabled site recruitment efforts to be concen-
trated on those practices with eligible patients close to the research
site locations. The provision of CRPD data to pre-screen for patients
meeting the study eligibility criteria reduced the amount of work
required from GPs. There were however a significant number of
screen-failures detected by GPs that were not covered by the search
criteria, suggesting further improvements can be made to the search
criteria to make this process more efficient. Through CPRD data we
were able to successfully screen and recruit patients with COPD from
GP practices within central London to participate in research over a
6 month period. This is an effective and novel method of using EHRs
to screen and recruit participants for research.
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Clinical Trials Units (CTUs) oversee a large resource of data and linked
samples generated from clinical trials and have a duty to facilitate
responsible sharing of these collections with the wider research com-
munity. Sharing has the potential to improve scientific and medical
knowledge, improve and validate research methods, encourage col-
laboration and reduce duplication of effort. Sharing must take into
consideration the scientific integrity of the original trial and the pro-
posed research, the terms of the consent with which tissue and data
were collected, relevant governance and regulatory requirements
and the terms and conditions of the sponsors and funders of the
original trial.
Clinical trials are conducted to provide a precise unbiased estimate
of effect to inform the next trial and influence clinical practice. It’s
imperative that the integrity of the trial is maintained until the pri-
mary research questions have been answered. When considering a
request for access to a specific trial cohort, CTUs consider: the clinical
importance of the hypothesis; whether the hypothesis requires
access to the specific trial collection; whether the relevant data or tis-
sue are held and are of sufficient quality and quantity; the statistical
validity of the proposed research; whether the proposed research is
validation or discovery; whether sharing would compromise the col-
lection or reporting of the original trial; and whether there are oppor-
tunities for collaboration.
There is a wealth of legislation and supporting codes of practice con-
cerning the appropriate use of tissue and data collected from clinical
trial participants. At the heart of this is the need to ensure appropriate
informed consent and to protect participant confidentiality. The use of
data and samples is limited by the scope of the consent and conditions
of approval under they were originally collected. Data and tissue may
be used without explicit consent if it is fully anonymised and the re-
search has been approved by a research ethics committee. However
fully anonymising data may be difficult to achieve and may even re-
duce the utility of the collection for the intended purpose. Ethics com-
mittees now accept the need to seek broad and enduring consent for
future use of data and tissue. However advances in technologies and
changes in societal expectations can make this difficult to achieve.
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are collected mostly prospectively in a systematic and unbiased fashion
and are well curated and documented. They are a precious resource
and represent a considerable investment from those involved in the
original trial including the clinical trial participants, investigators, CTU,
trial oversight committees, funders and the sponsor. Their opinions,
terms and conditions must be taken into account when considering
proposals for data sharing. This can be managed through formal access
policies, processes and agreements.
There is a balancing act between data sharing on one hand and pro-
tection of the collection and those who contributed to the collection
on the other. However sharing can and should be achieved ethically,
legally and with scientific probity with appropriate considerations
and controls.
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Background
Macleod et al. Criticized in 2014 that there is too much avoidable
waste and too little value in biomedical research and identified sev-
eral relevant issues (Lancet 2014:383:101–104).
Objective
As in the European Union all clinical trials have to be reviewed and
approved by a competent Ethics Committee prior to the start, it is
time to check whether Ethics Committees can play a role re reducing
waste and increasing value of clinical trials.
Results
Macleod et al., e.g. State that more than 50% of the studies are de-
signed without reference to systematic reviews of already existing
evidence. As experimentation and research with humans is ethically
only legitimate if the knowledge is not yet available and is at the
same time definitely needed, a systematic review should be an
absolutely essential part of each application dossier sent to an Ethics
Committee. Unfortunately, even the recently passed European
Clinical Trial Regulation 536/2014 which specifies the content of the
application dossier in Annex I does not require the submission of
such a systematic review. Another relevant issue is according to
Macleod et al. That adequate steps to reduce bias are not taken in
more that 50% of the studies and that there are still too many trials
with inaedequate statistical power. Examples and explanations for
these flaws and the ethical problems involved will be presented.
Conclusions
Ethics Committees can play an important role in improving the qual-
ity of clinical trials re substance, content and methods. It seems that
Ethics Committees are not yet sufficiently aware of their responsibil-
ities in this context. In addition there should be no Ethics Committee
any more without sufficient biostatistical expertise.
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Background
Rigorous clinical trial methodology is dependent on a number of fac-
tors, including but not limited to: appropriate team communication,
funding and compliance with ethical, legal and regulatory frameworks.Factors relating to statistics and clinical data management (CDM) how-
ever, are crucial to the planning, design, conduct, monitoring, analyses
and reporting of trials. Reliable results from statistical analyses are im-
perative to ensure confidence in the clinical interpretation of treat-
ments. Some key trial statistical and CDM aspects include: choosing
trial design, variables and outcomes, building databases, planning and
implementing randomization schedules, sample size calculations, statis-
tical monitoring and quality control, maintaining accurate statistical
documentation, Source Data Verification, interim and statistical analysis
and translating statistical results into clinically meaningful findings. One
key aspect to ensuring this ‘statistical rigour’, is having competent and
enthusiastic inter-disciplinary ‘Trialists’ - most notably: trial statisticians,
data managers and principal investigators (PIs).
Objectives
The objectives were to: 1) Develop an understanding of roles and re-
sponsibilities of statisticians, PIs and CDM team members in order to
2) Better understand the barriers and facilitators to statistical rigour
in clinical trials.
Methods
The Cochrane Library Databases, Google Scholar, pubmed and Web
of Science were explored using P(Population), E(Exposure) and
O(Outcomes) search terms, with no restriction on years. Snowballing
yielded Grey literature and international guidelines.
Results
The literature discussed roles, responsibilities and rights of statisticians,
but also of pis and CDM members - where the aforementioned trial
statistical aspects are often a joint effort. Key barriers and facilitators to
statistical rigour in trials were then identified from the literature.
A number of authors raise concerns of statisticians only being con-
sulted after data collection - for analyses and reporting. It is strongly
recommended however, to have skilled statisticians involved in the
design and implementation, which may prevent statistical pitfalls
during the trial. Errors in trial design, conduct and analysis may intro-
duce bias and affect patient safety.
Authors emphasize the importance of statistician involvement in
'teaching and learning'. They teach and inform colleagues about
important statistical information and interpretation of trial results.
Similarly, statisticians have a responsibility to be knowledgeable
about their therapeutic field of research, to be up-to-date with novel
statistical approaches and have a firm understanding of trial method-
ology. Statisticians also have a responsibility to ensure final study re-
ports are a 'fair reflection' of trial findings. Some authors also call for
statisticians to be recognized as ‘full-collaborators’ in the decision-
making aspects of trials, and maybe even as a ‘co-investigator’.
'Barriers' to trial statistical rigour include: lack of availability to statis-
tical expertise, timing and workloads and not adhering to regula-
tions. Facilitators include: understanding clear roles of statisticians
and CDM members in the oversight of certain procedures, adequate
resources, qualifications and experience.
Conclusions
Key factors contributing to statistical rigour, in a trials context, are
discussed. These findings support the importance of 'inter-disciplin-
ary' teamwork. Increased understanding of each other’s roles and
more transparency in communication between statisticians, CDM
members and healthcare professionals, is of critical importance to
determining and communicating the clinical relevance of statistically
significant findings.
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Many RC trials struggle to reach their pre-specified sample size. Screen-
ing logs offer an indication of eligibility and why patients do not enter
the trials as well as providing required figures for the CONSORT dia-
gram. The ROCS (Radiotherapy after Oesophageal Cancer Stenting)
study is a pragmatic RCT of external beam radiotherapy in addition to
stent versus stent alone in patients clinically assessed as requiring stent
insertion for relief of dysphagia caused by oesophageal cancer.
Aim
Re-design a screening log to provide data to optimise study design
and recruitment.
Methods
ROCS study screening logs were initially designed as a two-stage paper
form. The first form included all patients requiring stent insertion, and
then those potentially eligible were copied across onto a 2nd stage
screening form. Research nurses were involved in the re-design of the
screening logs at regular face to face ROCS Nurses Meetings. Modifica-
tions were made to criteria and subsequently the two forms were com-
bined onto one Excel sheet. Nurses were advised to include all patients
receiving an oesophageal stent for palliative reasons. Reasons for de-
clining the study and for ineligibility could be selected from drop-down
options. Completion electronically allowed less writing and nurses
could email back the results weekly. Summary data was presented to
the ROCS TMG regularly.
Results
After implementation, feedback from nurses was very positive, with
100% return rate, following reminders in some cases. The ongoing
personal contact with individual sites improved their engagement
with the study. Early in the trial, screening logs clearly demonstrated
to the funders that the predicted number of patients requiring stent
insertion was correct, and that 63% acceptance rate of the trial was
above the 50% initially predicted. The reason for lower than expected
recruitment was due to low eligibility of 26% against the original esti-
mate of 70%. The main reason for ineligibility was patients identified
only after the stent was inserted; 14% of patients were ineligible owing
to this reason. The TMG provided this as evidence to funder and
sponsor as reason to change the trial design. Since the change to allow
patients to be recruited after stent 55% of patients have been rando-
mised post stent. A change was also made to the histology eligibility
criterion, but the effect of this has not been seen yet as it was only
implemented recently. Screening logs also highlighted low acceptance
rates in some centres, which allowed the trial team to provide more ad-
vice and support to these sites. One site improved acceptance rate
from 35 to 50% following additional support.
Conclusion
Comprehensive screening log data can be collected. This is useful
to track proportions of incident patients that are eligible and
randomised. Data also provide information about non-eligibility
and non-participation to feedback to centres, the funders and TMG.
Commitment of the study centres played a key role to in the
screening data return. This was easier to achieve through direct en-
gagement at the regular investigator meetings and acting accord-
ingly on participating centres feedback.
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Background
Conducting a clinical trial during a public health emergency creates
novel challenges to successful execution and requires an innovative
approach to trial design. The ASAP trial (Adjuvant Steroids in Adults
with Pandemic Influenza) has been set-up in advance of an influenza
pandemic ready to be rapidly activated in such an event. All ap-
provals have been obtained, and documents and materials necessaryfor the conduct of the trial have been prepared. Upon activation, the
trial needs to recruit the first participant within 4 weeks, and to
complete recruitment of 2200 participants at approximately 40 sites
within the first pandemic wave of approximately 6 weeks.
Even with the best of planning, unexpected barriers and issues
affecting recruitment and trial conduct often occur; this is particularly
likely to be true of a trial to be conducted during an influenza pan-
demic. As recruitment to ASAP must be completed within the first
wave of the pandemic, it is important that key trial process have
been tested, and adjusted if necessary, prior to activation of the trial
and that the site activation plan is realistic and deliverable. We there-
fore conducted and evaluated a mock site activation.
Methods
Derby Royal Hospital was chosen as the target site given its close
proximity to the coordinating centre and established links with the
trial team. The site was alerted to activation via a “Declaration of
Activation” letter which provided detailed information on the actions
required to receive the “green light” for recruitment of a “patient”
(volunteer) to commence.
The mock activation allowed for the assessment of: 1) Investigational
Medicinal Product (IMP) manufacture, labelling and supply proce-
dures 2) training material for local investigators and site staff on trial
processes, 3) data management processes, 4) channels of communi-
cation between the coordinating centre and the mock activation site
and 5) the recruitment pathway.
Results
The site was mock activated on 15th September 2015, with recruitment
“green light” issued within 4 weeks, in conformity with trial targets. The
mock activation of the trial provided reassurance to the trial team that
trial processes and procedures were adequate for successful site activa-
tion and recruitment, it also helped to highlight a number of potential
areas in which trial processes could be improved.
As a result changes are being made to the trial including minor
amendments to the CRF and third party contracts, the streamlining
of IT processes and increasing staff resource; this will help to further
build trial resilience in the event of a pandemic, and reduce the
burden of any queries generated by unclear processes at activation.
An evaluation of the costs of conducting this mock activation will
also be reported.
Discussion
Mock activation allowed trial processes to be tested and problems
addressed before actual patient recruitment. Such activation may
have wider relevance for streamlining trials where rapid recruitment
is critical, or anticipated to be complex. Although mock activation
has cost implications in time and resources, the investment may be
worthwhile if it improves recruitment and trial conduct, improving
trial efficiency.
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Objectives
TIDIER guidance is an extension of CONSORT 2010 and SPIRIT 2013
statements and aims to improve intervention reporting [1]. Our ob-
jective was to use tidier to identify and reduce the uncertainties
about the design of a complex behaviour change intervention prior
to a feasibility randomised controlled trial to reduce obesity in men.
Background
Intervention development is seldom reported and can be viewed as a
black box [2]. Many interventions either do not result in a successful
trial or are not implemented and therefore do not impact on health
outcomes. This contributes to considerable research waste. Carefully
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sustainable are required. In our study, intervention engagement and
reach are crucial because the prevalence of obesity in men is high,
men infrequently engage with weight loss interventions and there are
considerable health inequality consequences.
Methods
We considered the literature on i) complex intervention development
methods ii) behaviour change theory (psychological and economic); iii)
systematic review evidence about weight loss; iv) health inequalities; v)
the acceptability to men and the public for similar interventions. With
Public Patient Involvement (PPI) and expert opinion, these sources were
used to populate the tidier checklist. We then decided how to fill the
gaps as robustly as possible in order to produce a replicable interven-
tion manual.
Results
Some intervention features had no evidence to inform a decision, so
we undertook a primary survey, qualitative research and PPI. Other
intervention features e.g. Behaviour change components had inform-
ative data from studies of varying quality which generated hypotheses.
A team decision was made about whether further primary research
data was required or whether PPI and expert opinion would suffice.
Some intervention features, particularly those relating to sustainability
(e.g. Website, text messages) and future implementation (who delivers),
had a strong underpinning logic which was considered sufficient for
the team to make a decision. Tidier helped to focus on the decisions to
be made. Limitations became apparent in relation to the intervention
context, delivery [3] and how the loose categories for intervention
features could be interpreted differently. Pragmatic decisions were
sometimes required due to limits in funding, time and staff availability.
Conclusions
With little literature on how best to develop successful complex inter-
ventions that eventually translate into health service implementation,
tidier guidance for reporting interventions provides a useful starting
point. However, prospective development of guidance on intervention
development may be preferable to retrospective approaches. Our
study begins to systematically address the uncertainties and deci-
sions involved to develop a complex intervention. This is necessary
so that more interventions proceed to become successful trials, are
implemented into policy and practice and have impact on health
care outcomes.
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Background
Over 70,000 primary total knee replacements are performed annually in
the NHS. People choose to undergo knee replacement with the hope
that surgery will improve their pain, but approximately 20% of people
who have primary total knee replacement experience chronic pain
afterwards. Our research has demonstrated that current UK NHS service
provision for people with chronic pain after knee replacement is patchy
and inconsistent. This reflects an absence of evidence about effective
interventions and highlights the need to develop and evaluate inter-
ventions to address chronic pain after knee replacement. We havedeveloped a complex intervention comprising a novel assessment clinic
and onward referral pathway for patients reporting moderate-severe
pain at 3 months after knee replacement. The initial development of
the intervention was informed by a systematic review, survey of NHS
service provision, qualitative work with health professionals, consensus
meetings with pain experts and patient and public involvement activ-
ities. The aim of this work was to refine the design and delivery of this
intervention before evaluation in a randomised trial, in keeping with
the Medical Research Council’s recommendations for complex interven-
tion development.
Methods
Three stages of work were undertaken over a 12 month period. To
develop the intervention, the first stage involved consensus ques-
tionnaires with 22 health professionals about the appropriateness
of individual components within a draft care pathway intervention.
Mean appropriateness ratings were calculated and discussed at
meetings with 18 healthcare professionals. To refine delivery of the
intervention and assess whether it was acceptable to patients,
Stage 2 involved scrutiny of the trial intervention with 10 patients
who attended an assessment clinic. Stage 3 involved 10 health pro-
fessional stakeholders to evaluate their views about implementa-
tion potential of the intervention using a questionnaire based on
the nomad instrument.
Results
In Stage 1 a number of substantive changes to the design of the
intervention were made, including the addition of a physiotherapy
referral pathway and rapid access to suitable medications for neuro-
pathic pain. Running the intervention in Stage 2 found that the as-
sessment clinic was acceptable to patients and highlighted the need
for some changes to the clinic processes, including the need for add-
itional self-report screening tools and standardised radiographs. This
work also informed development of a comprehensive training pack-
age for Extended Scope Practitioners who would deliver the inter-
vention during the trial. Stage 3 found that stakeholders understood
the intervention and could see how the intervention would affect
the nature of their own work. They were aware of the proposed ben-
efits of the intervention for patients and were keen to engage with
the new practices.
Conclusions
We have undertaken a comprehensive programme of research to
refine the design and development of a complex intervention prior
to evaluation in a randomised trial. Our study provides an example
of the methods that can be used to address key questions within
intervention design in a relatively tight timeframe. The next stage is
to evaluate the clinical and cost-effectiveness of the intervention in a
definitive multi-centre randomised trial, which will include an internal
pilot phase.
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Background
Complex surgical interventions are an indispensable part of modern
healthcare and there is increasing recognition that novel procedures
should undergo the same rigorous evaluation as other non-invasive
treatments. However, the multi-component nature of surgery compli-
cates evaluation. For instance, surgical procedures are delivered by
multidisciplinary teams and thus their outcome may vary due to pa-
tient characteristics, skill of the operators and the environment
within which they are conducted. Recognition and accommodation
of this variation is important in order to design adequately powered
related trials. The duration of postoperative Length-Of-Stay (LOS) (or
incidence of prolonged hospitalisation) has been the focus of many
surgical trials as it is a principal driver of surgical costs, and acts as a
surrogate for a range of post-operative complications. Therefore it is
Trials 2017, 18(Suppl 1):200 Page 96 of 235important to understand how and why this outcome varies, so that rec-
ommendations for trial design and analysis can be made. Traditionally,
surgical trial design suffered from a lack of detailed multicentre data.
The current availability of high-quality, routinely collected administra-
tive databases allows us to explore current practice and outcomes, in
order to inform trial design in this context.
Aims
This study aims to demonstrate how routine databases can be used to
explore variation induced by patients, provider and centre practices in
LOS outcomes, in order to inform surgical trial design and estimate key
design parameters.
Methods
We start by exploring the variation between surgeons and anaesthetists
separately, whilst adjusting for patient heterogeneity, using hierarchical
(random effects) models. In order to estimate the contribution of differ-
ent components of care and their interactions to variation in outcomes,
a series of hierarchical models with cross-classifications is employed.
Using the two most influential providers in the surgical treatment path-
way, the surgeon and anaesthetist, for illustration, we show that key
components of surgery do not necessarily follow a strict hierarchy e.g.
Patients are nested within surgeons nested within centres, but
surgeons are not nested within anaesthetists. We extend the proposed
models to accommodate an additional Centre level in the hierarchy
which introduces further variation due to infrastructure and policy
differences. Potential drivers of between-centre variation are further
examined through the incorporation of random coefficients. As there
may be multiple components that contribute to extended LOS, we
demonstrate how we can identify those which can be more effectively
manipulated in order to standardise practice in trials. We examine the
LOS both as continuous outcome, appropriately addressing its non-
normality, and as a binary outcome (prolonged hospital stay).
Results
An application of the methods in cardiac surgery, one of the most
expensive yet widely used surgery types, is presented using a cohort of
more than 100,000 consecutive case series patients from ten UK
specialist centres. The implications of the results for the design of re-
lated trials are also discussed.
Conclusions
High-quality routine databases can be used to identify sources of
variation in surgical care and outcomes. The resulting outputs can
then be used to inform surgical trial design and analysis to ensure
the robust and efficient analysis of intervention effects.
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Background
Process evaluations assess the implementation and sustainability of
healthcare interventions within clinical trials, offering explanations
for observed effects of trial findings and specifying the circumstances
under which interventions are likely to succeed or fail. Such evalua-
tions are particularly needed in trials of complex interventions which
contain multiple interacting components. However, while theoretical
models are available for evaluating intervention delivery within spe-
cific contexts, there is a need to translate conceptualisations of con-
text into analytical tools which enable the dynamic relationship
between context and intervention implementation to be captured
and understood.
Methods
In this paper we propose an alternative approach to the design, im-
plementation and analysis of process evaluations for complex health
interventions through a process of ‘context mapping.’ This innovativetechnique involves: 1) prospectively mapping contextual features
likely to affect intervention delivery; 2) using the mapping exercise
to identify likely pinchpoints in delivery; and 3) analysing imple-
mentation at the pre-identified pinchpoints during delivery. As an
example, we will present ongoing work from PREPARE-ABC - a
randomised controlled trial of suportive Exercise Programmes for
Accelerating recovery after major abdominal Cancer surgery.
PREPARE-ABC, funded by the NIHR, sponsored by Norfolk and
Norwich University Hospitals NHS Foundation Trust and co-
ordinated by the Norwich Clinical Trials Unit, University of East
Anglia, is recruiting 20 hospitals and 1146 patients in the UK requir-
ing surgery for colorectal cancer. Patients are randomised to one of
three arms: hospital based supervised exercise; home based sup-
ported exercise; or treatment as usual.
Results
Data collection is ongoing at the time of submission. We will present
findings from our current evaluation of standard care for patients pre
and post-surgery for colorectal cancer, conducted prior to main trial
recruitment. We will discuss what recommendations can be made
from these findings for improving main trial implementation, using
qualitative field notes from observations of pre and post-surgery con-
sultations, and quantitative and qualitative data obtained through a
telephone scoping exercise conducted at all colorectal units partici-
pating in the study.
Conclusions
The value of context mapping is that we can predict areas of vulner-
ability prior to intervention delivery, then make recommendations for
adapting flexible elements of the intervention during implementa-
tion. In addition, we can target and observe key pinchpoints as they
are enacted, thereby offering opportunities for exposing the ‘active
ingredients’ of interventions in action and providing insights into im-
plementation and theoretical fidelity.
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For many decades, the randomised controlled clinical trial has been the
gold standard of conducting research studies in health care. Its design
and aims orientate around proving or disproving hypotheses based on
the efficacy or safety of an intervention powered for a single primary
outcome measure. However, in the awake of many medical techniques
and devices, that reveal the complexity and depth of a disease, treat-
ments such as complex interventions, are often assessed to obtain a
comprehensive picture of these multiple manifestations. In order to
support this, a single end-point will not provide sufficient information
that is adequate in treatment assessment. The MRC complex interven-
tion framework guidance (2008) states “Identifying a single primary out-
come may not make best use of the data; a range of measures will be
needed, and unintended consequences picked up where possible.” The
choice of more than one primary outcome measure seems to be per-
fectly plausible from a clinical view point, but statistically it presents
many complexities.
The aim of this article is to present the different types that have
been detailed in the literature which aim to assess multiple out-
comes in clinical trials, which are considered to be equally important
in the assessment of the treatment effect. They include (i) co- primary
outcomes and (ii) composite outcomes. We outline the challenges
faced in the sample size calculation and the statistical analysis of co-
primary outcomes, given different distributions and approaches of
analysis. We also illustrate example of clinical trials where co-primary
outcomes have shown treatment efficacy, which is not evident with a
single primary outcome. For a composite outcome, we summarise the
challenges faced in the analysis and reporting and interpretation of
results. In addition, we illustrate the pitfalls and strengths of these
approaches.
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Short Message Service (SMS) is one of the basic functionality avail-
able in all types of mobile phones. Research had shown that almost
all SMS are getting read as soon as they reach. It is the easiest route
to anyone to be notified as it does not require computer/internet. It
is reliable and secured in all the situations as it is completely moni-
tored and controlled by the mobile service providers. One might be
surprised to know that SMS can be sent from Email to mobile num-
ber at free of cost. Every mobile number is uniquely attached to an
email address with the domain chosen by the mobile carriers. Every-
one will be interested to make use of a feature if it is available at free
and at the same time reliable. The proposed approach is exploring
and automating the feature of sending SMS to mobile phones from
Email to serve the following various activities in clinical trials. 1.
Reporting/Notifying the stake holders about importance occurrences
of events 2. Notifying the programming team about the current pro-
gram status. These two activities are completely SAS data driven. In
clinical trials, SAS is one of the widely used software for the data
management, analysis and reporting since the clinical trial datasets
are often available in SAS format. The analysis reports (Tables, List-
ings & Figures) are generated using SAS programming language for
the FDA submission. SAS programming language based automation
is implemented for these two activities. 3. Engaging Study partici-
pants 4. Reminder notifications to the project team on various activ-
ities. These two activities are completely Microsoft Excel data driven.
Excel is one of the Microsoft applications always available in all the
computers and VBA is the language of Excel application. Using Excel
VBA programming these tasks are automated. The data based
automations are always developed using at least one programming
language. In order to send the n number of SMS from Email without
any manual intervention, we are making use of SAS and Excel VBA
programming languages. The SMS can be triggered from Email at a
scheduled interval or whenever certain criterion is met. Even though
the whole process can be automated using only SAS programming
language, we have come up with Excel VBA based automation as
well since SAS is very expensive software and hence cannot be made
to be available for all the project team members. As Excel VBA is
available in everyone’s computer the VBA based proposed approach
can be utilized for various activities even if SAS is not available. This
proposed approach has wide range of cost effective applications
which can be quickly leveraged to perform various activities depend-
ing on the study requirement.
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Background
ICR-CTSU introduced Electronic Data Capture (EDC) in 2012; this neces-
sitated a revision of data management systems and processes. In trials
using paper case report forms (CRFs) –“paper trials” – data managers
(DMs) at ICR-CTSU manually check all paper CRFs during data entry.
With the introduction of EDC, they now perform manual checks and
additional programmed checks using data review software. Here we
describe how data management has changed as a result of the transi-
tion from paper to EDC trials.
Implementation
For paper trials, CRFs are received by ICR-CTSU and are entered onto
the database by DMs. CRFs are stored chronologically in a patient
folder, and are available for review at the time of data entry. Manualchecks are performed on all CRFs when the DMs at ICR-CTSU
transcribe data into the database. In-built database validations flag
discrepancies to DMs s during data entry. Resulting queries are docu-
mented, printed and sent to sites periodically and several months
can pass before query resolution occurs. Data entry of different forms
at any one time means trends in errors in data reporting are not al-
ways easily identified. In EDC trials, participating sites enter data into
an EDC system. Database validations highlight potential discrepan-
cies to sites at the time of data entry so that they can correct issues
immediately, reducing the number of data queries required. DMs at
ICR-CTSU receive daily automated emails listing newly completed
electronic CRFs from the database tracking system. Manual review of
specific forms is performed as required, for example, on trial entry
forms and important safety and endpoint data. Only one form per
patient can be open in the database for review at a time therefore
DMs also use advanced data review software to programme checks
which identify data discrepancies across forms for all trial partici-
pants. DMs run programmed checks at a frequency determined by
their priority, to systematically identify potential discrepancies. Data
are reviewed in context, and queries are raised electronically. These
are immediately available for sites to review and provide a response.
Trends in data entry errors can be readily identified during review of
the programmed checks. This allows specific data entry guidance tar-
geting common errors to be provided to sites sooner and changes
to the database or CRFs can be considered by the ICR-CTSU trial
team earlier. Sites are therefore less likely to make the same errors
during future data entry.
Conclusion
DMs at ICR-CTSU typically work on a combination of trials which
may include both paper and EDC, requiring excellent time manage-
ment skills and flexibility. Attention to detail, investigational skills
and effective communication remain crucial, however the transition
to EDC trials requires development of additional competencies and
technical expertise in order to support DMs to produce and review
programmed listings.
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Following encouragements from FDA guidance and the recent ICH
E6 Addendum, many organizations are adopting RBM (Risk-based
Monitoring). There is no single solution since RBM usually relies on a
combination of on-site monitoring visits and central monitoring
methods. CSM (Central statistical Monitoring) can play a major role in
the RBM strategy in detecting investigational sites with atypical pat-
terns in the collected data.
The aim of this presentation is to share lessons learned and best
practice in terms of integration of CSM within the clinical operation
processes. In particular, emphasis will be given on how the outcomes
from CSM can be utilized in order to drive on-site monitoring efforts
and in identifying areas with potential risk.
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The sharing and re-use of data for further hypothesis generation,
interrogation and analysis is now universally recognised as a key
principle in research. Furthermore there is acceptance that data gen-
erated by public funding, through participation of patients and the
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and, whenever possible, translated to deliver patient benefit. The
National Institute for Health Research (NIHR) is a major public funder
of research in the UK, and is committed to transparency. The NIHR
position on data sharing and access is an important factor support-
ing this, with its standard research contract containing a clause re-
garding data release for many years, and the NIHR Journals Library
requiring a specific data sharing statement since 2015 for all its open
access publications. Mechanisms and processes for sharing data
have recently been subject to a great deal of global debate and dis-
cussion. Although a consensus has now largely been achieved on
the “Why” Aspect, early activity has been stalled to a certain extent
by an inability to address the “How”, and provide suitable and af-
fordable repositories to permit data sharing, discoverability and ac-
cess. Against the backdrop of recent international developments,
NIHR has reviewed its requirements and processes on access to
data to ensure that NIHR activity was appropriately reflected and
that funded researchers were supported. A number of initiatives fo-
cused on or related to data sharing have been developed which
have all built on the iom/NIH report ‘Sharing Clinical Trial Data’
published in 2015. Key areas include the publication of the ICJME
proposal on data sharing following publication, proposals from the
MRCT Center at Harvard for ‘Vivli’ (as a centre for Global Clinical Re-
search Data), and the ongoing development of the Clinical Study
Data Request (CSDR) system. In light of these developments, the
NIHR is developing a revised position on the sharing of Anon-
ymised Individual Participant Data (IPD) generated by NIHR-funded
research and a managed-access system to support this. This seeks
to build upon and strengthen NIHR activity in this area and initially
includes; Confirmation that anonymised datasets from NIHR funded
research should be available for further analysis wherever possible.
NIHR data will be released via a ‘Managed Access’ System, subject
to data use agreement. NIHR protocols should contain a ‘Data Shar-
ing Plan’ which will be publically available. NIHR publications must
include a data sharing statement/access link which clearly explain
how data can be requested. The NIHR is aware of the demands
placed on researchers in this area, and the need to retain a focus
on this area. As a result it is noted that NIHR requirements and sup-
port will need to evolve as the wider data agenda develops.
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Background
Efficient and timely monitoring of data throughout the conduct
of randomised controlled trials (RCTs) is essential to ensure high
quality data and robust results; monitoring may include sum-
maries of recruitment, data completeness and data queries.
Here we focus on efficient methods for monitoring complete-
ness of trial data.
Methods
We have developed a Stata program that enables the user to simply
and effectively monitor data completeness rates. The program allows
the user to look at the overall completeness of case report forms
(CRFs) or at the completeness of individual data fields. To use the
program, three variables must be specified: the variable to be sum-
marised; an indicator for the subjects to be included in the summary;
and the variable by which the completeness of the variable of inter-
est is to be grouped. The program also handles conditional data (i.e.
Where the requirement for a response is conditional on the answer
to a preceding question). The program directly outputs the results to
Microsoft Excel, where they can be further manipulated if required.
The generated output contains the number and percentage of en-
tries with data present and the number and percentage of entries
with data missing, by group and overall.Results
An example of the basic output (for one group). In this example, CRF
A1 is present for 121 study participants in group 1 (95.3%) and miss-
ing for 6 participants in this group (4.7%).
Discussion
Writing the code to produce the tables is straight forward to do. The
program has been successfully used to produce data completeness
reports in several multicentre RCTs. It has significantly reduced the
time needed to prepare reports for study meetings and independent
oversight committees and has removed the risk of transcription
errors. The reports produced have been consistently well received.
The program can easily be used for reporting on other key aspects
of trial conduct not just completeness of data. Efficient routine cen-
tral monitoring of trial conduct can serve to highlight issues early
and help minimise risks to a trial.
Disclaimer
This work was supported by the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme and by the
NIHR Bristol Biomedical Research Unit in Cardiovascular Disease at
University Hospitals Bristol NHS Foundation Trust. The views expressed
are those of the authors and not necessarily those of the NHS, the NIHR
or the Department of Health.
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Background
Chinese herbal medicine (CHM) has a history of treating the symptoms
of UTIs for >2000 years. In the UK UTIs are the commonest bacterial
infection presented by women within Primary care. RUTIs have a signifi-
cant negative effect on QOL, impact hugely on health care costs from
outpatient visits, diagnostics and prescriptions. Current treatment of
RUTIs relies heavily on antibiotics.
Objectives
To explore the feasibility of conducting a clinical trial of CHM within
a primary care setting with particular reference to recruitment, refer-
ral patterns, compliance, drop out rates, the relevance of outcomes
measures, the QOL of participants, adverse effects, and differences
between standardised/individualised remedies.
To compare outcomes of duration and severity of acute UTIs, rates of
re-infection, measuring acute and prophylactic antibiotic use, and
evaluating long-term changes. These preliminary data may be used
to inform a future, adequately powered, definitive study.
Variations in the time herbs were taken will be explored with the
outcomes as there is no definitive length of time recognised - it will
vary from 4 to 16 weeks.
Method
A pragmatic, double blinded randomised controlled feasibility study in-
volving 4 groups of 20 women, using standardised or individualised
CHM for RUTIs in Primary care and traditional care. Women with a
history of RUTIs will be identified by medical record searches and in-
vited to participate. Within the Wessex, Western and Peninsula regions
allocation will be to the standardised arm of the trial (Primary care).
Women from London and Hove will be allocated to individualised CHM
treatment. MHRA approval was needed for the standardised arm but
not the individualised arm.
Results
Recruitment is challenging and varies greatly by region. Total recruit-
ment to date for the standardised arm n = 26, better in Peninsula
than anywhere else, for the individual arm total recruitment n = 21,
more participants found in Brighton & Hove by Kent, Surrey and
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date are in the standardised arm n = 1 with n = 5 loss to follow up
and n = 1 withdrawal and in the individualised arm n = 7 with n = 2
lost to follow up.
We have yet to analyse the full data for recruits including diaries for
QOL data.
We will be interviewing both NHS staff and participants for their
views on CHM and the processes involved.
The trial finishes recruitment at the end of October 2016 as the herb
expiry date is the end of November 2016.
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This abstract is not included here as it has already been published.
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Observational cohorts alongside randomised controlled clinical trials
can be very informative. They enable an assessment of the number of
patients that do not want to be randomised and reasons for non-
participation in the randomised controlled trial (RCT). They also allow
investigation of what is standard practice at each site. They can be ex-
tremely useful in hard to recruit trials to gain information about the
outcomes of these patients in standard clinical practice. Mammo-50 is a
multi-centre RCT of different mammographic surveillance schedules for
breast cancer patients aged 50 years or older at diagnosis. A total of
5000 patients are randomised to annual surveillance versus 2-yearly for
conservation surgery and 3-yearly for mastectomy patients. There was
a 24 month pre-planned internal feasibility study assessing recruitment,
acceptability to be randomised and logistical endpoints which in-
cluded a sister observational cohort. The aim of the cohort was to
assess standard practice for non-randomised patients in terms of
information given to patients, type of follow-up at each centre and
frequency of mammographic surveillance. During the 24 month
feasibility phase of the trial, 1354 patients were enrolled into the
study; 936 (69%) patients choosing to participate in the RCT and
418 (31%) patients were recruited into the sister observational
cohort study. The main reason for not going into the RCT but being
part of the observational cohort was patient choice. Patients
wanted to remain on their standard mammographic surveillance
and didn’t want the possibility of changing regardless of whether
the standard was more or less frequent. Cohort patients have simi-
lar baseline patient characteristics to those entering the RCT,
although the cohort did contain slightly more patients who had
undergone mastectomy for their breast surgery. The feasibility
phase demonstrated that the trial was acceptable by patients and
clinicians but the ratio of patients entering the cohort compared to
the RCT increased over the duration of the feasibility phase. The
cohort demonstrated that standard practice regarding mammo-
graphic surveillance and follow-up is highly varied across sites. Inconclusion the observational cohort can provide valuable informa-
tion about a population of patients that are not willing to partici-
pate in a RCT. The purpose of the cohort should be clear and
informative. Recruiting into a sister observational cohort may be
seen by sites as an easier option and thus detract from recruiting
patients into the main RCT. It may be advantageous to close the
observational cohort at a time when sufficient numbers are recruited
and the aims of the cohort fulfilled. Mammo-50 demonstrated the
strength of a sister observational cohort alongside the RCT, especially
within the internal feasibility stage, leading to the success of the
full RCT.
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Background
The sample size required to power a trial to a nominal level in a paired
comparative diagnostic accuracy trial, i.e. Trials in which the diagnostic
accuracy of two testing procedures are compared relative to a gold
standard, depends on the correlation between the two diagnostic tests
being compared. The lower the correlation between the tests the
higher the sample size required, the higher the correlation between
the tests the lower the sample size required. A priori, we usually do not
know the correlation between the two tests and thus cannot determine
the exact sample size. Furthermore, the correlation between two tests
is a quantity for which 1) it is difficult to make an accurate intuitive esti-
mate and, 2) it is unlikely estimates exist in the literature, particularly if
one of the tests is new, as is very likely to be the case.
One option, suggested in the literature, is to use the implied sample
size for the maximal negative correlation between the two tests,
thus, giving the largest possible sample size. However, this overly
conservative technique is highly likely to be wasteful of resources
and unnecessarily burdensome on trial participants - as the trial is
likely to be overpowered and recruit many more participants than
needed. A more accurate estimate of the sample size can be deter-
mined at a planned interim analysis point where the sample size is
re-estimated - thereby incorporating an internal pilot study into the
trial design, with the intention of producing an accurate estimate of
the correlation between the tests into the trial.
Methods
This paper discusses a sample size estimation and re-estimation
method based on the maximum likelihood estimates, under an im-
plied multinomial model, of the observed values of correlation be-
tween the two tests and, if required, prevalence, at a planned
interim. The method is illustrated by comparing the accuracy of two
procedures for the detection of pancreatic cancer, one procedure
using the standard battery of tests, and the other using the standard
battery with the addition of a PET/CT scan all relative to the gold
standard of a cell biopsy. Simulation of the proposed method are
also conducted to determine robustness in various conditions.
Results
The results show that the type I error rate of the overall experiment
is stable using our suggested method and that the type II error rate
is close to or above nominal. Furthermore, the instances in which the
type II error rate is above nominal are in the situations where the
lowest sample size is required, meaning a lower impact on the actual
number of participants recruited.
Conclusion
We recommend a paired comparative diagnostic accuracy trial which
used an internal pilot study to re-estimate the sample size at the in-
terim. This design would use a maximum likelihood estimate, under a
multinomial model, of the correlation between the two tests being
compared for diagnostic accuracy, in order to more effectively estimate
the number of participants required to power the trial to at least the
nominal level.
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Background
Clinical trials are typically designed based on the classical frequentist
framework constrained to some pre-specified type I and II error rates.
Depending on the targeted effect size, the sample size required in
such designs range from hundreds to thousands. Trials for rare
diseases with prevalence 1/2000 or fewer may find it challenging to
recruit patients to trials of large size. In this work, we examine the re-
lationship between prevalence and other factors with the size of
interventional phase 2 and 3 trials conducted in the US and/or EU.
Methods
We downloaded all trials from Aggregate Analysis of clinialtrials.gov
(AACT) in May 2016 and identified rare disease trials by matching mesh
terms in AACT with those in Orphadata. Actual sample sizes of com-
pleted trials or anticipated sizes of non-completed trials were used for
analysis. We investigated effects of trials’ characteristics such as: inclu-
sion criteria (e.g. Gender, age), intervention model (e.g. Factorial design,
single arm), lead sponsor type (e.g. Industry, US Federal Agency), trial
location, number of countries involved in the trial, year that enrolment
to the protocol began, number of interventions in the trial, whether or
not the trial had a data monitoring committee and whether or not the
intervention studied in the trial was FDA regulated on sample size. The
effect of prevalence on sample size was tested adjusting for phase,
interaction between prevalence and phase, and all other significant
covariates.
Results
Of the 186941 trials in clinicaltrials.gov, 1567 (0.8%) were studying
one rare condition only and with prevalence information from
Orphadata. There were 19 trials studying disease with prevalence <1/
1,000,000, 126 trials with 1-9/1,000,000, 791 trials with 1-9/100,000
and 631 trials with 1-5/10,000. Of these, 1160 were described as
phase 2 trials. All the covariates described above except type of lead
sponsor were significant and thus, were included in the regression
model. The estimated mean sample sizes in phase 2 trials were simi-
lar across all prevalence classes after adjusting for other covariates;
15.7 (95% CI, 8.7-28.1), 26.2 (16.1-42.6), 33.8 (22.1-51.7) and 35.6
(23.3-54.3) for prevalence <1/1,000,000, 1-9/1,000,000, 1-9/100,000
and 1-5/10,000, respectively. Phase 3 trials of rarer diseases (<1/
1,000,000 and 1-9/1,000,000) had similar size (estimated mean, 19.2,
6.9-53.2 and 33.1, 18.6-58.9, respectively) to those in phase 2 but
were statistically significant lower than the slightly less rare diseases
(1-9/100,000 and 1-5/10,000) trials (estimated mean, 75.3, 48.2-117.6
and 77.7, 49.6-121.8, respectively).
Conclusions
Our study shows that there was association between prevalence and
the size of phase 3 trials with rarest diseases trials noticeably smaller
than the less rare diseases trials. However, prevalence was not associ-
ated with the size of phase 2.
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Cancer clinical trials are expensive in terms of running costs and
time taken to complete, while the success rate of phase III cancerinterventional trials is low, around 34%. Many novel trial designs, espe-
cially using adaptive and Bayesian methods, have been developed to
help reduce costs and improve success rate of such trials. These novel
techniques, however, are not always easily implemented in practice.
We propose to apply the predictive power concept in the design of
feasibility studies.
BRAF +MEK inhibitor drugs are effective treatment for patients with
BRAF mutant melanoma, but benefit is limited by secondary resist-
ance and toxicity. Clinical case reports and animal models suggest
intermittent dosing may delay onset of resistance and reduce side-
effects. The INTERIM trial is an open label two-arm randomised phase
II feasibility trial designed to investigate the intermittent BRAF +MEK
inhibitor drug dosing. Eligible patients will be randomly allocated to
either the intermittent or the standard continuous dosing arm. Since
there are concerns whether patients and their doctors will accept
allocation to less than standard treatment, the overall objective of
the study is to determine the acceptability of randomisation and
compliance of patients allocated intermittent BRAF +MEK inhibitor
drug dosing. The study will also investigate the probability of a suc-
cessful follow-on phase III trial, measured using the predictive power.
The definitive phase III trial will be powered to test the hypothesis
that intermittent dosing will prolong progression-free survival (PFS)
compared with standard continuous dosing. It will need ~1000 pa-
tients (846 PFS events) to detect a hazard ratio (HR) = 0.80 with a 5%
significance level and 90% power. The log(HR) is normally distrib-
uted, and therefore the predictive power could be easily calculated.
Assuming a prior of no difference and 1 PFS event, that is log(HR) ~
N(0, 4), a significance level 5% and 90 PFS events observed in the
feasiblity study:
If the observed HR = 0.80 (an improvement in median PFS from 12 to
15 months) in the phase II feasibility trial, the predictive power to re-
ject the null hypothesis of no PFS benefit of intermittent dosing
schedule under the planned phase III trial (with 846 PFS events) is
72%. If the observed HR = 0.75 (an improvement in median PFS from
12 to 16 months) in the phase II trial, the predictive power to reject
the null hypothesis of no PFS benefit of intermittent dosing schedule
under the planned phase III trial (with 846 PFS events) is 81%.
We plan to recruit a total of n = 150 patients (75 patients in each
arm) to the INTERIM trial in 18 months. It is anticipated that approxi-
mately 90 PFS events will be observed with a minimum of 9 months
follow up.
The INTERIM trial proposal has received funding from the UK RFPB
NIHR programme. The concept of predictive power will provide us
with confidence to conclude whether the follow-on phase III trial is
justified, while it is easily implemented in practice.
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Background
Economic evaluations are commonly conducted within randomised
controlled trials in order to assess value for money by measuring both
the costs and the outcomes associated with a particular intervention.
However, resource-use measurement by patient recall in economic
evaluations is characterised by inconsistency and a lack of validation. A
well validated standardised resource-use measure could increase data
quality, improve comparability between studies and reduce research
burden on patients and health economists.
Aim
To identify a minimum set of core items of resource use that should
be included in a standardised instrument for health economic evalu-
ations conducted in the United Kingdom (UK).
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The content of 59 questionnaires in the Database of Instruments
for Resource-Use Measurement (www.dirum.org) was analysed to
generate a list of 60 resource-use items relative to an NHS and
personal social services perspective (e.g. Visits to healthcare profes-
sionals in the community; prescribed medications). An electronic
Delphi survey was developed, and health economists with experi-
ence of conducting economic evaluations in the UK were recruited
through personal approaches and a general request to the Health
Economists Study Group mailing list (a professional group based in,
though not restricted to, the UK). Respondents were asked to rate
items on a scale of 1 to 9 according to the importance of the item
in a generic context, and were encouraged to comment on their
choices or add additional items. Responses were used to identify
items considered less important according to predefined consensus
criteria. A second round was developed, in which feedback from
round 1 (median responses to each item and summarised com-
ments) was presented to respondents, alongside a reminder of their
own scores. An individualised email was sent to each participant
from round 1, and round 2 participants were asked to re-rate items.
A final item selection meeting of the project team and a represen-
tative of the participants was held to discuss the results of the
Delphi.
Results
45 health economists with wide-ranging trial experience completed
round 1. Following application of the consensus criteria, items such
as length of outpatient appointments (median = 3) and email/text
communications with healthcare professionals (median = 4) were
considered less important. The list of 60 items was reduced to 34
items for the second round; no new items were added. 42 respon-
dents completed round 2 (93.3% of the original respondents), and
the list of items considered important converged towards a shorter
list where there is greater consensus about importance (including
hospital outpatient appointments (median = 9) and appointments at
GP surgeries (median = 9)). Following the meeting to discuss the re-
sults, a list of 10 core items was identified with further items identi-
fied as suitable for development as ‘bolt-on’ modules.
Conclusions
The apparent consensus on which items are important to trialists in a
generic context suggests that a standardised instrument for core items
is feasible, provided it is developed with the flexibility to add ‘bolt-on’
modules. Although this work was conducted in the context of RCTs
within the UK, in principle, the items identified are generalizable to
other jurisdictions and study designs.
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Background
Modelling and simulation are increasingly being used to assist in
planning and decision making during drug development. This in-
cludes clinical trial simulation which has been applied to optimise
the design of drug trials; such as calculating sample sizes, determin-
ing the optimal dosing regimen or estimating the impact of protocol
deviations. This requires constructing a mathematical representation
of the trial processes and makes use of data on the population of
interest and likely effects of the interventions being studied. These
methods are typically applied to a specific compound in clinical de-
velopment to support decision-making and trial design in subse-
quent phases of development. Another potential application of
modelling and simulation, however, is in informing drug discovery
by identifying the theoretical properties of a drug which would maxi-
mise the desired trial outcomes.Knowledge of the clinical pharmacological properties of drugs in
development evolves throughout the drug development process.
Such properties include the absorption, distribution, metabolism
and excretion of the drug (pharmacokinetics) as well as its effect
on the body (pharmacodynamics), such as disease progression or
biomarker activity. Pharmacometric models can be deployed to de-
scribe these processes based on available data and simulation can
be used to both evaluate efficacy and safety in differing popula-
tions under different conditions to assess the impact of disease,
background medication or adherence. These estimates can further
be used as inputs to pharmacoeconomic models which compare
the costs and benefits of the hypothetical drug to those of existing
therapies. This has the added value of, going beyond efficacy, and
identifying what properties are most likely to result in a drug being
deemed cost-effective.
Methods
This study investigates the potential for using modelling and simulation
to inform drug discovery and development using a case study of urate-
lowering therapies (ULTs) used in the long term management of gout.
Gout is characterised by a reliable biomarker, serum uric acid (UA) con-
centration, which is also used as a primary endpoint in clinical trials.
Serum UA concentrations are well correlated with gout symptoms and
can also be predicted using pharmacometric models. This case study
focusses on estimating the desired clinical pharmacological properties
of uricosuric drugs, which stimulate the renal excretion of UA thus low-
ering the serum concentrations. Successful uricosuric drugs must bal-
ance the risks resulting from the renal excretion of large amounts of
UA against the benefits of reduced serum concentrations, while being
forgiving to poor adherence which is common for ULTs. The linkage to
economic modelling comparing the hypothetical drug with current
standard ULT is used to provide estimates of cost-effectiveness.
Results
The results reveal the optimal combinations of clinical pharmacological
properties for any future uricosuric medicine and therefore provide the
target characteristics to drive future drug discovery. The results of the
economic modelling show the probability that new drugs will be cost-
effective for a given willingness-to-pay threshold based on the impact
of these properties on the expected efficacy and safety. The findings
could serve as a guide of the potential for future innovation in the area
of uricosuric treatments for gout.
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Background & Aims
Chronic infection of hepatitis B virus (HBV) is the predominant cause
of cirrhosis and hepatocellular carcinoma (HCC) in China. However,
the real-world data on the clinical and treatment profile is still lack-
ing. Therefore, we initiated a nation-wide, hospital-based registry sys-
tem, China Registry of Hepatitis B (CR-HepB) in June 30, 2012.
Methods
This on-line registry system is owned by China Foundation for Hepatitis
Prevention and Control and academically supported by Chinese Society
of Hepatology. The criteria for inclusion to this registry was any adult
patients with HBSAG-positivity for than 6 months, meeting the diagnos-
tic criteria for various stages of chronic HBV infection and consent to re-
ceive follow-up per clinical practice guidelines (check HBVDNA,
biochemistry, alpha fetoprotein and ultrasonography at least every
6 months). The decision on treatment was at discretion of the patients
and the clinicians based on standard of care. The information system
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mation technology service provider and professional statistical and
methodological terms
Results
As of Oct 31, 2016, 38 tertiary or secondary hospitals across China
had participated in this registry, and totally122,987 patients and
486,976 visits were recorded. Among them 61.9% were men; the
average age at inclusion was 44.3 years, with 67.7% of them being
between 30 and 60 years old. Approximately 6.7% were initially
diagnosed with immune tolerance phase of HBV infection, 68.5%
with chronic hepatitis B, 14% with cirrhosis (compensated 6.3%; de-
compensated 7.7%), 1.8% with HCC, and 9% with others (including
acute-on-chronic failure and recovery phase of HBV infection). Forty
seven percent of the patients were positive for HBEAG and 74.1%
were positive for HBV DNA. Among 859 patients with liver biopsy the
necroinflammation score G0-G4 were seen in 2.6%, 30.5%, 36.2%,
25.6% and 5.1%, respecdtively; and fibrosis stage S0-S4 were seen in
12.5%, 34.8%, 28.9%, 18.3%, and 5.5%, respectively. Totally, 33,533
(27.3%) patients had therapeutic information, among them 10.6%
receiving conventional or pegylated interferon-alpha and 88.7% re-
ceiving nucleos(t)ide analogues (NAS). The split out of the NAS
showed that entecavir accounted for 51.2%, lamivudine for 18.8%,
adefovir for 16.1%, telbivudine for 12.5% and tenofovir (approved
but reimbursable for HBV therapy until recently) for 1.4%.
Conclusions
In this largest registry for HBV patients in China mainland, middle-
age men were predominant and less than half of all patients were
HBEAG positive. NAS were the most commonly used but nearly half
of the patients did not choose the recommended high potent and
less resistant agents. Long-term follow-up and judicial evaluation of
the antiviral efficacy and clinical outcomes would provide valuable
information for decision-making in clinical and public health sector.
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Background
Point-of-care registry trials extract data from existing Electronic Pa-
tient Records (EPR). Poor accuracy and completeness of EPR data are
key barriers to the success of such trials. Neonatal care in the United
Kingdom has a well-developed EPR database, the National Neonatal
Research Database (NNRD). We hypothesised that within neonatal
clinical trials there are a subset of common data items reported
across important trials, and aimed to assess the completeness of
these items in the NNRD.
Methods
We searched the four most cited general medical journals (New Eng-
land Journal of Medicine, The Lancet, BMJ and The Journal of the
American Medical Association) and extracted neonatal clinical trials
from 2006 onwards with no restriction on the disease area or treatment
type. The following data items were extracted from each identified
paper by two independent reviewers: baseline characteristics, items
used in stratification or minimisation, and items used to adjust the pri-
mary outcome. Data items were combined where clinically appropriate.
NNRD data completeness was examined over the period January to
June 2015 for infants <32 weeks gestational age in England, Scotland
and Wales. Missing was defined as an empty field or an invalid value.
This review was pre-registered (PROSPERO: CRD42016046138).
Results
We identified 46 studies involving 33,276 infants and 132 data items;
29 studies on pre-term babies, 12 on term babies and 5 studies where
either age was unrestricted or undisclosed. Thirty seven trials (80%)
were multicentre trials. Gestational age was the most commonlyreported data item (96%). Sex (89%) and birth weight (89%) were also
common items reported. Antenatal steroids were reported in 25 (86%)
pre-term studies and 1 (8.3%) term study. Mother’s ethnicity and mul-
tiple births were reported in 50% of all studies but the latter was pre-
sented in 72% (21) of pre-term studies and 8% (1) of term studies.
Gestational age, the most reported data item, was complete for 99.3%
of infants in the NNRD. With the exception of maternal ethnicity, none
of the commonly reported data items were missing in more than 10%
of babies in the NNRD.
Discussion
We show that there are a limited number of data elements which are
common to recent influential neonatal clinical trials. Such essential data
elements can be used to focus the measurement and improvement of
data quality in preparation for point of care trials. The NNRD has low
rates of missing data for these core data elements. This supports the
use of routinely collected NNRD baseline data in UK neonatal clinical tri-
als. Other key requirements are to establish national and international
consensus for common outcomes for neonatal trials and assess the
quality of corresponding NNRD data.
Conclusion
High impact neonatal clinical trials share core data elements. In the UK
these data can be obtained reliably from the NNRD, a well-established
EPR-derived national database, supporting its use for point-of-care
registry trials.
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Background
Type 1 diabetes is associated with cardiovascular disease (CVD) and
the electrocardiogram (ECG) is the most accessible test for screening
and detection of subclinical myocardial infarction and CVD. The Dia-
betes Control and Complications Trial (DCCT) and its follow-up study,
the Epidemiology of Diabetes Interventions and Complications (EDIC)
is currently following 1,214 of the 1,441 originally randomized partici-
pants (94% of the surviving). During the 30 years of follow-up, con-
tinual efforts were made to modernize systems and data processing
to improve efficiency and reduce cost.
Methods
Participants were administered a resting 12-lead ECG at each annual
visit during DCCT/EDIC. Paper tracings and accompanying paper
tracking forms were sent from the 27 clinics to the Data Coordinating
Center (DCC), then forwarded in monthly batches to the Central ECG
Reading Center (CERC) for analysis. In 2012 the paper tracking form
was replaced with direct entry into a proprietary data management
system. In 2014, the study implemented the use of digital ECG re-
cordings and transmission. Unlike paper ECGs, digital scans automat-
ically provide hundreds of waveform measurements and can be
stored indefinitely without the risk of deterioration. Digital ECGs are
transmitted directly to the CERC via analogue phone lines. Site coor-
dinators were centrally trained on the use of the new digital ECG ma-
chines and how to transmit the recorded ECGs electronically to the
CERC.
Results
Implementation of digital ECG recordings substantially reduced the
time between ECG acquisition and receipt by the CERC, with 49% of
the ECG’s transmitted on the day of the clinical visit (mean 14 ±
18 days). The time from ECG acquisition to generation of the ECG clin-
ical report was reduced by 52 days (120 ± 39 and 68 ± 21 days for
paper and digital ECGs, respectively). Furthermore, the DCC received
ECG results from the CERC 51 days sooner (108 ± 40 days and 57 ±
21 days for paper and digital ECG, respectively). There was no reduction
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digital transmission was offset and balanced by the reduction in the
cost of processing and reading paper ECG’s over time.
Conclusion
Digital ECGs have simplified and enhanced the processing of ECGs
between the reading center, coordinating center, and clinical sites by
reducing the processing time by 43% with less effort and cost.
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Background
As our Centre moves towards a standardised in-house platform for
ECRF development we are taking steps to modify supporting processes
(such as randomisation, pharmacovigilance and document manage-
ment) into ‘generic’ components to build into this system. Another such
component is the Drug Supply Management (DSM) tool suite which
has been critical in previous systems to ensure allocation and monitor-
ing of supplies across trial sites is accurate and efficient. Experience of
developing custom versions of the DSM components has thrown up a
number of challenges; these in turn have allowed refinement of
functionality across multiple distinct system deployments. Identifying
the ‘best’ features from each system will allow us to move towards the
creation of a generic system.
Methods
Common DSM components we provide include batch management,
order and receipt management (both manual and triggered), post-
receipt status updates and summary reporting tools. The processes
behind each component can vary slightly or significantly based on the
logistical challenges identified when reviewing a trial protocol and after
discussion with the trial management team and most importantly the
lead pharmacist or their equivalent. Although the basic functionality
appears to be the same the changes are usually identified ‘under the
hood’ and we will look to identify the different types of changes that
we have had to put in place from system-to-system. Developing sys-
tems like this as part of our Clinical Trials Unit (CTU) has allowed for
gradual refinement of functionality. However, we have faced increasing
challenges when integrating with third-party systems and working to
an external set of Standard Operating Procedures. These differences
will be considered and compared.
Conclusion
We will discuss the different scenarios faced when developing previous
DSM systems including why we had to modify the standard platform
and how we adapted it. We will also discuss how this experience can
be used to produce a generic system that is suitable to adapt to differ-
ent use cases as required. The difference between open-label and
double-blind DSM systems will be considered as this may be the reason
for two separate systems instead of just one. The feasibility of a ‘truly
adaptable’ system will be considered after this discussion.
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Background
Compared to most software development projects, clinical trial
electronic data capture (EDC) systems have a very long shelf life. It
is not uncommon for clinical trials to last ten years. Even when tri-
als themselves may be comparatively short lived, the systems usedto collect and collate the data must be usable and provide reprodu-
cibility potentially for decades after the trial has finished. This cul-
ture of long lived projects and gradual organic evolutionary change
in software development has many advantages. Ideally best of
breed features and solutions remain and weaker elements are re-
placed. However legacy artefacts are left over from all evolutionary
approaches. In geography there are ox bow lakes, in human anat-
omy there is the tailbone and in jeans the small inner pocket was
originally used to hold a pocket watch. In popular culture, the tele-
vision show “Lost” featured a character that lived in an under-
ground bunker and types a series of mysterious numbers into a
computer every 108 minutes or there would be undisclosed “disas-
trous consequences”. While a fictitious plot device, there are nu-
merous similar occurrences in real business software and processes
where the knowledge exchange process is simply - just enter a zero
in that field, we don’t know why, but it doesn’t work if you don’t.
When faced with the large amount of expertise gathered from past
EDC development in a CTU, the large number of processes involved
- the reason for which may or may not be understood, the risk of
mistaking valid important elements for legacy artefacts and com-
batting the phrase “that’s how it’s always been done”, creating a
new EDC system is difficult.
Conclusion
The authors will present the major design decisions faced during
the creation of a new EDC, the new features introduced for the
different staff roles involved with the EDC usage lifecycle, including:
extensible programming language and platform support, inter-
nationalisation, multiple means of API access, online/offline version-
ing system.
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Background
For many years Google have offered companies a range of tools to pro-
vide analytics on web sites. These tools can be used to track and report
on where or when the visitor to the site is having a bad experience and
does not complete a transaction or chooses to leave the site. Companies
use these tools to identify problem pages and further enhance the users
experience with a view to boosting sales and revenue. Clinical trials have
become less reliant on paper based systems and more reliant on elec-
tronic data capture (EDC) and electronic patient reported outcomes
(EPRO). This type of technology enables upfront validation of data, which
in turn should provide a cleaner data flow and should lead to less data
management queries. If however there is a problem with the design of
the system it may result in either partial completion or non-completion
this will lead to missing key data in any self-completion questionnaires in
the study. This is particularly dangerous in EPRO scenarios where there is
often less feedback from participants and there is usually the option to
skip most questions. The problem of questionnaire abandonment in
EPRO is somewhat similar to the problem of basket abandonment in
ecommerce websites in that it can be difficult to know what has caused
the abandonment and they both lead to significant loss.
Methods
To improve the user experience of EDC and EPRO and ultimately in-
crease the completion rate, a range of existing approaches from
mainstream web analytics and observational usability evaluations
sessions were combined and embedded within the EDC and EPRO
environments.
Conclusion
We will demonstrate the significant advantages this approach pre-
sents when combined and how it can be used to identify and resolve
issues when they arise rather than discovering than facing incom-
plete datasets at the end of the collection period.
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Web-based, direct data entry by research participant populations is
becoming more common. In a long running research study, transi-
tioning away from paper-based data entry provided opportunities
and highlighted challenges.
SEARCH for Diabetes in Youth (SEARCH) is an on-going, large, na-
tional multi-center and population-based epidemiological study of
youth with diabetes. Initiated in 2000, SEARCH was designed to esti-
mate the prevalence, incidence and clinical presentation of diabetes
in youth age < 20 years, by age, sex, race/ethnicity and diabetes type.
More than 25,000 youth have been enumerated as part of the regis-
try study; 3000 are enrolled in the longitudinal cohort study. These
individuals represent diverse racial and ethnic backgrounds helping
SEARCH determine the extent of diabetes in the community and its
impact on different populations. SEARCH has 5 clinical centers lo-
cated in South Carolina, Ohio, Colorado, California, and Washington.
Funding is provided by the Centers for Disease and Prevention (CDC)
and the National Institute of Diabetes and Digestive and Kidney Dis-
eases (NIDDK).
The cohort study sample, followed longitudinally for 16 years, is char-
acterized using a variety of age specific surveys and a physical exam
in which complications and laboratory measures are assessed. For
the present SEARCH visit, the study took the opportunity to broaden
the method of data collection to allow participants the choice of
using a web-based direct data entry approach or to have data
collected on paper forms. To facilitate this transition, data entry
forms were carefully evaluated, re-organized and updated to better
accommodate direct data entry. The goals are to facilitate a positive
end-user experience, ensure high quality data capture, increase re-
sponse rates and decrease clinic staff burden. In addition, because of
funding limitations, approximately half of the past participants were
invited to participate only in the online surveys (e.g., were not of-
fered an in person visit). To date, response rates are on track to meet
study goals.
Some of the challenges of adding the option of participant direct
data entry include creating an intuitive, seamless data entry flow,
encouraging participants to answer all questions and to complete all
modules, ensuring invalid or out of range answers are corrected and
that the participant understands overall navigation and the meaning
of individual questions and facilitating consistency in future analyses
after questionnaire updates and re-organization. This poster will
further explore the challenges encountered, both in planning and
programmatic implementation, and will describe the advantages and
outcomes both for clinic staff and study participants.
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REDCAP (Research Electronic Data Capture) is a secure, web-based
application designed to support data capture for research studies
and is free to non-profit organizations who join the redcap Consortium.
Its capabilities include the building of custom databases and surveys
(that supports online or offline data capture); it also has data manage-
ment features, such as participant scheduling calendars. Projects which
do not need highly specialized data collection tools or have theresources for programmer support to create such tools can greatly
benefit from REDCAP’s features, which are continually being advanced.
Piping is a capability within redcap that allows inserting values previ-
ously entered by the user into a survey’s text. This feature enables the
generation of dynamic questions that appear to be customized for a
specific individual.
The EPHIM (electronic Patient Health Information Management) Pro-
ject is a research study with the aim of understanding the factors
that facilitate and limit use of patient portal systems by older, lower-
income adults. Documenting human-technology interaction is a key
component of the project. To assess the participants’ interactions
with technology, we asked them about their e-mail use, and if they
had any of the following in their home: stationary computer, laptop
computer, tablet, smartphone, or internet. These items were to be
asked in a baseline questionnaire and in six follow-up questionnaires
spanning 12 months. While we wanted to follow any changes in the
status of these items, given the age of the participants and relatively
short time frame across visits, we decided it was unlikely there would
be many changes in the technology available in participants’ homes
during the two months between interviews. Thus, in order to prevent
discrepancies in responses across time we used a combination of the
piping feature and branching logic within redcap to remind the par-
ticipants how they answered previously. For example, if a participant
answered that he/she had a laptop computer in his/her home in the
baseline questionnaire, at the next visit the question would read,
“When we spoke last time you indicated that you do have a laptop
computer in your home. Is this still correct?” The response to this
yes/no question was stored and used within the next follow-up visit
questionnaire which would have the same wording (“When we spoke
last time you indicated that you? Is this still correct?”). This feature
was enabled using a series of conditional statement code similar to
syntax used within Excel.
In its simplest form, the piping feature within redcap allows for a more
personal correspondence with participants and increases efficiency in
the data collection process. We have highlighted a more advanced
example of the piping feature which, when used in combination with
branching logic, can be used to customize data collection and help pre-
vent discrepancies across time.
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Background
The REVEAL study is a streamlined randomized controlled trial (RCT)
investigating the effects of adding the CETP inhibitor anacetrapib
to LDL-lowering treatment with atorvastatin among 30 000 study
participants at high risk of vascular disease. It is coordinated by the
CTSU at the University of Oxford (the trial Sponsor) with 6 Regional
Coordinating Centres responsible for the conduct of the trial in 431
sites in 10 countries. Laptops are provided to all sites so that
participant visit data can be captured directly into the electronic
Case Report Form (ECRF) using software specifically designed for
this purpose by CTSU. The laptop database therefore contains the
source data.
Methods
Features of the laptop system used include: Consistency in laptop
setup by utilising a Windows 7 image which also allows for regional
variations where required. Remote central management of laptops
by CTSU, including user accounts and passwords plus distribution of
software updates. Timely, secure and regular transfer of data
between the laptops and the designated FTP & HTTPS servers via a
reliable internet connection. Robust laptop & data security achieved
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passwords, ‘Locked down’ user accounts and staff training. Partici-
pant identifiable data is retained on the laptop but only transferred
to CTSU if permitted by local data protection laws.
Discussion
Using laptops in REVEAL offers a highly effective and user-friendly
method of collecting good quality participant data with significant
advantages over paper-based systems. Careful scripting of the user
interface enhances compliance with the study protocol and proce-
dures, and prompts any necessary actions related to participant
safety. Data entry (which can be done offline) directly into an ECRF
provides immediate validation of data and a full audit trail, whilst
site investigators retain access to their participants? Data held lo-
cally and securely both during and after the trial. The use of a ‘thick
client’ rather than a web-browser provides resilience against inter-
net outages whilst enabling timely data management across
multiple countries and time zones. Potential drawbacks include reli-
ance on a good internet connection for regular data transfer
(ideally at least daily), central study databases not being updated in
real time (although this is much less of a problem than systems
that rely on transcription of data from paper forms), and restric-
tions on moving participant identifiable data out of some countries.
In addition the provision of laptops can be expensive and resource
intense requiring remote support and maintenance over many
years.
Conclusion
In comparison to paper-based clinical trials, the use of carefully pro-
grammed and managed study laptops has significant benefits for
participant safety, data quality and regulatory compliance. How-
ever, it is probable that in the future web-browser based systems
(including tablet and smartphone implementations) will become
the norm, with advantages in terms of cost, convenience, familiar-
ity, and usability. However, the lessons learned from delivering a
large-scale, laptop-based, direct data entry system will be valuable
if the potential of these newer approaches is to be realised in fu-
ture clinical trials.
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The Global Network’s (GN) clinical trials produce rich data sets to in-
form investigators about treatments to prevent, diagnose, or treat
human diseases. From these datasets, the clinical investigators pub-
lish results from their preplanned investigation to inform colleagues
of the outcomes of the clinical trial. These same datasets can be
used for secondary analyses to leverage the information available.
All of these publications enrich the understanding of a disease state
and possible therapies as well as serve as measurable deliverables,
demonstrating productivity to the funding source. Therefore, we
needed a system to track 1) data requests (for secondary analyses),
2) pre-publication development (includes all primary and secondary
reports using a clinical trial dataset) and 3) post-publication track-
ing (citation counts, journal impact factor and author h-index).
Since the GN is a collaborative network, comprised of several sites lo-
cated across the U.S and in other countries, the tracking system had to
be centrally accessible. To accomplish this, we chose to allow access
through our website. We developed this tracking tool such that the in-
vestigators could submit concepts, requesting data from a completed
clinical trial, in an easy and trackable way. By collecting additional infor-
mation about the concept, all stakeholders could access the informa-
tion and understand the current status of the progress. The system was
also developed to track primary manuscript development as the firstdissemination of a clinical trial as a journal publication. By inputting in-
formation about the process, the status of the manuscript is transpar-
ent. Finally, the system needed to provide an easy way for investigators
and other staff to show the effects that their completed clinical re-
search has had on the overall scientific community.
These challenges were addressed by looking at a number of offline
tracking systems that had failed to meet the needs of various clin-
ical networks, and finding ways to improve upon them. An extensi-
ble.NET module was developed to store and display all relevant
data for publications tracking. Web services were employed to con-
nect the system to popular publication data stores such as The
United States National Library of Medicine’s PubMed database,
Thomson Reuters’s Web of Science database, and the International
DOI Foundation’s digital object identifier (DOI) to retrieve and store
accurate information about publications at any point in the creation
process. The presentation will discuss the different technical chal-
lenges of this approach and how they were resolved. Pros and cons
of the approach will also be discussed along with methods used to
report information out of the system.
P278
Incorporating electronic health records data into efficient trial
interventions – cluster randomised trial to reduce antibiotic
prescribing in primary care
Dorota Juszczyk, Judith Charlton, Martin C. Gulliford, the REDUCE Trial
Research Group
King’s College London
Correspondence: Dorota Juszczyk
Trials 2017, 18(Suppl 1):P278
Background
Antibiotic resistance is a growing problem that transcends national
boundaries. 80% of all antibiotic used in the UK are prescribed within
primary care, and up to 50% of prescriptions may be unnecessary. In-
terventions are needed that can be delivered to prescribers at low cost.
Objectives
This study utilises electronic health record data (EHR) on antibiotic
prescribing for specific indications to provide feedback to prescribers.
This intervention is being evaluated in a cluster randomised trial.
Study setting
The study is currently being conducted in the Clinical Practice Re-
search Datalink (CPRD).
Methods and results
There were 80 CPRD general practices randomised. The trial interven-
tions include a webinar and decision support tools that are delivered
into general practice systems. In addition, intervention trial arm prac-
tices are sent monthly-updated reports on their prescribing of antibi-
otics for respiratory tract infections. During the 12 month intervention
period, electronic health records data are analysed from each month’s
CPRD release to provide detailed feedback on the number of RTI
consultations, number of antibiotic prescriptions and proportion of con-
sultations with antibiotics prescribed. Prescribing-report templates were
designed through qualitative research with non-trial practices. An R
program was written to extract, analyse and summarise electronic
health records data for intervention trial arm practices. The “reporters”
package in R was used to create personalised “Pdf” reports, based on
the templates, for each practice.
Conclusions
As well as informing the design of the cluster trial and outcome
evaluation, electronic health records were used as a key component
of the trial intervention. The automated system for writing feedback
reports was time-consuming to establish, but then worked efficiently.
The most time consuming elements of the report production were
those that could not be automated, such as updating the meta-files
and adjusting the template design and content.
Trial Registration and Funding: NIHR HTA Trial registration:
ISRCTN95232781
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Background
ASCEND is a randomised 2x2 factorial study of aspirin versus placebo,
and of omega-3 fatty acid supplementation versus placebo, for pri-
mary prevention of cardiovascular events in people with diabetes.
The study used a mail-based approach to identify and randomise
15,000 people with diabetes. The project is now approaching its final
follow-up stage. In the course of the study, the vast majority of data
collection was done via paper designed to be processed with Optical
Character Recognition software. In previous paper based studies,
double data entry was used, which meant sending paper forms to a
commercial company for data entry and finding and resolving any
data or keying discrepancies in-house (often with the necessity to
see the paper form). For ASCEND, a more streamlined and cost ef-
fective approach has been developed.
This presentation will discuss the methodology, costs and benefits of
this approach.
Methods
A third party OCR software, FORMS, from Readsoft (now Lexmark) was
identified as the best tool to scan, review and save form content for fur-
ther use in the study. The software gives a rich selection of ways the
process can be customised. An option to review different parts of the
form by users with different roles was required, e.g. Lists of medication
or medical events to be reviewed and coded by medical staff, the rest
of the form to be reviewed by administration staff. Using the FORMS'
API, extra validations and background calculations were performed and
bespoke dialogues were added. The dialogues made it possible to save
handwritten medical events and medications as Read codes. Another
required outcome was a digital archive of form images with links to
relevant participants for viewing at any later point (instead of pulling a
form out of the paper archive).
Study paper forms were designed to fit FORMS requirements and
printed in a professional printing house using specific Pantone colours,
as we wanted to drop-out some elements during scanning. Once the
form stationery was available, we could start a long process of imple-
mentation of our own validation rules into the, unfamiliar at that time,
FORMS processing flow. Later on frequent maintenance work was
needed. The trial was extended in length and size and additional stocks
of form stationery had to be ordered. The set-up had to be tuned each
time a new printout of a known form was to be used.
Results
In total, about 340,000 forms of seven types (with multiple printouts
in each type) were processed by a team not larger than 4 administra-
tive and 2 medical staff and this task was only one of their many du-
ties. Coding of medication and medical events reported was done
from the form image, while with a double data entry system it was
possible only after the keyed data was transferred into the database.
Conclusions
The choice of the OCR system to process the ASCEND form over
the traditionally used double data entry proved to be more effi-
cient, although the path to a working system was strenuous and
full of pitfalls.
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Background
Despite the tremendous strides in hypertension management over
the last 4 decades, blood pressure remains poorly controlled in 35-
50% of patients with hypertension. This research agenda has gener-
ally been led by the scientific community and pharmaceutical indus-
try. Integrating patients and other key stakeholders as co-builders in
the development of research priorities may offer a new strategy to
increase the direct relevance and applicability of research to ultim-
ately close the current gaps in hypertension management.
Objective
We aimed to identify the 10 most important research priorities for
hypertension management across all stakeholder groups: patients,
caregivers and healthcare providers (family physicians, nurses, phar-
macists and dieticians).
Methods
Using the James Lind Alliance approach, a national web based sur-
vey asked patients, care givers and health care providers to submit
their unanswered questions on hypertension management. This
questionnaire was distributed through a variety of partner organisa-
tions to try and reach as wide a population as possible. Questions
already answered from randomized controlled trial evidence were
removed. A second questionnaire containing 42 distilled unique
questions were distributed in a 2nd round for feedback and rank-
ing. An in-person priority setting meeting of patient, caregivers and
healthcare providers then ranked the final top 10 research
priorities.
Results
There were 386 respondents who submitted 598 questions (after
exclusions). The majority of respondents were patients or caregivers
(78%). In addition, 29% lived in rural areas, 78% were aged 50–80
years and 75% were women. The 598 questions were distilled down
to 42 unique questions and from this list, the top 10 research ques-
tions prioritized included: determining the combinations of healthy
lifestyle modifications to reduce the need for antihypertensive
medications, stress management interventions, evaluating treat-
ment strategies based on out-of-office blood pressure compared
with conventional (office) blood pressure; education tools and tech-
nologies to improve patient motivation and health behavior
change, management strategies for ethnic groups, evaluating nat-
ural and alternative treatments and the optimal role of different
healthcare providers and caregivers in supporting patients with
hypertension.
Conclusions
These research priorities can be used to guide researchers and
funding bodies on hypertension management research considered
most relevant to patients, caregivers and healthcare providers.
Given the challenging nature of these priorities, consideration of
what kinds of innovative clinical trial methodologies to answer
these questions is also needed.
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Investigator Initiated Trials (IITs) are academic sponsored trials funded by
industry. IITs expand product knowledge and are often seen to provide
more robust data in delivering evidence based practice. They provide evi-
dence for clinicians, funders and industries about what happens in the
real world (Suvarna, 2012) and can be used to show proof of principle.
Our academic unit is currently collaborating with industry (Zimmer Bio-
met) on the All Ligaments Left in Knee Arthroplasty Trial (ALLIKAT). We
report the challenges and benefits of the collaboration in a device based
trial and how a mutually acceptable study is being delivered.
Background
ALLIKAT compares the clinical and patient reported outcomes of the
new bi-cruciate retaining knee system (Vanguard XP) to the current
single cruciate-retaining knee system (Vanguard CR). It is sponsored
and managed by the Surgical Intervention Trials Unit (SITU) at the
University of Oxford and funded by Zimmer-Biomet. As a key stake-
holder in the trial, the needs of Zimmer Biomet, with its product-based
approach, had to be carefully considered alongside an academic assur-
ance of protocol integrity (Goldenberg et al., 2011). Challenges identi-
fied in our industry collaboration include:
– Ensuring compatibility of research questions.
– Developing a mutually acceptable protocol.
– Identifying and being explicit about potential bias.
– Developing solutions for potential bias.
– Keeping abreast of market forces.
– Ensuring the study is patient-focused.
– Agreeing resource allocation and ownership for data collection
Methods
Regular meetings were arranged with Zimmer Biomet, with updates on
progress and feedback on issues could be discussed. The trial was devel-
oped as a study providing evidence for current practice variations. Previ-
ously within industry, surgical implant-based research has been limited
and undertaken essentially for marketing purposes. ALLIKAT moved the
focus to providing robust evidence for the use of new implants. We also
ensured the protocol supported the funder’s objective to comply with
the Beyond Compliance programme, which was set up by the BOA
(British Orthopaedic Association) to monitor safety of new products.
Working together allowed us to manage the inevitable product
?A3B2 show $132#?>design modifications, so that the study was not
jeopardised or over-shadowed by market pressures from within the
company. As a pragmatic study within the NHS it also needed to be
patient-focused. This was achieved by utilising patient reported out-
come measures, rather than subjective clinical reports and ensuring pa-
tients were not referred to as ‘subjects’ In study related documents.
Discussion
A multi-disciplinary collaborative team have been involved in the de-
sign and set-up of the study and have produced a protocol that con-
siders academic, patient and industry needs, which is practicable and
will provide evidence for proof of principle of a new marketable de-
vice to be used in clinical practice. Maintaining a patient focus and
promoting evidence-based health care has been key to working with
industry and the open communication dialogue has been helpful in
achieving objectives. There has been a corollary advantage in the in-
creased network links with industry, orthopaedic consultants and
NHS Trusts around the UK and a greater understanding of the needs
of these different parties.
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Patients who sustain open lower limb fractures are at high risk of
postoperative surgical site infection (SSI); rates of up to 27% are re-
ported for deep SSI. The type of dressing applied after initial de-
bridement may influence postoperative wound infection and
healing. The aim of WOLLF is to investigate the effectiveness and
cost-effectiveness of standard postoperative wound dressings with
negative pressure wound therapy in adult patients undergoing sur-
gical management of open lower limb fracture. We supplemented
wound assessment data collection with digital photographic im-
ages of surgical wounds at six weeks postoperatively to investigate
the feasibility and utility of this methodology to aid the diagnosis
of wound healing and SSI.
Methods
Setting: This multicentre pragmatic 2-arm randomised controlled
trial (RCT) was conducted in 24 trauma centres in the UK. Partici-
pants: All adult patients presenting with an open lower limb frac-
ture, with a Gustilo and Anderson (G&A) grade 2/3, were eligible for
inclusion. Initial wound management in Emergency Departments
involved removal of gross contamination, followed by surgical de-
bridement under anesthesia, where contaminated tissue is removed
and the open fracture is washed out. The fracture is then immobi-
lized using internal or external fixation. Interventions: Participants
were then randomised to treatment allocation at the end of sur-
gery, to either usual wound care or to negative pressure wound
therapy.
Outcomes
The primary outcome is the Disability Rating Index (DRI) score at
one year. Secondary outcomes include incidence of deep infec-
tion of the limb, quality of life and postoperative complications.
Superficial and Deep SSI was assessed at six weeks after surgical
repair of open fracture. Research associates (ras) observed
wounds at six weeks and completed data collection forms. Clinical
and patient-reported criteria were used, based upon the Centers
for Disease Control diagnostic criteria (CDC, 2015). Photography:
Digital cameras were used to capture a one or more images of
trial wounds at six weeks postoperatively; no upper limit on num-
ber of images was applied. A protocol was developed for ras.
Photographs were taken in a variety of clinical settings whereby
light conditions were optimised to reduce glare. A 15-cm ruler
with clear millimeter divisions was placed next to the wound, with
participant identification number. Images were returned to and
stored by Warwick CTU.
Results
A total of 1515 images were obtained from 358 participants
(mean 4.2 images per participant). Two assessors independently
judged photographs; an experienced tissue viability nurse and se-
nior researcher with clinical background. A third independent
clinician acted as final arbiter where there was lack of agreement.
Assessors were blinded to treatment allocation. Wounds were
judged for healing and visual evidence of infection, without
knowledge of clinical and patient-reported criteria recorded by
RAs. We report inter-rater and intra-rater reliability (kappa values)
for agreement between clinical assessors and compare rates of
healing and SSI with and without photographic data. This poster
will present our experience of the feasibility of supplementing
standard data collection methods by the addition of a 2-
dimensional image to aid the accurate diagnosis of postoperative
infection in a large pragmatic trial.
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Background
Variation in ascertainment of diagnosis based on radiological im-
aging has implications for randomised trials that report outcome
based on radiological diagnosis. This variation is particularly import-
ant for neonatal trials where diagnosis of intraventricular haemor-
rhage (IVH) and its severity based on cranial ultrasound scan are
important outcomes.
As part of the preparation for independent adjudication of cranial
ultrasound scans in a perinatal trial (Cord pilot trial), we measured
the intra- and inter-observer agreement of interpretation of cranial
ultrasound scans by expert adjudicators.
Methods
Eight experienced neonatologists or radiologists with expertise in
cranial ultrasound scans completed standardised training from a
paediatric neuroradiologist. To measure intra- and inter-observer
agreement each trained assessor rated the same 64 anonymised
cranial ultrasound scan images; comprising two sets of 32 scans.
The second set was a duplicate of the first with order and anonymi-
sation code changed. These scans were prepared by the neuroradi-
ologist. Six different diagnoses (IVH grades 1 to 4, periventricular
leukimalacia (PVL) and ventriculomegaly) were represented at least
five times in the 32 scans, with some scans showing more than one
target pathology and at least five with no abnormality. Assessors
were unaware of the duplicates. Results are presented for any IVH,
mild/moderate IVH (grade 1 or 2), severe IVH (grade 3 or 4), PVL
and ventriculomegaly. The multiple rater Kappa statistic was used
to assess inter observer agreement. The intra-observer agreement
was assessed by calculating the intra-observer Kappa statistic be-
tween the two sets of scans for each adjudicator.
Results
Inter-observer agreement for severe IVH was substantial (multiple
rater Kappa 0.62), fair for mild/moderate IVH and all IVH (multiple
rater Kappa 0.26 and 0.37 respectively), moderate for ventriculome-
galy (0.59) and poor for periventricular leukomalacia (multiple rater
Kappa 0.11). Intra observer agreement was substantial for severe IVH
(mean Kappa 0.74) and ventriculomegaly (mean Kappa 0.78), fair to
moderate for mild/moderate IVH and all IVH (mean Kappa 0.44 and
0.53 respectively) and moderate for PVL (mean Kappa 0.46).
Conclusions
This study has shown that there is considerable variation in the clas-
sification of scan results between individual assessors and between
the same assessor on repeated review. This suggests that for peri-
natal and neonatal trials it is important to use standardised criteria
and centralised adjudication with a consensus process for interpret-
ing cranial ultrasound scans. This has implications for other trials
where radiological images are used to assess outcome.
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After cardiac surgery, post-operative adverse events are common and
many patients experience several events. Some are frequent and less
severe, others are rare but serious. Most trials are under-powered to de-
tect differences in specific adverse events and event rates are often de-
scribed but not formally compared. We have examined the timing and
ordering of adverse events to inform the development of a composite
objective measure of “recovery” for use in cardiac surgery trials.
Methods
A cohort of 1102 patients having coronary artery bypass grafting in four
trials was assembled. Data on 11 adverse events, recorded consistently
across trials, were analysed. For each event, the timing was compared
between patients with and without other adverse events. For the sub-
group with multiple events, the timing of other events experienced
relative to a target event (before, on the same day as, or after the target
event; each event considered as the target in turn) was summarised.
Sequential pattern mining techniques were used to identify common
sequences of events in patients with at least two adverse events.
Results
Common adverse events were supraventricular tachycardia/atrial
fibrillation (SVT/AF) (341/1102, 31%) and suspected infections (312/
1102, 28%); half of those with both complications (62/124) had the
SVT/AF prior to infection. Reoperation occurred less frequently (56/
1102, 5%), and typically occurred alongside other events (44/56,
79%). Where reoperation and reintubation both occurred, they typic-
ally happened on the same day whereas, when reoperation and sus-
pected infection both occurred, reoperation usually preceded the
infection. Trends were less apparent for rarer complications, but pa-
tients who had both a myocardial infarction (MI) and SVT/AF (10/13
of those who had an MI) all had the MI first.
Most events occurred early during the post-operative stay, and
timings were similar between patients with one or multiple events.
Exceptions to this were reoperation, which happened later in pa-
tients with multiple events (although most reoperations were still
within one day of surgery) and gastrointestinal complications (which
tended to occur later in patients with multiple events). Unlike other
events, tracheostomy happened at any time during the post-operative
stay but, when this occurred, it was typically the final event reported.
Twelve frequently occurring “event sequences” were identified, two
of which included three events. 5% of patients with two or more
events had SVT/AF and suspected infections following a reoperation;
25% of patients who needed reoperation went on to have SVT/AF
and suspected infections. Also, suspected infections and reintubation
were followed by a tracheostomy in 6% of after.
Discussion
The collection of comprehensive adverse event data across trials has
allowed us to identify temporal relationships between different events.
Some patterns were expected while others were less so. Some events
are complications (e.g. MI), while others represent actions taken as a re-
sult of complication(s) occurring (e.g. Reoperation or reintubation).
Working with clinicians, we are using these observations to inform dis-
cussions about which events to include in a composite outcome de-
scribing “post-operative course” and the relative importance of events.
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Background
Stroke is the leading cause of complex disability worldwide and up to
77% of stroke survivors experience impairments in arm function.
Rehabilitation of arm function is a research priority for stroke survivors,
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of arm rehabilitation measure numerous outcomes (e.g. Strength, pain,
ability to use arm) hindering comparisons and synthesis of trial data for
efficacy analyses to inform clinical practice. However, arm function is a
complex concept and a variety of outcomes and measurement tools
may be warranted. Therefore, we aim to develop consensus recom-
mendations on a toolbox of key outcome measures for use in arm re-
habilitation RCTs.
Objectives
Describe current outcome measures used in arm rehabilitation RCTs and
their psychometric properties. Identify outcomes important to stroke sur-
vivors with arm function problems, their carers and healthcare profes-
sionals. Produce final consensus recommendations to support selection
of outcome measures for use in future arm rehabilitation RCTs.
Method
Phase 1: systematically explore trial data within a Cochrane Overview
of arm rehabilitation RCTs, extracting data on assessment tool use.
Tools must be clearly defined and reproducible to be considered as
an outcome measure in phase 2 and 3.
Phase 2: using nominal group technique (NGT) identify and agree on
outcomes relevant to life after stroke with arm impairment. Eight NGTs
will be undertaken with stroke survivors and carers, and eight NGTs
with healthcare professionals experienced in arm function rehabilita-
tion. This will be supplemented by eight semi-structured interviews
with stroke survivors and carers. Data will be analysed using content
analysis. Outcome measures identified (Phase 1) will be linked with out-
comes from Phase 2 followed by systematic exploration of outcome
measures psychometric properties.
Phase 3: edelphi to achieve consensus amongst stroke arm rehabilitation
researchers on important and feasible outcome measures from phase 2.
A final consensus meeting with stakeholders (stroke survivors, carers, re-
searchers, trialists, and healthcare professionals) will determine which out-
come measures will be recommended as part of the SMART toolbox.
Results
Phase 1: We extracted data from 254 RCTs; 208 assessment tools
were identified of which 146 met the criteria of reproducible out-
come measure. The Fugl-Meyer (arm function section) was used most
frequently (79/254 (31%) RCTs). 120/208 (58%) outcome measures
were only used in one RCT.
Phase 2: 43 stroke survivors and carers, and 58 health professionals par-
ticipated in the NGT sessions. Ten stroke survivors and carers participated
in eight interviews. Data analysis will be completed by January 2017.
Conclusions
Phase 1 highlighted wide variation and lack of consistency in use of
arm function outcome measures in RCTs. Consensus recommendations
that account for psychometric properties, and the perspective of stroke
survivors, carers, and healthcare professionals, will enable valid, reliable
and meaningful measurement in future RCTs of arm rehabilitation.
Therefore, recommendations for priority outcome measures that meas-
ure important outcomes are warranted. By agreeing on a toolbox of
key outcome measures for inclusion, subsequent RCTs’ outputs will en-
hance comparability of RCT results and facilitate comprehensive meta-
analyses of the effectiveness of interventions.
P288
Using proxy responses from carers to collect quality of life data
on patients with brain metastases: an analysis from the UK MRC
quartz trial
Matthew Nankivell1, Paula Mulvenna2, Rachael Barton3, Corinne Faivre-Finn4,
Paula Wilson5, Elaine McColl6, Barbara Moore7, Iona Brisbane8,
David Ardron9, Richard Stephens10
1MRC Clinical Trials Unit at UCL AND MRC London Hub for Trials
Methodology Research; 2Northern Centre for Cancer Care; 3Queen’s
Centre for Oncology and Haematology; 4Institute of Cancer Sciences;
5Bristol Haematology and Oncology Centre; 6Newcastle Clinical Trials
Unit and Institute of Health and Society; 7Wales Cancer Research
Network; 8The Beatson West of Scotland Cancer Centre; 9Patient
representative; 10MRC Clinical Trials Unit at UCL (retired)
Correspondence: Matthew Nankivell
Trials 2017, 18(Suppl 1):P288Background
Clinical trials requiring patient reported data involving patients with
multiple symptoms and/or a poor prognosis are often considered
challenging. There is concern about over-burdening trial participants,
either through more regular follow-up or by using longer question-
naires. One possible solution is to obtain data about the patient in-
directly by asking their carer.
The QUARTZ trial assessed the use of whole brain radiotherapy
(WBRT) in patients with inoperable brain metastases from non-small
cell lung cancer. This is a very poor prognosis group, and patients
can experience rapid changes in condition, which necessitated fre-
quent data collection. As the trial focused on quality of life, patients
were asked to complete the EQ-5D questionnaire on a weekly basis.
At the same time, their carer was asked to complete the same ques-
tionnaire from the point of view of the patient, so that the potential
use of proxy scores could be assessed.
Methods
QUARTZ randomised 538 patients to receive either WBRT, or supportive
care alone, with 407 carers also agreeing to participate. Here we com-
pare the baseline responses to the EQ-5D-3 L questionnaire of the pa-
tients and carers. The trial’s primary outcome measure of quality
adjusted life years (QALYs) was also calculated separately from patient
and carer data, and the results compared.
Results
Overall levels of agreement between patient and carer responses to
the EQ-5D at baseline were 82% for mobility, 79% for self-care, 71%
for usual activities, 78% for pain/discomfort, and 66% for anxiety/
depression. For anxiety/depression, carers reported more problems
than patients in 25% of cases, with 9% reporting fewer problems.
For the other questions carers reported more problems as often as
they reported fewer: mobility 9% vs 8%; self-care 11% vs 11%; usual
activities 15% vs 15%; pain/discomfort 13% vs 9%.
QALYs were calculated for the 397 patients where both patient and
carer data were available. The average QALY was slightly higher
using patient data (45.3 days) than carer data (39.0 days). When
assessing the treatment effect, the difference in average QALY (95%
CI) was 3.2 days (−13.1, 7.4) when calculated from patient responses,
and 5.3 days (−15.4, 3.9) from carer responses.
Conclusions
The level of agreement between patients and carers was reason-
ably high on most questions. The agreement was lowest for the
question about anxiety and depression, with carers tending to re-
port more problems compared to the patient’s own assessment.
The level of agreement seen means it may be reasonable to use
the carer response in some situations where it is not appropriate
to ask the patient directly. Caution is advised though as even for
the question on mobility there was disagreement in 18% of cases.
The difference in the analysis of the trial’s primary endpoint was
minor and did not change the main conclusion of the study.
Therefore within the confines of a clinical trial, it could be appro-
priate to use these proxy assessments to assess treatment effects.
QUARTZ is one of few trials in this setting, and further studies
looking at the use of proxy responses in poor prognosis popula-
tions are warranted.
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Background
In a test evaluation study, where there are a number of target condi-
tions to be considered, not all of which have a perfect reference stand-
ard, there is a risk of partial or differential verification of the underlying
causes, with the inherent bias. One approach is to use an expert inde-
pendent panel (EIP) to determine the presence or absence of the target
Trials 2017, 18(Suppl 1):200 Page 110 of 235condition based on several sources of information, ideally using a pre-
determined algorithm.
Case study
The MEDAL study asked whether magnetic resonance imaging (MRI)
could replace or triage the use of laparoscopy in establishing gynae-
cological diagnosis among women with chronic pelvic pain (CPP).
The primary analysis assessed the accuracy of the MRI for identifying
the condition(s) causing CPP, using an EIP. The panel consisted of 15
Consultant Gynaecologists, not involved in the study recruitment,
with each meeting involving three members. The reference diagnosis
was made in two stages. 1. Using patient history and reported symp-
toms, clinical examination, ultrasound, laparoscopy and follow-up 2.
As above with MRI scan report For both stages, each member indi-
vidually recorded the condition(s) for which they were >50% certain
were the cause of pain, prior to a group discussion to achieve a final
consensus diagnosis for the reference standard. To assess the reliabil-
ity of the EIP diagnoses we considered the agreement between the
three individual ratings, using Kappa, made by the panel members
prior to any group discussion. We faced several challenges: 1. The
quantity of information to assimilate and use of summary or complete
data 2. Eliciting a binary response, when there are degrees of uncer-
tainty 3. Multiple potential causes of pain which are not directly corre-
lated with the extent of pathology observed 4. Avoiding incorporation
bias from knowledge of MRI results 5. Laparoscopy cannot identify
some target conditions, only MRI can 6. Potential dual purpose of lapar-
oscopy as diagnostic and therapeutic.
Results
The EIP could produce the same diagnosis with summary data as for
complete data, although the EIP preferred the complete data, or
used in conjunction with the summary report, where cases were
considered complex. Sometimes it was felt necessary to select two or
more conditions where they could equally be the cause of pain,
although the EIP member was required to be at least 50% certain.
The panel were in excellent agreement in identifying deep infiltrating
endometriosis and endometrioma of the ovary as causes of CPP, and
in good agreement for superficial peritoneal endometriosis and ade-
nomyosis when the MRI reports were used in the reference standard.
Lower levels of agreement were noted for deciding that adhesions,
fibroids and pelvic inflammatory disease were the cause of pelvic
pain. The EIP failed to demonstrate adequate reliability in determin-
ing whether any of the non-gynaecological causes were the cause of
CPP. Conclusion There is little evidence on how panels should be
convened, how information should be presented or what the best
methods for consensus are and the MEDAL study highlights many
potential challenges.
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Background
Crohn’s disease (CD) is a chronic condition causing digestive tract
inflammation. Treatments may be used in combination and include
corticosteroids, immunosuppressives, 5asas, biologics and antibiotics.
All carry risks of adverse events (AEs).The most important outcomes and AEs are not well defined, espe-
cially long term. There is no CD core outcome set (COS). One is pro-
posed for Inflammatory Bowel Disease (IBD) using the International
Classification of Functioning, Disability and Health (ICF) 1.
The study aim was to identify the important outcomes and AEs
resulting from treatments for CD.
The study objectives were to:
– Perform a systematic review of trials, extracting the reported
outcomes and AEs for CD.
– Classify the outcomes and AEs into a conceptual framework
proposed for developing COSs (OMERACT Filter 2.03, in such a
way as to rank their importance.
– Identify longer term AEs from the Summary of Product
Characteristics (SPCs) 2 for the identified treatments.
Methods
MEDLINE, EMBASE, CENTRAL and CINAHL were searched. The inclusion
criteria were: 1. Randomised controlled trials, 2. Adult patients with CD,
3. All interventions to treat CD and its complications.
AEs were standardised using the Medical Dictionary for Regulatory
Activities (MEDDRA)5 terminology. Outcome and AEs were classified
into domains using the ICF, the Wilson and Cleary model of health-
related quality of life (QOL)6 and other domains recommended by
OMERACT. The domains were used to populate the Filter 2.0 frame-
work, creating the ‘Crohn’s Filter’.
Results
98 unique outcomes were identified from 182 studies. The outcomes
were mapped to 37 outcome domains in Filter 2.0. Outcomes were most
common in the domains of the structure of the intestine, defecation
functions, pain in the stomach and abdomen and quality of life.
Disease activity indices and QOL questionnaires were used extensively
in the included studies. Their coverage of the Crohn’s Filter framework
domains is dependent upon the combinations in which they are used.
Five hundred ninety-three unique AEs were identified in the trials,
which mapped to 46 outcome domains in Filter 2.0. AEs were most
common in domains of infections, sensations of pain, the structure
of the intestine, pain in the stomach and abdomen and sensations
associated with the digestive system.
Conclusions and recommendations
There is large variation in the outcomes and AEs reported across RCTs for
CD, which supports the need for a core outcome set to be developed.
– Using an existing conceptual framework to organise outcomes
data into domains and assessing their importance by frequency
of reporting is a pragmatic solution in lieu of a consensus
approach.
– Making use of AEs data is complicated as they may reflect disease
process, failure or side effects of drugs and unrelated events.
– Researchers should make decisions on the use of disease
activity indices and QOL questionnaires by considering the
outcomes that will be captured. The mapping conducted here
will aid this.
– Further recommendations will follow when the work is
concluded (analysis of withdrawals and SPC data).
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Objectives
To analyze the outcome measures in clinical trials of Traditional Chinese
Medicine (TCM) for stable angina pectoris and provide data to develop
core outcome sets (COS) for clinical trials of TCM.
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Three Chinese electronic biomedical literature databases (sinomed,
CNKI and Wanfang) were searched to identify randomized clinical
trials (RCTs) of TCM for stable angina pectoris published in 2010.
RCTs evaluated the effectiveness of TCM for stable angina pectoris
were considered to be eligible. There was no limitation to the type
of TCM intervention and control. All reported outcomes and related
information of included trials were extracted. Two authors screened
literatures and extracted information dependently.
Results
Finally ninety-four RCTs (with 9111 subjects) were included for ana-
lyses. There were totally 79 outcome measures were reported in all
included RCTs. The ten mostly reported outcomes were efficacy
rate of ECG, efficacy rate of angina pectoris, efficacy rate of TCM
syndrome, fasting lipid profile, withdrawal rate of nitroglycerin,
total scores of TCM syndrome, rate of clinical efficacy, nitroglycerin
consumption, hemodynamic indexes, endothelin, efficacy rate of in-
dividual symptoms of TCM, frequency of angina attack. There were
also several significant problems about outcomes in the included
trials: (1) Significant heterogeneity of outcomes. The number of out-
comes ranged from 1 to 21 with an average number of 5. For a
same outcome, the evaluation points and detecting methods varied
(2) Continuous data were arbitrarily transformed into ranked data.
More than 90% of the trials reported the efficacy of outcome mea-
sures with percentages. (3) Only a few trials reported the outcomes
associated advantages and characteristic of TCM. (4) Outcomes
were randomly selected and reported with bias.
Conclusions
Inappropriate outcomes with wrong evaluating points and methods
will impaired the value of clinical trial. Establishing a core outcome
set (COS) of TCM for stable angina are warranted.
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Aim
Transanal total mesorectal excision (TATME) is a new innovative tech-
nique and theoretically allows more precise dissection with lower rates
of incomplete mesorectum and involved circumferential resection
margins comparing to laparoscopic TME. An international multicentre
randomised controlled trial (RCT) comparing the two operations has
been designed. Studies have shown the importance of standardisation
of interventions in surgical rcts, however it is poorly conducted. The
aim is to standardise the surgical steps and quality of tatme and
develop a competency assessment tool (CAT) for Surgical Quality
Assurance (SQA) of the trial.
Method
A robust 4-round Delphi methodology was applied with peer-
nominated international expert consultants in TATME. Semi-structured
interviews were conducted in Delphi round 1 where surgeons gave de-
tails on how they perform TATME. Interviews were transcribed and ana-
lysed using a qualitative analysis software. The result was used for
hierarchical task analysis (HTA) to identify the key stages and steps. The
HTA result was subsequently used in Round 2, 3 and 4 as question-
naires, which contained all the variations and were distributed to the
same group of experts. Each step was as rated mandatory, optional or
prohibited. The steps that have reached 70% agreement were used to
develop a competency assessment tool and operation manual for SQA.
Result
The 4 rounds of Delphi achieved 96.4% of response rate. Three main
phases were identified: peri-operative, abdominal phase and transanal
phase. Four main stages were identified within the transanal phase: (i)
Transanal platform set up, (ii) Purse-sting placement, (iii) TME dissec-
tion, and (iv) Specimen extraction and anastomosis. A seventy percentagreement level was achieved in 78 (83.4%) of procedural steps. For
example, it is mandatory to place transanal purse-string suture with
small bites (78.6%) to achieve a tight closure and stable pneumorec-
tum, and begin transanal TME with circumferential full thickness muco-
sal dissection (92.9%). A Competency assessment tool (CAT) of TATME
was developed incorporating the mandatory steps and quality from
the standardisation process.
Conclusion
Standardisation of techniques is crucial in a RCT in order to assess sur-
gical competency for pre-trial recruitment and monitor compliance dur-
ing the trial period. We have developed an objective and robust
methodology to perform standardisation, which was used in develop-
ing an operation manual and a competency assessment tool (CAT) for
SQA in an international multicentre RCT. Validation of TATME CAT will
be performed to ensure usability, reliability and validity.
The CAT will be used in video analysis during the trial entry process.
Surgeons that wish to participate will be invited to submit 2 unedited
full-length videos for transanal TME and 1 for laparoscopic TME. There
should be at least one male case for TATME; this is due to the fact that
pelvic dissection in a male patient is usually more challenging. Both the
abdominal and transanal components should be recorded and submit-
ted. Two assessors approved by the expert panel will assess the videos
independently using CAT.
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Background
Prostate cancer survival is improving, in the UK it has tripled in the last
40 years. Radiotherapy is an effective treatment with the aim of cure,
however, many patients experience a change in bowel habit, such as
urgency and incontinence, developing months to years after comple-
tion of treatment. Evidence suggests that management of these symp-
toms by a gastroenterologist can be effective when following a
detailed investigative and treatment algorithm and an equivalent level
of care can be given by a trained nurse. The EAGLE study focuses on
the early identification and management of radiotherapy-induced
bowel symptoms, with the aim of improving the quality of life of pros-
tate cancer survivors and their partners and/or families.
Methods
Successful evidence-based healthcare interventions are often challen-
ging to embed into local clinical practice. In this effectiveness-
implementation hybrid study, a multi-component intervention consist-
ing of: a simple screening tool to identify men with late effects of radio-
therapy in oncology follow-up clinics; rapid referral to a specialised
gastroenterology service; and enhanced algorithm-led assessment lead-
ing to targeted advice and treatment, was implemented in three UK
centres. Mixed method approaches to data collection and analyses are
used to assess the effectiveness of the intervention and the implemen-
tation strategy at baseline, six month and twelve month intervals.
Implementation outcome variables such as, acceptability to patients
and healthcare professionals, large scale adoption and sustainability are
addressed via longitudinal semi-structured interviews, alongside the
introduction of possible solutions to facilitate local implementation. A
control group of prostate cancer survivors with radiotherapy-induced
bowel symptoms from another local health board are followed up for
twelve months to assess the cost effectiveness of the intervention.
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The screening tool used in oncology to identify men suffering from
the late effects of radiotherapy has been validated against the
Gastrointestinal Symptoms Rating Scale (GSRS). Qualitative interview
data from patients suggests that the screening tool is quick and easy
to understand, addresses symptoms that are of most concern to pa-
tients, and facilitates open discussion of their bowel symptoms with
healthcare professionals. Final results will measure the effect of the
new service in terms of acceptability to staff and patients, quality of
life improvements, symptom control and cost effectiveness. Qualita-
tive interview data from healthcare professionals across the three UK
sites will address how each team is working towards sustainability of
the service.
Conclusion
This study evaluates the effectiveness of an enhanced assessment
and treatment service, spanning oncology and gastroenterology de-
partments, in improving the outcome of prostate cancer survivors
post-radiotherapy. The factors needed for successful implementation
into local practice, which are essential for new initiatives in health-
care settings, will act as examples of best practice for a network of
centres of excellence in this field.
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Background
Qualitative studies of participant experience embedded within oncol-
ogy ctimps are rarely undertaken but can usefully explain why recruit-
ment is slow, or why participants are unlikely to comply with the
intervention in a real world setting, or why they might decline to enter
or withdraw from the trial. Previous studies undertaken by the Marie
Curie Research Centre, using patient experience as a secondary trial
outcome, have: Highlighted patient preferences for treatment in a non-
inferiority trial, Exposed issues of clinical equipoise in two feasibility
trials that failed to recruit, Supported strategies for recruitment in a
primary care trial, Explored participant’s understanding of complex trial
processes in a stratified trial of personalised therapies, Articulated the
potential reasons that patients decline surgical trials. Additionally, par-
ticipant interview data may be used in real time for presentation to
TMG and TSC meetings to allow timely protocol amendments in order
to improve recruitment and retention of participants. This concurrent
approach is being successfully used in an HTA funded, ongoing clinical
trial (ROCS: NCT01915693), and has enabled protocol amendments,
such as timing of recruitment and assessments, that have improved re-
cruitment and improved data capture.
Aims
An integrated qualitative component within an adaptive design trial
can inform the primary and secondary trial objectives in the recruit-
ment and testing phases of the trial and, for the purposes of an
adaptive MAMS design, the stop/keep criteria per arm by assessing,
for example: The feasibility of patients; Recruitment to the trial by
examining their experience of consent and recruitment, including
reasons for declining participation; Participants’ motivation to accept
randomisation to different interventions; Potential improvements to
recruitment processes; Participants’ understanding and experience of
each trial arm; Participants’ experience and tolerability of toxicities;
Participants’ attitudes to the value of predicted treatment benefit.
Methods
Qualitative data sets can be analysed for common themes in relation
to real-time participant experience of the trial processes and treat-
ment protocols. The analysis takes into account spontaneously re-
ported participant experience, which reflects idiosyncratic attitudes
and personal contexts, to enable patient reported outcomes supple-
mentary to the stopping criteria in an adaptive design and main trial
outcomes. A range of qualitative analytic frameworks and samplingstrategies may be used according to the context and sensitivity of
topic and the quality of the data. Our previous trials have utilised
Thematic Analysis, Framework Analysis, and Interpretative Phenom-
enological Analysis, amongst others.
Discussion
Trials with adaptive designs attempt are intended to be efficient and
streamlined, by modifying parameters, as appropriate, usually based on
objective outcomes. The addition of participant experience as a sec-
ondary outcome measure allows for contextual factors and participant
preference to be included in decisions to adapt, therefore increasing
the likelihood of trial completion, and adoption and compliance with
interventions in a real world setting..Patient experience of the interven-
tion as a secondary outcome, combined with real time reporting of pa-
tient experience of trial processes can provide both immediate benefit
to trial processes, and a further understanding of the acceptability and
effectiveness of the intervention when aligned with the primary and
secondary trial outcomes.
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Background
Many stroke survivors have residual disability, even after discharge from
post-hospital community rehabilitation. Advancements in acute stroke
management suggest a role for the use of pharmacological agents in
enhancing the neurological response to rehabilitation therapy. STEMS-3
(ISRCTN16714730) was a feasibility, 2x2 factorial randomised controlled
trial of granulocyte colony stimulating factor (G-CSF) and/or physiother-
apy at least 6 months after stroke. Recruitment and retention to clinical
trials can be influenced by participant views, research design, context-
ual and environmental factors. It is reported stroke survivors believe
continued physiotherapy will be beneficial, but it is not known whether
these beliefs influence participation in clinical trials of rehabilitation.
Evidence suggests willingness to participate in drug trials is directly re-
lated to the presence of an illness the drug is designed to improve. It is
not known if this is true amongst stroke survivors or when drug ther-
apy is offered in conjunction with rehabilitation interventions. Family
members and carers frequently support older patients in decision mak-
ing about participation in clinical trials; this has not been studied
amongst stroke survivors. The aim of this study was to explore recruit-
ment and participation in STEMS-3 from the perspective of participat-
ing stroke survivors and their carers.
Method
Qualitative interview study underpinned by theoretical perspectives of
pragmatism and critical reflection using a purposive sampling strategy
to identify stroke survivors who had been recruited to the trial and their
carers. Semi-structured interviews were conducted, recorded and tran-
scribed verbatim. Thematic analysis using an iterative and emergent
approach was adopted. Results 16 participants (11 stroke survivors, 5
carers) were recruited from 60 participants in STEMS-3. 3 themes were
identified: personal, practical and procedural. Decisions to participate
were influenced by: opportunity for further treatment, potential bene-
fits to others, practical factors including treatment and assessment loca-
tion; side effects were considered worth the risk. Information given to
stroke survivors prior to consent was perceived as too long and difficult
to comprehend, and did not influence participation decisions. Carers
supported decision making and in contrast to participants, valued de-
tailed information. The principles of randomisation and blinding were
understood by participants, and participants thought the trial team
would not give them a treatment that was ineffective or harmful. There
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from existing services and trial completion was considered the ‘end
of the road’; this was most marked for those that received no active
intervention. Outcome measure assessments were often the first
time anxiety, depression and personal relationships were discussed
and heard by the carers.
Discussion
This study has highlighted how trial design results in multiple factors
that impact on stroke survivors and their carers’ decisions to take
part in clinical trials and their subsequent experiences. Feasibility and
acceptability studies are essential in the evaluation and development
of trials of complex interventions. They should include a qualitative
investigation of study design that focusses on the procedural, prac-
tical and personal factors that impact upon individuals’ decisions to
participate, and remain, in clinical trials. For trials involving stroke
survivors consideration should be given to incorporating the views of
caregivers who support stroke survivors.
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Background & Objective
Effective recruitment and retention in randomised controlled trials
(RCTs) is hugely important. Reduced patient recruitment rates may
prevent trial completion [1] and post randomisation dropout leads to
the loss of statistical power [2]. Recruitment to an RCT can be af-
fected if patients hold a preference for one of the treatments offered
in the trial [3]. Qualitative research methodology embedded in adult
RCTs has demonstrated that acknowledging and addressing patient
concerns about preference can enhance the acceptability of random-
isation and improve informed consent [4–6]. There is limited evidence
on whether or not preferences are expressed by young patients and
their parents during recruitment to paediatric trials, which have the
added complexity and interplay between patient, parent and health
professional equipoise [7]. The aim of the current research was to
investigate whether effective communication approaches used to
discuss treatment preference in adult trials were also effective in
paediatric RCTs.
Methods
Recruiters were offered one-to-one training and feedback on four
separate occasions as the feasibility trial progressed over a period
of 12 months [8]. Recruitment discussions were recorded, tran-
scribed and analysed thematically using techniques of constant
comparison [9].
Results
Thematic analysis revealed: 1. Acceptance of preference at face value
without exploration; this resulted in families declining the trial with
little understanding of the reasons that underpin preference:
Mum 140: if we were given the graded exercise, I think he would prob-
ably withdraw Recruiter: I think, if you feel very strongly that you would
want one treatment rather than the other, I think it’s better not to be in
the study…[patient declined trial].
2. Identification and exploration of preference; in-depth discussion
about reasons for preference allowed families to make a more in-
formed decision about study participation:
Patient 3: It’s the exercise one I don’t really like the sound of
Recruiter: graded exercise therapy doesn’t mean that you’ve got to
go and do, sort of a jog round the block, or anything like that, umm
what it’s doing is monitoring your activity and helping you to build
that up. We’re trying to sort out a better treatment for children in
the future…some of our patients when we’re talking about exercise,
umm, exercise for them is brushing their hair[patient accepted
randomisation].
3. ‘We’ Or ‘I’; parents often expressed preference on their child’s behalf:Mum 137: I think for us it’s probably gonna be the activity one, rather
than the graded, umm, exercise, because, err, we’ve been doing the
pacing, it’s been quite good, so that’s the one I’d probably lean
against but I’d like to know a bit more about them both.
Conclusions
Communication strategies and approaches used to train recruiters in
adult trials can be used in a paediatric setting with young patients
(aged 10-17 yrs) and their parents, but care should be taken to explore
reasons underlying both patient and parent preferences. Providing re-
cruiters with training and guidance can ensure families are more fully
informed about treatment options at recruitment, but further investiga-
tion of the effect on retention is required.
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Background
The intended purpose of the Pragmatic-Explanatory Continuum Indi-
cator Summary (PRECIS-2) tool is to help trialists consider the impact
design choices across nine domains have on the applicability of their
results in the clinical setting: from “1” Very explanatory (intervention
is tested under ideal conditions) to “5” Very pragmatic (intervention
is tested under usual conditions). Added value of increased adoption
of the tool is the emergence of a framework for investigators to com-
municate trial design decisions. PRECIS-2 is currently being used in a
National Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI) Pragmatic Trials Collaborative Project to explore
whether a rating adjustment from the planning phase to the first
year of implementation in a group of low-cost, pragmatic trials re-
flects true shifts in trial design.
Methods
PRECIS-2 ratings were collected at two annual in-person meetings of
the Pragmatic Trials Collaborative Project. After a presentation and
brief training at the first meeting (Time 1), Principle Investigators (PIs)
rated their trials as originally designed (prior to trial initiation). After
a refresher session at the second annual meeting (Time 2), PIs again
rated their trials on current status on each domain, without access to
their ratings from the first meeting. Qualitative telephone interviews
were conducted with each PI subsequent to the meeting (summer
2016) to review the domains with a rating change; domains that
were stable (no change in rating) were not discussed. The interview
protocol included questions about the PI’s experience with and per-
ception of the value of the PRECIS-2 tool. Interviews were recorded
and transcribed.
Results
Five PIs completed paired ratings for Time 1 and Time 2 for 9
PRECIS-2 domains, resulting in a total of 45 paired ratings. Of these,
over half (N = 24) demonstrated changes in ratings from Time 1 to
Time 2, and each trial had changes on at least three domains (range
“3” To “5”). Domains with the fewest changes were Recruitment Path,
Primary Outcome, and Primary Analysis; and those with the most
were Eligibility, Organization, and Flexibility of Adherence. Some do-
mains were rated as more pragmatic at Time 2 (11/24 domains with
higher rating), and others as more explanatory (13/24). Qualitative
analysis of the interview data identified three reasons for a rating
change: true change in design; change in interpretation of the do-
main; and misunderstanding of the PRECIS-2 domain. All PIs agreed
that the tool is useful during the planning phase of trial design, and
most have used the tool in subsequent work including proposals
and protocols.
Conclusion
The NIH Pragmatic Trials Collaborative Project demonstrates how the
PRECIS-2 tool can frame a conversation around initial trial design
Trials 2017, 18(Suppl 1):200 Page 114 of 235choices and provide clarity regarding where these decisions fall
along the pragmatic-explanatory continuum. In addition to advan-
cing our understanding of pragmatic trial design, discussions around
application of the tool can be used to reflect on drivers of genuine
adjustment to trial design as well as to help to clarify misunderstand-
ings about the definitions of the tool domains which could be ad-
dressed through training.
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Background
People with rare cancers need evidence-based treatment. Trials require
large samples to disprove no difference in treatment effect. Rare
cancers, like commoner malignancies, can be diverse affecting popula-
tion selection, stratification and applicability of trials. The aggressive
skin cancer, Merkel cell carcinoma (MCC) affects <300, predominantly
elderly, UK patients annually. Standard management with surgery and/
or radiotherapy for loco-regional MCC is based on retrospective data.
Rational MCC aims to compare surgery and radiotherapy as first defini-
tive treatment for MCC in control of loco-regional disease. The chal-
lenges encountered in designing this trial can be applied to many
disease areas.
Challenge 1 - Accommodating diverse populations: Rational MCC
accommodates biological diversity including presence of an inte-
grated virus, immune dysfunction, immune infiltration and somatic
mutations and multiple management pathways driven by clinical
variation, uncertainty and opinion. This has been achieved through
relaxed eligibility criteria and a focus on one question early in the
treatment pathway. An inbuilt 3-year feasibility study allows adapta-
tions to be made based on current data resulting in a more homoge-
neous population.
Challenge 2 - Design for rare populations: A conventional trial design
would require >3000 patients to prove superiority beyond reason-
able doubt. Instead, using a Bayesian probabilistic approach, ob-
served data from 250 patients can still be informative to guide the
decision-making process; providing clinicians and patients with prob-
abilities that either treatment out-performs the other in reducing risk
of loco-regional failure; aiding individual decisions.
Challenge 3 - Methodology for aggressive cancers: Rapidly progres-
sing diseases leave little time for screening. Rational MCC has min-
imal screening requirements and collects most baseline data from
routine investigations. In addition, sites are required to hit Protocol-
defined treatment target times that mirror optimal clinical practice,
ensuring that randomisation does not produce a delay to front line
treatments.
Challenge 4 - Overcoming clinical preconceptions: It can be difficult
for clinicians to consider alternative options when one treatment is
used more commonly. Rational MCC has an observational arm mir-
roring the interventional arm, which patients can enter if they are
unsuitable/unwilling to be randomised. This produces prospective
data even if no patients are randomised. Sites will be provided with
a checklist to guide SSMDT discussions to facilitate consideration of
treatment options.
Challenge 5 - Working with elderly populations: It is important to ad-
dress potential barriers in communication when working with elderly
populations. Rational MCC patient literature has been reviewed by
PPI representatives and multiple documents have been producedthat reflect the information required at different time points. Large
font versions of documents are available and information will also be
provided in DVD format Randomised trials are expensive and failure
to recruit wastes funding. The observational arm produces a bank of
biological and clinical data even if patients are not randomised.
Additional questions will be reviewed during the feasibility study to
further maximise value. Data from the feasibility phase will be used
to guide operational adaptations to ensure the Protocol continues to
be informed by best practice The Rational MCC trial is funded by the
Efficacy and Mechanism Evaluation (EME) Programme, an MRC and
NIHR partnership.P300
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Background
In randomised control trials where outcomes are collected via ques-
tionnaire, maximising the response rate is paramount. Loss to follow-
up reduces the effective sample size and can place added assump-
tions on analysis, potentially leading to bias and compromising the
validity of results. SIFT (ISRCTN76463425) is a multicentre randomised
controlled trial of a feeding intervention in very preterm or very low
birthweight infants (gestational age at birth <32 weeks; birth weight
<1500 g) in neonatal units in the United Kingdom and Ireland. Primary
outcome is the proportion of infants surviving without moderate or se-
vere disability at 24 months of age corrected for prematurity. This is
assessed via a questionnaire sent directly to parents asking for informa-
tion on their infant’s health and development.
Having confirmed address details and survival status, the SIFT Trial
Coordinating Centre sent participants’ parents a card for their
child’s second birthday and a thank-you note reminding them of
the questionnaire and encouraging them to update their contact
details. Staff then posted a questionnaire to the parent (including a
sticker set for their child) 17 days before the child’s age-corrected
second birthday. If there was no response, another copy of the
questionnaire plus reminder letter was posted on their age-
corrected birthday. Two weeks later, another copy of the question-
naire was posted, and two weeks after that, SIFT staff attempted to
call parents about the questionnaire.
Follow-up began in August 2015. By February 2016, response rate
remained low: approximately 50%.
Objective
To outline measures taken to increase follow-up response rate during
the trial and their efficacy.
Methods
The following adaptations were made to the follow-up process:
1) One week prior to sending the first questionnaire, the SIFT Trial
Coordinating Centre telephoned parents to confirm address details
and inform them that the questionnaire was to be dispatched. Parents
were also telephoned within a day of the second reminder being
posted (1 February 2016 onwards).
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parents with a valid email address or mobile number within a day of
posting the first paper version (26 February 2016 onwards).
3) Parents were contacted by text message as well as or instead of
by telephone at second reminder stage (29 March 2016 onwards);
charity for premature and sick babies BLISS promoted the follow-up
via Facebook and Twitter (5 April 2016).
4) Posters publicising follow-up were sent to recruiting sites for dis-
play, accompanied by a list of local participants with their response
status (20 June 2016 onwards).
Results
Response rate prior to all interventions was 51.0%. On 30 September
2016 it was 68.0%, a significant increase. The response rate also in-
creased (non-significantly) after implementation of each new initiative.
SIFT intends to initiate an incentives programme to further increase the
rate (subject to ethical approval).
Conclusion
Contacting parents prior to dispatching questionnaire; reminder to
parents via text message; availability of questionnaire electronically;
and promotion via hospitals or charities are approaches which, when
combined, can significantly increase follow-up rate.
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Background
Randomised controlled trials (RCTs) are the most rigorous approach
for evaluating health care interventions, but many fail to recruit to
target, requiring costly extensions. Anticipation of recruitment
challenges can also deter investigators and funders from tackling
important, potentially practice-changing clinical questions. Devel-
oping interventions to optimise recruitment is a priority in trials
methodology research, but few interventions are transferrable
across RCTs. The quintet Recruitment Intervention (QRI) aims to op-
timise recruitment in ‘difficult’ RCTs, whilst safeguarding informed
consent. The intervention comprises in-depth investigation of re-
cruitment obstacles (Phase I), followed by implementation of strat-
egies to address recruitment challenges as the trial proceeds
(Phase II). Having integrated the QRI in eight rcts anticipated by
funders/trial investigators to encounter recruitment challenges, we
undertook a preliminary evaluation of the QRI’s implementation.
Methods
The QRI was integrated into the recruitment processes of eight ‘diffi-
cult’ feasibility/pilot RCTs that addressed controversial issues or
compared very different treatment arms (including ‘no treatment’).
Phase I of the QRI involved collecting and analysing interview andaudio-recorded consultation data to understand recruitment chal-
lenges. Phase II involved tailored interventions to improve recruit-
ment, including components such as trial-specific feedback/training
and suggestions to clarify patient-facing documentation. Data pro-
vided by clinical centres were aggregated and displayed graphically
to compare targets with achievements over time, in relation to eligi-
bility assessment and numbers approached, consented, and rando-
mised. QRI intervention-components were also plotted over time.
Results
Recruitment in the initial periods of these RCTs rarely hit targets
(Phase I of the QRI), with the exception of one trial where recruiters
had previously received QRI training. Recruitment rates moved closer
to targets after implementation of QRI interventions (Phase II), with
the scale and patterns of improvement varying across RCTs. A sharp
increase in recruitment was evident in an RCT following a feedback/
training session attended by all centres, whereas smaller improve-
ments were seen in a multi-centre trial where a subset of centres
attended sessions. Other evidence of recruitment improvement in-
cluded centres moving from ‘no recruitment’ over weeks/months, to
recruiting first participants after feedback (four RCTs). Despite their
challenging nature, four pilot/feasibility RCTs recruited to target and
progressed to main trials, and two are currently recruiting well. Two
feasibility studies did not progress to main RCTs: one, because the
QRI enabled a nuanced understanding of equipoise issues previously
unbeknown to the trial management group, which were discussed
during a feedback session and found to be unsurmountable; and the
other, because a main trial was not feasible due to insufficient inci-
dent cases of eligible patients. Recruiters exposed to QRI training in
the latter trial went on to successfully recruit to a subsequent RCT
with integrated QRI, which consistently recruited above target des-
pite anticipated difficulties.
Conclusion
These preliminary observational data provide some evidence to show
an association between QRI interventions and improved recruitment in
very challenging RCTs. The QRI is increasingly appreciated by RCT in-
vestigators and funders. Formal evaluation of the QRI is itself challen-
ging, and will need to carefully consider appropriate markers of success
that include recruitment rates and levels of informed consent.
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Background
Surgical trials are complex; patient populations are heterogeneous,
interventions are difficult to standardise, and outcome measures are
difficult to assess. Fewer patients are recruited to trials in surgery and
anaesthesia than any other medical specialties. There is an urgent
need to train a cohort of future surgical trialists, equipped with skills
to convey clinical equipoise and appropriately recruit patients into
well-designed randomised studies.
Method
A national, one-day course (GRANULE) was conducted with support
from Birmingham Clinical Trials Unit, and the Bristol Medical Research
Council-funded conduct-II hub. Undergraduate medical students were
competitively selected from a national UK student research group (Stu-
dent Audit & Research in Surgery). Completion of Good Clinical Practice
(GCP) certification was required prior to commencement.
GRANULE course content was framed around active trials within colo-
rectal and oesophagogastric surgery, with a faculty of chief investiga-
tors and active trial recruiters. The course featured; 1. A series of
interactive lectures to give clinical context (STAR-TREC (Birmingham),
ACCURE-UK (Birmingham) and By-Band-Sleeve (Bristol)); 2. Structured,
Trials 2017, 18(Suppl 1):200 Page 116 of 235small group discussions surrounding challenges in trial recruitment; 3.
Simulated patient recruitment, with formative assessment of actor
interactions. Confidence and experience in trials recruitment was col-
lected pre- and post-intervention using paired, self-reported, 15-point
online tools. 5-point Likert scales were used to quantify confidence
across four domains (understanding of equipoise, ability to communi-
cate equipoise, communicating risks and benefits of research involve-
ment, gaining consent for participation in trials). A mix of positive and
negatively weighted statements were used to minimise acquiescence
bias. Changes in perceived confidence were tested to a 5% level of sig-
nificance using McNemar’s paired chi-squared test. Free text feedback
underwent thematic analysis.
Results
Twenty-four delegates (10 female, 14 male) were invited to complete
the course. All 24 completed GCP certification prior to attendance,
and completed feedback (response rate = 100.0%). After course
completion, participants felt more confident in their understanding
of clinical equipoise (P < 0.001), ability to communicate clinical equi-
poise effectively (P < 0.001), ability to communicate risks and benefits
of each trial intervention (P < 0.001) and gain consent for participa-
tion in trials (P = 0.004). In free-text analysis, the simulated patient
interactions, and the high facilitator: student ratio were highly com-
mended. Lessons learnt included reducing the complexity of included
trial interventions, and giving extended time for single delegates’ simu-
lated patient interactions.
Discussion
Feedback from the GRANULE course demonstrated that undergradu-
ate medical students in the UK can be trained to confidently recruit
patients to high-quality clinical trials. As an early-years intervention,
this course has the capacity to change the culture of trials recruit-
ment within surgery at a junior level. Course delegates can access ac-
tive networks of postgraduate, trainee-led surgical research networks
in the UK to foster new mentoring relationships and actively recruit
patients into portfolio trials. Further course iterations are planned for
Spring 2017 (UK) and September 2017 (Germany).
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Background
The Confidence in Care (CIC) trial is evaluating Fostering Changes
(FC), a training programme for foster and kinship carers which aims
to increase their skills and coping strategies and improve their rela-
tionship with their child. The CIC consortium of third-sector providers
train groups of 12 carers in both trial and non-trial settings. Groups
are timed to commence with each new school term, which is then
reflected by waves of recruitment to the trial. Previous evaluations
have found filling groups to be challenging, both Pallett et al. (2002)
and Briskman et al. (2012) ran groups with as few as six carers, which
impacts fidelity. FC requires carers to attend twelve 3-hour weekly
sessions, a considerable time commitment and possibly a recruit-
ment barrier. Randomised controlled trials in social care settings are
also uncommon compared to public and clinical health and in two
pilot sites we tailored, tested and revised our recruitment strategy.Methods
We piloted at two sites prior to the first main recruitment wave, and
further optimised recruitment strategy in initial main trial waves. Strat-
egies introduced both preceded and followed the piloting phase. These
included 1) supplementing postal approaches to carers from their re-
spective Local Authority (LA) or Independent Fostering Provider (IFP)
by asking LAs and IFPs to select eligible carers from their databases for
direct invitation, 2) increasing lead time from approaching provider to
group initiation to up to four months, 3) modifying the allocation ratio
from 1:1 to 2:1 (intervention:control) to increase the chances of obtain-
ing the required training group size, 5) revising participant materials to
better align with the expectations of foster carers.
Results
Since the changes were fully implemented after the pilot and the
first main recruitment wave, the average number of carers recruited
to each site increased from 9.17 (5.83 intervention: 3.33 control)
to14.25 (9.25 intervention: 5.00 control). While group sizes have in-
creased, it remains difficult to reach target group size. Most consent-
ing participants are now sourced via the direct approach from
providers (as opposed to the ongoing open approach letter). During
the second main recruitment wave, 85.09% of consented participants
were sourced directly from providers, whereas the remaining 14.91%
were self-nominated.
Conclusion
Recruitment to the CIC trial has improved since the above amend-
ments were made and we expect to reach our recruitment target.
Modifying the allocation ratio increases the target sample but we
considered on balance that this made the study both more likely to
achieve clinically viable groups and was more acceptable to pro-
viders. However, the impact of remaining sub-optimal group size on
fidelity will need to be determined. Similarly, the quality of communi-
cation about the trial to carers and also local providers will be
assessed in our process evaluation. One pilot site did not continue
into the trial phase but has enabled an on-going carer contact group
to provide timely input to both our recruitment and retention strat-
egy. Recruiting participants potentially well in advance of group on-
set introduces, as well as avoids some problems which will be
reviewed in our presentation.
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Background
Missing data in clinical trials is common and can reduce trial effi-
ciency and bias the estimate of treatment effect. Higher levels of
missing data have been associated with specific study areas (e.g.
Mental health, substance abuse), longer lengths of follow up, trials
with more than two arms, and poor allocation concealment. How-
ever, little is known about the prevalence of different causes of miss-
ing data. Analysis of the reported reasons for missing data within
published literature could provide valuable insights to inform the de-
velopment of effective strategies to mitigate the problem.
Methods
Two cohorts were identified: A search of Medline (Ovid) for rando-
mised trials published within the four major medical journals in 2013;
National Institute of Health Research Health Technology Assessment
Programme (NIHR HTA) monographs published between 2009 and
2014. Parallel, two arm randomised control trials were included. Early
phase trials and pilot studies were excluded. Data on the number of
patients randomised, analysed, excluded and imputed was independ-
ently abstracted by two authors along with reported reasons and trial
Trials 2017, 18(Suppl 1):200 Page 117 of 235characteristics. Missing data was defined as the number of randomised
patients who did not contribute primary outcome data to the analysis
either because it was not available or because the data was excluded.
Results
In 7/166 (4%) journal articles and 2/36 (6%) HTA monographs it
was not possible to determine the levels of missing data. 141/
159 (89%) and 34/34 (100%) trials had missing primary outcome
data with median [IQR] levels of missing data of 5.5% [1.5, 11.0]
and 11% [2.9, 19.8].
The impact of the missing data within the journal cohort meant that
454 months were wasted across 126 trials recruiting patients that did
not contribute outcome data (median [IQR] per trial: 1.5 [0.7, 3.2]).
Trials reported multiple reasons for missing data: patient withdrawals
(64%, n = 141); patients lost to follow up (60%); investigator exclu-
sions (53%) and failure of clinical staff to measure the outcome
(45%). 91/159 (57%) imputed data and 91 (57%) trials excluded
randomised patients with protocol deviations or missing data from
the analysis population. 41 (26%) trials used both approaches.
Abstraction of the levels of missing data was challenging. CONSORT
statements were often misleading around imputation of data and
did not clearly report the number of outcomes known.
Conclusion
The percentage of missing data within the leading journals was on
average lower than expected. However, a comparison with the HTA
monographs suggests this may reflect a difficulty publishing RCT’s
with missing data in the top journals. Patient withdrawal and loss to
follow up were the leading causes of attrition, although the failure of
researchers to measure the outcome in retained patients was cited in
nearly half of the trials. Reporting missing data was often inadequate.
We would recommend stricter adherence to the CONSORT flow
diagram and suggest revisions to ensure that the flow diagram could
be standalone with additional categories to allow distinction between
the numbers analysed and the numbers for whom the outcomes were
known and imputed.
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Background
Identifying strategies to minimise missing data was the second highest
methodological research priority in a Delphi survey of the Directors of
UK Clinical Trial Units (CTUs). However, a Cochrane Methodology Re-
view of nested randomised studies of missing data strategies shows a
substantial evidence gap. The review demonstrates an emphasis on im-
proving questionnaire response rates and an absence of evidence that
address the full range of causes of missing data. In addition, published
case studies frequently describe the use of strategies which have not
been evaluated. Our aim was to assess current retention practices
within the UK and identify priorities for future research to evaluate the
effectiveness of strategies to reduce attrition. Methods: 75 Chief Investi-
gators of National Institute of Health Research Health Technology
Assessment (NIHR HTA) funded parallel randomised control trials start-
ing between 2009 and 2012 and 47 UK Clinical Trial Units (CTUs) were
surveyed to identify what approaches and strategies were used to miti-
gate missing data in trial design and conduct.
Responses from the current practice survey were used to inform a
subsequent two round Delphi survey with CTUs to gain consensus
around research priorities to assess the effectiveness of missing data
interventions.
Results
50/75 (66%) Chief Investigators and 33/47 (70%) CTUs completed the
current practice surveys. 78% of Chief Investigators were aware ofretention challenges and implemented strategies at trial design. Pa-
tient initiated withdrawal was the most common cause of missing
data. CTUs routinely used newsletters, timeline of participant visits,
and telephone reminders to mitigate missing data. CTUs reported
evaluating 36 of the 59 strategies presented using nested studies or
a comparison of retention before and after implementation. How-
ever, some frequently used strategies such as site initiation training
have had no research to inform practice.
35 CTUs (74%) participated in the Delphi survey of which 34 (97%)
completed both rounds. Pre-defined consensus was reached on
seven topics. Six retention strategies met consensus that further re-
search was of critical importance: site initiation training; frequency of
patient contact during a trial; the use of routinely collected data; the
frequency and timing of reminders; triggered site training and the
length of time needed to complete questionnaires. In contrast, 82%
reached consensus that research into the effectiveness of Christmas
cards for site staff was of low importance.
Conclusion
The survey of current practices demonstrates a variety of strategies
are being used to mitigate missing data but with little evidence to
support their use. This Delphi survey has identified a consensus of re-
search priorities to be evaluated.
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Background
Randomised controlled trials (RCTs) are often considered the gold
standard of health intervention research. However, most RCTs under-
recruit ethnic minority patients, potentially jeopardising the external
validity of their findings. One recruitment challenge relates to asses-
sing whether patients have sufficient language proficiency to provide
informed consent and engage with the intervention. However, little
is known about how trial recruiters assess potential participants'
language proficiency. Using diabetes telehealth intervention RCTs as
a case study, we investigated the proportion of published trials that
include language proficiency as part of their inclusion criteria, includ-
ing how and why they do so. A secondary objective was to explore
any links between the inclusion of language-related eligibility criteria
and the proportion of ethnic minorities recruited.
Methods
A systematic review was conducted on telehealth intervention RCTs
that focused on type 2 diabetes and excluded ethnically-targeted
studies. Two reviewers independently conducted abstract and full-
text screening, risk of bias assessment, and data extraction.
Results
Of 3358 records identified in the search, 79 articles consisting of 58
distinct RCTs were included in the review. Half of the included RCTs
(29/58) referred to patients’ language proficiency as an eligibility cri-
terion. However, there were no common procedures across RCTs to
determine if patients had the requisite language ability to participate.
Whereas some studies listed different combinations of language skills
as being necessary (speaking, listening, reading, writing), others re-
ferred to patients’ need to be native speakers. In two RCTs, there was
a mismatch between the telehealth medium used and the language
skills cited (e.g., telephone intervention requires writing but not
speaking ability), whereas four underspecified the language skills re-
quired (e.g., speaking but not reading ability stated as necessary for
a telephone and computer-text intervention).
The 29 RCTs that referred to language as a patient eligibility criterion
tended to be larger-scale, recruiting nearly 1.7 times the total
number of recruited patients, compared to the 29 RCTs that made
no reference to language at all. Twenty-one RCTs in the former
group and 17 in the latter provided ethnicity information and
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a proportion of the total sample respectively. The RCTs that included
language proficiency as an eligibility criterion recruited a greater pro-
portion of ethnic minority participants (37.8% of all recruited partici-
pants) compared with those that did not (13.9%).
Conclusions
Approaches for assessing patients' language proficiency were found
to be inconsistent in the context of diabetes telehealth intervention
RCTs. Studies referring to language in patient screening might report
more on ethnicity because some ethnic minorities are also linguistic
minorities. Or it may be that these studies are more robust in terms
of research reporting and sample size. There was no evidence that
reference to language screening is associated with lower participation
from hard-to-reach groups, although the soundness and consistency of
individual inclusion/exclusion decisions on language grounds could not
be ascertained. Future research should focus on developing and
validating a language assessment tool that could be consistently
applied across RCTs to screen patients’ language proficiency during
recruitment.
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Background
A central tenet of recruitment to clinical studies is that participants
take part freely, armed with full information about the study. There
has been little research into how the appearance of the information
may affect recruitment. A study of Patient Information Leaflets (PILs)
concluded that PILs need ‘to be well structured and designed in an
appealing manner’. These aspects have not yet gained sufficient at-
tention [1]. In the case of paper information leaflets, production of a
high quality attractive leaflet is possible, but may require specialist
software, and incur extra costs for colour printing. Without the evi-
dence of benefit, the additional resources may not be justified.
Methods
To investigate if the appearance of pils affects recruitment, we chose to
embed a randomised controlled trial (RCT) within the Outcome Moni-
toring After Cardiac Surgery (OMACS) study. OMACS uses routine NHS
data alongside participant questionnaires, and consent is sought by
post at 3 months post-surgery. OMACS was chosen as the ‘host’ study
as around 120 patients are approached for participation per month,
allowing evidence to be collected quickly. Participants are randomised
to receive one of 3 PILs: a tri-fold coloured leaflet produced using a
graphic design package, indesign, (PIL A), a coloured A4 sheet pro-
duced in Microsoft Word (PIL B), and a standard A4 black and white
sheet (PIL C). Both coloured leaflets are printed professionally. The
information contained in each leaflet is identical and participants do
not know about the randomised element of OMACS. The sample size is
1590 which, assuming a consent rate of 70% (based on a previous simi-
lar postal questionnaire study that achieved this (personal communica-
tion)), will provide 90% power to detect a 10% difference in consent
rate between any pair of PIL formats, with an overall significance level
of 5%.
Results
After 5 months, we have sent out 436 invitation letters and have 182
consented participants. Consent rates for each PIL are: A - 68/181
(38%) B - 76/180 (42%) C - 76/180 (42%) An unexpected finding is
that consent rates are much lower across the study than was antici-
pated. We are currently investigating possible reasons for this. If the
current trend continues we will review the implications for the sam-
ple size and power of the study.There are a number of differences between OMACS and the previous
study which may explain the difference in response rates. Previously,
the timing of the approach for consent is different (1 year versus
3 months) and patient packs were simpler with fewer documents
than used in the OMAC study. In attempt to cater for participants’
preferences, OMACS invites participants to elect for alternative re-
sponse methods (e.g. Postal versus internet questionnaire) and also
allows them to opt out of some aspects of the study. The previous
study did not include this diversity of options.
Conclusion
At this early stage, no formal conclusions can be drawn as to the ef-
fect of the appearance of the PIL. One year results with a formal
comparison between the rates of each group will be presented.
Reference
1. Reinert, C., et al., Quantitative and qualitative analysis of study-related
patient information sheets in randomised neuro-oncology phase III-trials.
Eur J Cancer, 2014. 50(1): p. 150–8.
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Background
To reduce the risk missing data (MD) pose to the power, precision
and validity of trial findings, MD should not only be handled appro-
priately at the analysis stage, but more importantly potentially revers-
ible MD risk factors must be identified and modified at the design
and conduct stage. This mixed-methods study used palliative care tri-
als, where MD due to death and disease progression are expected, to
explore the association between primary outcome MD and partici-
pant, trial site and trial-level MD risk factors.
Methods
(i) Trial-level factors: systematic review and meta-regression of pri-
mary outcome MD in 108 palliative care trials; (ii) Participant and
site-level factors: multi-level cross-classified modelling using individ-
ual participant-level data (IPD) from 10 multi-site trials; (iii) Identifica-
tion and exploration of factors in more depth: thematic analysis of
interviews with 27 research personnel and participants.
Results
(i) Systematic review: MD was associated with increasing numbers of
questions/tests requested (odds ratio (OR) 1.19 per-doubling, 95%CI
1.05, 1.35) and longer study duration (OR 1.09 per-doubling, 95%CI
1.02, 1.17). (ii) IPD: At the participant-level (n = 1,846), MD was associ-
ated with baseline missingness (OR 17.19, 95%CI 8.55, 34.53) and
poorer Karnofsky Performance Status (10-unit increase: OR 0.78,
95%CI 0.70, 0.87); at the site-level (n = 35), MD at the end of follow-
up was associated with sites that randomised a greater number of
participants (per 10-randomisations: OR 1.08, 95%CI 1.01, 1.16) and
with fewer research personnel (4 personnel compared to 1: OR 0.07,
95%CI 0.01, 0.84). (iii) Interviews: themes included “attention-to-detail
vs. attention-to-person”, “clinical vs. research-role tension”, and “be-
yond GCP training”.
Conclusion
There is the potential to reduce MD in palliative care trials by modify-
ing the factors associated with MD identified from this study. Further
development of the theoretical framework is required, prior to devel-
oping an intervention to reduce MD that will be tested within trials.
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Introduction
Hearing impairment is common among the general public >50 years
of age however the relationship between type 1 diabetes (T1D) and
hearing impairment in this age group is not well-studied. To examine
this question, the Diabetes Control and Complications Trial/Epidemi-
ology of Diabetes Interventions and Complications (DCCT/EDIC) Hear-
ing Study is examining the prevalence of hearing impairment among
a well-phenotyped T1D cohort (mean age 55 years).
Objective
To determine the feasibility and comparability of using randomly se-
lected spouses of surviving DCCT/EDIC participants as a non-diabetic
control group.
Background
Use of spouses for the control group was based on unique factors.
Most spouses were familiar with the DCCT/EDIC study and staff by
virtue of their partner’s long-term participation and frequent accom-
paniment to study visits. Most important, the spousal group was
expected to be similarly distributed in age, race and socioeconomic
status to the DCCT/EDIC cohort. Additionally, practical efficiencies in
recruitment, scheduling, and travel were expected.
Methods
Of the total of 875 spouses, 510 were randomly identified for screen-
ing. Enrollment of 270 spouses would provide 90% power to detect
a clinically significant difference in hearing impairment between the
EDIC surviving cohort and controls. Permission from the EDIC partici-
pant was needed prior to contacting his/her spouse. Spouses with
known diabetes, or illness/disability that precluded travel to the clin-
ical center were excluded. A self-administered hearing assessment,
brief medical history, physical measurements, hba1c and audiometry
were performed on consenting participants and spouses. All data col-
lection methods and equipment were standardized and consistent
with DCCT/EDIC methods. Testing was performed by trained and
study-certified personnel. All audiograms were scored centrally.
Results
Of the 510 spouses identified, 39 (7.7%) were ineligible, 97 (19%)
were not approached (due to participant request, distance, illness/
disability, work demands, marital discord), and 88 (17.3%) were
approached but declined (work demands, travel, illness/disability, dis-
interest). A total of 289 spouses and 1150 (86.7% of surviving, 94.5%
of active) EDIC participants were evaluated. Spouses determined to
have diabetes based on hba1c (n = 5) were excluded from the ana-
lyses. The spousal group was similar in age, race, education, smoking
status and systolic blood pressure.
Conclusion
Spouses of research participants may be a resource for studies re-
quiring a comparison group with similar demographic characteris-
tics. Potential obstacles to spouse participation, such as participant
refusal to allow contact spouse, distance/travel, and illness/disabil-
ity need to be considered. Clearly defined eligibility criteria, recruit-
ment strategies and testing procedures are needed to ensure valid
comparisons between groups. Standardized evaluations by trained
staff may yield stronger results compared to the use of published
comparison groups.P312
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Background
Studies in which patient consent cannot be obtained prospectively
represent a particular methodological challenge. Approval can be
sought to include patients in a randomised study without their con-
sent, but every effort must be made to seek informed consent when
the patients has recovered sufficient capacity or to seek consent
from a consultee if this doesn’t occur. We describe our experience of
seeking retrospective consent in the context of the RAPIDO trial, and
the implications for the study analyses.
Methods
RAPIDO is a multi-centre RCT comparing the effect on mortality of con-
ventional versus rapid diagnostic pathways for suspected blood stream
infections in hospitalised patients. In the conventional pathway, infect-
ive micro-organisms in a blood sample are identified within 3–5 days,
whereas the rapid diagnosis pathway takes 1 hour or less. Identifying
the infective micro-organisms then allows an appropriate antibiotic to
be chosen for treatment. It has been suggested that earlier antibiotic
therapy could improve patient outcomes including 28 day mortality
(primary outcome), length of hospital stay and time to resolution of
fever (secondary outcomes). Due to the time-sensitive nature of this
study, participants were consented retrospectively; where patients had
left the hospital before consent was obtained, postal consent was
sought.
Results
A total of 8628 patients were randomised across 7 UK centres, 6692 of
which were found to be eligible for the study. Consent was obtained
before hospital discharge for 2606 (39%) patients and postal consent
was successfully sought for a further 521 (8%). 1142 (17%) declined. Of
the remainder, 1341 (20%) died before consent could be sought and
consent was not obtained for 1082 (16%) survivors. The research ap-
provals granted for the study allowed only very limited data to be
retained and used for this latter group. By definition their survival status
was known (allowing analysis of the primary outcome) but secondary
outcome data were missing not at random. Pre-specified sensitivity
analyses were undertaken to estimate the bias associated with not hav-
ing data on up to 33% of the study population. The results of these
analyses and their impact on the study conclusions will be discussed.
Discussion
The proportion of patients for whom consent was not obtained was
higher than had been predicted when the study was designed. The
requirement to obtain consent to use data collected in a trial after
the intervention is complete and when no further participant in-
volvement is required needs to be challenged. Disclaimer RAPIDO
was funded as part of an NIHR Programme Grant for Applied Re-
search. The views expressed are those of the authors and not neces-
sarily those of the NHS, the NIHR or the Department of Health.
P313
Imaging endpoint eligibility in oncology trials: what works and
what doesn’t
David Raunig
ICON Clinical Research
Correspondence: David Raunig
Trials 2017, 18(Suppl 1):P313
Background
There is almost nothing that will destroy a relationship with a site
than disagreement on the eligibility of a patient. Oncology studies
are particularly vulnerable to this problem because site investigators
are very interested in saving their patients’ lives and may inadvert-
ently be biased toward inclusion. For example, disease free survival
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bility review done by the site is then sent to central review for effi-
cacy imaging analysis, there is a small but real percentage of
patients that will be determined to have had disease at baseline.
These patients will, in the final analysis of risk, will be deleted from
the analysis since they would have progressed at baseline, an infinite
risk. Another example is the requirement in RECIST to have measur-
able lesions to determine response. Site determination of measurable
often does not coincide with the independent reader’s assessment of
measurable. Central confirmation of eligibility decreases the risk of
these patients being included but only if a certain amount of due
diligence is paid to the method of confirmation.
Methods
Methods to assess eligibility are site alone, site + central, central alone
and site with central confirmation. Each method will be reviewed and
case studies as well as simulations will show the risks and benefits of
each. Case Studies Several anonymized case studies will be used to
demonstrate the effects of each of the methods. Additionally, parame-
ters derived from these case studies will be used to simulate clinical
trials under different hazard ratios to demonstrate the impact of in-
appropriate eligibility on the final results.
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There is limited evidence as to the time taken by general practices to
respond to data requests for individual patients as research partici-
pants. In stroke trials, as patient mortality in the first 12 months is
high, it is common practice to ascertain participant status (dead/
alive) before contacting for follow-up; primarily to avoid emotional
distress to relatives. GPs are usually informed that a patient is partici-
pating in a trial via a letter sent directly from the admitting NHS
Trust. The letter details that they will be contacted at a given time
(dictated by data collection time-points) to ascertain patient status
and verify address and contact details. We have observed consider-
able variation in the time taken to reply to requests and significant
variation in how practices deal with such requests. Some practices
are happy to give the details over the phone following basic checks
with the researcher, some practices ask for a copy of the consent
form and some practices ask for a covering request by letter to be
sent via fax, with varying degrees of success in eventually getting
the information requested. Although numbers lost or delayed sub-
stantially are relatively low, they may still have an impact on loss of
valid outcome data and are resource-intensive but important. It is
therefore important to identify the approach that elicits the best re-
sponse from practices to inform the design of future studies. If
checking status is too costly or ineffective, then studies will adopt a
pragmatic model of contacting participants directly, which may not
be in the best interests of the patient or their families. We have
therefore designed a feasibility cluster RCT, nested within a larger
trial, using 12 sites and 4 different methods of approach. 1. Tele-
phone contact first and then Fax if requested using the letter format
already in use 2. Telephone contact first and then Fax using a new
letter format reminding them that they have already received con-
firmation of consent from their secondary care provider 3. Fax con-
tact first using the letter format already in use and then Telephone
contact if no response 4. Fax contact first using the new letter format
reminding them that they have already received confirmation of con-
sent from their secondary care provider Three sites were randomised
to each of these methods, with all general practices from which asite’s participants were recruited being allocated to that method. To
reduce differences in initial approach the same member of staff was
used for all requests. We have collected details of the amount of
extra information or processes requested by the practices and the
time interval from request to provision of the information (or to ter-
mination of our request). Analysis will be descriptive and inform the
feasibility and design of a full nested trial of these methods. Feasibil-
ity questions include whether there is the potential to detect an im-
portant difference on a key outcome and whether it is feasible to
design a trial for which randomisation is by secondary care provider
rather than general practice.P315
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Background
Intracerebral haemorrhage (ICH) is often complicated by haematoma
expansion (HE) with devastating consequences. The NIHR HTA TICH-2
study is a randomised controlled clinical trial that is testing whether
tranexamic acid arrests HE and improves outcome. Typically, stroke
treatments have greater efficacy if given early and so delays should
be avoided. Obtaining consent in the emergency situation is difficult
since many stroke patients lack capacity to consent and relatives are
often not present.
Methods
Ethics approval was obtained to allow full informed consent or verbal
assent (using a brief information sheet) followed by full written con-
sent at a later date. The brief information sheet is used when the
therapeutic time window is short and the use of full written consent
would inhibit recruitment into the trial. Where patients lacked cap-
acity, approval was obtained to enrol them with permission from a
relative, carer or friend acting as legal representative. If no one was
available to act as a legal representative, permission could be ob-
tained if two clinicians (one unconnected with the trial) agreed to
enrol the patient. Permission from legal representatives could be
given using a full information sheet, or the brief information followed
by full written consent.
Results
Of 1682 patients enrolled, 387 (23%) gave full informed consent and
201 (12%) gave brief verbal assent. Many patients lacked capacity
(65%) and were enrolled after proxy consent from a legal representa-
tive; full informed relative 720 (43%), brief relative 255 (15%), inde-
pendent physician 119 (7%). The mean (SD) time from stroke onset
to recruitment (in hours) for patients enrolled with full consent were
3.8 (1.6) for patient and 4.0 (1.7) for relative consent; this went down
to 3.4 (1.7) for brief patient and 3.6 (1.5) for brief relative. The quick-
est consent group was independent physician, with an average time
to recruitment of 3.2 (1.5) hours.
Use of a range of methods for consent enabled rapid enrollment.
Participants unable to consent had dysphasia and higher stroke se-
verity. Thirty nine participants who gave verbal assent died before
full written consent could be obtained, and two participants declined
to give further consent and later withdrew from the day 90 follow-
up; no participants who used brief consent were lost to follow-up.
Conclusion
Abbreviated information sheets supporting verbal assent and proxy
consent can ensure patients are enrolled rapidly into emergency
clinical trials. The use of brief consent or proxy consent did not lead
to large numbers of withdrawals or losses to follow-up, thus the use
Trials 2017, 18(Suppl 1):200 Page 121 of 235of two stage/or proxy consent for emergency clinical trials should be
considered.
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Background
Designing explanatory trials to answer additional questions such as
how and for whom treatments work should be a priority for im-
proving trial efficiency. Multiple arm trials are also more efficient, as
they provide more information about treatments over a shorter
time span [1]. We studied the benefits of multiple trial arms and ex-
planatory design using the Pacing, Graded Activity, and Cognitive
Behaviour Therapy: A Randomised Evaluation (PACE) trial as an ex-
ample. This trial studied three complex therapies and a specialised
medical care comparison arm for the treatment of chronic fatigue
syndrome. The study of how the treatments worked - mediation
analysis - was built into the trial design. In terms of mediation, one
interest was whether different treatments with some disparate
components might vary in mechanism. In other words, might the
effects of different treatments on a mediator (a paths or action the-
ories) be associated with different mediator-outcome relationships
(b paths or conceptual theories)?
Methods
Longitudinal structural equation models (SEM) for mediation were
applied to two-arm subsets and the overall four-arm trial dataset to
study longitudinal mediation of the effects of the PACE trial treat-
ments. Fear avoidance (FA) was used as an example mediator and
physical functioning (PF) as an example outcome [2]. A single model
was fitted to the dataset in each case with the pertinent contrasts
obtained. Treatment by mediator interaction terms were used to as-
sess differences in mediator-outcome effects (conceptual theories)
for different treatments. Informal comparisons of the standard errors
were used to assess precision.
Results
The multiple arms/explanatory design combination provided both
practical and statistical advantages. From the practical point of view:
A) the results from several two arm trials were obtained from one
trial, B) an explanatory design meant this was true for important sec-
ondary analyses as well, C) this particular design allowed for compari-
sons between active treatments and with the specialised medical
care comparison arm. One statistical advantage was increased power.
This may have been especially important for the mediation analysis,
as there is often low power to detect mediated effects [3] and some
useful methods for studying mediation suffer from lower precision.
For example, there was 25% gain in the precision of the parameter
estimate for the mediator-outcome relationship in the full four arm
dataset as compared to the two arm subset. Another statistical
feature was the ability to test whether the mediator-outcome effect
(conceptual theory) was similar across treatment arms (action
theories). This assumption held, and making this assumption allowed
for further precision gains.
Conclusions
Where indicated and/or sensible, designing trials to answer explana-
tory questions using a multiple arm design will be more efficient,
and provide more statistical power as well as a rich source of infor-
mation about treatments. Such designs should maximise efficiency
for primary outcome comparisons, and provide important informa-
tion about secondary questions of interest across multiple treatments
within a single study.References
1. Parmar et al. Lancet, 2014; 384(9940):283–234.
2. Chalder, Goldsmith et al. Lancet Psychiatry, 2015; 2(2):141–152.
3. Fritz and mackinnon. Psychol Sci, 2007; 18(3):233–239.
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Background
The GASP study (Groups for Alcohol Misusing Short-terms Pris-
oners) is a randomised trial of an intervention to improve partici-
pants’ sense of control and motivation to make changes. Men were
allocated to the control arm (standard prison regimen) or a
programme of nine group sessions over three weeks facilitated by
an experienced clinical psychologist and psychology assistant. Clus-
tering by group session is therefore present only in the intervention
arm. There were 8 facilitators in total, 5 psychologists and 3 assis-
tants, different pairs of facilitators ran the groups during the study.
Further clustering is therefore present by facilitator which varied
over the course of the study.
Objectives
To compare strategies for the analysis of clustered data where clus-
tering by group and facilitator is only present in the intervention
arm.
Methods
Recruitment and then randomisation to the intervention and control
arms was carried out in small blocks over the course of the study
due to a limitation on the maximum size of the group sessions. The
primary outcome, Locus of Control of Behaviour (LCB), was collected
for all men prior to randomisation and at the end of the group ses-
sions in the intervention arm and an equivalent time point in the
control arm. One analysis strategy could therefore involve the cre-
ation of control clusters contemporaneously equivalent to the inter-
vention group clusters. A second strategy would be to create clusters
of sample size one in the control arm and is the current standard
strategy for trials of this design. A third strategy would be to ran-
domly create control arm clusters of equivalent size, and variation in
size, to the intervention arm clusters, the ‘artificial cluster method’. A
forth strategy would be to group all the control men into a single
control arm cluster. The primary analysis is a two level general linear
model adjusted by baseline LCB. Secondary analysis will include the
additional level of facilitator in a three level model if the ICC warrants
its inclusion.
Results
All group programmes for the GASP study have now been com-
pleted and longer term follow-up data collection and data cleaning
is underway. Two hundred and thirty eight men were randomised
on a 1:1 basis and there were 15 intervention group programmes
(cycles) completed over 2 years. The total sample size target was
120 for the primary analysis. Primary outcome LCB data is available
for 68 in the intervention arm and 61 in the control arm. Results of
the statistical analysis of the primary outcome will be presented
discussing any advantages or disadvantages of the analytic strategy
employed.
Conclusions
The prison environment is a constantly changing and challenging en-
vironment for research. Prisoner numbers, prisoner mix, prison trans-
fers, staff to prisoner ratios, access to services and researcher access
to prisoners varied during the course of the group cycles, therefore
creating contemporaneously equivalent control arm clusters may be
preferable to the standard strategy in this trial. A discussion of any
bias that may be introduced or controlled for by any one of these
methods will also be addressed.
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Background
REACT is a phase III, multicentre trial of celecoxib vs placebo in primary
breast cancer patients in the UK and Germany. Patients receive blinded
treatment for 2 years and are followed up every 6 months, then annu-
ally up to 10 years for Disease Free Survival (DFS). This creates burden
on the site and the patient. For some sites it has been necessary to
move towards self-reported follow up (FU) via questionnaires to reduce
the burden. Not all sites have taken up the opportunity and it is not an
option in the UK. There was concern within the trial committees that
self-reported FU could result in a loss of data or accuracy, producing
bias in the principal analysis. It was agreed that the validity of self-
reported FU compared to conventional centre-based methods should
be retrospectively assessed within the trial.
Methods
A univariate Cox-model was fitted for time to first DFS event with FU
method as a time-varying covariate; observations were split at the time
a patient consented to self-reported FU unless an event occurred prior
to this. It was assumed that following consent patients could not revert
back to conventional FU. The model was repeated excluding the first
2 years of FU and a landmark analysis was also carried out looking at
0–2 years, 2–5 years and 5 years + separately. This was done to reduce
bias from early events; patients cannot switch to self-reported FU until
they have completed treatment (usually at 2 years) so events prior to
this could only occur on conventional FU. For each analysis the hazard
ratio for FU type and event rates in each group were calculated. Ana-
lysis was repeated separately for each type of DFS event; local relapse
(LR), distant relapse (DR) and death.
Results
FU data was more complete for self-reported FU patients. No significant
difference in event rate was observed for first DFS event. When looking
at event types separately, death rates for self-reported patients were
significantly lower compared to conventional patients (HR = 0.31, 95%
CI = 0.17-0.72). Although not statistically significant DR rates were lower
for self-reported FU (HR = 0.62, 95% CI = 0.22-1.72) and LR rates were
higher for self-reported FU (HR = 3.39, 95% CI = 0.72-15.87).
Conclusions
Within REACT self-reported follow up is a suitable alternative to col-
lect data for the primary endpoint of DFS. However for accurate
reporting of secondary endpoints a more robust method for report-
ing of deaths needs to be considered. Further research is also re-
quired into whether patients reliably report the correct type of
relapse. When reviewing impact of FU methods which can change it
is important to use a landmark analysis or other methods to reduce
the risk of bias if it’s possible for events to occur before the method
can change (e.g. If the method can’t change until treatment is
complete). For multi-event outcomes it is also important to analyse
separately by event type in case the overall result masks a difference
between event types. This is particularly an issue when secondary
endpoints use single events.
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Quality control is fundamental to ensuring both correct results and
sound interpretation of clinical trial data. Most QC procedures are afunction of regulatory requirements, industry standards, and corporate
philosophies. However, no one should underestimate the importance
of independent, thoughtful consideration of relevance and impact at
each step in the process from data collection through analysis.
Good QC goes far beyond just reviewing individual results and
should also consider monitoring data throughout the course of a
study. In particular, QC is essential when supporting a Data Monitor-
ing Committee. Given the nature of interim and incomplete data, in-
herent challenges exist when it comes to generation of DMC reports.
Many of the usual practices associated with quality control need to
be adapted to accommodate the repetitive nature of DMC review on
accumulating data that may have outstanding queries.
This presentation will explore adaptations to a typically rigid QC
process that are necessary when reviewing interim/incomplete data.
Such adaptations focus on a risk-based approach to QC to ensure
that a DMC can make informed decisions with more confidence in
the data and programming.
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The Coaching Boys into Men (CBIM) Middle School study is a cluster-
randomized trial of a middle school gender violence prevention pro-
gram. The primary goal is to examine the effectiveness of a program
for the primary prevention of adolescent relationship abuse (ARA) and
sexual violence among middle school sports teams in Western Pennsyl-
vania. Initially, 26 middle schools were randomized to receive either a)
the CBIM intervention, which trains athletic coaches by providing con-
crete strategies for discussing sexual violence as well as how to re-
spond to disrespectful behaviors, or b) control (standard coaching).
According to initial sample planning assumptions, this would yield
1980 students and provide 80% power to detect meaningful differ-
ences in the primary outcome, positive bystander behavior.
In the fall of 2015, it was noted that within-cluster recruitment was
slower than expected, so the decision was made to increase the
number of clusters to 40. In Spring 2016, available baseline data was
used to estimate the intra-cluster correlation coefficient (ICC) in order
to gauge whether the initial assumption of a 0.02 ICC was correct.
With an updated baseline ICC of 0.007 (95% CI: 0.0001-0.433) the ne-
cessary sample size decreased to 908 students. While favorable, this
left the study team with the following choice: a) assume the updated
ICC was closer to truth and proceed with the lower, more favorable
sample size; or b) assume the original ICC and continue with the
more conservative sample size of 1300. Given the instability of the
ICC estimate, the latter decision was made, but it raised the question
of whether previous cluster RCTs in adolescent medicine may have
benefited from sample size re-estimation using baseline ICC.
In this talk, we will review sample size re-estimation methods for cluster
RCTs and describe three completed studies: CBIM High School, SHARP
(School Health Center Healthy Adolescent Relationships Program), and
ARCHES (Addressing Reproductive Coercion in Health Settings). After
providing an overview of the study designs and primary outcomes, we
will discuss the initial sample size calculations with the assumed ICC as
well as the final ICC at the end of study. Additionally, we will highlight
the impact of post-hoc sample size re-estimation methods on the tar-
get sample size as well as the primary results.
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Individual populations within a research study are typically heteroge-
neous. Characteristics such as genetics, disease etiology and severity
vary between individuals and potentially affect the response to treat-
ment. Treatment effectiveness is, however, typically assessed using the
average treatment effect or at most treatment effect within (prespeci-
fied) subgroups. Recently, developed approaches allow researchers to
predict an individual's response to treatment allowing individualized
treatment instead of relying on averages from a group or subgroup.
Lamont et al. (2016) de ne Predicted Individual Treatment Effects (PITE)
and introduce the framework of PITE. The objective of this work is to
propose, derive and evaluate prediction interval for PITE.
Methods
The PITE can be estimated utilizing multiple imputation to obtain
treatment effect estimates on a patient level. Based on this approach
we develop a method to compute prediction intervals on an individ-
ual patient level. To ensure adequate estimate of the variability
which is required to obtain such intervals, we investigate different
model selection methods.
Results
We used continuous response variable and binary covariates to fit re-
gression model in all simulation studies. The simulation results show
that, using no variable selection leads to an under estimation of the
variability and hence under coverage. But the prediction intervals
achieve good coverage when we use variable selection methods
stepbic or Lasso. Lasso variable selection method works better even
with small sample sizes. We have considered different set of selected
variables used to get the PITE, those are separately selected variables
from each arm, union of selected variables from both arm and the
selected variables from joint model. Our simulation results indicates
all of these sets are perform well. In practice, the variables selected
from joint model would be more reasonable to use because we will
have new patients from any of the arms. We considered uncorre-
lated, perfectly correlated and partially correlated responses in the
simulation studies. Our proposed approach performs well with all of
these correlation structure. To illustrate proposed method, we used
PRO-ACT data (http://nctu.partners.org/proact) in ALS clinical trials.
We used patients with equal number of individuals (n = 1500) from
the placebo and active treatments group. We used the response vari-
able ALSFRS slope as used in Kuffner et al.(2015) compute from re-
peated measure of ALSFRS score (ALS Functional Rating Scale) and
covariates are several baseline information, Age, Gender, Ethnicity,
etc.… for each patient. We applied lasso regression and selected the
variables Gender, Age, Race, onset-delta and onset-site to get good
PITE for each individuals. We calculate 95% prediction intervals for
each patients. The estimated PITE and its intervals are reasonably
good. Discussion: Our proposed approach to find the prediction
interval for PITE performs well in the simulation studies and real data
example. We could use other type of response variables and covari-
ates in the model to estimate PITE and also we may use interaction
models and more complex mixed models to get PITE in future work.
References
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In clinical trials with time-to-event outcomes, interim or final analyses
are often planned after a pre-defined target number of events hasbeen reached. At the planning stage of such studies, the number of
events required for statistical analysis and predictions of the ex-
pected date when this target number of events will be reached, are
typically based on protocol assumptions and conducted by use of a
simple parametric model. A blinded re-evaluation of these predic-
tions is recommended to obtain more accurate predictions as the
trial progresses and events accumulate. Different statistical ap-
proaches have been proposed in the literature for making such
predictions, including parametric approaches assuming smooth
underlying survival functions, nonparametric approaches and hy-
brid methods applying a non-parametric model where data are
available, complemented with a parametric tail for regions where
no data are yet available. Factors such as study design and ratio of
number of events in relation to sample size can impact the model
estimates derived from the various statistical methods, thereby
making the choice of the optimal prediction method for a particular
study a key decision which can influence the reliability of the pre-
dictions. We report results obtained from a systematic comparison
of the different methods via simulation studies. The point estimates
of the predicted analysis times and number of events, along with
their variability as measured by confidence interval, are investi-
gated under varying study scenarios and findings are discussed.
Keywords: time-to-event, event prediction, parametric, hybrid.
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Background
Missing data are a potential source of bias in the results of randomised
controlled trials (RCTs), which can have a negative impact on guidance
derived from them, and ultimately patient care. However, missing data
are generally unavoidable in clinical research, particularly in patient re-
ported outcome measures (PROMs). For longitudinally collected out-
comes, often only a small subset of participant will have complete data
for all relevant time points. Multilevel mixed-effects linear regression
models are commonly used to analyse longitudinal data. A number of
methods are available to handle missing data in such analyses, includ-
ing maximum likelihood (ML), multiple imputation (MI) and inverse
probability weighting (IPW). Direct comparisons of such methods for
missing proms data in RCT settings are needed to ensure the bias intro-
duced in such analyses is minimised.
Objective
To compare ML, MI and IPW approaches for handling missing longi-
tudinal proms data in RCTs.
Methods
Real-life missing data following missing at random patterns were
simulated within the follow-up of an RCT using the Oxford Knee
Score. Datasets of sample sizes ranging from 100 to 1,000 with miss-
ing proms outcome data in 10% to 40% of participants were simu-
lated. Both intermittently missing data and monotone missing data
patterns were considered. Missing data was addressed using ML, MI
and IPW. Performance of the different approaches was assessed by
the bias introduced in the treatment coefficients from multilevel
mixed-effects linear regression models obtained for 1000 simulations.
Root mean square errors (RMSE) and mean absolute errors (MAE)
were used as performance parameters.
Results
Non-convergence issues were observed for the IPW approach for
small sample sizes. Complex MI models needed to be simplified to
obtain valid results for combinations of small sample sizes and large
proportions of missing data. Bias in the treatment coefficient in-
creased both with decreasing sample size and increasing proportions
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were included in both the imputation and analysis model, and when
the imputation model was restricted to baseline variables. However, MI
was less biased than ML when additional post-randomisation data were
used in the imputation model. Both approaches were less biased when
follow-up data was missing intermittently compared to monotone
missing data scenarios due to drop-out. IPW introduced more bias in
the model results than both ML and MI across all sample size and miss-
ing data scenarios.
Conclusions
MI can offer benefits over ML for handling missing longitudinal proms
data when additional post-randomisation information is available. For
RCTs with sample sizes up to 1000, the use of IPW is not recommended
to handle missing data. The findings also demonstrate the importance
of minimising missing data and continued data collection beyond
missed appointments to inform the analysis and imputation models.
The results presented in this presentation focus on missing at random
mechanisms, and sensitivity analyses to investigate the effect of other
missing data mechanisms remains imperative.
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Background
In this paper, we compare different methods of calculating sample sizes
for comparing two independent means of a continuous outcome with
baseline and post-intervention measurements of a randomised con-
trolled trial (RCT). Sample size calculations typically use published re-
sults from similar trials, and we illustrate the different methods using
published results from the MOSAIC trial.
Methods
The methods we discuss are suitable for sample size calculation using a
continuous outcome measure. Suppose the primary continuous
outcome measure is Y, with Y_0 and Y_1 denoting Y at baseline and
post-intervention, respectively. Let r denote the correlation coefficient
between Y_0 and Y_1. We discuss the following two factors:
1. The choice of the primary outcome measure: post-intervention
measure Y_1 vs. Change from baseline (i.e. Y_1-Y_0).
2. The choice of statistical methods for sample size calculation for
two independent means: t-test without using r vs. Analysis of covari-
ance (ANCOVA) using r.
We show how to use the Variance Sum Law to derive r between Y_0
and Y_1, and then how to use the derived r to calculate sample size
by ANCOVA. We discuss the assumptions of the ANCOVA method
and its implications for the trial design.
We discuss the existing research on how the value of correlation
coefficient r influences the sample size, using change score from
baseline vs. Post-intervention score alone.
We perform a sensitivity analysis on different values of r to show the
effect of the strength of the correlation on the sample size byANCOVA. The correlation between the post-intervention and baseline
measure is likely to reduce as the duration prolongs; therefore the
duration between the post-intervention and baseline need to be
taken into account For example, the MOSAIC trial reported the SF-36
energy/vitality score at 6 months, for which we have derived r = 0.7.
If the post-treatment time point of this measure in the planned RCT
is at 12 months, then we will need to reduce the value of r for the
sample size calculation. The resulting sample sizes are shown by the
sensitivity analysis in this paper.
Conclusions
ANCOVA allows efficient sample size calculation by utilising the cor-
relation between the baseline and post-intervention measurements;
however, one must be aware of its implications and consider factors
such as duration of the intervention. In comparison, using a t-test
produces a more conservative (i.e. Larger) sample size than using
ANCOVA.
In the situation when sample size is calculated by a t-test instead of
ANCOVA, sample size using change score from baseline can be smaller
or larger than that using post-intervention score alone, depending on
the value of the correlation coefficient r. The choice of the outcome
measure should be driven by clinical knowledge instead of a mere pur-
suit of small sample size.
We advocate reporting the standard error (SE) of the mean change
between the baseline and post-intervention measurements, as did
the MOSAIC publication. It provides insight into the correlation be-
tween the baseline and post-intervention measurements, and
therefore allows the sample size to be calculated and compared in
different ways.
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Background
In type 1 diabetes (T1D) there is a deficiency in the interleukin 2 (IL-2)
pathway leading to a loss of regulatory T cell (Treg) function. Dilfre-
quency aims to determine the optimal dosing regimen of ultra-low
dose recombinant IL-2 (aldesleukin) to improve Treg function while
limiting the activation of CD4 T effector cells (Teff) in participants
with T1D.
Methods
Thirty-six participants with T1D were administered repeat doses of alde-
sleukin with the aim of establishing the optimal dose-frequency to de-
liver drug to increase Tregs, CD25 (Subunit of the IL-2 receptor)
expression on Tregs, whilst minimising the increase in Teffs. There was
an initial learning phase with six pairs of participants, each pair receiv-
ing one of six preassigned dose-frequencies from 0.09-0.47x106 IU/m2
and 2–14 days, in order to model the dose-frequency response. At the
first interim analysis following the learning phase, the target increases
(30% Treg, 25% CD25, 0% Teff) for each of the endpoints were selected
by the dose frequency committee. The subsequent 3 groups of 8 par-
ticipants were administered dose-frequencies based on the results from
statistical analyses of all data from previous groups. When allocating
treatment regimens, consideration was given to the probability of the
predicted increases fall within the target ranges as well as the distance
the predicted increases are from the targets for each dose-frequency.
Results
We found at each pre-planned interim analyses, that the optimal dose-
frequency was estimated with increasing accuracy, thereby allowing
more participants to be allocated dose-frequencies close to the optimal
than would be possible in a non-adaptive design. The results from the
final interim analysis suggest that the optimal aldesleukin dose to
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tween 0.20 x106 IU/m2 and 0.32x106 IU/m2 at a frequency of every
3 days. Results from the final analysis are ongoing and will be pre-
sented when available.
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Background
Independent data monitoring in clinical trials of pregnant women where
successful pregnancy is one of the outcomes is hugely important given
the sensitive nature of these studies. Recommendations regarding early
stopping or protocol modification can only be made with appropriate
data available. Our experience in the NIHR-funded TABLET, PRISM and C-
STICH studies suggests certain elements of data monitoring - namely
oversight of interim estimates of the overall event rate and efficacy esti-
mates - require careful consideration and forward planning.
Methods
Primary outcomes for the aforementioned studies are variations of suc-
cessful pregnancy (either live birth > 34 weeks or pregnancy loss up to
the first week of life) and are planned to be analysed at the end of the
trial as dichotomous outcomes (success/fail) through the generation of
relative risks and associated confidence intervals using standard meth-
odology. However, interim assessment during the recruitment period
requires further thought as the failure rate is temporarily inflated due
to the fact that treatment failures (e.g. Miscarriage or still births) are
?A3B2 show $132#?>accumulated sooner than successful outcomes
(live births). In these circumstances, the Trial Statistician and Data Moni-
toring Committee need to consider their approach in how to monitor
both the sample size assumptions and interim estimates of efficacy.
Three approaches to this problem are apparent: i) analyse any partici-
pants that have currently completed the study accepting that the
success rate is temporarily reduced; ii) analyse a full cohort of pa-
tients that have completed the study using a pre-defined cut-off
period, e.g. Only those randomised greater than nine months previ-
ously; and iii) switch analytical methods during the interim period to
utilise survival analysis methodology (e.g. Kaplan-Meier, Cox Propor-
tional Hazards), censoring participants at the point of last know
follow-up if not yet completed the study.
Results
We will show that: option i) will not provide appropriate estimates of
current success rates and could potentially bias interim efficacy esti-
mates if there is a difference between groups in early failures; option
ii) will provide appropriate estimates of current live birth rate but will
limit the amount of data available for analysis and therefore poten-
tially hamper decision-making; and option iii) will utilise all available
data for analysis of efficacy and also provide appropriate interim esti-
mates of the live birth-rate.
Discussion
In studies of this type, Trial Statisticians should consider planning the
use of survival analysis methodology during the interim period regard-
less of planned final analysis methods to enable provision of inform-
ative estimates to independent Data Monitoring Committees.
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Background
Randomisation in clinical trials is often performed using permuted
blocks, in which the randomisation of a patient is dependent on the
randomisation of the other patients in the same block. This methodguarantees that similar numbers of patients are allocated to each
arm, within limits determined by the block size(s). This type of ran-
domisation can be stratified, so that balance is achieved within the
strata, rather than overall. The analysis of data from such trials should
be adjusted for the stratification variables [1]. Stratification variables
must be categorical, and therefore, if randomisation is to be stratified
on a continuous variable, the variable must first be split into categor-
ies (e.g. BMI is often categorised as underweight/normal, overweight,
or obese). It is well known that a continuous covariate should not be
categorised in an analysis (or anywhere else) without good reason.
The question this investigation aims to answer is: should the analysis
of a trial in which randomisation has been stratified on a categorised
continuous variable be adjusted for the categorisation, or the under-
lying continuous variable?
Methods
Simulations were performed to assess the effect on the significance
level and power of analyses in which the (continuous) outcome de-
pends on a continuous covariate, and the randomisation has been
stratified on a categorisation of this continuous variable. Three differ-
ent relationships between the variable and the outcome were tested:
linear, non-linear, and none, where the non-linear relationship meant
that different slopes were used for each level of the (binary) categor-
isation. The slopes in the linear and non-linear cases were varied in
magnitude. For each simulation, 10,000 data sets were generated,
and each was analysed in two models, one adjusting for the continu-
ous variable and the other for the categorisation. The simulations
were also conducted with unstratified randomisation.
Results
When the randomisation was stratified, the nominal power and sig-
nificance levels were maintained unconditionally. When the random-
isation was unstratified, the nominal power and significance levels
were maintained except when both (i) the analysis was adjusted for
the categorisation; and (ii) the effect of the underlying continuous
variable on the outcome was large.
Conclusions
When randomisation has been stratified on a categorised continuous
variable, there is no difference between adjusting for the underlying
continuous variable and adjusting for the categorisation. When the
continuous variable has a large effect on the outcome and the vari-
able has not been stratified on, power is lost if the analysis is ad-
justed for the categorisation as opposed to the continuous variable.
It is safer to always adjust for the underlying continuous variable.
Reference
[1] Improper analysis of trials randomised using stratified blocks or
minimisation, Brennan Kahan, Tim Morris, Statist. Med. 2012, 31 328–340.
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Background
Cluster randomized trials (CRTs) are becoming increasingly common
in primary care and public health. Often clusters are recruited and
randomised before suitable individuals are identified and recruited to
participate or consent to data collection, leading to possible bias if
the recruited/consented individuals differ systematically from those
who do not. It is often thought that this biases may be particularly
important when recruitment rates vary across clusters and interven-
tion arms.
Aim
The aim of this work is to use formal causal inference techniques to
help trial researchers understand when the treatment effect estimate
will be biased due to recruitment issues, by using Directed Acyclic
Graphs (DAGs) and d-separation, and to give a measure of the size of
these biases. Methods: We considered several situations that could lead
to recruitment bias in a CRT, namely where individual recruitment is
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measured or unmeasured), and use d-separation to show when the
treatment effect is biased due to the associations induced by condi-
tioning the analyses to those individuals in the population who are
recruited (or consented). We also conducted a simulation study in
which we varied the magnitude of association among the individual-
level covariate, treatment allocation at the cluster-level, the probability
of recruitment, and the outcome variable. We considered two different
individual recruitment rates: 50% and 75%.
Results
We have formal results showing when there is bias present, for ex-
ample when the probability of recruitment and the outcome both
depend on a common individual-level covariate, and these associa-
tions are differential by treatment allocated. In the simulations, we
found that where this bias is present, it can be over half a standard
deviation of the true causal treatment effect.
Conclusions
Recruitment bias in CRTs happens when recruitment/consent is dif-
ferential by treatment allocation and associated to a variable which
is also associated with the outcome. If this variable is observed, we
can control for it in the models, and our treatment effect will be un-
biased. However, if the variable is unobserved, the treatment effect
will be biased. This bias is small when recruitment rates are high. The
possibility that recruitment is associated with treatment assignment
can be minimised by identifying/recruiting individuals prior to cluster
randomisation, or by blinding recruiters and potential participants as
much as possible). In addition, if researchers know which individual
characteristic is likely to be associated with the systematic differences
in recruitment/consent, measuring this and adjusting for it, can miti-
gate the recruitment bias.
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Missing data can be a serious problem in longitudinal studies be-
cause of the increased chance of drop-out and other non-response
across the multiple time points, and can be particularly challenging
when there are different causes of the missing values. For instance,
the reasons that patients completely drop-out of the study (mono-
tone missingness) may be very different from those for failing to at-
tend a particular follow-up appointment (intermittent missingness).
Also, for some types of missingness, it is often plausible to assume
that data may be “missing not at random” (MNAR), i.e. after condi-
tioning on the observed data, the probability of missing data may
depend on the underlying unobserved values. For example, in critical
care trials the collection of hourly/daily biomedical data may take
place at the local physician’s discretion and lead to intermittent miss-
ingness that is related to the severity of the patient’s illness. Faced
with MNAR data, missing data guidelines recommend sensitivity ana-
lysis to allow for alternative assumptions about the missing data. A
useful approach is to use selection models, which specify a marginal
distribution for the outcomes (analysis model) and a conditional
distribution for the missing value indicators given the outcomes
(missingness model). Selection models are particularly attractive in
longitudinal studies, because they can recognise that the missing
data mechanism may be distinct across the different types of miss-
ingness. This research proposes flexible Bayesian selection models
for assessing the robustness of trial results to alternative realistic as-
sumptions about the different forms of missingness. In particular, we
consider i) the implications of different model choices to allow forcomplex longitudinal data structures and ii) the incorporation of
clinical expert knowledge about the reasons for the missing values
through informative priors in the missingness model. We illustrate
the methods using two examples: the Vasopressin and Septic
Shock Trial (VASST) and the Protease Inhibitor Monotherapy Versus
Ongoing Triple Therapy Trial (PIVOT). For VASST, we reanalyse the
cardiac index data, collected at baseline and 9 subsequent time-
points over the following 96 hours. Monitoring started after base-
line for a third of the patients and was discontinued as a result of
both death and recovery. For PIVOT, our interest is in the health-
related quality of life outcome, which was collected every 12 weeks
over a 3-year period, but suffered from substantial intermittent
(35%) and monotone (20%) missingness in both arms. For each
outcome, we compare the results from alternative assumptions
about the longitudinal missing data mechanisms with the pub-
lished trial results and assess the implications for decision uncer-
tainty. As an example, provisional results from the sensitivity
analysis for VASST find that the average cardiac index over time
was 9% higher for patients treated with vasopressin compared with
those treated with norepinephrine (95% credible interval: 1%-17%),
whereas the original analysis reported no difference. We conclude
that this approach to sensitivity analysis provides a flexible frame-
work to assess the implications of the missing data for the trial
conclusions.
P334
How and when do competing risks influence results from clinical
trials?
John Gregson
London Schoole of Hygiene and Tropical Medicine
Trials 2017, 18(Suppl 1):P334
Background
A competing risk is an event that prevents an event of interest, such
as a primary trial outcome, from occurring. The most common com-
peting risk is death. Ignoring a competing risk in the analysis of a
trial results in invalid estimates of the cumulative incidence (absolute
risk) of the event of interest. Ignoring competing risks can also result
in invalid comparisons between treatment and control groups, for
example by biasing the estimate of the hazard ratio.
Methods
We reviewed currently methods for dealing with competing risks.
The two most commonly used methods were the Fine and Gray
model and cause-specific hazards models. We aimed to illustrate the
effect of competing risks on estimates of cumulative incidence or es-
timates or hazard ratios. We aimed to characterise the scenarios
where bias is most likely to occur and most likely to be large.
We used data from 3 large Phase III randomised clinical trials in car-
diovascular disease: EMPHASIS-HF, EPHESUS and RALES. We chose
heart failure hospitalisation as the event of interest and cardiovascu-
lar death as the competing event.
Results
Cause-specific hazards over-estimate cumulative incidence, whereas
the Fine and Gray method correctly adjusts estimates of cumulative
incidence to take into account competing risk.
Both cause-specific hazards models and Fine and Gray models give
biased estimates of the hazard ratio for treatment effect. When using
the cause-specific hazards model, the likely size of the bias was small
or moderate in the examples we studied, but the bias was larger
when using the Fine and Gray model. Competing risks caused larger
biases when the event occurred in larger numbers of patients; oc-
curred earlier during follow up; or occurred more frequently in either
the treatment or control group.
Conclusions
The cumulative incidence of a primary outcome can be accurately es-
timated using the Fine and Gray method. However, when estimating
the hazard ratio for treatment effect of an event of interest, current
methods do not adequately deal with competing risks.
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Background
Kaplan – Meier (KM) graphs are the standard approach for depicting
outcomes and risks over time for time-to-event outcome measures, in-
cluding, for example, survival-based outcome measures which are
widely used in many disease areas. In the context of clinical trials using
these outcome measures, a KM graph is ubiquitous, and is intended to
provide a visual representation of any difference between groups or
lack thereof and is therefore critical to the interpretation and impact of
the trial results. We believe, however, that the standard version of KM
graphs can sometimes mislead. One challenge is that the number of
patients contributing information decreases as time increases, but the
eye is naturally drawn to the right-hand side of the graph where there
are fewer data. Another challenge is the uncertainty in the data under-
pinning the lines. There is no widely agreed way to depict this informa-
tion, and is insufficiently clearly presented in most journals’ graphs.
Methods
We explored a series of ways of modifying the KM graph with two ob-
jectives: (1) clearly and accurately representing the numbers censored,
experiencing events, and still ‘at risk’, and (2) displaying uncertainty. We
included combinations of often-used basics, such as censoring marks
and simple risk tables, to more sophisticated risk tables, companion
risk-and-event graphs, area shading graphs which represent at-risk pop-
ulations, and re-construction of the KM lines themselves with sampling.
We used trial data to illustrate the strengths and weaknesses of each
possible approach. An international survey is in development which will
seek responses during winter 2016 17 from people with a wide range
of relevant perspectives, including statisticians, clinicians, journal editors
and regulators. A fun, supplemental interactive vote would be under-
taken on-site during the conference.
Results
Several ways to improve depictions of survival data will be presented
on the poster. Results of the survey will be presented at the meeting.
We will summarise the strengths and weaknesses.
Potential Impact
There is potential to improve the presentation of KM graphs and,
furthermore, to convey more information about the results of clinical
trials. However, implementation in manuscripts would likely depend
on the willingness of editors to make the necessary space.
Discussion
If there is agreement on a new standard which is not yet routinely
available in the major statistical packages, work will be required to
make these routinely and simply available.
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Two-stage adaptive trial designs offer an efficient way of selecting
and validating multiple candidate treatments within a single trial. A
common strategy is to select the best performing treatment (accord-
ing to some ranking criteria) after an interim analysis, and to then
validate its properties in an independent sample in the second stage.
However, selecting and ranking candidates in this way can induce
bias into the naive estimates that combine data from both stages. Ifthe selection rules are not properly taken into account by the estima-
tion strategy, then intuitively one might expect overly optimistic esti-
mates of the treatment effect of the selected candidate, given that it
had to perform ‘well’ in the first stage in order to proceed to the sec-
ond stage.
To efficiently and completely correct for selection bias in adaptive
two-stage clinical trials, uniformly minimum variance conditionally
unbiased estimators (UMVCUEs) have been derived for a variety of
trial designs with normally distributed data. However, a common as-
sumption is that the variances are known exactly, which is unlikely to
be the case in clinical practice.
In this paper, we extend the work of Cohen and Sackrowitz (Statistics
& Probability Letters 1989), who proposed an UMVCUE for the best
performing candidate in the normal setting with a common un-
known variance, but only when the first stage sample sizes are all
equal and the second stage sample size is equal to one.
Our extension allows for arbitrary first and second stage sample sizes
for the different treatment arms, and can also be used to estimate
the outcome measure of the j-th best candidate out of k. We show
through a simulation study that the UMVCUE that assumes a known
variance and estimates it from the trial data is no longer unbiased,
and will have a higher mean squared error than our new estimator if
the variance is overestimated.
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Background
Clinical trials are valuable resources for biomarker exploration as
prospectively collected data and experimental designs minimise
bias. Models using multiple biomarkers to predict therapeutic re-
sponse are of particular interest; however, the high-dimensional,
small datasets come with challenges. This study aimed to high-
light over-fitting issues with producing predictive models using
commonly-used methods for Stratified Medicine in typical clinical
trial datasets, using an ovarian cancer trial derived dataset as a
case study.
Methods
Variable selection methods were performed on SCOTROC4 trial data
collected from Scottish Gynecologic Cancer Trials Group. The original
cohort included 964 patients, of which 155 patients had both
available protein expression data in tumour samples assessed by in-
dependent scorers, and evaluable CA125 data which monitored pa-
tients’ therapeutic response. Following clinical consultation, response
was defined as >50% reduction in CA125 baseline post-treatment. A
pre-selection method to improve variable selection efficiency re-
duced 26 candidate proteins to 6: cycline E, SENP2, p53, folr2, larp1
and Ki-67. Backwards selection (BS), Akaike Information Criterion
(AIC) and LASSO methods were then applied to create predictive
models. Accuracy (sensitivity and specificity) of models was assessed
through receiver operating characteristic (ROC) curve and area under
the curve (AUC). Discrimination ability was assessed through box-and-
whisker plots of predicted probability of responding/non-responding
groups (127 and 28 patients respectively). 10-fold stratified cross-
validation was applied to BS and AIC to control for over-fitting.
Performance ability from the full model, BS, AIC, LASSO, cross-
validated BS and cross-validated AIC were compared. To assess
clinical usefulness, Positive predictive value (PPV) and negative
predictive value (NPV) were calculated by extracting accuracy
values from the most accurate model and prevalence of thera-
peutic response from the original cohort.
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The full model, BS, AIC and LASSO produced similar performance
levels of accuracy (AUC = 0.80, 0.78, 0.80, 0.80). Discriminative ability
was also similar, as 75% of distributions between responding and
non-responding patients in box-and-whisker plots were distinctly
different from each other. LASSO demonstrated advantageous pre-
cision in discrimination ability. High correlation between the full
model, BS, AIC and LASSO models predictive probability (r ranged
from 0.8-1) suggested over-fitting in models produced by these
variable selection methods. This was supported by the substantial
drop in accuracy once BS and AIC models were cross-validated
(AUC = 0.57, 0.54 respectively). Cross-validated models showed lim-
ited ability to distinguish between responding/non-responding pa-
tients. PPV and NPV calculations implied that 10% of patients in
this dataset predicted as responders would not respond to therapy,
and 55% patients who would be predicted as non-responders
would respond to therapy using the most optimal sensitivity and
specificity values from the full model (70%, 75%) assuming the
prevalence of response is 77.4%.
Conclusion
Evidence of over-fitting issues were present in all variable selection
methods, including LASSO which supposedly controls for over-fitting
within its algorithm. LASSO proved advantageous with its enhanced pre-
cision in dichotomising patients, however, NPV and PPV values suggested
that a clinically useful model is unlikely to be found unless a dataset is
large, or odds ratios of biomarkers added in models are extreme.
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Background
Missing data pose a serious threat to the validity and interpretation
of noninferiority trials and may result in the rejection of a promising
new noninferior agent or the acceptance of what is, in fact, an infer-
ior treatment. While there are recommendations for principled ap-
proaches to handling missing data in superiority trials, there are
none for NI trials, and missing data can affect them differently.
Methods
We carried out a systematic review to investigate how researchers
are handling missing data in noninferiority trials: the amount of miss-
ing data; the analyses used and the missing data assumptions;
whether missing data were considered in the sample size calculation;
and whether any sensitivity analyses were carried out.
Results
Most trials had missing data, most used a complete case analysis,
about half accounted for missing data in the sample size calculation
and very few carried out a sensitivity analysis. About one-fifth ana-
lyzed both the intention-to-treat and per-protocol sets.
Conclusion
There is room for improvement in handling missing data in noninferi-
ority trials. There is also a need to carry out research in sensitivity
analyses for noninferiorityi trials with respect to missing data.
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Background
Phase II trials play a vital role in cancer drug development as they de-
termine whether a new drug should continue for further investigation.Most phase II cancer trials apply a single-arm design with a binary out-
come, and multi-stage designs are commonly used to stop for futility in
these settings. The most common design for single-arm phase II cancer
trial is Simon’s two-stage design. However, Bayesian design with con-
tinuous monitoring is getting popular in recently years as it is flexible
and efficient given its intensive statistical input. In this study, we
compared the operating characteristics of Simon’s two stage design
and Bayesian predictive probability (PP) design using a real life cancer
phase II trial.
Method
The phase II cancer was original designed as a Simon’s two-stage
Minimax with the primary outcome of clinical benefit, defined as
complete response, partial response or stable disease for 6 months.
The trial tested H0: p0 < =0.05 versus H1: p1 > =0.20 with type I error
of 0.05 and type II error of 0.20.The Bayesian PP design monitors the
trial continuously so that the Bayesian posterior probability is up-
dated after the outcome from each participant becomes available.
The predictive probability of concluding a positive result by the end
of the trial is calculated based on the updated posterior probability.
In this study, we used p0 = 0.05 and p1 = 0.20 to design the trial. If
the probability that the clinical benefit rate of p is larger than p0 ex-
ceeds a threshold of Theta-T at the end of the trial, the drug will be
concluded as effective. During the monitoring, the trial will stop for
futility if the PP is less than a threshold of Theta-L, and the trial will
not stop for efficacy (Theta-U = 1). To compare with the Simon’s
minimax design, the minimum sample size is selected among the
sample sizes satisfying the constraints of above type I and type II
error. The corresponding Theta-L and Theta-T are 0.001 and [0.86,
0.95], respectively.
Results
The futility boundaries in Simon’s minimax design are 0/13 and 3/27
with a sample size of 27 patients. In Bayesian PP design, the futility
boundaries are 0/14, 1/24, 2/26 and 3/27 with the same sample size
as Simon’s minimax design. The exact type I errors in Simon’s design
and PP design are both 0.042, while the powers are 0.80 and 0.81, re-
spectively. Although the probability of early stopping under null hy-
pothesis is significantly higher in PP design than that in Simon’s
design (87% vs 51%), the expected sample size under null hypothesis
for the two designs are the same (E(N|H0) = 19.8).
Conclusion
In this cancer phase II trial, where the clinical benefit rate of standard
treatment (p0) was relatively low, the Simon’s two stage design had
similar operating characteristics compared to Bayesian PP design. In
practice, this suggests that if a phase II trial has a stop boundary of 0
in the interim analysis of Simon’s design, the Bayesian PP design is
unlikely to be superior.
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Background
There have been intermittent calls in the health sciences for sample
size planning for randomised trials to be based on, or include, the ex-
pected width of the 95% confidence interval (CI) for the parameter
of interest. The relationship between power of a test at a 5% signifi-
cance level and the expected 95% CI width has appeared in the lit-
erature for trials planned with 80% or 90% power, most notably by
Goodman and Berlin over 20 years ago. However, this relationship
does not appear to be well known, has not been extended to treat-
ment effect parameters other than differences between randomised
arms, and it does not seem to have been realised that an even sim-
pler approximate relationship also exists.
Methods
We derive the basic relationship between power and expected CI
width, state its underlying assumptions, and illustrate its use in a
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used in randomised trials. We demonstrate that a linear approxima-
tion simplifies this relationship further.
Results
The expected 95% CI width calculated from the relationship with
power compares very favourably with asymptotic analytical formulae.
The simpler linear approximation is appropriate for any level of power
between 50% and 95%.
Conclusions
One can determine the expected 95% CI width given a certain level
of power, or vice versa, using an extremely simple relationship which
makes it easy to conceptualise the consequences of one for the
other. The relationship can be a useful rule of thumb to consider
when planning trials.
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The T1D Exchange Clinic Network consists of 81 endocrinology
practices throughout the United States. Eighteen of the centers
primarily care for adult patients, 38 for pediatric patients, and 25
care for both. Among the more than 100,000 patients with type 1
diabetes (T1D) who receive care at these centers, more than 30,000
have been enrolled in the T1D Exchange clinic registry. The diverse
size, resources, and practices among registry clinics may have an
impact on the diabetes management and diabetes-related out-
comes of participants. Understanding the variation in these re-
sources and practices is an important step in determining how to
improve diabetes management and diabetes outcomes. Statistical
quality control is a method for monitoring quality of conformance
and eliminating distinct causes of variability in a process through
the use of graphical displays. One such graphical display is a funnel
plot, which plots effect estimates from individuals against a measure of
size or precision. Funnel plots also include lines for expected value of
the effect and lower and upper control limits. These plots can be useful
in assessing the variation in mean, median, or proportion of diabetes
management factors and outcomes across clinic size. For example, a
funnel plot of the proportion of diabetes patients achieving target
glycemic control as measured by hba1c is an effective visual display of
glycemic variation across clinical centers. The funnel plot enables iden-
tification of high performing centers that may provide insights to in-
form practice improvements for other participants in the network.
Knowledge of variation in glycemic control, current use of advanced
diabetes technologies, and occurrence of acute diabetes-related out-
comes across varying clinic size is useful for learning and improving
practices and resources in delivering diabetes care.
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Background
We are interested in the problem of portfolio level decision making
in the context of a pharmaceutical portfolio containing combinationtherapies. There has been a recent rise in popularity of combination
therapies, particularly those containing new molecular entities. Our
particular area of interest is oncology, due to the recent develop-
ment of cancer immunotherapy treatments. While this development
is an exciting one, it poses new challenges for pharmaceutical
companies. One of these challenges is how to decide which combi-
nations, from the large set of possible combinations, is the most
promising and hence which therapies should be added to a com-
pany’s portfolio. In order to make the best decisions for the portfolio,
emerging information should be included alongside the available his-
torical data. However, in the context of combination therapies we
have a different source of information: the information from studies
involving similar combinations. We believe that incorporating infor-
mation from similar studies will lead to improved portfolio level deci-
sion making.
Existing Methods
We outline two conceptually different methods for optimising the
expected outcome of a pharmaceutical portfolio from the literature
and provide a discussion and comparison of these methods. The
first method is based on real options analysis and draws upon the
way in which the sequential nature of the investments made in a
drug development programme corresponds to a series of call op-
tions. The resulting model formulation is a mixed integer linear
programme which maximises the real options value of the portfolio.
The second method is similar to the stochastic version of the re-
source constrained project scheduling problem. In this setting, the
development programmes for each of the drugs within the portfo-
lio will be treated as projects which are made up of stochastic and
deterministic tasks. The resulting model formulation is a multi-stage
stochastic programme and has a particular focus on the technical
uncertainty involved in the process.
Our Contribution
The existing methods for portfolio decision making do not allow in-
formation about combination therapies specifically to be incorpo-
rated into the decision making process itself. Therefore, we provide a
comparison and discussion of these methods in the context of a
portfolio containing combination therapies before providing our own
extension. Our extension builds on network meta-analytic techniques
and allows information to be shared between studies for similar
combination therapies. Learning across trials of similar combinations
will allow us to improve the accuracy of our treatment effect esti-
mates which in turn will lead to better informed decision making
and hence better outcomes for the portfolio.
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Background
Preterm newborns are a very vulnerable population in which clinical
trials are extremely difficult and therefore rarely conducted. A phase
I/II trial aiming at finding the recommended dose of Levetiracetam
for treating neonate’s seizures was planned with a maximum sample
size of 50. In the trial, 4 dose levels (consisting in a loading dose and
up to 8 maintenance doses) are considered with 3 primary outcomes:
efficacy, short term toxicity (Ts) and long term toxicity (Tl). Tl occurs
at the same time as short term toxicity but can only be measured at
Trials 2017, 18(Suppl 1):200 Page 130 of 235a later time. In the absence of efficacy, physicians could add a sec-
ond agent as rescue medication, which could differ from centre to
centre.
Materials and methods
A Bayesian design was developed for this trial. The 3 primary outcomes
were modelled via a logistic model for efficacy, a time-to-event quasi-
likelihood for Ts and a quasi-likelihood with Ts as covariate for Tl, as Ts
is predictive for Tl. The quasi-likelihood method allows us to take into
account the fact that toxicity may be due to Levetiracetam or to
the added second agent or to both, in case the Levetiracetam
shows no efficacy and a second agent is added. Relevance weights
were added to the model to avoid stickiness (that is, to be stuck for
several patients at the same suboptimal dose level) due to early
toxicities along with small target probability. Finally, this model al-
lows sequential analyses on accumulating data. Dose escalation
rules were based on adaptive thresholds for posterior probabilities,
in the start-up phase considering only Ts while later considering
both Ts and Tl. A simulation study was conducted to assess the
design under several scenarios for sample size of 30, 40 and 50,
respectively. The same design without quasi likelihood part, that is
considering all toxicities due to Levetiracetam, and without rele-
vance weight was used for comparison.
Results
On average, the proposed design leads to recommendation of the
correct dose at about 60% for a sample size of 30, increasing up to
more than 80% in many scenarios for a sample size of 50. This model
maintains an acceptable number of neonates with toxicities when
compared to the same design without quasi-likelihood part and
without relevance weights.
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Objectives
Equal allocation of patients to one of two treatments is accepted al-
most universally in the design of randomised clinical trials and it is
often assumed that this approach provides the most efficient use of
available resources.
Background
Design of phase II studies with a binary endpoint is often carried out
in a two-stages following the principles of Simon and A’Hern and ex-
tended into randomised trials by Jung and Sargent. Assessments of
efficacy are often made via the odds ratio, the precision of which is
only optimal under equal allocation when there is no difference in
the response rates between the two treatment arms.
Methods
For trials where the response rates are p_x and p_y in the experi-
mental and control arm respectively, we propose to allocate 0 1 pa-
tients to the experimental arm such that
= (1 + A)^(−1)
Where
A = (p_x (1-p_x))/(p_y (1-p_y))
Results
Sample size calculations based on the exact methodology of Jung
and Sargent show that estimates are smaller than those where equal
allocation is used, with the discrepancy being greater as the re-
sponse rate tends towards 0 or 1. In studies where standard sample
size calculations are used, for a fixed sample size using unequalallocation will ensure a smaller standard error about the odds ratio
for studies where there is a positive response.
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Background
Interstitial lung disease (ILD) frequently complicates systemic auto-
immune disorders resulting in considerable morbidity and mortality. The
connective tissue diseases (CTDs) most frequently resulting in ILD include;
systemic sclerosis, idiopathic inflammatory myositis (including dermato-
myositis, polymyositis and anti-synthetase syndrome) and mixed con-
nective tissue disease. Despite the development, over the last two
decades, of a range of biologic therapies which have resulted in signifi-
cant improvements in the treatment of the systemic manifestations of
CTD, the management of CTD-associated ILD has changed little. At
present there are no approved therapies for CTD-ILD. Following trials in
scleroderma-ILD, cyclophosphamide is the accepted standard of care for
individuals with severe or progressive CTD-related ILD. Observational
studies have suggested that the anti-CD20 monoclonal antibody, rituxi-
mab, is an effective rescue therapy in treatment refractory CTD-ILD. How-
ever, before now, there have been no randomised controlled trials
assessing the efficacy of rituximab in this treatment population.
Methods
RECITAL is a multicentre, randomized, double-blind, double-dummy,
controlled trial funded by the Efficacy and Mechanism Evaluation
Programme of the Medical Research Council and National Institute
for Health Research. The trial, which has to date recruited ~30% of its
target recruitment, will compare rituximab 1 g given intravenously,
twice at an interval of two weeks, with intravenous cyclophospha-
mide given monthly at a dose of 600 mg/m2 body surface area in in-
dividuals with ILD due to systemic sclerosis, idiopathic inflammatory
myositis (including anti-synthetase syndrome) or mixed connective
tissue disease. A total of 116 individuals will be randomised 1:1 to
each of the two treatment arms, with stratification based on under-
lying CTD, and will be followed for a total of 48 weeks from first
dose. The primary endpoint for the study is change in forced vital
capacity (FVC) at 24 weeks. Key secondary endpoints include; safety,
change in FVC at 48 weeks as well as survival, change in oxygen re-
quirements, total 48 week corticosteroid exposure and utilisation of
healthcare resources.
Discussion
This is the first randomised control trial to study the efficacy of rituxi-
mab as first line treatment in CTD-associated ILD. To date we have
recruited 34 patients from 3 UK sites. Our recruitment accruals repre-
sent one of the largest cohorts worldwide in these rare diseases.
Herewith, we are presenting baseline characteristics of this unique
cohort. The results anticipated at the conclusion of the trial should
provide important information on the treatment of a life-threatening
complication affecting a rare group of CTDs.
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Thanks to the advances in genomics and targeted treatments, an in-
creasing interest is being devoted to develop prediction models with
biomarkers or gene signatures to predict how likely patients will
benefit from particular treatments. Despite the methodological
framework for the development and validation of gene signatures in
a high-dimensional setting is quite well established, no clear guid-
ance exists yet on how to estimate expected survival probabilities.
We propose a unified framework for developing and validating a
high-dimensional Cox model integrating clinical and genomic vari-
ables in a randomized clinical trial to estimate the expected absolute
treatment effect according to signature values, and to estimate ex-
pected survival probabilities for patients with associated confidence
intervals.
Methods
Based on a parsimonious selection model in a penalized (lasso or
adaptive lasso) high-dimensional Cox model, we investigated several
strategies to: estimate the individual survival probabilities at a given
timepoint (using single or double cross-validation); construct confi-
dence intervals thereof (analytical or bootstrap); and visualize them
graphically (pointwise or spline). We compared these strategies through
a simulation study covering null and alternative scenarios and we eval-
uated them by prediction criteria. We applied the strategies to a large
randomized controlled phase III trial in 1574 early breast patients that
evaluated the effect of adding trastuzumab to chemotherapy and for
which the expression of 462 genes were measured.
Results
Simulation results suggest that a penalized regression model estimated
using adaptive lasso estimates the survival probability of new patients
with low bias and standard error, and that bootstrapped confidence in-
tervals have empirical coverage probability close to the nominal level
across very different scenarios. The double cross-validation allows mim-
icking internally the prediction performance in absence of external val-
idation data. We also propose a visual representation of the expected
survival probabilities using splines. In the breast cancer trial, we identi-
fied a prediction model with 4 clinical covariates, the main effect of 98
biomarkers and 24 biomarker-by-treatment interactions. This illustration
also highlights the high variability of the expected survival probabilities,
with very large confidence intervals.
Conclusion
We propose a unified framework for developing and validating a gene
signature in a high-dimensional survival setting in order to calculate
expected survival probabilities at a given horizon for future patients,
and to visualize the survival predictions. Based on our simulations, the
adaptive lasso penalty can be useful to identify a signature and then,
to accurately estimate the expected survival probability of future
patients.
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Background
Disparities in health and health outcomes are a common feature in
health research. When these disparities are unfair and avoidable they
may be referred to as inequities. Due consideration of inequities is
important to inform the design and conduct of trials so that they do
not aggravate inequities, but instead capture the role of inequities in
a credible and informative way. In light of the lack of evidence on
equity and the absence of guidance on how to design a purposefullyequity-relevant trial, the Consolidated Standards for Reporting
(CONSORT) equity advisory group came together to address these
issues.
Content
This work is part of a broader project that includes the development
of a framework for defining equity-relevant trials and a CONSORT ex-
tension for equity-relevant trials. This work discusses approaches to
integrating equity considerations in equity-relevant randomized trials
by building upon the PROGRESS-Plus framework (Place of residence,
Race, Occupation, Gender, Religion, Education, Socioeconomic status,
Social capital and other context-specific factors) and covers research
questions formulation, two scenarios of equity relevant trials and
how the PROGRESS-Plus factors may influence trial design, conduct,
and analyses.
Conclusion
With an a-priori focus on certain equity items, trials can be designed
to optimize their ability to provide actionable and credible evidence
on equity, by careful consideration of design, conduct and analytical
issues that play a role in equity.
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Background
Blinding is a measure in randomized controlled trials (RCT) to reduce
performance and detection bias. There is evidence that lack of blinding
leads to overestimated treatment effects. Since, surgical trials use inter-
ventions with a physical component blinding is often complicated to
apply. The aim of this study was to analyse the actual impact of blind-
ing on outcomes in general and abdominal surgery RCT.
Methods
A systematic literature search in CENTRAL, MEDLINE and Web of
science was conducted to locate RCT between 1996 and 2015 with a
surgical intervention. General study characteristics and information
on blinding methods were extracted. The risk of performance and
detection bias was rated as low, unclear or high according to the
Cochrane Collaboration's tool for assessing risk of bias. The main out-
come was the association of a high risk of performance or detection
bias with significant trial results and was tested at a level of signifi-
cance of 5%.
Results
Out of 29´119 articles 378 RCT were included in the analysis investi-
gating a total of 62´522 patients of which 15´025 patients were
blinded (24.0%). Regarding performance bias 88 of 378 RCT (23.3%)
were at high risk of performance bias and 290 of 378 RCT (76.7%)
were not. Hereby, 50 of 88 high risk RCT (56.8%) showed significant
trial results compared to 134 of 290 non-high risk RCT (46.2%) result-
ing in non-significant association (OR 1.53; 95%-CI: 0.95 to 2.48; p =
0.08) of performance bias and trial results. Further, 59 of 378 RCT
(15.6%) were at high risk of detection bias and 319 of 378 RCT
(84.4%) were not. Hereby, 28 of 59 high risk RCT (47.5%) showed
significant trial results compared to 156 of 319 non-high risk RCT
(48.9%) resulting in non-significant association (OR 0.94; 95%-CI: 0.52
to 1.65; p = 0.84) of detection bias and trial results.
Discussion
Surprisingly, performance and detection bias do not distort treatment
effects in general and abdominal surgery RCT. Therefore, surgical re-
searcher can rely on this evidence and leave out complicated ways of
blinding methods. However, easily applicable blinding measures should
Trials 2017, 18(Suppl 1):200 Page 132 of 235be taken for the theoretical advantage. During critical appraisal of a
surgical RCT the threat to validity of trial results by performance and
detection bias should not be overestimated.
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Background
Large randomised trials tend to have a relatively short “in-trial” Follow-
up period and hence may underestimate any long-term benefits of the
assessed intervention or fail to detect delayed hazards. Post-trial follow-
up (PTFU), which we define as extended follow-up either after the
scheduled trial period or publication of the primary results, allows
detection of both persistent or enhanced beneficial effects following
cessation of study treatment (ie, a legacy effect) and the emergence of
possible adverse effects (eg, cancer). Despite these advantages, PTFU is
not routinely undertaken and, when implemented, methods vary
widely. This review describes methods of PTFU used in recent large ran-
domised trials, and will compare retention rates and study costs where
such information is available, and may help promote the use of effect-
ive PTFU for ongoing and future large trials.
Methods
A systematic search of electronic databases and clinical trial registries
was conducted using a pre-defined search strategy with the following
inclusion criteria: i) randomized trials with 1000 or more participants, ii)
published between March 2006–2016; iii) evaluation of medical, surgi-
cal or psychological interventions; iv) implementation of post-trial
follow-up reported. Two reviewers screened and extracted data from
eligible papers with the aim of 95% concordance and any discrepancies
were resolved by a third reviewer. Retention rates, costs and other de-
scriptive differences of PTFU were reviewed. The systematic review was
conducted following PRISMA guidelines.
Results
The search strategy incorporated relevant papers from Cochrane
Central Register, Embase, Medline and clinical trial registries yielding
50,153 papers from databases (49,915) and trial registries (218). After
excluding duplicates (22,168), studies of children and animals (1649)
and papers published before 2006 (9289). 17,027 abstracts were
screened by 2 reviewers using a concordance strategy. Reviewers were
73% concordant for the first 10% of abstracts screened, but after
discussion concordance rose to 99%. Following abstract screening, 239
papers and 218 protocols were eligible for full review and preliminary
results suggest that around half will represent unique studies with
relevant data to extract in the review. The length of PTFU ranged from
1–20 years and PTFU methods varied, including direct patient contact
via clinic appointments, postal questionnaires, telephone interviews
and indirect follow-up via national registries. Some trials used incen-
tives for participant retention, including free healthcare relevant to the
intervention. Several PTFUs were prompted by the Data Monitoring
Committee because of concerns about potential delayed treatment
hazards. Occasionally trials investigated an outcome different to the in-
trial primary endpoint. Where industry supported the in-trial period,
such funding for PTFU was infrequent. Final results of the review are
pending and will be presented.
Conclusions
Post-trial follow-up of large RCTs may allow more reliable estimation of
the long-term benefits of the study treatment and the detection of any
delayed adverse effects which might not emerge during the relative
“in-trial” period. This review will describe the methods of post-trialfollow-up used in a range of recent randomized trials. We anticipate
that PTFU using routinely collected health records will be more com-
prehensive and cost-effective than studies involving direct patient
contact.
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Background
Most systematic reviews are retrospective and use aggregate data
(AD) from publications, meaning they can be unreliable, lag behind
therapeutic developments and fail to influence ongoing or new trials.
Commonly, the potential influence of unpublished or ongoing trials
is overlooked when interpreting results, or determining the value of
updating the meta-analysis or need to collect individual participant
data (IPD). Therefore, we developed a Framework for Adaptive Meta-
analysis (FAME) to determine prospectively the earliest opportunity
for reliable AD meta-analysis. We illustrate FAME using two system-
atic reviews in men with metastatic (M1) and non-metastatic (M0)
hormone-sensitive prostate cancer (HSPC).
Methods
Key principles of FAME are: 1) Start the systematic review process
early, before all trials have completed 2) Comprehensively search for
published, unpublished and ongoing eligible trials; 3) Develop a de-
tailed picture of these trials, particularly how information and results
are likely to accumulate; 3) Predict the feasibility and timing of a reli-
able meta-analysis; 4) Interpret meta-analysis results accounting for
trials that have not yet completed/reported; 5) Determine if an up-
date based on AD or IPD is needed.
In 2014, using FAME, we initiated two systematic reviews to evaluate
the effects of adding docetaxel to standard care in men with HSPC.
We predicted that, by mid-2015, results of 3 of 5 eligible trials in M1
disease would become available, each with median follow-up of
around 4 years. They would represent around 90% of all men rando-
mised, giving 70 to >99% power to detect a 5% -10% absolute differ-
ence in 4-year survival. This provided a clear trigger for a robust
meta-analysis.
Also, for M0 disease, we anticipated the availability of results from 4
of 11 eligible trials, again with median follow-up around 4 years.
Power would be reasonable (60 to >99%) to detect similar absolute
effects, but only 60% of randomised men would be represented. Al-
though a meta-analysis would not be definitive, it could provide use-
ful context for the M1 results and for ascertaining when a robust
update of the meta-analysis might be feasible.
Results
In M1 disease, we found a clear benefit of docetaxel on survival.
FAME gave us confidence that the primary question was answered
definitively, without needing to wait for results of the remaining 2 tri-
als, or collecting IPD. Collaborating with trialists through FAME gave
us access to pre-publication trial results, and facilitated contemporan-
eous publication of the systematic review and the largest trial.
In M0 disease, there was a clear effect of docetaxel on failure-free
survival, but overall survival results were inconclusive. Therefore,
FAME provided an early signal of potential benefit, and highlighted
the value of a future update that includes longer-term follow-up of
included trials and results of currently unreported trials. Ongoing
collaboration with trialists will provide up-to-date information, en-
abling better prediction of the timing and feasibility of a definitive
Trials 2017, 18(Suppl 1):200 Page 133 of 235meta-analysis, and whether AD or IPD will be required. It will also
facilitate a co-ordinated dissemination strategy.
Conclusions
In piloting FAME, we have shown that meta-analysis can be done in
a timely and transparent manner without compromising reliability
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Randomized controlled trials of treatments and interventions are
typically described as either explanatory or pragmatic. Meta-analysis
of RCT studies typically pools evidence of treatment effects from
included studies, regardless of their classification as ‘pragmatic’ or
‘explanatory trials. Given that treatment effects in explanatory trials
may be greater than those obtained in pragmatic trials, conventional
meta-analytic approaches may not accurately account for the hetero-
geneity among the studies and may result in biased estimates of
treatment effects. Stratified meta-analysis of systematically review
studies in which treatment effects from explanatory trials are meta-
analyzed and reported separately from pragmatic trials is increasingly
being adopted in meta-analysis studies. But this approach might not
necessarily inform decision-making especially when stratum-specific
pooled treatment effects are in opposite directions. In this study we
investigate a variety of meta-analytic approaches for synthesizing
evidence from pragmatic and explanatory trials, including mixture
random-effects meta regression, robust random-effects meta-
regression, and hierarchical Bayesian meta-analysis techniques for
synthesizing evidence from pragmatic and explanatory trials. Data
from a systematic review of 55 published obesity prevention trials,
which investigated the effectiveness of public health intervention on
reduction of obesity, was used to demonstrate and compare these
methods. Discussions about the key statistical and design consider-
ations when pooling evidence from both types of trial designs are
provided.
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Background
In the last 25 years, ebm has increasingly found its way into clinical
practice and research. Existing evidence primarily serves doctors to sup-
port their decision-making, but is also the basis for providing scientific
proof for a health care intervention`s benefit to patients and ultimately
payers/health insurances. The closure of existing evidence gaps re-
quires substantial human and financial resources, and can only succeed
with the involvement of clinical and methodological expertise.
Objectives
Scientific Societies have a natural interest in detecting and closing
evidence gaps. Here we report a project of the German Society of
Otolaryngology, Head and Neck Surgery (DGHNOKHC) and the Ger-
man professional association of otolaryngologists (BVHNO) which can
serve as a master example for similar projects.
Methods
The two institutions have a vested interest in supporting their members
in the generation and dissemination of evidence, and to foster the
transfer of knowledge into practice. This includes the areas of diagnosis,
treatment, prognosis and prevention, comprising the application of me-
dicinal products, medical devices or surgical procedures. The executivecommittees of DGHNOKHC and BVHNO have together founded
the German Clinical Trials Unit for Ear, Nose and Throat medicine,
Head and Neck Surgery (DSZ-HNO) to assist their members in the
identification of evidence gaps and the planning and conduct of
systematic reviews and clinical trials. An interdisciplinary team of
statisticians, physicians, project managers, study nurses, data
managers and monitors provides the required expertise. The first
projects have been started, including a BMBF (German Ministry
for Education and Research)-funded clinical trial for the treatment
of sudden hearing loss. A survey among all members of both as-
sociations to detect evidence gaps was conducted. The results led
to a prioritization process and planning of trials, registries, sys-
tematic reviews and other projects with industry and academia
alike. A presentation at the Guideline Commission of the Working
Group of German Medical Scientific Societies led to further Soci-
eties wanting to copy the ENT example, thus a Clinical Trial Unit
as presented here can be a suitable model for closing evidence
gaps and fostering clinical trials.
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Background
Properly designed and implemented randomized controlled trials
(RCTs) serve as the ideal form of evidence-based research to estab-
lish efficacy of new therapies; however, substantial debate regarding
most appropriate trial designs persists today. Areas of confusion in-
clude: appropriate treatment allocation techniques to ensure com-
parable baseline arms, best reporting practices, and controlling for
influential variables at the analysis phase. While randomization litera-
ture promotes covariate adaptive methods (e.g., minimization, devel-
oped 1974) to protect against baseline imbalance and provide more
efficient analyses, many investigators prefer simpler methods (e.g.,
stratified blocking schemes) for their understandability and ease of
implementation. This manuscript reviews recently published rcts to
illustrate current practice.
Methods
We searched pubmed for articles indexed ‘randomized controlled trial’,
published in the New England Journal of Medicine, Journal of the
American Medical Association, British Medical Journal, or Lancet for two
time periods: 2009 and 2014 (before and after establishment of up-
dated Consolidated Standards of Reporting Trials [CONSORT] guide-
lines). Upon completion of screening, articles underwent full review to
collect data related to trial characteristics, the type of randomization
scheme used, and clarity of reporting.
Results
Our search returned 343 articles, 298 of which we included in full re-
view. The majority reported on superiority (86%), multicenter (92%),
two-armed (79%) trials. With respect to CONSORT adherence, 68% of
trials indicated a ‘randomizedr Trial in the title, and the randomization
scheme could not be determined in 10% of studies. Consistent with
our hypothesis, the majority of articles reported a stratified block
method (69%) of allocation, but 81% of trials involved covariates in the
treatment allocation procedure. The majority (84%) of trials reported
adjusted analyses, with 91% of these adjustments in analyses pre-
specified. Trials published in the later time period (2014 vs. 2009) were
more likely to have clearer report of randomization scheme (84% vs.
66%, p = 0.0003), report adjusted analyses (87% vs. 79%, p = 0.0100),
and pre-specify adjustment in analyses (95% vs. 85%, p = 0.0045). Study
start year significantly predicted whether design involved a covariate
adaptive method of allocation, but in the opposite hypothesized direc-
tion: odds of adaptive method use decreased for every one-year in-
crease in study start (OR = 0.89 [0.82, 0.96], p = 0.0045). However, odds
of pre-specified adjusted analyses tended to increase over time (OR =
1.13 [1.02, 1.24], p = 0.0145).
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Our findings suggest that while optimal reporting procedures and
pre-specification of adjustment in analyses for RCTs tend to be pro-
gressively more prevalent over time, we have evidence of the op-
posite effect on use of sophisticated covariate adaptive methods in
clinical trial practice. Many authors suggest covariate adaptive
methods as ideal in designing clinical trials, but there is a discon-
nect between theory and practice. Moreover, our results suggest a
widening of this gap as time moves on.
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Background
To support future clinical trial research it is important that those
planning a career in clinical trials are supported and trained to lead
on these trials. Training clinical investigators of the future in the
design, management and analysis of clinical trials is key [Sackett].
Clinical Trials Units (CTUs) have extensive experience in the design
and delivery of clinical trials, and provide an excellent training envir-
onment in which to embed researchers of the future. Ctus provide a
unique opportunity for researchers to learn about clinical trials in a
highly active research environment, alongside staff who work on
trials every day.
Methods
To develop a clinical trials clerkship for clinical investigators that
combines a programme of training with hands-on experience, men-
torship and access to experts working in clinical trials.
Results
At the Birmingham Clinical Trials Unit (BCTU) at the University of Bir-
mingham, we have developed a clinical trials clerkship where fellows
spend on average 15 days (including a 3 day Research Methods
Course) in BCTU over a 12 month period. The fellows will have the
opportunity to learn about various trial processes from study set-up,
protocol and case report form development, regulatory require-
ments, trial management, database development, statistical aspects
of clinical studies, recruitment strategies, data management and
monitoring, trial steering committees, interim and final data analysis
and submitting for publication. Each fellow is assigned a senior trial-
ist who acts as their mentor, who is responsible for working with the
fellow to tailor the training and learning experience. The fellow is ex-
pected to maintain a reflective log of their taught and experiential
training through completion of a workbook. For those planning to
run a trial as part of their fellowship, these can be embedded within
BCTU, with mentorship on delivering the project provided by a se-
nior trial manager, trial co-ordinator, database programmer and stat-
istician. Appropriate CTU costs to help the fellow deliver the study
can be included in NIHR fellowship applications.
Conclusions
Within BCTU, we are currently running our first cohort of fellows
following the above programme, and initial feedback is that it is an
enjoyable and highly valuable learning experience.Reference
David L. Sackett. Clinician-trialist rounds: 20. Shouldn’t “Trialists-in-training”
Rotate through RCT-clerkships; Clinical Trials 2013;0:1–4.
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Background
Anal cancer is a rare disease, but its incidence is rising rapidly. Approxi-
mately 1000 cases in the UK and 5,000 in the USA are diagnosed each
year. Standard treatment for anal cancer includes concurrent Mitomy-
cin C, 5-Fluorouracil (or more recently capecitabine) and radiotherapy.
Due to advances in radiotherapy technology, a new generation of clin-
ical trials is now required that optimises radiotherapy dose based on a
stratified risk assessment of the disease.
Methods
To capture as many anal cancer patients as possible, we developed
an umbrella protocol that would capture patients across the
spectrum of disease. PLATO (personalising Anal cancer radiotherapy
dose) (ISRCTN88455282) is an integrated protocol, comprising 3 sep-
arate trials (ACT3, ACT4 and ACT5) in which the most relevant clinical
research questions are asked across three distinct risk strata. Each
trial asks separate questions and has separate eligibility criteria and
sample sizes.
The ACT3 trial (n = 90) is a non randomised phase II study for low-
risk disease that will evaluate a strategy of local excision only versus
local excision plus radiotherapy, depending on the size of tumour
margin post local excision (>1 mm versus < =1 mm, respectively).
The ACT4 trial (n = 162) is a randomised phase II trial (2:1) for
intermediate-risk disease comparing standard dose chemoradiother-
apy with reduced-dose chemoradiotherapy. The ACT5 trial (n = 640)
is a seamless pilot (n = 60)/phase II (n = 140)/phase III trial (n = 672
total) for patients with high risk disease that will compare standard
dose chemoradiotherapy with two increased doses. Only one of the
dose escalated experimental arms will be evaluated for the phase III
component. The primary end point for each trial is 3 year locoregio-
nal failure. PLATO is funded by Cancer Research UK and is due to
open to recruitment in the UK and Ireland in Q4 2016.
Discussion
Time, money and resources could potentially be saved by incorporat-
ing more than one trial under the umbrella of one protocol. The
PLATO trial concept allows different research questions across the
locoregional disease spectrum to be addressed efficiently using a sin-
gle protocol and clinical trial funding application. This type of trial
design is increasingly important in the era of personalised medicine
and the need for clinical studies to address different research ques-
tions within the same disease. Sharing the details of this concept
should assist other investigators to develop similar future studies. De-
tails of our experience of implementing an integrated protocol along
with the pros and cons of this approach from a trial and data man-
agement perspective will be presented in more detail.
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tions of Cancer Centers coupled with the advent of molecularly tar-
geted agents and emphasis in precision medicine resulting in smaller
patient pool within a single institution entail the need to engage
multiple sites for the design and implementation of clinical trials. The
conduct of multi-center studies is necessarily complex, requiring in-
formatics tools and data management processes that need a coordi-
nated effort necessitating an infrastructure akin to Data Coordinating
Centers. We present a model whereby biostatistics and informatics
core facilities partner with community based research networks to
manage multi-center clinical trials. More specifically, we focus on
three critical areas in informatics and data management namely i)
development of an integrated set of standard operating procedures
(SOPs) between the community based network and MRU pertaining
to all aspects of data management; ii) improving utilization of a clin-
ical trial management system (CTMS), a biospecimen management
system and customized database applications to accommodate
multi-center studies and iii) adopting and expanding automated
statistical programs to monitor protocol-specific triggers including
subject accrual, safety, and efficacy endpoints into a multiple site
setting. The community research network focuses on administrative
coordination and site communication and management to serve as a
clinical coordinating center. We demonstrate this model for the con-
duct of a therapeutic intervention trial and non-intervention study;
provide the specific informatics, data management and statistical
tools we have implemented to manage multi-center studies; and dis-
cuss challenges and areas of improvement in this partnership infra-
structure for provision of an integrated clinical and data science
coordination for multi-center clinical studies.
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Background
Many clinical conditions require the identification and stratification
of risk to ensure that interventions can be targeted appropriately.
Challenges to identification of ‘at-risk’ patients using data from elec-
tronic health records include identification of relevant characteristics,
how data availability informs decision making, coding and storage of
data, and how data can be searched for, accessed and managed.
Each week in the UK, 22 patients die and 1400 are hospitalised due
to asthma (Asthma UK). Sixty per cent of patients with at-risk asthma
defined according to British Thoracic Society (BTS) guidelines have
an exacerbation requiring prednisolone per year compared to 10% of
the total asthma population and BTS guidelines suggest at-risk regis-
ters may be useful for asthma. The At-Risk Registers Integrated into
primary care to Stop Asthma crises - UK (ARRISA-UK) study group are
evaluating the effectiveness and cost effectiveness of generating and
implementing an at-risk asthma register.
Developing a risk profile for an at-risk register: importance of a
multi-disciplinary team
Candidate characteristic values to be included in the risk profile were
identified based on expert opinion, prior work and literature review.
This list was reviewed by a working group within the ARRISA-UK team
to identify additional characteristics based on clinical experience of
managing asthma, consider limitations/restrictions of GP Practices.
Clinical data systems in relation to the characteristics identified, and
evaluate reliability and variability of the characteristics in terms of real
world coding of clinical information. The characteristics contributing to
the identification of patients with a statistically significant risk of hospi-
talisation were determined in the Optimum Patient Care ResearchDatabase through an iterative process of regression analysis and re-
assessment. The coefficients of the characteristics (including age, smok-
ing status, comorbidities (rhinitis, diabetes, ischaemic heart disease,
anxiety and/or depression, and anaphylaxis), BTS treatment step, para-
cetamol treatment, lower respiratory tract infection, oral corticosteroid
therapy or hospitalisation in the previous year, body mass index and
blood eosinophil count) then are used in an algorithm to calculate a
risk score which was validated in a second database, the Secure Anon-
ymised Information Linkage databank.
Implementing an At-Risk Register Using this algorithm, the ARRISA-UK
search tool identifies at-risk individuals in general practices. Search re-
ports from the GP clinical database system for the characteristics above
are analysed, and the risk assessment is flagged in relevant patient re-
cords via specific Read or SNOMED codes. These inform the compu-
terised decision support system in the form of popup information
boxes prompting clinical action. They can also facilitate care manage-
ment tasks, data collection and further clinical coding.
Beyond ARRISA-UK
These experiences will be used to develop strategies using a multi-
disciplinary approach for identification and recruitment of at-risk
individuals in other disease areas. This will permit development of
methodology for efficient trial design, delivery and planning in primary
care.
Funding
The ARRISA-UK study is funded by the National Institute for Health
Research's Health Technology Assessment Programme (13.34.70). The
views and opinions expressed are those of the authors and do not
necessarily reflect those of the HTA, NIHR, NHS or the Department of
Health.
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Background
The NHMRC Clinical Trials Centre (CTC) based in Sydney, Australia
and affiliated with the University of Sydney is an Academic Research
Organisation (ARO) which develops and co-ordinates multi-centre
clinical trials in Australia, New Zealand and internationally. Working
across number of different fields including cardiology, oncology, neo-
natology and endocrinology the group collaborates with a number
of institutions including study sites, other international co-ordinating
centres, cros, cmos and central laboratories. As central coordinating
centre for a number of clinical trials, the CTC frequently works with
the same study sites (and personnel) across a number of different
trials. A need was identified to collate trial operations information
centrally to reduce time for individual trials collecting this informa-
tion in their own bespoke systems. There was also a need to be
able to collate core information (timelines, approvals) across trials
and report these centrally in order to generate metrics to review
performance. After consideration and review of the cost and func-
tionality of existing commercial software packages it was decided
to develop a custom system in-house, tailored to CTC specific trial
co-ordination requirements.
Aim
To develop and implement a user-friendly Clinical Trial Management
System (CTMS) to support the clinical trials team at the CTC that was
cost effective to develop and maintain. Project specification: The first
step was to develop a requirements document by seeking input from
relevant parties. The following key content domains were identified:
projects, organisations, people and documents and their relation-
ships specified. Key user requirements were ease of data entry
and reporting.
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System specifications were then prepared collaboration with a data
systems developer. A relational database design and (Oracle) written
in Java was used for development. After an initial prototype was
developed the system was released for user testing by trials staff
from the discrete functions within the trials teams. Once the system
was qualified, but prior to rollout, existing study tracking data was
imported into the new CTMS system. Reports (both within and across
projects) were developed prior to release to enable staff to access
key information.
Project deployment
Training sessions were conducted on the use of the new system.
Staff were also invited to specify what reports would be helpful to
their teams. Project Evaluation: After implementation, a process of
continual user feedback and enhancement was undertaken to im-
prove system usability and acceptability. Conclusion: Development of
the initial system took approximately 12 months from the decision to
develop, through specification and user testing, import of existing
data to release. Since this time additional functionality and reporting
has been developed and released periodically. The system has now
been in use for 3 years and feedback from users demonstrates in-
creasing acceptance of the system. However, there were key learn-
ings from the experience of implementing a new software system
e.g., unforeseen costs related to the lack of staff dedicated solely to
this project (and impact on timelines), resistance to change, and the
expansion of the original scope of the project with requests for fur-
ther functionality.
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Background
The National Institute for Health Research (NIHR) introduced Clinical
Trials Fellowships in 2012 with the aim of further developing existing
NIHR trainees’ skills and experience in clinical trials. Fellowships are
hosted within Clinical Trial Units (CTU) that are in receipt of NIHR
CTU Support Funding as these offer the best environment in which
to: expose trainees to all aspects/stages of clinical trials; cover mul-
tiple studies; understand how proposals are developed from initial
concept through to funding application by interdisciplinary, collab-
orative working; and tailor training to individuals’ needs. We reflect
on our experience of the fellowship from the perspective of the
trainee (PW) and the CTU mentor (KS).
Case study
Who's who - PW is a Clinical Trials Fellow and occupational therapist
with previous experience of feasibility RCTs in his NIHR Doctoral
Research Fellowship. A core aim of the fellowship was to develop
skills to become a future CI of a multicentre study. The Nottingham
Clinical Trials Unit (NCTU) is a UK Clinical Research Collaboration
registered unit, based at the University of Nottingham. The unit cur-
rently hosts a number of Fellowships and research training awards.
Application process - Collaborative meetings with NCTU helped bal-
ance the learning objectives of the trainee with the learning opportun-
ities available at NCTU and identify suitable trials.
Training programme - NCTU developed an extensive ‘menu’ Of activ-
ities from which a tailored programme was produced covering: trial
oversight, quality management and sops, pharmacy, trial set-up, site
set-up, recruitment, data management, follow-up, write up and dis-
semination. KS, as CTU mentor, led in the development and oversight
of PW’s training programme.
Integration into the unit - PW worked within three trials teams to
maximise experience and learning. During the course of the fellow-
ship, regular meetings were held between the fellow and mentor
to reflect on personal development and for NCTU to offer feedback
and guidance.Supplementary training - The “hands on” Experience in NCTU was
supplemented with formal training opportunities involving method-
ology and statistical courses, and presenting at national conferences.
Reflections
Benefits and Challenges Benefits included experiential learning by
involvement and integration into the unit and the various trials
teams, involvement in multidisciplinary working, observing multiple
chief investigators across multiple studies at various stages of the
trials, knowledge of processes and procedures and making contacts’
internal and external.
Challenges included capacity and availability of key activities across
trials and the unit, time-lag between the application (summer 2014)
and the commencement of the fellowship (2016) making it difficult
to plan specific activities in the unit. Some flexibility was required
due to the uncertain nature of clinical trials particularly in the set-up
phase when timelines can be fluid. This resulted in some adaptations
to the training package.
Conclusions
CT Fellowships offer a unique opportunity for trialists of the future to
get hands on experience at an early career stage and also to enable
CTUs to develop researchers leading to high quality multi-centre tri-
als. Both fellow & NCTU found the experience highly beneficial and
strongly support continuation of this NIHR training programme.
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inpact (CRUK/13/005, EA8134) is an international trial in penis cancer
developed under the auspices of the International Rare Cancers
Initiative (IRCI). It evaluates the combination and sequence of four
common treatments for penis cancer: Inguinal Lymph Node Dissec-
tion (ILND), chemotherapy, chemoradiotherapy, and Pelvic Lymph
Node Dissection (PLND). The interventions used within the trial
present a number of QA challenges to ensure that any differences in
trial outcomes are related to the randomisation schedules and not
deviations from the trial protocol. The rarity of the disease means
that, whilst networks of specialists have developed, experience at an
individual clinical team level can be limited. A number of inter-
national specialist subgroups were therefore set up during protocol
development to discuss areas of QA need and to agree on QA pro-
cesses for the trial.
Surgical procedures can be difficult to standardise due to the num-
ber of factors involved, including the surgeon’s skill and experience,
and decisions taken regarding the surgical procedure based on pa-
tient characteristics or fitness, variations in anatomy, etc. Each surgi-
cal procedure will, therefore, be open to variability which the QA
programme within inpact aims to minimise. Discussions among inter-
national surgical collaborators have led to agreement on precise sur-
gical details to be included in the trial protocol and supplementary
surgical trial guidance notes. Each surgeon will be accredited before
participation in the trial. Accreditation will involve independent re-
view of a number of surgical procedures by the inpact surgical QA
committee comprising US and UK surgical leads for the trial. During
the trial, photographs and operative notes will be reviewed and feed-
back will be given to individual surgeons at participating sites.
The randomisation schema within inpact requires knowledge of lymph
node involvement. Correct interpretation of protocol criteria is crucial.
Initially, prospective central review of all patient scans (to assess lymph
node involvement) prior to randomisation was envisaged, but during
protocol development it became evident that the logistics of this
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The Netherlands Cancer Institute shared anonymised images to enable
development of a web-based teaching and testing solution using the
ACR Radiology Curriculum Management System. Radiologists respon-
sible for assessing patient lymph node involvement at each of the par-
ticipating sites will be assessed through this training tool and
accredited prior to the trial opening at that site.
Other areas identified as requiring international QA consensus were
pathology and radiotherapy, the latter being led by the UK’s NCRI
Radiotherapy Trials QA Team and in the US, the National Clinical
Trials Network’s QARC. The organisation of separate QA subgroups in
addition to the standard trial set-up processes and protocol develop-
ment has been challenging, but the QA programme ultimately
underpins the quality of trial treatment in this rare cancer. Regular
international communication and the sharing of knowledge and experi-
ence with existing national QA processes and infrastructure have
ensured consensus on trial protocol and associated QA. Internationally-
harmonised QA programmes should optimise deliverability of this trial
across multiple countries.
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Objective
Substantial variability in adverse event (AE) reporting practices may
exist between sites, particularly in multicenter clinical trials involving
patient populations for whom AEs are prevalent. Variability is likely
to be multifactorial, involving differences in training, culture, docu-
mentation, and other parameters, but also, perhaps, upon the quality
of trial performance. We hypothesize that sites with very low or very
high numbers of AEs reported are more likely to also have excessive
data corrections identified during source document review by site
monitors.
Methods
In a recently completed randomized clinical trial of acute treatment
of patients with traumatic brain injury (protect NCT00822900), we
retrospectively determined the coincidence of enrollment sites being
outliers on both AE reporting and data corrections found by site
monitoring. Outlier sites were those outside 95% boundaries on fun-
nel plots of AE reporting and of data corrections. Variability in AE
reporting was assessed by examining the average number of AEs
reported at each site (the total number of AEs reported at a site di-
vided by the number of subjects enrolled at that site). Data correc-
tion at each site was assessed as the average number of data
clarification requests (DCRs) written by a site monitor during source
document verification visits that resulted in the site correcting erro-
neous data in the case report form (CRF). Analysis of coincidence
was descriptive in this exploratory study. Sensitivity analyses using
90% boundaries and looking at only serious AEs (SAEs) were also
visualized.
Results
882 subjects were enrolled at 49 sites between 2010 and 2013. 11
sites that did not enroll any subjects in the study were excluded,
leaving 38 sites for inclusion. Site enrollment ranged widely from 1
to 85 subjects with a median of 18. The average number of reported
AEs by site ranged from 0.5 to 12 (median 3.14). The average number
of DCRs resulting in data correction by site ranged from 0.75 to 15
(median 3.56). On funnel plots, 14/38 (37%) sites were outliers with
regard to AE reporting outliers (6 low, 8 high), and 7/38 (34%) were
outliers with regard to high data correction rate. Coincidence was
suggestive but not significant given the small numbers; 4/14 (29%)
of the AE reporting outliers were also high data correction outliers,
as compared to only 3/24 (13%) of the sites that were not AE report-
ing outliers. Unexpectedly, among the 4 coincident outliers, 2 werehigh and 2 were low AE reporting outliers. Findings were similar
using 90% boundaries and rates of SAE reporting.
Conclusions
Extensive variability in both AE reporting and data collection quality
exceed that expected by chance alone in this example trial. AE
reporting rates may be useful as a metric to incorporate into risk-
based site monitoring plans if similar patterns are found with larger
numbers of sites across additional clinical trials.
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Objective
The primary objective of this paper is to explain the differences be-
tween the Mexican, Colombian, and Brazilian clinical research regula-
tions and how these influenced the evaluation and implementation of
multi-national vaccine trials in these three countries.
Background
In 2005, the Panamerican network for the harmonisation of
pharmaceutical regulation (Red PARF in Spanish), based on the ICH
guidelines, introduced the Document of the Americas for the Good
Clinical Practices (DA-GCP) with the aim of harmonising clinical re-
search practices in the region. The DA-GCP was not mandatory to
all regulatory authorities. Therefore, each country had the inde-
pendence to develop their guidelines and regulations to allow clin-
ical trials. Colombia and Brazil in 2008 presented their resolution to
implement clinical research in the country adopting the ICH-GCP
guidelines, and in 2012 Mexico did the same. However, only
Colombia and Brazil stated in their regulation the adoption of DA-
GCP. Therefore, the question that emerges is how does the differ-
ence on the normativity between these countries have influenced
the sponsor strategies to coordinate, manage and implement multi-
national clinical trials in Latin America?
Methods
To answer this question, in first place three multi-site clinical trials to
evaluate vaccines were studied in Mexico, Colombia, and Brazil to
assess the influence of the national regulation on multinational pro-
jects. Also in each country, members of clinical research associations
were interviewed to understand better the local dynamics and the rela-
tionship between local normativity and the pharmaceutical industry.
Sixty-six semi-structured interviews were conducted with members of
the research site, sponsors, clinical monitors, ethic committees, regula-
tory agencies, and members of clinical research associations.
Results and conclusion
This qualitative study reveals that despite Red PARF efforts to har-
monise GCP in the American continent, this objective has not been
achieved in practice. Between Colombia, Brazil, and Mexico, it does
not exist a harmonisation which is reflected in four aspects. 1) The di-
vergence on requirements and procedures to approve the trial. 2)
The number of institutions involved in protocols evaluation. 3) The
restriction of Colombia regulation to hire certain professional profiles
to be part of research teams 4) The research capabilities requested
by each regulatory agency to implement the trial. These differences
made that each sponsor had to develop management strategies to
implement the vaccine trial in Colombia, Brazil, and Mexico which
demanded: 1) coordinate times among different countries to start
their trials. 2) Invest in the creation of research capabilities to imple-
ment its protocol. 3) Hire smos to coordinate trials at local levels and
manage research sites, and 4) design new training strategies to
create a knowledge-base among all clinical teams according to the
local requirements. In conclusion, despite Red PARF’s efforts, har-
monisation of clinical trial regulation in Latin America has not been
achieved. The difference between regulatory frameworks induced
the creation of unique strategies by sponsor to coordinate and
management the evaluation and implementation of multinational
clinical trials in the region.
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Background
Standardising the collection, reporting and monitoring of data rele-
vant to site performance could improve the effective and efficient
oversight of clinical trial delivery. Our surveys of UK Trial Manager
Network (UK TMN) members and NIHR chief investigators revealed
wide variations in how trial data are used to assess performance.
However, without consensus on optimal ways of utilizing perform-
ance metrics, trialists may focus on too many or uninformative
indicators, causing inefficiency in trial conduct and difficulty in com-
paring between studies. Ideally,
This project aims to improve trial conduct and efficiency by: Reach-
ing consensus on important metrics that should be monitored rou-
tinely in multicentre trials. Establishing initial baseline benchmark
indicators for each performance metric for trending and predicting
potential issues, so minimizing their impact and improving trial per-
formance and efficiency. Developing a standardised systematic
method for reporting and presenting these metrics to trial mangers,
tmgs and tscs.
Research Plan
Small focus groups of stakeholders will establish an initial list of per-
formance metrics and parameters that could be measured routinely
in trials. We will then design a Delphi survey using data from litera-
ture searches and the focus groups to develop a comprehensive list
of performance metrics and parameters for inclusion in the Delphi
survey.
The Delphi survey will be sent to Trial Managers and CTU directors
as they play key roles in ensuring the efficient delivery of multicentre
trials. Three Delphi rounds will be used to steer the groups towards
consensus, on a list of important performance metrics. We will docu-
ment the reasons for their decision-making with regard to selection
of metrics.
Data from the Delphi survey will be presented to stakeholders in a
priority-setting workshop with a wide range of trial stakeholders, pro-
viding participants with the opportunity to express their views, hear
different perspectives and think about monitoring of site perform-
ance. We will seek agreement on the top key performance metrics
(expected to be around 8–12 in number) and benchmark indicators
for each metric to trigger action to improve site performance.
Finally we will develop a simple tool (probably within Excel) for the
presentation of key metrics to Trial Managers, Trial Management
Groups and Trial Steering Committees in a standardised format.
Key Stakeholders: Trial Managers, Clinical Trials Units, NETSCC, NIHR
Clinical Research Network, Chief Investigators, Statisticians.
Results
We will present the outcomes of the focus groups and literature
search and discuss the design and development of our Delphi survey
questionnaire.
Discussion
The project will result in a reporting tool showing a standardised set
of clear, meaningful and easily accessible performance metrics. The
metrics will assist researchers to indicate change over time and iden-
tify potential problem areas early, allow better utilisation of resources
and timely action to be taken.P366
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Background
Good sites are vital to ensure that multicentre randomised con-
trolled trials (RCTs) are delivered on time, within budget and to a
high standard. For example, over optimistic recruitment targets
often mean the trial goes over budget and fails to complete on
time. To help improve trial efficiency, site selection questionnaires
(SSQs) to gather relevant information about potential sites are con-
sidered ‘best practice’ for selecting new sites in multicentre trials.
However, there is limited evidence about their effectiveness in im-
proving trial conduct.
This study aimed to evaluate the performance of an SSQ developed
by the Nottingham Clinical trials Unit (NCTU), using data on key
metrics collected from five randomised controlled trials. Previously
presented preliminary data comparing mean number of days to re-
cruit the first participant found that sites selected by both the Chief
Investigator (CI) and by blinded assessment of SSQs were 68%
more likely to have recruited their first participant than those
where the CI and the blinded assessment disagreed (Trials 2015,
16(suppl 2):P176.).
We now update our study and present data assessing how well the
SSQ predicted site recruitment.
Methods
For each of the five trials, SSQs were developed using questions
that were both generic and protocol specific. The SSQ was emailed
to the Principal Investigators (PIs) for potential sites, requesting its
completion and return. The Chief Investigators (CIs) had access to
these responses, and it was at their discretion whether they used
the information to select sites.
For sites selected by the CI, each completed SSQ was assessed by
an assessor who was ‘blind’ to the site and to the PI. This assess-
ment used seven pre-defined criteria: SSQ not returned, potential
pool of participants, available staff resources, clinical trials experi-
ence of PI, competing trials for target population, number of trials
competing for resources, and equipoise for the trial interventions. If
any one of the first three criteria was not satisfied, the site was
excluded.
For CI selected sites, the monthly recruitment rates (actual/target) of
sites that were and were not selected by blinded assessment of the
SSQs from these sites were compared.
Results
An SSQ had been returned for all sites selected by the CI. There were
105 sites across the five trials. Three trials had completed recruit-
ment, and overall sites had been recruiting for between 0.7 months
and 47 months.
The median monthly recruitment (actual/target) was higher in the
54 sites selected by blinded assessment of the SSQs (median re-
cruitment =78.5) compared with the 51 sites not selected by the
SSQ assessment (median recruitment =50.0) (p = 0.0019, Mann-
Whitney U test).
Conclusion
For CI selected sites, where the SSQ was reviewed by a blinded
assessor, those that were selected based on the blinded assess-
ment seemed to perform significantly better in terms of recruit-
ment than those rejected following blinded assessment. This
suggests that SSQs have potential as a tool to improve the se-
lection of sites for clinical trial. They merit further development
and evaluation as to whether they can improve efficiency of
trial conduct.
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Background
The Lung-MAP trial (Lung Cancer Master Protocol), launched in 2014, is
an umbrella protocol to evaluate targeted therapies in biomarker se-
lected patients for previously-treated stage IV or recurrent squamous
non-small cell lung cancer. The trial infrastructure also includes a “non-
match” study or set of studies for patients without any of the bio-
markers under study. Lung-MAP, conducted by SWOG, and involving
the National Clinical Trials Network of the National Cancer Institute
(NCI), is the first precision medicine trial launched with the support of
the NCI in the United States.
Methods
Lung-MAP has two steps, a screening step followed by sub-study regis-
tration step. In the screening step, tissue is submitted to determine pa-
tient eligibility for biomarker-selected or non-match sub-studies. For
patients with tissue that is determined to not be adequate for bio-
marker testing, either additional tissue or tissue from a fresh biopsy can
be submitted for retesting. Patients can either be screened at progres-
sion on therapy or pre-screened while receiving therapy for stage IV or
recurrent disease. The trial did not open with the pre-screening option;
this option was added at the end of 2015. The protocol-specified tar-
gets are that patients screened at progression receive their sub-study
assignment within 16 days from tissue submission and pre-screened
patients receive their sub-study assignment within one day of notifying
the study they have progressed on the prior treatment. If at any point
in time it is determined that a patient will not enroll on a sub-study,
the site submits a form noting the reasons for not registering.
Results
As of November 4, 2016, 1075 patients have registered to be screened
(714 (66%) screened at PD, 361 (34%) pre-screened). Upon initial sub-
mission, about 12% of submitted tissue was inadequate, with the most
common reason being an insufficient amount of tissue (N = 58). Pa-
tients resubmit tissue samples about 37% of the time and 79% of those
were analyzable; the tissue inadequacy rate overall is 8.8%.
Once a patient’s tissue has been successfully tested, the patient is
assigned and can then register to a Lung-MAP sub-study. To date,
785 patients have been notified of their sub-study assignment and
387 patients have registered to a sub-study.
Of the total 1075 registrations, 496 (46%) have submitted the form
noting that a patient will not register to a sub-study. Of note, pa-
tients without a matching biomarker who previously received im-
munotherapy are not currently eligible for any sub-study.
Discussion
Conduct of a complex trial platform including biomarker testing and
evaluation of multiple investigational therapies may continue to be a
valued approach for evaluating biomarker/investigational therapy
combinations. Lessons learned and views into their conduct are im-
portant to help inform future endeavors.
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Trials 2017, 18(Suppl 1):P368PERSEPHONE is a phase III non-inferiority RCT comparing six months
of trastuzumab to the standard twelve months in patients with HER2
positive early breast cancer. The primary endpoint is disease-free
survival (DFS), with cardiac function as a secondary endpoint. It was
assumed that the standard 12 months trastuzumab results in 80%
DFS at 4 years. With 5% 1-sided significance and 85% power, 4000
patients gives the ability to prove non-inferiority of the experimen-
tal arm, defining non-inferiority as no worse than 3% below the es-
timated 4-year DFS of the standard arm. The trial reached its 4000
patient target in July 2015, making this UK trial the largest of its
kind in the world.
Whilst waiting for the follow-up data to mature, we embarked on de-
signing a survey to canvass current clinician’s opinions on trastuzu-
mab duration that would provide insight into not only the potential
practice-changing impact of PERSEPHONE’S results, but also the most
appropriate non-inferiority limits to define for the future meta-
analysis of the “twelve month trastuzumab versus less” trials for fur-
ther investigation into pre-specified sub-groups of patients.
The survey aimed to record opinions on what clinicians considered the
effectiveness of each of PERSEPHONE’S two randomised treatment du-
rations, followed by what difference between them they would require
the results to prove in order to change their current practice. Opinions
on the two randomised arms’ rates of cardiotoxicity were also collected.
The next section of the survey depicted various hypothetical scenarios
of cardiotoxicity differences between treatment arms, with responders
asked what trade-off they would require in terms of the primary end-
point of DFS to change their current practice within those scenarios.
Exploration of possible measurement methods to best collect opin-
ions on trade-off levels was undertaken. One option explored was a
simple cross-tabulation of hypothesised levels of DFS and cardiotoxi-
city. Another avenue explored was the use of gaming chips placed
on separate continuums of perceived “costs” and “benefits” of the
two treatment arms. To assist in interpretation of the trade-off be-
tween perceived advantages and disadvantages, graphical aids were
also considered. One option investigated used pictures of old fash-
ioned weighing scales with two pans, one representing one treat-
ment arm with a hypothesised DFS and cardiotoxicity level, and the
other just a hypothesised cardiotoxicity level. Responders were asked
to choose the level of DFS required to make the scales balance.
Eliciting clinician’s opinions on acceptable trade-offs within one trial
endpoint for various levels of detriment in another endpoint is a
complex one. Surveys were sent out to all 152 hospitals involved in
the PERSEPHONE trial. Results will be presented of the success of the
methodology adopted to undertake this task.
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Background
Medical research methods, technologies and tools evolve rapidly. It is
essential guidance prioritising the safety of human volunteers is
reviewed at timely intervals. This study aims to provide clarity and
consistency to the assessment and reporting of adverse events in
clinical trials that do not involve an investigational medicinal product
(non-CTIMP). Non-CTIMP governance covers a broad spectrum of
non-pharmacological disciplines (e.g. Surgery, nutrition, psychological
and physical therapies etc.). Currently, this is a neglected area of clin-
ical trial research. The lack of consistent identification, categorization,
and reporting of harms prevent researchers from conducting reliable
meta-analyses and comprehensive systematic reviews on the bene-
fits and risks of non-drug interventions that help to guide clinical
practice. Non-systematic methods of assessing harms increase the
potential for reduced effect sizes, resulting in a bias towards the null
Trials 2017, 18(Suppl 1):200 Page 140 of 235(Type II error). Critically, a lack of evidence of harm does not equate
to evidence of safety.
The study will address variability in practice, defined in Standard
Operating Procedures, that UK Clinical Trials Units (CTU) have in
place for: i) defining, ii) classifying, and iii) reporting adverse events
in non-ctimps. Compared to drug trials, adverse events in non-ctimps
are not managed well. There is considerable inconsistency in report-
ing styles between trials of similar design and intervention type.
To promote increased consistency, we will conduct a consensus exer-
cise among non-CTIMP experts using a Delphi technique followed by
a face-to-face meeting. This method adheres to the recommended
sequence outlined by the international network for Enhancing the
Quality and Transparency of Health Research (EQUATOR) for develop-
ing health research guidelines.
A non-CTIMP expert is defined as: a CTU representative, a Chief
Investigator or trial manager of non-ctimps with >3 trials experience
in this role, or a senior member of the Health Research Authority’s
Operations team or Ethics Committee. As such, the participants in
the consensus exercises will also be the direct beneficiaries from the
project maximising its pathway to impact.
Following the face-to-face meeting, guidance and explanatory state-
ments will be drafted. The guidance statement will focus on: How ad-
verse events should be defined in relation to the non-pharmacological
intervention, How CTU standard operating procedures should be de-
signed to reflect the results of the Delphi exercise, How adverse events
should be classified following a judicious causal assessment, and
Recommended reporting methods that will promote more effective
meta-analyses of non-pharmacological interventions that provide a
balanced benefit-harm evaluation. Following study completion, we will
work with a selection of UK CTUs to evaluate the implementation of
any agreed modifications to current practice.
In addition to the protocol design the poster will present preliminary
survey data collected with 70 chief investigators of non-CTIMPs. The
survey questions and results are attached. Questions covered a series
of themes evaluating the range of inconsistency in defining, categor-
izing and reporting serious adverse events, and evaluated prefer-
ences for increased harmonisation in this area.
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The National Institutes of Health (NIH), as the largest public funder of
clinical trials in the United States, recognizes the importance of clin-
ical trials and well as recognizes the major challenges in the design,
efficiency and reporting of clinical trials. Over the years, NIH has
funded trials that are too complex, have small sample sizes, rely on
surrogate endpoints, have unrealistic enrollment goals, inadequate
budgets, etc. Many times these trials are not published nor data sub-
mitted to a public site. On September 16, 2016, the NIH announced a
series of efforts directed towards the improvement of clinical trials
efficiency, accountability and transparency. This presentation will
briefly discuss these activities, which are aimed to address the clinical
trials process from the time new ideas are generated to sharing data
to the public. The initiatives covers NIH review and selection of trials
to fund, clinical trials management and oversight, and data sharing.
More specifically, this presentation will discuss the variety of new
NIH policies, including Good Clinical Practice (GCP) training require-
ments for investigator and NIH staff, using clinical trials specific Fund-
ing Opportunity Announcements (FOAs), including appropriate
expertise to review sessions, using a protocol template (required for
FDA studies), using a single Institution Review Board (SIRB), and util-
izing clinicaltrials.Gov to register and upload results.P371
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Placebo Surgery Trials in the NHS are Possible Introduction Placebo sur-
gery trials are controversial and are not routinely conducted in the
NHS. Evidence related to the management of such studies is limited
and teams planning a placebo surgery trial need to carefully consider
how to manage such a trial.
Background
CSAW is a multicentre randomised placebo controlled blinded surgi-
cal trial assessing the effectiveness of arthroscopic sub-acromial de-
compression surgery versus an arthroscopy alone (the placebo or
sham procedure) versus a period of active monitoring with specialist
reassessment. Previously, a placebo surgery trial has been deemed
difficult to run in the NHS with additional challenges for the study
management team. These include (and supported by the literature)
increased concerns regarding risk, ethics, perceived patient decep-
tion, ability to recruit and the surgical community acceptance of the
placebo procedure.
Methods
A variety of strategies were utilised for the success of the trial.
These included; Inclusion of a medical ethicist on the investigator
team; A longer than normal set-up phase of the study for educating
sites about placebo surgery; A pre-trial survey where surgeons in-
terested in participating in the CSAW outlined their practices,
followed by in-depth interviews between the surgeons and the
study’s clinical leads; Use of a Prospective Patient Assessment (PPA)
at the main site. This involved presenting a hypothetical placebo
surgery trial to patients to gain feedback and ask whether they
would consider participation. A Qualitative Recruitment Investiga-
tion (QRI) was also undertaken in the early phases of the trial to ob-
serve transparency of information given to patients and to assess
the level of surgeon equipoise. Standard evaluation of the fre-
quency of study procedures was also undertaken.
Results
The strategies resulted in successful recruitment to the study. Feed-
back showed the benefit of involving the participating surgeons in
defining the placebo procedure arm. Regular monitoring of the
study showed surgeons were fully compliant with the restrictions
of the placebo operation (the arthroscopy only). The placebo elem-
ent was not an issue in relation to recruitment nor in implementa-
tion of the study arms. The PPA completed showed 90% of patients
would be interested in participating in a placebo surgery trial. Feed-
back on the hypothetical study also informed the research ethics
application. The QRI generated a “top tips for recruitment” list and
enabled training on the best approach to patients. CSAW success-
fully reached their recruitment target of over 300 patients, recruited
from 25 NHS sites.
Conclusion
With effective strategies in management and monitoring a placebo
surgery trial is possible in the NHS. No major challenges were faced
in the conduct of the study. CSAW has now successfully completed
and results will be published early 2017.
P372
Randomization balance in multicenter clinical trials with short drug
life and rapid allocation
Jeff Szychowski, Alan T. N. Tita, Gary R. Cutter
University of Alabama at Birmingham
Correspondence: Jeff Szychowski
Trials 2017, 18(Suppl 1):P372
Trials 2017, 18(Suppl 1):200 Page 141 of 235Introduction
The logistics of allocating an assigned drug treatment in a multicen-
ter randomized controlled clinical trial may be complicated by a
short drug shelf life and by the need for rapid allocation after
randomization. We conduct a simulation study to examine the effects
on randomization balance under these conditions, where the ratio of
rates of drug preparation and recruitment at study centers vary from
low to high. We further explore practical strategies to address these
logistical needs.
Background
Our study is inspired by the Cesarean Section Optimal Antibiotic
Prophylaxis (C/SOAP) trial, a double-blind, pragmatic, randomized
clinical trial conducted at 14 hospitals in the United States. Women
with a singleton pregnancy, at least 24 weeks gestation, and under-
going nonelective cesarean delivery were randomized to receive ei-
ther azithromycin (500 mg in 250 ml saline) or an identical-appearing
saline placebo prior to incision. All women were to receive standard
prophylaxis (cefazolin) prior to incision. The 250 ml bags were
prepared in advance by investigational pharmacists according to
site-stratified randomization schemes, kept in a secure refrigerator,
and had a 7 day shelf life. Only the investigational pharmacists who
prepared the study drug had access to the randomization scheme
through a dedicated password-protected website. Randomized
women received the next sequentially numbered study bag in the
refrigerator. Expired study bags were discarded.
At each site the investigational pharmacists prepared a pre-specified
number of study bags to be used or discarded within 7 days. Given
pharmacy costs and constraints, bags were typically prepared once
per week. The number of prepared bags was estimated to be the
number of patients enrolled over the course of the next 7 days. In
successful recruiting weeks, all prepared study bags were used. In
lower enrollment weeks, bags were discarded. Because of these con-
straints, the rates of study drug preparation and randomization were
continually monitored and modified as needed.
Methods and Results
We simulate the effects of underutilization of prepared study drug
on randomization balance and total drug waste. We consider differ-
ent combinations of randomization schemes (fixed blocks of 2, 4,
and 6, and variable block designs), total number randomized by
site, and ratio of prepared-to-used study drug. Randomization bal-
ance is lost, and waste increases, as the preparation rate exceeds
the randomization rate.
Conclusions
It is extremely important that we understand the characteristics of
potentially suboptimal randomization procedures, as they may lead
to increased waste, increased costs, and randomization imbalance.
The complications introduced by short drug shelf life and by the
need for rapid randomization are important in multiple contexts in-
cluding labor & delivery and emergency medicine. We discuss strat-
egies to optimize resources and minimize waste.
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Background
Falls are the leading cause of accident-related mortality in older
adults. Injurious falls, including fractures, are associated with func-
tional decline, loss of independence, disability, and significant health
and social care costs. Although numerous trials have been conductedto investigate the efficacy of falls preventions strategies on rate and
risk of falls, there is a lack of strong, robust evidence for multifactorial
or exercise interventions in preventing fractures. We developed two
complex falls prevention interventions for evaluation within the
framework of a large multicentre, pragmatic, randomised controlled
trial (RCT) (ISCTRN 71002650).
Methods
Prefit is a three-arm, cluster RCT, conducted within primary care across
England. We aimed to recruit 9000 participants, aged 70 and above,
from 63 general practices. Practices were randomised to deliver one of
three falls prevention interventions: (1) advice only; (2) advice with ex-
ercise; (3) advice with multifactorial falls prevention (MFFP). The Age UK
Staying Steady booklet was sent to all trial participants. The process of
developing the complex ‘active’ interventions is described below.
Development of the PREFIT Exercise Intervention: We undertook a
review of systematic reviews of exercise interventions to prevent falls in
community-dwelling older people. Based upon evidence from
Cochrane systematic reviews and UK clinical guidelines, we shortlisted
three standardised programmes for possible inclusion. To reflect the
pragmatic nature of the trial, we also reviewed surveys of NHS falls ser-
vices and conducted consensus work with clinicians working in falls
prevention. We selected the Otago Exercise Programme which targets
balance and strength, using ankle weights. The intervention is a six-
month programme, which is individualised and supported by trained
therapists who prescribe exercises and progress over time.
Development of the PREFIT MFFP
Intervention: Multifactorial interventions are defined as that where in-
dividuals receive ‘an assessment of known risk factors for falling and
an intervention matched to their risk profile’. To determine which risk
factors to include in PREFIT, we considered evidence from systematic
reviews, including a large Cochrane review of 34 RCTs of multifactor-
ial interventions to prevent falls in older people and evidence exam-
ining the effectiveness of MFFP delivered in primary care. We
referred to clinical guidelines from the American Geriatrics Society
(AGS), British Geriatrics Society (BGS) and National Institute for Health
and Care Excellence (NICE) to further inform selection of risk factors.
In addition, we elicited a range of views from clinical and practice ex-
perts within the field of falls and bone health. The final PREFIT MFFP
intervention comprised of seven risk factors which were assessed on
every participant referred for treatment. The model was based upon
individual assessment and onward referral to specialist services
where indicated. Results Pilot study We undertook a pilot study in 12
general practices (n = 1801) in Devon to determine the acceptability
and feasibility of delivering an exercise programme and a complex
MFFP intervention to older adults recruited from primary care. The
interventions were then rolled out to other regions within the main
trial.
Conclusions
These complex interventions are currently being evaluated within the
largest multicentre falls prevention clinical trial conducted in the UK.
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Background
Finding the optimal sample size for a trial is an important step in its
design. In many trials of complex interventions (such as psychother-
apies and behavioural interventions) this task is complicated by two
factors. Firstly, sample size can be defined by several design parame-
ters rather than a single n. For example, a trial which compares a
psychotherapy intervention with treatment as usual may be partially
nested, with patients nested within therapists in the intervention
arm but not in the control arm. The design parameters of such a trial
are the number of therapists in the intervention arm, the number of
patients seen by each therapist, and the number of patients in the
control arm. The second complication is that analytical formulae for
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instead be estimated through Monte Carlo simulation methods,
which may be computationally demanding. For example, such a
simulation of the TIGA-CUB study would involve the generation of a
large number of hypothetical trial data sets and fitting a multilevel
model to each one. In combination, these factors make finding an
optimal sample size a difficult and time consuming problem. We ex-
plore how modern optimisation algorithms can be used to solve
these problems in an effective, timely manner.
Methods
We propose using Bayesian optimisation to solve the sample size
problem. This method allows optimal or near-optimal choices for
sample size to be found with minimal computational effort. The gen-
eral approach involves the careful choice of the design parameter
values where power should be estimated using simulation. Conduct-
ing the simulations at these points, a statistical model is then fitted
to the output to describe the general relationship between the
design parameters and the trial power. This model is then used to
find the smallest design parameter values which will give power of
at least the nominal level. The method is flexible, can be used for al-
most any problem for which power can be estimated using Monte
Carlo simulation, and can be implemented using existing statistical
software packages.
Evaluation
To illustrate the approach we apply it to a partially nested psychother-
apy trial in an illustrative case study. We use the proposed method to
identify a set of candidate sample size options, each of which will give
power of at least the nominal rate. From this set of options, that which
is considered best in terms of its balance between number of therapists
and number of patients can be chosen. We compare this with an alter-
native approach using simpler heuristics, in terms of both the computa-
tion time required and the quality of the resulting solutions.
Conclusions
Bayesian optimisation can be an effective technique for performing
sample size calculations when power must be estimated using simu-
lation, particularly when sample size is characterised by several de-
sign parameters. By improving the efficiency of these calculations,
increasingly complex sample size problems can be solved without
the need for unrealistic simplifying assumptions.
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Background
The use of ehealth or digital health interventions has increased due
to rapid growth in information and communication technologies
(ICTs). This results quick appearance and change in digital interven-
tions that challenge the robust designing of such interventions. The
traditional intervention designs are somehow incapable to tackle
specific challenges of digital interventions. It is therefore important
to explore innovative research designs to handle the unique chal-
lenges of ehealth interventions.
Objective
This methodological research aims to analyse how different adaptive
research designs could be used in evaluation of digital behaviour
change interventions (DBCIs) without altering the nature of random-
ized designs.
Methods
An adaptive design allows modifications during the trial based on the
reports from interim analysis. We reviewed Medline available literature
related to adaptive designs and hand searched relevant medical
and statistical journals. We also assessed the published and on-
going (registered at www.clinicaltrials.gov/) ehealth interventions
from Jan 2011 to Oct 2016 to search any evidence of adaptive
designs in ehealth or digital health interventions.Results
We did not find any evidence so far of using adaptive designs either
in ongoing or published digital intervention trials literature. There-
fore, we discuss different adaptive design choices conceptually such
as adaptive randomisation design, group sequential design, sample
size re-estimation design, hypothesis-adaptive design and seamless
phase II/III design etc. Literature suggested that sequential, seamless
phase II/III and multi-arm multi-stage designs could improve effi-
ciency and maintain ethical considerations; changing- sample size
and hypothesis designs could handle the uncertainty and be flexible
to define end points; and enrichment designs could handle hetero-
geneity among responses and ease the data monitoring process. On
the other hand, multiple adaptive designs in a single trial require
more control in execution and should be handled with care. How-
ever, other adaptive designs such as treatment-switching and dose-
finding are yet to explore their usability in relation to ehealth
intervention. There are some statistical challenges that need address-
ing when designing such trials. For example, any adoption to the
design may increase the Type I error rate, difficulties in the analysis
of trial data including Bayesian approach (especially in deciding prior
distribution) and interpretation of results.
Conclusions
The adaptive designs showed potential to address various ehealth
specific challenges. Such designs could lead to simplified operational
complexities involved and make these interventions more efficient
and cost-effective. There is a need to encourage researchers to use
adaptive designs and set regulatory guidelines to handle practical
challenges.
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Background
To answer the question ‘does a complex intervention work?’ in a way
that distinguishes between failure of the intervention and failure of
its implementation, an evaluation of the process of intervention
delivery is required. Process evaluation data are collected from a
sample of the practitioners involved in implementation and interven-
tion delivery. However, the mechanism of selecting a sample is rarely
described in the literature. The aim of this project was to define a
framework to purposively sample clinicians in a trial conducted in 22
intensive care units (ICUs) which used a new invasive test for detect-
ing ventilator associated pneumonia in critically ill patients (the
vaprapid-2 trial, ISRCTN65937227). Methods Data analysis of context
and usual practice collected at the beginning of the trial, alongside
qualitative data collected from doctors, nurses, and laboratory staff
during the trial provided information on adoption and delivery of
the intervention in the ICUs. From this information, we constructed
themes describing what worked well, for whom and in what contexts
in terms of intervention delivery. These themes were explored with
clinicians at the end of the trial in order to identify factors and the
mechanisms of their interaction that were likely to impact on trial
outcomes. We purposively sampled 40% of ICUs for end of trial inter-
views, ensuring that we obtained maximum variation in barriers and
facilitators to the trial.
Results
In the analysis of data collected before and during the trial, we identi-
fied five themes. To enable easier sampling, we grouped the themes
into two broad categories to form a framework: (1) ICU situation which
reflected (positive or negative) issues with laboratories, workload, staff
availability, and fitting the trial into the ICU; and (2) perceived risk
(classed as high or low risk). This categorisation enabled sites to be
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examined recruitment data to assess the reach of the intervention i.e.
The percentage of eligible patients who were actually recruited into
the trial. We subsequently sampled ICUs from each of the four cells that
also captured the variation in reach.
Conclusion
Little information is available on the methods that might be used for
purposive sampling of practitioners implementing new interventions
in critical care research. We suggest a novel and practical method of
categorising data to produce a framework to guide maximum vari-
ation sampling.
P377
Minimising bias in surgical RCTs through blinding: a systematic
review
Sian Cousins, Katy Chalmers, Kerry Avery, Natalie Blencowe, Sara Brookes,
Jane Blazeby, M. Kobetic, T. Munder
University of Bristol
Correspondence: Sian Cousins
Trials 2017, 18(Suppl 1):P377
Background
Blinding, the process of withholding knowledge of treatment allo-
cation from participants and trial personnel, is critical in the design
of RCTs. It may reduce differences between trials groups in the as-
sessment of outcomes (detection bias), in the way interventions
and co-interventions are delivered (performance bias) and in with-
drawals from the trial (attrition bias). In addition, it may minimise
bias in the interpretation and reporting of analyses if data analysts
are successfully blinded. Indeed if there is inadequate blinding this
can exaggerate estimates of treatment effects by up to 25%. Blind-
ing, however, can be hard to achieve and maintain in trials asses-
sing non-pharmacological interventions such as surgery. Challenges
specific to surgical trials include, but are not limited to, difficulties
in delivering a control intervention indistinguishable from the
active intervention, and blinding personal who deliver the interven-
tion. This systematic review will describe the current methods used
to blind participants, intervention providers, care givers, outcome
assessors and data analysts in trials of invasive surgical interven-
tions across all surgical specialties. In addition, we will present
examples of trials where blinding was not attempted but may have
been possible, outlining how novel methods of blinding may be
utilised. Presently we outline results to date with a complete report
available in March 2017.
Methods
A systematic search was carried out in Medline (ovidsp), Embase and
CENTRAL databases for articles published between January 2006 and
June 2016 in the top 10 surgical and general medical journals accord-
ing to impact factor. Articles eligible for inclusion were RCTs of invasive
interventions, in which blinding of any participants or trial personnel
had been attempted. We define an invasive procedure to be where a
cut is made or access to the body is gained via cutting, instrumentation
via a natural orifice or percutaneous skin puncture where instruments
are used in addition to the puncture needle. Trials in which a medicinal
product is delivered via an invasive procedure and where there is ad-
ministration to targeted anatomical districts or where an action is per-
formed internally to administer the product, will be included. General
study characteristics will be extracted, in addition to data regarding
blinding specifically. Blinding status of participants and trial personnel,
method of blinding, instances where blinding may have been possible
but was not attempted and details of any reported tests of success of
blinding will be extracted. Quality of included trials will also be assessed
using the Cochrane Risk of Bias tool.
Results
The search retrieved 3946 articles. 1873 duplicates were removed
and 613 were removed on basis of journal. 1460 titles and abstracts
were screened for eligibility using standardised screening forms.
1129 articles were excluded after abstract review and 331 articles
were included for full text review. Full results will be available by
March 2017 and reported at the meeting.Discussion
We outline and summarise the methods of blinding used in high
quality surgical RCTs assessing invasive interventions. We highlight
good practice and will make recommendations for future research in
this field to minimise bias in RCTs in surgery.
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Periodical data review is very important and highly recommended
for all the ongoing clinical studies to ensure the data integrity and
quality. Each clinical study requires experts from various functional
groups like SAS programming, Biostatistics, Data Management and
so on. Each one of them have various data review requirements
and also one cannot expect everyone to familiar with SAS program-
ming as clinical datasets are often available as SAS datasets. Statisti-
cians prefer summary level data whereas others might need to look
at the summary level as well as granular level data. These reports
are static and hence end users do not have any choice to
customize or drill down the reports on their own. Currently it is al-
ways directed to a SAS programmer to update the reports which is
an overall time consuming process. Every clinical study is con-
strained with budget and it might be expensive for them for a so-
phisticated tool. These dashboards are created only once for each
study using SAS, Excel VBA & Excel Pivot Table and they are –Multi
user access at a time –Live Interactive Summary Reports and
Graphs –No Programming is required for the end user –100% Menu
Driven –Auto Refresh –Custom Filters –Drill Down to Raw Data The
master dashboard excel file can be copied by each user to their
local machine and each one can play around with the locally saved
reports without impacting the master dashboard & source files. The
following are the challenges faced during the developmental stage
along with their solutions.
1. SAS Formats cannot be applied while creating excel files using
proc export Solution: SAS macro program is written to handle the
format issue.
2. The Source data path changes of Pivot reports while moving the
reports Solution: There is a wide discussion can be seen in various
online forums on how to solve the pivot source data path changes
while moving the files with pivot tables. None of the solutions dis-
cussed online are simple and reliable. The simplest solution is open
the file and using SAVE AS option save it in the desired location in-
stead of the coping the master dashboard. How simple it is.
3. Pivot based reports are static with the number of rows in excel.
But for an ongoing study, this will be increasing and every time user
cannot change their reports for the rows. It becomes tedious to
manually do the same on several reports and it is error prone. Solu-
tion: While creating the pivot reports, 50000 rows are selected and
Whenever any SAS dataset exceeds 50000 rows, email notification is
sent.
4. Date based filtering criteria is one of the frequently used criteria
for the data monitoring. For example, number of subjects enrolled
during last 1 week or 1 month. Excel pivot does not provide an op-
tion to filter data using specified date ranges. Solution: Fortunately,
this is solved using the concept of SLICER available in excel 2010
onwards.
This paper proposes an easy and cost effective approach to develop an
Interactive Live Clinical Data Monitoring Dashboards with Drill-Down
Using SAS & Microsoft Excel.
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Trials 2017, 18(Suppl 1):200 Page 144 of 235Data management processes are required to ensure clinical trial
data is high-quality and captured according to protocol and regula-
tory requirements; a critical phase within clinical research. The
Edinburgh Clinical Trials Unit (ECTU) Data and IT Systems Team are
small yet well-established with a wide ranging remit from CRF
?A3B2 show $132#?>design, data entry, and data cleaning through
to the design and hosting of complex bespoke electronic data cap-
ture (EDC) systems. Historically, the majority of the EDC systems de-
veloped were used in studies fully supported by ECTU, with an
identified project manager assigned to the study who completed
many of the data management tasks together with the IT Systems
Team. However, there has been a recent demand for support only
from data management, with ECTU developing EDC systems for tri-
als with external trial coordination. In addition, with the continued
growth of the Trial Management teams, there was significant vari-
ation in CRF design and data management procedures between
the individual trial managers.
Subsequently, there was a need identified within ECTU for a forma-
lised procedure for data management activity, in particular where
there is no allocated Trial Manager. By first establishing a desig-
nated Data Manager role, ECTU have undertaken a schedule of
evaluation and improvement procedures to redefine data manage-
ment activity within the unit. The entire lifecycle of the evaluation
of the existing data management activity and formalisation of new
procedures will be detailed, including the development of an ECTU
data management plan and its standardised content. Through on-
going monitoring and feedback from Trial Managers and external
clients, future plans will also be identified, including suggestions
for future discussion with the wider data management community.
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Background
Data validation in clinical trials is an important procedure. Real time
validation checks may not pick up all errors and these need correct-
ing. A flagging system would help trial staff be more time effective
by preventing re-checking of problems that cannot be resolved. A
traffic light system was created and implemented at the Nottingham
Stroke Trials Unit.
Methods
The NIHR HTA Tranexamic acid for intracerebral Haemorrhage
(TICH-2) trial is a randomised, controlled, international, multicentre
trial aiming to recruit 2,000 patients. Data volume in such a trial is
large, and having numerous centres makes solving data queries
time consuming. The database in TICH-2 has built in logic checks
allowing real time validation and this identifies most but not all
data inconsistencies. A program was created that looks at the data
and checks it for values which lie outside the normal ranges or are
inconsistent between different data fields, this picks up queries that
the real time validation missed to ensure data is as complete as
possible. The checks are run for one centre at a time and sent to
trial coordinators, within the trial coordinating centre, to go
through them and resolve with sites. Coordinators highlight each of
the checks in either green, orange or red. Green shows the query
has been resolved, usually due to incorrect data that has been
checked with the recruiting site and updated. Orange means it has
not been resolved because the site has yet to respond; such queries
may be resolved at a later date. Red indicates that data cannot be
resolved or is correct as is and the statistician should remove the
value from further data checks.
Results
This traffic light system has proven easy to follow and understand
and has been effective at getting queries organised. It ensures coor-
dinators are not re-checking queries that cannot be resolved. Thedata checks were run recently for TICH-2, so all data are not yet avail-
able. Twenty seven queries were raised from a sample of 14 centres;
6 (22%) of these were coded green and were data corrected, the
remaining 21 (78%) were red and removed from the checks.
This system also led to changes in ECRFs; it was noticed that partici-
pant weight was often missing on the baseline form, so this was
moved to the day 2 form to give hospital staff more time to get the
information. Since the change, the number of completed entries has
increased from 69% to 75% (p = 0.03).
Conclusion
Putting in place small changes and guidelines can improve staff
productivity and save duplication of their workload. Having a sys-
tem which all staff can easily implement and use helps everyone
keep track of what has been done to deal with data queries. The in-
vestigations that come from these queries improves data quality
and efficiency of trial conduct. A similar approach is used in our
BHF RIGHT-2 trial.
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Background
There is limited research and literature on the data management
challenges encountered in adaptive platform trials. This trial design
allows both (i) seamless addition of new research comparisons, and
(ii) early stopping of accrual to individual comparisons that do not
show sufficient activity without affecting other active comparisons.
FOCUS4 (colorectal cancer) and STAMPEDE (prostate cancer), run
from the MRC CTU at UCL, are two leading UK examples of clinical
trials implementing adaptive platform designs.
To date, STAMPEDE has added four new research comparisons,
closed two research comparisons following pre-planned interim
analysis (lack-of-benefit) and completed recruitment to six research
comparisons. FOCUS4 has closed one research comparison follow-
ing pre-planned interim analysis (lack-of-benefit) and added one
new research comparison, with a number of further comparisons in
the pipeline. We share our experiences from the operational as-
pects of running these adaptive platform trials, focusing on data
management.
[Note: For lessons learnt from a central trial management perspec-
tive, see our companion abstract]
Methods
We critically reviewed data management challenges in STAMPEDE
and FOCUS4. These included implementation of case report forms
(CRFs), Clinical Data Management Systems (CDMS), randomisation
systems, report development, documentation, and other operational
challenges. We also sought specific challenges arising from electronic
(FOCUS4) or paper (STAMPEDE) CRFs.
Discussion
We found similar adaptive platform trial-specific challenges in both
trials. Adding and removing comparisons to open trials provides
extra layers of complexity to CRF and CDMS development. At the
start of an adaptive platform trial, CRFs and CDMS must be designed
to be scalable in order to cope with the continuous changes in this
trial design, ensuring future data requirements are considered where
possible. When adding or stopping a comparison, the challenge is to
incorporate new data requirements while ensuring data collection
within ongoing comparisons is unaffected. Some changes may apply
to all comparisons; others may be comparison-specific or only applic-
able to patients recruited during a specific time period. We will dis-
cuss the advantages and disadvantages of the different approaches
to CRF and CDMS design we implemented in these trials, particularly
Trials 2017, 18(Suppl 1):200 Page 145 of 235in relation to use and maintenance of generic versus comparison-
specific CRFs and CDMS.
The work required to add or remove a comparison, including the
development and testing of changes, updating of documentation,
and training of sites, must be undertaken alongside data manage-
ment of ongoing comparisons. Adequate resource is required for
these competing data management tasks, especially in trials with
long follow-up. A plan is needed for regular and pre-analysis data
cleaning for comparisons that could recruit at different rates and
times. We will discuss the ways that these data cleaning activities
can be split and prioritised.
Conclusions
Adaptive platform trials offer an efficient model to run randomised
controlled trials but setting-up and conducting the data manage-
ment activities in these trials can be operationally challenging.
Trialists and Funders must plan for scalability in data collection, and
the resource required to cope with additional competing data man-
agement tasks.
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Background
Randomization seeks to balance background factors across treatment
groups through random assignment, and stratified randomization im-
poses structure to help ensure balance of the stratification factors. Yet
randomization schemes that are over-stratified may not result in treat-
ment group balances in factors related to disease outcome, sometimes
making study interpretations difficult. Using dynamic randomization al-
gorithms in trials with a small sample size relative to the number of
stratification groups may improve the co-factor balance, allowing
for a clearer study signal. Periodontal Treatment to Eliminate
Minority Inequality and Rural Disparities in Stroke (PREMIERS) (NIH
Minority Health and Health Disparities Research) is a 2-center phase
III randomized, controlled trial that will enroll 400 patients to test
whether intensive periodontal treatment reduces the risk of recur-
rent vascular events among ischemic stroke and TIA survivors. Re-
searchers wanted to ensure balance of 4 different factors: race,
stroke severity, socio-economic status, and stroke risk.
Method
The Collaborative Studies Coordinating Center (CSCC) in the Depart-
ment of Biostatistics at the University of North Carolina serves as the
data coordinating center for the trial. A dynamically allocated biased-
coin minimization algorithm (Pocock & Simon, Biometrics 1975) was
designed and programmed at the CSCC as an application called from
the randomization electronic case report form (ecrf) from the CSCC-
developed, web-based data management system, Carolina Data
Acquisition and Reporting Tool (CDART). Each time a patient is to be
enrolled, the site enters the enrollment data, including all of the
stratification factors into the ecrf. The randomization application
within CDART calculates an imbalance score for each purported treat-
ment assignment that is based on stratification co-factor levels of
previously enrolled, randomized patients. The lowest imbalance score
has some influence when the treatment is assigned.
Objective
CDART has the functionality for complex calculations and custom re-
ports, yet operationalizing the dynamic allocation application was
new to CDART. A separate application developed in SAS was used to
validate the randomization algorithm within the data management
system is working as expected. The presentation will show the detailsof implementing the algorithm, the additional steps to safeguard
against changes in stratification data after a patient has been ran-
domized, and the double-programmed validation job confirming that
the treatment assignments are being correctly assigned.
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Background
The PRECIS-2 tool was developed to help trialists match their design
decisions to the information needs of those they hope will use the trial
results. PRECIS-2 has a highly visual wheel format with nine design do-
mains including Eligibility, Recruitment, Setting, Organisation and Pri-
mary outcome which are scored on a Likert scale from “1” Very
explanatory - Ideal world, to “5” Very pragmatic - Just like usual care.
The tool was developed to design Randomised Controlled Trials and is
being used internationally by health care professionals in a variety of
clinical areas. The aim of our study was to evaluate the usefulness of
PRECIS-2 for discussing the design of a feasibility study of an interven-
tion developed by a trial team including speech and language thera-
pists, oncology nurses, and a psychologist: a Swallowing intervention
Package (SIP).
Methods
The SIP team applied the PRECIS-2 tool to assess the pragmatism of
the SIP feasibility study design, using training materials and the soft-
ware on the PRECIS-2 website www.PRECIS-2.org to create their own
sip study wheel. The individual PRECIS-2 scores of the SIP trial team
were aggregated into a single PRECIS-2 wheel to indicate the median
and range of scores for each of the nine PRECIS-2 domains. The trial
team then used aggregated scores to discuss the design of the feasi-
bility study and reach consensus. Discussion focussed on domains
with the greatest range of scores (i.e. Widest discrepancy between
individuals). Members of the team were asked to complete an evalu-
ation form to determine the utility of using the tool with a view to
designing a future randomised trial.
Results
Ten out of the 14 members of the sip trial team used the PRECIS-2
tool to assess the pragmatism of the SIP feasibility study. Prior to the
meeting, the discrepancy between domain scores was up to 3 points
on a scale of 5, suggesting differing views of how explanatory or
pragmatic the study design was. The PRECIS-2 domains with greatest
consensus were Eligibility - To what extent are the participants in the
trial similar to those who would receive this intervention if it was part
of usual care, and Setting - How different are the settings of the trial
from the usual care setting. Some of the trial group believed that
certain aspects of the feasibility study for the sip trial were quite ex-
planatory, with four out of nine of the domains scoring "2": Flexibility
(Adherence), Follow up, Primary Outcome and Primary Analysis. Fol-
lowing discussion, the team reached consensus on scoring 7 out of 9
domains, assessing the overall design of the sip feasibility study as
more pragmatic than explanatory. With all but one of the meeting
participants independently scoring the sip trial using PRECIS-2, this
enabled meaningful discussion of the key elements of a future trial
design.
Conclusions
This exercise was useful for assessing the design of both the SIP
feasibility study and a potential future trial. PRECIS-2 is a relevant
framework for reaching consensus on design aspects of pilot and
feasibility studies as well as full trials.
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Background
Corticosteroids (CS) are key to achieving rapid disease control in chil-
dren and young people (CYP) presenting with new or flaring juvenile
idiopathic arthritis (JIA). Efficacy, duration of action and side effect pro-
files vary with the route of administration. Current routes of CS adminis-
tration are based on physician and patient preference, rather than
scientific evidence. A randomised controlled trial is needed to ascertain
the most effective routes and doses of CS. This paper will report on the
feasibility of a potential CS induction regimen randomised controlled
trial (RCT) in JIA from the perspective of CYP and their families.
Methods
Semi-structured in-depth interviews were conducted with a purpos-
ive sample of CYP with JIA and their families, recruited via rheuma-
tology clinics across the UK. All CYP and their families had recent
(<12 months) experience of CS treatment. The Framework Method
was used to support thematic analysis of the data.
Results
Findings will be reported on CYP’S and parents’ experiences of four
different CS delivery routes, treatment preferences and willingness to
participate in a CS induction regimen RCT, randomising patients be-
tween different steroid delivery routes and dose regimes. CYP’s and
parents’ questions about the planned RCT and their recommenda-
tions regarding its design will also be reported.
Discussion
The findings from this qualitative study will inform judgements about
the feasibility and design of a future RCT of CS induction regimens
for JIA. Corticosteroids are a very effective treatment for flaring JIA
but carry significant and challenging side-effects. The views and ex-
periences of CYP with JIA are an important outcome of this study
and are key to informing the feasibility and acceptability of a future
RCT from the patient perspective. Methodological issues about the
validity of pre-trial feasibility studies for informing decisions about
potential future trials will also be considered.
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The Marmot independent review of breast screening report pub-
lished in 2012 concluded that the breast screening programme
saves lives but significant overtreatment exists [1]. The review
called for randomised clinical trials to address overtreatment of
screen-detected DCIS.
More recently, Sagara et al. [2] conducted a retrospective longitu-
dinal cohort study in the USA investigating the survival benefit of
breast surgery for DCIS. They found no significant difference in breastcancer specific survival between patients who had surgery and those
who did not in the low grade DCIS group.
LORIS is a multi-centre, randomised controlled phase III trial of sur-
gery versus active monitoring in patients with low risk DCIS designed
to address the problem of overtreatment.
An independent patient advocate group (Independent Cancer Patients'
Voice) have been involved in the study since conception and provided
a direct patient perspective throughout the LORIS Trial.
Key eligibility criteria are; women aged 46 years and over with screen-
detected or incidental microcalcification with no previous invasive
breast cancer, no comedo necrosis and low risk disease confirmed by
Central Digital Histopathology Review. The primary outcome is ipsilat-
eral invasive breast cancer free survival up to 5 years.
34 sites have opened to recruitment across the UK, with enthusiasm,
commitment and support evident from the site research teams. Pa-
tients have responded favourably to the trial and the opportunity to
contribute to ground breaking research. Patients found the Patient
Information DVD informative and welcomed receiving information
early on in the patient pathway.
Reasons patients gave for participating in the trial include “the trial
offered the best treatment options” and that “others would benefit
from the results of the trial”. Patients have also commented that they
welcome the opportunity for independent pathology review of their
biopsies; a key quality assurance element of the trial. Feedback from
sites highlights the difficulty in conveying to patients the rationale of
replacing surgery with active monitoring, with 30% of patients stat-
ing a preference for surgery. To address this, regular communication
workshops are offered, phone-in sessions allow sites to share best
practice and frequent newsletters offer hints and tips to aid recruit-
ment. Media channels are being explored to raise public awareness
of the overtreatment of DCIS. Dissemination of this information will
help to engage future LORIS patients.
Following on from the successful launch of LORIS in the UK, the trial
is now leading the way internationally. LORIS is collaborating with
COMET (USA) and LORD (Netherlands).
Collaborative efforts and feedback from site staff, patients and over-
sight committees during the LORIS feasibility phase has allowed us
to establish LORIS as a world leading trial addressing the overtreat-
ment of DCIS.
The LORIS Trial is funded by the National Institute for Health Research
Health Technology Assessment programme.
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Background
It is common practice for clinical effectiveness trials to include an in-
ternal pilot but guidance on how they should be analysed is lacking.
The REST study is a pragmatic randomised controlled trial to deter-
mine whether Veno-Venous Extracorporeal Carbon Dioxide Removal
Trials 2017, 18(Suppl 1):200 Page 147 of 235(VV-ECCO2R) in mechanically ventilated patients with hypoxaemic re-
spiratory failure improves 90 day mortality. An internal 6-month pilot
study in 10 sites to confirm both recruitment and adherence assump-
tions that have contributed to study design will precede the main
trial.
Method
A statistical analysis plan (SAP) has been written for the internal
pilot for the REST trial which will be signed off separately to the full
trial SAP but will form an appendix to it once it’s written. It covers
the analyses required for the internal pilot to assist with making
the decision to progress to the full trial. For the REST internal pilot
the following analyses will be completed: The overall recruitment
rate will be compared to target recruitment of 7 per month.
Analysis of separation in terms of tidal volume (ml/kg predicted
bodyweight) between the two arms will be undertaken on an
intention to treat and a per protocol basis including the patients in
receipt of VV-ECCO2R on day 2 and 3. Completeness of datasets
with respect to the primary outcome measure of 90 day mortality
will be assessed for patients recruited in the first 3 months. Like a
full trial SAP, the SAP for the internal pilot was reviewed by the
Data Monitoring and Ethics Committee and the Trial Management
Group.
Discussion
A formal SAP for an internal pilot is not standard clinical trial meth-
odology and there are pros and cons to having one which are open
for discussion. In general, the advantages are as for the SAP for the
final analysis: to pre-specify the analysis and reporting in order to
avoid intentional or unintentional bias caused by multiple unplanned
analyses and selective reporting of data. Without a SAP, investigators
who are convinced of the usefulness of an intervention may manipu-
late pilot results to make a convincing case for progression to a full
trial ultimately leading to a trial showing no difference and a waste
of research funding. On the other hand, one may argue that the risks
of multiple analyses and “data dredging” leading to spurious findings
are primarily associated with large sample sizes that will not be
present in a pilot study. Furthermore, relying too strictly on pre-
specified criteria for progression to a full trial could result in stopping a
trial of a promising treatment in the presence of practical issues with
delivery that may be easy to overcome. One specific pro to having a
SAP for the internal pilot that is separate from the full SAP is the ability
to have the pilot analyses documented without the need to have the
full SAP signed off at an early stage of the trial. The SPIRIT guidelines
should give consideration to internal pilot studies and the need to
document planned analyses and progression criteria.
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Background
Weaknesses in the design, conduct and reporting of pilot/feasibility
studies have
Been shown by systematic reviews. Moreover, lack of agreement on
the definition of a pilot or a feasibility study has made difficult to
propose guidelines on the analyses and reporting of these studies,
which often ended up not being published. The working group on
developing reporting guidelines on pilot and feasibility studies, as
an extension to the Consolidated Standards of Reporting Trials
(CONSORT) Statement, created a conceptual framework to propose
definitions for pilot and feasibility studies (Eldridge et al. 2016), and
has recently published their guidelines (Thabane et al. 2016). We
propose to systematically review the pilot and feasibility studies
conducted at the Population Health Research Institute, McMaster
University (our group) in the last 10 years, and assess the applica-
tion of the new guidelines.Methods
We will select all studies that were defined as pilot or feasibility
studies in the study protocol, as well as any study that agrees with
the definition of pilot or feasibility studies under the guidelines. We
will follow the guidelines and report all of the elements proposed
(e.g. Design, sample size calculation, objectives, type of outcomes,
analyses, and whether they were used to estimate parameters that
supported sample size calculations for a full trial). We will also re-
port whether the study was an internal pilot or not, and whether
the results of the pilot/feasibility study were published separately
from the main trial.
Conclusion
A systematic review of pilot and feasibility studies under the recently
published CONSORT guidelines may improve understating their ap-
plication in a practical setting, and easy the implementation amongst
researchers.
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Background
The purpose of phase II trials is to assess the potential activity of
new therapies, which will then be investigated in larger, more time
and resource consuming phase III trials. Currently, in oncology, the
success rate of phase III trials is considerably low, suggesting that the
phase II trials are allowing the progression of too many inefficacious
therapies. Thus, early rejection of inactive treatments and moving
therapies that are most likely to be efficacious to phase III testing
would benefit patients and the drug development industry. The aim
of this research is to investigate the impact of various design param-
eters on the phase II trials’ ability to successfully screen new treat-
ments in phase III.
Methods
A literature review was conducted in order to determine which phase
II design parameters have previously been considered for impact on
phase III outcomes, and to identify any additional parameters that
may be considered. It also aimed to identify an appropriate measure
of success which allows comparisons of phase II trial efficiency to be
made. The impact of the varying design parameters on the identified
measure of success will then be evaluated.
Results
The literature review identified a number of parameters to be investi-
gated, including phase II sample size, distribution of the underlying
true treatment effect and phase II design. Additional parameters we
will investigate are the strength of relationship between endpoints at
phase II and III, and the population size. From the literature, a num-
ber of measures were found to quantify the impact of these parame-
ters on the success of phase II trials, including the number of
patients required in both phases II and III before the first successful
phase III.This measure takes into account the expected probability of
success in phase II, E(P_1), and the expected probability of success in
phases II and III, E(P_1 P_2). Since the phase III trial will only com-
mence if the phase II trial is successful, these probabilities can be
used to calculate the conditional probability of success at phase III,
E(P_1 P_2)/(E(P_1)).Using this measure, we analytically evaluate the
impact of each of the design parameters on the ability to successfully
screen treatments at phase II. To start with, the phase II and phase III
trials are assumed randomised, two-arm trials, with continuous nor-
mally distributed endpoints in both phases II and III, and with an
underlying true treatment effect that follows a normal distribution.
Conclusions
The impact of the strength of relationship between the endpoints,
and sample size, on the conditional probability of success of phase III
trials will be presented. Understanding the impact of each of the
Trials 2017, 18(Suppl 1):200 Page 148 of 235design parameters on phase III trials will allow us to design efficient
phase II trials which can more quickly move effective treatments to
phase III testing.
P389
A lifetime disease model based on an RCT: development, validation
and applications
Iryna Schlackow1, Borislava Mihaylova2, on behalf of SHARP Collaborative
Group2
1University of Oxford; 2Nuffield Department of Population Health,
University of Oxford
Correspondence: Iryna Schlackow
Trials 2017, 18(Suppl 1):P389
Background
Chronic kidney disease (CKD) increases the risk of cardiovascular dis-
ease (CVD) but, conversely, CVD may accelerate kidney disease
progression.
Aim
To develop, validate and make widely accessible a CKD disease model
that takes into account interdependence of CKD and CVD and can be
used to simulate disease outcomes and (quality-adjusted) life expect-
ancy and incorporate effects of interventions that modify cardiovascu-
lar risk in CKD patients.
Methods
The model is based on the individual patient-level data from the
Study of Heart and Renal Protection (SHARP), which included 9,270
participants with moderate-to-severe CKD but no major coronary
disease. Detailed sociodemographic and clinical characteristics at
study entry and serious adverse events during the 5 years’ follow-
up were recorded. A two-stage lifetime Markov model was devel-
oped, comprising of a CKD submodel simulating progression of
chronic kidney disease, and a CVD component simulating annual
experience of fatal and nonfatal cardiovascular events and non-
vascular death. Risk equations included baseline characteristics as
well as important time-updated covariates (age, cardiovascular
event and CKD status). Three external CKD cohorts (an observa-
tional study, CRIB, and two randomised controlled trials, 4D and
AURORA) were used to validate the model. Additionally, the model
performance was compared against an external CVD risk score (the
Pooled Cohort Risk Equations, PCREs) and an external risk score of
progression to end-stage renal disease (the model by Tangri et al.).
Results
Age, recent cardiovascular events and contemporaneous CKD status
were the most important determinants of adverse events. Predicted
event rates from the model corresponded mostly well to those in the
external cohorts. The model was superior to the PCREs in predicting
cardiovascular risk, with predictions by the PCREs not adequately
capturing variation in risk across CKD stages especially in CKD stage
3B (observed 5-year probability of a major vascular event in SHARP
8.6 [95% confidence interval 6.2-11.0] vs 9.4 predicted by the SHARP
model vs 15.3 predicted by the PCREs) and dialysis (19.3 [16.2-22.2]
observed in SHARP vs 17.9 predicted by the SHARP model vs 12.4
predicted by the PCREs). In predicting end-stage renal disease, the
model performance was comparable to that of the Tangri model
?A3B2 show $132#?>(observed 5-year probability of end-stage renal
disease in SHARP 36.5 [35.2-37.8] vs 34.2 predicted by the SHARP
model vs 34.3 predicted by the Tangri model).
To facilitate the use of the model, a practical and flexible web inter-
face was developed, which allows the user to execute analyses on
individuals or patient cohorts and provides estimates, including the
uncertainty, of the disease outcomes, life expectancy and cost-
effectiveness of interventions. We will illustrate the model, and its
interface, with examples of potential applications.
Conclusions
The SHARP CKD-CVD lifetime risk model is a novel resource for simu-
lating lifetime health outcomes, and effects of interventions to re-
duce cardiovascular risk and kidney disease progression, in people
with moderate-to-severe CKD. The freely available web-based inter-
face allows for a wide range of policy relevant analyses.P391
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Background
In many cancer trials, health related quality of life (HRQOL) are often
collected up to disease progression. For health economic evaluation,
a lifetime perspective of both costs and utilities is required to assess
cost-effectiveness of cancer drugs. Therefore, ideally, utility data is re-
quired beyond disease progression. In some cases assumptions are
made about the behaviour of utility data (e.g. Such as constant,
linear decline, or decaying). Other options include the possibility to
determine utilities from historical data and rarely is any attempt
made to extrapolate utility data beyond trial follow up, although this
is commonly used for survival data.
In this research, we demonstrate the feasibility of extrapolation of
utilities beyond disease progression and standard trial follow up for
the purposes of estimating quality adjusted life years (QALYs) over a
life time horizon through non-linear mixed effects modelling.
Methods
Data from an observational study in 100 lung cancer patients followed
up for at least 12 months was used to extrapolate EQ-5D-3 L utilities
after patients have progressed. Several non-linear models were postu-
lated including a Lorentz, Rational, 5-Parameter, Pareto, Exponential
and Linear models. Extrapolation of survival times were generated
using a Royston-Parmar (3 Knott) flexible parametric survival model in
order to estimate the QALY. Models were compared in terms of AIC
and impact on QALY estimates.
Results
Utilty extrapolation is feasible. The more complex 5-parameter model
appears to be the most useful (lowest AIC value of 92.4) in terms of
predictive ability beyond 12 months. Two parameters were statisti-
cally significant (p < 0.001). The Lorentz, Rational and 5-parameter
models generated the most accurate estimates of mean PP utilities
and QALYs: 0.474 vs. 0.508, 0.509 and 0.487 respectively for utilities;
and 3.176 vs. 3.37, 3.37 and 3.26 for QALYs.
Conclusion
Modelling post progression utilities as well as extrapolation of util-
ities beyond the study follow up appears feasible and is an alterna-
tive to mapping or using published utility estimates.
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There are opportunities to embed randomised trials of interventions to
promote the uptake of evidence-based practice within established,
large-scale improvement initiatives. Such “implementation laboratories”
offer an efficient means of producing robust evidence generalizable to
service settings. However, there are practical and methodological chal-
lenges in delivering such programmes of work.
Audit and Feedback (A&F) - defined as any summary of clinical per-
formance of health care over a specified period of time, to provide
healthcare professionals with data on performance - is widely used to
improve the quality of healthcare. However, its effects are often unreli-
able, indicating the need for coordinated research including more
head-to-head trials comparing different ways of delivering feedback.
Blood transfusions are a commonly used intervention in hospital
care. Repeated national audits in the United Kingdom suggest that
up to a fifth may be unnecessary when judged against recommen-
dations for good clinical practice. The AFFINITIE programme
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Increase evidence-based Transfusion practice) aims to test different
ways of delivering feedback within the existing UK National Com-
parative Audit of Blood Transfusion (NCABT). It includes two linked
2x2 factorial, cluster-randomised trials evaluating two theoretically-
enhanced A&F interventions to reduce unnecessary blood transfu-
sions in hospitals. Trial outcomes were derived from data collected
for the national audit.
A number of challenges related to, or increased by, embedding re-
search within an existing national audit programme have been
highlighted to date in the AFFINITIE programme. These include:
Communicating a message about equipoise to clinicians developing,
delivering and receiving different feedback interventions who might
otherwise feel advantaged or disadvantaged; Identifying and mitigat-
ing threats of contamination between the enhanced and standard
feedback arms of the trial; Preserving fidelity of intended enhanced
feedback interventions on the pathway to their delivery; Ensuring
that data quality and governance processes sufficiently meet the
needs of both a national audit programme and a rigorous evaluation;
Aligning research timelines with those of a rolling and evolving na-
tional audit programme.
From a methodological perspective these challenges suggest a ten-
sion between internal and external validity (that is, bias and general-
isability), characteristic of pragmatic trials, where greater importance
is placed on generalisability.
Embedding research within major improvement initiatives is, how-
ever, feasible. We will present our recommendations in response to
each challenge we have identified. These may assist researchers in
optimising the conditions for sustainable implementation laborator-
ies in the context of existing A&F programmes. These include:
Negotiating shared expectations and ground rules for collaboration;
Establishing joint processes for assuring the quality of data for audit
and research; Aligning audit standards and trial endpoints wherever
possible.
Our recommendations will be discussed in the context of a wider
literature on designing pragmatic trials.
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Clinical trials in organ donation and transplantation are increasing in
the UK but each presents their own set of challenges. The centrally
maintained UK Transplant Registry, held by NHS Blood and Transplant,
prospectively collects data on all organ donors, transplants and trans-
plant recipients, including periodic follow up data, and is a particularly
valuable resource for the conduct of clinical trials in this field. In particu-
lar it facilitates power calculations, and data collection, especially for
longer term outcomes. Alongside this, NHS Blood Transplant has a na-
tional network of Specialist Nurses for Organ Donation, who seek con-
sent for organ donation and the use of such organs in a clinical trial.
There is very little time from when the organ is deemed suitable
for transplantation, the potential recipient is notified and the organ
is transplanted. Consent from the recipient to participate, and
randomised treatment allocation, usually takes place in this short
window. Streamlining and simplifying of these processes is essen-
tial. Other challenges arise in trials in kidney transplantation, where
deceased donors typically donate both kidneys, which have differ-
ent anatomy, and are allocated in such a way a centre may receive
one or both kidneys from a donor. Randomisation therefore re-
quires careful consideration to take account of features such as this.
Typically in transplantation, the key outcome of interest is graft or
patient survival years. However, survival rates are high and differ-
ences to be detected are generally small, and hence such an out-
come can rarely be used as the primary outcome. Composite
outcomes, or biomarker data have then to be used.Many of these challenges, and their resolution, will be illustrated
using a randomised controlled trial of ex-vivo normothermic perfu-
sion, compared to standard cold storage in kidney transplantation.
P394
Developing a web-based central laboratory shipment scheduler
and information system
Kayla Daniels, Michael Frasketi, Dikla Shmueli-Blumberg, Peter Dawson
The EMMES Corporation
Correspondence: Kayla Daniels
Trials 2017, 18(Suppl 1):P394
The use of central laboratories in multi-site clinical trials is common
to ensure consistency in reporting and analysis of assay results. The
additional time between sample collection and analysis is typically
not a burden for frozen or otherwise properly stored specimens.
When assay results are time sensitive due either to the sample type
(e.g. Fresh cells) or need for immediate results, local laboratories are
often utilized. If an assay is novel or proprietary, however, the local
laboratory may not be able to perform the assay and a specific cen-
tral or research laboratory must be utilized. In several recent multi-
center studies, an assay required shipment of whole blood samples
and immediate labor intensive processing by a specific central la-
boratory. Despite extensive piloting to reduce time from collection to
analysis and obtain quality assay results, an unexpected predicament
developed during the trial in which sites were shipping more speci-
mens than the lab could successfully test in a timely fashion due to
limited central laboratory resources; resulting in failed assays. The co-
ordinating center for these studies had to find an immediate solution
that was convenient and accessible to both central laboratory and
site staff. In response, coordinating center staff developed and de-
ployed an access controlled shipment scheduler web site to allow
sites and lab staff to more efficiently coordinate. Clinical site users
entered shipment details and a validation routine capped each site
at a certain number and type of clinical sample shipments. Central la-
boratory users could then monitor when specimens would be
shipped to them and indicate lab closures or other dates shipments
could not be accepted, thereby allowing better allocation of lab staff
resources. Addition of the shipment scheduler to the laboratory man-
agement process resolved the difficulties involving laboratory cap-
acity and the studies were able to continue obtaining novel, high
quality assay results. This presentation will highlight some of the in-
frastructure and functionality of the system that may be relevant and
applicable for studies with existing laboratory management systems
or those interested in creating such a process. Furthermore, we will
discuss the importance of flexibility among the clinical trial manage-
ment team and the value of adapting processes to correspond with
constantly changing requirements of a research trial.
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Background
In September 2016 the UK competent authority in relation to clinical
trial regulations, the Medicines and Healthcare products Regulatory
Agency (MHRA) Ran an annual good clinical practise (GCP) sympo-
sium. One of the main topics discussed was data integrity and
numerous common problems found during site inspections. The
MHRA highlighted numerous deficiencies found in electronic
systems, the majority of these were well known and it could be con-
sidered surprising that such deficiencies still exist. There was how-
ever one particular notice from the MHRA that has wide reaching
implications for EDC systems as it is believed almost no systems are
currently compliant. The MHRA highlighted the case that when a
electronic record is saved, all of the variables on the page are saved
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saving, not when the individual fields were actually entered. Further-
more, the MHRA highlighted that the audit mechanism in electronic
systems usually operated in such a way that the electronic system
could allow unaudited changes to data which would be captured on
paper when following GCP guidelines. On paper, an edit to most
pieces of data require that the piece of data be scored through once,
and then a replacement value written down, dated and initialled. In
most electronic systems, only the state of data at the time of saving
is recorded; any changes made prior to saving are completely lost.
One could argue that keyboard usage is more prone to error, there-
fore typographical errors should not be recorded. However, how
could the system distinguish between typographical errors and
change of answers? There is a very real potential cost to this require-
ment in terms of data storage. A naïve solution would be to capture
the answer at every stage of entry; however this leads to huge over-
heads in data storage. If a surname is 10 characters long then typic-
ally that requires 20 bytes of storage, if however you storage each
state of the surname as it is entered, assuming there are no actual
edits or corrections then the storage requirement balloons to 100
bytes.
Methods
Various problems in audit trail mechanisms highlighted by the MHRA
will be discussed along with common solutions from production sys-
tems. A detailed investigation at the problem of between save auditing
will take place including discussion of various solution approaches and
their merit on a number of different electronic platforms.
Conclusion
All staff involved with the creation, maintenance or usage of EDC sys-
tems should be aware of the GCP audit requirements highlighted by
the MHRA in the UK. Even to those who deal with other competent
authorities, as this is a direct GCP requirement, it is likely the issue
will arise across all GCP bound component authorities.
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Background
An eval() mechanism is one which evaluates and executes code at run-
time, it exists in different forms in almost every programming ?A3B2
show $132#?>language and platform. In computing it has long been
known that the use of eval() mechanisms pose a security threat, the
code being executed likely originated with the user of a system and
therefore should be treated with caution. A large proportion of Clinical
Trial Management Systems (CTMS) and Electronic Data Capture (EDC)
systems allow users who design forms to type in snippets of code and
then run these during system use by using an eval() mechanism. Eval()
is employed despite the security concerns posed because it is an easy
way to incorporate user defined rules into a system e.g. Form skip fill
rules. The ability to pass the rule content to the underlying platform for
execution without the requirement to understand what is being
passed, drastically simplifies the development task when building the
system. Apart from the security concerns, not understanding the user
defined rules significantly limits the EDC’a abilities and function includ-
ing but not limited to: All user entered code blocks are subject to GCP
validation requirements however the EDC is limited in what tooling
and support it can provide when the user defined code block is not
understood e.g. Automated creation of test scenarios. Code blocks that
are not “understood” cannot be translated; therefore one is limited to
the language/platform they were written for initially. To run the code
on any new platform, one has to essentially emulate the old platform
in the new platform.
Methods
If the code blocks are “Understood” then they can be further trans-
lated to a non-programming language to allow all job roles – not justthose who are fluent in the specific programming language – to ver-
ify that the code meets the requirements.
Conclusion
The authors will present an overview of different mechanisms to break-
down code blocks into understandable units from classic compiler
design to more adhoc methods and the various things that can be
achieved including: test data generation, automatic test execution,
documentation production and programming language translation.
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Background
Sales in mobile devices are out stripping traditional PC sales and a
number of analysts expect this trend to continue and the gap to
widen. In line with this trend, the number of trials that wish to in-
clude mobile device based EDC systems has risen significantly in the
last five years.
There are two main types of EDC: Native application based or web
based. While the web based approach does support offline function-
ality, there are serious concerns over the security of data in offline
web based systems with the current technology. Therefore, if you
wish your mobile device EDC to function offline you are limited to
native applications.
There are three main mobile device operating systems: android, ios
and windows. Therefore having decided to produce a native applica-
tion one must consider which operating system(s) you will build
applications for.
Obviously building the same application for multiple operating
systems seems counter intuitive. To this end, a number of products
exist on the market offering a middle ground that allows you to
build one application that will run natively on all three operating
systems.
The authors utilised Xamarin, a system that advertises multiplatform
support to allow applications to be delivered for multiple operating
systems.
Methods
The authors have been involved in the delivery of eight separate mo-
bile device EDC systems, supporting online and/or offline modes,
four different languages, web based and native application and have
gained quite a lot of experience in this area in a short time due to
the nature of the studies involved.
Conclusion
The authors will present the best practises learned from delivering
these applications in their various modes and explain why as an or-
ganisation we have decided to develop future native applications in
their operating system specific development environment, despite
the duplication of work, rather than rely on an intermediary platform
like Xamarin.
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Identifying a safe, affordable, and well-tolerated intervention that
prevents or delays cognitive decline in older adults is of critical
importance. There is growing evidence from basic science and
small randomized trials that cocoa flavanols may provide protec-
tion against this decline. COSMOS-Mind is an NIA-funded ancillary
study to the Cocoa Supplement and Multivitamin Outcomes Study,
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flavanols (600 mg/d) and a multivitamin with matching placebo on
cardiovascular disease and cancer endpoints. The primary aim of
COSMOS-MIND is to assess the effects of COSMOS supplements on
cognitive trajectory over 3 years of follow-up using a composite meas-
ure of cognitive function. An important secondary outcome is incident
Mild Cognitive Impairment or Alzheimer’s disease and other dementias.
A validated telephone-based protocol conducted at baseline and
annually thereafter assesses attention, memory, executive function, lan-
guage, and global cognitive functioning in 2,000 women and men
aged 65 years and older without insulin-dependent diabetes. Add-
itional measures administered by telephone assess subjective memory
concerns, depression, and insomnia. For participants who score below
a pre-specified threshold on a test of global cognition, a study partner
will be interviewed to obtain additional information regarding cognitive
and functional status. A web-based telephone call tracking system is
used to prioritize COSMOS-Mind enrollment to ensure diverse represen-
tation. Real-time reports monitoring study calls provide information to
detect issues that may impact recruitment goals, data collection,
personnel resources, and costs. At the end of follow-up, cognitive status
will be adjudicated by an expert panel to identify Mild Cognitive Im-
pairment, and Alzheimer’s and related dementias. Enrollment will be
completed in the summer of 2017. COSMOS-Mind will establish
whether daily use of a cocoa flavanol supplement, with or without a
multivitamin, can protect cognitive function and reduce incidence of
cognitive impairment, including Alzheimer’s dementia.
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Background
Using routinely collected data for clinical trials is on the increase and
funders are recognising that this is an excellent method to get answers
to many research questions. In order to utilise non-consented electronic
records such as hospitalisation admission and discharge records, deaths
and prescribing data requires appropriate governance and a secure IT
environment which fulfils the requirements of the data providers.
Method
The Glasgow Safe Haven is a collaboration between University of
Glasgow (UOG) and Greater Glasgow & Clyde Health Board. Approval
is sought from a local privacy advisory committee for access to non-
consented data on a per research project basis. Once approved, the
data are extracted, anonymised and placed on an analytical platform
hosted by UOG where researchers can then perform their analysis in
a strictly monitored environment. In order to become a “safe haven”
analytical platform, certain requirements need to be adhered to. Se-
curity is paramount and for very sensitive datasets the creation and
use of a “safe room” is required.
Conclusion
The technical infrastructure to comply with data providers require-
ments will be presented. Governance procedures and oversight will
be discussed. Exemplar project to demonstrate the value of using
this method for research will be demonstrated.
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Trials 2017, 18(Suppl 1):P400Background
The UK Clinical Research Collaboration (UKCRC) partner’s goal is to
establish the UK as a world leader in clinical research. The UKCRC
provides a forum that enables all partners to work together to trans-
form the clinical research environment within the UK.
Methods
The Information Systems Operational Group has a mandate to foster
collaboration and improve quality through self-support (within the
group) to help ensure robust secure and regulatory compliant
provision of IS systems to registered CTUs. The objectives and sup-
port themes undertaken by the group evolve over time to take into
account changes in the regulatory environment and technological
methodology are directed by the UK group (consisting of representa-
tives from all registered CTUs) as a whole following national meet-
ings or feedback from working groups. The activities of the ISOG are
overseen and directed by a steering group consisting of members
proposed by the directors of the registered CTU’s and mandated by
the UKCRC executive.
Conclusion
The purpose, activities and outputs of the ISOG in collaboration with
other UKCRC operational groups will be presented.
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SWOG has a free set of online statistical tools that are used widely
across the world at stattools.crab.org. We were interested in further
expanding the reach of these tools by making them ‘mobile friendly’.
We wanted users to have a similar user experience on smartphones
and tablets as they would on a normal desktop computer. This would
give users an opportunity to use statistical tools wherever they went.
SWOG wanted to also give training sessions where we can demonstrate
statistical tools and then have attendees follow along on their mobile
device to provide an active learning experience.
In July 2016, SWOG upgraded its statistical tools site to be ‘mobile
friendly’ or responsive. The site is now able to dynamically change its
interface to accommodate the different devices, screen sizes, and
browsers of the different users that access it. The current site sup-
ports all mobile platforms including iphones, ipads, Android, black-
berry, and Microsoft devices. This presented a technical challenge
due to the sheer variety of devices and interfaces on the market.
To ensure a successful implementation of the site, SWOG added
website analytics to obtain more metrics on what devices are using
the site and how they’re using it. There were several questions we
wanted to answer: What devices are most commonly used on the
website and were they able to use the site successfully? Did allowing
mobile access give opportunities for new users? Are mobile devices
utilized differently by users in different countries? We plan to gather
this data to help answer these questions over the coming months
and use them to improve the site.
Support: NIH/NCI/NCTN grants CA180819, CA180888.
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High quality study drug distribution management is essential to the
operation efficiency and quality of large multicenter clinical trials.
First, each site must have a sufficient drug inventory, i.e. At least one
Trials 2017, 18(Suppl 1):200 Page 152 of 235drug kit for each treatment arm, in order to perform subject
randomization. When response adaptive randomization is applied,
the treatment allocation ratio may change multiple times during the
study period, and corresponding site drug inventory adjustment may
be needed. Second, the high cost and short shelf life of study drug
and the slow subject recruitment speed may demand to minimize
the site drug inventory. Finally, study drug distribution management
must take into account the protection of treatment allocation con-
cealment and treatment blinding, the time and financial cost of
study drug shipping. To accomplish these critical tasks, traditional
manual drug distribution coordination, often managed using spread
sheets, is not reliable. As the national data management center for
several NIH-funded clinical trial networks, we have developed a gen-
eric study drug tracking module integrated in the web-based clinical
trial management system. It provides automated coordination of
study drug distribution for multicenter clinical trials. Study drug re-
quests are automatically generated when the site drug inventory is less
than the pre-specified threshold and are triggered by a new subject
randomization, confirmation of drug removal from site inventory for
any reason. The entire study drug shipping process, from the central
pharmacy to the clinical sites, including optional multiple regional drug
depots, is tracked and information is shared among collaborators in real
time. Central and local pharmacy staff are notified by automated emails
when study drug distribution actions are requested. This module has
been implemented in 8 multicenter trials, and received very positive
feedback from investigators. This presentation will discuss the database
design and implementation of the automated study drug distribution
coordination module in the clinical trial management system.
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Background
CTC-STOP is a multicentre phase III trial for castration resistant prostate
cancer patients with bone metastases (MCRPC). The trial is designed to
determine if the use of serial circulating tumour cells (CTC) counts can
direct early discontinuation of docetaxel chemotherapy in mcrpc patients
without adversely impacting overall survival, when compared with stand-
ard approaches to guide treatment switch decisions. Treatment switch
recommendations based on CTC progression are centrally managed by
the co-ordinating clinical trials unit (ICR-CTSU) and require real time trans-
fer of CTC counts from the central laboratory to the ICR-CTSU.
Challenges
CTC-STOP blood samples are received and processed by the central
laboratory. CTC counts are recorded in the central laboratory’s information
management system (LIMS). The LIMS cannot be programmed to calculate
or alert staff to CTC progressions and the ICR-CTSU cannot access LIMS.
CTC counts are required by the ICR-CTSU trial team for CTC progression
calculations within the Electronic Data Capture (EDC) system, so treatment
switch recommendations can be issued promptly. Manual data re-entry of
the CTC counts into an EDC database would be time consuming and
could result in transcription errors; therefore a system was designed to
automatically import the CTC counts from the LIMS into the EDC system.
Solution
An in-house C#.net application was developed by ICR-CTSU to verify
and import CTC counts provided by the central laboratory LIMS. The
application locates and verifies the LIMS export file before validating
the subject identifiers and trial visit timepoint for each CTC count.
Once validated, the data is imported into the EDC system using its
Application Programming Interface. The application runs automatic-
ally every day via Windows Task Scheduler and generates a log file
for each export file to detail any errors found during processing andthe number of data rows successfully imported into the EDC system.
When the application has completed processing the log file is
emailed to the ICR-CTSU trial team for review. Details of each export
file processed are also written to a database history table.
The CTC counts imported into the EDC system are used to perform
computations to ascertain whether a treatment switch is required by
calculating whether each subject has progressed or responded. The
EDC system’s event management tool automatically alerts the ICR-
CTSU trial team if the imported results reveal an initial progression
event requiring a second confirmatory CTC count, a confirmation of
progression requiring a treatment switch recommendation or a con-
tinuation of therapy confirmation for any participant.
Conclusion
The application provides a robust, time critical, automatic solution to
accurately import LIMS data into the EDC system, reducing workload
for both the ICR-CTSU team and laboratory staff and removing error
rates associated with manual data entry. The application also provides
the ICR-CTSU trial team and site staff, including treating clinicians, with
real-time access to the CTC counts.
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Background
Patient and public involvement (PPI) in health research has grown rap-
idly and is considered a key component of good research. Patient and
public input into the development of core outcome sets (COS), which
specify which outcomes should be measured and reported as a mini-
mum in trials within specific health areas, is also increasing. It is vital to
the credibility of a core outcome set that the chosen outcomes are rele-
vant to both health professionals and patients and it is believed that
this can be assisted through PPI in the development process.
Whilst research has investigated PPI in clinical trials and service im-
provement, PPI in the development of COS is yet to be explored; des-
pite some distinct challenges and the need for guidance on how best
to involve patients in COS development. As part of a wider project to
inform methods to facilitate PPI in COS development, we are con-
ducted a review and qualitative meta-synthesis of published COS stud-
ies that have reported on PPI. Meta-synthesis involves the integration
of themes from numerous qualitative studies; the technique is inter-
pretive and yields findings that are ‘greater than the sum of the parts’.
As few published COS studies have reported on PPI, the scope of the
review was widened to also include PPI in the development of
patient-reported outcome measures (proms). It was anticipated that
the challenges encountered in the development of both COS and
proms would be analogous.
Objective
To identify studies which have involved patients and members of the
public (as research partners, co-investigators, advisors or research team
members), to develop COS or proms and describe the ways in which PPI
has been conceptualised and reported in these studies, the methods of
PPI used, and the contexts in which PPI has been employed.
Method
The review is currently underway; we are searching the COMET Initia-
tive’s database of all completed work in selecting COS to identify
studies with PPI. We developed a search strategy to identify PROM
development projects with PPI, via searches of MEDLINE, psycinfo,
hapi and the Cochrane Methodology Register.
Conclusion
Previous research has highlighted the need for guidance on how best
to seek the input of patients and the public in developing COS. As part
Trials 2017, 18(Suppl 1):200 Page 153 of 235of a wider project investigating PPI in COS development, the findings
from this review will inform the development of guidelines for the COS
development community on methods for involving patients as research
partners, co-investigators, advisors or research team members. These
guidelines will facilitate improved engagement with patients - one of
the key stakeholders in COS development.
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When evolving the design of a clinical trial, statisticians may spend a
considerable amount of time to optimise certain characteristics of the
proposed trial and there is considerable literature to support such work.
However, the literature is more sparse on the strategic factors that a
statistician should consider when involved with designing an entire
drug development programme. The aim of this work is to use a suitably
anonymised case study to inform the practising statistician about the
considerations for strategic drug development. Through liberal use of
scenarios covering topics such as Target Product Profile (TPP), Clinical
Development Plans (CDP), gating criteria and probability of success we
will offer suggestions for how a statistician can contribute to strategic
drug development. Many concepts are applicable across a variety of
therapeutic areas even if the technical implementations may differ. It is
hoped that with a wider understanding of strategic drug development,
more statisticians can be better equipped to contribute to the cross-
functional teams who perform this type of work when the plans are be-
ing developed for how to turn a molecule into a medicine.
P406
Challenges in teaching clinical trials: the experience of teaching
biostatistics in online post-graduate academic courses, target to
industrial biometrician
Laura Cavaliere1, Egle Perissinotto1, Ileana Baldi1, Beatrice Barbetta2,
Dario Gregori1
1University of Padova; 2Rottapharm Biotech
Correspondence: Laura Cavaliere
Trials 2017, 18(Suppl 1):P406
Background
At today, new technologies and widespread web access are moving
the traditional face-to-face teaching towards online and open digital
teaching processes. New technologies provide widespread flexible
and convenient learning tools overcoming any temporal and geo-
graphical constrains. The instances of innovation gradually enhanced
higher education institutions towards new models of e-learning. The
challenge is furtherly hard for teaching Biostatistics to health profes-
sionals and medical students, who are in general very little motivated
to learn statistics in the traditional academic courses.
Material and methods
In the academic year 2015/2016, first in the teaching experience at
the University of Padova, two fully online post-graduate courses of
Biostatistics were established: the first one taught basic biostatistics
and research methodology; the second one, advanced topics in
biostatistics. The courses were organized into two phases: modules
dealing with structured topics (25 weeks, each unit from 2 to
5 weeks) and a project-work (20 weeks). To perform statistical ana-
lysis, the R software was adopted. The student-centered model was
used instead of the traditional teacher-centered model. Each student
independently manages her/his access to the web pages contents,
without limits in number of accesses, within the timetable. She/he
attends the didactic activities individually, preforming self-test and
participating in the discussion online. From the teaching point of
view, the face-to-face lessons components of contents, interaction
and assessment were translated into digital and online contents and
tools; from the logistic point of view, the publication time of thework tools was planned, the quality and accessibility of platform was
conveniently tested and the students’ Access to the platform was
monitored. The computerized portal for education was based on
MOODLE platform. To realize the fully online courses, different tools
were built: streaming videos (10–40 minutes) with in person teachers’
explanation, slides highlighting central concepts, self-tests with
multiple-choice questions and simulation-based tests with unlimited
access, and homework with supervisor. Moodle platform allowed stu-
dents for documents download and upload. At the end of each mod-
ule a questionnaire regarding the assessment of teaching has been
reported, the questions were proposed in a Likert scale from 1 to 10.
Results
Twelve students in the basic course and thirteen in the advanced
course were able to access to Moodle platform. Most of the students
were workers. Median number of individual accesses to Moodle plat-
form was 458 for the basic course and 931 for the advanced one. They
mostly appreciated: self-administration of hour, number and time of ac-
cess and stimulating discussion board online. They reported as worst
limits: inadequate preliminary knowledge to understand new biostatis-
tics concepts (median score 6.3 for the basic course, 6.6 for the ad-
vanced one), too elevated study load in the advanced course (median
score 6.7), time-spending searching concepts in videos during study
and reviewing topics due to streaming modality.
Conclusion
Our experience supports feasibility and efficacy of online distance
learning in teaching biostatistics. The experience suggests elaborating
the following tools: videos length shorter than 20 min, lists of main
concept and definition indicating the position (minute) in videos, wide-
spread operative examples, timely matching of concepts and examples.
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Impressive advances in neonatology have occurred over the 30 years
of life of The Eunice Kennedy Shriver National Institute of Child
Health and Human Development Neonatal Research Network (NRN).
However, substantial room for improvement remains in investigating
and further developing the evidence base for improving outcomes
among the extremely premature. We discuss some of the specific
methodological challenges in the statistical design and analysis of
randomized trials in this population. Challenges faced by the NRN,
applicable to all neonatal trials, include designing trials for unusual
or rare outcomes, accounting for and explaining center variations,
identifying other subgroup differences, and balancing safety and effi-
cacy concerns between short-term hospital outcomes and longer
term neurodevelopmental outcomes. The constellation of unique pa-
tient characteristics in neonates calls for broad understanding and
careful consideration of the issues identified in this presentation for
conducting rigorous randomized trials in this population.
P408
Independent adjudication of neonatal cranial ultrasound scans in a
pilot randomised trial
Lucy Bradshaw1, Jon Dorling2, Lelia Duley1, Lindsay Armstrong-Buisseret1,
Joe Fawke3, Bernard Schoonakker4, Eleanor Mitchell1, Rob Dineen5
1Nottingham Clinical Trials Unit, University of Nottingham; 2Early Life
Research Group, University of Nottingham; 3Leicester Neonatal Service,
University Hosptials Leicester NHS Trust; 4Nottingham Neonatal Service,
Nottingham University Hospitals NHS Trust; 5Division of Clinical
Neuroscience, University of Nottingham
Trials 2017, 18(Suppl 1):P408
This abstract is not included here as it has already been published.
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Background
Trials are essential but often inefficient. Some of this inefficiency is
due to designs that burden both trial participants and trial teams
with measurements that are not essential to answer the trial’s main
research questions. Trialists are generally good at selecting their pri-
mary outcomes - the outcomes they consider most important. Trial-
ists have less focus when it comes to secondary outcomes.
Method
A random selection of 115 protocols for publicly funded, randomised
trials published 2010–2014 were selected (roughly 24 per year) for
analysis. To date, twenty trials have been examined. The primary and
secondary outcomes were extracted from protocols. Data on time to
complete each outcome were sought from protocols; where timing
was not available, these data were requested from the corresponding
author, or from trial managers familiar with the outcome. To date,
twenty trials have been examined.
Results
Trialists spend much more time on secondary outcomes than primar-
ies. This is not surprising; there are more secondary outcomes. What
is more surprising is how much more: some trials spend more than
20 times as much time collecting secondary outcome data as primary
outcome data. As an example, one trial spent 66 hours collecting
primary outcome data and 1466 hours on secondaries. Using UK
costing data, this is approximately £2908 on primary data collection
and £63990 on secondaries. Trials that spend less than 10% of data
collection effort on primary outcomes seem common. The median ra-
tio of time to obtain primary to secondary outcomes is 1:8.
Conclusions
Trialists routinely spend a far greater proportion of their time
obtaining outcomes that they themselves deem of lesser import-
ance than they do on primary outcomes. Given the significant ex-
pense of collecting data and the widely reported fact that much
trial data goes unreported, we suggest that trialists should have an
increased awareness of the burden and cost associated with each
outcome when making their selections.
This work is part of the Trial Forge initiative to improve trial efficiency.
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Background
Increasingly, researchers are being asked to demonstrate the impact
of their research to their sponsors, funders and fellow academics.
However, the most appropriate way of measuring the impact of
healthcare research is subject to debate. We aimed to identify the
existing frameworks used to measure healthcare research impact and
to summarise the common themes and metrics in an impact matrix.
Methods
Two independent investigators systematically searched, MEDLINE,
EMBASE, CINAHL+, the Health Management Information Consortium
and the Journal of Research Evaluation from inception until May
2016 for publications that presented an impact framework. We then
summarised the common concepts and themes across frameworks
and identified the metrics used to evaluate differing forms of impact.Results
Twenty-four unique frameworks were identified, addressing five broad
categories of impact: (1) ‘Primary research-related impact’, (2) ‘Influence
on policy-making’, (3) ‘Health and health systems impact’, (4)
‘Health-related and societal impact’, and (5) ‘Broader economic im-
pact’. These categories were subdivided into 16 common impact
subgroups. Authors of the included publications proposed 80
different metrics aimed at measuring impact in these areas.
Conclusions
The measurement of research impact is an essential exercise to help
direct the allocation of limited research resources, to maximise bene-
fit and help minimise research waste. This review provides a collect-
ive summary of existing impact frameworks, which funders may use
to inform the measurement of research impact and researchers may
use to inform study design decisions aimed at maximising the short,
medium and long-term impact of their research.
Keywords: medical research impact, impact metrics, research impact
framework
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Background
The usefulness and importance of a core outcome set (COS) is well
recognised, as is the need for patient participation in its develop-
ment. A COS needs patient input to ensure it is credible and that
future studies using the COS can provide patients and clinicians
with relevant knowledge regarding interventions, consequently re-
ducing the amount of wasteful research. Researchers are increas-
ingly aware of this and are progressively including patients and the
public alongside other stakeholders in identifying what outcomes
to measure in clinical trials. Whilst only 22% of 300 published COS
reported that there was input from patients in their development,
nearly 90% of 146 ongoing studies report including patients in
some capacity. However, nobody knows the best methods for facili-
tating the participation of patients in COS development. There are
numerous challenges in enabling patient
Participation in a COS study and these will depend on the pa-
tient group and the methods chosen. Therefore, this project aims
to investigate and develop methods for including patients as par-
ticipants in COS development in a meaningful and productive
manner.
Objectives
To investigate which methods are being used by COS developers to
facilitate patient participation in ongoing studies and the rationale
behind using that method.
Methods
The COMET database currently has 146 ongoing registered studies,
of which 124 aim to include patient and public representatives. We
will identify the COS developer leads for these studies and invite
them to participate in a short online survey. The survey will establish
the capacity in which patients are being included (involvement vs.
Participation), developers’ methods for enabling patient inclusion,
and their rationale for choosing a particular method(s). This survey
will be conducted in English.
Expected results
The results will provide insights into the COS developers’ Plans
and rationale for facilitating patient participants in their studies.
Details about methods used for recruitment (social media, NHS
services etc.) And methods used for eliciting the outcomes will be
obtained (qualitative interviews, Delphi survey etc.). We will also
establish the reasoning for using these methods. We will then use
this information to purposively sample COS developers and pa-
tients to participate in a subsequent qualitative interview phase
of our study.
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Objective
To provide a comprehensive review of the methodological challenges
in designing trials where progression in the brain is the primary end-
point and to provide concrete clinical design recommendations.
Background
The presence of brain metastases in cancer patients often indicates
poor prognosis. Additionally, the presence of brain metastases can
directly impact a patient’s quality of life. Controlling brain disease is im-
portant and has been one current focus of clinical trials and retrospect-
ive reviews [Preusser et al., Eur J Cancer 2012; Lin, ecancer 2013].
However, there are challenges in conducting such studies and interpre-
tations of results are not uniform. For instance, patients may progress
extracrainially before progression in the brain can be assessed, thereby
creating a competing risks analytic setting. Assessing true brain recur-
rence versus radionecrosis and the use of consistent criteria to assess
brain recurrence have also been methodological issues.
Methods
Simulations modifying the following factors 1) sample size, 2) censor-
ing, 3) effect size, 4) correlation between competing events, 5)
degree of endpoint misclassification (pseudo-progression), and 6)
method used for analysis (Kaplan-Meier, Cox regression, cumulative
incidence, subdistribution regression) are conducted. The effect of
these factors on power and type I error in Phase II clinical trials are
reported.
Results
Simulations on the randomized phase II design show that per arm sam-
ple sizes of 75 to 100 have sufficient power to detect hazard ratios in
the range of 1.7 and 2.0 where the endpoint is brain-specific. Higher
correlation between competing risks (e.g. Brain vs systemic progres-
sion) and the method used for analysis (e.g. Cause-specific hazard or
cumulative incidence subdistribution) have effects on sample size.
Misclassification of the endpoint (eg pseudo- progression) also has a
demonstrable effect on inference. These simulation findings will be de-
scribed in detail. Results from ongoing simulations under other Phase II
designs will also be described along with design recommendations.
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Objectives
The aim of this study was to investigate the benefit of adjudication
of stroke type at trial entry in a large stroke trial. The three objectives
were to: (1) compare stroke diagnoses made by site clinicians and in-
dependent adjudicators; (2) assess the impact of adjudication on the
primary analysis and a subgroup analysis by stroke type; (3) using
simulation, explore the effects of increasing levels of misclassification
on analyses.
Methods
The Efficacy of Nitric Oxide in Stroke (ENOS) trial examined the safety
and efficacy of glyceryl trinitrate (GTN) versus no GTN in patients
with acute ischaemic or haemorrhagic stroke. Independent expert as-
sessors, referred to as adjudicators, who were masked to treatment
allocation, centrally assessed cranial scans to inform diagnosis of
stroke type. For this study, diagnoses made by local site clinicians are
referred to as Hospital diagnosis, whilst diagnoses with input from in-
dependent adjudicators are referred to as Trial diagnosis. The Trialdiagnosis was the diagnosis used in all ENOS analyses. Agreement
between Hospital and Trial diagnoses was determined using un-
weighted kappa. The trial primary analysis and subgroup analysis
by stroke type were re-analysed using Hospital diagnosis as base-
line covariate and interaction factor respectively. Statistical simulations
were created to: (1) increase misclassification of Hospital compared
with Trial diagnosis; (2) introduce an interaction (subgroup effect) be-
tween ENOS treatment arm and stroke type.
Results
Of 4011 participants randomised, 3857 (96%) had baseline scans
that were assessed by adjudicators. There was excellent agreement
between Hospital and Trial diagnoses (crude agreement 98%,
unweighted kappa, k = 0.92). Adjudication of stroke type had no
impact on the primary outcome (p = 0.95) or subgroup analysis by
stroke type. These findings were robust to all except the most
extreme simulated non-differential misclassification of stroke diag-
nosis and subgroup effect.
Conclusion
This study found that clinicians at ENOS trial sites largely were correct
in their diagnosis of stroke, and adjudication did not impact on the trial
results. Diagnostic adjudication may be important if diagnosis is com-
plex and a treatment-diagnosis interaction is expected. Researchers
should consider the value adjudication may bring to their study by
using pilot or feasibility studies to estimate misclassification and poten-
tially avoid substantial resource implications.
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Background
Blinded endpoint review committees (BERCs) comprise of a panel of
clinical experts blinded to trial allocation. They are responsible for
reviewing trial outcome data reported by participating centres, to
?A3B2 show $132#?>ensure they meet the protocol-specified criteria.
This can be particularly useful for outcomes which are complex to
assess, include subjective components, or when the original data
collection could not be blinded.
SIFT (ISRCTN: 76463425) is an open-label multicentre randomised
controlled trial of a feeding intervention in very preterm or very low
birthweight infants in neonatal units in the United Kingdom and
Ireland. Infants were randomised to receive either a faster rate of
feeding (30 ml/kg/day) or a slower rate of feeding (18 ml/kg/day).
BERCs were set up to assess the incidence of two primary short-term
outcomes; late onset invasive infection (LOII) and necrotising entero-
colitis (NEC).
Objective
To ascertain the impact of the BERC review on the reported inci-
dence of LOII and NEC, compared to those derived from the original
data collection forms (DCFs).
Methods
Pairs of BERC reviewers independently reviewed Gut Signs and Infec-
tion dcfs, feeding log data and any additional data requested (e.g.
Discharge summaries) and completed a diagnostic classification form.
These were cross-validated for discrepancies and referred to a third
BERC reviewer if agreement could not be reached.
The incidence of LOII and NEC were calculated for each arm before
and after BERC review; firstly, using data obtained from the Gut Signs
and Infection dcfs, applying an algorithm detailed in the statistical
analysis plan; and secondly, using the diagnostic classifications deter-
mined by the BERC.
For both outcomes we compared the risk ratio (fast/slow) and 95%
confidence interval derived from the DCF and BERC classification.
For each arm we also investigated the concordance between the
classification of infants before and after BERC review, using the
kappa statistic and mcnemar’s test.
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There was little change in the risk of LOII for either arm, however
there was a slight reduction in the risk ratio for NEC after BERC re-
view; (RR 0.89, 95% CI 0.65 to 1.23) compared to (RR 1.00, 95% CI
0.73 to 1.36).
There was strong concordance between the classification of infants
before and after BERC review, with over 95% agreement for both
outcomes in both arms. Among the discordant cases the original
DCFs were more likely to classify an infant as a case than the BERC,
however this discordance was only marginally statistically significant
for NEC in the fast feeding arm (p = 0.04).
Conclusion
The two methods were highly concordant, however, there was
marginal evidence that unblinded local investigators were more
likely to assign a diagnosis of NEC in the fast feed arm, in infants
deemed not to have NEC by the BERC. This may suggest a poten-
tial bias, reflecting concerns about rapid advancement of feeds
and its possible effect on the gut. Thus, while the addition of
BERC reviews did not alter the conclusions of the trial, this investi-
gation highlights their importance in reinforcing confidence in
the outcome results.
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Background
The choice of outcome measure is a critical decision in the design of
any clinical trial, but many phase III clinical trials in critical care fail to
detect a difference between the interventions being compared. This
may be because the surrogate outcomes used to show beneficial ef-
fects in early phase trials (which informed the design of the subse-
quent phase III trials) are not valid guides to the differences between
the interventions for the main outcomes of the phase III trials. We
did this review to determine the variability in reported surrogate out-
comes in early phase, critical care trials.
Methods
We undertook a systematic review to generate a list of outcome
measures used in early phase critical care trials. We searched for trials
published in the six top-ranked critical care journals between 2010 and
2015. The review was conducted according to the protocol
published on the PROSPERO website (http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42015017607). We searched
MEDLINE and EMBASE using key words such as intensive care unit, crit-
ical care and randomised controlled trials. Two independent reviewers
were involved in the search and article screening. All articles meeting
inclusion criteria and published in 2010 were selected for data extrac-
tion and data saturation was achieved during this process. Therefore,
we included only an additional 10% of the articles from 2014 and 2015
to boost the sample with some more recent papers. We extracted de-
scriptive data including trial registration details, outcome measures re-
ported in the methods, definition, and time-points. We classified
outcomes into body organ systems, severity of disease and quality of
life with sub-categories based on clinical judgement, and tabulated
them to understand underlying patterns and variations.
Results
A total of 5448 references were screened. The total number of in-
cluded articles was 48, and based on the preliminary analysis, these
mentioned over 300 outcomes in their methods sections. Focusing
specifically on outcomes reported in the respiratory category, there
were ten sub-categories and the number of different outcomes in
the subcategories. The reported outcome measures were analysedand reported in a variety of ways. The definition of specific measure-
ment (mechanical ventilation), participant level analysis metric (dur-
ation of mechanical ventilation or time to extubation), method of
aggregation (mean & SD or median & IQR) and time points vary
across trials.
Conclusions
There is large variability in outcome reporting in early phase, critical
care trials. This creates difficulties for synthesizing data in systematic
reviews and planning definitive trials. This review highlights an ur-
gent need for standardization and validation of surrogate outcomes
reported in critical care trials. Future work will validate and develop a
core outcome set for surrogate outcomes in critical care trials.
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Objective
The use of controlled vocabularies like meddra are essential to prac-
tical useful adverse event (AE) reporting, but have limitations. The
use of autocoding in meddra allows objective mapping of verbatim
terms (VT) to preferred terms (PT) but can result in the listing of clin-
ically identical events into a variety of effectively synonymous PT, an
effect we call splintering. A potential solution involves a clinician
grouping these splintered PT into a single collapsed PT relevant to
the medical context of the trial. Both splintering and collapsing AE
have the potential to obscure safety signals.
Methods
We reviewed all AE reported in two clinical trials performed in
our clinical trials network, protect (NCT00822900) and ATACH
(NCT01176565) both of which were reported in the New England
Journal of Medicine. For each trial, a splintered and collapsed list
of PT were compared. Protect published the collapsed list and
ATACH the splintered list. Splintered lists were generated primar-
ily by autocoding, with manual coding by a data manager during
the conduct of the trial when autocoding failed. Collapsed lists
were generated from the splintered lists using clinical judgement
by the trial investigators in protect at the end of the trial. For
ATACH, the collapsed list was generated in part by investigators
at the end of the trial and in part by the authors of this abstract.
All splintered and collapsed lists used only meddra PT. Descrip-
tive statistics were used to characterize and compare splintered
and collapsed AE lists.
Results
Substantial splintering was found in both trials. 3032 AE occurring
in 810 patients in protect were coded under 399 unique PT in the
splintered list, and under 235 unique PT in the collapsed list. Simi-
larly, in 1000 subjects enrolled in ATACH, 3140 AE were coded
under 344 unique PT in the splintered list and 193 unique PT in the
collapsed list. There were 235 and 193 collapsed PT terms in pro-
tect and ATACH respectively and collapsed terms included a mean
of 3.00 splintered terms with a range of 2 to 9 PT. Illustrative exam-
ples of splintered and collapsed terms in these two trials include:
bronchopneumonia, lung infection, pneumonia aspiration, and 7
other PT that collapsed under the PT ‘pneumonia’; and embolic
stroke, cerebral artery embolism, cerebral infarction and 5 other PT
clinically equivalent to the collapsed PT ‘ischemic stroke’. An ex-
ample of the potential effect of splintering was found in ATACH
where splintered terms related to renal injury were similar between
the two treatment groups as individually reported, but demon-
strated a potentially significant difference when collapsed.
Conclusions
We have demonstrated that autocoding AE VT to PT in meddra is
objective but results in significant splintering as compared to
clinically relevant collapsed terms, obscuring medically important
safety effects. Use of clinical judgement to combine effectively
synonymous PT is subjective, but is a practical solution.
Trials 2017, 18(Suppl 1):200 Page 157 of 235P417
What does qualitative case study methodology have to offer the
interpretation of findings from trials of complex interventions?
Reflections from a large complex intervention study
Caarol Bugge1, Aileen Grant1, Sarah Dean2, Jean Hay Smith3,
Doreen McClurg4, Suzanne Hagen4
1University of Stilring; 2University of Exeter; 3University of Otago;
4NMAHP RU, Glasgow Caledonian University
Correspondence: Caarol Bugge
Trials 2017, 18(Suppl 1):P417
The contribution qualitative research can make to improving interven-
tion and trial design, evaluation and implementation is well recognised
(O’Cathain et al., 2014; Moore et al. 2011). Qualitative methods are often
used alongside quantitative methods within a process evaluation to ex-
plore trial processes, intervention components and mechanisms in rela-
tion to context (Grant et al. 2013). This paper describes the use, and
presents the advantages, of a two-tailed qualitative case study meth-
odological design linked to a trial of a complex intervention for women
with urinary incontinence (UI) (OPAL ISRCTN 57746448).
OPAL (optimising pelvic floor exercises to achieve long-term benefits) has
three elements: a large multi-centre trial, a mixed methods process evalu-
ation, and a longitudinal qualitative case study. The trial investigates the
effectiveness of biofeedback intensified pelvic floor muscle training
(PFMT) versus PFMT alone in improving UI symptoms for women with
stress or mixed UI. The case study is a two-tailed design, one tail is the
control (PFMT) the other the intervention (intensified PFMT), exploring
the views and experiences of trial women about UI and the interventions
to identify barriers and facilitators to intervention delivery and adherence
and to inform potential roll-out of the intervention.
Case study methodology is advocated for exploring real life phenom-
ena within a contemporary context. The nature of the design lends it-
self to addressing questions that aim to understand, in detail, how or
why events occur. The two-tailed design, offers a comparative focus; in
the case of clinical trials the tails can be the control and intervention
arms enabling comparison of relevant features of the control and inter-
vention. OPAL uses a two-tailed longitudinal case study, where women
are interviewed at four time points (baseline, post-treatment, 12 months
and 24 months post-randomisation); mirroring the trial data collection.
The nature of the analysis encourages a move beyond description to
explanation; for example, identifying factors that may interact to influ-
ence participant outcomes, and the mechanisms of action.
In the OPAL qualitative longitudinal study the aim is to understand
the links between context, delivery, and outcomes in each arm for
women with UI. In a complex intervention such as that evaluated in
OPAL, many factors could impact on the final outcome for a woman;
only some of these factors may relate to intervention delivery. For
example, women are asked to exercise at home in both trial arms
and in the intensified arm women are asked to use biofeedback to
support PFMT at home. There may be many psychological, social, or
practical variables that influence a woman’s ability to use biofeed-
back, or do this in the home environment. The case study design
aims to support the identification of these factors and, importantly,
how their influence may differ on the trial primary outcome (UI at
two years) between the control and intervention arms.
In this paper we will explore: 1. The nature of case study methodology.
2. Why case study methodology might be useful for qualitative studies
linked to complex intervention trials. 3. Lessons for researchers from
our use of case study methodology within OPAL.
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Self-management (SM) is endorsed by clinical guidelines for osteo-
arthritis (OA) and chronic low back pain (CLBP), but there is a current
lack of multi-joint interventions to target both conditions in group
settings. The 6 week group-based self-determination theory (SDT)
driven education and exercise SOLAS intervention was developed in
consultation with primary care physiotherapists through the interven-
tion mapping process. Following Medical Research Council (MRC)
guidelines for complex interventions, the SOLAS cluster randomised
controlled feasibility trial aims to assess the (1) acceptability and
feasibility of the SOLAS intervention to patients and physiotherapists
compared to usual individual physiotherapy, (2) feasibility of trial
procedures and sample size for a definitive trial and (3) effect on
secondary outcomes. The aim of the present study was to explore
physiotherapists' views of the SOLAS intervention’s acceptability and
feasibility.
Methods
Individual semi-structured telephone interviews were conducted by
an independent researcher with 10 physiotherapists (PTs) within
one week of their completion of delivery of the SOLAS intervention
in the feasibility trial. The interviews were audio-recorded, tran-
scribed verbatim and analysed using inductive thematic analysis,
based on Braun and Clarke’s method. Coding frames were developed,
re-examined and refined. The reliability of the identified themes was
established by a second researcher who independently coded a ran-
dom sample of 25% of the data using the coding frame, with 70%
agreement taken as the minimum cut-off rate of agreement.
Results
Twenty-six themes were identified that related to six topics; i.e. 1)
overall views of the intervention; 2) experience of implementing the
intervention; 3) changes made/suggested to the intervention; 4)
views on participants’ experience of the intervention; 5) perception
of the intervention’s feasibility for future delivery; and 6) views and
experiences of training, and were mapped to the feasibility criteria:
acceptability, demand, implementation, practicality, adaptation and
integration.
PTs were positive about their experience of training and implementing
the SOLAS intervention and its support materials to a mixed group of
participants, reporting it acceptable and feasible to deliver. Key de-
mands in delivering the intervention that impacted on implementation
included the high volume of education content during class one, which
required shortening the exercise session, and the challenge of using
the needs supportive communication skills during goal setting and the
group exercise component, highlighting the need for additional train-
ing. However, PTs felt that overall they implemented the intervention
content and structure according to the protocol. Some PTs reported
adapting the education component to include additional information
based on their clinical expertise and participant needs. Practical consid-
erations for future integration of the intervention into health services
included attaining a minimum of six participants to run a successful
group, the accessibility of the intervention in some primary care set-
tings, and the need to address health literacy for some participants.
Conclusions
The SOLAS intervention content and support materials were considered
acceptable and feasible to deliver within the trial and in future health-
care services provided sufficient numbers of clients could be enrolled
and retained. Further training in the intervention SDT-based needs sup-
portive communication skills is being developed through E-learning.
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Image modification journaling for reproducibility and fraud
prevention
Paul Thompson
Sanford Research
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Background
In scientific discussions, images are analyzed to make scientific points.
In basic biology, in clinical trials, in clinical research, images are used to
present information, show differences between conditions, and define
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by rules which have been defined by editors of scientific publications.
The images can be cropped (to select parts of a larger image). The con-
trast of the image can be increased so long as the changes are made
over the entire image. The colors of the image can be adjusted over
the entire image. Images can be places together, so long as it is clear
what is done to the final image and that the component portions are
not part of the original image (this can be done by lines of a black
color). In recent years, the amount of fraudulent manipulation in im-
ages is becoming alarming. Fraud takes many forms, including re-using
the same image for different purposes, adding new components to an
existing image without clear markings and so forth. Image fraud is fre-
quently discussed on the Retraction Watch blog.
Results
Several new approaches are presented here for partial solutions to
these problems. When images are manipulated in an interactive tool,
a record of the actions can be kept. This is called a “journal”. This is a
common part of a number of statistical analysis programs (JMP keeps
a journal of analysis steps, which can then be used to analyze the
data). GIMP has been modified to journal the process of manipulat-
ing the image to allow the process to be repeated and to allow in-
spection of the process. A shiny app (in R) has also been created to
perform analysis and journal that analysis using imagemagick code.
By making the process of image analysis transparent, fraud in the
image manipulation will be reduced.
Presentation
Several examples of image manipulation will be presented to demon-
strate this new tool and capability. Other image manipulation programs
will be discussed to determine if the capability can be extended to
them.
P420
Perceptions and experiences of participant recruitment:
a qualitative interview study with trial stakeholders
Heidi Gardner, Katie Gillies, Shaun Treweek
University of Aberdeen
Correspondence: Heidi Gardner
Trials 2017, 18(Suppl 1):P420
Background
Recruitment to randomised controlled trials can be extremely difficult,
and poor recruitment can lead to extensions to both time and budget,
potentially resulting in an underpowered study which does not satisfac-
torily answer the original research question. In the worst cases, a trial
may be abandoned, causing huge waste. Consequently, recruitment is
considered the number one problem in trial methods research.
Objectives
To understand how the process of participant recruitment impacts
the day-to-day lives of those charged with the task, we conducted a
qualitative semi-structured interview study with a wide range of trial
stakeholders. This study will help trial methodologists to understand
the challenges that trial recruitment generates on the ground, which
will enable them to better design future research work so that its re-
sults are more relevant and applicable to the challenges faced by
those tasked with recruiting individuals to trials.
Methods
A mix of purposive and convenience sampling generated trial stake-
holders that represented views of those that work within the Na-
tional Health Service, academia and industry. Individuals categorised
themselves as “designers”; those directly responsible for the design
or recruitment methods, or “recruiters”; those who implement recruit-
ment strategies to recruit participants to trials. Currently we have de-
veloped an interview topic guide that will allow us to investigate and
explore the views of trial designers and recruiters. We will also ex-
plore how best to present research evidence about recruitment
methods so that evidence-based recruitment strategies are effect-
ively disseminated and implemented.
Results
Role type and recruitment experiences were varied, spanned various
therapeutic indications, intervention types and trials units. Our samplewas mainly UK based but does have some representation from
further afield. Interviews are scheduled for fall 2016. We have
approached 27 individuals in roles such as Research Nurse, Head of
Patient Engagement, Clinical Trial Educator, Senior Research Man-
ager and Professor of Health Services. Everyone we approached
agreed to take part, giving our sample a split of 14 “recruiters” And
13 “designers”, 23 of which are UK-based, 1 from Holland, 2 from
South Africa and 1 from Italy. A Framework analysis approach will
be used to analyse the data from one-to-one interviews. Antici-
pated and emergent themes will be identified, defined and linked
through continual comparison of data both within and across
stakeholder groups.
Conclusions
The results of this study will give a clear description of current recruit-
ment practice. This is turn will make it easier for trial methodologists
and others to design and present evidence-based recruitment strat-
egies and highlight what sort of evidence future research should
provide.
This work is part of the Trial Forge initiative to improve trial efficiency.
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Over the last several years, oncology drug development has fo-
cused on molecularly targeted agents necessitating development
of early phase clinical studies driven by a need to better under-
stand underlying molecular mechanisms, provide delivery of tar-
geted interventions in enriched patient subgroups and evaluate
biological outcomes. Given the relatively safe profile of these tar-
geted therapies, dose-finding clinical trials aim to evaluate both
toxicity and biological effectiveness. An isotonic regression model
was utilized in the design and conduct of a dose escalation trial to
determine an admissible set of drug doses based on toxicity out-
comes and selects the lowest dose with the highest biological re-
sponse rate within the admissible set of doses. Simulations under
different scenarios of dose toxicity and biological effectiveness
rates demonstrate optimal operating characteristics of this design
based on high selection probabilities of the correct safe and bio-
logic effective dose, increased number of patients allocated to the
right dose and low toxicities on the correct dose. Implementation
of the isotonic regression is underway to guide dose escalation de-
cisions. We present the performance of the model based on ob-
served toxicity and pharmacodynamic (PD) biological response at
each dose level as well as varying scenarios of toxicity and PD rates.
As expected, dose escalation was guided by doses closest to the
target biologic response rate within doses with acceptable toxicity
rates. We also present comparison of performance and dose escal-
ation decisions of this model compared to algorithm-based method
for assessing biological or tumor response rate for dose escalation
recommendations. The application of this model has provided a
flexible and efficient use of limited patient data to determine not
only safety but incorporation of proof of concept of biological re-
sponse in the very early phases drug development.
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Support for the use of qualitative methods within trials is widely
recognised; however, reports indicate their full potential is not being
realised, and issues ensue with the visibility, recognition and report-
ing of the qualitative approach in trials. It is important to understand
the global view of the historical and contemporary make-up of quali-
tative research linked to trials if we are to identify potential areas of
improvement. As part of a larger project to explore patterns in, and
status of, the use of qualitative methods in trials, a review of trial
registries was conducted to determine the extent of qualitative
methods' use in trials.
Methods
A search of clinical trials registers (globally) was conducted and deci-
sions were made as to the suitability of the registry. Included registries
were searched using the term ‘qualitative’ and returns logged and
analysed by; 1. Year Registered 2. Country of Sponsor 3. Type of Trial
(Drug, medical device, surgical or other). Trials were only included if the
researcher confirmed that they included qualitative methodology (i.e.
Using qualitative data collection methods and analysis techniques).
Trials reporting qualitative testing and statistical analysis were excluded
(i.e. ‘qualitative’ was tagged to quality of life measures, reports about
medical tests were included such as ‘qualitative urine test’ or statistical
tests, such as ‘qualitative Fishers Extract test’ were in evidence). Initially,
all registers were searched from first record available up to 31st
October 2013. The activity was repeated to update records up to
November 2016.
Results
Three registries were included and searched; clinicaltrials.gov, Inter-
national Standard Randomised Controlled Trial Number Register
(ISRCTN) and World Health Organisation (WHO) International Clinical
Trials Registry Platform (ICTRP). The initial search in 2013 found an
extremely small proportion of the 382,944 trials being carried out
worldwide were utilising qualitative methods. The overall percentage
of registered trials confirmed as including qualitative methods was
less than 0.2%. This number appears to have increased over time,
but is limited to ‘developed countries’ such as the U.K. and U.S.A.
Most trials using qualitative methods appeared to be non-clinical,
and were mostly testing behavioural interventions (87%). Of the
small percentage of those trials which appeared clinical in nature,
drug trials appeared to utilise qualitative methods more than either
medical device or surgical trials (7%, 4%, 2% respectively). This was
consistent across the three trial registries. Early indications from the
repeated 2016 activity show a continuation of the initial pattern of
less than 0.2% of a total 428,175 trials recorded using qualitative
methods. Full findings will be reported at the conference.
Conclusions
This study has highlighted the increasing use of qualitative methods
over time and the use of these methods worldwide. However, the
use of qualitative methods is restricted to ‘developed countries’ and
non-clinical trials. More needs to be done to increase the use and
benefits of qualitative methods in ‘under-developed’, or ‘developing’
countries, and the reasons for their lack of inclusion in clinical trials
needs further investigation and development.
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Background
A frequent problem in clinical trials is the failure to attain complete
outcome data for all randomised participants. Loss to follow-up (attri-
tion) is problematic as it can introduce bias and reduce the power of
a trial. However, until recently the main focus has been on enhancing
recruitment rather than retention. As part of a multi-method study,
this qualitative study, sought to explore retention strategies used bytrial teams within ongoing trials and factors which may influence the
adoption of such strategies.
Methods
A purposive sample of five trials was selected from the NIHR HTA
portfolio of ongoing trials. Semi-structured interviews explored strat-
egies utilised by trial teams when collecting outcome data and in
retaining participants. With the aid of nvivo, the interview data were
analysed thematically using techniques of constant comparison.
Results
Nineteen semi-structured interviews were conducted with trial team
members along with three supplementary interviews with experi-
enced senior trial managers. Participants recognised the context of
the wider focus on recruitment to the detriment of retention by
limiting motivation and resources to maximise retention. In trial re-
searchers’ accounts, their retention practices were shaped by factors
which were recognised and conscious, and unrecognised and
unconscious.
Interviewees recognised that fostering positive relationships with
participants was a key strategy for enhancing participant retention.
Interpersonal connections were forged by social relational actions
such as making cups of tea during trial appointments and offering
flexible appointments to suit the participant’s needs. However, these
activities required additional time which the trial researchers felt was
not always acknowledged by funders or valued by the wider trial
team.
Interviewees were not aware of how their own ‘moral compass’ influ-
enced retention of participants. However such unrecognised or un-
conscious strategies were present in their accounts. They expressed
how they often utilised their own beliefs and values regarding how
to interact with participants, reflecting for example on how they
would want their own parents to be treated, or projecting their own
feelings onto a situation which may conflict with obtaining data.
The influence of the level of experience of team members on reten-
tion practices also appeared unrecognised. Researchers lacking
experience reported having less confidence to pursue participants
for outcome measure data, especially when participants wished to
withdraw from the trial, worrying about coercion. More experienced
researchers were happy to negotiate with participants in order to
at least collect primary outcome data. Novice researchers presumed
the participants wanted to withdraw from all aspects of the trial
and made no further contact with them.
Researchers recognised that incentives influenced retention but
seemed unaware that incentives may affect their own behaviour.
Trial staff felt more confident and comfortable maintaining contact
with participants over a period of time and more motivated to pur-
sue acquisition of data from participants.
Conclusions
Strategies deployed by trial researchers to enhance retention include
a combination of recognised and unrecognised influences. These are
underpinned by relational factors as well as researchers beliefs about
their responsibilities and professional values. However, the pursuit of
retention is constrained by a systemic emphasis on recruitment.
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Background
Fibrotic Interstitial Lung Diseases (ILD) are rare, chronic and often
progressive conditions resulting in substantial morbidity and mor-
tality. Shortness of breath, a symptom often linked to oxygen desat-
uration on exertion, is tightly linked to worsening quality of life in
these patients. Although ambulatory oxygen is used empirically in
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our knowledge, no studies are available on the effects of ambula-
tory oxygen on day to day life in patients with ILD.
Methods
Ambulatory oxygen in fibrotic lung disease (AMBOX) is a multicentre,
randomized, cross-over controlled trial (RCT) funded by the Research
for Patient Benefit Programme of the National Institute for Health
Research. The RCT will evaluate the effects on health status (measured
by the King’s Brief ILD questionnaire: K-BILD) of ambulatory oxygen
used at home, at an optimal flow rate determined by titration at
screening visit, and administered for a two-week period, compared to
two weeks off oxygen. Key secondary outcomes will include breathless-
ness on activity scores, as measured by the University of California San
Diego Shortness of Breath questionnaire, global patient assessment of
change scores, as well as quality of life scores (St George’s Respiratory
Questionnaire), anxiety and depression scores (Hospital Anxiety and
Depression Scale), activity markers measured by sensewear Armbands,
pulse oximetry measurements, patient reported daily activities, patient
and oxygen company reported oxygen cylinder use. The study also in-
cludes a qualitative component and will explore in interviews patients'
experiences of the use of a portable oxygen supply and trial participa-
tion in a subgroup of 20 patients.
Results
We have completed recruitment of 87 patients to the study which rep-
resents one of the largest such cohorts world-wide. We are presenting
here the trial design and baseline characteristics.
Discussion
This is the first RCT of the effects of ambulatory oxygen during daily
life on health status and breathlessness in fibrotic lung disease. The
results generated should provide the basis for setting up ILD specific
guidelines for the use of ambulatory oxygen.
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Objective
The way trial information is presented is a key determinant of re-
cruitment to randomised controlled trials (RCTs), which can be
modified in order to encourage patients to participate. Recruiters in
a full-scale surgical RCT comparing a surgical procedure with
physiotherapy were trained based on a simple six-step model to
support recruitment (Realpe et al. 2016). This paper shows how the
model was implemented. We compared communication practices
in consultations where patients decided to take part versus those
consultations in which patients declined participation in the trial in
order to validate and expand the six-step model.
Methods
A sample of recruitment consultations with participants (n = 32) and
decliners (n = 28) were recorded during a full-scale RCT. Recordings
were analysed using techniques of thematic analysis and focused
conversation analysis pioneered in previous studies.
Results
Recruitment to trial was successful, with 60% of patients approached
across 20 centres agreeing to take part in the RCT. Recruiters used
the six-step model to structure their consultations. However there
were differences in the way recruiters addressed patient questions
and concerns in participants’ versus decliners’ consultations. Differ-
ences were also observed in patients’ view of the trial, those who de-
clined to take part expressed more concerns and preferences and
asked fewer questions than participants in the trial.
Conclusions
The six-step model provided a useful framework for recruitment to
RCTs that was easy to implement. However further skill developmentto maintain patient equipoise is required when addressing patient
questions and preferences. Patient views and their particular circum-
stances are important factors when deciding whether or not to par-
ticipate in a surgical RCT with a less intensive comparison arm.
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Objective
Multi-centre RCT designs provide robust evidence of therapeutic ef-
fect of health interventions. However participating centres often dif-
fer in how well they conduct the trial and the number of patients
successfully recruited. This paper describes barriers different research
teams encountered when conducting a complex RCT comparing a
surgical procedure with physiotherapy, and the actions taken by the
trial management group to overcome obstacles that were hindering
recruitment.
Methods
We conducted 22 interviews with principal investigators and research
associates at 14 sites involved in the delivery of a surgical RCT that
compared hip arthroscopy and physiotherapy for hip pain. Interview
transcripts were analysed thematically and case study approaches
were utilised to present results to the trial management group.
Results
Research teams reported difficulties related to logistics (e.g. Room
space); motivation (e.g. PI reluctant to approach patients); and skill
(e.g. Lack of knowledge about the treatment arms). Similar Issues
were shared by sites that recruited to target and those that did not,
however there were differences in the team’s response to challenges.
Whilst on-target sites found local solutions to issues or support
through their research infrastructure or the trial TMG, off-target sites
usually did not show proactivity. Site profiles were created and
action plans designed based on aspects that were particular to the
individual sites. These plans were implemented in collaboration with
site teams.
Conclusions
This qualitative study added to the growing evidence of how aspects
of team functioning are important for recruitment to complex RCTs.
Trial Management Groups can help research teams identify and ad-
dress issues, and therefore contributing to a sense of ownership by the
research team. Empowering research teams to find solutions at local
level is essential to conduct multi-centre RCTs successfully.
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Background
Low response rates to participant follow-up questionnaires in trials
place the validity and generalisability of results in jeopardy. Evidence
provided by the iquad Trial demonstrated that using the Theoretical
Domains Framework (TDF) to identify theoretical targets for behaviour
change interventions and incorporating these into a theory-based
cover letter randomly issued to 1192 participants with their postal
questionnaire at year 1 and year 2 of annual follow-up had a beneficial
impact on response rates [1]. Lack of replication of research findings
Trials 2017, 18(Suppl 1):200 Page 161 of 235has been highlighted as a key limitation across health and related disci-
plines. To address this limitation, the strategy was replicated in the
INTERVAL Dental Recalls trial to investigate if the intervention would
improve participant questionnaire response rates in a similar patient
population (primary dental care), with a similar level of non-response.
Method
1867 INTERVAL participants were sent annual questionnaires at year
2 and 3 of follow-up and randomly allocated to receive either the
standard covering letter (control group) or theory-based cover letter
(intervention cohort). The response rates between the groups to both
the iquad and INTERVAL replicated SWAT were estimated with 95%
confidence intervals. A fixed effect meta-analysis was calculated
using the Mantel-Haenszel method.
Results
The participants in both the iquad and INTERVAL trials had similar
baseline characteristics; the mean age of INTERVAL participants was 48.4
(14.9) years, 60% female and iquad participants 47.8 (15.7) years, 64% fe-
male. The response rate in INTERVAL was 67% for the intervention cohort
and 66% in the control group. There was a +1% difference (95% CI −3 to
5%) between groups favouring the intervention. In iquad the response
rate was 72% in the intervention cohort and 65% in the control group.
There was a +7% difference (95% CI +2 to +12%) between groups
favouring the intervention. On meta-analysis of results there is a risk dif-
ference of 3% (95% CI 0 to +7%) in favour of the intervention.
Conclusions
To our knowledge, this is the first true replication of a behaviour
change intervention for improving response rates in a similar popula-
tion. These results indicate that inclusion of a theory-based cover let-
ter with postal questionnaires provides a cheap and effective
method for improving participant response rates by 3% compared
with a standard letter in a dental primary care population. We be-
lieve this study provides strong evidence of the effectiveness of the
intervention in this population. However, the study has raised inter-
esting methodological challenges around when should replication
stop and the role of context (settings and population). As such fur-
ther replication of this strategy is planned in different trial settings
and populations through the Trial Forge initiative (http://trialfor-
ge.org) and through the Medical Research Council (MRC) Hubs for
Trial Methodology Research (https://www.qub.ac.uk/sites/thenorthern
irelandnetworkfortrialsmethodologyresearch/swatswarinformation/) to
add to the evidence base.
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Background
It’s important when designing clinical trials to select an appropriate
method of recruitment. Traditionally research nurses recruit participants
from GP practices. They are often familiar to the patients which could
mean those patients are more likely to enter and complete clinical
trials. A randomised controlled trial to test the effectiveness of a brief
intervention for weight management in primary care compared
practices using research nurses (N = 17) with practices using research
assistants (RA) (N = 44) to opportunistically recruit participants.
Aims
Compare two different methods of recruitment, specifically the effect
on participant enrolment and follow up.
Methods
Data was analysed as proportions. We reported the number of those
enrolled and those being followed up in each group, divided by the
total number eligible and the total number enrolled in each group
respectively i.e. the risk ratio with 95% confidence intervals.Results
93.8% in the RA group and 96.6% in the nurse group (RR 0.97 95% CI
0.94, 0.99) were enrolled of those that were eligible. 58.1% in the
nurse group and 81.1% in the RA group (RR 0.71 95% CI 0.65, 0.79)
were followed up at 3 months.
Conclusions
Research nurses were slightly more effective at successfully enrolling
eligible participants into the trial than research assistants however
the difference between the groups is barely significant. Once en-
rolled, participants were more likely to return for follow up in the RA
group. This significant result suggests that using research assistants
for recruitment is more likely to result in better follow up rates.
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Background
Community based Rehabilitation after Knee Arthroplasty (CORKA) is a
multicentre two-arm individually randomised controlled trial with
blinded outcome assessment at 12 months. It aims to determine if a
multi-component rehabilitation programme, provided to patients who
had knee replacement (KR) and are deemed at risk of poor outcome, as
measured by the Late Life Function and Disability Instrument (LLFDI)
score, is better than usual care.
Objective
To describe the development of the trial’s screening tool to recruit
KR patients at greater risk of poor outcome and who therefore might
benefit more from the intervention.
Methods
The screening tool was developed based on the principles of prognos-
tic model development, using data from the KAT randomized clinical
trial [1] which contains pre-operative and 12 months outcome data on
more than 2,192 KR patients. As a proxy for poor outcome, since the
KAT trial did not include the LLFDI score, poor outcome was defined as
a score 26 in the Oxford Knee Score (OKS). Pre-operative characteristics
considered as candidate predictors in the development of the screen-
ing tool included age, sex, height, body mass index (BMI), mobility, ASA
grade, SF-12 (questions 6 and 11) and OKS (question 1) components.
Multivariate imputation by chained equations (MICE) was used to han-
dle missing data in the KAT dataset. Ten complete datasets were pro-
duced by MICE. One of these datasets was selected at random and
multivariable logistic regression models were fitted to identify the sta-
tistically significant predictors of poor outcome after KR. Predictors
were selected by using backwards elimination (stepwise) procedure.
The final model was aimed to be simple and easy to implement in the
clinical setting, considering both the clinical and statistical relevance of
the predictors. Model simplification was done by rounding up the logis-
tic regression coefficients (odds ratio) of the predictors in the final
model to the nearest integer. Model performance was evaluated in
terms of discrimination and calibration. Discrimination was quantified
by the c-index (area under the receiver operating characteristics curve).
Calibration was assessed by grouping individuals into tenths of pre-
dicted risk and graphically comparing the agreement between the
mean predicted risk and the observed events in each tenth. The cut-
offs to classify individuals at increased risk of poor outcome was deter-
mined with the aim of achieving a balance between model’s specificity
and recruitment feasibility.
Results
Subjects in the KAT dataset were aged 71(SD = 7.1) years on average,
with a mean ASA grade of 2(SD = 0.6). From a total set of nine candi-
date predictors, four were selected for the screening tool: BMI, ASA
grade, OKS question 1 and SF-12 question 6. Model discrimination,
as measured by the c-index was 0.67. The screening tool score range
is 0–10 and patients scoring 5 or more (29% of the KAT sample) are
considered at increased risk of poor outcome following KR.
Trials 2017, 18(Suppl 1):200 Page 162 of 235Conclusions
We developed a simple and objective screening tool to identify pa-
tients at increased risk of poor outcome for inclusion in to the CORKA
randomized clinical trial, with a moderate discriminatory ability.
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Introduction
Decisions about the participation of adults lacking mental capacity in
medical research are complex, and raise considerable legal and eth-
ical issues. There are differences between decisions relating to the
medical treatment of adults lacking capacity, and those concerning
their participation in medical research. Carers and relatives of adults
lacking capacity are regularly called upon to make such decisions on
their behalf, however little is known about the ethical basis on which
these proxy decisions are made and there is a dearth of information
or support available. The coming decades are expected to see a sig-
nificant rise in health challenges resulting from ageing populations,
with a proportionate rise in conditions characterised by cognitive dis-
orders. Ambitious UK research agendas have been set out in order to
address these challenges, however these will require considerable
numbers of research participants.
Background
There are specific legal provisions in England and Wales governing
proxy decision making by another individual, such as a family mem-
ber of friend, for those unable to provide consent for themselves to
participate in research. Data regarding the ethical and regulatory fac-
tors influencing these decisions, and interventions to inform and sup-
port those involved, are urgently required in order to maximise the
participation of adults lacking capacity in research. Research partici-
pants, their families and carers, clinicians and researchers require a
clear, evidence-based ethical framework for research enrolment of
adults lacking capacity. This systematic review forms part of an NIHR
Doctoral Research Fellowship to investigate informed consent and
proxy decision making in research involving adults lacking capacity,
and the development of an intervention to support informed proxy
decision making, set within ethical and legal frameworks.
Methods
A mixed methods systematic review will be conducted to determine
the ethical and legal issues encountered in proxy decision-making
for research participation by adults lacking capacity, using a frame-
work synthesis approach. The aim is to synthesise empirical evidence
from qualitative, quantitative or observational studies which examine
the relevant ethical issues. The review will be registered with PROS-
PERO database of systematic reviews.
Results
The findings from the systematic review will be presented, which will
include an examination of the ethical issues encountered, what fac-
tors are involved when proxy decisions are made, and factors that
affect the quality of informed consent and proxy decision making in
practice. The review will provide an overarching synthesis of proxy
decision-making for research participation, and the development of a
conceptual framework.
Conclusions
This systematic review will examine a range of factors encountered
in research involving adults lacking capacity, and what influence
these and other factors have on informed consent and proxy deci-
sion making in practice. The findings will be used to develop a con-
ceptual framework of proxy decision making which will form the
basis of a subsequent qualitative study to explore how proxy deci-
sions are made, and whether legal and ethical obligations are beingmet. The review and the qualitative study will then be used to deter-
mine the factors that must be included in a decision support inter-
vention for research participation by proxy decision makers for
adults lacking capacity.
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Background
Research into optimising recruitment to RCTs is commonly undertaken,
however there is no agreed method for organising and reporting
studies. Adequately describing and classifying recruitment study types
may enable researchers to evaluate and compare studies more reliably.
Aim
This study developed and applied a categorisation system for differ-
ent recruitment studies, encountered during a systematic review of
recruitment to RCTs in unplanned hospital care (UHC), to inform fu-
ture recruitment research.
Methods
Search strategy
The ORRCA (Online Resource for Recruitment Research in Clinical
Trials; www.orrca.org.uk) database was utilised in this systematic re-
view. ORRCA includes studies of all designs, systematically extracted
from the literature, reporting on recruitment into RCTs and non-
randomised clinical studies. In this review, ORRCA was searched for
primary research reports of studies that reported on recruitment to
RCTs in adult patients receiving UHC.
Development of study categories Reading the articles led to initial
categorisation of the recruitment studies into those with a rando-
mised or non-randomised recruitment designs. Iterative refinement
of the study structured categories through discussion between study
authors (CR, JMB, LR, JR).
It was noted that papers reporting surveys in the community (commu-
nity consultations) had been undertaken to establish the likelihood of
recruitment success or acceptability of a trial. In recognition of this, a
clear differentiation was made between studies that focused on recruit-
ment to an actual clinical RCT (a ‘host RCT’) versus potential recruitment
to a RCT that did not yet exist (a ‘hypothetical RCT’).
Latterly a further categorisation was introduced to classify whether
the recruitment study evaluated an intervention to modify recruit-
ment, or simply reported on recruitment experiences. The final classi-
fication for papers was formulated based on whether i) randomised
or non-randomised study design was employed during the recruit-
ment study ii) an intervention to optimise recruitment was evaluated,
and iii) a host or hypothetical RCT was used.
Category A - Randomised controlled trials of interventions to optimise re-
cruitment within one or more host RCTs Category B - Non-randomised
studies of interventions to optimise recruitment within one or more host
RCTs Category C - Non-randomised studies without interventions evaluat-
ing recruitment to one or more host RCTs Category D - Randomised
studies to consider recruitment within proposed hypothetical RCTs
(community consultations) Category E - Non-randomised studies to
consider recruitment within proposed hypothetical RCTs (community
consultations).
Results
3114 papers were available in ORRCA and 39 met the inclusion cri-
teria. The new categorisation was able to be applied to all papers
with 1, 11, 16, 0 and 11 within categories A to E respectively.
Conclusions
This case study illustrates new methods for categorising recruitment
studies. It has potential utility to researchers by encompassing the
Trials 2017, 18(Suppl 1):200 Page 163 of 235different aspects of the recruitment study design and the use of real/
hypothetical RCTs. This categorisation requires further evaluation in
other recruitment settings to establish its validity and role.
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The success of long-term studies rely heavily on the ability to retain
participants for the entire study duration which may span much of
the participant’s adult life. Researchers must accommodate partici-
pants’ life changes including moving to locations that are no longer
near a clinical center, personal circumstances that prevent in-person
clinic visits, and most importantly aging. Prolonged illness and de-
creased mobility of aging participants create barriers to clinic access
for data collection. In such cases, performing collection at convenient
locations for participants including their home, work or nursing
home may boost retention. In studies with event driven analysis
approach, the data for every participant is valued. Their individual
contribution may be small but their retention is essential to the suc-
cess of the study; as a result, a critical concern is how we can expand
our reach and continue to maximize data collection on all partici-
pants. Questionnaire data collected over the phone may not be
enough and phenotypic data can offer a more complete picture.
Thus to improve retention and minimize participant burden, cost-
effective approaches to conduct remote visits can be implemented
to collect anthropometric measurements and biospecimens with the
use of external examination services.
However, many challenges abound in conducting sporadic remote
visits by an external examination service technician. A clear and
precise protocol is essential to ensure fidelity and consistency in
data collection and equipment. Prioritizing data collection for non-
clinic visits will help simplify the visit flow for external technicians
to balance the capture of essential outcomes and participant bur-
den. Training and communication are critical to facilitate interac-
tions among the external examination service central office, the
technician completing the visit, the clinical coordinator, the coord-
inating center staff, and the participant. In this presentation, we will
describe the process of working closely with an external examin-
ation service for a long-term multi-center clinical trial with an aging
cohort. We will present our experiences, both the successes and
failures, over the first year of remote visit implementation within
the framework of a national multi-center clinical trial. If long-term
studies can overcome these obstacles, the use of external examin-
ation services to conduct remote visits may provide a cost-effective
solution to boost participant retention and support study validity in
otherwise hard to reach populations.
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Many clinical trials experience recruitment difficulties, leading to
underpowered studies, costly extensions or early closure. Trials in
paediatric critical care encounter additional practical and ethical
difficulties as there is no time to seek prior informed consent in an
emergency situation. Eclipse is an unblinded pragmatic randomised
controlled trial that explores the treatment (levetiracetam versus
phenytoin) of status epilepticus in children. Challenges to the suc-
cess of eclipse include: a vulnerable target population (children
aged 6 months to <18 years); the need to administer the interven-
tion without prior informed consent (deferred consent); and use of
levetiracetam, an anti-epileptic medication which is not traditionally
usually used in this clinical setting. We evaluated the effectiveness
of site training on healthcare practitioners’ (HCP) confidence in the
recruitment of patients to eclipse. The interactive site training in-
cluded: protocol presentations from the trial team; screening and
randomisation simulation (video and real-time); a deferred consent
scenario video informed by pre-trial feasibility work with parents,
and a question and answer session.
Methods
Mixed method study including a 14 item questionnaire administered
before and immediately after the site training as well as telephone in-
terviews with eclipse HCPs in the first 12 months after site opening.
Results
In total, 156 HCPs from 25 UK hospital completed a before and after
site training questionnaire. We interviewed eight HCPs involved in
patient-recruitment and deferred consent in eclipse. Prior to site
training, HCPs were concerned about recruitment because of a lack
of knowledge about the trial protocol and apprehensions about par-
ents’ response to deferred consent. We found that site training im-
proved HCP confidence in the trial, including being better able to
discuss the study with parents (p < 0.001), explain randomisation (p
< 0.001) explain deferred consent (p < 0.001) and address parents’
objections to their child being randomised (p < 0.001). HCPs valued
the clarity and content of site training and described how videos
helped them to visualise recruitment and consent processes. HCPs
offered suggestions about how the trial management team could
provide ongoing recruitment and consent support through study up-
dates, recruitment-training tips and advice from study team mem-
bers as and when required.
Conclusions
Interactive site training can assist important HCP ‘buy in’ for challen-
ging clinical trials. Our findings highlight how pre-trial feasibility work
with parents can improve HCP confidence in recruitment and de-
ferred consent seeking in a paediatric critical care trial.
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Background
Sub-optimal participant recruitment rates are common in trials. A multi-
tude of factors have been suggested to explain this [1], including the
task of opening sites to recruitment. Clinical trials of investigational me-
dicinal products (CTIMPs) may pose additional challenges in primary
care compared to other healthcare settings due to the need to engage
busy general practitioners (GPs) in research processes. A recent report
[2] highlighted the increasing pressures on GPs to meet the clinical
needs of patients during routine consultations. Given this backdrop, fa-
cilitating GPs to recruit participants can prove challenging. This abstract
presents the experiences of opening sites to recruitment for a nation-
wide clinical trial based in primary care: Injection versus Splinting in
Carpal Tunnel Syndrome (instincts) [3].
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Recruiting sites were GP practices, GPs using a ‘hub-and-spoke’ model,
and primary-secondary care Interface Clinics. Practices were identified
via the Primary Care Rheumatology Society and through the relevant
Clinical Research Networks (CRN). Training was undertaken at regional
workshops and individual sites. Some sites had access to Research
Nurses, or support from the CRN for set-up. Support with completing
site set-up paperwork was offered to sites by the Clinical Trials Unit
(telephone or visit).
Results
Of the 59 sites expressing interest, 27 opened, 12 were trained but
did not open, and 20 were not trained and did not proceed further.
Of the sites which opened to recruitment, 13 were GP practices,
seven were GPs using a ‘hub-and-spoke’ model, and seven were
Interface Clinics. Time from training to site opening ranged from two
to 24 months. Delays between training and site opening were
experienced for a variety of reasons related to overall trial set-up and
site-specific set-up. The change from Primary Care Trusts to Clinical
Commissioning Groups delayed sites engaging with the trial. Site-
specific issues included delays completing site set-up paperwork and
meeting the additional requirements for conducting CTIMPs (e.g.
Good Clinical Practice training). Delays to site opening meant some
sites needing re-training and others never opening. Reasons for
trained sites never opening included changes in clinician availability
and service re-structure. As a consequence, there was a need to recruit
sites for longer than anticipated. Support from a Research Nurse or
CRN had a positive effect on site set-up. GPs using a ‘hub-and-spoke’
model and Interface Clinics were eventually targeted as priority for site
opening, as initial patterns of recruitment showed these sites
gave a better return in terms of recruitment for the time invested
in site set-up.
Conclusions
Targeting GPs using a ‘hub-and-spoke’ model and Interface Clinics
was generally most efficient for site opening and most productive
for subsequent participant recruitment. Web-based initial training
would have allowed sites to register interest after seeing what the
trial involved, thereby saving time and resources. Ensuring sites
were ‘research ready’ and had completed site set-up paperwork be-
fore training would have reduced the delay in site opening. GPs
were required to offer each participant several appointment slots
to screen, consent, randomise and treat, which may have dissuaded
them from engaging: providing support with these activities may
have encouraged more sites to participate.
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Background
It is common for many trial participants (sometimes more than 20%)
to drop out before the trial finishes. Drop out seriously affects the
credibility of trial results and significantly affects a trials potential to
influence clinical practice. Recent estimates have shown that in up to
53% of trials the results could have been overturned if the outcomes
from those who had dropped out were known. Trial Managers are
often faced with identifying ways to improve retention but the evi-
dence base on effective methods in this area is lacking. Exploring
and identifying Trial Managers experience and tacit knowledge re-
garding what they perceive as the biggest barriers and facilitators for
retention in RCTs can contribute to this evidence base and identify
areas for further research.
Methods
A web-based survey was conducted as a scoping exercise to explore
what Trial Managers perceive as the biggest barriers and facilitators
for retention in randomised trials. Trial Managers were sent an invita-
tion to complete the survey through the UK Trial Managers Network
(UK TMN) listserv to all listed members (i.e. Those trial managers whoare employed on a publicly funded trial and registered with the UK
TMN). In addition to questions about demographics, there were 4
broad open-ended questions that asked Trial Managers about: experi-
ence of retention and what they perceive as main issues; thoughts on
ways to improve retention; how trial design could be changed to im-
prove retention; and to identify one thing in relation to retention that
would make their lives easier. Demographic data was analysed using
descriptive statistics and the free text responses were coded using a
thematic analysis approach.
Results
The email invite was sent to 501 list SERV members and we received
48 responses (9.6% response rate). The duration of trial management
experience of respondents ranged from 0.8 to 34 years (median 5
(Q1:3; Q3: 12.25)). The types of trial managed by respondents showed
wide variation and covered all phases of trial (Phase I-Phase IV) includ-
ing pilot trials; trials set within primary, secondary and tertiary care; with
children and adults; in a range of clinical areas; and interventions under
investigation also varied (included CTIMPS, devices, surgery, educa-
tional, service level). The findings could be grouped in two main
themes: considerations relating to trial design; and considerations relat-
ing to participant perspectives. The overwhelming issue raised in the
48 responses from across the UK was that many aspects of retention
are context dependent: at the level of the clinical condition; its associ-
ated population; and the individual trial (i.e. Type of follow-up, differ-
ences across sites with relation to how retention is discussed and the
rapport between recruiter and participant).
Discussion
This survey identifies some of the main barriers and facilitators to
trial retention as perceived by Trial Managers. Specifically, the results
focus on trial design and participant perspectives, how poor proto-
cols make retention harder, and identify potential priorities for future
evaluation.
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Background
It is estimated that around 50% of trials fail to recruit to target. Po-
tential implications of this is that trials require extensions to their re-
cruitment period, their sample size is revised, or the trial is closed,
leaving the clinical question unanswered. In multi-centre trials, sub-
stantial time and effort is spent setting up clinical recruitment sites,
and this has inherent cost. Experience suggests that some sites will
recruit to target and others will not. The more sites that fail to recruit
to target, the less likely the trial will meet recruitment targets.
Aims
We explored whether trial managers (involved in recruitment site
set-up) were able to predict whether a site would recruit to target or
not before the site was opened to recruitment, the reasons for these
predictions, and their subsequent reflections.
Methods
Trial managers based in a registered CTU involved in setting-up re-
cruitment sites during 2014/15 predicted the recruitment success of
each site they opened: whether the site would recruit to target (ie re-
cruit the number of participants documented in the site agreement)
or not, and reasons for this. Predictions were placed in sealed enve-
lopes and opened after a minimum of 8 months recruitment at each
site. A focus group was held with the trial managers where predic-
tions were revealed and compared with the actual recruitment
achieved by the site; reasons for and accuracy of the prediction were
discussed.
Results
10 trial managers working across 7 randomised trials and one non-
randomised diagnostic study participated; 56 predictions were made.
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were that the site would recruit to target; 17 of these (55%) were
correct and the site met target. Of 17 predictions made about sites
in the diagnostic study, 12 (71%) were that the site would recruit to
target; all 12 did so. Reasons for positive predictions were similar
across the types of studies and included engaged/enthusiastic PI/
team, experienced research nurses, consideration of trial logistics
prior to site initiation. Eight sites involved in randomised trials were
predicted not to recruit to target; 6 of these predictions were correct.
Five sites involved in the diagnostic study were predicted not to
recruit to target; only 1 site did not recruit to target. Reasons given
for these predictions included lack of interest/engagement, slow
responses, involvement in multiple studies. Results from the focus
group will be presented. We will also explore whether there is any
difference between accuracy of prediction in sites where training
was on-site or carried out remotely.
Conclusions
Trial managers were generally optimistic in their predictions. For the
randomised studies, predictions were more likely to be correct when
trial managers predicted that a site would not meet recruitment tar-
gets. We propose that the trial manager’s tacit knowledge at site set
up may help to target time and resources more effectively during
site set-up: the implication of this is that time and resource may be
directed away from sites predicted to not meet recruitment targets.
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Background
ARIC (Atherosclerosis Risk in Communities) is a prospective study
funded by the National Heart, Lung and Blood Institute (NHLBI) that
began over 30 years ago in 4 communities in the United States: Forsyth
County, North Carolina; Jackson, Mississippi; Minneapolis Minnesota;
and Washington County Maryland. At that time, 15,792 participants be-
tween the ages of 45 and 64 were enrolled and have been successfully
followed over the years with an impressive response rate.
Methods
ARIC’s key to successful retention include information that was gath-
ered at visit 1, and consistent contact with the participant over the
years. At visit 1, information on the participants’ address, physicians,
contacts, and other items were well documented. Spousal participation
in the study was also encouraged in hopes of keeping both spouses in-
volved. Annual and semi-annual phone interviews that include health
related questions also verify contact information. This includes current
participant physical and mailing address; multiple contact names, ad-
dresses and phone numbers; physician name, address and phone num-
ber; as well as a designated proxy who can represent the participant
given any future health or cognitive problems (which is especially im-
portant with an aging cohort). Phone interviews are done at optimal
times such as evenings or weekends. At the time of the call, inter-
viewers have at their fingertips all the relevant information on the par-
ticipant via reports produced on a web-based data management
system called Carolina Data Acquisition and Reporting Tool, or CDART
(developed by the ARIC coordinating center at the University of North
Carolina at Chapel Hill). This report provides participant information to
facilitate the call such as living arrangements, potential hearing loss,
study history and other administrative notes. Long-term and dedicated
interviewing staff provide familiarity for the participant, and go through
annual interviewing recertification to ensure quality. Periodic clinic visits
are done (currently conducting visit 6) where various interviews and
medical tests are completed. The participants are offered a small sti-
pend for the visit, as well as comprehensive test results that they can
share with their physicians. If the participant is unable to come to the
clinic, in-home visits are offered. To further engage the participant, peri-
odic newsletters and birthday/greeting cards are mailed, and a partici-
pant focused public website (in both English and Spanish) is available.Results
Currently, the ARIC study follow-up has over 80% response rate of
those participants still alive, providing over 30 years of robust data
sets for investigators worldwide, and contributed to over 1600 peer-
reviewed articles. ARIC continues to follow these participants and has
plans for its seventh clinic visit in 2017.
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Background
Maximising recruitment in trials is an important goal for trial teams;
however a trial that has met recruitment targets can be underpow-
ered with inconclusive results if retention rates are poor. Trialists an-
ticipate around 10% of participants will withdraw from a trial or are
“lost to follow up”, however, there are few interventions with high
quality evidence of benefit for increasing retention in trials [1–2].
The need for more rigorous evaluations of interventions to increase
retention in trials has resulted in the Trial Forge Initiative (http://
trialforge.org) coordinating SWAT studies (“study within a trial”):
evaluations of trial methods innovations embedded within a host
trial Research teams can use the same SWAT protocol, thus the re-
sults can be combined in a meta-analysis which may provide high-
quality evidence to inform their trial design. The SWAT 24 protocol
focuses on increasing the return of outcome data collected through
participant-completed questionnaires. The completion and return
of the questionnaires is a “behaviour” Which could be influenced
by an intervention targeting participants’ willingness “to do” this
behaviour.
The iquad trial team [3] has developed a template for a theory-
based cover letter (the intervention) using the Theoretical Domains
Framework (TDF) [4] to identify theoretical targets for behaviour
change interventions. This letter is issued to participants with
follow-up questionnaires.
In the iquad trial the theory-based letter was associated with a 6%
increase in questionnaire return rate when compared with the
standard letter [5]. This is promising but needs replication to inves-
tigate if this effect can be repeated in other trials with different pa-
tient populations that may have different barriers to “behaviour
change”.
Objectives
To ascertain whether a theory-based cover letter accompanying pa-
tient follow-up questionnaires improves response rates in two trials
with differing patient groups; the AMBER (neurogenic bowel) and the
OPAL trial (urogynaecology) [6,7].
Methods
AMBER and OPAL trial participants are randomly assigned to receive
a theory-based cover letter (group 1) or a standard letter (group 2)
with follow-up postal questionnaires; 24 weeks in AMBER; 12 and
24 months in OPAL. Questionnaire response rates across time-points
in the AMBER and OPAL trials will be presented.
Results
Sixty-four letters (group 1:32, group 2: 32) will be sent in the AMBER
trial (41 sent to date). 384 letters (group 1: 205, group 2: 179) will be
sent in the OPAL trial (174 sent to date). These data will be pooled
with the iquad data to create a cumulative meta-analysis, which will
also form part of future versions of the Cochrane review of interven-
tions to improve retention.
Conclusions
We will provide evidence as to whether a theory-informed question-
naire cover letter can improve trial questionnaire response rates, and
whether some patient populations are more receptive to these letters
than others.
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Clinical trial designs which focus resources on treatments that show
promise in early accrued data are efficient and desirable, particularly
when resources are constrained. To help stop trials, or trial arms, which
show a low likelihood of confirming a treatment effect at final analysis,
typically one could include an interim analysis in a parallel-groups
?A3B2 show $132#?>confirmatory clinical trial, or adopt an adaptive
multi-arm design, for example a seamless phase II/III design. These
strategies all feature one or more interim analyses during trial recruit-
ment to assess whether the trial is to continue to completion. In a typ-
ical interim analysis, the hypotheses tested at interim/transition are
principally concerned with whether the trial is likely to observe a treat-
ment effect which meets the chosen limit for statistical significance, at
the final analysis. This analysis only indirectly tests whether the treat-
ment is likely to produce a useful clinical effect at final analysis. Treat-
ment selection designs may be better served by confidence intervals
and estimation methods, than more traditional hypothesis testing ap-
proaches. Using confidence intervals at interim gives the researcher a
better idea of an interim estimate’s precision, and therefore provides
more information about a treatment’s potential efficacy than a p-value
alone allows. A researcher interested in establishing the efficacy of an
intervention may wish to continue a trial showing a large variance
(imprecise estimate) at interim, in the hope that the later analyses
(either interim or final), which feature more participants, may reveal a
more precise estimate of the true treatment effect of the intervention.
Interim analyses using p-values as the stopping criteria do not address
this issue.Instead, imprecision in the estimate increases the likelihood
of the trial stopping. To resolve this problem, the stopping criterion of
a typical interim analysis for futility could be modified to instead stop a
treatment arm when the interim treatment effect confidence interval is
contained entirely within a region deemed clinically unimportant – an
indication that the treatment is likely to not be of benefit. Interim
estimates which are imprecise (have wide confidence intervals) are pro-
tected from stopping using this rule, rather than with a hypothesistest using a p-value as the criterion. Confidence intervals produced
using interim data have limitations – most obviously the fact that
they will be wider (less precise) than those expected at the final
analysis of the trial, given the lower sample size, which, using the
proposed stopping criteria. To avoid these intervals being so inad-
equately wide at a low sample size that all trials continue to com-
pletion, the use of normal-based confidence intervals at a lower
nominal confidence level (e.g. 90%), ‘predicted intervals’, which re-
place elements of the confidence interval calculation with assumed
values, Bayesian estimation, or novel, bootstrapping-based
methods, could be used instead, all of which have varying implica-
tions on the analysis. A comparison of this method is discussed,
using simulated data.
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Background
Individually randomised trials often have the added complication
of a comparison of interventions administered in different ways,
where groups of outcomes are correlated in one trial arm and
not the other, termed a partially nested design. The correlation
of outcomes is defined by the nature of the intervention itself,
for example, a comparison of group therapy intervention and
drug therapy control. Small clusters, small intracluster correlations,
and differential variance between the control and intervention
arms are often present in partially nested trials. If not accounted
for in the design or analysis this may result in biased effect size
estimates with spurious precision.
Objective
To evaluate statistical methods to analyse partially nested trials and
provide practical advice on the analysis of partially nested trials using
a simulation study, with focus on the most appropriate method for
imposing clustering in the unclustered control arm.
Methods
Simulation studies will be used to explore varying scenarios of cluster
size, number of clusters, intra-cluster correlation, and differential
variance between the two trial arms and their impact on bias, power,
precision and ICC estimation. In theory the mixed effect models for
partially nested trials do not model clustering in the control arm, how-
ever, when fitting these models in statistical software it is necessary to
impose clustering in the unclustered control arm. We will explore the
various methods for imposing clustering in the control arm: a unique
singleton cluster of size one for every individual; one large single clus-
ter; or pseudo random clusters.
Results
Results will be presented reporting the bias, power, precision and
ICC estimation using the different analysis models. The effect of the
choice of imposed clustering on the intracluster correlation estimate
will be presented and the most appropriate method for imposing
clustering in the unclustered control arm.
Conclusions
Partially nested trials are commonly used in complex intervention re-
search. The design and analysis of these trials can take account of
the hierarchical data structure and needs to consider the choice of
imposing clustering in the unclustered control arm.
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gression models in surgical trials In surgical trials it is necessary to
adjust for the clustering effect of the operating surgeon, as outcomes
will be more similar for patients with the same operating surgeon
than for those with a different surgeon. Due to the incremental na-
ture of surgeon recruitment into a large surgical trial, it is likely that
within a trial there will be a large number of surgeons that operate
on only a few patients each, causing small cluster sizes. It is also
likely that there will be a few surgeons’ recruited to the trial earlier -
that operate on a lot more patients than the rest of the surgeons in
the trial, creating unbalanced cluster sizes. Practically, the potential
effects of these small or unbalanced cluster sizes on the bias and
convergence of a multi-level model can be a concern when a trial is
forced to recruit many more centres or surgeons than originally
planned, for example to bolster recruitment. A simulation approach
was used to explore and quantify the potential risk of recruiting
many additional surgeons (while keeping the sample size fixed).
A binary endpoint (success/failure) was modelled using a multi-level lo-
gistic model, treating operating surgeon as the unit of clustering. The
number of patients assigned to each surgeon was simulated using a
gamma distribution, which allowed the small and/or unbalanced clus-
ter sizes described above to be simulated.
A ‘surgeon effect’ was included in the simulation that would increase
the probability of success based on the experience, skill etc. of the sur-
geon. Another ‘surgeon treatment effect’ was included that allowed the
surgeon effect to be different depending on the treatment being
performed.
Patients were allocated to one of two treatments using a minimisa-
tion algorithm, stratifying for the operating surgeon.
The patients were assigned a probability of success based on their
treatment. The surgeon effects were incorporated to calculate a
different probability for each surgeon and treatment combination.
The outcome was then generated from a binomial distribution using
the calculated probability as the probability of success. Both random
intercept and random slope models were investigated. The effects of
changing the number of surgeons, changing the variance of the
?A3B2 show $132#?>surgeon effect and changing the variance of the
surgeon treatment effect on model bias and convergence were in-
vestigated, as well as their effects on the power of the trial.
Early results suggest that unbalanced and small cluster sizes do not
appear to effect the convergence of the model or cause bias in the
fixed effects of the model. The effects of different cluster size distri-
butions on the power of the study will be investigated. The conse-
quences of changing the variance of the ‘surgeon effect’ and the
‘surgeon treatment effect’ will also be investigated as these may vary
depending on the difficulty of the operation and the difference in
the skill required for each operation within a trial.
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Background
Data obtained from randomised controlled trials (RCTs) contribute
important information to the harm profile of a drug as they provide
unbiased estimates of harm effects and provide a controlled com-
parison allowing causality to be evaluated.
The most common approach for harm monitoring and analysis dur-
ing a RCT is to tabulate event rates by treatment arm and sometimes
the difference in event rates is estimated and p-values from hypoth-
esis tests are presented. Data are examined by an independent data
monitoring committee (DMCs) who will make a recommendation to
proceed or halt a trial based on these presentations. More formal as-
sessments and integration of existing or emerging knowledge for
drug harm into the DMC report is rare and as a result there is an in-
efficiency present when monitoring and analysing harms in trials. Inthe last 15 years new methods for improving the monitoring and ana-
lysis of harms in trials have been proposed. We review these methods,
outline when they are appropriate to implement, examine their use in
published studies and discuss challenges of their implementation.
Results
The review identified 11 methods for use for harm monitoring and
analysis in clinical trials. We have categorised these as: sequential
methods, group sequential methods and surveillance methods.
The four sequential methods have been designed to be implemented
after each observed harm event. They have been developed for use in
a single treatment arm setting and require a pre-specified harm of
interest and a pre-specified hypotheses to be tested. Since they are
implemented after each observed event they are best suited to the
evaluation of serious adverse events where immediate evaluation is ne-
cessary in order to determine whether the trial should continue.
Group sequential methods primarily proposed for use in monitoring
efficacy outcomes have been extended by several authors for the
purpose of harm monitoring. Analogous to the methods for efficacy
each require a pre-specified harm of interest with a pre-specified hy-
pothesis to be tested.
Four surveillance methods have been developed for multi-arm stud-
ies with the purpose of monitoring emerging harm events i.e. The
harm is not pre-specified. The applications of these methods to date
have been applied at body system level rather than reported adverse
event level.
In a review we undertook to examine the methods and reporting of
harms in rcts we found none of the 189 included trials used any of
these methods.
Conclusions
Statistical methods have been proposed for use in a clinical trials set-
ting to flag signals for adverse drug reactions for both pre-specified
harm events and for emerging harm events. However the clinical
trials community are not currently implementing these harm moni-
toring methods and tabulations of adverse events remains the most
popular choice to evaluate disproportionalities between treatment
arms. The reasons for this are unclear but could be due to: their rela-
tive infancy; sophisticated methodology; the computational intensity
and increased resource level needed; and no formal requirement
from regulatory bodies and the wider clinical community for more
robust methods.
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Background
The target difference, or ‘effect size’, is an important component of a
sample size calculation as the calculations are extremely sensitive to
assumptions as to what the effect size will be. A review of 117 NIHR
Health Technology Assessment funded randomised controlled trials
indicated that over 50% of randomised controlled trials report that
they have used a previous study or previous research to estimate
their target effect size.
Objective
The objective of this presentation is to examine the issues that can
arise when designing one trial based on the results of a previous
trial, or previous research using a simulation study. When basing one
study on the results of another, there is a bias which is introduced
called regression to the mean. This bias means that there would be
an over-estimation of the effect size, and the effect size observed in
the second trial is likely to be considerably less than that which the
study was powered on.
Methods
Simulations were performed to quantify the impact of using previ-
ously observed responses to design future studies. The inputs used
in the simulations were based on the findings of the review. The sim-
ulations were completed under the context of having one trial based
Trials 2017, 18(Suppl 1):200 Page 168 of 235on the results of another. Various end-points were used to build from
the simplest case to cases where biomarkers or surrogate end-points
were used. The simulation results will be used to inform a mathemat-
ical solution using a truncated Normal distribution. This mathematical
solution will provide an adjustment which can be used to better
estimate sample sizes when using previous results. The results will be
extended to different powers and significance levels.
Results
Using effect sizes previously observed to design a new study can
lead to an over estimation of the treatment effect. This over estima-
tion could be as much as 15% which, if not allowed for, could lead
to studies with sample sizes that are too small and therefore are
underpowered. Designing a trial dependent on the results of a first
trial impacts on the distribution of plausible responses for this initial
trial and leads to bias in effect size estimation. Methods will be pre-
sented that allow for this over estimation. The level of adjustment
will depend on factors such as the statistical power of the first study
or the p-value of a meta-analysis to combine previous studies.
Conclusions
When designing a clinical trial which is dependent on the results of a
first trial, the effect size used will be overestimated and so as a result
the sample size will be too small. The effect size should be adjusted
to account for the sequential nature of the trials being investigated.
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Background
The intra-cluster correlation coefficient (ICC) is a statistic that is used
to describe the variation between and within clusters. A trial ICC can
be calculated from a pilot study but when calculated has a large
confident interval. Alternatively we can select an ICC for a trial from
previous trials ICC’s that have similar cluster type and outcome.
Aim
We aim to collect data available on ICC’s from previous trials to create a
prior distribution of ICC’s and then combine these with the data from
pilot studies in a Bayesian analysis.
Methods
As an example we use simulated data of 10 clusters with 200 patients
in each cluster with an ICC of 0.05 with four priors for the ICC. A non-
informative prior and three informative priors, one based on 56 studies
for continuous outcomes of GP surgeries from University of Aberdeen,
one based on QMUL’s cluster randomised course containing 150 ICC’s
and a prior based on 10 studies specific to asthma questionnaire data
from GP surgeries.
Results
The ICC was calculated from Bayesian software winbugs and returned
to R. The mean and credible interval for ICC were calculated from the
posterior distribution. The different methods of ICC calculation along
with their means and confidence/credible intervals are summarised
and compared.
Discussion and Conclusion
Bayesian methods of calculating the ICC are similar to frequentist
methods when a non-informative prior is used. If a more informative
prior is used based on existing trials we can reduce the credible
interval for the ICC in order to better inform sample size calculations
and sensitivity analysis of sample size calculations. More disease spe-
cific trial ICC’s need to be found to create more prior distributions for
specific disease outcomes.P446
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Axio Research has served as an independent statistical group serving
Data Monitoring Committees (DMCs) for industry and government
clinical trials in pharmaceuticals and devices for over two decades.
Accepted, best, and most common practices have changed greatly
over this period. The practice of DMCs continues to evolve and emer-
ging trends will be discussed. Current trends include: program-wide
DMCs, teleconference and web meetings, reduced sponsor and DMC
interaction, focused DMC recommendation delivery, electronic
reporting, DMCs for more studies (early phase, single-arm, open-
label), expertise of DMC members. Pros and cons, implementation,
and what to expect in the near future will be covered from the per-
spective of an independent statistician with guidance for both spon-
sors and DMC members.
P447
Use of instrumental variables within randomised controlled trials
Katie Pike1, Chris A. Rogers1, Gavin J. Murphy2, Massimo Caputo3,
Alasdair MacGowan4, Barnaby C. Reeves1
1Clinical Trials and Evaluation Unit, University of Bristol; 2University of
Leicester; 3Bristol Royal Hospital for Children; 4Southmead Hospital
Correspondence: Katie Pike
Trials 2017, 18(Suppl 1):P447
Background
Randomised controlled trials (RCTs) are widely considered the gold
standard study design for quantifying the effect of an intervention,
due to the minimal risk of bias from confounding. Some RCTs are de-
signed whereby subjects are randomised to different strategies, for
example differing criteria for red blood cell (RBC) transfusions to be
given, rather than specifically to an intervention or control treatment.
In such studies the groups should differ substantially overall in terms
of the intervention received (e.g. The average number of RBC units
transfused), but within each of the randomised groups there will be
heterogeneity in the intervention received. Such situations give an
opportunity to estimate across the RCT as a whole the effect of dif-
fering amounts of intervention (i.e. An observational analysis within
the RCT). The latter can be estimated using instrumental variable (IV)
techniques with randomised allocation as an instrument, avoiding
the problem of confounding (measured or unmeasured) that is often
a concern in observational analyses.
Methods
We have used this approach in three RCTs. In the titre2 trial a liberal
RBC transfusion strategy after cardiac surgery was compared with a
more restrictive strategy, creating two groups with different risks of
transfusion and distributions of numbers of RBC units transfused. The
Thermic trials compared paediatric cardiac surgery performed at
warmer (normothermic) vs colder (hypothermic) temperatures, gen-
erating groups with different average surgery temperatures. Finally,
the RAPIDO trial compared a rapid diagnostic pathway with the con-
ventional method for patients with blood stream infections, with the
resultant groups differing substantially in terms of the time until
microbiological information is returned from the laboratory.
In addition to the primary intention-to-treat (ITT) analyses an IV analysis
was performed for each trial, with randomised allocation as an instru-
ment. Such models estimate different effects to the ITT analyses,
namely: each RBC unit transfused on severe post-operative complica-
tion (titre2); each degree Celsius on intubation duration (Thermic); each
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ity (RAPIDO). Models were fitted in Stata. For titre2 and RAPIDO IV pois-
son models for binary outcomes were used. For Thermic an IV linear
regression model was used.
Results
For titre2 the ITT estimate of the odds ratio for allocation (liberal vs
restrictive) on post-operative severe complications was 0.87, 95%
confidence interval (CI) (0.72-1.05). The IV estimate of the relative risk
of each unit transfused on outcome was 0.89, 95% CI (0.75-1.06). In
the Thermic trials the geometric mean ratio (GMR) from the ITT ana-
lysis of the effect of allocation (normothermic vs hypothermic) on in-
tubation duration was 0.77, 95% CI (0.57-1.04). The IV estimate of the
GMR of each degree Celsius was 0.95 (0.89, 1.02). Results from the
RAPIDO trial are forthcoming.
Discussion
Although the ITT and IV models are estimating different effects we
anticipated that the direction of effects would be consistent, which
was the case in the examples we considered. The use of IV tech-
niques to address secondary objectives in RCTs can be a useful tool
in certain settings, although such models are generally low powered.
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Cox’s proportional hazards regression modelling is a common
method for analysing time-to-event data in clinical trials, and pro-
vides an estimate of the hazard ratio (HR) as a measure of the overall
treatment effect. This semi-parametric model relies on the assump-
tion that the hazard ratio remains constant over time, such that the
hazards between the treatment groups are proportional. If this
assumption is violated, the Cox’s proportional hazards model can
lead to a reduction in power for the corresponding tests of signifi-
cance and more crucially, imprecise and misleading estimates of the
treatment effect.
ADMIRE is a two-arm Phase II randomised-controlled trial, in 215 pa-
tients with Chronic Lymphocytic Leukaemia (CLL). Progression-free sur-
vival (PFS) was one of the key secondary endpoints, the intention for
analysis was via a multivariable Cox regression model and presentation
of the Kaplan-Meier survival estimates. On analysis of PFS, there was
strong evidence that the proportional hazards (PH) assumption did not
hold, as indicated by the crossing of the survival curves, putting into
question the reliability of the estimate of the HR in the Cox regression
model.
I will present common methods for testing for non-proportional
hazards in the analysis of survival data. I will then present an alter-
native method for estimating the treatment effect when the pro-
portional hazards assumption is violated known as restricted mean
survival time (RMST).
RMST provides a way of estimating the treatment effect when the
PH assumption is in doubt or has clearly been violated as recom-
mended by Royston and Parmar (2011). It is a measure of average
survival from time 0 up to a restricted pre-specified time t, and can
be estimated as the area under the survival curve using a pseudova-
lue approach. The difference in RMST between treatment groups can
be calculated using standard regression methods and provide an ap-
propriate estimate of the treatment effect, when non-proportional
hazards exist.
The results of the RMST method when applied to analyse the PFS
data in ADMIRE will be presented and compared to the results from
the Cox proportional hazard model, which is inappropriately applied
when the proportional hazards assumption fails to hold.P449
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Background
Repeated post-randomization longitudinal measurements are often
not used to maximum efficiency at the analysis stage, with baseline
data being disregarded or used simply to derive a single ‘change
from baseline’ measurement. We have previously presented a simula-
tion model comparing different statistical methods of dealing with
repeated biomarker measurements over time. This abstract extends
that work to consider how the relative precision of the different
methods are affected in different biomarker scenarios, both by simu-
lation and using real data. Biomarkers can represent a physiological
state (S) at any time (e.g. Reflecting a comorbidity such as chronic
kidney dysfunction) or only reach measurable levels after an event
(E; e.g. Organ-specific response to injury). Our previous work only
considered the former scenario, using a simulation model. Here, we
use data for creatinine and myocardial troponin from a trial to illus-
trate the two scenarios. Using the simulation model, or boot-
strapped estimates for the trial data, we quantify how the relative
precision of different methods for analysing repeated longitudinal
measurements is affected, when: (a) adjusting for a baseline meas-
urement or not, and (b) when varying amounts of data are missing-
at-random.
Methods
We are using the simulation model to generate biomarker data of
the S and E type. Four different analysis methods are being used
to analyse the simulated biomarker data and estimate the relative
precision of each model: t-test of the maximum change from
baseline; area under the curve; multiple comparisons with Bonfer-
roni correction; and a multilevel model. We are boot-strapping
data on creatinine (type S biomarker) and troponin (type E bio-
marker) collected in a randomised controlled trial to mirror the
simulated scenarios with real data. We are also investigating the
impact on relative precision of removing varying amounts of data
(5%, 10% and 20%) at random, since repeated biomarker mea-
sures are often incomplete.
Results
This work is ongoing. We know from our previous work that the
multilevel model has the best precision compared to the other
methods. What is unknown is whether the relative precision of the
methods varies, and if so by how much, in these different scenarios.
Results will be presented at the conference.
Conclusions
Awareness of the greater precision afforded by modern statistical
methods of analysis is limited, leading to inefficiencies in translat-
ing discovery science into clinical settings. This research will high-
light to researchers and funders the extent of the inefficiency and
how practical constraints in doing the research, such as complete-
ness of data, modify the penalty of using old-fashioned methods of
analysis.
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Trials 2017, 18(Suppl 1):200 Page 170 of 235In group sequential designs, adjusting for baseline variables and
short-term outcomes can lead to increased power and reduced sam-
ple size. We derive simple formulas for the efficiency gain from such
variable adjustment using semiparametric estimators. The formulas
reveal the impact of the prognostic value in the variables and how
the impact is modified by the proportion of pipeline participants,
analysis timing, and enrollment rate. While strongly prognostic base-
line variables are always valuable to adjust for, the added value from
prognostic short-term outcomes is limited. For example, if at least 2/
3 of the enrollees have primary outcome observed, the equivalent
sample size reduction from prognostic short-term outcomes is at
most half of the reduction from an equally prognostic baseline
variable. The added value from prognostic short-term outcomes is
generally smallest at later interim analyses which are the ones that
tend to impact power the most. A practical implication is that in trial
planning one should put priority on identifying prognostic baseline
variables. Our results are corroborated by simulation studies based
on data from a real trial, using the class of readily implemented semi-
parametric estimators.
P452
Analysis of an ordinal endpoint for use in evaluating treatments
for severe influenza requiring hospitalization
Ross Peterson1, David M. Vock1, John H. Powers III2, Sean Emery3,
Eduardo Fernández-Cruz4, Sally Hunsberger5, Mamta K. Jain6, Sarah Pett7,
James D. Neaton1
1University of Minnesota, School of Public Health, Division of
Biostatistics; 2George Washington University School of Medicine; 3Kirby
Institute, University of New South Wales; 4Hospital General Universitario
Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio
Marañón, Departamento de Microbiología I/Inmunología, Facultad de
Medicina, Universidad Complutense de Madrid; 5National Institute of
Allergy and Infectious Disease, Biostatistics Research Branch; 6UT
Southwestern Medical Center, Department of Internal Medicine; 7CRG,
Infection and Population Health, UCL and MRC CTU at UCL, University
College London
Correspondence: Ross Peterson
Trials 2017, 18(Suppl 1):P452
Background
A single best endpoint for evaluating treatments of severe influenza
requiring hospitalization has not been identified. A novel 6-category
ordinal endpoint of patient status is being used in a randomized con-
trolled trial (FLU-IVIG) of intravenous immunoglobulin (IVIG). We sys-
tematically examine four factors regarding the use of this ordinal
endpoint that may affect power from fitting a proportional odds model:
1) deviations from the proportional odds assumption which result in
the same overall treatment effect as specified in the FLU-IVIG trial
protocol and which result in a diminished overall treatment effect; 2)
deviations from the distribution of the placebo group that researchers
assumed in the FLU-IVIG trial protocol; 3) the effect of patient misclassi-
fication among the 6 categories; and 4) the number of categories of
the ordinal endpoint. We also consider interacting the treatment effect
(i.e., Factor 1) with each other factor.
Methods
We conducted a Monte Carlo simulation study to assess the effect of
each factor. To study factor 1, we developed an algorithm for deriving
distributions of the IVIG group that deviated from proportional odds
while maintaining the same overall treatment effect in the form of an
average log odds ratio. To construct the algorithm, we know that for
large samples the average log odds ratio of a misspecified model is the
value for which the expected score function equals zero. Given infor-
mation about the trial, our algorithm constrains the distribution of the
IVIG group to maintain the average log odds ratio across deviations
from proportional odds. Our algorithm can handle ordinal endpoints
with any number of levels. For factor 2, we considered placebo group
distributions which were more or less skewed than the one specified in
the FLU-IVIG trial protocol by adding or subtracting a constant from the
cumulative log odds ratios. To assess factor 3, we added misclassifica-
tion between adjacent pairs of categories that depend on subjectivepatient/clinician assessments. For factor 4, we collapsed some categor-
ies into single categories.
Results
Deviations from proportional odds reduced power at most from 80%
to 77% given the same overall treatment effect as specified in the
FLU-IVIG trial protocol. Misclassification and collapsing categories can
reduce power by over 40 and 10 percentage points, respectively,
when they affect categories with many patients and a discernible
treatment effect. But, collapsing categories that contain no treatment
effect can raise power by over 20 percentage points. Differences in
the distribution of the placebo group can raise power by over 20
percentage points or reduce power by over 40 percentage points
depending on how patients are shifted to portions of the ordinal
endpoint with a large treatment effect.
Conclusions
Provided that the overall treatment effect is maintained, deviations
from proportional odds marginally reduce power. However, devia-
tions from proportional odds can modify the effect of misclassifica-
tion, the number of categories, and the distribution of the placebo
group on power. In general, adjacent pairs of categories with many
patients should be kept separate to help ensure that power is
maintained at the pre-specified level.
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Introduction
We suggest that use of more appropriate statistical methods will im-
prove interpretability and inferences for early phase II trials that use
continuous fractional outcomes. Typically such trials are designed
and analysed based on transformed data (e.g. Log transformation),
with sample size calculations based on standardised effect sizes and
results summarised using less familiar measures such as geometric
means. We illustrate these issues in terms of Ki67, a common meas-
ure of tumour response in early breast cancer studies.
Background
Guidelines on assessment of Ki67 scores in breast cancer (Dowsett
et al., 2011) give advice on the role of Ki67 in clinical management
and methodological issues for its measurement, but neglect methods
for statistical analysis. Ki67 scores are expressed as a percentage and
hence restricted to the range 0–100. Despite the natural bounds of
the data, recommendations propose Ki67 be analysed assuming a
log-normal distribution.
Methods
We illustrate with both real and simulated datasets that the use of
log transformed data when the data naturally bounded is not al-
ways appropriate. Particularly in randomised studies, it is often the
case that a log transformation may be suitable for one, but not
both arms of the study. Further, interpretations of the data are typ-
ically dependent on differences between means and may ignore
changes in variation.
We show how beta regression and fractional logistic/probit model-
ling directly relate to the original (untransformed) scale can account
for shifts in both location and spread. We also provide suggestions
on sample size estimation.
Conclusions
Analysis of phase II trials that use continuous fractional outcomes
should reflect the underlying nature of the data recorded. We hope
to have increased researchers’ awareness of better methodology that
will enhance comparative analysis, and to provide suggestions for
statistical colleagues who may be asked to perform such work.
We would also encourage researchers to provide summary data such
as distributional shape, mean and variance along with their main
results. Where a transformation is used, justification for choice and fit
of chosen transformation should be provided.
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Evidence shows that there is an increase in the number of unsched-
uled medical contacts amongst school-aged children with asthma at
the beginning of the school year (September). It has been suggested
that this is caused by a viral challenge influenced by the return to
school. It is hypothesised that this challenge is exacerbated as some
children may stop taking their medication over the summer holiday.
The aim of this research is to identify factors that can be used to pre-
dict which children are more likely to have an unscheduled medical
contact in September.
A mixed methods approach is being used to investigate the factors
that affect children having unscheduled medical contacts at the be-
ginning of a new school year. The quantitative data comes from the
PLEASANT (Preventing and Lessening Exacerbations of Asthma in
School-age children Associated with a New Term) cluster intervention
study. PLEASANT investigates whether a simple letter intervention
reminding children to take their asthma medication during the sum-
mer holidays reduces unscheduled contacts. The quantitative compo-
nent includes daily data over a two year period from approximately
12,000 children aged 5–16 with asthma. The qualitative data comes
from a study which will be done in two stages, before and after the
summer holidays. This qualitative research will explore why children
may not take their medication and what factors the children think
trigger their asthma symptoms. The first stage of the study will be
used to inform the quantitative data analysis and the second stage
will be used to validate the results. The two stages will also be used
to investigate any differences from the children’s responses before
and after the summer holidays.
The first stage of the qualitative study was conducted in June/July
2016 and the second stage will have been conducted in Oct/Nov
2016. In the first stage there were 17 interviews with children aged
5–14, with a mixture of boys and girls.
The information collected from the qualitative studies will be used to
identify any possible subgroups that could be incorporated into the
quantitative analysis. Subsequently, a quantitative analysis will be
performed to identify the subgroups for which the PLEASANT inter-
vention could have been most effective.
This is one of the first studies using a mixed method design with
children that have asthma. The findings can be used to propose a
possible intervention that can be targeted at those who are most
likely to have an unscheduled medical contact in September.
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Background
The FDA suggests that participants who discontinue or otherwise
deviate from randomised treatment should continue to be followed
up in order to facilitate the estimation of the de facto treatment
effect in superiority trials.
Objective
We set out to explore how to perform the analysis where data collec-
tion is continued in some, but not all, patients after discontinuation
of randomised treatment: we call this off-treatment data. The work
was motivated by the problem of writing a statistical analysis plan
for a pharmaceutical trial.Methods
We consider several alternative multiple imputation methods that
can be used. The methods vary in their use of earlier outcomes and
treatment discontinuation time in the mean part and in their use of
treatment discontinuation in the variance part. Different methods
make different assumptions about the missing data, specifically
about what observed data to condition on in order to justify a
missing at random (MAR) assumption, and whether or not treat-
ment discontinuation is considered to represent a treatment failure
outcome; they also make different demands on the observed data.
We explore the performance of the methods in a simulation study,
aiming to quantify the impact of different MAR assumptions and
different variance assumptions.
Results
The proposed imputation methods are shown to be valid when treat-
ment discontinuation is not at random, provided that subsequent
loss to follow-up after treatment discontinuation (i.e. Failure to pro-
vide off-treatment data) is at random. We show that the loss of per-
formance due to making simpler assumptions when only the more
complex assumptions are true must be balanced against the gain of
performance due to making simpler assumptions when they are true.
Optimal choice of model depends on likely assumptions and on the
number of treatment discontinuations.
Conclusions
The proposed methods provide a framework for choosing a suitable
imputation model in this setting, and the simulation results were
used to support the choice of sensitivity analysis methods included
in the statistical analysis plan for the pharmaceutical trial.
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Recruitment in clinical trials can often be problematic and marred by
unforeseen circumstances. This often leads to requests from trial
teams to the funders for extensions to their recruitment period, so
that planned sample sizes can be reached. While numerous factors
will play a role in deciding the future of an under-recruiting trial,
futility analyses are a method sometimes used to assess whether
there is hope for a significant result in a trial, should recruitment be
allowed to continue. A funder may ask investigators to conduct such
an analysis to determine whether an extension should be granted.
This was the case for the SALVO trial - an evaluation of the effect of
intra-operative cell salvage during caesarean section on the need for
donor blood transfusion. The funding body requested that the trial
team conduct an analysis to assess the probability of obtaining a sta-
tistically significant result at the end of the study, given the data col-
lected by that time. We proposed an approach to the futility analysis
based on stochastic curtailment and predictive power, with the idea
to evaluate the conditional power i.e. The probability of obtaining a
statistically significant result at the end of the trial, given the data
that had already been collected. There is no absolute cut-off for con-
ditional power in deciding whether to continue a trial; instead it
must be considered alongside other factors.
We also sought advice from the independent Data Monitoring Commit-
tee (DMC) for the trial, and sent them results from our futility analysis,
generated by an independent statistician. In open correspondence the
Trials 2017, 18(Suppl 1):200 Page 172 of 235DMC raised questions about the need for a futility analysis, and follow-
ing a closed meeting they recommended that the funder extend the
study recruitment period. The SALVO trial recruited to completion after
a 13 month extension was granted.
We present the methods used and results of the futility analysis
that was conducted, as well as final results of the primary analysis
and other findings of the study for comparison. We discuss inter-
pretations that could have been drawn from the futility analysis
and provide a discussion of the pros and cons of conducting futility
analysis with the help of hindsight and with particular reference to
the events which occurred in the SALVO trial.
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Introduction
Recent studies investigated the possible role of Human Epidermal
Growth Factor Receptor 2 (HER2)-targeting compounds as first-line,
single-agent therapy for HER2-over-expressing Breast Cancer (BC) with
promising results. In particular, for a subgroup of patients the observed
disease control duration was similar to that reported for the
commonly-used anti-HER2 and chemotherapy combination treatment.
In order to gather further insights about the biomarkers that character-
ise the patients that can benefit from anti-HER2 single-agent therapy
and to evaluate the efficacy of this therapy in patients not previously
treated for HER2-positive metastatic BC, two clinical trials were initiated:
HERLAP I and HERLAP II, both testing two anti-HER2 agents: trastuzu-
mab and lapatinib. However HERLAP I was prematurely terminated,
also due to the slow accrual of patients.
Objective
We devised to measure the Progression Free Survival (PFS) for pa-
tients in single-agent therapy from the HERLAP trial data, in order
to compare it to the combination treatment. However, the small
sample size makes it difficult to apply frequentist statistical ap-
proaches and calls for an integration of the information derived
from the two trials. In this regard, the Guidance for the Use of
Bayesian Statistics in Medical Device Clinical Trials, issued by the
Food and Drug Administration, states the opportunity to use a
Bayesian approach to combine prior information with new observa-
tions, suggesting to base this information on empirical evidences.
Using this approach, we generated prior distributions from the data
of the early-stopped HERLAP I trial, devising to use them in the ana-
lysis of the HERLAP II trial results.
Methods
We planned to employ a hierarchical Bayesian Weibull survival model
to characterise both the ‘Biological PFS’ (i.e. Taking in consideration
only the period of exclusive administration of anti-HER2 agents) and
the ‘Total PFS’ (regardless of protocol failures). In particular, using non-
informative prior distributions, we derived posterior distributions for
the parameters of the Weibull model based on the HERLAP I data, and
we have planned to use them in turns as prior distributions to derive
the posterior distributions for the parameters based on the HERLAP II
data, thus ‘borrowing strength’ from the first trial to the second.
Results
After describing the statistical method in details and presenting the
data, in this contribution we shall discuss preliminary results that weobtained by deriving the posterior distributions from the HERLAP I data.
In particular, we observed that the median survival times in days (and
the extremes of their 95% credible intervals) for the biological PFS and
the total PSF are 190 (96; 355) and 333 (172; 672), respectively. If we
take into account only the trastuzumab-treated patients, then these
values become 335 (139; 893) and 442 (162; 1304); whereas considering
only the lapatinib-treated patients they become 99 (46; 232) and 250
(102; 805). It is interesting to note that these survival times are similar
to those reported for the combination treatment.
Conclusions
These data, albeit very preliminary, represent an additional sugges-
tion for the efficacy of the single-agent therapy for HER2-positive
metastatic BC.
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Background
Building Blocks was a pragmatic randomised controlled trial asses-
sing the effectiveness of giving the Family Nurse Partnership (FNP)
home-visiting programme to teenage first-time mothers on infant
and maternal outcomes up to 24 months after birth (Robling et al.,
2016). One of the primary outcomes was to investigate the effective-
ness of the intervention in reducing smoking during pregnancy. At
baseline and late pregnancy, we collected a large amount of self-
reported data on smoking habits from each participant during a
face-to-face and telephone interview respectively. It is well known
that self-reported smoking can be inaccurate and therefore some
participants are likely to report smoking fewer or more cigarettes
than they actually do. In the Building Blocks study, we collected urine
samples at the same time as the baseline interview and at follow-up
in late pregnancy. The cotinine levels within the urine sample were
used to supplement the participants’ self-reported behaviour and
then further calibrate their number of cigarettes smoked per day
(Dukic et al., 2007). However, this calibration approach requires
complete and well-synchronized collection of self-reports and urine
samples. The main challenge of our study lies in the collection of
urine samples, particularly at follow-up stage. Some urine samples
were collected at different time points from their interview and some
were missing for a variety of reasons, which cause incompleteness in
participant’s data and potentially lead to bias in the results.
Methods
We tackled these issues using a validation and calibration process.
Firstly, participants were divided into three categories according to
their completeness of these outcomes. Secondly, time gaps between
the urine sample and self-report dates were assessed over different
thresholds. Thirdly, we examined the feasibility of inferring partici-
pants’ reporting behaviours at follow-up stage by their baseline
outcomes.
Results
870 participants with different levels of non-contemporary outcomes
collection at follow-up stage were sub-grouped and investigated
over their consistency in reporting behaviours. We further validated
222 participants with incomplete data at follow-up stage and calibrated
their self-reported tobacco accordingly, which strengthened the power
for the main analysis.
Discussion
It is not rare that difficulties arises when collecting data at follow-up
stages, especially in populations that may be vulnerable and often
mobile as in this study. Rather than losing those participants for key
analyses, this proposed process could further validate and calibrate
self-reported tobacco of participants for public health studies with
similar settings. Because of the costings and challenges in urine sam-
ple collections, investigating the participants’ reporting behaviours
Trials 2017, 18(Suppl 1):200 Page 173 of 235by some associated factors, such as social and demographic factors,
has become one of our follow-up research topics.
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Background
Stratification variables are confounding variables which could po-
tentially influence the outcomes being measured within a trial. The
aim of this work is to extend a dynamic adaptive randomisation al-
gorithm to be able to accept continuous stratification variables,
such as age. Many randomisation algorithms categorise such vari-
ables, however specifying a measure of imbalance with an aim to
minimise imbalance should improve the sensitivity of stratification
schemes. From the literature two methods have been tested to in-
tegrate into the algorithm published previously by the North Wales
Organisation for Randomised Trials in Health (NWORTH), Bangor
University (Russell, Hoare, Whitaker, Whitaker, & Russell, 2011).
Method
Method Firstly we test a method that utilises the rank information
of the covariates (Hu & Hu, 2012). Using a computationally effi-
cient search the method finds the maximum possible difference
resulting from assigning a new participant. Secondly we test a
method that minimises the Kullback-Leibler divergence (Endo,
Nagatani, Hamada, & Yoshimura, 2006). This method is based on
probabilities of assigning a new participant to a group and there-
fore needed to be adapted in order to be integrated. A trial of
332 participants was simulated, using centre (6 centres recruiting
72, 66, 66, 62, 34, and 32 participants, respectively) and age (continuous
18–65 inclusive) as stratification variables. Comparisons of the methods
were based on the resulting differences in means of the variable in two
groups, results of t-tests and f-tests of the final allocations, sequence
length and the imbalance.
Results
Results are displayed in for parameters total = 0.5, centre = 0.5,
age = 0.5 and stratum = 0.5, which are set to control the amount
of imbalance allowed for each variable. Reducing these parame-
ters lessens the control on imbalance while increasing them will
increase predictability. We have also tested different parameters
to assess the effect of increasing and decreasing the stratum and
strata. Increasing the weight for age decreases the difference be-
tween means overall, but increases the difference between means
within centre for method 1, because the imbalance within the
strata are not as well controlled. The 1st percentile for the t and f
tests increase for both methods. Increasing the weight for the
strata decreases the difference between means overall for both
methods and within centre for method 1. Method 1 requires
searching the randomised data so it does take longer to compute
the result than for method 2. Despite this method 1 can still pro-
duce a randomisation result in a few seconds, even with 300 par-
ticipants randomised.
Conclusions
Both methods produce similar acceptably balanced results how-
ever method 1 has been chosen as the best option to integrate
into the current algorithm. Method 1 directly produces a measure
of imbalance which is more easily integrated, whereas method 2
needed to be adapted to allow integration. In summary, inclusion
of continuous stratification variables in randomisation schemes
without the need to categorise allows more sensitivity to the vari-
able and has indirect impact on the analysis. We advocate the use
of stratification variables within models of analysis, if continuous
then these should be utilised as such.P460
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Background
Trials of tests may evaluate their role as screening, diagnostic,
staging, monitoring or prognostic tests. The National Institute of
Health Research (NIHR) programme has over 20 years experience
in commissioning trials of tests for these clinical roles through
the Health Technology Assessment (HTA) and Efficacy and Mech-
anism Evaluation (EME) Programmes. Trialists often struggle to
identify appropriate methods for computing sample size for test
evaluation trials, and there is often little data available to inform
the assumptions made in sample size calculations.
Objective
To review the methods used for sample size calculation for trials of
tests and assess the evidence base for the assumptions made in the
original sample size calculation and assess their validity in compari-
son with the experience of the trial.
Method
Final study reports, published protocols, and (where available)
grant applications from the NIHR HTA and NIHR EME programmes
for trials evaluating tests were identified. The theoretical approach
used for computation of sample size was identified and classified
according to (i) the study outcome to which it related, (ii) whether
it was based on consideration of statistical power to test a hypoth-
esis or precision to estimate a parameter, and (iii) whether it was
judged an appropriate method to compute sample size in compari-
son with the established literature. Estimates of key parameters de-
scribing the baseline scenario (such as disease prevalence and
progression, the performance of comparative tests, the correlation
between tests) were identified from the protocol and their sources
identified. Assumed values for key parameters in each sample size
calculation were compared with the estimates observed in the tri-
als. Details of any sample size revisions undertaken during the
study were identified and reported. All assessments were initially
undertaken independently in duplicate and consensus reached
through team discussion.
Results
62 reports of test evaluation studies were identified from the NIHR
HTA and NIHR EME published monographs. Their evaluation is cur-
rently ongoing, and we will report on the aspects detailed above. We
are considering whether it is possible to predict particular scenarios
in which sample size estimates are most challenging and least likely
to be valid.
Discussion
We will discuss the challenges that researchers across the NIHR pro-
grammes have faced in identifying methods and computing sample
size calculations for test evaluation studies, and assess the import-
ance of considering planning sample size revision processes in test
evaluation studies.
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SWOG S0819 is a phase III trial evaluating both the value of cetuxi-
mab in the treatment of advanced non-small cell lung cancer
(NSCLC) and epidermal growth factor receptor (EGFR), as measured
by FISH, as a predictive biomarker for cetuximab efficacy in NSCLC.
The design of the study incorporated co-primary objectives to assess
cetuximab in both the overall study population and among EGFR
FISH-positive (FISH+) patients. Activated July 15, 2009, it was one of
the first trials in SWOG requiring tissue to evaluate a primary object-
ive in a biomarker-defined population. We will outline how methods
for obtaining adequate tissue, and monitoring results from the FISH
assay in comparison with design assumptions impacted the conduct
of the study.
Methods
All patients were required to submit a paraffin-embedded tissue
block or at least 10 unstained slides. In addition to the EGFR FISH
assay, if additional tissue remained, secondary objectives included an
investigation of the efficacy of cetuximab in patents whose tumor
expressed EGFR by immunohistochemistry (IHC) and in patients
whose tumor harbored a KRAS mutation, with priority given to IHC if
tissue was limited. The FISH assay was performed at University of
Colorado and results reported to the SWOG stat center on a monthly
basis. IHC was performed at University of Colorado and KRAS per-
formed at UC Davis.
Results
A total of 1333 patients were registered to S0819. Usable tissue
specimens were obtained from 1208 patients, of which, 1046 were
adequate for FISH. Of these, 406 were FISH+. Comparisons between
the study design assumptions and the observed proportions were
monitored on a monthly basis. The proportion of FISH+ patients was
lower than anticipated as was the assay success rate. This monitoring
resulted in the following interventions in the study conduct: efforts
to improve these numbers included development of a form that re-
quired the local pathologist to review and confirm that the tissue
contained at least 100 tumor cells prior to submission. An automated
email notification system to prompt sites for additional tissue if their
initial submission was deemed to be inadequate when the FISH assay
was attempted at Colorado. The study design was modified in June
2015 as a result of the lower than expected number of EGFR FISH+
patients.
Discussion
Although activated in July 2009, planning for the study began two
years earlier in July 2007. Around this time, data from multiple stud-
ies suggested that the efficacy of EGFR tyrosine kinase inhibitors was
likely concentrated in patient with tumors harboring EGFR mutations.
As EGFR mutation status and EGFR expression by FISH are correlated,
this development could have affected accrual to this first line study
and may have reduced the proportion of EGFR FISH+ observed.
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Background
Total knee replacement is conducted to relieve pain and improve func-
tion, most commonly as a treatment for osteoarthritis. Over 90,000 op-
erations take place annually in the NHS, and knee replacement
provides pain relief for most people. However, at three months or more
after surgery, around 20% of patients report moderate to severe pain.
To inform the design of an intervention to improve management of
chronic pain after knee replacement, we conducted a systematic review
that identified only one small randomised controlled trial assessing an
intervention to treat chronic pain following knee replacement. Giventhe fact that chronic post-surgical pain is multifactorial with surgical,
biological and psychological contributions, we undertook a broader
systematic review to evaluate the evidence for the management of
chronic pain after any surgery type.
Methods
The protocol for the review was registered on PROSPERO in 2015. PICO
criteria were: patients aged 18 years, with 90% of participants reporting
chronic post-surgical pain; interventions for pain delivered a minimum
of three months after surgery: control patients receiving placebo, usual
care or alternative pain management intervention. Searches were con-
ducted in MEDLINE, EMBASE, CINAHL, psycinfo, The Cochrane Library,
and opensigle. Screening was performed by a single assessor with 10%
of records double-screened. The primary effectiveness outcome was
pain; that for harm was serious adverse events. Risk of bias was
assessed using the Cochrane Risk of Bias tool.
Results
Searches run in March 2016 yielded 17,027 records. 66 trials with data
from 3,149 participants were included. Most trials included patients
with chronic pain after spinal surgery (23 trials) or phantom limb pain
(21 trials). Interventions were predominantly pharmacological, including
anti-epileptics, capsaicin, epidural steroid injections, local anaesthetic,
neurotoxins, N-methyl-D-aspartate receptor antagonists and opioids.
Other interventions included acupuncture, exercise, limb liner after am-
putation, spinal cord stimulation, further surgery, laser therapy, mag-
netic stimulation, mindfulness-based stress reduction, mirror therapy
and sensory discrimination training. Opportunities for meta-analysis
were limited by heterogeneity. For all interventions, there was insuffi-
cient evidence to draw conclusions on effectiveness.
Conclusions
The aim of our systematic review was to synthesise data on the man-
agement of chronic pain after surgery. Chronic pain is difficult to
treat and combination treatments matched to patient characteristics
are advocated. In this review, the majority of studies evaluated
pharmacological interventions and we found no studies investigating
multidisciplinary or individualised interventions for management of
pain after surgery.
The results of our systematic review highlight the need for further
evidence to inform recommendations about care provision for pa-
tients with chronic post-surgical pain. We are now addressing this
gap through a multi-centre randomised controlled trial evaluating
the clinical and cost-effectiveness of a care pathway for patients with
chronic pain after knee replacement.
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Background
A linear mixed model incorporating a random cluster effect is
the most commonly used model for analysis of complete
stepped wedge designs with Gaussian outcomes and a repeated
cross-sectional sampling structure. It is recognised that the max-
imum likelihood estimator of the treatment effect in this model
is a combination of horizontal (within cluster) and vertical (be-
tween cluster) comparisons. However, the precise nature of this
combination has not previously been clearly articulated for
these designs.
Methods
We apply standard results using partitioned matrices to derive a
simple expression for the weighted combination of the horizontal
and vertical components of the treatment effect estimator, each
presented as linear combinations of cluster-period means. We ex-
tend the mixed model to incorporate random effects appropriate
for a closed cohort design and derive the analogous results under
this design.
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The weights assigned to the horizontal and vertical comparisons
involve a simple expression depending on the number of periods in
the design, the cluster size and the intra-cluster correlation. We use this
result to describe scenarios in which the treatment effect estimator is
dominated heavily by the horizontal comparisons. We provide explicit
expressions for the horizontal and vertical components of the treat-
ment effect estimator in a number of example designs and ?A3B2 show
$132#?>explain the intuition behind them. We also describe how the
decomposition provides a basis for the construction of randomisation
tests. The extension to the closed cohort design involves identical hori-
zontal and vertical components as the cross-sectional sampling design,
the only difference being in the construction of the weights.
Conclusions
The decomposition into horizontal and vertical components en-
ables a better understanding of the explicit linear combinations
of cluster-period means underlying the treatment effect estimator.
It also describes where the maximal information resides in these
designs, leading to suggestions for optimal incomplete designs.
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Background
Wolfram Syndrome (OMIM 222300) is an ultra-rare, monogenic,
neurodegenerative disorder of children and young adults. Prevalence
is approximately 1:700,000. The prognosis is poor as premature death
and severe neurological disabilities are not uncommon. The natural
history of Wolfram Syndrome includes progressive optic and brain-
stem atrophy. Many children are registered blind by the age of
18 years. There is no effective treatment.
Sodium Valproate is classed as an anticonvulsant and is currently
approved for use in the treatment of epilepsy and bipolar disorder.
The cell cycle regulator p21cip1 has been identified as a therapeutic
target for Wolfram Syndrome and one of the mechanisms through
which sodium valproate is expected to mediate its effect is by in-
creasing p21cip1 expression levels. We investigate the hypothesis
that it slows the progression of symptoms.
Methods
We present a randomised, double-masked, placebo-controlled, multi-
centre, international clinical trial to investigate whether sodium valpro-
ate halts the progression in clinical symptoms of Wolfram Syndrome.
We propose the dual primary outcomes: (i) Visual acuity (VA), measured
on the logmar scale using standard charts; and (ii) Ventral pons volume
(VPV), measured in mm3 by MRI scan. These continuous outcomes are
chosen because they are clinically meaningful and associated with dis-
ease progression. VA is very important to patients and their families,
and any reduction in sight deterioration will be welcome.
Recruitment is severely constrained in this ultra-rare condition. We in-
crease statistical power by conducting longitudinal analyses of the pri-
mary outcomes. This is feasible in Wolfram Syndrome because the
symptoms under study tend to deteriorate linearly over time. Justifica-
tion for this claim is given.
Mean outcome trajectories are modelled using linear mixed effects
regression, allowing the average rates of change to be different in
each arm, and each patient to have their own intercept. This method
allows the study of serially-correlated outcomes. Treatment effect is
tested by likelihood-ratio test using an alternative, nested model with
no fixed effects for treatment arm. Treatment will be considered suc-
cessful if it is associated with a significant, clinically-relevant reduc-
tion in the rate of degradation.
Results
We assess VA every 6 months for 3 years. To investigate a 60% re-
duction in the annual rate of degradation from 0.075 to 0.03 logmarunits requires 60 evaluable patients in total to provide 80% power
and 10% significance.
We assess VPV every year for 3 years. To investigate a 70% reduction
in the annual rate of degradation from 81.6 to 24.5 mm3 requires 60
evaluable patients to provide 81% power and 7% significance.
We infer operating characteristics by simulation. The equivalent non-
longitudinal analyses would require approximately 120 patients in total.
Conclusion
This efficient design, which uses a repeated-measures analysis of the
primary outcome, will achieve conventional statistical error rates,
thereby enabling a potentially practice-changing clinical trial in this
ultra-rare condition.
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In several clinical trial settings, it is difficult to recruit the overall sample
provided at the design stage, and different problems may occur in pa-
tient’s enrolment. The amount of information conveyed by a trial termi-
nated prematurely for poor accrual may be minimal. A Bayesian
analysis of such a trial may salvage this information, by providing a
framework in which to combine prior with current evidence. In this
work we propose a Bayesian analysis of a trial candidate for termination
due to poor accrual. RESCUE trial is a randomized controlled trial evalu-
ating the effect of adjunctive oral steroids to prevent renal scarring in
young children with febrile urinary tract infections. Primary outcome is
the difference in scarring proportion between standard antibiotic ther-
apy versus standard therapy + corticosteroids. By study protocol, a fre-
quentist approach to sample size calculation require 92 randomized
patients per arm, considering 20% lost follow-up. After 2 years, only 8
patients completed the follow up to determine the study outcome
(3 in corticosteroids therapy group and 5 in control group). The
sample size was recalculated with the Bayesian Worse Outcome Criter-
ion for differences in proportions (length = 0.3 and coverage = 0.9) ap-
plying a 0.5% down-weight. An informative prior on scar proportions
was derived from literature considering a scar probability of 0.33 and
0.66 respectively in treatment and control group (Huang YY, 2011). An
interim Bayesian analysis on recruited patients has been performed;
having a few data to estimate the likelihood, inference was expected to
be seriously conditioned by the prior. To assess robustness of conclu-
sion a sensitivity analysis on prior definition has been performed
considering 1) informative Beta prior as in sample size estimation 2)
informative Beta with 0.5% down-weight 2) uninformative Beta (1,1)
prior. Results are compared in term of posterior probability. The esti-
mated Bayesian sample size is 41 infants per arm, leading to a reduc-
tion of 51 patients compared with frequentist oneThe Bayesian
inference is a flexible tool, compared to frequentist one, taking into
account of a-priori knowledge about treatment effect. The informative
inference, on small sample, may be weakly influenced by data. How-
ever, sensitivity analysis lead to consider the inference robustness.
Nevertheless, we advocate to choose beforehand a Bayesian design
and not to switch to a Bayesian analysis method that produces a more
favourable outcome after observing the data.
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Background
As medical imaging technology advances, analysis methods mature
and scanners become more globally available, there is an increasing
interest to use advanced or novel imaging biomarkers as clinical tri-
als endpoints. MRI, PET, high resolution CT and even ultrasound have
demonstrated unique abilities to measure diseases closer to the
mechanism of action. Many novel biomarkers are able to show both
structural and functional changes and validation studies provide
good evidence that imaging may provide both the sensitivity and
specificity that have eluded the assessment of these diseases and
their absence may actually be at least partly responsible for the
failure to develop effective therapeutics. However, many of the pub-
lished studies that declare biomarkers to be validated for use fall far
short of demonstrating fitness for use. In 2015, the Quantitative
Imaging Biomarker Alliance published the results of a two-year col-
laborative effort to standardize the statistical and technical methods
and metrics to validate a biomarker for use as an endpoint in a
clinical trial. Since then, these methods have been used to validate
several imaging biomarkers for study-specific use as primary and sec-
ondary endpoints by providing statistically and clinically rigorous
study designs to sufficiently demonstrate that these biomarkers are
reliably acquired and analyzed and that there is reasonably good
prediction of a clinically accepted outcome.
Methods
Standardized statistical methods that are globally recognized by me-
trology standards agencies, including the Bureau of International
Weights and Measures (BIPM) and the National Institutes of Stan-
dards and Technology (NIST) are used to define reliability in terms of
repeatability, reproducibility and linearity. Standard metrics include
statistical estimation of the variance components that eventually de-
fine how reliable the imaging biomarker would be in a clinical trial
setting, and a linear relationship to the truth. An additional compo-
nent to validation is the ability of the imaging biomarker to predict
clinical outcome. Results Two case studies, one with a quantitative
and one with a semi-quantitative imaging biomarker evaluation of
medical imaging will be examined for what would comprise a
complete dossier for validation or qualification. From these case
studies, we will summarize a standard protocol for a quantitative im-
aging biomarker validation study, risks to the successful completion
of these trials and methods to incorporate biomarker validation into
the drug development process.
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Background
Trials of complex health services interventions often lack detailed
preparatory work explicating the mechanisms by which the interven-
tion is supposed to work. This lack of preparatory work contrasts
sharply with drug trials, which can be the culmination of many years
of preclinical work. The UK Medical Research Council provides guid-
ance that underscores this issue, and highlights the need for better
theory development and modeling to support, justify, and optimize
trials of complex interventions. We propose that this requires an under-
standing of when ‘hypothetical’ Elements (e.g. Using healthy partici-
pants instead of patients; piloting interventions on physicians outside
their clinical practice) can be used to predict ‘real-world’ Outcomes,
analogous to our extensive understanding of which animal models areappropriate to different human biological mechanisms. At the moment,
studies involving hypothetical elements are discounted in the literature
(i.e. Considered not clinically relevant, excluded from systematic
reviews), often because of implicit and unsupported objections that
such data cannot predict real-world outcomes. While many literatures
have explored predictors of the association between hypothetical and
real-world decisions, none has summarized these in a manner that
would help health care intervention developers know when hypothet-
ical pilot data are likely to agree with the real world.
Objective
To conduct a systematic concept review of the factors affecting the
association between hypothetical and real-world decision-making.
Methods
Our research question was: ‘What are the factors that affect the asso-
ciation between hypothetical and real-world decisions?’ A systematic,
peer-reviewed search strategy was developed based on keywords,
?A3B2 show $132#?>titles, and MESH headings related to (i)decision
making or behaviour (and related concepts e.g. Reasoning, risk
taking); (ii) hypothetical situations (e.g. Uncertainty, proxy), and (iii)
real world situations (e.g. Reality, everyday), and applied to psychinfo
and Medline in December 2015. Two coders extracted study spe-
cifics, as well as quotations describing the relevant factor associating
hypothetical and real outcomes. Factor wordings were standardized,
collated, and organized into themes.
Results
A total of 1846 studies captured by our search strategy ultimately
yielded 59 studies that contributed at least one factor. Contributing
articles addressed issues of behavioural economics(80%), psychology
of reasoning (31%), social psychology (17%), health behaviours
(12%), and neuroscience(5%). A total of 42 factors were grouped into
5 categories, including Personal Characteristics (9 factors e.g. Age,
cognitive ability, personal relevance); Presentation Characteristics (8
factors; e.g. Framing effect, time for reflection, issue salience); Cogni-
tive Factors (17 factors; e.g. Discounting, normative beliefs, social de-
sirability); and Participant Characteristics (1 factor; samples match
target population).
Discussion
This work provides a summary of the factors known to affect when
studies with hypothetical elements might be expected to agree with
real world decisions. Based on a range of related literatures, our
framework will aid investigators who are interested in understanding
whether the design of their pilot study will allow them to draw con-
clusions about the real world. This initial work will help us to pilot
our health services trials more effectively, making the ultimate inter-
ventions more efficient and effective.
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Background
Neuromyelitis optica (NMO) is a rare, autoimmune disease of the cen-
tral nervous system that affects approximately 700 patients in the
United Kingdom. It is characterised by relapses of the optic nerves and
spinal cord. To reduce the severity and frequency of these attacks, pa-
tients are treated with immunosuppressants, including rituximab which
is a second line therapy for NMO. Rare diseases pose unique challenges
for clinical trials, including difficulties in recruiting sufficient numbers.
Many studies are observational and prone to bias. In the absence of
high quality randomised controlled trials, the use of individual patient
data (IPD) meta-analysis to synthesise the results of existing studies
whilst accounting for confounders provides an opportunity to summar-
ise the available evidence to inform treatment decision making.
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The aim of this paper is to review all available information to evalu-
ate the effectiveness of rituximab in NMO.
Methods
We included all experimental and observational study types that
assessed rituximab for the treatment of NMO patients. We performed
a literature search using MEDLINE, EMBASE, Web of Science, and
Cochrane. Risk of bias was assessed for each study. The primary out-
come was time until relapse; other outcomes of interest included
?A3B2 show $132#?>Expanded Disability Status Scale (EDSS), patient
demographics, annualized relapse rate, NMO igg status, disease dur-
ation, number of relapses (before and after treatment), number and
timing of rituximab doses. The authors of each study were contacted
to obtain individual patient data. Where data were not forthcoming,
data was extracted electronically by digitising figures presented in
published papers.
Results
Thirty-five studies involving 393 patients have been included. Of
these, 30 were case studies and the remaining 5 were only available
in abstract form, no RCT were identified. IPD for 186 patients were
extracted from papers. Variable quality of the data has been noted
with some papers not reporting key outcome information. All studies
were poor quality with no study adjusting for confounders. Authors
of selected studies have been contacted to share their data,re-
sponses have been positive, however no disclosure of data have
been made at this time. There were 131 (70%) women, 13 (7%) men
and 42 (23%) unknown participants, with a mean age of 37 years
and disease duration of 41 months. The most-frequently used rituxi-
mab regimen was two 1 g doses separated by 14 days in 37 cases
(28%).The average EDSS score before (after) treatment was 5.3 (4.3).
The average number of relapses before (after) treatment was 5 (1).
We will be using a Cox-(proportional hazards) regression model to
predict the time to relapse rate whilst adjusting for important
confounders.
Conclusions
This study is ongoing and these preliminary results are susceptible to
change. It is hoped that constructing a robust evidence based review
can lead to more efficient RCTs. Bayesian design RCT have been sug-
gested as a solution to small population trials, incorporating prior in-
formation on efficacy, can increase the possibilities for other RCT
designs i.e. Non- inferiority or adaptive designs that previously were
not feasible for a rare disease trial.
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Background
Increased quality of reporting of randomized controlled trials (RCTs)
has been associated with the publication of the main CONSORT
Statement. Over time there have been a number of extensions to the
CONSORT Statement, such as the Non-Pharmacological Trial [NPT] ex-
tension, yet we have little data on how these have changed the
reporting practices of investigators.
Objective
The aim of this paper was to assess the change in quality of report-
ing of RCTs for behavioural weight loss programs using CBT with the
2008 publication of the CONSORT NPT extension.
Methods
A systematic review was conducted to identify randomised controlled
trials that assessed the efficacy of cognitive behavioural therapy-based
weight loss interventions on eating behaviour or psychological vari-
ables. The Downs and Black checklist was used to score the quality ofreporting of 15 RCTs that were published before (3 trials) and after (12
trials) the publication of the 2008 CONSORT NPT.
Results
There was a significant increase in the number of criteria that were
fully met (M (SD) pre-2008 = 15.0 (1.0) vs. Post-2008 = 20.0 (2.7), F =
9.75, p = .008) and fully or partially met (M (SD) pre-2008 = 15.7 (1.2)
vs. Post-2008 = 20.2 (2.6), F = 8.50, p = .012). There was also a signifi-
cant reduction in the number of criteria that were not met or were
ambiguous (M (SD) pre-2008 = 11.3 (1.2) vs. Post-2008 = 6.8 (2.6), F =
8.50, p = .012). However, it should be noted that even with the im-
proved reporting many checklist items were still not being included
(e.g., adverse event reporting, representativeness of the sample,
blinding).
Conclusions
This study showed that, although there seems to be some improve-
ment with the publication of the CONSORT NPT Statement, its effects
are still less than ideal. CONSORT should be more widely and
strongly endorsed, and enforced, in order to have complete and
understandable behavioural RCT reports.
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Background
Successfully recruiting the pre-specified number of patients to time
and target within clinical trials remains a difficult challenge that
negatively impacts all stakeholders in a clinical trial. Current methods
to monitor recruitment in practice appear limited to the usual com-
parison of the predicted and actual recruitment curves and the size
of discrepancy. In 2010 a systematic review of methods to predict re-
cruitment was conducted, which identified five classes of models
and their limitations.
Objectives
To update the systematic review by Barnard et al. (2010) to identify
new methods to predict recruitment in clinical trials and determine
whether these new methods address the limitations of methods pre-
viously identified. Identify perceived barriers to implementing these
models in clinical trials.
Methods
The project will update the systematic review of Barnard et al.
(2010). This update will include methods identified and published
from August 2008 until present. The Online Resource for Recruit-
ment Research in Clinical Trials database (ORRCA) will be used to
identify relevant literature. Newly identified methods will be
assessed for eligibility. Methods will be assigned to existing
proposed classifications of unconditional, conditional, Poisson,
Bayesian and Monte Carlo Simulation Markov Model with new clas-
sifications as appropriate. The assumptions made by each method
will be identified and compared between models. Levels of infor-
mation required to implement the models, will be considered and
applied to real examples of ongoing or recently completed clinical
trials.
Expected results
The results of this systematic review will explore the advances in
methodology to predict recruitment in clinical trials. It will highlight
limitations of existing methods and barriers to implementation
highlighting direction for further developments. In this way we can
provide more reliable predictions of recruitment based on each dif-
ferent trials recruitment needs. The benefits of more accurate predic-
tions will be the reduction of the deviation between observed and
expected recruitment curves.
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Subgroup analysis has received extensive attention in recent clinical
research for the development of stratified medicine. This tendency
reflects the advance of genetic testing and the potential exploitation of
heterogeneity in subgroups. It also emphasises the identification of
medical interventions to suitable subpopulations (as defined by bio-
markers) for efficacy and against the others for safety. Graphical ap-
proaches are routinely employed in subgroup analysis, typically for
describing effect sizes of subgroups. Such visualisation encapsulates
subgroup information and greatly boosts the clinical decision-making
process. However, existing approaches still have inherent drawbacks
and their use may lead to misinterpretations to subgroup effect sizes.
For instance, forest plots provide no insight on the overlap of different
subgroups; additionally, whether or not a subgroup’s confidence inter-
val crosses the no-effect point does not necessarily imply a lack of ef-
fect or contribute an effect to the subgroup. It is therefore crucial to
correctly depict the effect sizes and information, particularly in order to
prevent overstating effects. To develop an optimal visualization ap-
proach, we assessed graphical approaches for subgroup analysis under
a synthetic dataset. Several techniques (such as level plots, barcharts,
Venn diagrams, tree plots, forest plots and matrix plots) were applied
to exhibit certain subgroup information. Some have been further im-
proved by mitigating their original demerits. In final, we summarise the
general strengths and failings of the graphical approaches and outline
potential visualisation techniques.
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Evidence Synthesis
Fixed-effect meta-analysis is a powerful instrument for combining
related studies but such a combination is considered flawed if studies
use different methods or investigate different populations. If differences
are merely statistically detected then techniques of random-effects
meta-analysis are employed to combine them. On the other hand,
complex knowledge is difficult to interpret and although Bayesian
methods are currently being developed they are unable to deal with
complex knowledge when heterogeneity is statistically detected.
Venous Thromboembolism and Cancer
According to a large meta-analysis from 2008, around 10% of pa-
tients having acute unprovoked venous thromboembolism are ex-
pected to be diagnosed with cancer within a year. Nevertheless,
several recent clinical studies indicate a lower incidence of diagnosis
of cancer in such patients and also a lower sensitivity of extensive
screening for cancer than the large meta-analysis suggests. Despite
similarities, heterogeneity was statistically detected between those
studies. The variability in screening designs requires a method that
can deal with complex knowledge to combine them.
Method
A new method for meta-analysis that deals with both complex know-
ledge and unexplained heterogeneity was developed. The method is
thus applicable to synthesise a wide range of related medical trials in
different fields. The method uses propositional probabilistic logic to
represent complex findings and merges them using an operator that
was shown to be appropriate in the presented setting by an argu-
ment related to the maximum entropy principle.Results
Our meta-analytical findings indicate the following: The incidence of
diagnosis of cancer in patients with unprovoked venous thrombo-
embolism is somewhere between 6.97% and 9.79%. Routine evalu-
ation detects between 36.59% and 49.61% of those cancers while
the combination of routine and extensive screening methods detects
between 74.99% and 83.25% of those cancers. Therefore, the inci-
dence of cancer diagnosis is still relatively high and the combined
screening is superior to routine evaluation in detecting such an oc-
cult cancer.
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Background
When designing and analysing clinical trials, using previous relevant
information, perhaps in the form of evidence syntheses, can reduce
research waste. We conducted the INVEST (investigating the use of
Evidence Synthesis in the design and analysis of clinical Trials) survey
to summarise current evidence synthesis use in trial design and ana-
lysis, to capture the opinions of trialists and methodologists on such
use, and to identify any barriers.
Methods
We distributed the INVEST survey during the two-day International
Clinical Trials Methodology Conference in November 2015, and pro-
vided access to an online version for one month following the con-
ference. All respondents were asked to indicate their views on use of
evidence synthesis in trial design and analysis and to rank what they
considered to be the three greatest barriers to such use. Respon-
dents who indicated that they had been involved in trial design and/
or analysis were asked additional questions about whether and how
they have used evidence synthesis in practice. Among these respon-
dents we contrasted their views on whether evidence synthesis
methods should be used versus actual use.
Results
Of approximately 638 people attending the conference, 106 (17%)
completed the survey, half of which were statisticians. Support was
generally high for using a description of previous evidence, a sys-
tematic review or a meta-analysis when designing a trial. Fewer
participants indicated support for use of network meta-analyses,
decision models and value of information analyses. Only about 5%
felt that external evidence should not be used in the analysis of a
trial, with an additional 20% being unsure. Among respondents in-
volved in trial design and/or analysis, fewer indicated that they had
used evidence syntheses to inform design or analysis during the
last 10 years than indicated that these methods should be used.
For example, only 6% (5/81) had used a Value of Information ana-
lysis to inform sample size calculations, compared with 22% (18/81)
feeling that this was desirable. The greatest perceived barrier to
using evidence synthesis methods in trial design or analysis was
time constraints, followed by a belief the new trial was the first in
the area.
Conclusion
The INVEST survey indicates that, generally, trial teams are using
evidence synthesis in trial design and analysis less than they think is
desirable. Since evidence syntheses can be resource-intensive, we ad-
vocate additional research and training on ways to undertake them
efficiently. Investment in adequate resources and training at this
stage could lead to cost savings in the long term.
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Background
Successful blinding of participants, healthcare providers and trial
personnel prevents knowledge of assignment from influencing ad-
herence to intended interventions. However, blinding in nonphar-
macological trials is difficult, and these trials are often considered
to be at high risk of performance bias. The revised Cochrane risk of
bias tool for randomized trials (rob 2.0) differentiates between the
effect of assignment to intervention and the effect of starting and
adhering to intervention. The former is the effect of interest in an
intention-to-treat analysis and the latter is the effect of interest in a
per-protocol analysis. Issues of blinding, implementation and adher-
ence to intended interventions differ importantly between these
two effects.
Objective
To provide guidelines for trialists to reduce bias due to deviations
from intended interventions in nonpharmacological trials in the con-
text of an intention-to-treat analysis.
Methods
Within the development of the rob 2.0 tool, one working group
was tasked with the development of signalling questions, criteria
for reaching a judgment and full guidance on the domain ‘bias
due to deviation from intended interventions’. The new tool pro-
vides a more nuanced judgement of performance bias in non-
pharmacological trials. In trials that aim to assess the effect of
assignment to intervention, deviations from intended interven-
tions that reflect usual care do not lead to bias. In the current pro-
ject we extended the insights acquired during development of
the rob 2.0 tool to propose guidelines for clinical trialists. These
guidelines aim to inform trial conduct from planning through to
reporting, with the aim of minimizing performance bias in non-
pharmacological trials.
Results
The guidance includes three components. First, interventions
should be clearly articulated in the protocol, including any plans
to stop or modify interventions in response to clinical events. In
particular, trialists should define in advance any co-interventions
that would be administered as part of usual care. Second, during
the trial, all deviations from the protocol interventions that do not
reflect usual care should be monitored and recorded. These
deviations from the intended interventions might include co-
interventions, contamination, switches to other interventions,
non-adherence, or failure to implement some or all of the inter-
vention. The important consideration is that these deviations
occur because of the trial context rather than as a reflection of
routine care. Third, the departures identified should be reported
fully and clearly to facilitate risk of bias judgements by trialists
themselves, peer reviewers and systematic review authors.
Conclusion
Development of the rob 2.0 tool has led to supplementary guid-
ance aimed at clinical trialists. The work around performance bias
presented here is part of the wider initiative to cover all biases
that might arise in clinical trials. This initiative recognises that
clinical trials and evidence synthesis are part of the same continuum of
effectiveness research and aims to ensure that method development inone area is maximally integrated with applications in the other area to
ensure optimal trial conduct and reporting.
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Aim
To identify priorities for methodological research to assist the design,
conduct, analysis and reporting of clinical trials in low and middle in-
come countries (LMICs).
Background
Research into methods used to design, conduct, analyse and report
clinical trials is essential to ensure that clinical decisions made are de-
rived from robust and reliable evidence. In a previous study [1] the key
stakeholder group of Directors of UK Clinical Research Centre (UKCRC)
registered clinical trials units (CTUS) identified the most important
methodology research topics. However, it cannot be assumed that
these research priorities reflect those in LMICs. There is a need for re-
search to come from LMICs countries and it has been stated, in the
2013 World Health Report, that LMICs must become the generators
and not the recipients of research data in order for improvements in
public health outcomes in these most undeserved regions of the world.
In order for any progress to be made in LMICs there is a critical need
for this research. This is to ensure that particular methodological issues
are identified and communicated to health care workers in these re-
gions so that they might optimise future designs for trials.
Methods
An online survey will be conducted November 2016 to March 2017
with members of the Global Health Network, globalsurg, The Clinical
Research Initiative, Cochrane, Evidence Aid and other clinical trials re-
searchers with LMIC experience. The first round will be an online sur-
vey in relation to the design, conduct, analysis, reporting and
interpretation of a trial. Participants will be asked to list up to three
topics they feel are important priorities for trials methodology re-
search. Topics identified will be independently reviewed and cate-
gorised by two members of the research team and split into two
separate lists for the second round. The primary list will consist of
topics identified by more than one respondent and the second list
will consist of topics identified by a single individual. In the second
round the participants will rank the topics in order to identify prior-
ities within both the primary and secondary lists.
Results
A list of the top priorities for trials methodology research in LMICs
countries will be presented. Common priorities to those in high in-
come countries will also be noted.
Conclusions
By presenting these top priorities we will have the foundations of a
global health trials methodological research agenda which we hope
will instigate further methodology research in specific areas in order
to increase and improve trials in LMICs.
Reference
[1] Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson PR. The Trials
Methodological Research Agenda: Results from a priority setting exercise.
Trials 2014; 15:32 doi:10.1186/1745-6215-15-32.
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As highlighted by a recent report for the National Institute for Health
Research's Health Services and Delivery Research funding stream,
bridging the implementation gap is increasingly being recognised as
an intransigent challenge for complex interventions in health services
research. Patient and Public Involvement (PPI), process evaluation
and the use of theoretical frameworks have all been highlighted as
being important ‘meta-processes’ in trial conduct and design to re-
duce research waste and improve implementation of trial evidence.
In addition, early consideration of an interventions pathway to
impact has been advocated. The aim of this exploratory study was to
examine the Cochrane Database of Trials over the last six years to
determine the level of utilisation of PPI, process evaluation and
theoretical frameworks alongside dental trials, whilst concurrently ex-
ploring whether the pathway to impact and implementation was be-
ing considered.
The Cochrane Database of Trials was searched for reports on Rando-
mised Controlled trials (RCTs) and protocols of RCTs over a five year
period (2010–2016). As the aim of this exploratory study was to get a
‘snap-shot’ of current activity, other subscription databases, open
access databases and the grey literature were not searched. Any den-
tal intervention that would have utilised psycho-social mechanisms
explicitly or implicitly was included, whilst any intervention that
acted through a pharmacological mechanism was excluded. Included
studies were assessed to determine whether they reported on any of
the ‘meta-processes’ detailed above. Titles and abstracts identified by
the electronic search were downloaded to a reference management
database and duplicates were removed.
582 of 932,577 records had the term ‘dental’, ‘oral’ and ‘trials’ in the
Title, Abstract or Keyword. 56 studies related to psycho-social inter-
ventions or had psycho-social pathways to implementation. The pro-
portion of trials that reported PPI, process evaluation, theoretical
framework or mentioned implementation 0%, 21.7%, 43.5% and
4.3% respectively, whilst the proportion of protocols was higher
(46.7%, 60.0%, 73.3% and 6.7%).
The use of ‘meta-processes, in trial design and conduct has im-
proved, although considerations about pathway to impact and the
implementation of the research evidence, once generated, appears
to remain poor.
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Upon release of primary results from a positive SWOG-coordinated
Phase III myeloma trial, a pharmaceutical company supplying study
drug plans to retrospectively use the results in a regulatory filing
exactly two years after presentation of results. The trial accrued 525
patients from 2008 to 2012 with patients being followed for six
years after randomization. After an initial meeting between the
SWOG Statistical and Data Management Center (SDMC) and the
company in May 2016, the company outlined an aggressive plan to
reconsent all living patients in order to extend follow-up, capture
additional data and initiate site monitoring including 100% source
data verification (SDV) for all registered patients. All patient data as
of December 2016 needs to be complete, query-free and verified
by March 2017 in order meet the timeline for submission to the
FDA in December 2017.The protocol revision requiring reconsent and addition of new case
report forms (CRFs) was distributed to the sites on 10/1/2016. Local
institutional review board (IRB) review was required as this study was
initially reviewed by such prior to formation of the CIRB. A CRO was
hired and trained on the SWOG SDMC systems in September 2016 to
facilitate onsite monitoring of nearly 100 physical sites beginning in
November 2016. Data are to be complete and every data point veri-
fied by the CRO by February 2017 in preparation of a final data trans-
fer in March 2017 to the pharmaceutical company.
An overview of all systems used during the conduct of this trial
highlighted challenges including implementation of an online EDC
system and subsequent capabilities for amending data online.
Required updates in adverse event reporting (CTCAE 3.0 to 4.0) over
the tenure of this trial also complicated the monitoring efforts. Drug
company and CRO staff education of both legacy and current
systems was necessary in order to evaluate and query all data for
regulatory submission.
The membership structure and alignment of participating sites chan-
ged as the NCTN and NCORP networks replaced the cooperative
group structure in 2014. With the configuration of the network mem-
bership shifting, it is vital to identify updated site contacts, as well as
track and communicate with the cross-network membership. Sites
have experienced staff turnover and some no longer participate in
cooperative group research.
Lessons learned
Achievable goals, concise training, communications, and sufficient
timelines are critical to prepare sites and monitors for extensive data
verification. The SDMC staff has evaluated over 4500 inquiries gener-
ated by the company after initial review of clinical data, posting and
resolving the relevant queries to sites (only 1350/3600 remain out-
standing) while reviewing incoming data generated by additional
CRFs and other site-initiated questions. Sufficient staffing and dy-
namic data management systems are vital.
The clinical data management system (CDMS), Medidata Rave®, pro-
vided by the NCI will benefit future endeavors similar in nature, both
in communication and monitoring efforts. We will continue to iden-
tify additional challenges and lessons learned as well as strive to
compare potential key outcomes based on standard data collection
and review compared to the intense retrospective review.
P483
Design and coordination of the DECAAF II randomized international
trial
Richard Holubkov, Tom Greene, Leonie Morrison-de Boer,
Russell Telford, Tyler Bardsley, Molly McFadden, Alicia Peterson,
Christina Pacchia, Jeffrey Yearley, Ashley Snyder
University of Utah
Correspondence: Richard Holubkov
Trials 2017, 18(Suppl 1):P483
The Efficacy of Delayed-Enhanced MRI-Guided Fibrosis Ablation vs.
Conventional Catheter Ablation of Atrial Fibrillation (DECAAF) II trial is
evaluating catheter-based ablation, guided by 3-dimensional MRI
highlighting areas of fibrosis, as treatment for atrial arrhythmia. The ob-
servational DECAAF I cohort study found an association of atrial fibrosis
burden with arrhythmia recurrence. Therefore, DECAAF II is comparing
ablation specifically targeting visualized fibrosis to standard-of-care
ablation performed without MRI guidance, among atrial arrhythmia
patients undergoing first-time ablation.
Design and execution of DECAAF II are complex for several reasons.
First, before a clinically eligible patient can be randomized, the baseline
3-dimensional MRI must be obtained, confirmed to be of adequate
quality for study use, and processed by a central core laboratory, all
with rapid turnaround to have these images available during interven-
tion for patients assigned to the MRI-guided strategy. The core labora-
tory also determines extent of coronary fibrosis, a stratification factor
for trial randomization. Second, the primary outcome of (time to) atrial
fibrillation recurrence is mainly determined by a smartphone-based ap-
plication that enrolled patients must implement daily. This technology
is expected to increase statistical power to detect a treatment effect
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rence assessment methods such as standard ECGs that are adminis-
tered much less frequently. However, adherence to this self-
administered approach must be aggressively monitored. While the
smartphone-based application generates regular reminders, the
Coordinating Center must be aware of centers that have substand-
ard patient compliance. The primary recurrence outcome will in-
corporate all available testing performed on the patient, including
standard of care ECGs and Holter monitors, to eliminate depend-
ence on full compliance with daily self-assessment.
Third, the trial design includes a 90-day post-intervention “blank-
ing period” That allows atrial tissue targeted during the ablation
procedure to respond to treatment and heal. Therefore, the suc-
cess of the procedure is more appropriately assessed excluding
any arrhythmias observed during this period. In the primary
analysis, “time zero” for counting arrhythmia recurrence events
therefore begins at 90 days after initial intervention (any repeat
ablations after this time will also count as primary outcomes).
This “blanking period” is potentially advantageous for training pa-
tients in the habitual daily use of the monitoring device. By the
end of this period, participating physicians are encouraged to dis-
continue patients from treatment with anti-arrhythmic medica-
tions, whose use is considered a confounding factor for primary
outcome assessment.
Assuming that MRI-guided ablation reduces relative risk of atrial
arrhythmia recurrence by 25%, DECAAF II must observe 517
events in the two equally sized treatment arms to yield 90%
power for a logrank test to detect a treatment effect with re-
spect to recurrence time. With enrolled patients followed up to
18 months after index procedure, various realistic event rate
scenarios indicate that from 750 to 1100 (best estimate: 900)
patients will need to be recruited. The first patient was random-
ized in July 2016.
We will present details of the DECAAF II study design and implemen-
tation, and issues encountered in the initial rollout of the trial at
vanguard study centers.
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Informed consent is a high-risk activity that should be monitored.
The FDA’s ‘Oversight of Clinical Investigations- A Risk-Based Approach
to Monitoring’ encourages alternative approaches to traditional mon-
itoring procedures to improve sponsor oversight of human subject
protection. It specifically permits the use of internet portals where
sites can upload signed consent (IC) forms or other records for re-
mote verification by designated monitors. Functionality was inte-
grated into the Clinical Trial Management System (CTMS) for DEFUSE
3, a NINDS-funded Stroke Trial Network study, to facilitate remote
monitoring of informed consents. This presentation will explore the
implementation strategy utilized which links IC submissions directly
to the subject ID and ecrf submission, while storing Protected Health
Information (PHI) on a separate server. This strategy allows for IC sub-
missions to be processed in a similar way as other clinical trial data,
while allowing access to PHI only to designated remote monitors.
While the potential benefits of this technique include reducing costs,
increasing efficiency, and early detention of errors, serious privacy
and confidentiality issues had to be addressed. Implementation strat-
egy, advantages, challenges, lessons learned from the Defuse 3 Trial,
and other applications of this monitoring strategy will be discussed.P485
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According to ICH GCP guidelines, investigators and research staff
with delegated trial-related duties should be “Qualified by education,
training, and experience” (ICH E6 GCP, 1996) to maintain integrity
and quality in clinical trials. Training documentation is essential to
demonstrate compliance of the investigator and research staff of
these guidelines. Nonetheless, many researchers and sponsors, in
particular in multicenter trials, find it difficult to adequately and ac-
curately document the staff training requirements. When multicenter
trials are conducted within a network, it is important to develop a
sustainable level of standardization in training requirements across
sites and studies that demonstrate the competency of the individuals
being trained.
The Training Documentation Form (TDF) is a comprehensive docu-
ment that tracks all training requirements for each study staff mem-
ber correlated to their study role(s). The TDF clearly defines the
training expectations and requirements from various stakeholders
(e.g., the Sponsor, Institutional Review Board) as they relate to the re-
sponsibilities for each study role, and consistent with the Study Train-
ing Plan (STP) and Site Delegation of Responsibilities Log. When
completed, the TDF demonstrates that staff members are qualified
and fully trained for their study role(s) prior to performing delegated
study activities. The TDF developed for the National Drug Abuse
Treatment Clinical Trials Network (NIDA-CTN) by the Clinical Coordin-
ating Center at The Emmes Corporation is a user-friendly modifiable
electronic document that includes these basic elements critical to a
TDF. It captures each staff member’s name, research site, and dele-
gated study role(s). The TDF lists all training outlined in the STP and
maps the minimal required training and certification prescribed per
study role in a grid, based on the staff’s assigned role (e.g., study
physician,) and assigned tasks (e.g., prescribe medication, data entry)
for the study. The TDF efficiently organizes the training curriculum in
accordance with the investigative team’s predetermined decisions as
to the various roles and associated training requirements. It includes
both general training (e.g., Human Subjects Protection) and protocol-
specific training requirements (e.g., administration of investigational
product, conduct of study assessments). The TDF also captures the
dates that staff completed each required training task and the final
date of overall training completion, the latter of which is docu-
mented on the Site Delegation of Responsibilities Log to serve as the
staff’s starting date on the study. When all required training has been
completed, the TDF is signed by the staff member and endorsed by
both the site’s Principal Investigator and the research center’s train-
ing representative, who collectively confirm that staff members are
ready to begin study responsibilities.
The NIDA CTN has implemented this standardized TDF on seven
studies since 2013, aiding in setting up expectations for training
documentation across studies while minimizing the difficulty of pre-
paring and tracking the training completed by research staff. The
TDF has been welcomed by the quality assurance monitors and the
research management teams and has lead to more efficient study
start up as well as provided a valuable tool for documentation of re-
search staff competency in delegated study activities.
CTN Contract # HHSN271201500065C
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Introduction
Keele Clinical Trials Unit (CTU) is a UKCRC registered CTU based
within the Faculty of Medicine and Health Sciences at Keele Univer-
sity. It specialises in the development and delivery of both feasibility
and definitive multicentre clinical trials, an increasing portfolio of
Clinical Trials of Investigational Medicinal Products (CTIMPs) and epi-
demiological studies, in primary care and at the primary-secondary
care interface. An effective project management structure is essential
for the delivery of high quality research.
Background
97% of Keele University’s research was deemed to be world-leading,
or of international importance in the REF 2014 and Keele CTU, ?A3B2
show $132#?>providing support for the design, delivery, analysis,
reporting and dissemination of applied clinical research is contribut-
ing to this success. Specialist expertise in the areas of trial design,
intervention development, biostatistic approaches, and regulatory
?A3B2 show $132#?>coordination have been developed and de-
ployed. This expertise requires a strong project management struc-
ture to conduct and deliver clinical research to the highest quality
standards.
Methods
A structural flow beginning at project conception through to suc-
cessful dissemination of results for each CTU supported research
project is employed. From conceptualisation, early research ideas
are presented and discussed at a Clinical Studies Think Tank,
attended by specialist and generalist clinicians as well as methodol-
ogists, resulting in research design improvements. Prior to grant ap-
plication, projects seeking CTU collaboration are considered against
CTU adoption criteria including; strategic fit, sponsorship, expertise,
capacity and funding. Next follows project feasibility and visualisa-
tion of project operationalisation, then review by a team of re-
search partners that includes the NIHR Clinical Research Network,
before moving into the business of a CTU Operations Group. From
here, projects are allocated to CTU Trials Managers and by employ-
ing the skills from a variety of integrated working groups, the re-
search is delivered. Working groups, such as the Health Informatics
and Standard Documents working groups, provide invaluable sup-
port for project delivery. Within each working group, innovative
and effective methodologies are developed, that include techno-
logical advances and standardised resources. This process is under-
pinned by a Quality Management System (QMS) implemented from
the Quality Assurance office, ensuring consistency and adherence
to regulatory obligations.
Results
Employing this project management structure results in a transparent
and auditable flow of information and processes within Keele CTU.
Dedicated project management forges strong communication links
within research teams and with collaborators and participants. Over
25 projects are presented at Clinical Studies Think Tank meetings per
year and Keele CTU is currently supporting a portfolio of over 40 re-
search projects, each managed efficiently and effectively within the
resources available to secure the delivery of projects to time and
target.
Conclusions
Keele CTU is increasing its portfolio of research projects whilst making
strides with innovative and effective methodologies. This all needs to
be carried out within a robust and supportive QMS to ensure successful
project delivery. Good order is key to the foundations of any project.
Our strong project management structure has allowed us to work col-
laboratively, integrating all specialties and expertise required, transpar-
ently, in order to achieve the successful delivery of research.P487
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This abstract is not included here as it has already been published.
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Background
Delays in site set-up are a common problem in multi-centre rando-
mised controlled trials. The frequency and format of contact with po-
tential sites could play a role in reducing delays. Preliminary contact,
prior to sites submitting for R&D approval, may involve liaising with
healthcare professionals at the site to discuss the trial rationale and
design, responding to queries, finalising local arrangements, and
obtaining agreement to participate in the study. Such contact can be
conducted as face-to-face, on-site meetings, or remotely via email,
web or telephone correspondence. We sought to compare the effect-
iveness of remote versus face-to-face initiation, followed by a final
on-site set-up meeting, on recruitment to the SWIFFT trial, and to in-
form the feasibility of undertaking such a comparison across other
trials.
Methods
This cluster randomised, feasibility trial was a study within a trial
(SWAT) embedded within the SWIFFT surgical trial.
The primary outcome was the number of patients recruited per site.
Secondary outcomes included: time to (i) submission of R&D applica-
tion, (ii) receipt of R&D approval, (iii) final on-site set-up meeting prior
to starting recruitment, and (iv) first randomised participant; number of
patients screened; the proportion of hospital forms and participant
questionnaires returned; and the time to return these forms.
No formal power calculation was conducted, as the sample size was
restricted by the number of sites approach to take part in the host
trial. All sites were randomised (except the site of the Chief Investiga-
tor), and blinded to their involvement. Allocation was 1:1 via mini-
misation balancing on (i) whether the Principal Investigator had
previous experience of working on a multi-centre surgical RCT, (ii)
whether the site had a research nurse in place, and (iii) the size of
catchment area (< vs > 500,000).
The main analyses used intention to treat. Site-level, time to event
outcomes were compared between the trial arms using Cox propor-
tional hazards regression, and recruitment outcomes were analysed
via Mann-Whitney U tests. Return of questionnaires and time to re-
turn were analysed at the participant-level using logistic and Cox re-
gression as appropriate accounting for clustering by site using robust
standard errors (logistic) or a shared frailty (Cox).
Results
Thirty-seven sites were included (20 face-to-face and 17 remote), of
which 33 (89%) opened to recruitment. The median number of par-
ticipants recruited from sites allocated to receive on-site initiation
was higher than from those allocated to remote initiation (10 (inter-
quartile range 1.5 – 17) vs 6 (5 – 23)), though this difference was not
statistically significant (p = 0.79). No statistically significant differences
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crossovers: 3 on-site to remote, and 1 remote to on-site.
Conclusion
In this feasibility trial, we found no evidence that face-to-face prelimin-
ary initiation of sites recruited to take part in a multi-centre RCT is more
effective than remote contact on reducing set-up time, or improving
recruitment or data collection. The cost of the two approaches will be
explored.
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Background
The recruitment and retention of patients are significant methodo-
logical challenges for trials. Whilst research has focused on recruitment,
the failure to retain recruited patients and collect outcome data can
lead to additional problems of biased interpretation of results. Research
to identify effective retention strategies has focused on influencing pa-
tient behaviour through incentives, reminders and alleviating patient
burden, but little attention has been giving to exploring how retention
is explained to patients at consent.
Aim
To assess how withdrawal, retention and the value of outcome data
collection is described within Patient Information Sheets (PIS).
Methods
50 adult or parent PIS from a cohort of 75 National Institute of Health
Research Health Technology Assessment (NIHR HTA) programme
funded trials that started between 2009–2012 were obtained from
protocols, websites or by contacting trialists. A checklist of PIS
content developed from UK Health Research Authority and ICH GCP
Guidelines was supplemented with retention specific questions.
Corresponding trial protocols were obtained and evaluated to cross
reference trial specific procedures with information communicated to
patients.
Results
PIS frequently reiterated the patient’s right to withdraw at any time
(n = 49, 98%), without having to give a reason and without penalty
(n = 45, 90%). However, few informed patients they may be asked to
give a withdrawal reason where willing (n = 6, 12%). Statements
about the value of retention were infrequent (n = 8, 16%). Consent
documents failed to include key content that might mitigate with-
drawals, such as the need for treatment equipoise (n = 3, 6%). Nearly
half the trials in the cohort (n = 23, 46%) wanted to continue to col-
lect outcome data if patients stopped trial treatment. However, in
70% (n = 33) of the trials using prospective consent, withdrawal was
described in generic terms leaving patients unaware of the differ-
ence between stopping treatment and all trial involvement. Nineteen
(38%) trials offered withdrawing patients the option to delete previ-
ously collected data.
Conclusions
Withdrawal and retention is poorly described within PIS and address-
ing this might positively impact levels of patient attrition, reducing
missing data. Consent information is unbalanced, focusing on pa-
tient’s rights to withdraw without accompanying information that
promotes robust consent and sustained participation. Future research
is needed to explore the whether the lack of retention information
given at consent is impacting on attrition and if so, how retention
can be described to patients to avoid concerns of coercion.P490
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Safari is a UK multi-site, parallel-group, randomised controlled,
unblinded surgical trial investigating the use of the FENIX MSA
(magnetic sphincter augmentation) device, as compared to the
current standard treatment of SNS (sacral nerve stimulation) for adult
faecal incontinence. Whilst the trial team were aware of the chal-
lenges and complexities associated with the design and implementa-
tion of surgical trials, a number of unanticipated issues arose during
the set-up of safari which severely impacted the trial timelines to the
point where funding of the trial was at risk. The issues experienced
were related to funding, associated training and supply of the new
FENIX device within the trial.
The new intervention, FENIX, provided a cost saving compared to
SNS. For non-commercial research within the UK, treatment costs
should be met through the normal NHS commissioning process. SNS
is funded at a national level through NHS England as a specialised
treatment, therefore FENIX should have been funded in the same
manner. At the time of safari set-up, NHS England was a relatively
new entity. It transpired there was no formal route for approving
funding of FENIX other than the lengthy NHS England formal adop-
tion process which could take up to 2 years, with no guarantee of
success. Although a quicker alternative route was eventually identi-
fied and funding for FENIX confirmed, this caused significant delays
as sites were not willing to proceed with set-up until this confirm-
ation had been received.
A baseline level of experience for surgeons was set for both proce-
dures to minimise any potential learning curve effect or bias. This
was not an issue for SNS as this is an established procedure, however
most participating surgeons did not have the required FENIX proced-
ure experience at the outset. The trial set-up period was extended to
allow time for surgeons to gain this required experience, in addition
to incorporating a registration phase within the protocol to facilitate
local approvals for use of a new device. Identification of dates for
FENIX ‘training cases’ took much longer than anticipated and last mi-
nute cancellations were experienced e.g. Due to lack of beds or pa-
tients being unfit on the day of surgery.
Finally, an alternative process had to be implemented for supply of the
FENIX device. FENIX is available in 7 different sizes with the required
size only confirmed at the time of surgery. A set of different sized FENIX
devices are therefore required at the time of each operation. Participat-
ing sites were reluctant to purchase a full set devices given that only
one would be used during each operation. We secured an agreement
from the device manufacturer that a set of devices would be provided
to each site and remain the property of the device company, with pay-
ment only required for a successfully implanted device.
Further details on the issues faced during set-up of the safari trial
and how these were resolved will be presented, in addition to
reflecting on lessons learnt.
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Background
Multi-center clinical trials are often plagued with slow starts due to de-
lays getting sites started and slow recruitment. Frequently we assume
we know the cause of the problems, e.g., slow reviews by multiple
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However, there are often other factors, which we can control, that con-
tribute to the delays. Information on performance can be presented in
tables, but graphical displays are often useful to show patterns, as it is
with outcome and safety data, to help identify modifiable factors that
contribute long start-up times and slow recruitment as well as to plan
for drug packaging, monitoring meetings, and close of recruitment.
Methods
We present a range of graphical methods for monitoring clinical center
start-up and recruitment in clinical trials that may be useful for recog-
nizing patterns in performance. Examples are provided from displays
we have developed in two clinical trials consortium, the American Lung
Associations Airways Clinical Research Centers (ALA-ACRC) and the
Multicenter Uveitis Research group (MUST), as well as displays devel-
oped by others.
Results
We have developed and utilized a number of graphical tools that have
been effective for identifying key logjams in the conduct of trials, some
of which can be addressed by investigators once they have been iden-
tified. For example, a display of the stages of trial start-up along with
the duration for each individual center identified that training and certi-
fication of clinic personnel contributed as much or more to delay in
opening trials as IRB reviews. By distributing and discussing this graphic
with investigators, we were able decrease start-up times at many sites.
We also use a display of recruitment information that integrates infor-
mation on two characteristics, total number of participants per site and
the time since the last participant was recruited at each site. This
display differentiates among sites that have recruited well in the in the
past but have either stopped recruitment efforts or have run into diffi-
culties finding more eligible patients versus sites that have fewer pa-
tients but are actively recruiting. Typically the graphics reporting
recruitment emphasize totals without examining recent recruitment ac-
tivity. Displays make the information easily accessible to all investiga-
tors and can serve to motivate investigators.
Conclusions
Assuming that we know what the obstacles to clinical trials start-up
and recruitment without examining the actual data on these metrics,
can be counterproductive. We have found that graphical displays
can facilitate identification of problems, many of which can be ad-
dressed once investigators are made aware of the barriers.
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Background
With advancements towards precision medicine and development of
novel targeted agents to actionable mutations, collection of bio-
logical samples is a key component of many oncology trials. The use
of samples for biomarker characterisation, to determine eligibility or
as primary/secondary endpoints emphasises their integral nature to
the outcome of the trial. Ensuring the quality and integrity of these
is vital and at ICR-CTSU the development of procedures to improve
sample collection, processing, transfer and storage is ongoing.
Key considerations
Sample collection should be considered at an early stage and funding
applications should include sufficient funds for consumables, shipment
and storage, and trial management time for central coordination. The
principle use of samples and mandatory/optional collection require-
ments should be considered when developing procedures for ensuring
sample integrity and evaluability. Prospective use (e.g. For eligibility
in biomarker-driven trials) and type of sample required (e.g. Tumour
biopsy vs blood sample) can add additional complexities and time
constraints.Liaison with sites in advance through feasibility assessment is import-
ant to determine their capability and resources to perform sample
collection. During site set-up, training on sample collection proce-
dures should be provided to research teams. If biopsy collection is
required, engagement with relevant staff, e.g. Surgeons/radiologists,
is key.
Early engagement with the central laboratory is important to ensure
robust procedures are in place at the laboratory to maintain sample
and trial integrity, through training and SOP development. A labora-
tory manual for sites is developed in collaboration with the central
laboratory to ensure that instructions for sample processing and
handling at sites and shipment methods are adequate.
Patient information sheets should describe provision, storage and fu-
ture use of samples to ensure that the informed consent provided by
patients is sufficient to cover future translational work.
Issues and resolutions
To maximise participation in sample collection studies, it is crucial
that patient advocates are involved in study design and in develop-
ing sample collection schedules. This will ensure that sample dona-
tion is acceptable to patients and as simple as possible, for example
using generic consent to collect research samples at the same time
as diagnostic samples. Where possible diagnostic samples should be
used, with bespoke additional research biopsies or other samples
taken as required.
Sample quality may be compromised by delays in processing and
lack of resources at site and an adaptable approach is often required
to resolve these issues with sites, e.g. Re-training on collection and
processing procedures if necessary, provision of additional resources
if feasible.
To optimise potential recruitment in multi-centre trials, ICR-CTSU acts
as the key point of contact between the site and central laboratory
when real-time testing of samples is required. Discrepancies between
information provided by sites and the central laboratory regarding
samples collected do occur, and sample reconciliation is conducted
throughout the duration of a trial to identify issues at an early stage.
Conclusion
Sample collection in clinical trials is becoming increasingly important,
but introduces logistical issues. ICR-CTSU constantly works to resolve
these issues, and best practice is shared across the unit to minimise
repeating problems.
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Background
Policies regarding publication of articles that describe design features
of an individual trial in journals of the Society for Clinical Trials have
varied by editor. In 2004, the editor of Clinical Trials specified that
such manuscripts must be “instructional” in order to be considered
for publication in the Society’s new journal. Subsequently, authors of
design manuscripts submitted to the journal frequently received a
letter that referred to the editorial, reviewed the requirements, and
provided good examples. As review and publication of design articles
typically require expenditure of as much or more resources as other
types of articles, a question of interest is whether the frequency of
citation of design articles has been similar to frequency of citation of
articles of other types.
Methods
All issues of Clinical Trials published from 2004 through 2015 were
searched to identify design and all other articles. We excluded papers
published as part of proceedings of meetings, letters, editorials, invited
commentaries, columns, etc. For our preliminary estimates of citation
frequency, we randomly selected 20 articles of each type. We searched
the Web of Science and Google Scholar databases to determine the
number of citations per article as of October 31, 2016. We summarized
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citation database by the median and interquartile range (IQR).
Interim Results
Of the 598 articles published in Clinical Trials in the 12-year period,
80 (13.4%) were design articles. The 20 design articles selected ran-
domly had been cited from 0 to 58 times per Web of Science for a
median of 11.0 citations per article (IQR: 7–20) and 5 to 91 times per
Google Scholar for a median of 17.0 (IQR: 9–41). The 20 “other”
articles selected randomly had been cited 9 to 49 times per Web of
Science (median: 17.0; IQR: 4–18) and 2 to 93 times per Google
Scholar. (median: 24.6; IQR: 7–30).
Current Status
We have begun to search for citations in the Scopus database for
comparison with citation counts from the other two citation data-
bases for all 598 articles. We also plan to compare the two types of
articles for self-citation patterns, distributions of time from publica-
tion to citation, and other citation metrics.
Interim Conclusion
Based on findings for the random samples of 20 articles of each type,
design articles published in Clinical Trials during 2004 to 2015 have
been cited as frequently as other articles published in the journal
during the same time period based on citations in the Google
Scholar database but have been cited somewhat less frequently
according to citations in the Web of Science database. Final conclu-
sions await completion of data collection and analysis of all 598
articles.
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Background
Studies with a non-inferiority (NI) objective have become more popular
since the 1990s. A NI study is designed are used to demonstrate that
the new treatment is not worse than the proven active comparator.
There are methodological and regulatory challenges associated with
the planning, conducting and interpretation of these studies and there
are a number of regulatory guidelines. The main aim of this review was
to investigate the design, analysis; interpretation and reporting of non-
inferiority trials in the four top medical journals (Lancet, BMJ, JAMA,
The New England Journal of Medicine) in accordance with CONSORT
statement.
Methods
A search for Non-inferiority trials in Pub Med database that published
between 1/1/2015 and 31/12/2015 was performed. The inclusion cri-
teria were; Non-inferiority trials that were randomised clinical trials,
done on adult humans, published in English and with the full text
available. From this search, 387articles were retrieved. Only 45 arti-
cles published in the Lancet, BMJ, JAMA and NEJM, 37 of them were
analysed.
Results
Of 37 articles included in analysis, 15 were published in The Lancet, 12
in the New England Journal of Medicine, 5 in BMJ and 5 in JAMA. Ac-
cording to the source of funding: 18(48.6%) of the trials were publicly
funded, pharmaceutical companies funded 15(40.5%), and in 4(10.8%)
trials, the funding was a combination of public and private sectors. All
of the trials were multicentre trials. With respect to the blinding; 24
(64.9%) of the studies were open label studies (no blinding); in these
open-label trials, 14 (58.3%) blinding was not possible, no specific rea-
son was giving for non-blinding in the other 10(41.7%) trials. Only 8
(21.6%) of the trials were double blinded with 5(13.5%) single blinded.
Phase III trials were the most common types of trials - 24 of the 37
(64.9%) while 3(8.1%) were phase IV trials, and 1(2.7%) was a phase II
trial. The phase of the trial was not provided in 9 (24.3%) trials. All the
trials reported their NI margin. The methods for determining NI margin
were not clear in 5(13.55%) trials. In 13(35.1%) trials the margincalculated by the investigators based on previous studies, in 12(32.4%)
trials the NI margins Based on both clinical judgment and historical tri-
als, in 5(13.5%) the NI margins based on the regulatory guidelines, and
in 2(5.4%) trials the NI margin based on clinical judgment only. Regard-
ing the conclusion, non-inferiority established in 24(64.9%) trials, 8
(21.6%) trials failed to establish the non-inferiority, 5(13.5%) trials con-
clude the superiority of the tested drug compared with the active
control.
Conclusion
Most of published NI trials in the four journals did not follow the
regulatory guidelines regarding conduct and interpretation of NI
trials. There is a need to improve the conduction, interpretation and
inference of published NI trials.
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Background
In a multi-center obstetric randomized trial, a key outcome was a la-
boratory value not routinely collected for clinical reasons at most
centers. We determined early in recruitment that a substantial pro-
portion of these results were being missed. We describe the steps
implemented to decrease these missing results, and some measures
of their effectiveness.
This trial required collection of paired umbilical cord blood samples
(artery and vein) for measurement of gases. Collection in the delivery
room and testing by the hospital laboratory are time-sensitive, logis-
tically challenging, and require the cooperation of clinical staff with
competing priorities. Drawing blood from the correct vessel is chal-
lenging, testing must be completed promptly, and there is little
chance for a second opportunity if there is any error. Meanwhile,
clinical staff are focused on two patients – mother and baby. There-
fore, our strategies focused on minimizing non-research staff partici-
pation where possible.
Results
After recruiting 3% of the participants, we realized that cord blood
gases were missed for 20% of deliveries. Missed, incomplete, or er-
roneous results occurred even in centers where pre-trial collection
was routine. Three successive strategies were implemented to im-
prove this rate. The first was alerting the staff. With each center
aware of its individual rate and receiving regular updates, unique
center-initiated strategies were implemented. Research staff made
collection a higher priority, often being present in the delivery
room, hand-carrying specimens to the laboratory, troubleshooting
with laboratory staff, and occasionally drawing the blood them-
selves. A video was distributed showing proper technique for draw-
ing the sample. Next, centers were offered a point-of-care blood
testing device, which allowed research staff to perform the test
with a smaller volume and without involving the laboratory. It also
facilitated repeat testing if needed. Lastly, additional funds were
provided for after-hours staffing, making it more likely research
staff could be present at delivery and facilitate sample collection.
After each time point, improvements were observed. The missed
rate decreased to 11%, then 9%, and 7.5%, respectively, after each
of the three strategies were implemented.
Not all centers implemented these strategies, nor implemented them
at the same time. However, we will describe the rates before and
after, including a subset who did not use the point-of-care device
nor extended their staffing coverage. Results varied; however in the
final year when all strategies were implemented, centers that used
both a point-of-care machine and extended hours achieved 3 per-
centage points fewer missed results than those who implemented
neither. The improvement was also noted beyond the trial. Trial-
collected quality control data were provided to the clinical depart-
ments, which encouraged them to improve collection procedures for
all patients.
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When laboratory outcomes in a hospital setting are essential to a
clinical trial, systems that rely less on clinical staff are advantageous.
These strategies could apply to other settings in clinical research,
such as emergency departments or remote-care locations. Further-
more, the systematic collection and review of data quality measures
within a trial can provide useful information for clinical care outside
the research setting.
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The NIH-funded THAPCA randomized trials compared efficacy of
therapeutic hypothermia (target temperature 33 degrees C) to
normothermia (temperature 36.8 degrees) after cardiac arrest in
children >48 hours to <18 years of age. One trial enrolled children who
sustained out-of-hospital arrest (target n = 250 analysis-eligible), and a
second trial enrolled children with unplanned in-hospital arrest (target
n = 504 due to smaller expected hypothermia benefit). The primary effi-
cacy outcome was survival with favorable neurological outcome 1 year
post arrest. Due to key differences in arrest etiology and post-arrest
outcomes, the parallel trials were monitored separately.
An NIH-appointed DSMB monitored safety and efficacy of both trials.
A charter specified meetings approximately twice yearly. Symmetric
O’Brien-Fleming boundaries were used for monitoring treatment
superiority, with an informal <20% conditional power criterion
specified for declaring futility.
Recruitment began in September 2009. The first safety-only DSMB
review in 2010 combined adverse outcome data across trials as event
numbers were small. Subsequent study-specific, safety-only DSMB
reviews occurred until the first interim efficacy look for both trials in
November 2012.
In the out-of-hospital trial, a treatment difference was noted among
141 children with 1-year outcomes available, but the treatment com-
parison (nominal p-value = 0.03) did not approach the conservative
stopping boundaries. Enrollment continued, with n = 250 target sur-
passed at 2012 year-end. A second interim analysis in August 2013
(n = 213) found that the previously observed treatment difference di-
minished (nominal p = 0.12). Results of the ‘negative’ out-of-hospital
trial were published in 2015.
The in-hospital trial encountered enrollment difficulties due to below-
expected patient volumes. During the November 2012 interim analysis,
for which 74 children had one-year outcomes available, no treatment
difference was noted. Due to the slow accrual, the DSMB skipped effi-
cacy monitoring during the 2013 meeting. The second efficacy analysis,
in March 2014 (n = 149), again did not approach statistical significance.
By late 2014, despite extended enrollment and addition of centers, only
254 eligible patients had been enrolled, indicating final enrollment
would be substantially below target. Given these circumstances, the
DSMB elected to consider stopping for futility during their January
2015 meeting. Conditional power for the primary efficacy outcome was
found to be very limited under a range of assumed treatment effects
and realistic final enrollment numbers ranging from 300–400. However,
the DSMB decided to continue enrollment and reconvene after add-
itional information about potential utility of the trial was available. In a
supplemental February 2015 meeting, the DSMB reviewed conditional
power estimates for exploratory outcomes, some ad hoc with postu-
lated treatment effects based on out-of-hospital trial trends, and subse-
quently recommended stopping enrollment. In-hospital trial results are
under journal review as of November 2016.The THAPCA trials provide an interesting study of long-term DSMB
review of two parallel studies with differing enrollment patterns.
For example, the DSMB elected to remain masked to treatment arm
identity in both trials throughout all reviews, recognized the mar-
ginal benefit of repeated efficacy monitoring under slow enroll-
ment, and considered implications of futility stopping beyond the
primary trial outcome. Our experience may help optimize strategies
for successful DSMB involvement in randomized trials with long-
term follow-up.
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Background
Pilot and feasibility studies are increasing in popularity, as demon-
strated by the launch of the focussed Journal of Pilot and Feasibility
Studies in January 2015. Pilot studies are defined as a mini replica-
tion of a proposed full study, used to identify any potential issues. A
feasibility study is similar but considered as more exploratory and is
used to judge the suitability of a proposed study by assessing the
viability of each of the elements individually. In this review, we aim
to assess the prevalence of pilot and feasibility studies in recent prac-
tice and determine whether the two differ on key characteristics. We
envisage this work will then guide future research into the use of
pilot and feasibility studies to better inform full studies.
Methods
Data on pilot and feasibility studies have been collected from the
International Standard Randomised Controlled Trial Number (ISRCTN)
registry website. As the website does not provide a downloadable
database, a web scraping methodology was adopted and imple-
mented using the R programme. Pilot and feasibility studies were
identified using a keyword search on the main title. Unique trial re-
cords were extracted using regular expressions and collated in an
Excel spreadsheet.
Results
Out of the 658 unique trials that were found within the ISRCTN data-
base, 456 (69%) of these were labelled as pilot studies, 196 (30%) as
feasibility studies and six (1%) considered both a pilot and feasibility
study. The overall prevalence of all pilot or feasibility studies does
not seem to be showing any particular trend over time. Initially, pilot
studies were much more common; however, in recent years feasibil-
ity studies have increased in popularity and are now on a par with
pilot studies. The median number of target participants for each trial
was 50 (range: 5–130,000). When considered separately, pilot studies
had a target of 44 (range: 5–130,000) with feasibility studies being
slightly larger with a target of 60 (range: 6–1,600).
On average, the trials ran for a period of 18 months with pilot studies
reporting a slightly shorter time (17 months) than feasibility studies
(18.5 months), which aligns with the larger sample size target.
Mental and behavioural disorders accounted for the highest propor-
tion of studies (20%), followed by cancer studies (13%).
The majority of the studies within the data were interventional (96%)
and defined as randomised controlled trials (85%). A hospital envir-
onment is the most likely setting for the studies (45%) and in most
cases, the recruitment was in a single country (97%). This is consist-
ent between the pilot and feasibility studies within the database.
Conclusions
In recent years, the prevalence of feasibility studies has begun to
match that of pilot studies but the characteristics found for the two
are very similar. Due to their similar nature, there could be an argu-
ment that pilot and feasibility studies should considered as one.
Alternatively, if these studies are to be separate more education is
required to outline the differences and provide guidelines for each
to help shape future research projects.
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There are a number of administrative datasets that routinely record
information on individuals in the UK. Such routine or ‘Big Data’
sources record data for a specified primary purpose and are regu-
lated for security, confidentiality and disclosure by The Data Protec-
tion Act 1998 and Freedom of Information Act 2000. Access for
secondary uses such as clinical research is permitted when health
and social care benefit can be demonstrated. Routine sources include
clinical datasets such as Hospital Episode Statistics (HES) and the
Clinical Practice Research Datalink (CPRD) and non-clinical datasets
such as data recorded by the Department of Work and Pensions
(DWP), HM Revenue and Customs (HMRC) and The Driving and
Vehicle Licensing Authority (DVLA).
Routinely recorded data used in clinical research is potentially cost
and resource-use effective. Clinical sources of data such as HES and
CPRD are commonly accessed to provide data for retrospective
observational and record-linkage studies and provide a valid dataset
for this purpose. Routinely recorded data may also present advan-
tages to prospective clinical research such as randomised controlled
trials (RCTs). For example, routinely recorded data have been used to
inform judgements about the feasibility of sample size and recruit-
ment targets and measure participant outcomes. Pragmatic cluster
RCTs have even been conducted through routine data sources in-
cluding patient recruitment, randomisation, administration of inter-
vention and trial assessments, such as through The Clinical Practice
Research Datalink (CPRD). The majority of RCTs incur health service
costs as clinicians assess participants, record outcomes and complete
Case Report Forms (CRFs) - hence using routinely recorded data may
provide an efficient alternative method for data collection in addition
to reducing the burden on participants. Furthermore, data from non-
clinical routine sources may inform outcomes beyond the standard
RCT assessments of clinical efficacy and effectiveness. For example,
cost data (such as use of healthcare resources) and socio-economic
data (such as employment and means-tested benefits data) may in-
form health economic analyses and the assessment of the broader
societal impact of healthcare interventions.
However, limitations with accuracy of coding, confidentiality, owner-
ship and access have previously been identified as significant barriers
to accessing routinely recorded data for prospective research.
This study has assessed the feasibility of accessing both clinical and
non-clinical routinely recorded data within the context of a RCT and will
assess the agreement and additional benefits of routinely recorded
data compared to data collected using standard prospective methods
in a RCT.
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Background
Patient recruitment is often a major challenge for randomised trials.
Reviews of publicly funded UK trials have found that 45 to 69% fail
to recruit to target. This increases costs, delays results, and adversely
impacts on the feasibility of conducting trials for conditions where
there is a limited patient pool.
For some conditions, patients may require treatment on multiple occa-
sions. For example, patients with sickle cell disease require pain relief
for each new pain crisis, and women using fertility treatment mayundergo multiple treatment cycles until they become pregnant. The
current norm for trials in these conditions is for patients to be enrolled
for only one treatment episode.
An alternative approach is the re-randomisation design. This design al-
lows patients to be re-enrolled and re-randomised for each new treat-
ment episode. The number of times each patient is re-randomised is
determined by the number of treatment episode each patient ex-
periences, rather than by the trial design. Because each patient can
contribute multiple treatment episodes, this design can facilitate an
increased recruitment rate, potentially making trials easier and
quicker to conduct.
Methods
We describe some properties of the re-randomisation design, such as
the conditions required to obtain unbiased estimates of the treatment
effect and control type I error rate. We also evaluate the likely impact
of re-randomisation on the recruitment rate is several clinical areas.
Results
The re-randomisation design can provide unbiased estimates of treat-
ment effect and control the type I error rate under some very simple
conditions. Furthermore, in some instances this design will have the
same or even higher power than a parallel group with an equivalent
number of observations. Based on a modelling study across three dif-
ferent clinical areas, we estimated that re-randomisation could reduce
the time to complete recruitment between 19-45%.
Conclusions
The re-randomisation design can increase the recruitment rate compared
to parallel group designs, which could reduce costs and make trials more
feasible to conduct. If used appropriately, it can provide unbiased esti-
mates of treatment effect, control the type I error rate, and maintain or
even increase power compared to a parallel group design.
O5
Adaptive non-inferiority margins under observable non-constancy
Brett Hanscom1, Deborah Donnell1, Brian Williamson2, James P Hughes2
1Fred Hutchinson Cancer Research Center; 2University of Washington
Correspondence: Brett Hanscom
Trials 2017, 18(Suppl 1):O5
Background
A central assumption in the design and conduct of non-inferiority
(NI) trials is that the active-control therapy will have the same degree
of effectiveness in the planned non-inferiority trial as it had in the
prior placebo-controlled trials used to define the non-inferiority mar-
gin. This is referred to as the ‘constancy’ assumption. If the constancy
assumption fails, the chosen non-inferiority margin is not valid and
the study runs the risk of either approving an inferior product or fail-
ing to approve a beneficial product. The constancy assumption is
unlikely ever to be met completely in practice, and it cannot be
validated in a trial without a placebo arm. However, it is often the
case that there exist strong, measurable predictors of constancy, such
as dosing and adherence. Such predictors can be used to identify
appropriate non-inferiority margins during the planning phase, as
well as adjust the margin during the monitoring and analysis phases.
Methods
We propose using meta-analysis regression to model the association
between population characteristics and the effectiveness of an
active-control therapy, and assume that the model provides an un-
biased estimate of effectiveness. Together with expected population
characteristics, the fitted model parameters are used to specify a
non-inferiority margin targeted to the planned study population.
During interim and final analyses, observed population characteristics
are used in combination with the initial meta-regression results to
adjust the margin. Two methods of adjustment are proposed: one
that maintains a pre-planned minimal clinically important difference
(MCID) over an inferred placebo, and a second that maintains a fixed
proportion of the estimated active-control benefit over placebo. In
the second scenario, sample size adjustment may be necessary.
Results
We consider a hypothetical NI trial of an experimental HIV Pre-exposure
Prophylaxis (PrEP) drug versus a standard PrEP drug (active control)
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due to lack of adherence to the standard drug, the constancy assump-
tion fails and the active-control therapy is 10% less effective than
planned, the probability of a false non-inferiority finding rises from
2.5% to 16%. If the active control therapy is 10% more effective than
planned (for example, if adherence were higher than planned), power
falls from 90% to 52%. By revising the NI margin according to the pre-
specified meta-regression model, and maintaining the pre-specified
MCID, both alpha and power can be corrected to planned levels with-
out modification to the planned sample size. If the allowable effective-
ness of the experimental therapy is permitted to vary depending on
the estimated active-control effect, alpha and power can be partially
corrected by updating the margin, and fully corrected by updating
both the margin and the sample size.
Conclusion
If prior placebo-controlled trials provide evidence of an association
between population characteristics and the effectiveness of an active-
control therapy, non-inferiority margins can be adjusted based on ob-
served population features, effectively maintaining pre-specified levels
of Type-I error and power.
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Background
The Cochrane risk of bias tool for randomized trials seeks to determine
whether the findings of a randomized trial can be believed. First
released in 2008, and revised slightly in 2011, it is the most widely used
risk of bias tool in both Cochrane and non-Cochrane reviews on the
effects of interventions. However, evaluations of the tool have
highlighted some problems. Objective: To introduce a revised tool to
assess risk of bias in randomized trials (RoB 2.0), which builds on the
established Cochrane risk-of-bias tool as well as the thinking behind
the recently developed tool for non-randomized studies (ROBINS-I).
Methods
Over the last year, we assembled collaborators from across the world
to develop RoB 2.0. We held an initial development meeting in Au-
gust 2015 where the main structure of the tool was agreed. Working
groups were formed and tasked with developing signalling ques-
tions, criteria for reaching a judgment and full guidance. Working
groups’ contributions were collated and the draft version of the new
tool was extensively piloted by individuals with varying degrees of
experience, at a three-day event held in Bristol in February 2016 and
remotely. The piloting feedback was considered at a second develop-
ment meeting in April 2016, where refinements to the tool and to
the written guidance that accompanies it were made. The working
groups were further tasked with developing algorithms for reaching
a domain-level judgment and creating worked examples. Further
pre-release piloting took place in September 2016.
Results
Key changes in RoB 2.0 compared with the 2011 version of the tool
are: − simplification of issues into fewer (mandatory) bias domains; −
clearer focus on risk of bias in a specific result from the randomized
trial; − introduction of signalling questions - which are reasonably fac-
tual in nature - to facilitate risk-of-bias judgements; − algorithms to
reach risk of bias judgements; − clarification of differences between the
review team's interest on the effect of assignment to intervention (the
intention-to-treat effect) versus the effect of starting and adhering to
intervention: issues of blinding, implementation and adherence differ
importantly between these; − clarification that selective reporting
should be assessed only when a result is available (whereas selective
non-reporting should be assessed at meta-level); − separate templates
for parallel group trials, cluster-randomized trials and cross-over trials.Conclusions
We believe the new tool will offer considerable advantages over the
existing tool. Once programmed into software, we expect the tool will
be easier to use than the first version. Some issues remain to be re-
solved, however, such as how many results should be assessed for each
study, and how best to integrate the assessment into the data extrac-
tion process. This presentation will provide an introduction to the tool.
Further details of RoB 2.0 will be available from riskofbias.info.
Funding
MRC Network of Hubs for Trials Methodology Research (MR/L004933/
1- N61); MRC ConDuCT II (MR/K025643/1), NIHR CLAHRC West.
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The random allocation and masking of participants to treatment are
procedures in a study design essential to minimizing bias and the suc-
cess of a clinical trial. The essence of the randomization process is to
ensure an equal probability for each participant to be assigned to ac-
tive or control treatment groups, which naturally leads to three proper-
ties of the randomization procedure: balance in sample size and
constitution between treatment and control groups, unpredictability in
the allocation of a participant to a certain group, and simplicity for an
investigator to implement without compromising the randomization
principle. With recent advances in biomedical and statistical method-
ologies, the area of clinical trial design is evolving rapidly with varying
opinions on an optimal randomization method. Randomization
methods have now expanded into more advanced approaches beyond
the classical assignment to treatment groups (e.g. covariate adjustment
in the randomization procedure, changing probability of assignment as
in adaptive designs). Thus, the traditional randomization method faces
new challenges, both theoretically and pragmatically. With increasingly
complex trial designs, it becomes more challenging to determining the
most appropriate randomization method. To help select an optimal
randomization method, we performed numerical simulations to assess
various randomization strategies in a centralized randomization system
for multicenter clinical trials, by considering varying values for several
design parameters including trial sample size, covariate strata,
clinical sites, treatment arms, and allocation schema. For each sce-
nario of simple, permuted block, stratified permuted block, and
adaptive randomization strategies, imbalance and predictability
were estimated through numerical simulations (repeated 10,000
times). Simulation results are tabulated in a series of tables
serving as a useful reference for choosing an appropriate
randomization method given a particular trial design. The goal of
this study is to provide data support for identifying an optimal
randomization method, accounting for the trade-off between pre-
cision of randomization balance and simplicity of implementation
since more complex methods may lead to a greater likelihood of
randomization schedule or allocation algorithm errors during im-
plementation and human errors during the trial.
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Transparent reporting of missing data is crucial to the critical ap-
praisal of trial results. This is particularly important in palliative care
trials where large amounts of missing data and truncated data due
to death occur. Although the CONSORT 2010 statement recommends
the impact of missing data on the validity of intention-to-treat ana-
lyses be reported, it does not provide specific guidance on how to
report: methods to handle missing data, assumptions about the miss-
ing data mechanism and missing data sensitivity analyses. Several
other groups have provided further missing data reporting recom-
mendations that include such criteria. Whether trials report missing
data according to the recommendations by CONSORT and other
groups however is not known.
Objectives
Assess (i) the quality of reporting and handling missing data in pallia-
tive care trials against current guidance, (ii) any differences in the
complete reporting of criteria specified by the CONSORT 2010 state-
ment compared to those not specified by CONSORT, (iii) the association
between the quality of missing data reporting and journal impact factor
and CONSORT endorsement status, to explore how implementation of
reporting guidance may be optimised.
Methods
Systematic review of palliative care randomised controlled trials. An
information specialist searched CENTRAL, MEDLINE, and EMBASE
(2009–2014) with no language restrictions. A random sample of iden-
tified trials were screened, selected and had data extracted by two
independent reviewers.
Results
108 trials (15,560 participants) were included. In general missing data
reporting was incomplete and not handled in accordance with
current guidance. Reporting criteria specified by the CONSORT state-
ment were better reported than those not specified by CONSORT
(proportion of trials reporting CONSORT criteria: account for all par-
ticipants who enter the study 69%, data completeness 94%, reason
for missing data 71%). However item-level (15%) and secondary out-
come (9%) missing data were poorly reported, so the proportion of
missing data stated is likely to be an underestimate. Provided rea-
sons for missing data were unclear for 54% of participants. 48% of
trials clearly reported their method to handle missing data, of the
trials with missing data (n = 93): 60% used complete case analysis
alone and 16% reported a missing data sensitivity analysis. Only one
trial used a recommended method to handle truncated data due to
death. As the journal impact factor doubled the odds of reporting
the flow of participants (odds ratio (OR) 1.54, 95% CI 1.20, 1.97), data
completeness (OR 1.39, 95% CI 1.15, 1.69), comparison of baseline
characteristics of those with and without missing data (OR 1.50, 95%
CI 1.20, 1.87), and method of handling missing data (OR 1.40, 95% CI
1.13, 1.73) were statistically significantly increased. There was insuffi-
cient evidence that the criteria specified by CONSORT were more
likely to be reported in journals that endorsed the CONSORT
statement.
Conclusion
The rigorous methods, evolving nature, and wide recognition of the
CONSORT statement make it ideally placed to facilitate better reporting
of missing data. Further development and implementation of the
CONSORT missing data reporting guidance is likely to improve the
quality of reporting. Specific suggestions for CONSORT will be discussed.
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In the future, clinical trials will have an increased emphasis on pragma-
tism, providing a practical description of the effects of new treatmentsin realistic clinical settings. Accomplishing pragmatism requires better
summaries of the totality of the evidence that allow for informed bene-
fit:risk decision-making and in a way that clinical trials consumers, pa-
tients, physicians, insurers find transparent. The current approach to
the analysis of clinical trials is to analyze efficacy and safety separately
and then combine these analyses into a benefit:risk assessment. Many
assume that this will effectively describe the impact on patients. But
this approach is suboptimal for evaluating the totality of effects on pa-
tients. We describe a broad vision for the future of clinical trials consist-
ent with increased pragmatism. Greater focus on using outcomes to
analyze patients rather than patients to analyze outcomes particularly
in late-phase/stage clinical trials is an important part of this vision. We
discuss partial credit, a strategy for design and analysis of clinical trials
based on benefit:risk assessment that has greater pragmatism than
standard methods. The strategy involves utilizing composite benefit:risk
endpoints with a goal of understanding how to analyze one patient be-
fore trying to figure out how to analyze many. With a desire to measure
and weigh outcomes that are most important from the patient’s
perspective, we engage patients as a resource to inform analyses. We
discuss partial credit within the context of antibiotic clinical trials.
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Background
Regression discontinuity (RD) is a quasi-experimental method that
utilizes threshold rules for determining treatment assignment to esti-
mate causal effects when randomization is not available. Examples of
clinical threshold rules include CD4 count for determining antiretro-
viral therapy eligibility in HIV-infected individuals or blood pressure
determining eligibility for hypertension treatment. However, the val-
idity of RD has not been established via direct comparison to effects
estimated via the gold standard randomized controlled trial (RCT).
Here, two concurrent RCTs allow us to directly compare an effect size
from an RCT to that of RD. We utilize a continuous enrollment criter-
ion in the RCTs to test if regression discontinuity achieves similar re-
sults to the intention-to-treat (ITT) effect from the trial itself.
Methods
The Mycotic Ulcer Treatment Trials (MUTT-I & MUTT-II) were two con-
temporaneous randomized controlled trials with identical outcome
assessments designed to compare strategies for the treatment of
fungal corneal ulcers. MUTT-I, which enrolled patients with better
best spectacle-corrected visual acuity (BSCVA) (<20/400), compared
topical voriconazole to topical natamycin. MUTT-II enrolled patients
with worse BSCVA (20/400) and compared adding oral voriconazole
versus placebo to topical voriconazole. We estimated the RD effect
of natamycin versus voriconazole on 1) 3-month BSCVA and 2) odds
of perforation and/or requiring a therapeutic penetrating kerato-
plasty (TPK), and compared these results to those estimated in the
trial. We utilized enrollment visual acuity as a clinical decision rule to
replicate the results of MUTT-I, using the natamycin arm from MUTT-I
and the placebo arm of MUTT-II, and 20/400 as the threshold for re-
ceiving natamycin (<20/400) or voriconazole (20/400), representing
an RD design. The RD model included terms for being above or
below the threshold and a term for baseline visual acuity above and
below the threshold.
Results
In the MUTT-I RCT, patients randomized to natamycin had a nearly 2-
line improvement in BSCVA at 3 months (logMAR −0.18, 95%CI −0.30
to −0.05) and reduced odds of perforation and/or TPK (OR = 0.42,
95%CI 0.22 to 0.80) compared to voriconazole. In the RD model,
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at 3 months (logMAR −0.29, 95%CI −0.50 to −0.08) and reduced odds
of perforation/TPK (OR = 0.35, 95%CI 0.15 to 0.82). Results were ro-
bust to multiple sensitivity analyses, including flexible functional
forms of visual acuity and restricting the analysis to narrower band-
widths around the cutoff (20/400).
Conclusions
While RD and RCT results were similar, the RD effect was larger,
although not significantly so (P = 0.52 for BSCVA). These results sug-
gest that the use of threshold rule in an RD design may be useful for
estimation of causal effects under conditions where trials are not
possible, or for replication of trial results.
O11
Evaluation of failure time surrogate endpoints in individual patient
data meta-analyses of randomized clinical trials. A poisson
approach
Federico Rotolo1, Xavier Paoletti1, Toasz Burzykowski2, Marc Buyse2,
Stefan Michiels1
1Gustave Roussy/INSERM; 2I-Biostat U Hasselt/IDDI
Correspondence: Federico Rotolo
Trials 2017, 18(Suppl 1):O11
Surrogate endpoints are often used in randomized clinical trials in-
stead of well-established hard endpoints for practical convenience:
they are usually cheaper, more rapid, or less invasive to measure.
The meta-analytic approach relies on two measures of individual
level surrogacy (R_indiv^2) and trial level surrogacy (R_trial^2) [1].
This approach was extended to the survival data case [2], with a
first step using copulas to measure individual level surrogacy in
terms of Kendall's tau and a ?A3B2 show $132#?>second step using
weighted regression to compute R_trial^2. Despite being the refer-
ence method for survival data today, this approach can suffer from
convergence problems in the second step, which is the one which
computes R_trial^2. In the present work, we considered a bivariate
survival model with (i) an individual random effect shared between
the two endpoints to measure individual level surrogacy (Kendall's
tau) and (ii) correlated treatment-by-trial interactions to measure
R_trial^2. We used auxiliary mixed Poisson models to jointly esti-
mate the parameters of such model with piecewise constant base-
line hazards. To reduce the computational complexity, we also
considered reduced Poisson models, accounting for only individual-
or only trial-level surrogacy. We studied via simulations the operat-
ing characteristics of this mixed Poisson approach as compared to
the two-step copula approach, with Clayton, Plackett and Hougaard
copulas and with or without adjustment of the second-step regres-
sion for measurement error. The Clayton copula model was the
most robust and reliable of the copula models compared; the Pois-
son model with both individual- and trial-level random effects out-
performed its reduced equivalents. We also applied the methods to
an individual patient data meta-analysis in advanced/recurrent gas-
tric cancer (4069 patients from 20 randomized trials). As the conver-
gence rate and the estimation results may vary substantially
between models, we encourage the user to carefully evaluate the
convergence of each alternative approach and to report the results
of different models. We implemented the methods presented here in
the R package surrosurv (https://cran.r-project.org/package=surrosurv).
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Objective
Selective reporting of outcomes in clinical trials is a serious
problem. We aimed to investigate the influence of the peer
review process within biomedical journals on the reporting of
primary outcome(s) and statistical analyses of reports of rando-
mised trials.
Methods
Each month, we searched PubMed (between May 2014 and April
2015) to identify primary reports of randomised trials published in
six high impact general and 12 high impact specialty journals. The
corresponding author of each trial publication was then contacted
by email asking them to complete an online survey investigating
changes made to their manuscript as part of the peer review
process. Our main outcome was the nature and extent of changes
made to manuscripts by authors as part of the peer review process,
in relation to reporting of the primary outcome(s) and/or primary
statistical analysis. We also assessed how often authors follow these
requests and whether this was influenced by specific journal or trial
characteristics.
Results
Nine hundred eighty-three corresponding authors were invited to
take part in the online survey, of which 258 (29%) responded. The
majority of trials were multicentre (n = 191; 74%), parallel group (n =
225; 86.5%); median sample size = 325 (IQR 138 to 1010). Half
assessed drug interventions (n = 127; 49%), over half were non-
industry funded (n = 159; 62%) and the primary outcome was clearly
defined in 92% (n = 238), of which the direction of treatment effect
was statistically significant in 48%.
The majority of authors responded (1–10 Likert scale) they were
satisfied with the overall handling (mean 8.6, SD 1.5) and quality of
peer review (mean 8.5, SD 1.5) of their manuscript by the journal.
Only 3% (n = 8) said the editor or peer reviewers asked them to
change or clarify the trial’s primary outcome. However, 27% (n = 69)
reported they were asked to change or clarify the statistical analysis
of the primary outcome; most responded they fulfilled the request,
the main motivation being to improve the statistical methods (n =
38; 55%) or avoid rejection (n = 30; 43.5%). Overall there was no dif-
ference between authors being asked to make this change and the
type of journal, intervention, significance of the primary outcome
or funding source. 36% (n = 94) responded that they were asked to
include additional analyses that had not been included in the ori-
ginal manuscript; in 77% (n = 72) these were not pre-specified in
the protocol. 23% (n = 60) were asked to modify their overall con-
clusion, in most cases (n = 53; 88%) to provide a more cautious
interpretation.
Conclusion
Overall there was little evidence of a negative impact of the peer
review process in terms of selective reporting of the primary out-
come. Most changes requested resulted in improvements to the
manuscript, improving clarity of statistical methods used, and
providing more cautious conclusions. However, some changes re-
quested by peer reviewers were deemed inappropriate and could
have a negative impact on reporting of the final publication,
such as the adding of unplanned additional analyses.
Trials 2017, 18(Suppl 1):200 Page 191 of 235O13
Agreeing outcomes that matter to patients? What are the
challenges?
Heather Bagley, Bridget Young
University of Liverpool
Correspondence: Heather Bagley
Trials 2017, 18(Suppl 1):O13
This abstract is not included here as it has already been published.
O14
Opportunistic trial recruitment during routine primary care
consultations for acute conditions: a mixed methods evaluation
of recruitment performance and barriers
Jeremy Horwood, Niamh M. Redmond, Christie Cabra, Emer Brangan,
Petra Manley, Sophie Turnbull, Jenny Ingram, Patricia Lucas,
Alastair D. Hay, Peter S. Blair
University of Bristol
Correspondence: Jeremy Horwood
Trials 2017, 18(Suppl 1):O14
Background
Evaluating the effectiveness of interventions for acute conditions in
primary care often necessitates clinicians opportunistically recruiting
patient during time-pressured consultations.
Aim
To describe the performance of, barriers to, and implications of
clinicians recruiting trial participants during consultations within two
primary care feasibility cluster randomised controlled trials, CHICO
and IMPACT-PC.
Methods
For the CHICO trial GP practices were randomised to a within con-
sultation web-based intervention to reduce antibiotic prescribing for
children with acute cough and respiratory tract infection, or usual
care. For the IMPACT-PC trial GP practices were randomised to a
nurse-led telephone based management service for patients testing
for Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG), or
usual care. Performance data analyses were conducted and 44
clinicians and 26 trial participants (patients/parents) were interviewed
post recruitment and analysed thematically to explore their
experiences.
Results
For CHICO, 32 practices were randomised and 501 children were re-
cruited one month ahead of schedule. More children were recruited
to the intervention (292, 58%) than the control (209, 42%) arm. There
was a difference in clinician type (higher proportion of nurses) and
more unwell children in the intervention arm. Although just over a
quarter of clinicians were nurses, they recruited more frequently,
recruiting 220 (44%) of the children. Interviews revealed that many
clinicians prioritised dealing with the cough first and only afterwards
attempted to recruit children. This meant that clinicians, particularly
in the control arm, reported they preferentially recruited less unwell
children, because these were quicker and it was easier to ‘fit in’ the
research on top of the normal consultation.
For IMPACT-PC, 11 practices were randomised, 1154 patients were re-
cruited (60% of eligible patients) and 30 (2.6%) patients tested posi-
tive for CT, 9 (0.8%) tested positive for NG and 3 (0.3%) tested
positive for both. CT positivity was higher (4.3%) amongst individuals’
eligible but not recruited to the study in intervention practices. Inter-
views revealed the main reason for failure to recruit eligible patients
was insufficient time to undertake consent procedures. Despite pa-
tient consent being recorded, patients were sometimes unclear that
they were participating in a research study. However, patients found
both the intervention and the use of their medical records in evalu-
ation acceptable, as long as their anonymity was maintained.
Conclusions
Recruitment to both trials was successful in terms of numbers re-
cruited and timescales and the interventions were acceptable andfeasible to clinicians and patients/parents. However, the requirement
for individual patient/parent consent during the consultation was a
barrier to recruitment and may have introduced bias. Given the na-
ture of the interventions and the views expressed it is viable and
valid that future trials of both interventions should not require indi-
vidual consent providing the choice to opt out is provided and fol-
low up procedures maintain patient anonymity. Trials evaluating the
effectiveness of interventions for acute conditions in primary care
should avoid recruitment processes that add burden to routine prac-
tice. The study highlights the value of conducting mixed method
evaluations of recruitment performance and barriers during feasibility
trials to inform future trial design.
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Background and Objectives
The incidence of age-related chronic diseases rises exponentially
with age. This parallels the exponential increases with age in rates
of major disease-specific deaths tracked by the US National Center
for Health Statistics, including those for heart disease, cancer,
stroke, type 2 diabetes mellitus, and Alzheimer’s disease. It has re-
peatedly been shown that the major, and by far the most potent,
risk factor cutting across age-related chronic diseases is age itself.
There is growing evidence for a biologic construct underlying
aging, leading to the potential that interventions may be devel-
oped to slow its progression. The primary goal is not to increase
the number of years lived, but to increase the number of years
lived with better health and function. The NIA Interventions Testing
Program has been established to organize research towards this
goal across model organisms. As interventions emerge from this
program as candidates for human intervention, clinical trials will be
mounted to assess their efficacy. We discuss design and analytical
issues, including the choice of outcomes, eligibility criteria, monitor-
ing rules, and analytical strategies. We present projections of rates
at which outcomes occur, as benchmarks for estimating the statis-
tical power for future trials.
Methods
Parallel analyses were conducted using data from three large cohorts
of older individuals: the Rochester Epidemiology Project, the Health
and Retirement Study, and the Women’s Health Initiative Observa-
tional Study. These allowed us to contrast outcomes, evaluate poten-
tial eligibility criteria, and project incidence rates.
Results
The incidence rate of composite multi-morbidity outcomes and the
rate that they accumulate over time are attractive clinical trial out-
comes. Rates increase with age and, for cohorts at suitably in-
creased risk due to choice of eligibility criteria, are sufficiently great
enough to support the development of tractable (4–6 years; N =
3,000) multi-center clinical trials. To provide evidence that interven-
tions target aging and health span, rather than individual compo-
nents of the composite outcome measure, nuanced approaches to
monitoring and analysis are required, which we describe. The
benchmarks and methods that we present support the feasibility of
designing efficient clinical trials for interventions targeting aging.
As an example, we describe the design of the Targeting Aging with
Metformin (TAME) multicenter clinical trial.
Conclusions
Clinical trials targeting aging are feasible, but require careful design
consideration and monitoring rules.
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Introduction
The National Heart, Lung, and Blood Institute (NHLBI) established the
Biologic Specimen and Data Repositories Information Coordinating
Center (BioLINCC) www.biolincc.nhlbi.nih.gov in 2008 to provide online
access to NHLBI data and biospecimen resources. To assist non-study
investigators’ use of the datasets, each study’s BioLINCC webpage
provides information on the study design and results, including docu-
ments that provide insight into the study data. Given the recent inter-
est by journal editors in the rapid release of publication data, the need
for efficient curation methods is becoming more important. The proce-
dures that have been developed by BioLINCC to review and prepare
study datasets and documents for sharing with secondary users are
one example of how this can be accomplished.
Methods
Data packages submitted to BioLINCC undergo review for secondary
usability. Data dictionaries are examined for ease of use by researchers
outside of the original study group. Reviews are performed to find any
data elements that are considered personally identifiable information
(PII) which are then redacted or recoded in order to de-identify the
data for distribution. An informed consent questionnaire is completed
to discern if there are any restrictions related to wide data sharing. A
comparison of the data with a publication representative of the study
as a whole, such as a primary outcome manuscript, is conducted. The
population included in the analysis as well as key statistics are repro-
duced and deviations identified. Key variables used in the analysis (e.g.
inclusion criteria, adjudicated variables, outcomes) are noted and the
documentation is examined to ensure these variables are well anno-
tated. If study biospecimens are being transferred to the NHLBI
Biorepository, the link between clinical data and those specimens is
verified. Additional documentation including the study protocol, in-
formed consent templates, MOP/MOOs, annotated forms, codebooks,
and a publications list are collected to provide a useful context for the
data and biospecimens.
Results
Over the first seven years of BioLINCC, data from 139 completed stud-
ies were made available through BioLINCC and 666 requests for 1496
data packages were fulfilled. A total of 130 original data packages and
updates were processed and shared with an average effort of 75 hours
per data package. The level of effort varied, not according to the
complexity of the study design, but due to the stage of curation of the
submitted data and documentation. Additional effort at both BioLINCC
and the parent study’s coordinating center was required in nearly all re-
views to prepare and obtain missing information such as algorithms for
calculated analysis variables, explanatory data labels, code books, keyvariables used in analyses, annotated forms, and biospecimen linking
files. To date, over 600 publications are known to have resulted from
requestors using BioLINCC resources.
Conclusion
Efficient preparation of study data and documents is essential to
maximizing the scientific utility of study resources. Preparing data for
release to the general scientific community requires a significant
commitment of time and effort to ensure investigators, not affiliated
with the original study, have sufficient information to effectively con-
duct secondary analyses.
O18
Patient preferences for outcomes in clinical trials: implications for
medicines optimization
Emily Holmes1, Anthony G. Marson2, Dyfrig A. Hughes1
1Bangor University; 2University of Liverpool
Correspondence: Emily Holmes
Trials 2017, 18(Suppl 1):O18
Background
Drug choices for given therapeutic indications are often guided by
clinical trial evidence, however, patients may consider outcomes
beyond those measured as primary endpoints within trials in their
decision to adhere to medication. Discrete choice experiments (DCEs)
are a valid method that has been used to quantify patient prefer-
ences for drug outcomes. Data from DCEs may be combined with
the results of clinical trials to provide a more patient-orientated per-
spective on drug choice.
Objective
To demonstrate the impact of incorporating patients’ benefit-risk
preferences into the results of clinical trials, using a case study of
preferences for anti-epileptic drugs (AEDs).
Methods
Preference weights for outcomes of AEDs (12-month remission, fewer
seizures, depression, memory problems, aggression, foetal abnormal-
ity) were derived from a web-based DCEs of 414 adult patients with
epilepsy. Rates for each of these outcomes were extracted from a
large randomised controlled trial comparing the effectiveness of new
and standard AEDs (SANAD), and from a systematic review of treat-
ments of epilepsy in pregnancy. The preference weights were com-
bined with the clinical event rates to estimate of patient utility for
each AED. The probability of patients preferring each AED was then
calculated as the ratio of exponentiation of the utility of each individ-
ual AED to the sum of the exponentiation of the utilities of all AEDs.
Results were compared to rankings of AEDs as indicated by clinical
trials.
Results
The rank order of AEDs based on trial data for remission: lamotrigine,
carbamazepine, topiramate, oxcarbazepine, then gabapentin, chan-
ged when patient benefit-risk preference was considered. The prob-
ability of patients with partial epilepsy preferring each AEDs was, in
descending order: carbamazepine (0.29), lamotrigine (0.26), oxcarba-
zepine (0.24), gabapentin (0.15), topiramate (0.07). Women with the
potential to become pregnant, had a preference probability of: lamo-
trigine (0.31), oxcarbazepine (0.21), gabapentin (0.20), carbamazepine
(0.19), topiramate (0.09). Comparable results were found for patients
with generalised or unclassified epilepsy. Changes to rank ordering
are explained by patients’ stronger preferences for reducing the risk
of AEs than for improving treatment benefit. In return for a 1% im-
provement in 12-month remission, the maximum acceptable risk of
adverse events was: depression 0.31%, memory problems 0.30%, ag-
gression 0.25%. The maximum acceptable risk of adverse event in ex-
change for a 1% improvement in 12-remission was, for women with
the potential to become pregnant was: depression 0.56%, memory
problems 0.34%, and foetal abnormality 0.20%.
Conclusions
DCEs represent a robust method for quantifying benefit-risk prefer-
ences that can be analysed alongside clinical trial data, to provide a
patient-orientated perspective on the optimal choice of treatment.
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Background
Patient and Public Involvement (PPI) is increasingly important in the
design of research and surgical trials. Evidence on PPI for paediatric
trials appears is limited. Using a case study, the NINJA study, the po-
tential impact of PPI on the design of a new paediatric surgical trial
is highlighted.
NINJA study: Nail bed injury is the commonest hand-related cause of
emergency paediatric consultation. After nailbed repair, there is de-
bate whether the nail should be replaced or not. There is controversy
and uncertainty around whether replacing the nail is beneficial in
causing or preventing infection. A 60 patient pilot study (NINJA-P)
was conducted to demonstrate the viability of a large multicentre
paediatric surgical trial comparing infection rates in patients with re-
placed and discarded fingernails. Patients were recruited in just over
4 months at 4 sites and followed-up for 4 months. The paediatric
population created some unique aspects and challenges, especially
with retention and completion of patient-reported assessments.
Methods
The issues raised by the pilot were put to a youth group - the Young
Person’s Executive (YiPpEe) group based at Oxford University Hospitals
NHS Foundation Trust and also to a focus group of parents (and one
toddler). Information from both groups was collated to inform the de-
velopment of the definitive study. The issues discussed were: Choice of
the primary outcome measure and how to administer this; Retention of
this study population; Presentation of study information.
Results
Regarding the outcome, the appearance of the nail was overwhelm-
ingly the most important variable. This was in contrast to the clinicians’
choice of outcome; the incidence of infection. The NINJA study now
has co-primary outcome measures of appearance and infection rates.
The groups shared ideas for how children (or parents) could measure
their satisfaction with their nail appearance. A simple 3 point scale
showing facial expressions was developed. This was favoured over the
5 point scale used in the pilot. Both groups were clear about the
method of collection for follow up data. This population includes busy
working parents. They suggested moving away from postal question-
naires and clinical visits, if not necessary, and employing mobile tech-
nology i.e.: ‘apps’ to upload photographs and complete questionnaires.
The parent group felt the option to complete follow up requirements
in this manner would improve the retention rate. Both groups had spe-
cific ideas regarding patient information presentation. The use of tech-
nology, videos, and comic-strips showing real people was supported.
Collaboration with YiPpEe will continue to help develop information
portals for the study.
Conclusions
Due to PPI involvement, the full NINJA study objectives were modi-
fied and a follow-up regime and content designed to suit this very
specific patient population was developed. Our experience shows
that solutions offered by children and parents can be incorporated
into trial design at an early stage. The PPI exercise helped address
and titrate issues raised in a pilot study and generated design and
procedural elements that had not previously been discussed.
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In trials of emergency care interventions standardised pathways for
obtaining participant consent can be inappropriate and alternative
models are required. Unless specific approval is granted, obtaining par-
ticipant consent is an essential prerequisite to research participation.
OBS2 was a randomised trial evaluating the effectiveness of using early
fibrinogen replacement in the management of complex postpartum
haemorrhage. Reflecting the range of potential clinical scenarios in
which recruitment could potentially occur, and to meet NHS ethics
committee requirements, several consent pathways were identified,
each requiring tailored patient information and consent forms.
Methods
All women booked to give birth at the six participating maternity
units during the recruitment period, were provided with written in-
formation about the study during the antenatal period. Five consent
pathways were developed: (1) for women at higher risk of postpar-
tum haemorrhage, pre-event consent; (2) for women with controlled
haemorrhage, written consent at the time of the bleed; (3) for
women competent to provide assent during the bleed, but unable to
provide written consent, verbal assent at the time of the bleed; and
in the event of women lacking capacity to provide assent, pathways
utilising a personal (4) or professional representatives (5). All women,
regardless of the pathway followed, once well enough following their
bleed were also required to provide written consent for use of their
collected data.
Results
The study recruited 663 women who experienced a moderate to se-
vere postpartum haemorrhage, with a minimum of 1,000 ml blood
loss. Data relating to the mode of consent were captured on the site
screening logs for 511 participants. No participants were recruited
using the pathways developed for written consent provided at the
time of the bleed, nor for the pathway utilising a professional legal
representative. Antenatal (pre-bleed) consent was obtained from 15
(2.9%) recruited women; verbal assent was provided by 473 women
(92.5%) during the haemorrhage, and for 23 women (4.5%) assent
was provided by a personal representative, a relative or friend present.
All women, once well enough following their bleed, provided written
consent to the use of collected data.
Discussion
Appropriate recruitment and consent pathways are an essential com-
ponent in the design of all trials. Trials of emergency intrapartum care
bring particular challenges as they combine a known population,
women booked to give birth at participating units, with unknown eli-
gible potential participants, in the case of OBS2, women who went on
to have a postpartum haemorrhage of >1,000 ml. The requirement to
provide all potentially eligible women with antenatal information was
intensive of professional time and resources. The pathways of consent
available to staff in the recruitment of women were identified to have
strengths and weaknesses, and these were reflected in the utilisation of
each. Based on the experience of the OBS2 trial, the legal and logistic
complexities of consent in emergency trial settings will be presented
and discussed.
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Background
Recruitment and retention is critical for trials, yet both remain sig-
nificant problems. Very little evidence exists on effective methods
to boost recruitment and retention. There is increasing interest in
exploring financial and non-financial incentives.
Trials 2017, 18(Suppl 1):200 Page 194 of 235We asked the question: “How can incentives best be designed and
used to improve recruitment and retention in ways that are effective,
efficient and ethical?”
Methods
We conducted a structured scoping review to explore the current lit-
erature on the use of incentives in health care (inside and outside of
trials).
The review was underpinned by a conceptual framework drawn from
microeconomics, agency theory and behavioural economics to help us
determine which elements of incentive design to consider. We also
explored potential intended and unintended effects of incentives.
We also ran interactive sessions with experts in the field (trials and be-
havioural economics), principal investigators, regulatory representatives,
and patients, to better understand stakeholder views.
Synthesising these two forms of data, we developed guidance for the
design and delivery of incentives in trial recruitment and retention.
Results
We searched PubMed and Econlit, securing 963 eligible studies, of
which 123 were included. Some of the core recommendations from
the review are as follows:
1. When designing an incentive system it is vital to consider the
current incentives already operating
2. The evidence is mixed about who incentives should be directed
towards (patients, recruiters, clinicians or a combination)
3. Incentivising processes (such as invitations to a trial) is likely to in-
duce more effort than incentivising outcomes (e.g. recruitment and
retention). However, there is a danger that changes in process do
not translate to increased recruitment and retention, or lower the
overall suitability of recruits
4. Complex payment schemes can better direct incentives to increased
activity, limiting costs. However, they will take more time and effort to
implement, and may fail to induce increased effort
5. Monetary incentives are likely to have a larger direct price effect,
but may have negative psychological effects (e.g. crowding out
altruism)
6. Other unintended consequences of incentives may include effects
on the types of patients recruited and research integrity
The impact of incentives will be influenced by many features, such
as the setting of the trial, the risk inherent in trial procedures, and
the social and demographic characteristics of patients. Patients dis-
cussed the importance of the language used in offering incentives,
and the impact on the professional-patient relationship. Patients re-
ported less concerns over the use of incentives for retention com-
pared to recruitment.
We will present our findings in full, and explore incentives schemes
which illustrate different features, advantages and disadvantages.
Conclusions
There is a need to consider the role of incentives in enhancing re-
cruitment and retention, taking account of the ethical issues and
thinking creatively about design to maximise benefit and minimise
harm. Equally, there is a need to test their effectiveness and effi-
ciency using appropriate randomised and non-randomised methods
to ensure that any systems are a good use of public funds.
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Background
Managing drug supply for large clinical trials presents significant logis-
tical challenges. The MRC CTU at UCL has used either an external drug
supply management system (DSMS) or in-house tools (spreadsheets orMS Access databases). However, there are challenges integrating these
systems with internal study databases to work seamlessly.
Add-Aspirin is a phase III double-blind, randomised trial with over
180 sites in the UK, aiming to recruit 10,000 patients. The size of the
trial and the use of double-blinded drug as part of the trial design
led to a decision to develop an in-house DSMS.
Methods
We will describe the key considerations that influenced the design of
the DSMS, whilst focussing on scalability, as the DSMS was intended
to be a cost-effective solution that could be used by a number of tri-
als within the unit.
The key activity was building a forecasting-and-site-refill algorithm to
minimise drug wastage whilst optimising shipment quantities, there-
fore reducing shipping costs. To achieve the required scalability, the
first consideration was introduction of flexibility into the algorithm. It
was developed with many inputs/parameters to cater for variation
across future trials and sites in terms of number of patients, recruitment
rates, site capacity and location. Each shipment request is reviewed
and approved by the trial team, which further allows the process to be
fine-tuned for each study.
Integration with internal and external contract research organization
(CRO) systems was fundamental to building a successful system. The
DSMS is a web-based system (C#/MVC.NET/SQL Server database) and
has been integrated with an existing randomisation system and
study database. The system allows for pack/kit numbers to be used
in blinded trials, therefore integration with CRO systems is vital to an
efficient pack selection process for site shipments.
Another important consideration to facilitate scalability was ensuring
ease of setting up new trials and studies, which has been enabled by
how the DSMS integrates with internal systems which house both
trial and site data. In addition to this, a metadata template was cre-
ated to expedite the process of gathering new requirements from
new trials. This has been successfully implemented for Add-Aspirin
and its use has already been extended to the FOCUS4 biomarker-
stratified platform trial.
Finally another important component was the ease of use, supported
by the provision and implementation of system training. Training has
been developed using different formats, webinars, user guide, slides
and videos. The training materials are available from within the system
and on the trial website; they can easily be adapted by new trials.
Conclusion
In the Add-Aspirin trial to date, over 1,500 participants from 128 UK
sites have been dispensed 3,000 treatment packs using the DSMS.
The number of shipments created so far is in line with what was pro-
jected using simulation before the start of the trial. The shipments
have been optimised for low, medium and high recruiting sites. The
DSMS is a platform that continues to evolve as new functionality is
required for the Add-Aspirin trial and other trials within the MRC CTU
at UCL portfolio.
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Background
Increasingly drugs are being developed with consideration to a bio-
marker defining a sub-population where the drug will demonstrate
increased clinical benefit. However, frequently the prior evidence of
the necessity of the marker isn’t overwhelming or the exact defin-
ition of the biomarker cannot be specified in advance either in terms
of a cut-off and/or the optimal assay or property of the biomarker
that will be used to define the sub-population. In these cases a study
will typically be run in an unselected population, and the analysis
performed in both the whole study population as well as biomarker
defined sub-populations. In these situations, although many separate
biomarker hypotheses may be tested, it is desired to maintain an
overall type-1 error rate control for testing the single hypothesis that
the drug has an effect within a patient population.
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Spiessens-Dubois (2010) provide an approach for controlling overall
type-1 error rate when all biomarker hypotheses are nested by consid-
ering the correlation between different tests using an analogous
approach to group sequential analysis. This describes the situation of a
single biomarker being investigated at multiple cut-offs. In this presen-
tation, this is extended to the more general case of non-nested tests
representing the situation of multiple biomarkers which may be corre-
lated but not ordered, still using the intrinsic correlation from overlap-
ping populations to construct an efficient test. This solution generates
sets of significance boundaries all maintaining an overall type-1 error
rate which can be optimized according to a variety of different optimal-
ity criteria based upon different characteristics of the study including
functions of power, effect size and significance levels.
Results
We present and compare the results of optimising the significance
boundaries of a study using different optimality criteria and link this
to the properties of the biomarkers being investigated. We give guid-
ance as to how this approach may be implemented in practice and
the beneficial discussions within clinical teams that adopting these
approaches will facilitate.
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Background
Successful and timely participant recruitment is a key aspect of clinical
trial conduct. Failure of potential participants to complete screening is
often reported as an issue in prevention studies. The T4DM diabetes
prevention study, being conducted at 6 sites around Australia, employs
a step-wise screening process. Potential participants first complete an
online study registration questionnaire and, if eligible, the online sys-
tem generates consent and laboratory forms. Participants are then re-
quired to attend for lab screening before being allocated to the nearest
study site. After the first 12 months, only 58% of men who registered
online had attended the lab for screening. Given the cost and difficulty
associated with attracting men to register, a quarterly email reminder
and ad-hoc phone reminders were introduced to improve uptake of
lab screening. After a further 24 months, we observed that the number
of men attending for screening late (more than 12 weeks after registra-
tion) had grown but the overall lab screening rate remained largely un-
changed at 60%.
Aim
In this sub-study we aimed to assess the impact of phone and SMS
(text message) reminders on lab screening rates while also maximiz-
ing lab screening uptake in the lead up to recruitment close in
December 2016.
Method
Between June and October 2016, 709 participants who did not at-
tend lab screening within 4 weeks of online registration were ran-
domized to receive either an SMS or a phone reminder to attend for
lab screening. This was in addition to an automated email reminder
that all registered participants receive at 4 weeks. Participants were
followed to determine whether they attended lab screening by 8
and 12 week time points. The sub-study completed enrollment in
October 2016 with all data collection to be complete by the end of
2016.
Preliminary results
Prior to the introduction of the reminder sub-study, only 12% of men
who didn’t attend lab screening within 4 weeks had done so by
8 weeks. To date, the introduction of reminders has increased this to18% (a 6% increase) based on the 358 participants who had reached
the 8 week time point by October 2016. Completion of the sub-study
later in 2016 will reveal how effective phone reminders were com-
pared to SMS reminders. The cost of an SMS reminder is approxi-
mately $0.18AUD with negligible staff time required per person
reminded. The cost of a phone reminder is approximately $0.48AUD
with an average of 4 minutes of staff time required per person
reminded.
Conclusion
This sub-study will establish the extent to which phone and SMS
screening reminder strategies increase participant follow-through
with the screening process. It will also assess the relative costs of
each approach in terms of cost per notification, cost per participant
screened and cost per participant enrolled. These findings have the
potential to inform the choice of screening reminder strategy in future
prevention clinical trials.
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There has been a surge in designing clinical trials based on the as-
sumption that a biomarker is predictive of treatment response. Pa-
tients are stratified by their biomarker signature, and one tests the
null hypothesis of no treatment effect in either the full population or
the targeted subgroup. However, in order to directly verify the pre-
dictability of a biomarker, it is essential that hypothesis be tested in
the non-targeted subgroup too and within a randomised controlled
trial [1]. In a Phase IIB oncology trial with progression free survival
(PFS) endpoint, the data obtained can inform the Phase III design
aimed at establishing overall survival whether to restrict recruitment
to just the targeted subgroup or not.
We propose a new two-stage adaptive randomised Phase II popula-
tion enrichment trial design, with PFS as the primary endpoint and
comparing an experimental drug with a control treatment. We adap-
tively test the null hypotheses of hazard ratios in both the targeted
as well as the non-targeted subgroups, with strong control of the
familywise error rate. It is assumed that the hazard ratio of the tar-
geted subgroup is much less than that of non-targeted, since the
drug is expected to be more beneficial for the biomarker-positive
subpopulation.
Simulations for an example trial in non-small cell lung cancer show
that the probability of recommending an enriched Phase III trial in-
creases significantly with the hazard ratio in the non-targeted sub-
group. We compare our decision rules with [1] and illustrate the
efficiency achieved. Our adaptive design testing first in the non-
targeted subgroup followed by testing in the targeted subgroup for
a randomised controlled trial constitutes part of the proof of a bio-
marker’s predictability.
Reference
[1] Mehta C, Schafer H, Daniel H, Irle S. Biomarker driven population
enrichment for adaptive oncology trials with time to event outcomes.
Statist. Med 2014; 33: 4515–4531.
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There are an increasing number of studies described as pilot and
feasibility studies. A pilot or feasibility trial conducted in advance of a
future definitive trial is a study where part or all of a future trial is
carried out on a smaller scale to see whether it can be done and
whether we should proceed with it. Reporting of pilot and feasibility
studies is poor, and these studies are particularly important when de-
signing cluster randomised trials (CRTs), which bring with them extra
complications.
Objectives
To systematically review the quality of reporting of pilot and feasibility
CRTs. In particular, to identify 1) The number of pilot CRTs conducted
between 01/01/2011 and 31/12/2014, 2) Whether pilot CRTs have ap-
propriate objectives and methods, and 3) The extent to which the qual-
ity of reporting of pilot CRTs is sufficient.
Methods
We searched PubMed (2011–2014) for CRTs with “pilot” or “feasibility”
in the title/abstract, that were assessing some element of feasibility and
showing evidence the study was in preparation for a main effectiveness
trial. Quality assessment criteria were based on the CONSORT extension
for CRTs, and the CONSORT extension for pilot trials which was in the
final stages of development.
Results
Eighteen pilot CRTs were identified, with most (56%) published in
the UK. 44% did not have feasibility as their primary objective, and
many performed formal hypothesis testing for effectiveness/efficacy
despite being underpowered (50%). Most pilot CRTs (83%) reported
the term “pilot” or “feasibility” in the title, and discussed implications
for progression from the pilot to the future definitive trial (89%), but
less than half gave reasons for the randomised pilot trial (39%), re-
ported a rationale for the sample size (44%), reported criteria used to
judge whether or how to proceed with the future definitive trial
(17%), or reported where the pilot trial protocol could be accessed
(39%). Most pilot CRTs defined the cluster (100%), and reported the
number of clusters randomised (94%) and assessed for the primary
objective (82%). Items reported least well included how clusters were
consented (11%), the cluster design during the description of the ra-
tionale for numbers in the pilot (17%), who enrolled clusters (17%),
the number of exclusions for clusters after randomisation (18%), a
table showing baseline characteristics for the cluster level (11%), and
from whom consent was sought (11%).
Conclusions
The identification of just eighteen pilot CRTs highlights the need for
increased awareness of the importance of carrying out and publish-
ing pilot CRTs and good reporting. It is possible that some pilot CRTs
were missed because they did not include “pilot” or “feasibility” in
the title/abstract. Pilot CRTs should primarily be assessing feasibility,
with methodology reflecting this focus. Improvement is needed in
reporting reasons for the pilot, rationale for the sample size, progres-
sion criteria, and where the protocol can be accessed. Cluster level
items also need better reporting, since these are important for asses-
sing feasibility. We recommend adherence to the new CONSORT ex-
tension for pilot trials, in conjunction with continued adherence to
the CONSORT extension for CRTs.
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Managing study drug throughout a trial is a complex, vital task further
compounded when there are multiple research sites participating.
Adherence to good clinical practice (GCP) requirements and all applic-
able regulatory requirements is paramount. The National Drug AbuseTreatment Clinical Trials Network (CTN) Clinical Coordinating Center
(CCC) and Data and Statistics Center (DSC), both at the Emmes Cor-
poration, collaboratively developed a series of processes and tools,
some of which are incorporated in the electronic data system, to
ensure an efficient and controlled chain of custody and process be-
ginning from initial supply distribution through dispensing proce-
dures at the research sites and final reconciliation and destruction.
The CCC and DSC consider several factors when determining the
process for study drug management, including treatment blinding,
drug type, quantity and packaging, frequency of distribution, expir-
ation dating, and the number of sites. Based on these parameters,
the CCC assists the study teams in development of clear and thor-
ough drug management logs as well as defining drug storage and
temperature monitoring requirements. To remedy last minute re-
quests, supply hoarding, and waste at the sites, the coordinating
centers have developed a centralized inventory tracking and reor-
dering process to monitor drug supply and distribution. In this
process, research staff report inventory weekly directly in the Elec-
tronic Data Capture (EDC) system, and the data is pulled into re-
ports, which identify reorder needs based on thresholds and usage.
Before shipping initial supplies to each site, all regulatory docu-
ments are collected and training is provided to research sites on
the importance of drug accountability and consequences for par-
ticipant safety if inaccurately reporting drug dosing and disposal.
Site monitors review the drug logs, medication storage, and regula-
tory documentation throughout the trial (remotely or on-site) in
order to identify and resolve any improper practices, discrepancies
and errors. The Emmes Corporation has supported substance use
treatment interventions implemented in the CTN for over 11 years,
and throughout that time have developed best practices including
using systematic, clear and precise processes for study drug pro-
curement, distribution, and monitoring. Over 14 clinical trials across
105 clinical sites have involved study drug, including 4 double-
blinded studies and 4 Investigational New Drugs and 6 studies
using controlled substances. Effective communication between the
CCC/DSC, central pharmacy, third-party vendors, research sites, and
all other stakeholders allows for efficient planning and prompt
resolution to problems that arise. Supporting this communication
with real time data collection and reporting allows for the proper
maintenance of a comprehensive and accurate study drug manage-
ment system. This presentation will emphasize best practices for
achieving an organized and controlled chain of custody throughout
the life of a trial.
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Sharing collected data from trials has the potential to exponentially
increase the efficiency and accuracy of research and reduce research
waste through repeated trials. Unfortunately, barriers to do so still
exist. These include the difficulty to find, access and use previously
collected research data sets because they are not centrally indexed
or standardized.
The European Commission unveiled its plans in April earlier this year
to create a new European Open Science Cloud that will offer
Europe's 1.7 million researchers and 70 million science and technol-
ogy professionals a virtual environment to store, share and reuse
their data across disciplines and borders. The aim is to make all data
derived from EU-funded research projects Findable, Accessible,
Interoperable and Reusable (FAIR). The European Union has fully
embraced the FAIR principles, which are created to ensure high data
quality, shareability, and usability.
We will discuss the benefits of FAIR data, explain what is required for
FAIR data, and give guiding principles on how to create FAIR data.
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towards the worldwide implementation of FAIR.
These challenges include: Ensuring all research data is of high quality
Standardization of research data at the source Provide everyone with
the ability to make FAIR data (FAIRification)
We will discuss how to deal with these challenges and present our
solution to make capturing FAIR data accessible for every researcher
worldwide. By making these data available in environments like the
European Open Science Cloud, the world will experience a major
increase in the quality and efficiency of research. This in turn will
help to improve healthcare in the long run, by ensuring better qual-
ity of evidence to base our medical guidelines on.
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Background
Patient and public involvement (PPI) in clinical trials describes a
variety of activities ensuring that research is carried out collabora-
tively with patients and/or members of the public. Traditionally, the
patients and public involved have not been taking part in the study
in question and in the UK, guidance from INVOLVE suggests that it is
not appropriate to involve clinical trial participants in PPI activities.
However, as part of a study exploring PPI in randomised controlled
trials conducted by the MRC CTU at UCL, we identified 3 studies
(2 trials and 1 cohort study) where participants had been in-
volved. In the light of this we reviewed the concept of participant
involvement, setting out to develop guidance based on our
experience.
Methods
Two workshops were held at the MRC CTU at UCL to discuss: defini-
tions; rationale; potential advantages and disadvantages; models;
and appropriateness of participant involvement in clinical trials. We
considered how participant involvement might overlap with, or differ
to, involvement of other patients and the public. Workshops were
attended by two patient representatives and seven staff members,
each of whom has experience of PPI. Staff members from studies
that had actively involved participants shared details of that work to
inform discussions.
Results
Trial participants were defined as individuals taking part in the study
in question, irrespective of whether or not they have completed their
trial treatment and follow-up. Their direct experience of taking part
in the trial may be especially useful in studies of new interventions
or procedures, where they may be the only people who have experi-
ence of the interventions, or where it is hard to identify patient or
community groups that include or speak for the study population,
for example in prevention trials. Participant involvement is possible
at all stages of a trial, except identifying the research question and
trial design (when, there are no participants to involve). Participants
can be involved in trials through a range of models, with managerial,
oversight or responsive roles (as for PPI). The only specific role identi-
fied as being inappropriate for trial participants was involvement in
data safety and monitoring committees, because of the likelihood of
obtaining information about the arm of the trial they are in and the
potential for unblinding. Involvement of participants can benefit tri-
als by improving the trial experience for participants; optimising
study procedures; and improving the communication of key mes-
sages and results. Specific challenges to involving participants in-
cluded managing confidentiality; practicalities around payments; and
ethical concerns around recruitment for involvement.Conclusions
Our experiences of participant involvement have demonstrated that
trial participants can add insight to the studies they are involved in.
Participant involvement in clinical trials is feasible and seems to offer
significant benefits in some circumstances. We recommend that current
INVOLVE guidance on PPI should be updated to include participant in-
volvement as a valid and potentially useful approach to PPI. Participant
involvement can complement other forms of PPI in clinical trials in ap-
propriate circumstances. We are developing plans and strategies to fur-
ther explore its potential.
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Background
In clinical trials, patient-reported outcome (PRO) questionnaires
offer information about the impact of disease and treatment from
the patients’ perspective. The ‘Clinical Research Coordinator (CRC)’
is typically responsible for PRO data collection. Recent evidence
suggests CRCs are not offered adequate PRO-specific trial guidance.
As PROs are increasingly being valued in the interpretation of can-
cer trials, the need to scrutinise current practice has become ever
more important. The present study explored the experiences of
Australian CRCs responsible for PRO assessment in cancer trials.
Methods
Cancer trial CRCs at approved Australian sites with 12+ months PRO
experience were eligible. Interested CRCs provided informed consent.
Semi-structured interviews were audio-recorded and transcribed ver-
batim. Interviewees discussed their PRO-specific skills, responsibilities,
challenges, procedures, PRO training received and training needs. Re-
cruitment continued until data saturation. Transcripts underwent
content analysis; codes were applied to organise interview content
inductively and deductively by RMB and 20% were checked by DK.
The study team agreed on the final code structure.
Results
Twenty participants (19 female) were interviewed (mean 9.3 years’
experience) with professional training in nursing (n = 12), science/re-
search (n = 4) or both (n = 4)). Participants worked in medical
oncology (n = 10), haematology (n = 5), radiotherapy (n = 4), and
endocrinology (n = 1) departments. Skills and responsibilities: All
CRCs described organisational and communication skills, the ability
to multi-task and work around patient needs. Differences included
whether CRCs explained the purpose of PRO assessments to patients,
which may result in bias if patients alter their responses if patients
believe it will impact their care. There were also differences in assist-
ance provided to patients; some CRCs read questions aloud and re-
corded patient responses, some paraphrased questions, others
excluded patients who could not independently self-complete. This
may lead to bias as a result of missing data from sicker patients, or
differences in explanations of question meaning. Some CRCs pursued
responses for accidentally missed questions; potentially leading to
differences in data quality across sites. Some CRCs checked for con-
cerning data or general outcome profile, whereas others felt ques-
tionnaires should be kept confidential and not checked, which may
lead to bias if these CRCs adapted procedures of care in response to
PRO data. Challenges: CRCs described challenges with electronic PRO
assessment, non-English-speaking patients, dealing with patients’ rel-
atives who inappropriately attempted to complete questionnaires,
and patient unwillingness to complete questionnaires. Inconsisten-
cies in data collection and the nature of challenges experienced
supports the need for increased PRO-specific training. Training: PRO-
specific training received varied considerably; ranging from dedi-
cated PRO training (study-specific or general); PROs being addressed
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training from colleagues; and no PRO training. Many agreed that
additional training was needed to improve current practices.
Conclusion
Differences between trials in PRO administration are expected, but
the described differences between CRCs regarding communication,
patient assistance and checking are concerning as they may lead to
various forms of bias and poor data quality. PRO training received
varied considerably between CRCs and may be a key reason for
these differences. Our findings highlight the importance of providing
clear, PRO-specific guidance to CRCs.
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Background
The Clinical Data Interchange Standards Consortium (CDISC) data
standards for clinical trials (http://www.cdisc.org/) are widely used in
the pharmaceutical industry and are now mandatory for FDA submis-
sions of studies started from December 2016. Relatively few trials run
by academic groups are submitted to regulators for marketing
authorisation, and the adoption of CDISC standards by them is sub-
stantially lower than in industry. We present the advantages and dis-
advantages of using CDISC standards in the light of the experience
of the CTSU in the University of Oxford across multiple phase II to IV
trials ranging from 400 to 30,000 participants.
Experience
CTSU first used CDISC when providing Study Data Tabulation Model
(SDTM) data for an FDA submission after the main analyses had been
developed without using CDISC. The resulting discrepancies between
CDISC and non-CDISC analyses took considerable effort to resolve. In
subsequent studies, whether or not regulatory submissions are
planned, a more systematic approach has been used. Collected data
is mapped to SDTM datasets, from which Analysis Data Model
(ADaM) datasets are derived. All analyses and complex reports, both
during and at the end of the trial, are performed on these ADaM
datasets. This approach has been successfully employed for a num-
ber of large trials at different stages (completed, currently undergo-
ing analysis and ongoing), which together have randomized over
70,000 participants, and more recently to partially convert some leg-
acy studies to CDISC for particular analyses.
Benefits
(1) CDISC standards eliminate the need for an organisation to de-
velop its own data standards, and, since they are developed by a
wide range of stakeholders over many years, are more comprehen-
sive and coherent than any single organisation is likely to achieve.
(2) Analysis and validation tools are available which support CDISC
standards. (3) CDISC-compliant datasets are well documented, so
statisticians, data analysts and researchers can easily switch between
studies without having to learn a new data schema. (4) The effort re-
quired to respond to queries about CDISC-compliant data is consist-
ently less than that for non-compliant data. (5) CDISC standards
provide a useful common framework for data sharing and long term
data and metadata storage. (6) The large CDISC user community is a
valuable source of support.
Costs
The most significant cost of using CDISC standards is staff training,
both technical and on the value of using CDISC. When processing
data, extra effort is required to ensure compliance with the stan-
dards. Where data are not collected using CDISC, a labour-intensive
mapping stage is required, which is more onerous the later in the
study life cycle it is done.
Discussion
We find the considerable investment required for CDISC at the start
of a study, particularly when CDISC is first used, to be worthwhile inview of the benefits which are seen later. Because of the reuse of
metadata and controlled terminology, costs are lower for subsequent
studies. The benefits of CDISC for data analysis and reporting are
maximised when their needs are built into the systems used to
capture and process the data.
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Objectives
To identify unanswered questions around trial recruitment, and then
prioritise those that stakeholder groups including members of the pub-
lic, recruiting clinicians and researchers, agree are the most important.
Background
The PRioRiTy study - Priority Setting Partnership (PSP) included stake-
holders involved in all aspects of clinical trial recruitment; members
of the public approached to take part in a randomised trial or who
have sat on randomised trial steering committees, health profes-
sionals and research staff with experience of recruiting to rando-
mised trials, people who have designed, conducted, analysed or
reported on randomised trials and people with experience of rando-
mised trial methodology.
Methods
This partnership involved eight key stages: (i) formulating the PSP
idea and identifying a unique, relevant prioritisation area within clin-
ical trial methodology (ii) establishing an oversight Steering Group
(iii) identifying and engaging with partners and stakeholders (iv) for-
mulating an initial list of uncertainties from a stakeholder survey (v)
collating the uncertainties into research question format (vi) checking
existing research evidence to confirm that the questions are a
current recruitment challenge (vii) shortlisting questions in an interim
priority setting exercise through another survey of stakeholders and
(viii) final prioritisation through a face to face workshop with stake-
holders to agree a top 10 list of priorities of methodological uncer-
tainties around trial recruitment. Both surveys were open to all
stakeholders and were disseminated through national clinical trial re-
search networks, patient groups, funding bodies and other relevant
stakeholder channels including social media and direct emails.
Results
A total of 1,880 questions were extracted from 790 survey respondents,
which after merging duplicate questions, was reduced to 496 ques-
tions. Merging appropriate questions together and excluding questions
asked by fewer than 15 people and/or fewer than 6 of the 7 stake-
holder groups resulted in 31 unique research questions. All questions
were retained after confirming a lack of relevant, up to date research
evidence addressing the question.
Currently (Nov 2016), the partnership is undergoing the interim pri-
oritisation process in which stakeholders are shortlisting the top 10
questions they regard as important uncertainties. The top 10 prior-
ities of methodological uncertainty around trial recruitment will be
agreed at a final prioritisation stakeholder workshop scheduled for
1st December 2016. Full results will be available for presentation at
ICTMC 2017.
Conclusion
Despite the global problem of inadequate recruitment to randomised
trials, there is little evidence to guide researchers on decisions about
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process has been undertaken, with participation from key stake-
holders, including members of the public. Priority areas of focus in
trial recruitment methodology have been identified by those for
whom it matters most. The Top 10 list should inform the scope and
future activities of funders and researchers in the area of trial recruit-
ment methodology.
Sponsorship
This project was funded by the Health Research Board (Ireland)
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was supported by the James Lind Alliance and NIHR.
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Background
The past two decades have seen dramatic changes in clinical trial
conduct and methodology. From trial regulation to data analysis, the
rapid rise of randomised control trials (RCTs) has introduced many
new techniques. Some methods of designing and conducting RCTs
have been widely adopted, whereas other ideas have been used
sparingly, despite their promise. Large-scale phase III trials are no dif-
ferent. We present a case study to highlight the changes experienced
in designing, setting up, and conducting a large-scale multicentre
phase III trial over 14 years.
AspECT is a phase III RCT investigating the use of aspirin and Proton
Pump Inhibitors to prevent oesophageal cancer and death in Barrett’s
Oesophagus patients. Trial follow-up will end in May 2017, 14 years
since design and set-up began in 2003. Many challenges have been
encountered and addressed by the trial team over this time. With
the trial’s close, we reflect on its set-up and management, to identify
lessons learned and discuss these issues in relation to future trials.
Methods
We conducted semi-structured interviews with researchers involved
with the set-up and running of the trial at any stage of its 14 years,
such as trial coordinators, trial statisticians, and clinicians. The inter-
view structure ensured each individual was asked to address the
same key topics and also allowed them to provide their personal
views of the changes in trial methodology and set-up. Thematic ana-
lysis identified the major challenges experienced by the respondents.
Results
Interviews conducted with the current trial coordinator, current trial
statistician, and a clinician involved throughout the trial’s history re-
vealed the 14-year lifespan of the trial and regulation changes in this
time to be the main challenge. AspECT was begun before the current
clinical trials regulations were published as Statutory Instrument
2004/1031. The regulations are set to change again soon.
Themes reported included the difficulty in maintaining knowledge of
the trial with changing PI’s and study nurses in the hospital sites, main-
taining and auditing a high quality database over the trial lifespan,
handing over study roles, dealing with an ever-evolving and scepticalclinical world, and adapting to the changing processes for obtaining
national regulatory and local R&D approval and multicentre trial set-up.
Also, the trial management had to repeatedly react to poor quality epi-
demiology claims about drug reactions or side effects, or unproven
benefits. We will also discuss issues around the evolving world of meth-
odology, including placebo blinding costs today compared to during
trial set-up and the potential for Studies Within A Trial, an emerging re-
search movement to make better use of trial data.
Conclusions
Many changes have occurred since the set-up of AspECT in 2003.
Some of these changes have made trials more transparent and
safer for the patients involved, benefiting the medical research
world. However, some changes may deter and slow good research,
inhibiting the emergence of new treatments. Our experiences over
a 14-year phase III trial highlight the issues experienced by the trial
research community and are presented to inform the design and
conduct of similar future trials.
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Background
The Flexibility in Duty Hour Requirements for Surgical Trainees
(FIRST) trial was a pragmatic cluster randomized trial (CRT) involving
117 surgery residency programs in the United States. It evaluated
non-inferiority of flexible duty-hour policies compared to standard
restricted duty-hour policies with respect to surgical resident well-
being and patient safety. Investigators concluded that flexible duty-
hour policies were non-inferior to standard duty-hour policies. The
ethics of the FIRST trial have been vehemently debated. One com-
mentator describes it as “among the most unethical research studies
[he has] ever seen.” Another argues that it was “not just ethical but
laudable to comparatively evaluate duty-hour policies. The FIRST trial
illustrates the complex ethical challenges posed by CRTs of policy in-
terventions involving healthcare professionals.
Objectives
The Ottawa Statement, published in 2012, provides researchers and
research ethics committees (RECs) with specific guidance for the eth-
ical design and conduct of CRTs. Our objectives are to: (1) review crit-
ically the FIRST trial controversy; (2) apply the Ottawa Statement to
the FIRST trial; and (3) identify issues not adequately addressed by
the Ottawa Statement, thus requiring further analysis and guidance.
Results
Objective 1: Controversy erupted following publication of the FIRST
trial in New England Journal of Medicine in 2016. Critics accused the
investigators of “egregious ethical and regulatory violations,” arguing
that the flexible duty-hour intervention knowingly exposed residents
and their patients to increased risks of serious harms. They decry the
decision by Northwestern University’s REC exempting the trial from
human subjects research regulation, calling it a “colossal failure” of
all participating RECs. Critics also denounce the resultant consent
waiver as a violation of the ethical principle of respect for persons.
Defenders of the FIRST trial argue that the flexible duty-hour inter-
vention did not pose a greater risk to participants, and conditions for
the waiver obtained. We critically review the FIRST trial controversy,
finding that commentators fail to identify the relevant ethical issues
systematically. Objective 2: We examine the utility of the Ottawa
Statement for CRTs of policy interventions involving healthcare pro-
viders. We find that the Ottawa Statement provides much-needed
clarity by identifying systematically the ethical issues common to all
CRTs, including: justifying the cluster design, identifying research par-
ticipants, consent, gatekeepers, benefit-harm analysis, and vulnerable
participants. Objective 3: We show how the FIRST trial raises unique
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For instance, does clinical equipoise obtain when a novel policy is
compared to an existing policy that has little or no evidence-base?
How should researchers and RECs conceptualize healthcare providers
targeted by policy interventions? Are they obligated to participate in
research? If so, what are the implications for consent? Alternatively,
should healthcare providers be conceptualized as vulnerable partici-
pants? A power-differential often exists between healthcare providers
and their superiors, particularly when providers are trainees or em-
ployees. Does this relationship undermine the validity of their con-
sent? If so, what safeguards might be implemented to ensure
protection of healthcare providers, while at the same time ensuring
that important research proceeds both feasibly and expeditiously?
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Background
There is increasing enthusiasm for the use of mediation analysis in
the secondary analysis of complex interventions with the aim of iso-
lating the causal mechanisms through which an intervention pro-
duces the outcome of interest.
Recent guidance from the Medical Research Council (MRC) on evalu-
ating complex interventions suggests that Randomised Controlled
Trials (RCTs) should be complemented by process evaluations which
might provide evidence about the possible causal mechanisms that
produce intervention effects. Process evaluations often include the
development of an intervention theory of change - a description of
how the intervention inputs, change mechanisms and context are
hypothesised to produce the intended outcomes. It is recommended
that these intervention theories are represented and evaluated using
‘logic models’ which visually demonstrate the pathway of effect
between intervention inputs and intended outcomes. Mediation
frameworks are potentially useful here as they can generate tests of
the logic model and hence the intervention theory of change.
The traditional framework for mediation analysis applies structural
equation modelling (SEM). While SEM has been valuable because of
its relatively simple approach to analysing mediators, recent ad-
vances in mediation theory have shown that the SEM approach has
theoretical limitations which make it insufficient for more complex
applications. An alternative nonparametric approach is based on the
‘potential outcomes framework’ and applies the logic of counterfac-
tuals in an attempt to identify causal pathways.
Materials and methods
The PRIME intervention was designed to attract patients to seek care
and to improve the quality of care, including for the diagnosis and
treatment of malaria, delivered at public health centres. The complex,
multi-component intervention focused on ensuring access to appro-
priate treatment and diagnostic tests at health centres through a
range of components to improve provider behaviour and health
centre operations. Following the MRC guidance, the impact of the
PRIME intervention was comprehensively evaluated including a rigor-
ous outcome evaluation; a cluster Randomised Controlled Trial (cRCT)
with data from community cross-sectional surveys, and a parallel
mixed-methods ‘process’ study. Here we explore the use of the ‘po-
tential outcomes framework’ to undertake a mediation analysis of
the PRIME intervention theory of change.
Results, conclusions and future research
We demonstrate the challenges and limitations of mediation analysis in
this context and suggest a cautious approach for incorporating the
ideas of mediation analysis into evaluations of complex interventions.
Building on this experience, we discuss the utility of the suggestedapproach in the design process of the UPAVAN trial- a three-year, four
arm cRCT to assess the impact and cost-effectiveness of three variants
of an innovative intervention to improve agricultural and nutrition out-
comes, with an integrated theory of change.
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Background
The COMET (Core Outcome Measures in Effectiveness Trials, http://
www.comet-initiative.org.uk) Initiative brings together people inter-
ested in the development and application of agreed standardised
sets of outcomes, known as “core outcome sets” (COS). These sets
represent the minimum that should be measured and reported in all
clinical trials of a specific condition, and are also suitable for use in
clinical audit or research other than randomised trials. One of the
successes of COMET has been the development of a publicly avail-
able searchable database of completed and ongoing projects in COS
development. This database is currently searchable by population,
intervention and condition, but as yet has not been categorised ac-
cording to outcome (the fourth of the essential elements that should
be defined for a trial, according to the PICO model). Similarly, out-
comes in trials registries (including the EU Clinical Trials Register,
ClinicalTrials.gov and ISRCTN registry) can be entered as free text
only, leading to inconsistencies. Ninety percent of queries related to
requests to register a trial relate to outcomes (Alison Cuff, ISRCTN,
personal communication). Standardised terminology to describe out-
comes is starting to come into use in pre-clinical research (Robinson
et al. “The Human Phenotype Ontology: A Tool for Annotating and
Analyzing Human Hereditary Disease” (2008) The American Journal
of Human Genetics 8: 610–615), but there is currently no consensus
on how trial outcomes should be classified. The lack of a standard
taxonomy relating to trial outcomes impedes the ability to efficiently
and effectively search the literature. A standard classification system
for trial outcomes would facilitate literature searches to identify the
use of a particular COS, as well as being of use to reviewers when
annotating Cochrane Reviews according to outcome, as part of the
PICO review description (via the Cochrane Linked Data Project,
http://linkeddata.cochrane.org/).
Methods
The COS outcome classification project involves the extraction of all
core outcomes/domains from existing COS through the COMET
database and reviewing the systematic reviews of outcomes in the
COMET database to determine how outcomes were classified. Exist-
ing conceptual models (including The International Classification of
Functioning, Disability and Health (ICF), Patient-Reported Outcome
Measurement Information System (PROMIS) and the Wilson and
Cleary framework) will be reviewed for suitability, with a view to-
wards developing a standardised ontology for classification of re-
search outcomes.
Results
Results on the progress of this project, in terms of the classification
of COS outcomes within the COMET database and development of a
standardised outcome taxonomy for the classification of COS out-
comes, will be reported, along with any conclusions drawn during
discussions which took place during the ‘Outcome Classification’ ses-
sion at COMET VI (November 2016).
Conclusions
The ultimate aim of this project is to agree on standardising termin-
ology and definitions through consensus among different stake-
holders, including patients, clinicians and methodologists. Progress
made to date on achieving this aim will be presented.
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Introduction
Clinical trials are commonly affected by slow recruitment, leading to
prolonged study duration and increased cost, and also attrition,
which weakens trials. It has been suggested that patient and public
involvement (PPI) in designing and/or conducting trials could help to
alleviate these problems, yet PPI is often implemented with little
planning or thought as to the role of PPI contributors and how their
input might benefit the trial. We are developing a PPI intervention
aimed at improving recruitment and retention in surgical trials, which
can be particularly difficult to recruit to. As part of this process we
explored surgical trial staff and PPI contributors’ views regarding
how PPI might achieve such improvements.
Methods
Participants were recruited via surgical and PPI networks and organi-
sations. 6 focus groups (4 with surgical trial staff and 2 with PPI con-
tributors) were facilitated at 4 sites across the UK. PPI contributors
unable to attend focus groups were offered a one-to-one interview
in person or by telephone. All participants as well as those unable to
attend focus groups were invited to submit additional comments in
writing. Verbatim transcripts and textual data were analysed themat-
ically by three researchers who identified emerging themes.
Results
Fifty-four people took part, of whom 31 were surgical trial staff (15
trial managers/coordinators, 7 investigators, 7 research nurses, 1 clin-
ical trial administrator and 1 research associate), 21 were PPI contrib-
utors and 2 were PPI coordinators. Staff took part in focus groups at
surgical research centres in Oxford (N = 7), Aberdeen (N = 8), Bristol
(N = 9) and Birmingham (N = 7), while PPI contributors took part in
one of two focus groups at the Library of Birmingham (N = 6 and
N = 8) or a one-to-one interview (N = 7). Eleven people submitted
written contributions.
Drawing on their experiences, participants proposed several ways in
which PPI contributors could improve recruitment to trials: improving
the relevance of the research question; informing trial design includ-
ing the benefits and burdens for participants, recruitment process
(where, when, who) and participant information sheets; assessing pa-
tients’ willingness to take part; directly recruiting participants; and
publically endorsing the trial
Suggested ways in which PPI contributors could improve retention in
trials included: changing which outcomes are collected and how;
assessing the burden or acceptability of follow-up methods to poten-
tial participants; suggesting appropriate incentives; communicating
with participants during the trial (e.g. newsletter updates, explaining
why it is important to stay in the trial); challenging regulatory barriers
to adopting new data collection methods.However, it was also suggested that PPI contributors could be un-
helpful in some circumstances, for example if involved too late (e.g.
only in developing informed consent documents), if their literacy
level is too high, or if they are not from the trial’s target population.
Conclusion
Participants proposed a variety of ways in which PPI contributors
might improve recruitment and retention in surgical trials, also giving
examples of when PPI might be unhelpful or even harmful. Trialists
should carefully consider how to involve patients and members of
the public most effectively.
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Introduction
Long stay in hospital and poor mobility put people at risk of devel-
oping pressure ulcers (PU) at a number of areas of the body (but-
tocks, heels etc.). PUs result in admission to hospital, prolonged
hospital stay, impaired quality of life, significant cost to the NHS and
have been described as a key quality indicator for the Department of
Health. Motivation PUs are classified on a 4 point ordinal scale from
1–4 with 4 the most severe category. In RCTs skin assessment for on-
set or progression of PUs is scheduled to take place at a number of
fixed time points, resulting in serial measurements of PU categories
at up to 14 skin sites. Thus each patient typically has 50–100 PU as-
sessments during trial follow-up. However, due to administrative and
patient-related events, scheduled measurements may be missed or
only partially completed. This results in observation times that are
different for different patients and different skin sites, and intervals
between assessments may vary. Moreover, the reasons for missing
data may not be independent of the PU category. Typically, the pri-
mary outcome for PU prevention trials is the time from randomisa-
tion to the first category 2 PU at any skin site, so that the 50–100
assessments per patient are reduced to a single outcome measure-
ment. This outcome is inefficient in that it ignores the information
from serial measurements and multiple skin sites; it may also be
biased due to the interval censoring between observations and the
missed assessments. Thus sample sizes for PU prevention trials may
be larger than necessary, resulting in delays in getting effective treat-
ments into practice, or in ruling out ineffective treatments. Aim The
aim of this study was to investigate the use of multi-state models of
PU onset and progression, in order to provide less biased and more
efficient estimates of treatment effects.
Methods
In this study we show how to design a PU prevention trial and analyse
resulting data. Specifically, multi-state models that incorporate both the
sampling process (availability and completeness of follow-up) and the
observed PU categories at all skin sites are developed. The assumptions
that are required for different models, their implications and their valid-
ity in this context are presented. Methods for estimation of commonly
used outcome measurements within this framework are presented.
Through re-analysis of an existing serial measurement from a PU pre-
vention study we demonstrate how fixed covariates (e.g. treatment
group and stratification factors) can be incorporated into the analysis.
Efficiency is explored using simulation studies based on the example
trial to demonstrate potential influence on sample size estimates, of
using more informative designs and analyses.
Conclusion
Given the current difficulties in recruiting patients to RCTs it is im-
portant to make best use of the rich data that accrue during trials.
Important reductions in sample size for PU trials may be possible if
all available observations are included in the analysis.
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The Study Data Tabulation Model (SDTM) defines a standard structure
for submission of electronic clinical trial data to a regulatory authority,
such as the FDA. These electronic listings of individual observations
comprise the essential data reported from a clinical trial and are sub-
mitted with the analysis datasets.
The Clinical Data Interchange Standards Consortium (CDISC) team at
the Emmes Corporation, developed a novel process to map data col-
lected in electronic case report forms (eCRFs) to the SDTM paradigm
with these unique advantages: the mapping specifications are devel-
oped alongside the design of the CDASH conformant CRFs; Advan-
tage eClinicalSM, Emmes' form building and data capture and
management suite, provides an intuitive user interface that permits a
non-programmer to specify the mapping to SDTM - this process is
completed before the initiation of data collection; then the mapping
is executed on the production data in an automated fashion at least
daily while the trial is accumulating data, and the results are written
to a tabulation database. This enables the use of SDTM data struc-
tures for oversight and safety reporting. The use of standardized data
tables throughout the life cycle of the study yields efficiencies in stat-
istical reporting and reduces the timeframe required for delivery of
the final databases and code at the end of the study.
Quality control of the mapping process is partially automated. The
proposed automated QC report algorithm reduces the amount of
work involved in validating the mapping against a discrete set of
rules (e.g. every variable is mapped, no cell in the mapping tool is
left blank, each required variable in the domain is mapped, compare
mapping to a gold standard - a protocol that was tested and can
serve as a template, all fields in the mapping entries start with the
form code, all subjects belong to the protocol).
The program creates a complete set of reports for the entire proto-
col, for each combination of domain and eCRF. Each report has a
summary of the failed tests and hyperlinks are utilized so that the
tester can easily navigate the report, see the description of the test,
the mapping code used, and the relevant data, as well as the reason
for failure. This program has been utilized and tested on Emmes plat-
forms and has consistently helped to identify errors while saving tes-
ters time. It provides all the information for the tester to evaluate the
results and relevant code if they want to execute it themselves. The
more accurately this QC of the SDTM mapping is done, the more effi-
cient subsequent testing will be.
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Background
The Medical Research Council (MRC) 1998 Guidelines for Good Clinical
Practice in Clinical Trials recommend that, in the UK, trial oversight is
managed by three committees: a trial management group (TMG), trialsteering committee (TSC) and data monitoring committee. This model
is endorsed by several UK funders. According to these Guidelines, the
Principal Investigator (PI) has the central role and overall responsibility
for the co-ordination and day-to-day management of the trial. How-
ever, recent quantitative evidence suggests heterogeneity in trial over-
sight and some confusion regarding the diverse roles of stakeholders,
indicating the MRC Guidelines may be outdated. Aim: To explore roles
and relationships in trial oversight to ascertain current practice and sug-
gest recommendations to support an update of the MRC guidelines.
Methods
Using an ethnographic study design, 8 TSC and 6 TMG meetings
from eight trials were observed and audio-recorded and 65 semi-
structured interviews conducted with 51 purposively sampled key in-
formants (members of the trials’ TSCs/TMGs and other relevant infor-
mants). Selected trials represented a range of clinical topics and were
all dealing with challenging scenarios (e.g. recruitment issues, proto-
col deviation or amendments). Data were analysed thematically and
findings triangulated and integrated to give a multi-perspective ac-
count of current oversight practices.
Results
The primary themes identified were the role of the CTU in trial over-
sight and power issues within trial oversight. The central role of the
PI in the MRC Guidelines was not reflected in our data. Instead, the
clinical trials units (CTUs) supporting the trials took on the responsi-
bilities of the PI outlined in the Guidelines. We observed CTUs per-
forming additional roles such as advising the PI on research
methodology, being the main channel of communication for the trial
and arbitrating between the PI and other trial oversight groups. The
perceived power of individual oversight groups over trials was influ-
enced by the behaviour of funding bodies. For example, by appoint-
ing their own TSC members, funders were viewed as reducing the
power of TSCs and trial sponsors to make independent decisions.
This could lead trial teams to fear their funder’s power and be
guarded in their communication with the funder. Trial oversight
groups had differing views regarding who has the power to stop tri-
als. The sponsors, independent TSC members, TSC chairs and funders
all believed they had the power to terminate the trial and that the
buck stopped with them.
Conclusions
The roles and relationships of trial oversight groups have changed
since the publication of the MRC Guidelines in 1998. We found that
CTUs, and not the PI or TMG, had responsibility for the day to day
management of trials, and this should be acknowledged when the
MRC Guidelines are revised. The TSC, funder and sponsor all have
the power to stop trials, and acknowledging this may be useful to
raise the awareness of all the parties concerned, in order to facilitate
the constructive collaboration of trial oversight groups.
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In a conventional randomized controlled trial (RCT), randomization is
in fixed, usually equal, proportions throughout. As judgments of rela-
tive treatment superiority are suspended until the end of the study,
there is no reason to use accruing data to adjust allocation, other
than in planned interim analyses. In trials using outcome-adaptive
randomization (OAR), allocation to treatment arms is repeatedly ad-
justed, to weight allocation to the hitherto more effective treatment.
This has the ethical merit of seeking to maximize the number of pa-
tients experiencing a treatment success. However, this apparent eth-
ical advantage is offset by other issues concerning equipoise,
informed consent and the methodology of the trial.
Equipoise
Equipoise indicates genuine uncertainty as to the relative merit of
the treatments being tested. In a conventional RCT this is established
at the outset and only revisited if interim analyses occur. Hence, no
patient is knowingly disadvantaged by allocation to either treatment.
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tion. Accordingly, allocation is increased to the treatment showing
superiority - but patients are nonetheless still knowingly allocated to
the apparently inferior treatment, albeit in smaller numbers, and
thereby disadvantaged. Whilst action is taken in response to changes
in equipoise, equipoise is not thereby completely restored.
Additionally, at the end of the trial, OAR may have required a larger
sample than a conventional RCT; whilst the proportion of participants
disadvantaged by a poorer outcome may decrease, the number
doing so may increase.
Consent
The moral force of consent depends on information about the trial
being adequately understood. Empirical research suggests that this is
hard to achieve, but it is likely to be even harder if one has to ex-
plain how randomization is continually readjusted in relation to out-
comes. This is likely to increase the ‘therapeutic misconception’:
participants’ tendency to think that treatment allocation is based on
their individual clinical need, rather than being (semi-)random. A
further complication is that the information required by new partici-
pants will vary over the course of the trial, as it should reflect the ac-
cruing outcomes within the trial (rather than just external evidence
that may become available). Conveying appropriate information is
therefore challenging, and if not achieved, the value of consent will
be reduced accordingly.
Crucially, simply telling participants that allocation reflects accumu-
lating evidence without also indicating which specific treatment is
currently favoured may be insufficient for consent to be informed.
Methodological issues
A study is only ethical if it generates methodologically robust find-
ings. However, some features of OAR may have undesirable meth-
odological implications. Thus, the fact that differing information
should be given to patients entering the trial at different times may
lead to contamination, or, coupled with the changing allocation ratio,
may be a confounder. Additionally, the need to monitor outcomes
repeatedly to determine allocation may limit the degree of blinding
achievable.
Conclusion
Initially, OAR appears to have ethical merit in terms of maximizing
the number of participants who receive the superior treatment
within the trial, but this claim needs to be tempered by other ethical
considerations.
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Background
Performance bias arises in randomized controlled trials (RCTs) if care
providers implement co-interventions differentially on the basis of
their knowledge of participants’ treatment allocation. It can especially
affect surgical trials because it is rarely possible to blind surgeons
and randomization within the operating theatre environment (i.e. as
close to intervention delivery as possible) poses logistical challenges.
This study aimed to measure and assess the influence of performance
bias in a surgical RCT.
Methods
Participants having general abdominal surgery or caesarean section
at five hospital sites are being recruited to a pilot RCT investigating
the influence of wound dressings on surgical site infection. They are
randomized twice: first, to the type of dressing to be applied (simple
wound dressing, glue-as-a-dressing, or no dressing) and, second, to
the time of disclosing the allocation (before or after the surgeon
closes the wound at the end of operation). The protocol specifiesthat users should log into the randomization system at the begin-
ning of surgery. The user is then either given the allocation or asked
to log in again after wound closure to obtain the allocation. When
logging in again, the user has to enter the time of wound closure.
Acceptability of the double randomization is assessed from three
sources of information: times for system log-on, knife-to-skin and
wound closure from the trial database; in-depth interviews with
health care professionals; feedback from participating centres about
their ways of working.
Results
At present, 55 and 57 participants (before and after wound closure)
have been allocated to no dressing; 52 and 54 to simple dressing; 54
and 54 to glue-as-a-dressing. Nine allocation disclosure deviations
were identified. For 5/165 participants randomized to allocation dis-
closure AFTER wound closure, system log-on times for obtaining allo-
cation were >50 minutes before the manually entered time of
wound closure; another 2 participants had first and second log-on
times <2 minutes apart. For 2/161 participants randomized to alloca-
tion disclosure BEFORE wound closure, the manually entered ‘knife-
to-skin’ time preceded the first system log-on time by >90 minutes.
Informants were not specifically aware of any attempts to work
around the double-randomisation system; some were aware that
such behaviours could be detected, and one questioned why one
might try to ‘cheat the system’, acknowledging this as a protocol de-
viation. Practical issues, such as limited internet access in theatre or
no one available to log into the database, were also reported. Feed-
back from two centres suggested that theatre staff are ringing a re-
search nurse outside theatre to log-on when required. On at least
one occasion, a surgeon first logged in after wound closure, to avoid
having to log-on twice. Centres have also reported occasional diffi-
culties in accessing the database from theatres. Generic usernames
for randomization only, accessible using a mobile phone, were of-
fered to improve access.
Conclusions
Timings collected during the trial demonstrate good adherence to the
double randomization. Methods adopted by research personnel in
order to adhere may not be practicable in a large trial. Generic access
for randomization may facilitate theatre personnel doing this task.
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Background
The Global Burden of Disease Study identified the leading causes of
chronic disorders worldwide. If the findings from this study are to
guide future health research, it is important to ensure that appropri-
ate outcomes are measured in that research. Core outcome sets
(COS) will help to achieve this. COS represent an agreed minimum
set of outcomes that should be measured and reported, as a mini-
mum, in all clinical trials for a specific health condition. The applica-
tion of COS allows the results of clinical trials to be appropriately
combined, minimising waste and ensuring that usable evidence is
made available. If COS were available for the leading causes of
chronic disorders, this should accelerate the impact of research and
result in improvements in global health. No prioritisation for COS de-
velopment has previously been undertaken, therefore this study
aimed to identify COS that have been developed in relation to the
most prevalent chronic conditions throughout the world, and to
highlight areas for future COS development or improvement.
Methods
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative
promotes the development and application of COS, by including per-
tinent individual studies in a publically available online database. The
COMET database is a unique inventory containing references of
planned, ongoing and completed work relating to COS development.
In total, there are more than 300 published and ongoing COS
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to identify published and ongoing COS that might be relevant to the
25 conditions with the highest global prevalence of chronic sequelae
identified in the Global Burden of Disease Study.
Results
A search of the COMET database identified 33 published and on-
going COS that are relevant to 13 of the world’s most prevalent con-
ditions. The majority were developed only with the involvement of
people from North America and Europe (n = 27/33). Thirty-one COS
involved clinical experts in the development and 18 involved pa-
tients. No published or ongoing COS have been identified for the
remaining 12 of the 25 most prevalent conditions.
Conclusion
This study describes the first approach to identifying gaps in existing
COS, and to priority setting in this area. Important gaps have been
identified for at least 12 of the 25 most prevalent conditions. The de-
velopment and application of COS in these areas would provide the
foundation for ensuring that appropriate outcomes are measured
and reported in clinical trials for these most prevalent disorders
worldwide. Without such international consensus on the key out-
comes for research in these conditions, new studies might not make
a full contribution to improving global health and opportunities to
reduce waste in research will be lost. A wider range of perspectives,
including those of patients, on existing COS are also needed when
not otherwise included. Furthermore, it is evident that COS are failing
to include a range of international stakeholders within the develop-
ment process. Therefore, the inclusion of stakeholders from Asia,
South America, Australia, and Africa is an additional gap that future
research should aim to address.
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Randomised controlled trials (RCTs) are expensive, the pragmatic inte-
grated randomised controlled trial has been proposed to deliver large
scale RCTs at a much reduced cost. In these studies elements of the
trial such as recruitment, randomization, intervention, data collection
and/or long term follow up are integrated into standard practice to re-
duce costs and increase potential sample size. These designs are par-
ticularly appropriate for screening where practice is standardized and
many centres use the same software systems. We present an example
of a pragmatic integrated randomised controlled trial design in breast
cancer screening, the Changing Case Order to Optimise Patterns of Per-
formance in Screening (CO-OPS) ISRCTN46603370. The study was de-
signed to examine whether breast screening radiologists experience a
vigilance decrement of decreasing ability to detect cancer in x-rays with
time on task, and whether an intervention to change case order could
reduce such an effect. The trial was funded as part of an NIHR postdoc-
toral fellowship and cost less than £300 k. Of the 80 breast screening
centres in England, 46 consented to take part in the trial for 1 year. This
included research active centres and those with little experience of re-
search. Consent was at the centre level rather than the individual
woman screened, as both intervention and control groups were consid-
ered different versions of standard practice as both were implemented
in different parts of the NHS. The trial was implemented through the
National Breast Screening Service computer system, which is used at all
English breast screening centres. The software was adapted to random-
ise women in batches to intervention or control, and display the cases
in the desired order. A total of 1,194,147 women were randomised and
analysed. A standard Crystal report was designed to extract trial out-
comes from the NBSS computer system. Data extraction was delayeduntil after each centre completed their annual reports for routine qual-
ity assurance, as the datasets are cleaned in preparation for these.
Further data cleaning was conducted in collaboration with each
centre. As a result there was very little missing data, making up less
than 0.1% of the final dataset. This is an example of implementing
a successful pragmatic integrated trial in screening. Such trials are
effective in situations where some of the following conditions are
met: individual informed consent for the trial is not necessary, the
intervention itself is inexpensive, trial outcomes are already rou-
tinely recorded in a standard way, routine data collection is accur-
ate and audited, and management pathways are standardized and
the intervention does not require major changes to these. The ad-
vantages of this design are the low cost and large sample size, and
the opportunity to involve a greater number of hospitals to in-
crease generalizability.
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Background
Most confirmatory clinical trials are designed so as to achieve a spe-
cified power, usually 80% or 90%, for a hypothesis test conducted at
a given significance level, which is almost invariably set to be 5% for
a two-sided test. Licensing decisions by regulatory agencies are then
based on the result of such a significance test informally combined
with other information to balance the risk of adverse events against
the value of the treatment to future patients. In the setting of a rare
disease, recruitment of the number of patients required to achieve
conventional error rates for clinically reasonable effect sizes may be
infeasible or even impossible, suggesting that the decision-making
process should reflect the size of the population for whom the treat-
ment can be used in the future.
Methods
We have considered the use of the decision-theoretic value of infor-
mation (VoI) method to obtain the optimal sample size and signifi-
cance level for definitive randomised controlled clinical trials in a
range of settings, focussing particularly on the impact of different
population sizes. For simplicity we have assumed the primary end-
point to be continuous and normally distributed with unknown
mean with some normal prior distribution, the latter representing in-
formation on the anticipated effectiveness of the therapy available
from sources external to the trial itself. We explicitly specify the gain
in terms of improvement in primary outcome for patients treated
with the a new therapy and compared this with the costs, both fi-
nancial and in terms of risk of potential harm, of treating patients, ei-
ther in the trial or in the future if the therapy is approved.
Results
We have found that as the size of the population that can be
treated in the future increases, the optimal sample size for the clin-
ical trial also increases. If there is a non-zero cost, whether financial
or in terms of potential harmful effects, of treating future patients,
stronger evidence is required for approval as the population size in-
creases, though this is not the case if the costs of treating future
patients are ignored.
Conclusions
The results of clinical trials are often summarised by a frequentist
hypothesis test conducted at a 5% significance level with the sam-
ple size chosen to give specified power of 80% or 90%. These
values are arbitrary. We showed how decision-theoretic analysis
suggests a more flexible approach with both type I error rate and
Trials 2017, 18(Suppl 1):200 Page 205 of 235power (or equivalently trial sample size) depending on the size of
the future population for whom the treatment under investigation
is intended.
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The conduct of pragmatic randomized controlled trials is increasing
due to their societal importance and their role within the Patient-
Centered Outcomes Research Institute (PCORI) initiative “to improve
the quality and relevance of evidence available to help patients, care-
givers, clinicians, employers, insurers, and policy makers make informed
health decisions.” Cluster randomized trials (CRTs), in which groups
rather than individuals are randomized to intervention and control con-
ditions, naturally tend to be more pragmatic. CRTs may be categorized
as “individual-cluster trials” where the intervention is delivered directly
to individuals, or “cluster-cluster trials” where interventions are not
divisible at the individual-level. The Ottawa Statement is the first com-
prehensive ethical guidance document specific to CRTs. Whereas the
Ottawa Statement generally presumes that informed consent will be
sought for individual-cluster trials, such trials’ when used to evaluate
usual care interventions’ raise particular ethical issues that require fur-
ther analysis and guidance. This paper has three objectives: to (1) de-
scribe current practices and reporting of ethical issues in published
individual-cluster trials; (2) present an in-depth ethical analysis of an
individual-cluster trial randomizing dialysis centres to two different
usual care interventions; and (3) identify ethical issues that require fur-
ther analysis and guidance.
Objective 1: Systematic review of individual-cluster trials Using an
electronic search strategy, we identified a random sample of pub-
lished individual-cluster trials in Canada, the USA, UK, France,
Australia and Low and Middle Income Countries. Two reviewers inde-
pendently extracted details about ethical issues and practices (e.g.,
justification for the cluster randomized design, prevalence of seeking
informed consent, presence and roles of gatekeepers). Practices will
be compared over time, between countries, types of clusters and in-
terventions, and other descriptors.
Objective 2: An ethical analysis of the TiME trial the optimal
duration for individual hemodialysis treatments in chronic renal
failure is currently unknown. The Time to Reduce Mortality in
End-Stage Renal Disease (TiME) trial is a PCORI funded individual-
CRT in which dialysis treatment centres are randomized to one of
two hemodialysis durations (usual care or extended) to evaluate
their comparative effectiveness. The main outcome measures are
mortality, hospitalization, and quality of life. The trial uses an IRB
approved “opt out” approach to informed consent. Applying the
Ottawa Statement highlights a range of issues, including justifica-
tion for the study design, participant identification, informed con-
sent, gatekeeper permission, benefit-harm analysis and protection
of vulnerable participants.
Objective 3: Ethical issues that require further analysis and guid-
ance While the Ottawa Statement provides a systematic approach
to the ethical analysis of CRTs, we conclude that further analysis
and guidance is required for individual-cluster trials of treatments
adopted as policy at cluster-level. The TiME trial highlights a num-
ber of generalizable ethical issues, including (1) whether there is
an appropriate justification for the cluster randomized design (e.g.,
what justifies adoption of cluster randomization if individual
randomization is feasible in principle?), (2) the appropriateness of
the consent procedure (e.g., can consent be waived due to prag-
matic challenges?), and (3) how we should understand gatekeeper
permission (e.g., is gatekeeper permission identical to obtaining
proxy consent?).O48
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Background
Health economists working on clinical trial based economic evaluations
are often asked at a preliminary stages of studies, and sometimes be-
fore data are available, to propose a plan for the collection and analysis
of information on resource use, costs and quality of life. Questions that
frequently arise when designing a Health Economics Analysis Plan
(HEAP) for a clinical trial include what information should be included
as standard within the HEAP, whether and how a proposed plan can
be changed, how health economists and statisticians should split re-
sponsibility for data preparation and analyses, how missing data should
be dealt with, and whether there are circumstances when a HEAP is
not needed (for example in a feasibility study).
Objective
The aim of this study is to develop agreed guidance for health econo-
mists who work on clinical trials on how to pre-plan their analysis in the
absence of any data and how to present it in an unambiguous but flex-
ible way.
Methods
Guidelines on how to perform economic evaluations based on clinical
trials were searched from the literature. HEAPs were also obtained from
a few clinical trial units, although there were certain confidentiality is-
sues that had to be surpassed. Section headings (domains) and items
were extracted on pre-specified schema we have designed for trial-
based HEAPs.
Results
We have identified a lack of guidance or any standardised templates on
how health economists should present HEAPs for clinical trials. In the
current climate where clinical trials units increasingly rely on standard op-
erating procedures (SOPs) that need to be followed, SOPs for economic
evaluations should also be considered as good practice. We identified
nine main sections that should be presented in a HEAP with a provisional
total of 15 items included. We further recommend the analysis be carried
out by an identified, appropriately qualified and experienced health
economist, who should ensure the integrity of the data during process-
ing. Any deviations from the health economics analysis plan should be
described and justified in the final report of the trial.
Conclusions
Certain items should be included when designing a HEAP for a clin-
ical trial, but others require debate and consensus. Senior health
economists and principal investigators should be involved in writing,
reading and authorising a HEAP. Deviations from or changes to the
HEAP should be reported and justified when reporting.
O49
Statistical considerations for analyzing multiplex biomarker data
from prospective studies
Shun Fu Lee1, Guillaume Paré1, Matthew J. McQueen1, Hyejung Jung1,
Sibylle Hess2, Hertzel Gerstein1
1Population Health Research Institute; 2Sanofi Aventis Deutschland
GmbH R&D Division Diabetes
Correspondence: Shun Fu Lee
Trials 2017, 18(Suppl 1):O49
Background
Biochemical markers of disease have the potential to both enhance
our understanding of disease pathophysiology and identify as-yet
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cost of measuring large sets of biomarkers has fallen, a growing
number of prospective cohort studies and trials are including bio-
marker measurement in their design. However many of these studies
are limited by the absence of a systematic, statistically conservative
approach to integrating these measures into the reported findings.
Method
After preparing a prespecified analysis plan, the three main statistical
considerations when using with multiplex biomarkers to predict out-
comes based on survival data are, data preparation, model building
and validation. Data with multiplex biomarkers require an extensive
data cleaning process including handling the missing information,
assessing the distribution for each biomarker, and normalizing and
standardizing the biomarkers analyzed. During the model building
phase, the approaches used to select the variables, to correct Type I
error for multiple testing and to handle proportionality hazards
assumptions in survival data are critical to identify the sets of bio-
markers to predict the outcome. Lastly, both internal validation
(sample splitting vs. bootstrap) and external validation from an inde-
pendent sample can be used to assess the performance of the
model. Biobanked serum samples from 8494 participants with dys-
glycemia in ORIGIN trial were assayed for 284 biomarkers. The object-
ive of the study was to identify sets of biomarkers that could identify
people with dysglycemia at risk for a CV outcome or death when
added to well-established clinical predictors of the relevant out-
comes. The results of this study will be used for illustration.
Conclusion
These statistical considerations provide a reproducible approach for de-
veloping clinically useful prognosis model with multiplex biomarkers
based on survival data.
Funded by Sanofi; ORIGIN NCT 00069784
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Background
Sample size calculations for cluster randomised trials (e.g. parallel,
stepped wedge, crossover) require specification of one or more intra-
cluster correlations (ICC). With Gaussian outcomes, sample size for-
mulae can be specified equivalently in terms of ICCs directly, or using
variance components of a linear mixed model. However, with binary
or count outcomes, recommended methods use one or the other ap-
proach due to lack of direct relationships between the values of ICCs
on the ‘raw’ (i.e. binary or count) scales and the variance components
from generalised linear mixed models (GLMMs). In this presentation
we describe an approach for sample size calculations that reconciles
the two by employing GLMMs with a logarithmic link function and
normally distributed random effects.
Methods
Using the properties of the log-normal distribution we specify the re-
lationship between ICCs on the raw data scale and the variance com-
ponents from GLMMs. Results are exact when no covariates are
present and we describe an approximate method in the presence of
covariates. We implement these results in sample size calculations
for a parallel cluster randomised trial with multiple baseline measure-
ments and multiple followup measurements. We compare power for
given sample sizes using specification of ICCs on the ‘raw’ data scale
using the formulae in the approach of Hooper et al. [1] with that
from numerical simulations of the corresponding GLMMs in which
the variance components are computed from the relationships withICCs assuming a log link and normally distributed random effects.
We also describe a method for checking the compatibility of the
specification of ICCs with random effects from GLMMs by solving a
set of nonlinear equations.
Results
For our simulated examples the empirical power from the GLMM-
based simulations using ICCs ranging in value up to 0.10 closely
matched that of the formulae of Hooper et al. [1]. For binary out-
comes, although large variance components can lead to simulated
probabilities above unity, this caused only minimal bias in our exam-
ples. For count data one needs to be careful that specification of the
marginal overdispersion is compatible with the specified ICCs.
Conclusion
GLMMs with log link and normal random effects can be useful for
simulating binary and count data with specified marginal ICCs. Our
results indicate that the approach of Hooper et al. [1] can be ex-
tended to binary and count outcomes under such models.
Reference
1. Hooper R, Teerenstra S, de Hoop E, et al. Sample size calculation for
stepped wedge and other longitudinal cluster randomised trials. Statistics
in Medicine 2016;35(26):4718–28.
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Background
An important challenge in recruiting people to clinical trials is
explaining randomised controlled trials, and this is exacerbated in
the context of emergency situations. In the pilot phase of a feasibility
randomised controlled trial (RCT) involving babies born at less than
32 weeks gestation that aimed to compare delayed and early cord
clamping (CORD pilot trial), clinicians found it particularly difficult to
explain why mothers in the study could not choose either option
and why randomisation was important. We asked healthcare con-
sumers, familiar with RCTs, to help us find ways to explain these is-
sues in time-limited recruitment situations.
Methods
An interactive two-stage workshop was devised for consumers active in
the Cochrane Collaboration at an annual Cochrane Colloquium. The
aim of the workshop was to gain understanding in how to communi-
cate randomisation to the public and to better inform potential
participants of clinical trials. In stage 1, workshop members were given
magazine adverts promoting purported clinical benefits and asked to
design a study that would address the claims made. Subsequent dis-
cussion progressed to the concept of randomisation, potential biases
that can arise and how these can be minimised with careful study de-
sign. With this background, in the second stage of the workshop, the
consumers were asked to develop statements describing randomisa-
tion to potential study participants of the CORD pilot trial. The con-
sumers, working in groups, were specifically asked for ways to explain
to women why trial participants would not be able to choose which
study group they could go into, and so would not have a say in when
their baby’s cord would be clamped. The final statements produced by
the different groups were discussed by all workshop members and
modifications suggested. This work was later presented at a CORD pilot
trial collaborators’ meeting.
Results
The process identified expressions that consumers disliked and ex-
pressions that consumers preferred when discussing clinical trials.
The issues raised will be presented along with the statements the
consumers produced explaining the CORD RCT. The feedback from
collaborators in the CORD pilot trial will also be reported.
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Healthcare consumers can contribute to recruitment to RCTs by devel-
oping wording to help explain randomisation to potential trial partici-
pants. We used an interactive workshop to generate useful insight
about consumer views about clinical trial participation. This approach
could be extended to other areas to gather further ideas from health-
care consumers.
O52
Maximising trial efficiency in the airways-2 trial using a
multi-functional database
Lauren Scott1, Jodi Taylor1, David Hutton1, Barney C. Reeves1,
Jonathan R. Benger2, Chris A. Rogers1
1Clinical Trials & Evaluation Unit, University of Bristol; 2Faculty of Health
and Applied Sciences, University of the West of England
Correspondence: Lauren Scott
Trials 2017, 18(Suppl 1):O52
Background
Airways-2 is a cluster randomised trial comparing two airway manage-
ment devices for the treatment of out-of-hospital cardiac arrest. Partici-
pating paramedics from four UK ambulance trusts are randomised to
manage the patient’s airway using either an i-gel device or intubation.
We are aiming to recruit 1,500 paramedics, screen approximately
60,000 patients and enrol more than 9,000 patients over a two year
period. As patient recruitment takes place in an emergency setting and
patients who survive to hospital admission could be admitted to one of
100 hospitals, data collection needs to be as efficient and streamlined
as possible.
Methods
We designed a multi-functional database to track patients’ progress
through the trial, as well as capture the trial data. Data collection has
been organised in sections reflecting the different stages of the pa-
tient journey. Access to the different sections is dependent on the
outcome of the previous section, e.g. it is not possible to access the
area of the database that captures hospital admission data if the pa-
tient died at the scene of the arrest. Access is also restricted accord-
ing to role and location, e.g. hospital based researchers cannot
access the sections relating to pre-hospital paramedic data collection.
User access is via a secure NHS web server. Data quality is maximised
by validation checks on data items; the database allows users to save
invalid data or leave items blank but such instances generate queries.
Users may correct data entry errors or provide responses to queries
within the database, resulting in a complete audit trail of any changes.
A “traffic light” system helps users to keep track of outstanding queries.
Additionally, the database creates reports to facilitate the coordination
team in identifying patients who are due 3 or 6 month post cardiac ar-
rest follow-up. Documents for follow-up containing mail merged pa-
tient details can be downloaded from the database.
Results
The Airways-2 database has approximately 300 users undertaking
one of five different roles. So far, over 44,000 patients have been
screened and nearly 6,000 patients have been enrolled. Data queries,
along with regular central monitoring, have enabled successful pa-
tient tracking and over 99% data completeness for the primary out-
come. User feedback has been positive. The system is intuitive and
easy to use.
Discussion
When running a large complex trial involving a diverse range of staff
and researchers working across different health care settings, it is im-
portant to consider using IT solutions to optimise efficiency and data
quality. Database features developed for the Airways-2 trial are now
being implemented in other studies.
Funding
The Airways-2 trial is funded by the National Institute for Health
Research (NIHR) Health Technology Assessment (project number
12/167/102). The views and opinions expressed are those of the
authors and do not necessarily reflect those of the NIHR, NHS or
the Department of Health.O53
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Background
Despite increasing international interest, there is a lack of evidence
about the most efficient, effective and acceptable ways to implement
patient and public involvement (PPI) in clinical trials. This study
aimed to identify the priorities of UK PPI stakeholders for methodo-
logical research to help resolve uncertainties about PPI in clinical
trials.
Methods
A modified Delphi process including a two round online survey and
a stakeholder consensus meeting. We used snowball sampling to
identify and invite PPI stakeholders to take part in the online Delphi.
Stakeholders included PPI contributors, lay and non-lay reviewers
from funding panels and Research Ethics Committees, PPI coordina-
tors, PPI Planners (e.g. Chief Investigators and Trial managers), PPI ad-
visors (e.g. Research Design Service members) and PPI researchers.
Results
In total, 237 stakeholders registered of whom 219 (92%) completed the
first round. 187 of 219 (85%) completed the second; 25 stakeholders
attended the consensus meeting. Delphi findings were presented and
considered at the consensus meeting. 16 of the 42 topics were rated of
critical importance by over 70% of stakeholders at the meeting. 96% of
stakeholders rated the top three topics as equally important. These
were: research on ways to develop strong and productive working rela-
tionships between researchers and PPI contributors; exploring PPI prac-
tices in selecting trial outcomes of importance to patients; and a
systematic review of PPI activity to improve the accessibility and useful-
ness of trial information materials for clinical trial participants.
Conclusions
The prioritised methodological research topics identified by the Delphi
process indicate important areas of uncertainty about PPI in trials. Ad-
dressing these uncertainties will be critical to enhancing PPI. Our find-
ings should be used by those involved in the planning and funding of
PPI in clinical trials to help focus research efforts and minimise waste.
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Background
Recruitment to randomised controlled trials can be challenging, par-
ticularly when the burden of participation is high (e.g. long and/or
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ferent (e.g. surgery versus best medical management) and there are
strong preferences amongst clinicians and/or potential participants.
To help overcome these challenges, a quintet recruitment interven-
tion (QRI) was developed by Donovan and colleagues in the context
of the ProtecT trial. The QRI is a complex intervention with several
components. These include detailed assessment of screening logs,
in-depth interviews, audio-recording of recruitment consultations,
and expert review and analysis of the consultations to allow group
and individual feedback to recruitment teams on how to optimise in-
formed consent. The impact of the individual elements of the QRI
have not been previously explored. The aim of this study is to exam-
ine the association between trial recruitment and audio-recording of
consultations.
Methods
Data from two on-going “difficult-to-recruit to” multi-centre RCTs in
surgery with an integrated QRI were used for this study; one compar-
ing the effectiveness and cost-effectiveness of three types of bariatric
surgery for severe and complex obesity (By-Band-Sleeve) and the
other comparing open versus video-assisted thoracotomy (key hole)
surgery for early stage lung cancer (Violet). In both trials, recruiters
and eligible participants were invited to have their recruitment con-
sultation audio-recorded. We examined the rate of consent amongst
patients who did and did not agree to audio recording.
Results
Over the two trials, approximately two-thirds of eligible patients
agreed to their consultation being audio-recorded (By-Band-Sleeve
1209/1806, 67%; Violet 149/185, 80%), with some variation in
audio-consent rates across centres. In both studies the proportion
of patients agreeing to randomisation is higher amongst the group
who consented to audio-recording and the pattern is consistent
across the two studies (By-Band-Sleeve 39% vs 9%, Violet 76% vs
16%). The probability of consenting to randomisation is four-times
higher (risk ratio 4.45, 95% CI 3.2-6.1) when the consultation is re-
corded. The overall randomisation rate is 29% in By-Band-Sleeve
and 50% in Violet. Withdrawal rates following consent are low in
both trials (By-Band-Sleeve 4%, Violet 6%).
We will describe the variation in audio-consent rates by centre and
recruiting surgeon and the impact of QRI feedback on trial recruit-
ment rates.
Discussion
This is the first study to examine the association between consent for
audio-recording and trial participation. Whilst we have demonstrated
an association, the reasons for this are unclear and require further in-
vestigation. They may be patient-related, recruiter-related, or both. For
example, a patient who consents to audio-recording may be naturally
more predisposed to research, or they may feel they should agree to
randomisation because the consultation could be listened to (although
we have no evidence of coercion). Similarly, recruiters who consent to
audio recording may be more comfortable with and better at conduct-
ing recruitment consultations. They may also “try harder” to recruit the
patient when the consultation is being audio-recorded. It is important
to explore and better understand the factors that might underlie this
association to further support trial recruitment.
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Background
The investigation of treatment effect moderation is a common research
objective in psychological studies. The benefit or harm of an interventionmight vary within a study according to patient characteristics or between
studies due to contextual factors such as the composition of the study
population or the study setting. Statistically the investigation of treatment
effect moderation amounts to an assessment of interactions between
putative moderators and treatment groups. Interaction tests tend to be
underpowered when based on individual participant data (IPD) from a
single study. Pooling multiple trials aimed at evaluating the same inter-
vention offers a way forward here.
Aggregate data meta-analytic techniques are routinely used to com-
bine results from multiple studies. Specifically meta-regression ob-
tains treatment effect estimates (and associated precision estimates)
from different trials and then investigates the association between
the trial-level treatment effect estimates and contextual factors using
a weighted regression approach. Importantly, meta-regression is only
able to assess trial-level variability in treatment effects. In addition,
the number of replicate trials tends to be small and hence limits the
ability for making adjustments in the analysis.
In order to investigate treatment-effect moderation by individual
participant characteristics it is necessary to retrieve and analyse the
IPD. Two strategies for IPD meta-analysis exist: A two-stage ap-
proach analyses the IPD for each trial separately, generates appro-
priate trial-level summaries and then combined these in a second
step using aggregate data meta-analysis. In contrast multilevel
modelling of the pooled IPD from all trials assesses moderation in a
single analysis. Importantly, the latter approach can assess both,
moderation by variables that vary between trials and by variables
that vary within trials.
Methods
We pooled IPD from 13 European trials of the Incredible Years (IY)
parenting intervention aimed at improving disruptive child behaviour
(Eyberg Child Behavior Inventory) in children with conduct problems.
We considered a number of pre-specified putative individual-level
moderators of the IY intervention effect. We assessed moderation ef-
fects using both, meta-regression based on published effect sizes, as
well multilevel modelling of the pooled IPD.
Results
IPD meta-analysis performed by multilevel modelling was able to ac-
count for trial design features such as variation in randomisation ra-
tios, stratification and clustering; and enabled principled analyses to
be carried out in the presence of missing values. It also allowed us to
separate trial-level from individual-level moderation effects and to
make adjustments. The comparison of the modelling results with the
findings from a standard meta-regression showed that IPD meta-
analysis can avoid aggregation bias (also known as the ecological fal-
lacy), and can produce more powerful inferences when moderation
effects do not differ between the trial level and the individual level.
Conclusion
We encourage the use of the one-stage multilevel modelling ap-
proach to IPD meta-analysis. A two-stage IPD meta-analysis does not
require explicit assumptions regarding the variability of effects across
trials and tools are increasingly becoming available. While there is a
lot to be said for simplicity, we prefer the more complex one-stage
approach as it offers the flexibility to address all the moderation
questions with optimal efficiency.
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There is growing understanding of the value of qualitative research to
elucidate the conduct and impact of randomised trials, and to guide fu-
ture trial conduct. Some of the most challenging trials assess interven-
tions aimed at improving care for seriously ill patients and so can take
place in the context of major life events. For qualitative research to
offer insights into such trial processes and settings, researchers must
engage with potentially vulnerable populations to ask often difficult
questions. As researchers, we must take responsibility for the proper
care and treatment of those who take part in our research and engage
with those questions, and so need appropriate research tools and sup-
port systems to work with challenging trials.
Methods
The BRACELET Study involved bereaved parents whose babies died
subsequent to enrolment in five neonatal intensive care trials. A suite
of strategies was developed to: maximise collection of good quality
data, ensure data collection processes were sensitive and supportive
to contributors, and to facilitate involvement of hard-to-reach be-
reaved parents. Data collection and support strategies were devel-
oped in response to the sensitivities involved. BRACELET involved
face to face interviews with bereaved parents. Recognising that some
parents would not wish to be interviewed, two alternative participa-
tion routes were developed, an online comments option and short
questionnaires. A detailed Code of Practice was developed to guide
the conduct of lone and joint interviews which took into account
challenges of discussing bereavement and trials with potentially vul-
nerable individuals. The Code was organised around five key princi-
ples: the interviewees should be given control of the physical
environment; the interviewee should be given control over the pro-
gress of the interview; the distinction between counselling and re-
search should be clear; all interviewees will be treated with courtesy
and respect; and the interviewee should have access to information
and support after the interview. Each principle had multiple dimen-
sions which were explored and operationalised in the Code. To meet
the final principle, dedicated support systems were developed in
collaboration with local and national support providers to ensure par-
ticipants could access help and information post-interview should it
be needed. A post-interview questionnaire was used to monitor reac-
tions to the interviews.
Results
Fifty-one bereaved parents were interviewed, and the online com-
ments option and short questionnaires yielded valuable extra data
from 8 parents which offered new insights and confirmed themes
arising from interviews. Thirty-nine post-interview questionnaires
confirmed that, although the process was deeply emotional for many
of the parents, it was perceived as valuable both for themselves and
for parents in the future.
Conclusions
The BRACELET study enabled parents to elucidate their bereavement
experiences in a trial context, and to offer guidance on good conduct
for future trials where mortality is anticipated. The strategies devel-
oped for the BRACELET study were crucial factors in its success and
ethical conduct, and may be adapted by others exploring sensitive
issues for trials with vulnerable populations. While our strategies in-
cluded elements tailored to our specific challenges, they are readily
adaptable for other trial-related sensitive research areas.
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Background
Recent advances in the understanding of disease at a genetic level have
demonstrated that many conditions are not a single homogeneousentity. However, while these insights provide valuable evidence on dis-
ease mechanisms, the fragmentation of conditions leads to challenges
in trial design. Instead of a classical Phase 3 mega-trial, with wide eligi-
bility, the evaluation of targeted therapies requires the identification of
subgroups of patients, some of which might be very small. Agents may
be at different stages of development; and further still, clonal evolution
can mean that agents are not equally efficacious at different stages of
disease.
Aims
To design trials to accelerate the evaluation of new targeted therap-
ies which may be at different stages of development or relevant to
different stages within the patient pathway.
Results
Patient eligibility for different treatments may change throughout
their journey, mirroring the choices that are made in clinical care. At
any one time, umbrella trials provide an infrastructure for screening
patients and directing them to an appropriate treatment, and these
can be combined with a platform trial which evaluates various differ-
ent treatment options for each subgroup. However, numbers soon
become vanishingly small and even large national collaborative
groups can struggle to find sufficient patients. We present therefore
an extension of these approaches called the Patient Journey Planner.
The combined design allows different national collaborative groups
to maintain their own trials infrastructure while contributing to mul-
tiple evaluations of targeted therapies. Evaluations will typically take
place at different stages through a patient’s “journey” with a condi-
tion; at each stage (e.g. induction, maintenance, relapse), a number
of different options will be available based upon genetic characteris-
tics or response to prior therapies. The design of the evaluation of
each of these is appropriate to the stage of development of the
therapy, and the aspirations for the treatment or the patient group.
Such an approach is proposed and illustrated for the treatment of
Acute Myeloid Leukaemia, and also in solid tumours such a skin can-
cer, where there is a similar degree of heterogeneity, and the re-
quirement to evaluate novel targeted therapies at different disease
stages. The approach also allows the integration of supportive care
and prevention studies.
Conclusion
Relying on appropriate exchange of data the Patient Journey Planner
allows the evaluation of therapy, using modern trial designs, across
multiple collaborative groups, not only speeding up drug development
but enabling the assessment of treatments in groups which otherwise
would be too small for formal trials run by a single centre or collabora-
tive group.
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Background
Initial evaluations of treatment activity are typically performed in
Phase 2 clinical trials. Historically, such trials used either one or two-
stage single-arm designs, such as the Gehan, A’Hern, or Simon ap-
proaches. Such designs rely on identifying the level of outcome (e.g.
response rate) which merits further investigation, and the design of
such a trial would specify a minimum number of responses to
proceed to further evaluation. The choice of threshold depends on
the condition being studied, which is often informed by historical
data. By contrast, randomised Phase 2 trials do not specify an abso-
lute threshold of response, but rather a level of improvement that is
required to be seen.
Methods
We present here the results from the control arm of the UK National
Cancer Research Institute Pick-A-Winner programme for older patients
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programme uses a seamless Phase2/Phase 3 design to evaluate treat-
ments, with an early assessment for futility. New treatment options can
be brought in at any time to replace options which are closed, and
evaluation only takes place between novel therapy and control among
contemporaneously randomised patients. Therapies which pass the ini-
tial futility hurdles proceed seamlessly to Phase 3 evaluation within the
programme. The programme has been running for over 10 years, and
over 1500 patients have entered the randomised comparisons for 11
different novel therapies.
Results
Outcomes of the control arm of low-dose ara-C show a wide vari-
ation in complete remission rates from comparison to comparison,
ranging from less than 10% in some cases to more than 30%.
Response rates can fluctuate by comparator drug based upon the eli-
gibility criteria for the treatments; but even when eligibility criteria
remain constant, wide variation is seen in remission rates, which may
be explained by differing referral patterns and the perceived attract-
iveness or toxicity of the novel therapies. The wide variation in re-
sults shows the issues associated with using a single arm phase 2
trial in a heterogeneous condition: setting an ‘average’ target of 20%
response rate (similar to that seen in the original trial of low-dose
ara-C), some treatments which showed a remission benefit would
have failed to pass the hurdle, while others closed for futility would
have proceeded to further evaluation.
Conclusion
Our results demonstrate the need for randomisation in phase 2 trials
in this group of patients, and indeed in other heterogeneous condi-
tions, to ensure interpretability of results.
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Background
Co-publication of papers to coincide with conferences is not yet
standard for clinical trials, although improving e.g. a selection of
plenary abstracts at European Society of Medical Oncology 2016
were co-published in high-impact medical journals. For clinical trial
methodology, publication usually lags presentation (if achieved); the
conference abstract is the key written information available. The
International Clinical Trials Methodology Conference (ICTMC) 2015
presented 3 invited talks with 94 oral and 238 poster presentations.
We are interested in their online attention.
Methods
Abstracts were available online in a supplement to BioMed Central’s
Trials from conference Day 1. Initially motivated in tracking interest
ICON6 (#P184), we used an algorithm applied to the journal website
to collect basic article view metrics from Trials giving a snapshot of
cumulative online views. The impact on abstract views of presenta-
tion type, submission category and title form can be explored.
Results
The results describing the views over time for every accepted ab-
stract from ICTMC 2015, along with a summary of wider themes, are
available at http://andyembleton.me/ICTMC/ The abstract addressing
“Longitudinal mediation in the PACE trial” was consistently the most
popular abstract from Day 4 onwards (i.e. post-conference). This ab-
stract gained 527 views between Days 4 and 8, the largest uptick in
views, perhaps due to its posting on a popular Twitter account and
discussion on a patient forum. There was little overall difference be-
tween those oral and poster abstracts initially, but this manifestedinto an expected hierarchy over time. Though focusing specifically on
the top-viewed 5% abstract (n = 16): at Day 3, 12 of these were poster
presentations, including all the top 10; by the latest data capture at
Day 55, the top four abstracts were oral presentations, although posters
still occupied 11 out of the 16. The most viewed theme from oral ab-
stracts was “Adapting Trials Based on Internal Data” (median 124 views
by Day 55), with Trial and Project Management least popular (median
68 views by Day 55). The poster themes varied greatly in the number
of comprising abstracts but the “Use of Innovative Methods in Active
Trials” garnered the most average views (median 91), and “Involving
Research Partners” least (median 60).
Potential Results
We propose presenting both short- and long-term findings from
ICTMC 2015 plus initial, short-term results from ICTMC/SCT 2017 con-
ference, possibly as a penultimate talk in the final session. We will
provide an on-line searchable resource for this conference using at
least daily views of abstract, during and beyond the conference.
Potential Impact
We can draw together conclusions from the previous conference,
compare and contrast the abstract views from the two conferences
and highlight any changes or consistent themes. Also, just as cru-
cially, we will be tracking abstracts views over time beyond the end
of the conference and ensuring access is available to both authors
and external researchers, both on the website and in dataset format.
This will ensure that interested parties from the 2017 conference can
clearly gauge the impact of their own work and any promotional ef-
forts they make.
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Background
Good reporting of research findings in primary papers is crucial to allow
meta-analyses to include all available studies on the topic of interest.
However, key information in trial results is still commonly missing (Alt-
man, 2015), such as standard deviations (SD) of continuous outcomes.
Specific recommendations in the Cochrane Handbook and PRISMA
statement on handling missing data include retrieving all connected in-
formation and performing sensitivity analysis to challenge the missing
data assumptions. These are not frequently followed, nor is there a sim-
ple method to evaluate the impact of omitting a study from a meta-
analysis. We propose a statistic that would help reviewers to assess the
influence that a study without an SD estimate may have on the pooled
effect meta-analysis and calculate this statistic across multiple Cochrane
meta-analyses. We also report on whether reviewers could have de-
duced or approximated the missing SD in primary papers or imputed
the SDs by those reported in other studies in the same meta-analysis.
Methods
We used the whole Cochrane Database of Systematic Reviews issued
in January 2008 (Davey et al., 2011) to identify studies omitted with a
missing SD from 6672 continuous-outcome meta-analyses. A sub-
sample of these, published since 2006, was selected and enabled
hand-searching and extracting to assess whether SDs could have
been deduced or approximated and to calculate the influence statis-
tic. We report on fixed effect meta-analyses.
Results
Amongst the 6672 sampled meta-analyses, 396 (6%) were affected
by omitted studies. The hand-searched sub-sample comprised 52
studies, from 28 meta-analyses within 18 Cochrane reviews, including
33 subgroup meta-analyses. In 5 (28%) reviews, reviewers did not at-
tempt to contact original publication authors to retrieve missing in-
formation and only one meta-analysis reported sensitivity analysis to
assess the impact of imputing SDs. For 12 (36%) subgroup meta-
analyses, the SDs could have been externally imputed from other
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internally retrieved through either deducing (8%) or approximating
(29%) from available information. Developed from the inverse-
variance weighting formula for fixed effect models, we proposed an
‘influence statistic’ that tells us whether, and by how much, a study
that does not report the precision of an effect could influence the
overall meta-analysis estimate, defined as the Z-statistic ratio of the
distance between the omitted study effect from the pooled effect
and the standard error of this distance. This statistic was calculated
and its distribution displayed across 16 studies that were omitted
from 12 subgroup meta-analyses. Nineteen percent of these had a
high influence (Z > 2) on the subgroup meta-analysis pooled effect.
Conclusions
Incomplete reporting of variance estimates in continuous outcomes
by study authors still remains a reality. We proposed a tool that
would help authors to determine the influence of a missing trial in
the pooled meta-analysis estimate. Current work includes develop-
ment of the influence statistic to include random effects models and
to the influence of multiple omissions per meta-analysis. References
Altman, 2015. doi:10.1186/s13063-015-0575-7 Davey et al., 2011.
doi:10.1186/1471-2288-11-160
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Unfortunately, there will often be uncontrollable developments in
clinical trials which result in the occurrence of missed patient
visits or unrecoverable outcome measures. However primary ana-
lysis is approached, we must make an untestable assumption
about the distribution of the unobserved data. It is then import-
ant to perform sensitivity analysis to explore the robustness of
the conclusions to alternative plausible assumptions about the
missing data.
In primary analysis it is most often reasonable to assume that con-
ditional on any covariates included in the analysis, data is Missing
at Random (MAR). Or equivalently, that the conditional distributions
of the outcome data for observed and unobserved patients are
equal. For sensitivity analysis it may then be of interest to explore
the impact of unobserved patients having a poorer/better response
than those observed. The so called `Delta- method’ is an accessible
pattern-mixture approach which enables such investigation using
multiple imputation. Imputations are conducted under MAR, then
edited by a postulated amount, Delta, to reflect a worse or better
response. The primary analysis model is retained in the sensitivity
analysis to asses purely the impact of alternative behaviour among
the unobserved on the primary outcome.
In the sensitivity analysis we do not want to lose any of the valuable
information collected in the trial. A natural principle, which we refer
to as the information anchoring principle, is to preserve the informa-
tion loss due to missing data in the primary analysis in the sensitivity
analysis. However, it is also possible to have much less information in
the sensitivity analysis than in the primary analysis. Moreover, a naïve
sensitivity analysis may insert more information than we would have
had if we actually observed the data. Conclusions from the primary
analysis can then be overturned.
We show how an information anchored variance estimate is obtained
for the treatment estimator when a fixed Delta adjustment is used.
However, when uncertainty surrounds the value of Delta and we
incorporate a prior distribution on Delta in imputation, there will
be less information in sensitivity analysis than primary analysis. Re-
sults from a peer review trial demonstrate the consequences sur-
rounding the choice of Delta in a real life setting and why careful
elicitation is required.O62
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Background
The use of common data elements (CDEs) to standardize data collec-
tion in clinical trials is widely viewed as a mechanism to improve effi-
ciency in trial design and conduct and to improve the quality of
research. CDEs have the potential to enhance the comparability of
data from different clinical trials, reduce development time for
clinical trial protocols, and significantly reduce the time needed to
develop electronic data capture (EDC) systems. There are several
challenges to leveraging CDEs effectively on large clinical trial net-
works. Such networks typically comprise several collaborating institu-
tions that conduct multiple trials, typically over a 5-year funding
cycle. Each protocol is developed by a group of investigators in col-
laboration with staff from a data coordinating center. Due to the na-
ture of this work flow with individual trials developed over a period,
it is common for the definitions of individual data elements to evolve
over different clinical trials.
Methods
The system design and methods encompassed several components,
including: (1) an automated tool to import study metadata from
previously implemented studies into a centralized repository; (2) a
tool to standardize key study metadata elements to support curation
and output to multiple EDC systems; (3) an efficient search engine to
identify and group elements into new case report forms; and (4) the
ability to output metadata to define a new study in the EDC system
along with PDF versions of the case report forms. Study metadata for
an EDC system is typically defined in a structured CSV or XML-based
format and includes definitions of individual data elements, case re-
port form (CRF) structures, and the study event structure. These
metadata include the name of the variable, question text, data type,
allowable values if categorical or range if numeric, and whether the
variable is required. In addition, data elements are grouped into elec-
tronic case report forms, where related variables are collected to-
gether (e.g., demographics, medications, etc.). These elements were
automatically extracted using a connector program and formatted
for importing into a central repository.
Results
Data elements were imported from the EDC systems of two research
networks. A total of 8,620 unique data elements, derived from 291
unique CRFs, were imported from 4 clinical research trials. Initial
searches of the repository revealed interesting patterns in the data
elements and clearly showed inconsistencies between similar vari-
ables collected across the trials. Examples included the same variable
collected in multiple studies with different variable names, different
response options for the same variable in different studies, and the
same variable names used for different variables. After curation, the
system was used to generate formatted CRFs and the associated EDC
system.
Conclusion
Our previous efforts to standardize data collection in clinical trials fo-
cused on standardization at the CRF level but this approach was often
unsuccessful. In contrast, standardization at the data element level, al-
lows flexibility across studies while collecting variables in a standard-
ized way. The collection of standardized metadata also enables the
development of EDC systems for new trials extremely quickly.
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The subjective assessment of informed consent for clinical trials, and
the potential difficulties associated with it, has led several studies to
develop objective measures of informed consent for clinical trials.
These objective measures of informed consent are often specific to a
particular population or clinical condition and largely focus on under-
standing of (some or all of) the key elements of informed consent,
namely: capacity, disclosure, understanding, voluntariness and permis-
sion. Many of the developed tools are study-specific, but some vali-
dated measures exist. Whether these objective tools conceptualize and
measure informed consent in the same way is not known. As such, it is
not clear whether meta-analyzing data from studies reporting different
tools is worthwhile. The aim of this systematic review was to critically
appraise the evidence on the conceptualization and item content of
validated questionnaire based measures of informed consent for rando-
mised controlled trials.
Methods
A systematic search of the literature was conducted to identify rele-
vant articles that described the development, and/or validation, of
measures of informed consent for RCTS. General data extraction cat-
egories were split into those relating to the context of the included
study and those relating to items included in the instrument. Data
was synthesized by coding of the items identified into domains and
sub-domains which were determined by nomenclature defined in in-
cluded studies. Both for descriptions of included studies and of the
instruments reported in those studies, descriptive statistics were used
to describe general information and instrument detail. A narrative
synthesis of the instruments and their inter-related domains and sub
domains was conducted to identify areas of both convergence and
divergence.
Results
The search identified 6669 citations. After screening titles and abstracts,
16 complied with our pre-specified inclusion criteria. The included stud-
ies report 16 separate instruments whose aim is to measure an aspect
of informed consent for RCTs. Four of the included instruments report
development of a tool to assess competence of research subjects to
consent to participation in RCTs i.e. was set amongst participants who
may have diminished decisional capacity (e.g. early stage Alzheimer’s,
schizophrenia, etc.). Of the 16 instruments, 3 explicitly reported a theor-
etical or conceptual framework underpinning their development, a fur-
ther 3 implicitly refer to the “conceptual dimensions of informed
consent” or “principles of research ethics” as informing their develop-
ment and 10 reported no guiding theoretical framework. Linked to this,
some instruments were explicit with regard to which constructs they
were measuring while others were more vague. Finally, only 3 of the 16
studies reported patient or public involvement in the development of
the tool. Findings from the narrative synthesis of individual constructs
will also be presented.
Discussion
This presentation will discuss the key issues relevant for this work
specifically relating to the issues surrounding the heterogeneity of
existing measures of informed consent to RCTs. The results from the
narrative synthesis will be discussed with explicit considerations re-
garding the conceptualization of informed consent and inclusion of
constructs and items that matter to potential trial participants.
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Background
The stepped wedge trial (SWT) design has gained popularity in recent
years and may have practical and methodological advantages over the
classic parallel group design especially in the context of health services
research. The use of statistical methods in economic evaluations con-
ducted alongside SWTs have hitherto not been systematically explored.Objectives 1. To systematically review economic evaluations alongside
SWTs to examine statistical methods used to adjust cost and outcome
variables for clustering and time effects inherent to the stepped wedge
design. 2. To explore theoretical models that combine existing ap-
proaches to the joint (bivariate) modelling of cost and effectiveness in
cluster randomised trials with multi-level models that have been pro-
posed for univariate outcomes in stepped wedge trials.
Methods
An ad-hoc search strategy of Medline/PubMed, DARE, NHS-EED, HTA
and the Cochrane Library was used to identify economic evaluations
alongside SWTs or related methodological studies. Abstracts were inde-
pendently screened by two investigators using the following inclusion
criteria: (i) use of the SWT design and (ii) economic evaluation as part
of the research question(s) in the study. Modelling the cost-
effectiveness alongside SWTs We propose in which the multi-level
model for effectiveness (on a continuous scale) mirrors the multi-level
model for cost, with corresponding random effects and error terms in
the two models assumed to follow bivariate normal distributions.
Results
A total of 100 abstracts identified by the electronic search were
screened. A total of 18 papers were included in our review: 15 were
study protocols, 1 gave insights on the methods for economic evalu-
ation alongside SWTs and 2 papers were trial results. Methods used
(or intended to be used) in studies can be grouped into three main
categories: mixed/multilevel models, generalized estimating equa-
tions and (generic) bootstrap, but there is an underlying vagueness
in the models (to be) used given also the limited guidance available.
We present the results of a set of simulations exploring the perform-
ance of the proposed method under different assumptions related to
the number of participants per cluster, number of clusters in each
trial arm and values of the ICC.
Conclusions
SWT designs are gaining popularity, but statistical methods for
economic evaluation conducted alongside SWTs have not been suffi-
ciently explored and used. The use of appropriate methods that ac-
count for time, clustering, and correlation between costs and
outcomes is an important part of SWT health economics analysis.
Thus study aims to demonstrate how such models perform and
can be implemented in the context of economic evaluation
alongside SWTs.
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Background
Surgical randomised controlled trials (RCTs) often present additional
challenges in design, conduct and analysis to those evaluating pharma-
cological treatments. This is especially evident when the interventions
being evaluated are quite different, for example, the comparison of sur-
gery with a non-operative intervention such as physiotherapy. Specific
methodological issues have been reported such as the impact of treat-
ment preferences of both patients and participating clinicians on re-
cruitment, difficulties with blinding and standardising interventions.
The aim of this study was to systematically review the methodological
challenges and limitations in musculoskeletal RCTs which compare a
surgical and non-operative interventions (e.g. drug treatment or
physiotherapy).
Methods
A search of the MEDLINE and CENTRAL databases between 2010 and
2015 was conducted. Randomised orthopaedic clinical trials which
had a surgical and non-operative comparison such as physiotherapy
were included. Data were extracted and summarised on the study
characteristics such as target and actual recruitment, adherence to
randomisation allocation, and in addition reported challenges to
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sessment was also conducted using the Cochrane Risk of Bias tool.
Results
In total, 6484 records were identified and 54 trials were included in
the review. The majority of included studies were of fracture man-
agement (28, 52%). Twenty three (43%) were multi centre studies,
with a sample size of 85 (median, IQR [50,150]). The main interven-
tion comparisons of the included studies were of surgery and physio-
therapy interventions (44, 81%). Methodological problems identified
included a high proportion of participant crossover from their rando-
mised intervention and difficulties reaching target sample size. Chal-
lenges reported by the authors included the impact of both patient
and clinician preference for particular treatment on the number of
potentially eligible patients recruited. In addition, various practical
challenges were reported related to the nature of the interventions
evaluated and health care systems in which the research was being
conducted. This included difficulties implementing blinding of patients,
care providers, and outcome assessors and post-randomisation delays
in receiving an intervention.
Conclusion
This review demonstrated that trials which compare a surgical
and non-surgical interventions have been successfully conducted
for a number of conditions, however, several methodological
issues were identified that have the potential to impact on the
design, conduct and analysis of these trials. If not adequately ad-
dressed, these issues may introduce significant bias and threaten
the validity of the trial results. The planning and design of future
studies should take into account and consider the specific chal-
lenges associated with the evaluation of surgical and non-surgical
interventions.
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Background
Randomised controlled trials (RCTs) of rehabilitation in the chronic
stroke population are complex and challenging. Patient-therapist
relationships within a rehabilitation setting can be strong and
powerful. This is associated with treatment satisfaction in the trad-
itional healthcare setting but it is unclear if this could impact on re-
cruitment to clinical trials. The aims of clinical practice and clinical
research can be different: clinical practice is focused on individual
care and research on population benefit. Allied Health Professionals
(AHPs) are known to be reluctant to recommend oncology and pal-
liative care patients to clinical trials through well intentioned as-
sumptions that it might not be in the best interests of the
individual patient. This attitude has not been explored in chronic
stroke rehabilitation trials. STEMS3 (ISRCTN16714730) was a feasibil-
ity, 2x2 factorial randomised controlled trial of granulocyte colony
stimulating factor (G-CSF) vs placebo, and community stroke
physiotherapy vs none, in stroke survivors discharged from rehabili-
tation services. ISRCTN1671470. The aim of this study was to ex-
plore recruitment by AHPs to STEMS-3.
Method
Qualitative interview study underpinned by theoretical perspectives
of pragmatism and critical reflection. We used a purposive sampling
strategy to identify AHP’s working in a community stroke team (CST)
involved in participant identification. Semi-structured interviews were
conducted, recorded and transcribed verbatim. Thematic analysis
using an iterative and emergent approach was adopted.Results
Six NHS staff were recruited: 3 physiotherapists, 1 Occupational ther-
apist, 1 speech and language therapist and 1 specialist mental health
nurse. 3 main themes were identified: information, eligibility and
intervention. AHPs felt informed about the trial and professional re-
sponsibility to recruit to clinical trials including STEMS-3; they consid-
ered the regular presence of a member of the trial team a valuable
resource. Despite clear and broad inclusion criteria, AHPs were reluc-
tant to approach eligible stroke survivors with communication, cogni-
tive and low mood problems. A strong sense of duty of care to
patients stemmed from perceptions that: the intensive physiotherapy
intervention provided in the trial contradicted CST goals of self-
management and independence; randomisation to the control group
with no physiotherapy could not be blinded and might distress pa-
tients with expectations of further physiotherapy; patients might
have misplaced expectations of G-CSF providing a 'miracle cure’; and
wanting to identify patients that would benefit from further
treatment.
Discussion
Gatekeeping was evident throughout the recruitment process and re-
flects possible tensions between research and clinical priorities. AHPs
act to promote patient autonomy in their transition from acute
stroke care and rehabilitation to self-management. This contrasts
with protective behaviours evidenced in identifying potential pa-
tients for clinical trials and denying some eligible patients the oppor-
tunity for participation. The motivation for this was “acting” in the
patient’s best interests: this manifested itself in presenting the trial as
the potential opportunity for further treatment when patients were
discharged or not discussing the trial when they thought patient ex-
pectations of treatment were too high, or patients would not under-
stand the implications of no active treatment allocation. Training of
AHPs in study design issues should be considered especially when
they have an active role in recruitment and delivery.
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Background
Frequent data collection is desirable in randomised controlled trials
(RCTs) where time-to-event is the primary outcome, in order to ac-
curately capture the event of interest with reduced risk of recall bias.
However, an inevitable problem with repeated data collection is
missing data caused by participants’ loss to follow-up prior to the oc-
currence of the event or the end of the planned follow-up period.
This undermines the Intent-To-Treat (ITT) principle, leads to reduced
power, and possible bias. Analytical strategies for drawing inferences
from incomplete data, including the non-informative censoring for
time-to-event data, rely on untestable assumptions about the miss-
ingness mechanism. Therefore, it is key to minimise the chance of
dropouts at the design stage. Postal or electronically-sent question-
naires are not ideal for collecting frequent follow-up data as they
often yield poor response rates even after reminder mailings. Short
message service (SMS) using mobile telephones might offer a new
way to enhance real-time outcome data collection. We describe the
use of SMS to obtain weekly data on recovery of sciatica patients in
the SCOPiC trial, describe the response patterns in the short and lon-
ger term and consider the implications for data analysis.
Method
We used data from 314 participants randomised to date (target recruit-
ment of 470) to a trial that is testing the clinical and cost-effectiveness
of stratified care versus usual care for patients with sciatica in primary
care (SCOPiC Trial; HTA 12/201/09) in order to evaluate weekly response
rates to SMS. The primary outcome measure is patient-reported time to
resolution of sciatica symptoms (defined as completely recovered/
Trials 2017, 18(Suppl 1):200 Page 214 of 235much better) measured on a six-point global perceived change scale,
collected using regular SMS (with the alternative of brief phone calls for
those where text messaging is not possible or missed) for the first
16 weeks for all participants, and thereafter monthly up to month 12,
or until stable resolution of symptoms (defined as two consecutive SMS
responses of patient-reported resolution).
Results
In total, 90% (n = 283) of participants opted for SMS follow-up and
10% (n = 31) for phone calls. There have been 4,299 valid responses
via SMS out of the expected 4,787 (90% response rate), compared to
74% (417/567) telephone call responses. The median (IQR) weekly re-
sponse rate over the first 16 weeks was 93% (90%, 95%) and 75%
(71%, 77%) for texts and calls, respectively. There was no evidence of
decrease in weekly response rate over time (i.e. pattern of missing-
ness was intermittent). The median response rate for months 5 to 12
was 70% (62%, 80%) for SMS and 67% (63%, 82%) for telephone
calls. 190/283(67%) and 3/31(10%) participants completed 100% of
the expected texts and calls, respectively. 243/283 (86%) and 20/31
(65%) participants completed 80% texts and telephone calls,
respectively.
Conclusion
Collecting frequent follow-up outcome data with SMS is feasible in
an RCT and provides high response to both short and longer term
follow-up. This could be an additional and/or alternative strategy to
collecting data in large pragmatic trials, and is particularly useful for
collecting regular primary outcome data, which is key to time-to-
event and pragmatic ITT-evaluation.
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Introduction
Randomised Controlled Trials (RCTs) are universally considered as the
most reliable way to demonstrate and assess causal relationships
between treatments and outcome; science-based medicine is rooted
in them. Spurious relationships between the outcome and a time-
fixed treatment-variable are eliminated by randomising patients over
two or more arms of the trial. Hence, the randomisation procedure
initiates the process by which treatment and outcomes of interest
should be interpreted in a causal way. However, treatment is not al-
ways administered as intended, not least because of the occurrence
of side effects and adverse events. In RCTs of chemotherapy, for ex-
ample, the treatment administered may differ from the intended one
because of the application of either cycle delays or dose reductions.
Background
Opposite to the *intention-to-treat approach*, a statistical analysis
based on actual treatment data might be problematic due to the
presence of the so-called *treatment-adjustment bias*. Exposure to
chemotherapy agents may in fact be reduced and/or delayed as a
consequence of previous-treatment side-effects. In particular, both
reductions and delays contribute to lowering the value of the so-called
Received Dose Intensity.
Methods
Inverse Probability-of-Treatment Weighting (IPTW) is a general meth-
odology for removing treatment-adjustment bias. Working under the
hypothesis of *No Unmeasured Confounding*, it creates a pseudo-
population by weighting each patient with the inverse probability of
observing a certain treatment administration given the past treat-
ment and toxicity history. However, a review of data collected from
RCTs on osteosarcoma suggests that treatment side-effects may not
be sufficiently well-documented.The pseudo-population created by IPTW has the following two
properties:
1. Pseudo-patients’ past toxicity-history no longer predicts exposure
to chemotherapy in the next cycle; 2. The causal effect of treatment
modifications on outcome is the same in both original and pseudo-
populations.
Results
Using data from Medical Research Council trial BO06 (European
Organisation for Research and Treatment of Cancer trial 80931) we
will illustrate the use of IPTW and Marginal Structural Models
(MSMs) for estimating the causal effect of dose reductions on
Event-free Survival (EFS). The use of IPTW and MSMs allows to
move beyond intention-to-treat and unbiasedly estimate the effect
of treatment modifications on EFS.
Conclusions
We demonstrate that, even with complex and entangled data such as
those collected in a RCT of chemotherapy, constructing and estimating
a causal model is possible, provided that side-effects are well docu-
mented. When this is not the case, the removal of treatment-
adjustment bias via IPTW might be problematic, if not prevented at all
by the presence of unmeasured confounder. As such, good-quality
toxicity data should be regarded as important enablers of causal mod-
elling in RCTs of chemotherapy.
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The COMPASS Study is a pragmatic, cluster-randomized trial of 41
hospitals in North Carolina designed to determine the effectiveness
of a comprehensive model of post-acute stroke care (i.e. the COM-
PASS intervention) compared with usual care (Control).
The COMPASS intervention includes activities such as: a follow-up
telephone call two days after having been discharged; a 7–14 post-
acute stroke clinic evaluation and take a patient-reported functional
assessment; and generation of a individualized patient-specific care
plan that is clearly discussed by the clinical provider with the patient
and caregiver; and follow up phone calls 30, 60, and 90 days post
discharge.
In order to efficiently implement COMPASS in participating hospitals,
Wake Forest Baptist Health developed a web-based application that
manages assessment collection, generates a series of helpful reports
for the clinical provider and most importantly, uses a series of propri-
etary decision algorithms to dynamically in real time generate a pa-
tient specific care plan that identifies current health concerns for a
patient, coaches the patient and family to access resources and to
self manage health behaviors to improve recovery, independence,
and health.
In this presentation, we will describe and demonstrate the COMPASS
web-based application including the dynamic generation of patient
specific care plans. Implementation of this care plan is a model of
value based clinical care, meeting numerous CMS quality metrics.
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Background
Data Monitoring Committees (DMCs) are charged with evaluation of
accumulating patient safety data in ongoing clinical trials. Periodic
review involves scrutinizing rates of adverse event (AE) coded terms,
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ECG, vital sign and other assessments. DMC members of varying
backgrounds complete their review in a brief time prior to and
during the DMC meeting. Missing data from early drops-outs due to
adverse event in the active treatment group or lack of efficacy in pla-
cebo group, plus missing at random (MAR) data caused by ongoing
participants who have not yet had an assessment or experienced an
event can impede data interpretation. Data reports that accurately
and clearly display trends are essential for the identification of poten-
tial safety concerns. Both reviewability and statistical rigor are crucial,
yet most common reporting formats used in manuscripts or study re-
ports for completed studies lack both.
Methods
In this talk we present data reporting strategies that best help a
DMC evaluate safety signals through (a) clear graphical displays, and
(b) identification and adjustment for potentially differential rates of
missing data caused both by early discontinuations and ongoing
study participants. A simulation of typical DSMB data is used to dem-
onstrate the impact of differential discontinuation on adverse event
incidence rates compared to incidence densities.
Results
The reporting methods were implemented and refined through an
unblinded independent statistical analysis center (ISAC) for a DMC of
a program of phase II/III pharmaceutical clinical trials. Reviewability is
substantially improved by maximizing the use of graphical displays
at both the treatment group and patient level. Adverse events rates
are accurately portrayed through incidence densities. We present
best practices for graphical displays of disposition, AE rates, individ-
ual event profiles, assessment trends and abnormal values. All dis-
plays provide transparency of the ongoing or early discontinuation
status of the participant and are producible by SAS. DMC members
have assisted with further display refinement and have enthusiastic-
ally received these methods.
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Introduction
The harm profile of a drug is developed through a cumulative process
incorporating information from preclinical through to post-marketing
studies. An integral part of this process is the information elicited from
randomised clinical trials (RCTs), as while RCTs are often not large
enough to signal rare adverse drug reactions, they provide unbiased
estimates of harm effects and provide a controlled comparison allow-
ing causality to be evaluated. Many studies have demonstrated that
the reporting of adverse events (AEs) in published trial reports is often
inadequate, this is despite the gathering of high quality AE data re-
quired by regulators.
We undertook a systematic review to ascertain current approaches to
the collection, selection, analysis and presentation of AEs in RCTs
published in high impact journals. We identify examples of good
practice and provide recommendations for future practice.
Methods
Original phase II-IV studies looking at the efficacy/effectiveness of an
intervention published in the Lancet, British Medical Journal (BMJ),
New England Journal of Medicine (NEJM) and Journal of the Ameri-
can Medical Association (JAMA) in the period September 2015 to
September 2016 (inclusive) were included. RCTs where the interven-
tion was non-medicinal and where harm/s was the primary outcome
were excluded. We manually searched the archives of each journal
for original reports of RCTs.
Using a standardised, pre-piloted, 60-point checklist we extracted
data on trial characteristics, methods of collection, assessment of se-
verity and causality, selection criteria for reporting, analysis methods
and presentation of harm data. Descriptive analysis was performed.Results
We identified 189 eligible trial reports (Lancet n = 62; BMJ n = 4;
NEJM n = 85; and JAMA n = 38). AEs that cause patients to discon-
tinue treatment or withdraw from the study are useful indicators of
severity and impact to patients. We found that 56% reported the
number of withdrawals/discontinuations due to AEs by treatment
arm but only 14% included information on which AEs caused with-
drawal. Only a quarter of reports included information on the sever-
ity of specific AEs, with several studies instead using severity to
select events to report e.g. only reporting those of grade 3–5. Assess-
ment of disproportionalities of AEs between arms was predominantly
undertaken by means of tabulations, including frequencies (90%)
and percentages (80%), allowing for informal comparisons. Despite a
lack of power to undertake formal hypothesis testing of event
counts, 39% of studies reported p-values and many studies included
statements such as “no statistical differences found” to summarise
the harm profile. Several studies only included AE data in online sup-
plementary material.
We will also present exemplary examples of AE reporting, pre-
specified analysis methods for emerging AEs, criteria used to select
which AEs to report and classification used, if any, to group AEs e.g.
organ system.
Conclusions
Guidance is required to improve the consistency of selection, analysis
and reporting multidimensional harm data in clinical trials. The use
of online supplementary appendices for journals provide an oppor-
tunity to include more detailed information on AEs but this should
not negate the inclusion of a useful harm profile summary in the
main paper.
O72
Continue or stop: the rationale for early closedown of a clinical
trial as a result of stopping rules within the data monitoring
committee charter
Lisa Woodhouse1, Jason P. Appleton1, Lelia Duley1, Ian Ford2,
Didier Leys3, Stuart Pocock4, Nikola Sprigg1, Catherine Sudlow5,
Matthew Walters2, Philip M. Bath1
1University of Nottingham; 2University of Glasgow; 3University of Lille;
4London School of Hygiene & Tropical Medicine; 5University of Edinburgh
Correspondence: Lisa Woodhouse
Trials 2017, 18(Suppl 1):O72
Background
The international Triple Antiplatelets for Reducing Dependency after
Ischaemic Stroke (TARDIS) trial assessed the safety and efficacy of in-
tensive (combined aspirin, dipyridamole and clopidogrel) versus
guideline (aspirin/dipyridamole, or clopidogrel alone) antiplatelets
given for one month in patients with acute stroke or transient ischae-
mic attack (TIA). The primary outcome was the incidence and severity
of any recurrent stroke or TIA within 90 days. Recruitment com-
menced on 7 April 2009 but was halted on 18 March 2016, with a
total enrolment of 3096 participants (of a planned target of 4100,
75.5%), on the advice of the independent Data Monitoring Commit-
tee (DMC).
Methods
The DMC for the TARDIS trial followed a pre-defined charter, which
included stopping rules for safety and efficacy. The DMC charter did
not include any stopping rules for futility. With respect to safety, the
DMC charter listed the following reasons for recommending early
stopping of the trial: the primary outcome favoured the control
group, P < 0.01 (nominal, 2-sided); the combined outcome of fatal or
non-fatal stroke or major bleeding favoured the control group, P <
0.01 (nominal, 2-sided); the overall rate of symptomatic intracranial
haemorrhage exceeded 2%; that during the start-up phase, major
bleeding favoured the control group, P < 0.01 (nominal, 2-sided). For
efficacy, the DMC was to conduct formal interim analyses, after 40%
and 70% of the target number of participants had had their 90 day
outcome assessed, based on whether the combined outcome of fatal
or non-fatal stroke or major bleeding event favoured the control
group, P < 0.001 (2-sided). Before making any decision, the DMC was
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multiplicity of testing and the possibility that trends in the data
might be reversed with longer follow-up or increased recruitment.
Results
The DMC reviewed unblinded data in confidence every 6 months.
Overall, the DMC met on 13 occasions and recommended trial con-
tinuation for all but the last data review. The recommendation to
stop was based on a combination of three observations: (i) although
intensive antiplatelet therapy was associated with a non-significant
reduction in the primary outcome, a conditional power futility ana-
lysis suggested the trial was highly unlikely to ever demonstrate a
significant difference in the primary outcome; (ii) the presence of a
significant increase in major (including fatal) bleeding in participants
randomised to intensive antiplatelet therapy (this increase was not
present during the start-up phase as per the pre-defined stopping
rules); and (iii) overall neutral findings with no difference in the net
balance of death, stroke, myocardial infarction and major bleeding.
The Trial Steering Committee (TSC) reviewed the same data (and
subsequent additional analyses) and agreed that the trial should stop
recruitment and complete follow-up on the basis of futility.
Conclusions
Even though the DMC charter for TARDIS did not include stopping
rules for futility, it was agreed by both the DMC and TSC to stop the
trial on this basis. DMCs may need to stop such trials in certain cir-
cumstances, as seen here.
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Background
There is limited research and literature on the trial management
challenges encountered in running adaptive platform trials. This trial
design allows both (i) seamless addition of new research compari-
sons when compelling clinical and scientific research questions
emerge, and (ii) early stopping of accrual to individual comparisons
that do not show sufficient activity without affecting other active
comparisons. FOCUS4 (colorectal cancer) and STAMPEDE (prostate
cancer), run by the MRC CTU at UCL, are two leading UK examples of
clinical trials implementing adaptive platform designs with biomarker
stratified and non-stratified comparisons all within one protocol.
Adaptive platform design trials offer many potential benefits over
traditional trials, from faster time to accrual to contemporaneously
recruiting multiple research comparisons, added flexibility to focus
on more promising research comparisons via pre-planned interim
analyses and potentially shorter time to primary results. To date,
STAMPEDE has added four new research comparisons, closed two
following pre-planned interim analysis (lack-of-benefit) and com-
pleted recruitment to six research comparisons. FOCUS4 has closed
one research comparison following pre-planned interim analysis
(lack-of-benefit) and added one new research comparison, with a
number of further comparisons in the pipeline.
We share here our experiences from a trial management perspective,
highlighting the challenges and successes.
(Note: our lessons learnt from a central data management perspec-
tive are reported in our companion abstract: “Changing platforms
without stopping the train: A Data Management Perspective on the
operational aspects of adaptive platform trials”).
Methods
We systematically evaluated the operational aspects of making changes
to these adaptive platform trials and identified both common and trial-
specific challenges. The operational steps and challenges linked to boththe addition of new research comparisons and stopping recruitment
following pre-planned interim analysis were considered in our
evaluation.
Discussion
Specific operational challenges in these platform trials, additional to
those in traditional two-arm trials, were identified that should be
considered when setting up an adaptive platform trial.
During set-up of an adaptive platform trial, it is important to carefully
consider the practicality of the protocol structure (modular versus
single protocol), the longevity and continuity of trial oversight com-
mittees and having clear clinical and scientific criteria for the
addition of new research comparisons. The common challenges in
introducing a new research comparison were linked to the need for
fast development timelines and a continuous training and communi-
cation programme with sites to ensure the protocol is clearly under-
stood and followed.
Early stopping of a research comparison due to lack-of-activity also pre-
sents operational challenges, specifically when planning for stopping to
recruitment is balanced with management of ongoing comparisons
and sometimes the development of new research comparisons.
Conclusions
In our experience, the benefits arising from rapid acceleration of re-
cruitment and shortened time to primary results outweighs the oper-
ational challenges. Careful planning is paramount when making all
changes to ensure that day-to-day running is not affected and imple-
mentation of all changes is time-effective and efficient. Adaptive
platform trials offer an efficient model to run randomised controlled
trials and we are continuing to work to reduce further the effort re-
quired from an operational perspective.
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Background
In 2012 National Institute of Health Research funded the By-Band-
Sleeve study (BBS), a multi-centred, pragmatic trial comparing the ef-
fectiveness and cost effectiveness of three surgical interventions for
weight-loss: the gastric bypass, the adjustable gastric band and the
sleeve gastrectomy (Byrne et al. 2015). This was anticipated to be a
“hard to recruit” study with the goal of recruiting 1,341 patients. The
QuinteT Recruitment Intervention (QRI), a method of understanding
recruitment and responding to trial recruitment difficulties (Donovan
et al., 2016), was integrated with BBS. Over the last three years the
QRI has informed recruitment by identifying issues with patient path-
ways, improving patient information leaflets and education sessions
and providing regular feedback to surgeons and nurses. With 570 pa-
tients randomised, BBS is at an advanced stage of recruitment.
Methods
The QRI methods were employed by a) incorporating key findings
from the internal pilot phase into the (pre-recruitment) training pro-
vided for the new centres in the main phase and b) concurrently ini-
tiating the QRIs in the new centres to identify challenges specific to
each centre. This involved thematic analysis of a purposive sample of
198 audio-recorded consultations from 11 centres, observations of
education sessions where details of the surgical procedures were ex-
plained to patients and analysis of screening log data. Findings were
used to deliver group and individual feedback on recruitment across
the BBS sites. Centre reviews, similar to those used in previous stud-
ies (ProtecT trial), were undertaken for the centres with particularly
low recruitment.
Findings
The QRI identified new and unforeseen barriers to recruitment in each
centre. Findings show how changes to staff, or changes to the organ-
isation of patient care, present unexpected obstacles to recruitment.
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in opinion within the broader clinical community. These issues under-
mined recruiters’ confidence and ability to approach patients and
obtain informed consent, bringing individual discomforts or conflicts
about recruitment to the surface. Centre reviews were helpful in identi-
fying where training and intervention could be most effective.
Conclusion
The By-Band-Sleeve study is a complex, multi-centred and pragmatic
trial within a changeable clinical environment. The value of the QRI
in the By-Band-Sleeve RCT has been in transforming recruitment in a
difficult surgical RCT. More importantly, the flexible, iterative and re-
sponsive approach has helped to sustain recruitment and address
emergent challenges.
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Background
With the introduction of remote electronic data capture (EDC) at ICR-
CTSU in 2012, a new process for data management was required to
detect data discrepancies that would previously have been identified
during central data entry. Use of a data review program was intro-
duced in 2015. This software is now in use for several EDC trials,
?A3B2 show $132#?>necessitating a standard approach.
Implementation
Data are remotely entered into the EDC system by staff at participat-
ing sites and are immediately available for review at ICR-CTSU. How-
ever, only single forms can be opened in the EDC system at a time,
making checks across several forms difficult. The data review soft-
ware can be programmed to extract data from several forms for mul-
tiple trial visits across different participants. Reports are created,
validated and saved to be run at required time points to extract live
data, so irregularities can be identified and queried. This is now the
principle method of data verification and validation for EDC trials at
ICR-CTSU.
A data management plan (DMP) is developed for each trial and in-
cludes a comprehensive list of the data points which require verifica-
tion. Data management checks can be grouped and programmed
into reports produced using data review software. Higher priority
checks, such as those related to eligibility criteria, safety data and
endpoint data, are programmed first.
Filters can be built into reports to select specific patient subsets such
as treatment cohorts. Reports can be programmed so that cells or
lines are highlighted, to identify data that are outside of an expected
range. Reports are saved within the system according to a standar-
dised naming convention. Complex reports which filter or extract
data from multiple forms are validated to ensure accuracy. Upon a
change to the EDC system, reports may need to be altered and re-
validated.
Report specification details are documented and reports are run ac-
cording to priority. A log is completed to track when reports have
been run. Report outputs can be exported to Microsoft Excel for
further manipulation. Advanced filtering techniques can be used to
distinguish new data from previously checked data.
Following the identification of data discrepancies, queries are raised
in the EDC system and are available for immediate review by sites.
Conclusion
Data review software is now used at ICR-CTSU to facilitate data man-
agement in EDC trials. Implementing this new process can be time
consuming, and manual checks are necessary while reports are beingprogrammed and validated. Once in place the programmed checks
are easy to run and streamline data management.
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Background and Aims
Patient adherence to treatment is a key determinant of outcome
for healthcare interventions. Nonadherence likely influences thera-
peutic outcomes and, if unmeasured, introduces uncertainty into
trial data. Whilst nonadherence has been well evidenced in settings
such as drugs therapy, there is a paucity of information regarding
patient adherence to rehabilitative or “removable” devices, such as
splints and braces, whereby unscheduled removal may lead to irre-
versible deterioration of the injured structure. The aim of this study
was to identify and summarise the methods reported in the litera-
ture for assessing patient adherence to removable devices to
inform further research in this area and improve the quality of
outcomes.
Methods
A systematic review was undertaken in seven electronic bibliographic
databases including MEDLINE and CENTRAL, using terms relating to the
device and assessment of adherence. Included were all types of trial,
observational study, and case study/series prescribing a removable de-
vice after trauma or surgery. Devices were eligible for the review if they
were removable by the patient, applied to a bone or joint of the appen-
dicular skeleton, and provided full or partial immobilisation. Studies
with children or animals published before 1990 were not included.
Screening and data extraction were conducted with standardised online
forms developed by the researchers. Screening was conducted in full by
two reviewers and discrepancies were resolved by two further reviewers.
Data were summarised by study design for injury type, device, and
methods for assessment of adherence. We scrutinised the papers to
understand how authors valued adherence within the context of their
study. The value of the methods to future research was considered.
Results
A total of 1655 de-duplicated records were screened for eligibility,
resulting in 28 studies in the analysis (RCT = 7; Comparative study =
4; Non-comparative study = 17). The most frequently employed
methods of adherence assessment were non-validated participant
self-completion questionnaires and attendance at follow up appoint-
ments, with four studies using multiple methods (RCT = 3; Non-
comparative = 1). More complex methods were used by one study
only, i.e. sensors. The association between patient adherence and pa-
tient outcomes was evaluated by 13 studies (RCT = 2; Comparative =
1; Non-Comparative = 10) with the majority of studies reporting
poorer outcomes with poorer adherence. Three studies inferring an
association between outcome and adherence in the discussion pre-
sented neither methods nor data for the assessment of adherence.
Reasons for non-adherence were reported by only nine studies
(32%), most commonly citing discomfort as the cause.
Conclusions
This study provides novel information regarding methods for the
assessment of patient adherence to a removable device. The major-
ity of studies in this analysis employed low burden methods easily
implemented into a trial protocol. A combination of methods would
therefore represent a practical approach for future trials whilst
providing both objective and subjective data for increased validity.
Trials 2017, 18(Suppl 1):200 Page 218 of 235Given these findings, expensive and complex methods such as sen-
sors may not be required. Developing a validated questionnaire
would further increase validity and allow for comparison between
studies. The paucity of data regarding reasons for non-adherence
calls for a mixed methods approach including qualitative research
to identify and explore patient factors.
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Background
Randomised controlled trials provide an opportunity to examine
patient-level resource-use data to assess the costs associated with an
intervention. Combined with outcome data in an economic evalu-
ation, these measurements gauge the value for money that a particu-
lar intervention represents. Typically, researchers develop a bespoke
questionnaire on a trial by trial basis to ask patients about their re-
source use. However, the advent of electronic data sources that are
routinely collected within the health service has opened up new op-
portunities for collecting resource-use data without burdening
patients.
Methods
We describe current electronic data sources that may be suitable for
use in economic evaluations conducted alongside randomised con-
trolled trials, including Hospital Episode Statistics (HES) and Second-
ary Users Service (SUS) datasets for secondary care in England; the
Clinical Practice Research Datalink (CPRD), ResearchOne and in-
practice software systems for primary care data; commissioning data-
sets and their potential use for research; as well as looking to future
developments such as GP Connect and the need to link electronic
datasets. We also describe the current status of instruments for
measuring resource use via patient self-report, and discuss initiatives
to improve the methodology. We assess the risks and benefits associ-
ated with each method, and compare the suitability of the two
methodologies.
Discussion
Patient self-report forms a pragmatic and cheap method of data col-
lection that is largely under the control of the researcher. However,
there are known issues with the validity of the data collected, loss to
follow-up may be high, and questionnaires suffer substantially from
missing data. Routinely collected electronic data may be more accur-
ate, although the validity of the datasets is not commonly assessed
for the purposes of health economic evaluation. The use of routine
datasets is likely to be more practical than patient self-report if large
numbers of patients are involved. However, access to datasets often
incurs a significant cost and researchers are bound by the time for
data approval and extraction by the data holders.
Conclusions
Owing to information governance and issues with timeliness of ac-
cess associated with electronic datasets, self-reported methods may
currently be the preferred option. In particular, patient self-report is
necessary if the study perspective encompasses costs borne by the
patient themselves. However, hospital data are relatively easy to ob-
tain electronically; in trials where secondary care constitutes a major
cost driver, detailed electronic data may be considered superior to
self-reported methods.
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Background
Qualitative research is often used to inform the development of com-
plex interventions in health care. However, study designs rarely use a
phased approach to fully understand the chain of events in any
healthcare process, and tend to rely on a small and predictable set
of data collection methods and qualitative analytical frameworks,
which may not be best suited to either the research questions or
data collected. We used a multimethod qualitative approach, tailored
to each phase, research question, and data type to inform the devel-
opment of a complex intervention to support patients and their clini-
cians when considering treatment options following a diagnosis of
advanced lung cancer (The PACT study).
Methods
The PACT study is a five-stage prospective, qualitative and multicentre
exploratory study. Data is collected from: I. Non-participant observation
and audio recording of multi-disciplinary team (MDT) meetings to
determine how patients were allocated to treatment pathways. II.
Audio recording of patient-clinician consultations to measure patient’s
involvement in decision-making (stage II). III. From the same cohort,
separate audio recorded and observed interviews with patients IV. And
their clinicians to explore the perception of treatment options and
involvement in decision-making. V. An expert consensus meeting to fi-
nalise the content and format of the intervention Qualitative analytical
frameworks were used according to data type, research question and
included: I. Mediated discourse analysis (MDA) II. Thematic Analysis and
Option Grid scoring III. Interpretative Phenomenological Analysis (IPA)
IV. Framework Analysis V. Consensus methodology and cognitive
interviewing.
Results
Stages I to IV have been completed and stage V is currently under-
way. Data from stages I to IV provided an in-depth analysis of key
turning points influencing information sharing, communication and
decision-making between patients and clinicians. Based on the find-
ings of stages I to IV, an expert consensus group to select the do-
mains for decision-making, and mode of intervention followed by
cognitive interviews using probing and “think-aloud” protocols with
patients, will determine the face-validity of the intervention. The next
step will test the intervention in a cluster randomised controlled trial
to include QoL and economic outcomes in order to establish the
intervention as effective and beneficial. This multimethod approach
has enabled a reflection of the complexity of the clinical pathway,
and has mapped what happens during the patient-clinician consult-
ation. We hope that this example will encourage a broader approach
to qualitative study design when developing complex interventions
in health care.
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research community due to its generous licensing terms and its ease
of use in setting up and managing research studies.
Many randomised clinical trials implement complex treatment alloca-
tion algorithms such as minimisation that are not supported by the
REDCap tool. This forces study designers into building in additional
complexity to the design to enable the study to proceed.
An outcome of this is that research nurses often need access to two
systems’ REDCap itself, plus an external randomisation system.
Additional complexity such as this should be avoided in a well-
designed research study.
We propose to demonstrate a mechanism where we leverage the
REDCap data trigger mechanism, the REDCap API and Edinburgh
Clinical Trials Unit’s own Randomisation Service to seamlessly inte-
grate an external randomisation service with the REDCap data collec-
tion process.
The practical outcome of implementing the mechanism is that the
end-users - our research nurses - are unaware they are in fact using
two separate systems. Our stated aim of reducing complexity is thus
achieved.
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Introduction
Randomised Controlled Trials (RCTs) are the most rigorous study
design to evaluate healthcare interventions. However, their success
relies on patient recruitment. The QuinteT Recruitment Intervention
(QRI) aims to address recruitment difficulties and enhance informa-
tion delivery in RCTs, using qualitative methods. It has been imple-
mented in 26 current and completed RCTs, either as part of the
initial study design, or brought in part-way through when recruit-
ment is particularly challenging. The QRI comprises two-phases:
Phase I - investigation of recruitment processes, using interviews,
screening logs and recordings of trial consultations; Phase II - devel-
oping an action plan in agreement with the RCT’s Chief Investigator. A
QRI typically takes 12–18 months. Where trials are experiencing recruit-
ment difficulties, and have to respond swiftly to funders it may not be
possible to complete a full QRI. We report and reflect on a develop-
mental abridged version of the QRI as applied to a UK-based RCT com-
paring urological surgical procedures.
Methods
An abridged QRI was applied at two time points, 20 and 30 months
into the recruitment phase of the RCT, each culminating in a collabo-
rators’ workshop. Semi-structured interviews were undertaken with
the CI, 16 recruiting urologists, and 2 research nurses (time point 1)
and 5 urologists (time point 2). Interviews, screening and recruitment
data were analysed to explore reasons for patient non-participation.
Workshops were attended by the majority of recruiting centres and
involved facilitation of an interactive discussion session based on
emergent findings from the QRI. Attendees discussed the implica-
tions of these findings, and considered whether they would be able
to amend their subsequent recruitment practices.
Results
Issues that may have hindered recruitment emerged from the ana-
lysis: different interpretations of eligibility criteria reduced the poten-
tial sample population in some centres, and different positions of
equipoise emerged in relation to one very familiar and established
procedure, and a newer, less well-established technique. Additionally,
there was inconsistency between the reasons for patient preferences
as documented in screening data and described in interviews. Prior
to the first meeting, 113 patients had been randomised (average 4.7
per month). In the subsequent 10 months, 135 patients were rando-
mised (average 13.5 per month). The second collaborators’ meetingwas held in November 2016. If current rates are maintained, the
study is now expected to successfully achieve its recruitment target.
Conclusions
An abridged QRI in the form of interview data and good quality
screening information, combined with the accumulated knowledge
of the commonly-cited barriers to trial recruitment, appeared to lead
to an increase in the average number of monthly randomisations in
this RCT. If RCTs require a short-term fix to recruitment challenges,
an abridged version of the QRI may be useful. However, without the
benefit of a full Phase I of the QRI, there is a limited understanding
of recruitment barriers and processes, reducing opportunities to offer
tailored suggestions for improving communication which may be ne-
cessary in some RCTs.
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Background
Two-stage, single-arm designs are commonly employed phase II
oncology trials. Typically these designs aim to determine whether
the experimental treatment has sufficient activity to warrant further
development, without formally testing the safety of the treatment.
Bryant and Day (1995) developed a two-stage design to formally
evaluate both response and toxicity. This design allows early termin-
ation at the interim analysis due to inadequate response rate and/or
excessive toxicities.
A disadvantage of these designs is early termination can only occur at
the end of stage one, after a pre-specified number of patients are re-
cruited and followed up. However it may be the case that during the
trial, insufficient number of events occur such that early termination of
the trial may occur at any point. Exposing more patients to a treatment,
which has for example already observed too few responses and won’t
be recommended for further development, is unethical. Additionally,
this is wasting precious time and resources, which could be used else-
where. Implementing continuous monitoring throughout these de-
signs, could help overcome this issue.
Here we consider the statistical implications of employing continuous
monitoring in the Bryant and Day design, to allow stopping when
the desired outcome becomes unachievable or already achieved.
Methods
Kunz and Kieser (2012) explained that type I error and power are pre-
served when non-stochastic curtailment (NSC) - a form of continuous
monitoring - is implemented, as the trial is terminated once the
desired result is impossible to achieve or already achieved. We there-
fore focus on the impact on probability of early termination and
expected sample size. We consider the case where a treatment
successfully makes it past stage one and continuous monitoring oc-
curs in stage two.
Simulations were used to implement NSC in stage two of the Bryant
and Day design considering a range of scenarios. Response and tox-
icity rates between 0.05-0.8 and 0.6-0.95 were investigated, respect-
ively. The probability of early termination and expected sample size
conditional on making it to the second stage of the trial were calcu-
lated, when allowing early stopping for futility or efficacy (simulated
under the null or alternative hypotheses respectively).
Results
Under all scenarios investigated, on average 77% of trials were termi-
nated early during the second stage for futility, compared to 89% for
termination due to efficacy. Without curtailment, the mean total sam-
ple size was 29.9 patients, whereas when allowing early stopping for
futility during stage two 26.4 patients were expected and for efficacy
26.7. This equates to savings of 12% and 11% respectively.
Conclusion
On average, a smaller sample size was required when implementing
NSC in scenarios with larger toxicity rates. When allowing stopping
for futility, greater savings in expected sample size were seen in the
Trials 2017, 18(Suppl 1):200 Page 220 of 235scenarios with larger toxicity rates. However greater savings were
seen in the lower toxicity scenarios, when stopping for efficacy. The
probability of early termination was significantly larger when allow-
ing early stopping for efficacy compared with futility.
Where recruitment is slow or observations may be monitored in a
short-time frame, NSC for futility and efficacy may be beneficial.
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Non-inferiority trials are often used to compare a novel treatment
with an active treatment in hopes of showing the novel treatment is
not clinically worse than the proven standard therapy. Factors such
as the choice of non-inferiority margins make these trials difficult to
design, but these trials become significantly more complex when the
condition being treated is associated with another disease that war-
rants additional treatment, making it difficult to tease out treatment
effects. The Diabetic Retinopathy Research network designed a non-
inferiority trial to determine whether intravitreous ranibizumab (IVR),
an anti-VEGF agent, with deferred panretinal photocoagulation (PRP)
resulted in outcomes that were non-inferior to prompt PRP alone for
the treatment of proliferative diabetic retinopathy (PDR). Diabetic
macula edema (DME) can occur concomitant with PDR and is usually
treated with an anti-VEGF drug if visual acuity is decreased. In this
trial, about 35% of the prompt PRP group received the study drug
(IVR) in addition to prompt PRP for the treatment of DME at baseline,
and an additional 18% received it during follow up, after developing
DME. This presentation will highlight some of the challenges encoun-
tered in designing this trial such as choosing an appropriate non-
inferiority margin, appropriate statistical methods and approach to
treatment of DME in the standard treatment group. We discuss the
advantages and disadvantages of the approaches taken to design
this trial and discuss alternatives for handling these challenges. Our
experience will help to inform investigators on possible solutions to
similar situations in the future.
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Minimization is increasingly recommended as the method of choice for
allocating subjects to treatment groups in clinical trials. The method is
designed to eliminate chronological bias by guaranteeing similar num-
bers of patients in treatment groups throughout the trial recruitment
phase and to ensure treatment groups are balanced on prognostic and
other baseline characteristics at the end of the trial. Primarily because
of its superior capacity to balance treatments across large numbers of
baseline variables, minimization has been referred to as the platinum
standard for treatment allocation in clinical trials. In multi-center trials,
study center is typically one of the minimization variables. In its original
form, minimization deterministically (p = 1.0) allocates the next patient
to the least common treatment for previously allocated patients with
the same combination of baseline characteristics. Subsequent exten-
sions to the minimization algorithm included the addition of a random
element to the allocation process (p between 0.5 and 1.0) to mitigate
the risk of a clinician predicting the next treatment to be allocated. We
argue that the risk of selection bias is negligible in multi-center trials
that use an interactive central allocation system (web-based or voice
response). We present data showing that the addition of a randomcomponent to the minimization algorithm can be detrimental to
the objectives of minimization and reduce the efficiency with which
a trial can be conducted. Unpublished data from case studies of on-
going and completed multi-center clinical trials that are using or
used minimization with a random component show that imbalance
in treatments at study centers often occurs throughout the recruit-
ment phase and treatment balance at all study centers is not guar-
anteed at the end of the trial. Through simulation studies we show
that these problems are less evident when minimization is used
without a random component. We discuss the contexts (e.g., medica-
tion kits shipped in advance of need and stored at study centers) in
which trial inefficiencies and cost overruns occur with the inclusion of a
random element to the minimization algorithm. We conclude that con-
sideration should be given to not adding a random component to
minimization in multi-center clinical trials that use an interactive central
allocation system and recommend that decisions about the statistical
aspects of trial design, especially decisions about treatment allocation
methods, be made in the context of planned procedural and oper-
ational aspects of a trial.
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Employing efficient strategies for monitoring clinical trials is para-
mount to mitigating risks using limited resources. While effective
monitoring is crucial in protecting the well-being of trial participants
and maintaining the integrity of data, in recent years there has been
a gradual shift towards a risk based monitoring (RBM) approach. In
2011, An MRC/DH/MHRA Joint Project produced a paper entitled
“Risk-adapted Approaches to the Management of Clinical Trials of
Investigational Medicinal Products”, which aimed to facilitate a risk-
proportionate approach in applying the principles of GCP when
running clinical trials in the UK. In the same year guidance was also
released by the U.S Food and Drug Administration on the expanded
use of RBM.
Like many clinical trials units, Leeds Institute of Clinical Trials Re-
search (LICTR) previously assessed the risk for the trial as a whole
and established a relatively inflexible monitoring plan whereby a des-
ignated number of visits was performed at each of the sites, with
extra visits only being performed at sites that recruited large num-
bers of participants. Sites that had a good record of trial conduct and
data compliance received the same number of visits as sites that had
a poor record. The only monitoring above the standard would be
when a triggered monitoring visit was required, such as if a site had
breached the protocol and this was reportable to the MHRA. In order
to prioritise finite resources, a formal, documented methodology was
required for analysing trial-specific risks, and determining when more
frequent, targeted monitoring was necessary.
With this goal in mind, a risk-based monitoring tool was developed
for use in the early phase myeloma portfolio being run at the LICTR.
Data regarding site performance is collated on a monthly basis. Each
metric relating to the safety of participants, data management, regu-
latory compliance and adherence to protocol has parameters for low,
medium or high risk scores. Sites are given an overall risk rating de-
pendant on the number of areas in which they are considered a low,
medium or high risk. The risk assessment is examined regularly
throughout the course of the trial to ensure that the risk score and,
subsequently, the monitoring approach is amended according to the
changing quality of site performance. This tool involves collaboration
between trial coordinators, data managers and monitors and enables
simple and quantitative reporting at meetings and gives closer align-
ment of data management, trial management and site monitoring
processes. Our monitoring plans still incorporate visits to every site
but are now also adaptive, allowing the monitoring strategy for a
particular site to evolve as the trial progresses.
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implemented a site monitoring tool for our phase two trials in the
myeloma portfolio.
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Objectives
To report the rationale for, and initial performance data of, a measure
of quality of patient decision making about research participation.
Background
To understand patients’ decisions about research participation,
including trials, or to evaluate interventions intended to boost re-
search recruitment rates, it is useful to assess quality of decision
making about participation. It would be equally useful to do this
when the patient has opted to participate or has declined. The
QuIC measure [Joffe, 2001] has been used in several studies but
there are concerns about its completion rate and the relevance
of some items to non-drug trials. The ICQ measure [Guarino,
2006] has some useful items but also those that depend on post-
study completion. There are established, well-performing mea-
sures of patient decision making about treatments [O’Connor,
1995; Parayre, 2014] but both these measures contain items that
do not apply to decisions about research participation. Given
these problems we devised a new measure and tested it with a
small sample of people who had consented to take part in the
REFORM study [Cockayne, 2016].
Methods
The measure was intended to be short (to limit patient data burden)
with items referring to elements of participant information required
under UK research governance. The measure has 5 items (covering:
potential benefits of participation; potential disadvantages; likely
experience of participation; possible changes to treatments or care;
and an evaluation of the overall extent to which choice was in-
formed), each using 5 Likert responses (from ‘strongly agree’ to
‘strongly disagree’, scored 5 to 1 respectively) This derives a total
score with possible range 5–25, and higher scores indicating greater
agreement. The measure was included in the baseline pack posted
to participants in the REFORM study [Cockayne, 2016], which used a
“trial within a cohort study” design to evaluate the effectiveness of a
falls prevention intervention in older people living at home. The
measure was posted to 301 people (aged 64–98; 50.8% were female)
in 4 centres in northern England.
Results
280 (93.0%) participants completed at least some of the measure, of
whom 98.9% completed all items. The mean total score was 20.03
(SD 2.44; range 12–25; mode 20; median 20). Individual item means
ranged from 3.81 (“possible changes to treatment or care”) to 4.24
(“overall informed choice”). Internal consistency was high (Cronbach
alpha 0.83) and alpha was not increased by the deletion of any of
the 5 items.
Discussion & Conclusions
The scale was acceptable to respondents and shows promise as a
measure of the quality of decision making about research partici-
pation. Mean scores were relatively high, which may indicate the
quality of information provision in this study but could also re-
flect the positive wording of the measure’s items. Further evalu-
ation is needed, particularly in studies with different age groups
and lower participation rates. Also needed are consideration of a
threshold approach to scoring, defined by minimally acceptable
values to indicate that informed consent has been obtained; and
evaluation of the measure’s ability to discriminate and its sensi-
tivity to change.O86
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Background
The importance of pragmatic study design is gaining increasing rec-
ognition in research. A distinctive feature of this is the selection of
clinically relevant outcomes that are meaningful to patients. Studies,
therefore may choose to focus on the symptomatic condition of
interest rather than the asymptomatic presence of a condition alone.
However, there are challenges associated with this, including the
selection of symptoms and their assessment. Here we describe the
methods used to design a questionnaire that aims to identify the im-
portant symptoms of the relevant condition. In a future study, we in-
tend to set a threshold to define participants as symptomatic and
use this as part of the definition of the primary outcome. This work
highlights how built in feasibility work can be used to develop pa-
tient centred symptom-based outcomes to inform a pragmatic trial
design.
Methods
The first phase of the project (Phase A) consists of built in feasibility
work designed to inform the future study (Phase B). This methodo-
logical work, performed as part of Phase A, has three main compo-
nents: i) Identification of known and unknown healthcare domains
from the literature and qualitative interviews with patients living with
and without the condition and interviews with clinicians and special-
ist nurses, ii) Development domains into questions within a question-
naire for completion by patients, iii) pre-testing the questionnaire in
patients living with and without the condition to refine the instru-
ment and develop thresholds (green, amber and red) to trigger fur-
ther investigation for the condition of interest.
Results
169 relevant descriptions of known symptoms were identified from
the literature, which were grouped into health domains independ-
ently by two researchers, resulting in 19 domains that included pain,
body image and social functioning. These domains formed the basis
of the topic guides for the semi-structured interviews. 10 healthcare
professionals with clinical experience of the condition of interest and
17 patients (9 living with the condition and 8 without, on review of
medical records) were interviewed. The topic guides were updated
iteratively as new lines of enquiry were uncovered during the inter-
views. Interviews were analysed through constant comparison ap-
proaches. Transcripts were coded line by line and categorised into
themes using NVivo software. The Interviews identified 16 additional
symptom domains. Work is ongoing to develop items from the do-
mains. Future work will pre-test the tool and establish thresholds to
define participants as symptomatic.
Conclusion
This mixed methods feasibility work developed a patient centred
outcome measure to inform a pragmatic study design. It focuses on
endpoints relevant to patients (i.e. a symptomatic condition of inter-
est). Further work is planned in the main study to validate the clinical
findings with symptomatic and asymptomatic patients.
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Collection of outcome data within randomised controlled trials (RCTs)
can be challenging, especially in trials with a lengthy follow-up phase. If
the outcomes of interest are participant-reported, for example, quality-
of-life, then participant contact is unavoidable. However, if the out-
comes are clinical, for example, re-operation or hospitalisation then rec-
ord linkage of trial datasets to hospital admission records (or other
routine data-sets) may be an option and could potentially overcome
some of the issues associated with participant retention.
Methods
Two surgical RCTs that utilised a dual model of data collection
whereby clinical outcomes were reported by the participant and
through record linkage were examined. In both trials the use of hos-
pital admission data was appropriate as the key clinical outcome was
further surgical intervention for reoccurrence of the condition. Con-
sent for record linkage was obtained from all participants at the on-
set of the trials which allowed the collection of data from those
participants who subsequently declined further questionnaire follow-
up or who were lost to follow-up (unless their consent to do so was
withdrawn). Both trials have reported their primary outcome and one
has entered a longer follow-up phase.
Results
The supplementation of participant-reported clinical outcomes with
routine hospital admission data allowed us to better evaluate the key
clinical question; approximately 20% of relevant hospital readmis-
sions were obtained from routine admission data only. However the
exercise also highlighted potential issues with the coding of routine
admission data: for 5.8% of index operations, the coding in the rou-
tine data did not match that recorded within the trial dataset.
Discussion
Inconsistencies between the participant-reported account and the
record linkage report were detected. In an attempt to address this
issue contact was made with the hospital site to extract information
directly from the patients’ notes. If no response was received, the
participant’s record of the event was included in the analyses in both
trials. For an event reported by record linkage that could not be veri-
fied by the hospital (and was not reported by the participant) the
event was excluded from the analyses.
Issues surrounding the collection of record linkage data were also iden-
tified. This was particularly problematic for data collected through the
Health and Social Care Information Centre (now known as NHS Digital).
Problems encountered included a lengthy application and approval
process, mainly due to changes in the application process, the name of
the service provider and to the legal gateway for consent.
We also experienced lengthy applications to extend retention periods be-
yond the initial agreement (to comply with sponsor and funders regula-
tions) and extensive data security checks of the University’s policies. In
addition, there is still ongoing confusion regarding data classification, in
particular, what constitutes derived reversible or irreversible source data.
Conclusions
The collection of hospital readmission data to supplement participant-
reported outcomes was a worthwhile exercise across both trials as it re-
sulted in a more complete dataset. However it was a time consuming
process and had implications in terms of staff time preparing the appli-
cation, analysing the data and resolving any inconsistencies observed.
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Background
In mental health trials there is concern that the control treatment might
be contaminated, meaning that a participant in the comparator arm
receives the active intervention. This can often be avoided by design
through the use of cluster randomisation, with clusters defined by thelevel at which contamination is thought to take place. One alternative
to this problem is to account for contamination in the analysis by using
complier average causal effect (CACE) estimation.
Method
This methodological research was motivated by a trial of nurse-
delivered cognitive behavioural therapy and motivational interview-
ing for people with poorly controlled type 2 diabetes in primary care.
Participants were offered either this (in addition to standard care) or
standard care with attention control. The primary outcome was
glycated haemoglobin. Contamination was anticipated if a given nurse
were asked to deliver both intervention and comparator treatments.
Therefore cluster randomisation was used with treatment allocation at
the level of the primary care centre. However, in practice both non-
compliance and contamination did occur due to variation in nurses’
skills and possibly as an effect of the attention control design.
Treatment fidelity was measured using two fidelity scales, which were
then used to construct measures of treatment receipt and subse-
quently to account for non-compliance and contamination in the ana-
lysis of the trial. One measure was of binary treatment receipt and this
was used to perform a CACE efficacy analysis using instrumental vari-
able methods. Another was a continuous measure of dose of treat-
ment. In addition, existing methodology was developed to allow the
estimation of the effect of exposure on the causal treatment effect
where exposure is dose of treatment and is measured in control and
intervention participants.
Results
The treatments that those in the intervention and control arms re-
ceived were unexpectedly similar. This appeared to represent a mixture
of treatment non-receipt in the active arm (non-compliance) and treat-
ment receipt in the control arm (contamination).
The intention-to-treat analysis suggested little effectiveness of treat-
ment. The efficacy analyses, which accounted for non-compliance
and contamination, gave estimates that were a little larger and with
wider confidence intervals. However, these did not show a statisti-
cally or clinically significant effect.
Conclusions
The similarity between the treatment groups may in part explain the
lack of a treatment effect in this trial. This research has demonstrated
the importance of measuring treatment fidelity for all participants as
a post randomisation process variable. Such a measure enables an
assessment of fidelity and adjustment for treatment receipt in the re-
sults of a trial of a psychotherapy. The motivating trial also highlights
the difficulty of training non-clinical psychologists to provide psycho-
therapy and possibly the drawback of the use of attention control.
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Background
The TIME (Treatment in Morning versus Evening) Study is a rando-
mised study of the effect of timing of antihypertensive medication
administration on cardiovascular outcomes using an online method-
ology [1]. This presentation will describe and discuss the methods
used to surpass the study recruitment target. Background TIME aims
to determine if antihypertensive therapy taken in the evening results
in improved cardiovascular outcomes compared with conventional
morning dosing. Over 20,000 participants, followed-up over 4 years,
will be required to generate the necessary number of cardiovascular
events to answer this question. The TIME study is funded by the Brit-
ish Heart Foundation and we wanted to develop novel methods of
recruitment to maximise cost efficiency.
Methods
Prospective TIME participants are invited to visit a secure study website,
https://www.timestudy.co.uk/. All study procedures are conducted
Trials 2017, 18(Suppl 1):200 Page 223 of 235online. Several different methods were used to identify potential par-
ticipants including: letters sent from Primary and Secondary Care
(using the NHS-approved Docmail service), emails sent to partici-
pants in biobank projects, pharmacy searches and more traditional
advertising by poster and print media articles.
Results
21,415 participants throughout the UK were randomised between
the start of the initial pilot study in 2012 and November 2016. The
total cost of recruitment methods was £277,139. Primary care patient
identification (PIC) sites sending letters of invitation generated the
most participants (n = 16657). An arrangement with UK Biobank invit-
ing potential participants by email resulted in 3210 randomisations.
Recruitment strategies such as posters and media advertising had lit-
tle impact on recruitment despite relatively high costs.
Discussion
Successful recruitment to the TIME study was mainly due to a com-
bination of efficient study design with the use of IT to facilitate send-
ing high numbers of study invitations at low cost. It is hoped that
these methods can be used to streamline the recruitment process for
future studies.
Reference
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Methods of a large prospective, randomised, open-label, blinded end-
point study comparing morning versus evening dosing in hypertensive
patients: the Treatment In Morning versus Evening (TIME) study.
O90
Building comprehensive searches through a machine learning
approach for systematic reviews
Ileana Baldi1, Corrado Lanera1, Clara Minto1, Dario Gregori1,
Paola Berchialla2
1University of Padova; 2University of Torino
Correspondence: Ileana Baldi
Trials 2017, 18(Suppl 1):O90
Background
Systematic reviews of clinical trials are an important means of synthe-
sizing medical evidence. The validity of systematic reviews depends on
the ability to fully capture the complete body of evidence through
searches of many data sources. Nevertheless, examination of clinical tri-
als registry databases is not routinely included in systematic reviews
(Jones et al., 2014). A possible explanation is that all databases have
their own unique features and creating consistent search strategies
across literature and registry databases may be challenging.
Materials and Methods
The main idea is to use the title and abstract text fields of relevant
articles, identified by a literature search, for training purposes of a
machine learning algorithm. Next, the trained algorithm may be used
to identify documents with a comparable word characterization in a
registry database. A hypothetical research question concerning
nursing research is used to demonstrate the proof-of-concept. The
PubMed database was searched for articles published from 2006/01/
01 to 2016/11/01, tagged with Clinical trial Publication Type and
appearing in journals allocated to the Nursing subject area according
to the Journal Citation Reports®. To provide a training set with “posi-
tives” and “negatives”, we selected also a set of clinical trials run in
other research fields. The following text pre-processing procedures
were applied to the title and abstract fields of the retrieved records
in the following order: conversion to lowercase, removing numbers,
removing punctuation, removing stop-words, stemming words, strip-
ping white space, and building a sequence of two adjacent words
from the text (bigrams). The whole collection was finally tokenized in
a document-term matrix (DTM) which was used to train and test a
logitBoost MLT classifier (Dettling and Buhlmann, 2002). The classifier
was 10-fold cross-validated using 1,000 bootstrap iterations at each
step. Next we accessed records of all clinical trials registered in the
International Clinical Trials Registry Platform (ICTRP), established by
World Health Organization in 2006. After eliminating duplicates, the
same above mentioned text pre-processing strategy was applied tothe title and condition fields and the DTM was built. A prediction
task was then performed by applying the validated classifier to the
ICTRP DTM.
Results
In the PubMed training set, the sensitivity of the classifier was good
(81.2%) and the specificity was excellent (99.3%). When applied to the
ICTRP database it allowed to identify a set of protocols likely pertaining
to nursing research. We are currently organizing data and code in a R
software package which will be freely available on GitHub.
Conclusions
Routine examination of registry databases deserves further consider-
ation since it may allow a more accurate characterization of publica-
tion and outcome reporting biases and improve the validity of
systematic reviews. The approach described here provides an auto-
mated solution that can be tailored to address a variety of clinical
trial-related questions by building a comprehensive search on both
literature and registry databases.
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Background
Response review is a necessary stage in the verification of efficacy
endpoints in trials of multiple myeloma (MM) as it provides an indi-
cator of quality assurance. UK NCRI Myeloma XI is probably the lar-
gest randomised clinical trial in newly diagnosed patients with MM
conducted so far, with 4420 recruited patients. A large trial requires a
robust method of assessment of response and progression through-
out the patient pathway. As Myeloma XI requires response assess-
ment after completion of key treatment periods, and progression
monitoring throughout the protocol, a semi-automated verification
process is considered essential to ensure robust results and manage
resources efficiently.
Methods
Response and progression in MM were defined according to the Inter-
national Myeloma Working Group (IMWG) Criteria. Myeloma XI collected
local laboratory results alongside local response assessments, and for
consenting patients - equivalent data from an experienced central labora-
tory. All data was stored on bespoke trial databases which could be easily
imported into statistical software packages. We developed a suite of SAS
programs which apply the IMWG criteria to reported laboratory values
and verified local and central response and progression assessments, and
validated local and central assessments against each other. If assessments
were concordant, these were considered to be validated and required no
further review. If results were discordant, the patient file was selected for
review by a committee of clinicians.
Preparing the clinical review data involved collation of all local and
central results available. This was achieved using a suite of R and
Java programs to produce an MS Excel clinical review file for each
patient. The clinical review file contained derived and reported as-
sessments, as well as details of key assessment timepoints within the
study. The review files were sent to clinicians for review via a Secure
File Transfer System (SFTS). The reviewer considered available data to
determine the response/progression and for difficult and discordant
cases, a clinical committee meeting was convened to determine a
consensus or classification of the case as unable to determine (UTD),
or to request that more data be sought from site. When review was
completed the review file was returned via SFTS.
Results
At final analysis in July 2016, 3894 patients had undergone central
review. At this time 1848 subjects had demonstrated progression
Trials 2017, 18(Suppl 1):200 Page 224 of 235and 3795 had a response assessment. After computer-based verifica-
tion and validation of progression, 443 patients (24.0%) required sub-
sequent clinical review. A similar process for response resulted in 477
patients (12.6%) requiring clinical review. All remaining progressions
and responses were considered verified without the need for review
by clinician (83.7% of potential response and reviews). In clinician re-
view of progression a decision was reached in most cases with only
25 patients (5.6%) classified as UTD.
Conclusions
This semi-automated process of central review will increase confi-
dence in the robustness of reported results from Myeloma XI. This is
an efficient process which has saved man-hours for data manage-
ment and clinical reviewers. The software tools developed are being
further validated for use in data management and central review of
new trials of MM.
O92
Exploring and adjusting for potential learning effects in
ROLARR - a randomised controlled surgical trial
Neil Corrigan, Helen Marshall, Julia Brown
University of Leeds
Correspondence: Neil Corrigan
Trials 2017, 18(Suppl 1):O92
ROLARR is an international, randomised controlled, confirmatory
surgical trial designed to perform a rigorous comparison of robotic-
assisted surgery against standard laparoscopic surgery for the cura-
tive treatment of rectal cancer. At the beginning of trial recruitment,
the standard laparoscopic approach was already well-established,
with many centres and expert surgeons proficient in delivering the
intervention, whereas the robotic-assisted approach was relatively
new, with only several centres having an established track record of
delivering it. Proficiency in standard laparoscopic surgery coupled
with enthusiasm for, but relatively little experience with, robotic-
assisted surgery was a common trait of potential participating sur-
geons in ROLARR.
This situation is common in surgical trials and must be addressed
during the design and analysis, since a naïve comparison of out-
comes of patients who underwent a well-established technique in
which the operating surgeons were already proficient vs. patients
who underwent a new technique which operating surgeons were still
learning would be inappropriate. Ideally, comparisons between the
two interventions should be made when they are both being per-
formed optimally i.e. when surgeons are proficient in both. Tradition-
ally, this issue is addressed at the design stage by stipulating that
any participating surgeon in the trial must have some minimum level
of experience in each intervention before randomising any patients.
This was done in ROLARR, with inclusion criteria stipulating that par-
ticipating surgeons must have performed at least 30 rectal cancer
operations (with at least 10 using each intervention).
However, as alluded to by Cook, Ramsay & Fayers [1], this is only a
partial answer to the problem; in principle, statistical exploration of
any potential learning effects within a trial is required to more fully
address the issue. Following this guidance in ROLARR, data on the
number of robotic-assisted and standard laparoscopic rectal cancer
operations performed both within and outside of the trial was col-
lected periodically throughout the trial. At analysis, for every ROLARR
operation performed we had data about how many previous robotic-
assisted and standard laparoscopic rectal cancer operations the oper-
ating surgeon had performed. This allowed us to perform sensitivity
analyses exploring potential learning effects within the trial, in par-
ticular addressing the question of whether or not the estimated dif-
ference between the arms yielded by our primary analysis changed
depending on operating surgeon experience.
Collecting this data and performing these analyses allowed us to
quantify and adjust for the confounding effect that the difference in
proficiencies between the arms had on the primary analysis, which
was invaluable to our understanding and interpretation of the out-
comes that we observed in ROLARR. Details about the approachesused in ROLARR, the resulting learning effects analyses that were
performed and the impact that they had on our understanding of
the outcomes that we saw in trial will be presented. Time permit-
ting, the limitations of these particular analyses, including areas
where further work is required and recommendations for future trials,
will also be discussed.
Reference
[1] Cook JA, Ramsay CR, Fayers P. Statistical evaluation of learning curve
effects in surgical trials. Clinical Trials 2004; 1: 421–427.
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Background
Stratified medicine aims to identify patients most likely to respond to
treatment. However, individual trials are rarely powered to detect in-
teractions between treatment effects and participant characteristics.
Network meta-analysis (NMA) models potentially have greater power
to identify such treatment-covariate interactions, particularly when
individual participant data (IPD) are available. The Royston-Parmar
model, fitted in a Bayesian framework using WinBUGS, provides a
practical and flexible approach for IPD NMA of time-to-event data.
Pairwise IPD meta-analysis of treatment-covariate interactions contains
so-called “within-trial” and “across-trial” information, where across-trial
information is particularly susceptible to confounding and ecological
bias. The same is true of IPD NMA; therefore it is important that the
within- and across-trial information are reviewed separately, before de-
ciding whether to combine them. A further frequent complication is
missing patient-level covariate data. We show that using a Bayesian
framework for IPD NMA allows this to be handled relatively easily.
Methods
Our motivating data come from a network of IPD from 37 trials com-
paring combinations of radiotherapy, chemotherapy and surgery
from 5922 patients with cervical cancer (2394 events), where age
and disease stage are two potential interaction covariates. We show
how the Royston-Parmar NMA model can be fitted using restricted
cubic splines, and then extend it to include treatment-covariate inter-
actions. We propose two models: (i) two effects separating out the
within- and across-trial information and (ii) a single interaction effect
(combining within- and across-trial information). We argue for a vis-
ual assessment of the consistency of the within- and across-trial in-
formation. We also discuss more detailed aspects of meta-analysis
interaction modelling, such as common vs trial-specific main effects
of the covariate, and suitable approaches for handling missing covar-
iate data. This leads us to propose a practical framework for IPD
NMA with treatment-covariate interactions.
Results
The cervical cancer network showed no evidence of a treatment-age
interaction, but there was some evidence for a treatment-stage inter-
action. A visual assessment highlighted inconsistency between the
within- and across-trial information. Following our proposed framework,
the within- and across-trial information should not be combined. The
remaining within-trial evidence for a treatment-stage interaction is weak;
most evidence for an interaction is across-trial, with the NMA providing
additional power for this over and above the pairwise evidence.
Conclusion
A Bayesian approach for NMA using the Royston-Parmar model with
splines naturally handles missing covariate data and allows the separ-
ation of within- and across-trial treatment-covariate interaction infor-
mation. Our proposed framework, incorporating this model, provides
practical guidance for researchers, and reduces the risk of unduly
optimistic interpretation of treatment-covariate interactions.
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Background
The Clinical Trials Transformation Initiative (CTTI), a public-private
partnership established by the FDA and Duke University, is interested
in assessing whether an Early Enrollment (EE) strategy can improve
enrollment rates for HABP/VABP clinical trials. Using this proposed
strategy, patients at high risk for developing HABP or VABP, or their
legally-authorized representatives (LARs), would be asked to give
their consent to enroll in a trial before the patient develops symp-
toms of pneumonia. Patients would agree to being monitored by
study staff, and if pneumonia develops, to being randomized to
receive the study antibiotics. We conducted formative research to as-
sess the acceptability of and preferences for components (e.g., opt-
out process) of an EE strategy for a HABP/VABP clinical trial among
key stakeholders.
Methods
We conducted 52 qualitative, in-depth interviews with patients at risk
for HABP/VABP (n = 18), caregivers/LARs (n = 12), members of Institu-
tional Review Boards (IRBs) (n = 10), investigators (n = 7), and study
coordinators (n = 5). We provided stakeholders with an overview of
the proposed EE study prior to questions on acceptability and prefer-
ences. We also explored the acceptability of two treatment designs:
randomization to 1) one of two FDA-approved antibiotics commonly
used in hospitals to treat pneumonia (one approved for lower re-
spiratory infections and the other for serious infections other than
pneumonia), and 2) a new, investigational antibiotic (not FDA-
approved) compared to a standard-of-care antibiotic. We used ap-
plied thematic analysis to analyze the data.
Results
None of the patients or caregivers/LARs expressed concern about study
staff accessing patients’ medical records to monitor for infection. Nearly
all patients (88%) believed they could understand the study and give
consent, even though they would not have pneumonia at the time of
enrollment. While appreciated by many (56%), some patients (44%)
said they may experience anxiety after being informed they are at risk
for pneumonia. None of the IRB members raised concerns regarding
the EE strategy, although suggestions were made about information to
include in the study protocol. Most investigators and coordinators
(83%) believed the EE strategy would improve recruitment. Half of IRB
members believed an opt-out process was necessary and sufficient,
while 40% believed it was unnecessary because initial consent was pro-
vided and participants can always withdraw from research at any time.
Most patients (65%) favored an active opt-out process at the time of
randomization. Stakeholders’ views were mixed on the LAR’s role in the
opt-out process when patients provide initial consent but later become
unable to opt out. While patients and caregivers/LARs did not perceive
any physical risks from enrolling early, perceived risks were associated
with treatment: using two FDA-approved antibiotics was viewed as low
risk, whereas the “unknown” aspects of a new investigational treatment
generally heightened risk perceptions. As a result, most patients
(67%) and caregivers/LARs (67%) were willing to enroll in a trial
with FDA-approved antibiotics but were far less willing to partici-
pate if an investigational antibiotic would be used (patients = 28%,
caregivers/LARs = 25%).Conclusions
The EE strategy was overwhelmingly accepted by stakeholders. Spon-
sors should evaluate whether this strategy improves enrollment rates
in prospective HABP/VABP clinical trials.
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Clinical trials of behavioural and psychological interventions often in-
volve therapists or other clinical specialists. This adds further com-
plexity to the trial design and leads to considerations relating to
clustering effects (i.e. intra-cluster correlation, cluster size), random-
isation, contamination, and the impact on analysis. In individually-
randomised controlled trials (RCTs) the involvement of more than
one therapist per site can introduce selection bias, whereby thera-
pists can choose which participants they treat. If therapist selection is
based on participants characteristics, for example with the “best”
treating the “worst”, the effects of therapists and participant charac-
teristics may be confounded. This limits the inferences a trial is able
to make, particularly if the therapist effect is of interest in its own
right. It also reduces the ability to attribute treatment effects to treat-
ment alone, thus impacting a trial’s internal validity. To reduce the
overall sample size required, and avoid problems fitting analysis
models, trialists may also wish to ensure similar cluster sizes. To avoid
this source of selection bias, allocation of therapists to participants
can be concealed and random. However, doing so under constraints
of therapist capacity, location, and a trial’s relative priorities can be
problematic. The success of therapist involvement and implications
on randomisation can be further influenced by the context in which
they work (e.g. involvement of ‘research’ therapists or those working
within the NHS).
We summarise our experience of randomly allocating therapists in
three clinical trials with different designs: (i) SHIFT, an NIHR HTA-funded
phase III definitive RCT set in NHS Child and Adolescent Mental Health
Services (CAMHS), had teams of Family Therapists (employed for the re-
search) working together to deliver therapy across services. Where
teams worked across a number of services, the lead therapist was
randomised, otherwise participants were assigned to the single lead
therapist for a particular service. (ii) TIGA-CUB, an NIHR RfPB-funded
feasibility RCT, similarly set in CAMHS, has greater constraints on ther-
apist capacity. Trial therapy is provided ‘within’ therapists NHS role, with
variable numbers of therapists per service, and complications for ther-
apist allocation to primary carer as well as child participants. (iii) OK-
Diabetes, an NIHR HTA-funded feasibility RCT recruited community-
based participants with diabetes and a learning disability. Diabetes
nurse specialists were allocated to participants based on prior contact
to ensure consistency in contact and nurse randomisation occurred
where there had been no prior contact.
Challenges have included the practicality of randomising therapists
within a restricted service, therapist capacity following variable re-
cruitment rates, impact on recruitment, waiting lists, and deviations
from the allocated therapist. Randomising therapists also has poten-
tial implications for the intention-to-treat principle, where partici-
pants are analysed as allocated, with consideration required as to
how to analyse according to therapist.
The context in which therapists work, their capacity and the needs of
the trial population all influence the feasibility and appropriateness of
randomising therapists. We will discuss the methodological benefits of
including therapist randomisation and the implementation challenges
this introduces, providing guidance on when it is appropriate and how
to ensure it ‘works’ for therapists, participants and trial delivery.
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Background
To successfully execute clinical trials the study operations team must
have an appreciation of the capabilities of the clinical sites. This is
particularly vital in developing countries where necessary infrastruc-
ture, availability of qualified staff and proper facilities are often scar-
cer than in wealthier nations. The AIDS Malignancy Consortium
(AMC) is a National Cancer Institute supported multicenter clinical tri-
als group founded in 1995 to support innovative trials for AIDS-
related cancers. In 2010 the AMC was tasked with expanding opera-
tions internationally in sub-Saharan African countries with a high
prevalence of HIV, with the goal of identifying and engaging a core
group clinical sites that were capable of conducting contextually ap-
propriate therapeutic and prevention trials in a variety of HIV-
associated cancers and contributing to the AMC’s scientific agenda.
Methods
In response to this new initiative, the AMC developed a two-tiered
strategy to select international sites. This began by soliciting applica-
tions from 14 sites in which a member of the site staff had a pre-
existing relationship with an AMC investigator, and systematically
gathering written information about their resources, clinical research
experience and active collaborations with other clinical trials organi-
zations. After review of these data, the nine top-ranked sites partici-
pated in a structured data collection exercise that involved collection
of disease-specific patient information about three AIDS-related can-
cers, auditing that data, and conducting site visits. Each site visit
team included an oncologist and a representative from the AMC Op-
erations and Data Management Center (ODMC) and evaluators filled
out a site visit worksheet at the end of each visit.
Results
The information gathered from the sites provided insight into the identifi-
cation, diagnosis, and treatment of patients at each of the sites. However,
it was the on-site visits that proved most valuable in assessing suitability
for participation in AMC trials. Based on the site visit evaluations the four
top sites (in Zimbabwe, Uganda, Kenya, and South Africa) were selected
for participation. Lessons learned from the implementation of the process
allowed the ODMC to improve site selection methods by standardizing
the site visit worksheets, and asking more targeted questions that better
identified particular issues that were critical to study conduct. These
changes streamlined the process and allowed for better comparison of
the sites in the next round of site selection that occurred in 2014–5, dur-
ing which three additional sites were selected.
Conclusions
The AMC has developed a detailed and methodical process for
selecting international sites that have the clinical research infrastruc-
ture, data management operations and the human and material re-
source capacity required to successfully participate in clinical trials in
HIV-associated malignancies. In our experience, the most essential
and valuable part of that process is the on-site visits, which have
been successful in vetting research sites that would be able to pro-
vide high quality data and contribute to AMC’s mission of investigat-
ing new treatment and prevention interventions of malignancies in
people living with HIV both in the USA and internationally. Strategies
for maximizing the value of these visits and collection of material
from the visits will be discussed.
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It is common for randomized controlled trials (RCTs) to have some
missing outcomes. Yet recent reviews indicate that some authors
analyze using only available outcome data (sometimes called a
complete records analysis) without explicitly addressing the nature of
the missingness. In most cases, this will lead to bias due to selection of
a non-representative population. This can throw in to doubt the evi-
dence generated from the trial. However, when proper adjustments are
made, a complete records approach can provide valid inference under
certain conditions. Yet, there are misconceptions and difficulties in de-
termining when such an approach is valid.
Background
There is a growing literature in the field of causal inference that fo-
cuses on the use of causal diagrams to determine when bias might
arise in estimating a causal relationship of interest. Recent work by
Daniel et al. (SMMR 21(3); 2011) used this approach to guide analyses
with missing data. In the current talk, we adapt their approach to be
specifically applicable to the RCT setting. Our goal is to provide a
strategy to determine when a complete records analysis will be un-
biased and therefore to determine when alternative methods (e.g.
imputation or weighting) are required in order to avoid biased esti-
mation of the intervention effect.
Methods
We consider three outcome-generating models where the outcome
(Y) is dependent on: (1) the treatment arm (A) only, (2) on both treat-
ment arm and a predictive baseline covariate (X) through an additive
relationship, and, (3) additionally dependent on the interaction of A
and X so that there is treatment heterogeneity by levels of the pre-
dictive covariate X. For each of these three outcome-generating
models, we consider a range of common missing outcome mecha-
nisms including: missing completely at random (MCAR), missing at
random (MAR), including covariate dependent missingness (CDM), as
well as specific examples of missing not at random (MNAR) mecha-
nisms. Specifically, we consider the following missing data mecha-
nisms, where the probability of an outcome being missing is
dependent: (1) on neither A nor X (MCAR), (2) on treatment arm only,
(3) on X only, (4) on A and X additively, (5) additionally on an inter-
action between A and X so that there is differential missingness by
treatment arm (all examples of CDM), (6) on observed levels of the
outcome (MAR), and, (7) on unobserved levels of the outcome
(MNAR).
Results and conclusion
We show that in order to determine when a complete records ana-
lysis is valid it is as important to focus on the form of the outcome
data-generating model as well as the missing data mechanism. By
providing an easily implementable strategy with simple rules, we
seek to aid a broad audience to understand when analysis of only
available RCT data will be sufficient to address the causal research
question of interest without the need for the sometimes complex im-
putation and weighting methods that are commonly used to address
missing outcome data.
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Background
Conventional dose-finding approaches in oncology of phase I trials aim
to identify the maximum tolerated dose (MTD), based on toxicity events
observed during the first treatment cycle. Even though this is relevant for
cytotoxic agents, this may not be the case for molecularly targeted
agents, usually administered in chronic schedules. Lately, continuous
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efficacy does not necessarily increase monotonically with dose and
as corollary both toxicity and efficacy should be considered for the
identification of the optimal dose. The optimal dose will be defined
as the lowest dose that achieves high efficacy, while satisfying cer-
tain toxicity requirements.
Methods
We present an adaptive dose-finding method, using a joint model-
ling technique (Barrett J. et al., 2015) of a longitudinal outcome for
continuous biomarker efficacy measurements and a probit time to
first severe toxicity model, with shared random time slope. This
method allows for exact likelihood inference, an important property,
in the context of both missing at random due to low efficacy or in-
creased toxicity and the case of small sample sizes. We combined
this technique with the continual reassessment method, and used
data collected over all treatment cycles. The selection of the dose at
the entry of every new patient was based on the trade-off algorithm,
proposed by Thall and Cook (2004), adapted to the situation of con-
tinuous efficacy measures. For the evaluation of the method we run
a set of simulations for two scenarios. Dose and time were included
in both models, with the addition of dose-time interaction for the
longitudinal outcome. We considered up to 9 dose levels, 3 treat-
ment cycles, a maximum of 12 visits for the efficacy measurement
and 66 patients.
Results
In the first scenario the optimal dose was the first one and the MTD
the second. The optimal dose was chosen at 85.6% of the cases, and
another 12.8% was assigned to the MTD. For the second scenario,
we assumed the fourth dose to be the optimal and the fifth to be
the MTD. The optimal dose was suggested for 32.3% of the cases,
while the MTD for 17.3% of them. At no point was the last dose level
recommended. Our design performs very well when the optimal
dose is at the edge of the dose range. This is because the desirability
of certain doses around the optimal dose and MTD tends to be very
close to one another. Even though this may be an issue when the
optimal dose is located at the middle of the dose range, it is also the
reason patients are very rarely allocated to doses far from the
optimal dose. Finally, the method had interesting behavior regarding
its ability to select the right dose in presence of missing data due to
severe toxicity.
Discussion
In the future, we would like to test more scenarios and to evaluate
more flexible models for dose-response relationship, providing the
number of parameters to estimate remains in line with the sample size.
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Background
Pragmatic trials often rely on pre-existing data systems to evaluate
trial outcomes. HPTN 065 used US HIV Surveillance data to evaluate
the outcomes of a clinic-randomized strategy trial to test the use of
financial incentives to improve viral load suppression outcomes in
the Bronx NY and Washington DC.
Methods
In a collaborative effort between study and surveillance staff, aggregate
clinic outcomes were defined using variables available in surveillance
data and aligned with the financial incentive intervention. Outcomes
were centrally programmed by surveillance experts for evaluation using
local surveillance databases. Pre-trial data on trial outcomes were used
to conduct a restricted randomization of the 38 trial clinics, with the
goal of achieving balance in pre-trial viral load suppression and numberof patients per clinic. During the trial, triangulation of data from the
clinics, surveillance and the financial incentive delivery was used to as-
sess data completeness. Sensitivity analysis and multiple imputation
were subsequently used to evaluate 1) randomization balance based
on incomplete pre-trial data in the restricted randomization; 2) the im-
pact of incompleteness in baseline data on efficacy evaluation and 3)
the sensitivity of the trial results to sites with missing data during the
primary evaluation period.
Results
Data triangulation throughout the trial revealed missing data in sur-
veillance for some clinics in Washington DC. Evaluation of data in-
consistencies and investigation into the causes of incompleteness,
together with extensive collaboration with HIV surveillance staff,
were largely successful in remediating the missing data for the trial
evaluation period. Some baseline data could not be corrected due to
lost access to data. During initial trial evaluation of effectiveness, ex-
ploratory data analysis of time trends revealed a small number of
clinics with more subtle data incompleteness issues, complicating
the evaluation of the effectiveness of financial incentives. Increased
imbalance on the restricted factors was observed using corrected
data compared to the pre-trial data. Missing data in the baseline out-
come assessment decreased the precision of efficacy estimates, with
a 57% higher SE of the efficacy estimate in DC vs. NY. Trial efficacy
results were sensitive to the effect of missing data, with the initial
analysis of effectiveness of financial incentives showing an increase
in viral load suppression of 3.9% (−3.4%, 11.1%; p = 0.27), changing
to 3.7% (0.5, 6.9%) p = 0.022 after data completeness was addressed
in Washington DC HIV surveillance.
Conclusion
Program assessments that utilize external data sources to evaluate
outcomes need to conduct ongoing exploratory data analysis to
understand and monitor data quality and completeness during the
trial as trial results and study power will be affected by problems in
the data source. Close collaboration with data source experts is crit-
ical to assure quality and completeness of outcome data.
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Up-and-Down (U&D) is an established dose-finding approach used
in many fields, yet all but forgotten by the Phase I design commu-
nity. With respect to finding Phase I’s Maximum Tolerated Dose
(MTD), when used with an appropriate estimation method U&D is
on par with more complicated state-of-the-art designs, and its over-
all behavior is more tractable and stable (Oron and Hoff, 2013).
However, unlike some novel methods U&D cannot “sharpen” its
dose-allocation random walk over time.
We present an enhancement to U&D, one that gradually limits dose
allocations to within a tolerance interval around the MTD, using
Sequential Probability Ratio Test (SPRT) decision rules. The interval
boundaries can be rendered “soft” or “hard”, via SPRT decisions that
are reversible or not, respectively. With some limitations, SPRT-
enhanced U&D converges almost surely to a random walk confined
inside the tolerance interval. An asymmetric “soft/hard” rule com-
bination is possible, and is rather suitable for toxicity studies such
as Phase I.
SPRT-enhanced U&D generates treatment distributions more sharply
peaked around the MTD than ordinary U&D, and with fewer toxicities
on average. Despite the added complication, it is still simpler, more
robust, and more tractable than most leading novel designs, thus
presenting a highly attractive design choice for Phase I trials. The
development and use of SPRT-enhanced U&D for several ongoing
Phase I immunotherapy trials at Seattle Children’s Ben Towne Center
is described.
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Background
Since 2008 U.S. federal law requires the submission of summary results
to, and public posting on, ClinicalTrials.gov for certain clinical trials of
FDA-regulated drugs, biologics and devices. We aimed to determine
ways in which reporting to ClinicalTrials.gov has expanded the public
availability and use of clinical trial information. Specifically, we assessed
the extent to which ClinicalTrials.gov has improved the reporting of
“full sets” of trials for specific drug products (aim 1). We also examined
how researchers have used ClinicalTrials.gov data (aim 2).
Methods
For aim 1, we examined ClinicalTrials.gov records for phase 2–4 clin-
ical trials of drugs or biologicals with at least one U.S. study location,
completed or terminated between 2007–2009, and funded by indus-
try. We grouped trials into a “drug trial family” when the drug, condi-
tion, and sponsor appeared to be the same across trials. We limited
our analysis to a convenience sample of the first 96 drug trial families
identified. For each trial, we assessed the presence of results posted
on ClinicalTrials.gov and publications cited in PubMed as of June
2015. For aim 2, we searched PubMed to identify publications in Eng-
lish between 2010–2015 that conducted original research using data
retrieved from the ClinicalTrials.gov registry and/or results database.
Authors manually reviewed eligible publications to categorize how
ClinicalTrials.gov data were used in the study.
Results
For aim 1, our sample of 96 drug trial families included 329 trials,
studying 86 drugs for 78 conditions by 45 companies. Of the 329 tri-
als, 109 (33%) had results posted on ClinicalTrials.gov only, 42 (13%)
in PubMed only, 81 (25%) in both, and 97 (29%) in neither. Of the 96
drug trial families, 45 families had results disclosed in at least one
source for all trials. Of these 45 families, 15 families had results dis-
closed only in ClinicalTrials.gov. For 18 drug trial families with a total
of 48 trials, no results were available from any source.
For aim 2, we identified 404 research articles and 1,588 systematic re-
views published between 2010–2015 that used data from the Clini-
calTrials.gov registry, results database, or both. We categorized each
research article into: characterization of clinical research for specific
conditions (48%); research on ethics, adverse event reporting, and
data mining (15%); quality of registered data and consistency with
reporting policies (10%); characterization of the overall clinical re-
search landscape (10%); evaluating publication bias or selective
reporting (9%); and assessing specific research-related methods and
issues (7%).
Conclusion
We found that results for 33% of sampled clinical trials were available
only on ClinicalTrials.gov, suggesting the database may be a useful
resource to identify clinical trial results that would not otherwise be
publically available for specific drug products. Although there were
still gaps in the public availability of trial results, the existence of the
trials is publicly known because of the registry entries. ClinicalTrials.
gov data is increasingly being used to assess a broad range of
research questions, many of which would have been difficult or
impossible to address using published literature alone.O102
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Objectives
In 2016–2017, the National Institute of Neurological Disorders and
Stroke (NINDS), NIH, and their partners have put forth new data stan-
dards recommendations for the following diseases: (1) Cerebral Palsy;
(2) Chiari I Malformation; (3) Headache, Version 2.0; (4) Sport Concus-
sion; and (5) Subarachnoid Hemorrhage. The partners in develop-
ment of these common data element (CDE) recommendations are
the American Academy for Cerebral Palsy and Developmental Medi-
cine, the Chiari & Syringomyelia Foundation, the Department of
Defense, and the National Library of Medicine. Goals of the overall
project include reducing study start-up time; increasing the efficiency
and effectiveness of clinical research studies and treatment; and in-
creasing data quality and data sharing across studies.
Background
CDEs were developed for 18 neurological disease areas prior to these
five newly developed areas. There are over 11,000 CDEs in the NINDS
library and over 600 validated instruments, Case Report Forms (CRFs),
and study recommendations. The CDE initiatives strive to identify
CDEs, template study forms, data dictionaries and guidelines to assist
investigators who are initiating and conducting related clinical stud-
ies. Use of standardized CDEs is critical to ensure that data housed
within a database are of better quality; improve data sharing and
meta-analyses; and help educate new clinical investigators.
Methods
Each new disease CDE working group (WG), consisting of 40–60
worldwide experts with varied fields of related expertise, met regu-
larly to select from existing CDEs or refine and add from field-
tested data elements from national registries and funded research
studies. For most diseases, these WG members are divided into sub-
groups applicable for each disease based on domains (e.g., Imaging,
Demographics, Treatment/Interventions, Biomarkers). For Sport Concus-
sion, subgroups are based on disease characteristics; Acute, Sub-Acute
and Persistent/Chronic. All WGs began by reviewing CDEs previously
developed for different diseases, conditions and symptoms to avoid
unnecessary duplication. After the subgroup recommendations are
completed, there is an internal review followed by public review in
which time the recommendations are posted on the NINDS CDE
Website for 1–2 months.
Results
All comments are collated and incorporated into the final CDE version
release on the NINDS CDE website. The website provides uniform
names and structures for each data element, as well as guidance docu-
ments and template CRFs using the CDEs. WGs are also given the
charge to classify the recommended CDEs as “Core, Supplemental-
Highly Recommended, Supplemental or Exploratory” according to set
definitions from the NINDS CDE project.
Conclusion
Researchers who receive funding from NINDS are encouraged to
use the CDEs in their CRFs and data management systems when-
ever possible. To date, the feedback has included the CDE project’s
impact on reducing study start-up time. Continued feedback is
essential. The NINDS CDEs are a continually evolving resource, re-
quiring updates as research advancements indicate. These newly
Trials 2017, 18(Suppl 1):200 Page 229 of 235developed CDEs serve to be a valuable starting point or update for
many neurological disease researchers and facilitate harmonization,
streamlining and sharing of data.
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Background
Electronic health records (EHRs), available for every patient who visits
the UK NHS, are primarily used to inform the care of patients. They
contain clinical information about primary and secondary care and
treatments provided. Current literature suggests that EHRs can be
used to inform the design and analysis of clinical trials, subject to ap-
propriate data protection and governance, with potential to be more
efficient in terms of costs and data return. Research funders are keen
for trials to consider the use of routine data sources, where possible.
Here we describe our progress with accessing EHRs and other elec-
tronic data sources to support our research that crosses primary and
secondary care. Methods: The National Institute for Health Research
(NIHR) ISCOMAT Programme (Improving the safety and continuity of
medicines management at care transitions) aims to design and
evaluate an intervention to make best use of medicines and reduce
harm through effective medicines management for heart failure (HF)
patients following hospital discharge and across the primary care
transition. It is a series of interlinked projects, culminating in a defini-
tive cluster randomised controlled trial of 2,100 HF patients from 42
NHS Trusts in 3 UK regions. The primary endpoint is all-cause mortal-
ity and HF related hospitalisations from hospital discharge. Key sec-
ondary endpoints are medications prescribed post discharge. The
majority of these data are held in the EHR.
A data linkage project is in progress to determine the feasibility of
the EHRs to obtain the data for the definitive trial. We will recruit 60
HF patients, who will provide written informed consent to access
their EHR data from multiple data providers. The output will be (1)
robust data linkage algorithm; (2) processes to access data for use in
the definitive trial.
Current progress
We have recruited 43 patients and actively engaged with five data
providers: National Institute for Cardiovascular Outcomes Research
(NICOR) for national HF audit data; SystmOne & EMIS clinical systems
for primary care data; NHS Digital for secondary care and mortality
data and Community pharmacy/NHS Business Authority for dispens-
ing and prescribing data.
Discussion
We will describe progress with accessing data and our approach to
developing a data linkage pipeline. This includes: Mapping contact
points where decisions are made about medicines management and
identifying data providers at each contact; Mapping data fields from
each provider with primary and key secondary endpoints; Identifying
process to allow access to the data from the patient and from the
data provider; Establishing robust processes to allow for the data to
flow from the provider to the research team, including multiple data
sharing agreements; Familiarisation with data sources through access
to dummy data sets; Implementing governance requirements and
submitting requests for data.
We will describe challenges, variations in processes across data
sources; the impact on establishing the data linkage pipeline and
how this knowledge will streamline processes for the definitive trial.The use of EHRs is becoming more established with trials, thus we
provide recommendations for trialists seeking to access EHR across
different health care providers.
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Background
Trial-specific training provided during the start-up phase of studies has
not been thoroughly investigated. In fact, little attention has been
given to the role and structure of trial-specific training and how best to
organise and implement it to ensure in-depth understanding of the
trial protocol and trial-related procedures by trial staff.
Aims
To investigate the ways in which trial-specific training is provided
during site initiation and explore trial managers; and site staff views
on the importance of trial-specific training during study conduct.
Moreover, ATLAS aimed to evaluate the process of trial-specific train-
ing and make recommendations for improving the educational sup-
port provided to site staff during the site start-up process.
Methods
Six studies were purposefully selected to serve as case studies for
the ATLAS study. Within each case study, trial managers (n = 6) fa-
cilitating trial-specific training sessions as well as healthcare profes-
sionals (principal investigators and research nurses, n = 13) from
trial sites receiving the training, were interviewed between June
2015 and April 2016. Semi-structured face-to-face and telephone in-
terviews were conducted using a topic guide. Interviews were
audio-taped, transcribed verbatim and analysed thematically using
NVivo. Non-participant observations of trial-specific training ses-
sions (n = 13) as well as questionnaires completed by trial managers
and site staff (n = 120) were also used to gain an overview of site
staff and facilitators’ experience.
Results
A variety of training modes (face-to-face, teleconference, online)
were used to deliver training across the six case studies. However,
face-to-face interaction was considered most beneficial in facilitating
learning and enhancing personal relationship building and network-
ing. Despite acknowledging the significance of the decision-making
process in selecting the appropriate level and mode of training re-
quired, this process was often overlooked at the early planning
stages of trials and was usually poorly documented. Although evalu-
ation of site initiation training to identify key areas where follow-up
training might be required and improve future training sessions was
considered best practice, it was not routinely conducted. The pur-
pose of site initiations slightly differed between trial managers and
site staff. Trial managers’ focus was to check that everything was in
place at the site and that staff were aware of their roles and respon-
sibilities in the trial, whereas, site staff viewed site initiations as the
best time to meet and connect with the trial team. Additional train-
ing and support provided to site staff over the course of the trial was
considered of paramount importance in ensuring trial’s successful
conduct. However, this was mainly provided retroactively on an ad-
hoc basis.
Conclusions
There is high variation and uncertainty on the ideal ways to provide
trial-specific training to facilitate trial conduct. Based on the findings
of the ATLAS study, a more standardised approach in the form of a
Trials 2017, 18(Suppl 1):200 Page 230 of 235training toolkit was developed. The ATLAS training toolkit aims to
bring together information from the current literature, regulations
and various stakeholders’ views to advance the trial-specific training
process.
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Background
The REACT study (https://www.reacttoolkit.co.uk/) is an online study
to compare the effectiveness of a Relatives Education And Coping
Toolkit (REACT) with an online Resource Directory. Half the people in
the study receive the REACT toolkit, and half will receive the Re-
source Directory. In this study the intervention and data collected
from the participants is provided via the Internet, with little or no dir-
ect interaction with the study team. This study opened in April 2016
and recruitment will close in early 2018. The REACT study comprises
two disparate systems, the first being a bespoke data collection sys-
tem that manages the eligibility/consent/registration/data collection
processes, whilst the second system is a customised version of Word-
Press that is used to deliver both arms of the intervention.
Participants within this study do not attend regular clinical appoint-
ments. As such retention at the two follow-up points and usage of
the intervention requires automated reminders and more importantly
the triggering of warnings/help to participants when they provide
certain answers to specific questions.
The data required to determine the effectiveness of the intervention
is taken from two sources: The response by the participants to out-
come measures and data collected on the usage of the application
(obtained from google analytics, server logs and custom reporting
software).
Objective
This presentation will discuss the electronic solutions required by the
design of the study and the processes by which these systems were
designed and implemented. A comparison of the data collected via
google analytics and the server logs will be compared and commen-
ted on, with a discussion about discrepancies being made.
Conclusions
Online interventions and data collection systems provide great prom-
ise for efficient trial design however, there are challenges to ensure
that systems are user friendly and intuitive to use, yet still allow the
collection of data to validate the outcome of the study.
The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health.
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Background
Bias has long been recognised as an issue that can seriously com-
promise the validity of study trial results. Assessing bias from trial
reports is often not easy. The Cochrane risk of bias tool is well estab-
lished tool for facilitating this. This tool has recently been updated
and as part of the new tool there is a specific adaptation for clusterrandomised trials which takes account of the design of these trials
and specific issues for assessing bias in these trials.
Aim
The aim of the tool is to support reviewers of trial reports to assess
bias in cluster randomised trials. In this talk we describe the aspects
of bias which are particular to cluster randomised trials or operate
differently in these trials from the way they operate in individually
randomised trials.
Methods
A multi-disciplinary group of researchers including statisticians, other
triallists, those leading the development of the new Cochrane risk of
bias tool and experts in cluster randomised trials met over a period
of a year to discuss the five different bias domains (bias arising from
the randomization process, bias due to deviations from intended in-
terventions, bias due to missing outcome data, bias in measurement
of the outcome, bias in selection of the reported result) that are part
of the new Cochrane risk of bias tool and how they relate to bias in
cluster randomised trials.
Results
Given the extent of the differences between assessing risk of bias
in individually randomised trials and in cluster randomised trials,
the group developed an adapted Cochrane risk of bias tool for clus-
ter randomised trials. Differences occur in relation to assessing
allocation concealment; appropriate assessment of bias in relation
to blinding of participants and assessors; and ensuring missing clus-
ters are considered in addition to missing values from participants.
We also added an additional domain (bias arising from the timing
of identification and recruitment of individual participants in rela-
tion to timing of randomization) to cover the bias that may occur
when individual participants in a cluster randomised trial are re-
cruited after randomisation.
Conclusions
Assessing bias in cluster randomised trials is not the same as asses-
sing bias in individually randomised trials. Authors and peer re-
viewers should be aware of key elements to include in trial reports
to provide evidence that their trials are protected from bias. System-
atic reviewers should use the Cochrane risk of bias tool adapted for
cluster randomised trials to assess these trials for bias.
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Traditional phase I oncology clinical trial designs have morphed into
multiple, parallel phase I trials incorporating concurrent expansion
cohorts across multiple diseases or disease subtypes. These cohorts
are used to provide additional safety data, as well as preliminary effi-
cacy data. As a result, some of them have become quite large. For
example, a recent study [Cancer Letter, Oct 7, 2016] looked at PD-1
drug development, and identified 35 phase I trials with 200 patients.
In such trials, dose escalation is typically done using a standard
phase I design, e.g. “3 + 3”, to determine the maximum tolerated
dose (MTD), which is followed by the enrollment of multiple expan-
sion cohorts in different disease types or biomarker-defined sub-
groups. Safety is typically monitored only within each expansion
cohort, and the results are not jointly evaluated in real time across
the multiple expansion cohorts.
Here we propose to use a continuous safety monitoring approach
based on the sequential generalized likelihood ratio test (SGLR) and
discuss its application to adverse event (AE) monitoring for such
large phase I trials with multiple concurrent expansion cohorts. This
approach is commonly used in vaccine studies [Shih et al.; Statistics
in Medicine, 2009] to monitor rare events, and can be similarly used
in phase I clinical trials to monitor the frequency of rarer high-grade
or serious adverse events (SAEs), as well as to further evaluate
whether the presumed MTD is near the targeted percentile. Trial
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monitoring boundary with a rejection number for each additional AE,
while preserving the overall Type I and Type II error rates for the
assumed AE rates. The boundaries can be calculated using existing
software.
We consider two different implementations of the SGLR procedure:
the first employs an overall monitoring rule based on pooled data
across the multiple cohorts; the second monitors each cohort separ-
ately, allowing for dose reduction in a given cohort if the boundary
is exceeded. We simulate data using multiple expansion cohorts with
different Poisson rates of AE’s, and evaluate the operating character-
istics of these SGLR procedures.
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Background
Clinical trials in oncology use disease-free survival (DFS) or progression-
free survival (PFS) as study endpoints. DFS and PFS are composite
endpoints of disease status and overall survival. The tumor status is typ-
ically measured by a computerized tomography (CT) scan which can be
done every few months and the scan interval is typically determined
by the treatment guideline. For example, DFS and PFS are common
endpoints used in stage 3 colon cancer study and stage 4 colorectal
cancer study, respectively. In stage 3 colon cancer, the CT scan interval
used to be every 3 months and was extended to every 6 months. Re-
cently, 12-month intervals between CT scans was proposed to reduce
unnecessary radiation exposure. In stage 4 coloretal cancer, the typical
CT scan interval is every 8–12 weeks due to the aggressive nature of
the late stage disease. In clinical trials, if disease recurs or progresses,
the event date is the date of the CT scan. As the interval length be-
tween each assessment gets longer, we lose more precision regarding
the actual event time and increase the potential bias as well. In this
study, we examine how much information is lost due to interval-
censoring, in particular, the number of events required to recover the
loss of power.
Methods
A numerical approximation of the exact distribution function for the
hazard ratio (HR) sample statistic was used to assess the effect of
interval censoring and determine the actual number of events
needed to attain a given power. Monte-Carlo simulation was used to
examine the extent of power loss using typical assumptions for stage
3 and 4 colorectal cancer trial design.
Results
For stage 3 colon cancer, assuming an exponential distribution with
a 3-year DFS rate of 75% in the control arm and 84% in experimental
arm (HR = 0.6), we found that 170 events are required to power the
study with a one-sided alpha = 0.025 and beta = 0.1. If the patients
received a scan every 3 months or 6 months, the study power is
maintained. If scan frequency decreases to every 12 months, 2 add-
itional events are required to maintain the study power. For stage 4
colorectal cancer, assuming the exponential distribution with median
PFS equal to 2 months for the control arm and 4 months for the
experimental arm (HR = 0.5), 90 events are required to provide 90%
power with one-sided alpha = 0.25. For scan frequency of every
1 month, 6 additional events are required to maintain the study
power. For scan frequency of every 2 and 3 months, which are stand-
ard of care, 14 and 26 additional events are required to maintain the
study power.
Conclusions
A sparse CT scan frequency can affect the study power requiring
additional events to maintain the study power. The loss of powercan be quantified using a numerical approximation of the underlying
distribution function. The effect of interval-censoring on accuracy of
the time-to-event estimate is not the focus of this study but should
be investigated to insure the point estimate is not horrendously
biased when the scan interval lengthens.
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The National Health Service (NHS) has established procedures to sup-
port research activities covered by the Research Governance Frame-
work (RGF). These include Health Research Authority (HRA) approval
to ensure regulatory compliance, and site-specific Research and De-
velopment (R&D) agreement to support project delivery (capacity/
capability). In addition, the importance of research has been embed-
ded in the NHS constitution (including Frameworks and Pledges) en-
dorsed by the UK Government. The National Institute for Health
Research (NIHR) Research Networks have also been established to
embed Research infrastructure - primarily in the NHS setting -sup-
porting research activities (trained research practitioners) and fund-
ing via the Research Capability Funding (RCF). Research in non-NHS
settings, such as Care Homes, is increasing however standardised
procedures to support the delivery of high quality research have yet
to be embedded in practice. Complexities arise in this setting as Care
Homes are often independent businesses which vary in infrastructure
with often a unique mix of funding streams including Local Author-
ities, NHS (Continuing Healthcare), and self-funding - therefore rele-
vant permissions will vary dependent upon the sites selected. Work
has been done within the social care setting to bridge the gap, with
the development of the “Implementation plan for research govern-
ance in social care”, however the scope and applicability to Care
Home research varies with no fixed format for formal research per-
missions. Existing literature highlights the barriers to implementing
the principles of the RGF in the Care Home setting, often referencing
experiences from individual projects. However these experiences
have yet to be consolidated into a robust summary of complexities
with strategies to manage them in practice whilst still ensuring the
delivery of quality research. We will present our experience from two
randomised controlled trials within the care home setting alongside
findings from a review of existing literature regarding trials imple-
mentation in care homes. We will also outline an approach devel-
oped to support the delivery of high quality research projects in this
setting, summarising the key considerations for successful delivery in
the absence of research infrastructure, the impact on timelines, re-
source use, and trial implementation. We will also discuss in more
detail the key considerations during trial set-up, such as: i) Develop-
ment and completion of formal permissions (Care Home Letter of
Agreement) to document requirements for trial delivery at site, ii)
Using quality/performance markers to inform site selection and on-
going assessment of contextual factors impacting on trial delivery; iii)
Selection of appropriate sites (eligibility/feasibility/recruitment) re-
flective of the setting, iv) Developing processes to deliver the project
in line with the principles of GCP (i.e. documented informed consent,
data storage and transfer in accordance with DPA), and v) Incentives
which sustain Care Home engagement, vi) Establishing informa-
tion available within care records and development of appropriate
data collection tools to support trial analysis. We have identified a
series of challenges and proposed solutions which may help with
future research in the Care Home setting and provides a useful re-
source for researchers to deliver high-quality research in a research
naïve setting.
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Background
Previous research published in the Lancet has estimated that as
much as 85% of healthcare research might actually be wasted. A
contributing factor to this may be interventions that are delivered
with poor fidelity within clinical trials. Intervention fidelity is the
extent to which an intervention is delivered as intended by its devel-
opers, and assessing it is crucial as it increases confidence that
changes in study outcomes are due to the effect of the intervention
itself and not due to variability in implementation. Complex interven-
tions involve several aspects with the potential to be implemented
variably, therefore it is important to ensure a comprehensive evalu-
ation of the fidelity of intervention delivery in such interventions.
However, fidelity continues to be poorly assessed in clinical trials
across multiple disciplines. At present there is a lack of pragmatic
guidance and an insufficient focus on developing feasible ways of in-
corporating fidelity assessment into clinical trials.
Objectives
This research aimed to provide guidance on assessing fidelity of inter-
vention delivery within clinical trials, i.e. to inform appropriate choice of
fidelity assessment methods and how to achieve a balance between
comprehensiveness and feasibility. Specifically, the study aimed to do
this through establishing the fidelity of delivery of a behaviour-change
physiotherapy-led intervention within the context of a clinical feasibility
randomised controlled trial (RCT) and to explore the potential factors
that may have influenced these fidelity results.
Methods
This mixed methods study was a convergent triangulation design. 60
intervention sessions were delivered across seven sites by nine physio-
therapists. Fidelity was assessed quantitatively using audio-recordings
(n = 60), direct-observations (n = 24) and self-report checklists (n = 60)
and qualitatively using individual semi-structured interviews with all
physiotherapists (n = 9). Quantitative data were analysed using means
and standard deviations. Qualitative data were analysed using thematic
analysis. Integration of qualitative and quantitative data occurred at an
interpretation level using a triangulation methodology.
Results
Quantitatively, the fidelity scores were high for all assessment methods;
with self-report (92.7%) consistently higher than direct-observations
(82.7%), or audio-recordings (81.7%). There was significant variation be-
tween physiotherapists’ fidelity scores but all scored above 50%. These
findings were corroborated by the physiotherapist interviews. In terms
of factors influencing fidelity, both qualitative and quantitative data
found that physiotherapists’ knowledge and previous experience may
have influenced their fidelity of the delivery. The physiotherapist quali-
tative data additionally showed that participant-level and programme-
level factors also influenced their fidelity.
Conclusions
The research identified a number of key findings that can enable a
feasible and comprehensive assessment of fidelity in clinical trials.
Although conducted in the context of a feasibility RCT of a complex
behavioural intervention, these findings can be generalised to other
areas. Firstly, a ‘spectrum’ of quantitative assessment methods exists
and choice may be guided by specific trial factors (e.g. size, resource
availability). Secondly, a mixed methods approach provides a more
comprehensive assessment of fidelity and can be feasibly done by
utilising pre-existing trial qualitative data collection. Finally, assessing
fidelity and its influencing factors can help understand how and why
adaptations and deviations have occurred and can guide potential
refinements.O111
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Group-randomized trials (GRTs) are randomized studies that allocate
intact groups of individuals to different comparison arms. A frequent
practical limitation to adopting such research designs is that only a
limited number of groups may be available, and therefore, simple
randomization is unable to adequately balance multiple group-level
covariates between arms. Therefore, covariate-based constrained
randomization was proposed as an allocation technique to achieve
this. Constrained randomization involves generating a very large
number of possible allocation schemes (with a small number of
groups to be randomized it is possible to generate all of them), cal-
culating a pre-specified balance metric that assesses covariate imbal-
ance, limiting the randomization space to a pre-specified percentage
of those possible and randomly selecting one randomization to im-
plement. However, related statistical issues on testing for interven-
tion effect under such designs have not been thoroughly studied
with binary outcomes. Motivated by two recent trials, we conduct a
series of Monte Carlo simulations to evaluate the statistical properties
of two model-based F-tests (linearization and likelihood F-test) and
two randomization-based permutation tests (residual and likelihood
P-test) under both simple and constrained randomization designs,
with varying degrees of analysis-based covariate adjustment. Our re-
sults indicate that constrained randomization improves the power of
linearization F-test and two permutation tests when the prognostic
group-level variables are controlled for in the analysis and the size of
randomization space is reasonably small. We also demonstrate that
constrained randomization reduces power loss from redundant
analysis-based adjustment for non-prognostic covariates. Design con-
siderations such as the choice of the balance metric and the size of
randomization space are emphasized throughout.
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Background
Phase II clinical trials aim to potentially screen out ineffective and iden-
tify effective therapies to move forward to the randomized phase III set-
ting. In phase II trials, the most common way of assessing tumor
shrinkage is to dichotomize the patients by the response rate according
to RECIST. Besides loss of statistical efficiency, studies have shown that
designs using response rate require much more patients than those
using continuous tumor size shrinkage. Further, drugs can be still active
even if they do not lead to high levels of tumor regression, as could be
observed with molecular targeted therapies and immunotherapies.
These treatment strategies come often with lower toxicity profiles than
traditional cytotoxic treatments, and have shifted the drug develop-
ment paradigm into establishing evidence of biological activity, target
modulation and pharmacodynamics effects of these therapies in early
phase trials. As such, these trials need to address simultaneous
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ity or changes in continuous tumor size instead of binary response
rates. However, there is a lack of interim strategies developed to
monitor futility and/or efficacy for these types of continuous outcomes,
especially in the single-arm setting.
Objective
We propose a two-stage single-arm design for continuous endpoints
that allows for early futility stopping while maintaining desirable stat-
istical properties.
Methods
Lee and Liu (2008) developed a predictive probability design for
binary outcomes in a single-arm phase II cancer clinical trial. We ex-
tend their design into a two-stage setting for continuous endpoints
assuming a normal distribution with known variance. We evaluate
and present the design properties for both optimal and minimax
designs.
Results
Both simulation results and presented case study have demonstrated
that the proposed design can incorporate an interim stop for futility
that controls both type I and type II error rates. As expected, using
continuous tumor size resulted in lower expected and maximum
sample sizes. A limited exploration of the choice of prior was per-
formed and the numeric results were shown to be robust.
Conclusions
The proposed two-stage design based on predictive probability is
efficient with similar sample size reduction for continuous out-
comes and possess desirable operating characteristics. As research
rapidly moves to incorporate more immunotherapies and targeted
therapies, it will accommodate new types of outcomes while allow-
ing for flexible stopping rules for futility and/or efficacy to continue
optimizing trial resources and prioritize agents with compelling
early phase data.
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Bayesian approaches to phase II clinical trial designs usually base
the inferences on the posterior distribution of the parameter of
interest. If the posterior probability is computed and assessed in a
sequential manner, the design may involve the problem of multipli-
city, which, however, is often a neglected aspect in Bayesian trial
designs. To effectively maintain the overall type I error rate, we
propose solutions to the problem of multiplicity for Bayesian se-
quential designs and, in particular, the determination of the cutoff
boundaries for the posterior probabilities. We present both theoret-
ical and numerical methods for finding the optimal posterior prob-
ability boundaries with alpha-spending functions that mimic those
of the frequentist group sequential designs. The theoretical ap-
proach is based on the asymptotic properties of the posterior prob-
ability, which establishes a connection between the Bayesian trial
design and the frequentist group sequential method. The numerical
approach uses a sandwich-type searching algorithm, which im-
mensely reduces the computational burden. We apply least-square
fitting to find the alpha-spending function closest to the target. We
discuss the application of our method to single-arm and double-
arm cases with binary and normal endpoints, respectively, and pro-
vide a real trial example for each case.
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Efficient recruitment to randomised controlled trials (RCTs) is vital in
high-quality, cost effective, clinical research. Under-recruitment, re-
cruitment extensions and supplementary funding requests are com-
mon. Under-recruitment leads to underpowered trials, inconclusive
results and wasted research effort. Efficient recruitment to stroke re-
habilitation RCTs is considered particularly problematic but has yet to
be investigated.
Aims and Objectives
We aimed to examine stroke rehabilitation RCTs’ (i) recruitment effi-
ciency (ii) trial features associated with recruitment efficiency and (iii)
reporting of recruitment information.
Methods
We included all trials identified by the Cochrane Stroke Group’s trial
register. This includes trials identified from 35 electronic databases
(e.g. Medline, CINAHL, EMBASE); numerous clinical trial registers; and
hand-searching other resources. We included publications between
2005–2015, grey literature, and had no language restrictions. Records
that reported RCTs of stroke rehabilitation non-pharmacological
interventions with patient populations were included. We extracted
recruitment efficiency data (i) Rate: numbers randomised as a per-
centage of those screened for eligibility (ii) Speed: average monthly
recruitment numbers across sites (iii) overall Dropout rates. Data on
recruitment sites, recruiters, setting, funding support, ethical review,
intervention type, targeted impairment, control comparison, and coun-
try of recruitment were extracted by two independent reviewers. Dis-
crepancies were resolved by a third reviewer.
Results
Two independent reviewers screened 12,939 titles, 1,270 abstracts
and 788 full texts for eligibility. 515 trials were included. Only 39% of
stroke survivors screened were subsequently randomised. Subgroup
analysis revealed that recruitment efficiency was significantly affected
by the intervention type, control condition, targeted impairment, re-
cruitment time point and setting.
Conclusions
Stroke rehabilitation trials experience notable recruitment inefficiencies.
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Background
First-in-human clinical trials are a crucial stage in the development of
novel oncology drug candidates. Despite their importance, the de-
sign of these trials varies significantly. An improved understanding of
these variations is needed in order to improve the impact of cancer
research and make the process more economical. The aim of this re-
search was to review, analyse and compare the dose escalation
methods used in first-in-human small molecule oncology clinical
trials to provide greater understanding of the variation of oncology
clinical trial design.
Method:
The literature databases PubMED, Web of Science and Wiley Online
Library were searched to identify published first-in-human trials of
small molecule oncology candidates. Search terms used were: [1]
“first-in-man” [title] OR [2] “first-in-human” [title] OR [3] “oncology OR
cancer”. Further searches were completed which replaced terms [1]
and [2] with [4] “dose escalation”. A total of 69 trial publications ap-
plicable to the aim of this review were identified. Each publication
was reviewed and relevant data extracted which included the type
of dose escalation method and individual dose levels used. To enable
comparative analysis of 3 + 3 and “accelerated trial design” (ATD) es-
calation methods (the most popular methods with trials of suitable
number for comparison), dose level data was translated to “Unique
Dose Levels” (UDLs). The mean number of UDLs and dose increments
of 3 + 3 and ATD trials were then compared. We hypothesised that,
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ation method would have fewer dose levels and larger increments
between doses and thereby achieve the maximum tolerated dose
(MTD) quicker.
Results
Of the 69 trials identified for review, 64 were parallel multiple dose
design and five were parallel single dose design. Of the parallel mul-
tiple dose trials, 54/64 used a rule based dose escalation method
with only 4/64 opting for a model based dose escalation method.
The most popular rule based dose escalation methods were 3 + 3
(31/54) and ATD (16/54). The mean number of UDLs of 3 + 3 and
ATD trials did not differ significantly (9.4 vs. 8.5; p-value = 0.31 for
two-tailed t-test with 95% confidence intervals). Through use of a
graphical heat map method of analysis, the dose increments of ATD
trials do not appear to be greater than those of 3 + 3 trials. Given
these findings, the research hypothesis was disproven.
Conclusion
The findings of this research suggest that the ATD dose escalation
method may not achieve the MTD quicker than the traditional 3 + 3
dose escalation method. If ATD is in fact not accelerated, this finding
has implications for drug development organisations where a pro-
longed clinical trial process has large cost implications, and also for
patients who may have to wait longer for drugs to reach the clinic.
Future research will seek to compare the dose escalation methods
used in first-in-human clinical trials of the same drug candidate (e.g.
in Caucasian and Asian populations) to control the effect of drug
variation on dose escalation whilst acknowledging and accounting
for population differences.
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Background
Cost effectiveness analyses (CEA) of randomised trials are an import-
ant source of information for health commissioners to decide on
how to best allocate limited resources. Missing data are a common
issue in trials, and is particularly problematic in CEA which require
complete information on both costs and effects. Recent guidelines
addressing this issue encourage the use of suitable methods such as
multiple imputation and recommend the conduct of sensitivity ana-
lyses under varied missing data assumptions. It is however unclear to
what extent these recommendations have affected practice. Aim: To
review the extent of, and methods used to address, missing data in
trial-based cost-effectiveness analysis.
Methods
We conducted a review of trial-based CEA published in the Health
Technology Assessment journal between January 2013 and Decem-
ber 2015. This journal is a key depository of full-scale economic eval-
uations funded by the UK National Institute for Health Research
Health Technology Assessment Programme (NIHR HTA), where each
report includes details of the analysis methods and results.
Results
Fifty-two eligible trials were identified. Nearly all of them had missing
data, with a median proportion of participants with complete cost-
effectiveness data of 63% (IQR 47% to 81%). Restricting analysis to
complete-records remains the most common approach (43% of pri-
mary analysis), followed by multiple imputation (30%). Only half of
the studies conducted sensitivity analyses for missing data, and it
was typically using a limited range of assumptions such as data being
either “missing completely at random” or “missing at random”.
Conclusions
Missing data remain a major concern for trial-based CEA. In spite of its
limitations, restricting analysis to the subset of complete records is the
most common approach. Analysts typically do not follow guidelines in
evaluating the robustness of inferences to departure from the missingat random assumption. There may be lack of lack of awareness of the
issue, or guidance on how to conduct such analyses.
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In event-based clinical trials it is common to plan interim analyses to
take place at planned event counts. Accurate prediction of these event
times can support trial planning and the efficient allocation of re-
sources. Available methods to create such predictions include paramet-
ric cure and non-cure models and a nonparametric approach based on
the Bayesian bootstrap. The parametric methods work well when their
underlying assumptions are met, and the nonparametric method gives
calibrated but inefficient predictions across a wide range of models.
However, in the early stages of a trial, when predictions have the high-
est marginal value, there is insufficient data to provide evidence about
the form of underlying model, including whether a cure fraction exists.
In this paper, we propose an adaptive method to address this defi-
ciency. The method draws predictions from the model with the highest
Bayesian posterior probability within a range of candidate models. To
further capture the uncertainty in clinical trial prediction, we apply a
simulation strategy using the Bayesian bootstrap. A simulation study
demonstrates that the adaptive method produces prediction intervals
that have good coverage and are slightly wider than non-adaptive in-
tervals but narrower than nonparametric intervals. It leads to some im-
provements in making predictions with data from the International
Chronic Granulomatous Disease Study.
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With the emergence of novel targeted anti-cancer agents, drug
combinations have been recognized as cutting-edge development in
oncology. However, limited attention has been paid to the overdose
control in the existing drug-combination dose-finding trials. We
develop the multi-agent nonparametric overdose control (MANOC)
design for dose finding in phase I drug-combination trials. Based on
a Bayesian decision-theoretic approach, we control the probability of
overdosing in a local region at the current dose combination. Simula-
tion studies are conducted to investigate the performance of the
proposed design. While the MANOC can prevent patients from being
allocated to overtoxic dose levels, its accuracy and efficiency are still
competitive to the existing designs. As an illustration, the MANOC is
applied to a phase I clinical trial for identifying the maximum toler-
ated dose combination of buparlisib and trametinib.
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Introduction
In precision medicine, drugs are developed to target patients with
certain genetic profiles. Targeted trials test treatment benefit only in
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(BSD) allow a complete assessment of the effect of the new drug rela-
tive to the standard drug overall as well as in various biomarker-
defined subgroups. However, a BSD trial often requires enrolling a large
number of patients, especially when the proportion of the biomarker
positives is small and thus the conduct of a BSD trial is expensive when
the cost of ascertaining the true biomarker status is high.
Methods
We propose a special type of biomarker enrichment design, Biomarker
Stratified Design Enriched by Auxiliary Variables (ABSD), in which a sub-
group of patients, typically the biomarker-positive patients, are
enriched based on the value of an inexpensive auxiliary variable that is
positively correlated to the true biomarker. In such a design, all
auxiliary-variable-positive patients and a proportion of the auxiliary-
variable-negative patients are selected and included in the randomized
trial. We compared the efficiency of ABSD with BSD in estimating vari-
ous treatment parameters that are estimable in a BSD trial including
the treatment effect in all patients and in specific biomarker subgroups
and the interaction effect. We compared the efficiency of the two
designs in term of the number of treated patients and the cost of the
trial, assuming a range of prevalence of the true biomarker-positive
patients in the overall population, the positive predictive value of the
auxiliary variables for the true maker, and configurations of cost utilities
of various items in conducting such trials.
Results
The proposed ABSD always reduces the total cost of the trial relative to
a BSD when the prevalence rate is small and the PPV, the probabilitythat a patient with positive auxiliary variable also has a positive true
biomarker, is large enough.
When employing the proposed design in a practical study, Gefitinib
or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma in North
America, for testing the treatment effect among EGFR mutants and
the interaction effect, ABSD requires 155 randomized patients com-
pared to the 930 randomized patients required by a BSD. In addition,
ABSD reduces the total cost cost by 64.6%.
Another advantage of ABSD is that in most cases we can immedi-
ately randomize patients selected in the screening process without
waiting for the result of true biomarker test, which can substantially
reduce reduce the waiting time.
Since PPV plays a very important role in the proposed design, a
Bayesian adaptive ABSD is also proposed to deal with the mis-
specified PPV.
Conclusion
A biomarker stratified design enriched by an auxiliary variable can be
more efficient than the standard BSD design. The efficiency gain can
be particularly significant when the auxiliary variable has a high PPV,
the prevalence rate of the biomarker-positive subgroup is small and
the cost of ascertaining the true biomarker status is high relative to
the auxiliary variable.Publisher’s Note
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